<?xml version="1.0" encoding="utf-8"?>
<Schedule xmlns:schedule="http://schedule.pharmac.govt.nz/2006/07/Schedule#" xmlns:html="http://www.w3.org/1999/xhtml" xmlns:math="http://www.w3.org/1998/Math/MathML" xmlns="http://schedule.pharmac.govt.nz/2006/07/Schedule#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nzmt="nzmt.org.nz" xsi:schemaLocation="http://schedule.pharmac.govt.nz/2006/07/Schedule# http://schedule.pharmac.govt.nz/2006/07/Schedule.xsd">
  <Front>
    <Title>Pharmaceutical Schedule</Title>
    <Country>New Zealand</Country>
    <Edition>March 2024</Edition>
    <Volume>31</Volume>
    <Number>0</Number>
    <Published>2024-03-01</Published>
  </Front>
  <Section ID="B">
    <Name>Community Pharmaceuticals</Name>
    <ATC1 ID="A01">
      <Name>Alimentary Tract and Metabolism</Name>
      <ATC2 ID="A0101">
        <Name>Antacids and Antiflatulents</Name>
        <ATC3 ID="A010102">
          <Name>Antacids and Reflux Barrier Agents</Name>
          <Chemical ID="C0101021021">
            <Name>Alginic acid</Name>
            <Formulation ID="F010102102103" Rank="2" Units="sach" Weight="225">
              <Name>Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet</Name>
              <Brand ID="B01010210210301">
                <Name>Gaviscon Infant</Name>
                <Pack ID="P494275" Specified="true" nzmt:ctpp_id="50092391000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>5.31</Subsidy>
                  <Price>5.31</Price>
                  <Alternate>5.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0101022125" Statim="Must">
            <Name>Sodium alginate</Name>
            <Formulation ID="F010102212525" Rank="3" Units="ml">
              <Name>Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml</Name>
              <Brand ID="B01010221252525">
                <Name>Acidex</Name>
                <Pack ID="P2196786" Specified="true" nzmt:ctpp_id="50031441000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>1.50</Subsidy>
                  <Price>7.50</Price>
                  <Alternate>1.50</Alternate>
                  <Surcharge>0.01200</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010102212526" Rank="1" Units="tab">
              <Name>Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour</Name>
              <Brand ID="B01010221252625">
                <Name>Gaviscon Extra Strength</Name>
                <Pack ID="P2215241" Specified="true" nzmt:ctpp_id="50305121000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>1.80</Subsidy>
                  <Price>13.61</Price>
                  <Alternate>1.80</Alternate>
                  <Surcharge>0.19683</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A010104">
          <Name>Phosphate Binding Agents</Name>
          <Chemical ID="C0101041038" Statim="Must">
            <Name>Aluminium hydroxide</Name>
            <Formulation ID="F010104103804" Rank="1" Units="tab" Weight="600">
              <Name>Tab 600 mg</Name>
              <Brand ID="B01010410380401">
                <Name>Alu-Tab</Name>
                <Pack ID="P200417" Specified="true" nzmt:ctpp_id="50000401000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>12.56</Subsidy>
                  <Price>12.56</Price>
                  <Alternate>12.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0101041191">
            <Name>Calcium carbonate</Name>
            <Formulation ID="F010104119127" Rank="3" Units="ml" Weight="1250">
              <Name>Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml)</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B01010411912725">
                <Name>Roxane</Name>
                <Pack ID="P2428407" Specified="true" nzmt:ctpp_id="50148841000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>39.00</Subsidy>
                  <Price>39.00</Price>
                  <Alternate>39.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01010411912726" S29="true">
                <Name>Calcium carbonate PAI</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2652935" Specified="true" nzmt:ctpp_id="50310501000117102">
                  <Quantity>473</Quantity>
                  <Subsidy>47.30</Subsidy>
                  <Price>47.30</Price>
                  <Alternate>47.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0104">
        <Name>Antidiarrhoeals</Name>
        <ATC3 ID="A010401">
          <Name>Agents Which Reduce Motility</Name>
          <Chemical ID="C0104011728" Statim="Must">
            <Name>Loperamide hydrochloride</Name>
            <Rule Type="FormMax" Value="30" Attribute="PSO"/>
            <Formulation ID="F010401172801" Rank="2" Units="cap" Weight="2">
              <Name>Cap 2 mg</Name>
              <Brand ID="B01040117280125" PSS="2025-06-30">
                <Name>Diamide Relief</Name>
                <Pack ID="P2365545" Specified="true" nzmt:ctpp_id="50119711000117109">
                  <Quantity>400</Quantity>
                  <Subsidy>7.25</Subsidy>
                  <Price>7.25</Price>
                  <Alternate>7.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010401172802" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B01040117280225">
                <Name>Nodia</Name>
                <Pack ID="P2184427" Specified="true" nzmt:ctpp_id="50030221000117103">
                  <Quantity>400</Quantity>
                  <Subsidy>10.75</Subsidy>
                  <Price>10.75</Price>
                  <Alternate>10.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A010404">
          <Name>Rectal and Colonic Anti-inflammatories</Name>
          <Chemical ID="C0104041168">
            <Name>Budesonide</Name>
            <Formulation ID="F010404116809" Rank="2" Units="cap" Weight="3">
              <Name>Cap modified-release 3 mg</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1886"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1886">
                <Title>
                  <range>Budesonide - Cap 3 mg Controlled Release</range>
                </Title>
                <Case When="Initial application" Category="Crohn's disease">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Diabetes</ci>
                        <ci type="logical" class="Indication">Cushingoid habitus</ci>
                        <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci>
                        <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci>
                        <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci>
                        <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high</ci>
                        <ci type="logical" class="Indication">Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)</ci>
                      </apply>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
                <Case When="Initial application" Category="collagenous and lymphocytic colitis (microscopic colitis)">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
                <Case When="Initial application" Category="gut Graft versus Host disease">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">Patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                  <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                    <p>Indication marked with * is an unapproved indication.</p>
                  </div>
                </Case>
                <Case When="Initial application" Category="non-cirrhotic autoimmune hepatitis">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has autoimmune hepatitis*</ci>
                      <ci type="logical" class="Indication">Patient does not have cirrhosis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Diabetes</ci>
                        <ci type="logical" class="Indication">Cushingoid habitus</ci>
                        <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci>
                        <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci>
                        <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci>
                        <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high</ci>
                        <ci type="logical" class="Indication">Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)</ci>
                        <ci type="logical" class="Indication">Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth) </ci>
                      </apply>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                  <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                    <p>Indication marked with * is an unapproved indication.</p>
                  </div>
                </Case>
                <Case When="Renewal" Form="SA0459 SA0488 SA0512 SA0698 SA0913 SA1155 SA1886">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
                <Case When="Renewal" Category="non-cirrhotic autoimmune hepatitis" Form="SA0459 SA0488 SA0512 SA0698 SA0913 SA1155 SA1886">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.</p>
                </div>
              </Request>
              <Brand ID="B01040411680901" ToBeDelisted="2024-04-01">
                <Name>Entocort CIR</Name>
                <Pack ID="P2272547">
                  <Quantity>90</Quantity>
                  <Subsidy>166.50</Subsidy>
                  <Price>166.50</Price>
                  <Alternate>166.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2536528" Specified="true" nzmt:ctpp_id="50042711000117104">
                  <Quantity>90</Quantity>
                  <Subsidy>166.50</Subsidy>
                  <Price>166.50</Price>
                  <Alternate>166.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01040411680902" ToBePSS="2024-04-01">
                <Name>Budesonide Te Arai</Name>
                <Pack ID="P2661454" Specified="true" nzmt:ctpp_id="50319351000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>87.60</Subsidy>
                  <Price>87.60</Price>
                  <Alternate>87.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0104041606">
            <Name>Hydrocortisone acetate</Name>
            <Formulation ID="F010404160602" Rank="3" Units="g">
              <Name>Rectal foam 10%, CFC-Free (14 applications)</Name>
              <Brand ID="B01040416060201">
                <Name>Colifoam</Name>
                <Pack ID="P462829" OP="true" nzmt:ctpp_id="50087911000117109">
                  <Quantity>21</Quantity>
                  <Subsidy>26.55</Subsidy>
                  <Price>26.55</Price>
                  <Alternate>26.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2611120" Specified="true" OP="true" nzmt:ctpp_id="50290921000117105">
                  <Quantity>15</Quantity>
                  <Subsidy>26.55</Subsidy>
                  <Price>26.55</Price>
                  <Alternate>26.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01040416060202" S29="true" ToBeDelisted="2024-04-01">
                <Name>Cortifoam</Name>
                <Pack ID="P2608707" Specified="true" OP="true" nzmt:ctpp_id="50286941000117102">
                  <Quantity>15</Quantity>
                  <Subsidy>26.55</Subsidy>
                  <Price>26.55</Price>
                  <Alternate>26.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0104042144">
            <Name>Sodium cromoglicate</Name>
            <Formulation ID="F010404214406" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B01040421440602">
                <Name>Ralicrom</Name>
                <Pack ID="P2628295" Specified="true" nzmt:ctpp_id="50294291000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>113.35</Subsidy>
                  <Price>113.35</Price>
                  <Alternate>113.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0104042205">
            <Name>Sulfasalazine</Name>
            <Formulation ID="F010404220501" Rank="1" Units="tab" Weight="500" Statim="Must">
              <Name>Tab 500 mg</Name>
              <Brand ID="B01040422050101">
                <Name>Salazopyrin</Name>
                <Pack ID="P251615" Specified="true" nzmt:ctpp_id="50052851000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>16.52</Subsidy>
                  <Price>16.52</Price>
                  <Alternate>16.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404220502" Rank="1" Units="tab" Weight="500" Statim="Must">
              <Name>Tab EC 500 mg</Name>
              <Brand ID="B01040422050201">
                <Name>Salazopyrin EN</Name>
                <Pack ID="P251585" Specified="true" nzmt:ctpp_id="50052831000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>17.86</Subsidy>
                  <Price>17.86</Price>
                  <Alternate>17.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0104042384">
            <Name>Olsalazine</Name>
            <Formulation ID="F010404238401" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B01040423840101">
                <Name>Dipentum</Name>
                <Pack ID="P588679" Specified="true" nzmt:ctpp_id="50097641000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>53.00</Subsidy>
                  <Price>53.00</Price>
                  <Alternate>53.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404238402" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B01040423840201">
                <Name>Dipentum</Name>
                <Pack ID="P426342" Specified="true" nzmt:ctpp_id="50084531000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>93.37</Subsidy>
                  <Price>93.37</Price>
                  <Alternate>93.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01040423840202" S29="true">
                <Name>Atnahs Olsalazine</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2641704" Specified="true" nzmt:ctpp_id="50303651000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>56.02</Subsidy>
                  <Price>56.02</Price>
                  <Alternate>56.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0104042533">
            <Name>Mesalazine</Name>
            <Formulation ID="F010404253302" Rank="1" Units="tab" Weight="500">
              <Name>Tab long-acting 500 mg</Name>
              <Brand ID="B01040425330201">
                <Name>Pentasa</Name>
                <Pack ID="P768618" Specified="true" nzmt:ctpp_id="50111321000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>56.10</Subsidy>
                  <Price>56.10</Price>
                  <Alternate>56.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404253303" Rank="5" Units="en">
              <Name>Enema 1 g per 100 ml</Name>
              <Brand ID="B01040425330301">
                <Name>Pentasa</Name>
                <Pack ID="P715867" Specified="true" nzmt:ctpp_id="50105001000117107">
                  <Quantity>7</Quantity>
                  <Subsidy>41.30</Subsidy>
                  <Price>41.30</Price>
                  <Alternate>41.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404253304" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B01040425330401">
                <Name>Asacol</Name>
                <Pack ID="P241113">
                  <Quantity>100</Quantity>
                  <Subsidy>49.50</Subsidy>
                  <Price>49.50</Price>
                  <Alternate>49.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2536544" Specified="true" nzmt:ctpp_id="50051561000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>49.50</Subsidy>
                  <Price>49.50</Price>
                  <Alternate>49.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404253305" Rank="5" Units="supp" Weight="500">
              <Name>Suppos 500 mg</Name>
              <Brand ID="B01040425330501">
                <Name>Asacol</Name>
                <Pack ID="P462543">
                  <Quantity>20</Quantity>
                  <Subsidy>22.80</Subsidy>
                  <Price>22.80</Price>
                  <Alternate>22.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2536560" Specified="true" nzmt:ctpp_id="50087861000117101">
                  <Quantity>20</Quantity>
                  <Subsidy>22.80</Subsidy>
                  <Price>22.80</Price>
                  <Alternate>22.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404253325" Rank="5" Units="supp" Weight="1000">
              <Name>Suppos 1 g</Name>
              <Brand ID="B01040425332525">
                <Name>Pentasa</Name>
                <Pack ID="P2111985" Specified="true" nzmt:ctpp_id="50019841000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>50.96</Subsidy>
                  <Price>50.96</Price>
                  <Alternate>50.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404253327" Rank="2" Units="sach" Weight="1">
              <Name>Modified release granules, 1 g </Name>
              <Brand ID="B01040425332725">
                <Name>Pentasa</Name>
                <Pack ID="P2601354" Specified="true" OP="true" nzmt:ctpp_id="50129091000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>118.10</Subsidy>
                  <Price>118.10</Price>
                  <Alternate>118.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010404253328" Rank="1" Units="tab" Weight="800">
              <Name>Tab 800 mg</Name>
              <Brand ID="B01040425332825">
                <Name>Asacol</Name>
                <Pack ID="P2470616">
                  <Quantity>90</Quantity>
                  <Subsidy>85.50</Subsidy>
                  <Price>85.50</Price>
                  <Alternate>85.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2536552" Specified="true" nzmt:ctpp_id="50186641000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>85.50</Subsidy>
                  <Price>85.50</Price>
                  <Alternate>85.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0104044118">
            <Name>Hydrocortisone acetate with pramoxine hydrochloride</Name>
            <Formulation ID="F010404411825" Rank="3" Units="g" Weight="1">
              <Name>Topical aerosol foam, 1% with pramoxine hydrochloride 1%</Name>
              <Brand ID="B01040441182525" S29="true">
                <Name>Proctofoam</Name>
                <Pack ID="P2572176" Specified="true" OP="true" nzmt:ctpp_id="50266251000117106">
                  <Quantity>10</Quantity>
                  <Subsidy>26.55</Subsidy>
                  <Price>26.55</Price>
                  <Alternate>26.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0104044131">
            <Name>Prednisolone sodium</Name>
            <Formulation ID="F010404413125" Rank="10" Units="pack">
              <Name>Rectal foam 20 mg per dose (14 applications)</Name>
              <Brand ID="B01040441312525" S29="true">
                <Name>Essential Prednisolone</Name>
                <Pack ID="P2598469" Specified="true" OP="true" nzmt:ctpp_id="50281711000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>74.10</Subsidy>
                  <Price>74.10</Price>
                  <Alternate>74.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0105">
        <Name>Local preparations for Anal and Rectal Disorders</Name>
        <ATC3 ID="A010501">
          <Name>Antihaemorrhoidal Preparations</Name>
          <Chemical ID="C0105011521">
            <Name>Fluocortolone caproate with fluocortolone pivalate and cinchocaine</Name>
            <Formulation ID="F010501152101" Rank="5" Units="supp" Weight="630">
              <Name>Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg</Name>
              <Brand ID="B01050115210101">
                <Name>Ultraproct</Name>
                <Pack ID="P257478" Specified="true" nzmt:ctpp_id="50055961000117108">
                  <Quantity>12</Quantity>
                  <Subsidy>7.30</Subsidy>
                  <Price>7.30</Price>
                  <Alternate>7.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010501152102" Rank="3" Units="g">
              <Name>Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g</Name>
              <Brand ID="B01050115210201">
                <Name>Ultraproct</Name>
                <Pack ID="P257451" Specified="true" OP="true" nzmt:ctpp_id="50055951000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>11.06</Subsidy>
                  <Price>11.06</Price>
                  <Alternate>11.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0105011632">
            <Name>Hydrocortisone with cinchocaine</Name>
            <Formulation ID="F010501163201" Rank="3" Units="g">
              <Name>Oint 5 mg with cinchocaine hydrochloride 5 mg per g</Name>
              <Brand ID="B01050116320101">
                <Name>Proctosedyl</Name>
                <Pack ID="P208388" Specified="true" OP="true" nzmt:ctpp_id="50013821000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>15.00</Subsidy>
                  <Price>15.00</Price>
                  <Alternate>15.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010501163204" Rank="5" Units="supp" Weight="5">
              <Name>Suppos 5 mg with cinchocaine hydrochloride 5 mg per g</Name>
              <Brand ID="B01050116320401">
                <Name>Proctosedyl</Name>
                <Pack ID="P208396" Specified="true" nzmt:ctpp_id="50013861000117109">
                  <Quantity>12</Quantity>
                  <Subsidy>9.90</Subsidy>
                  <Price>9.90</Price>
                  <Alternate>9.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A010502">
          <Name>Management of Anal Fissures</Name>
          <Chemical ID="C0105021577" Statim="Must">
            <Name>Glyceryl trinitrate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1329"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1329">
              <Title>
                <range>Glyceryl trinitrate Oint 0.2%</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient has a chronic anal fissure that has persisted for longer than three weeks</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F010502157726" Rank="3" Units="g">
              <Name>Oint 0.2%</Name>
              <Brand ID="B01050215772625" PSS="2024-06-30">
                <Name>Rectogesic</Name>
                <Pack ID="P2120313" Specified="true" OP="true" nzmt:ctpp_id="50021721000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>22.00</Subsidy>
                  <Price>22.00</Price>
                  <Alternate>22.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0107">
        <Name>Antispasmodics and Other Agents Altering Gut Motility</Name>
        <ATC3 ID="A010701">
          <Name>Antispasmodics and Other Agents Altering Gut Motility</Name>
          <Chemical ID="C0107011631" Statim="Must">
            <Name>Hyoscine butylbromide</Name>
            <Formulation ID="F010701163101" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B01070116310101">
                <Name>Buscopan</Name>
                <Pack ID="P252328" Specified="true" nzmt:ctpp_id="50150341000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>6.35</Subsidy>
                  <Price>6.35</Price>
                  <Alternate>6.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F010701163102" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B01070116310203" PSS="2026-06-30">
                <Name>Spazmol</Name>
                <Pack ID="P2656027" Specified="true" nzmt:ctpp_id="50315031000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1.91</Subsidy>
                  <Price>1.91</Price>
                  <Alternate>1.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0107012381" Statim="Must">
            <Name>Mebeverine hydrochloride</Name>
            <Formulation ID="F010701238101" Rank="1" Units="tab" Weight="135">
              <Name>Tab 135 mg</Name>
              <Brand ID="B01070123810101" PSS="2026-06-30">
                <Name>Colofac</Name>
                <Pack ID="P2535297" Specified="true" nzmt:ctpp_id="50097511000117100">
                  <Quantity>90</Quantity>
                  <Subsidy>8.50</Subsidy>
                  <Price>8.50</Price>
                  <Alternate>8.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0107014047">
            <Name>Glycopyrronium bromide</Name>
            <Formulation ID="F010701404725" Rank="4" Units="inj" Weight="200">
              <Name>Inj 200 mcg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <Brand ID="B01070140472526" PSS="2025-06-30">
                <Name>Robinul</Name>
                <Pack ID="P2254484" Specified="true" nzmt:ctpp_id="50040341000117102">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>19.00</Subsidy>
                  <Price>19.00</Price>
                  <Alternate>19.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0110">
        <Name>Antiulcerants</Name>
        <ATC3 ID="A011001">
          <Name>Antisecretory and Cytoprotective</Name>
          <Chemical ID="C0110012546" Statim="Must">
            <Name>Misoprostol</Name>
            <Rule Type="Wastage"/>
            <Formulation ID="F011001254601" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mcg</Name>
              <Rule Type="FormMax" Value="120" Attribute="PSO"/>
              <Brand ID="B01100125460101">
                <Name>Cytotec</Name>
                <Pack ID="P561630" Specified="true" nzmt:ctpp_id="50096901000117108">
                  <Quantity>120</Quantity>
                  <Subsidy>47.73</Subsidy>
                  <Price>47.73</Price>
                  <Alternate>47.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011002">
          <Name>Helicobacter Pylori Eradication</Name>
          <Chemical ID="C0110022809">
            <Name>Clarithromycin</Name>
            <Formulation ID="F011002280925" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Rule Type="FormMax" Value="28" Attribute="Rx"/>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly.</p>
                <p/>
                <p>Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole.</p>
              </div>
              <Brand ID="B01100228092527" SoleSupply="2027-06-30">
                <Name>Klacid</Name>
                <Pack ID="P2605295" Specified="true" nzmt:ctpp_id="50284701000117107">
                  <Quantity>14</Quantity>
                  <Subsidy>14.58</Subsidy>
                  <Price>14.58</Price>
                  <Alternate>14.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011003">
          <Name>H2 Antagonists</Name>
          <Chemical ID="C0110032373" Statim="Must">
            <Name>Famotidine</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F011003237301" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B01100323730105" S29="true">
                <Name>Famotidine Hovid</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2581752" Specified="true" nzmt:ctpp_id="50273131000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>4.91</Subsidy>
                  <Price>4.91</Price>
                  <Alternate>4.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011003237302" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B01100323730205" S29="true">
                <Name>Famotidine Hovid</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2581957" Specified="true" nzmt:ctpp_id="50273791000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>10.32</Subsidy>
                  <Price>10.32</Price>
                  <Alternate>10.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011003237325" Rank="4" Units="inj" Weight="40">
              <Name>Inj 10 mg per ml, 4 ml</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidy by endorsement â€“ Subsidised for patients receiving treatment as part of palliative care.</p>
              </div>
              <Brand ID="B01100323732525" S29="true">
                <Name>Mylan</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2602776" Specified="true" CBS="true" nzmt:ctpp_id="50270251000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011010">
          <Name>Proton Pump Inhibitors</Name>
          <Chemical ID="C0110101022" Statim="Must">
            <Name>Lansoprazole</Name>
            <Formulation ID="F011010102201" Rank="2" Units="cap" Weight="30">
              <Name>Cap 30 mg</Name>
              <Brand ID="B01101010220126" PSS="2024-06-30">
                <Name>Lanzol Relief</Name>
                <Pack ID="P2482541" Specified="true" nzmt:ctpp_id="50184091000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>5.26</Subsidy>
                  <Price>5.26</Price>
                  <Alternate>5.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011010102225" Rank="2" Units="cap" Weight="15">
              <Name>Cap 15 mg</Name>
              <Brand ID="B01101010222526" PSS="2024-06-30">
                <Name>Lanzol Relief</Name>
                <Pack ID="P2482533" Specified="true" nzmt:ctpp_id="50183521000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>4.20</Subsidy>
                  <Price>4.20</Price>
                  <Alternate>4.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0110101098" Statim="Must">
            <Name>Pantoprazole</Name>
            <Formulation ID="F011010109801" Rank="1" Units="tab" Weight="40">
              <Name>Tab EC 40 mg</Name>
              <Brand ID="B01101010980127" PSS="2025-06-30">
                <Name>Panzop Relief</Name>
                <Pack ID="P2637154" Specified="true" nzmt:ctpp_id="50302361000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>2.74</Subsidy>
                  <Price>2.74</Price>
                  <Alternate>2.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011010109802" Rank="1" Units="tab" Weight="20">
              <Name>Tab EC 20 mg</Name>
              <Brand ID="B01101010980227" PSS="2025-06-30">
                <Name>Panzop Relief</Name>
                <Pack ID="P2637146" Specified="true" nzmt:ctpp_id="50302351000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>1.99</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0110102639">
            <Name>Omeprazole</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
              <p xlink:type="simple" xlink:href="standard-formulae">For omeprazole suspension refer Standard Formulae</p>
            </div>
            <Formulation ID="F011010263901" Rank="2" Units="cap" Weight="20">
              <Name>Cap 20 mg</Name>
              <Brand ID="B01101026390128" PSS="2026-06-30">
                <Name>Omeprazole actavis 20</Name>
                <Pack ID="P2604949" Specified="true" nzmt:ctpp_id="50285811000117104">
                  <Quantity>90</Quantity>
                  <Subsidy>2.02</Subsidy>
                  <Price>2.02</Price>
                  <Alternate>2.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011010263903" Rank="4" Units="inj" Weight="40" Statim="Must">
              <Name>Inj 40 mg ampoule with diluent</Name>
              <Brand ID="B01101026390325" PSS="2025-06-30">
                <Name>Dr Reddy's Omeprazole</Name>
                <Pack ID="P2310201" Specified="true" nzmt:ctpp_id="50046961000117102">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>37.38</Subsidy>
                  <Price>37.38</Price>
                  <Alternate>37.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01101026390326" S29="true">
                <Name>Ocicure</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2586908" Specified="true" nzmt:ctpp_id="50275521000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>37.38</Subsidy>
                  <Price>37.38</Price>
                  <Alternate>37.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011010263904" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B01101026390428" PSS="2026-06-30">
                <Name>Omeprazole actavis 10</Name>
                <Pack ID="P2604930" Specified="true" nzmt:ctpp_id="50285801000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>2.06</Subsidy>
                  <Price>2.06</Price>
                  <Alternate>2.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011010263905" Rank="2" Units="cap" Weight="40">
              <Name>Cap 40 mg</Name>
              <Brand ID="B01101026390528" PSS="2026-06-30">
                <Name>Omeprazole actavis 40</Name>
                <Pack ID="P2604957" Specified="true" nzmt:ctpp_id="50285821000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>3.18</Subsidy>
                  <Price>3.18</Price>
                  <Alternate>3.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011010263925" Rank="3" Units="g" Statim="Must">
              <Name>Powder</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only in extemporaneously compounded omeprazole suspension.</p>
              </div>
              <Brand ID="B01101026392525">
                <Name>Midwest</Name>
                <Pack ID="P2387085" Specified="true" nzmt:ctpp_id="50123501000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>42.50</Subsidy>
                  <Price>42.50</Price>
                  <Alternate>42.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011013">
          <Name>Site Protective Agents</Name>
          <Chemical ID="C0110132191">
            <Name>Sucralfate</Name>
            <Formulation ID="F011013219101" Rank="1" Units="tab" Weight="1000">
              <Name>Tab 1 g</Name>
              <Brand ID="B01101321910101">
                <Name>Carafate</Name>
                <Pack ID="P2602288" Specified="true" nzmt:ctpp_id="50094851000117105">
                  <Quantity>120</Quantity>
                  <Subsidy>35.50</Subsidy>
                  <Price>48.28</Price>
                  <Alternate>35.50</Alternate>
                  <Surcharge>0.10650</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0110134063">
            <Name>Colloidal bismuth subcitrate</Name>
            <Formulation ID="F011013406325" Rank="1" Units="tab" Weight="120">
              <Name>Tab 120 mg</Name>
              <Brand ID="B01101340632525" S29="true">
                <Name>Gastrodenol</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2501619" Specified="true" nzmt:ctpp_id="50234111000117102">
                  <Quantity>50</Quantity>
                  <Subsidy>14.51</Subsidy>
                  <Price>14.51</Price>
                  <Alternate>14.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0111">
        <Name>Bile and Liver Therapy</Name>
        <ATC3 ID="A011101">
          <Name>Bile and Liver Therapy</Name>
          <Chemical ID="C0111014033">
            <Name>Rifaximin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1461"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1461">
              <Title>
                <range>Rifaximin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose</ci>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant>hepatologist</Applicant>
                <Applicant Referring="gastroenterologist or hepatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1461">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant>hepatologist</Applicant>
                <Applicant Referring="gastroenterologist or hepatologist">Practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F011101403325" Rank="1" Units="tab">
              <Name>Tab 550 mg</Name>
              <Brand ID="B01110140332525">
                <Name>Xifaxan</Name>
                <Pack ID="P2449935" Specified="true" nzmt:ctpp_id="50180541000117108">
                  <Quantity>56</Quantity>
                  <Subsidy>625.00</Subsidy>
                  <Price>625.00</Price>
                  <Alternate>625.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0113">
        <Name>Diabetes</Name>
        <ATC3 ID="A011301">
          <Name>Hyperglycaemic Agents</Name>
          <Chemical ID="C0113011570">
            <Name>Glucagon hydrochloride</Name>
            <Formulation ID="F011301157004" Rank="10" Units="kit" Weight="1">
              <Name>Inj 1 mg syringe kit</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B01130115700401">
                <Name>Glucagen Hypokit</Name>
                <Pack ID="P462519" Specified="true" nzmt:ctpp_id="50087831000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>32.00</Subsidy>
                  <Price>32.00</Price>
                  <Alternate>32.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113013996">
            <Name>Diazoxide</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1320"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1320">
              <Title>
                <range>Diazoxide</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1320">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F011301399625" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B01130139962525" S29="true">
                <Name>Proglicem</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2434601" Specified="true" nzmt:ctpp_id="50164561000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>280.00</Subsidy>
                  <Price>280.00</Price>
                  <Alternate>280.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011301399626" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B01130139962625" S29="true">
                <Name>Proglicem</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2434628" Specified="true" nzmt:ctpp_id="50164551000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>110.00</Subsidy>
                  <Price>110.00</Price>
                  <Alternate>110.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011301399627" Rank="3" Units="ml">
              <Name>Oral liq 50 mg per ml</Name>
              <Brand ID="B01130139962725" S29="true">
                <Name>Proglycem</Name>
                <Pack ID="P2457849" Specified="true" OP="true" nzmt:ctpp_id="50124441000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>620.00</Subsidy>
                  <Price>620.00</Price>
                  <Alternate>620.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130139962726" S29="true">
                <Name>e5 Pharma</Name>
                <Pack ID="P2635674" Specified="true" OP="true" nzmt:ctpp_id="50301881000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>620.00</Subsidy>
                  <Price>620.00</Price>
                  <Alternate>620.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011303">
          <Name>Insulin - Short-acting Preparations</Name>
          <Chemical ID="C0113031648" Statim="May">
            <Name>Insulin neutral</Name>
            <Formulation ID="F011303164801" Rank="3" Units="ml" Weight="100">
              <Name>Inj human 100 u per ml</Name>
              <Brand ID="B01130316480101">
                <Name>Actrapid</Name>
                <Pack ID="P797103" Specified="true" OP="true" nzmt:ctpp_id="50116661000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>25.26</Subsidy>
                  <Price>25.26</Price>
                  <Alternate>25.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130316480102">
                <Name>Humulin R</Name>
                <Pack ID="P518913" Specified="true" OP="true" nzmt:ctpp_id="50093801000117109">
                  <Quantity>10</Quantity>
                  <Subsidy>25.26</Subsidy>
                  <Price>25.26</Price>
                  <Alternate>25.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011303164803" Rank="4" Units="inj" Weight="300">
              <Name>Inj human 100 u per ml, 3 ml</Name>
              <Brand ID="B01130316480301">
                <Name>Actrapid Penfill</Name>
                <Pack ID="P797138" Specified="true" nzmt:ctpp_id="50116681000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.66</Subsidy>
                  <Price>42.66</Price>
                  <Alternate>42.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130316480302">
                <Name>Humulin R</Name>
                <Pack ID="P282790" Specified="true" nzmt:ctpp_id="50063031000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.66</Subsidy>
                  <Price>42.66</Price>
                  <Alternate>42.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011305">
          <Name>Insulin - Intermediate-acting Preparations</Name>
          <Chemical ID="C0113051649" Statim="May">
            <Name>Insulin isophane</Name>
            <Formulation ID="F011305164903" Rank="4" Units="inj" Weight="300">
              <Name>Inj human 100 u per ml, 3 ml</Name>
              <Brand ID="B01130516490301">
                <Name>Protaphane Penfill</Name>
                <Pack ID="P797162" Specified="true" nzmt:ctpp_id="50116711000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>29.86</Subsidy>
                  <Price>29.86</Price>
                  <Alternate>29.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130516490325">
                <Name>Humulin NPH</Name>
                <Pack ID="P2207931" Specified="true" nzmt:ctpp_id="50033071000117102">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>29.86</Subsidy>
                  <Price>29.86</Price>
                  <Alternate>29.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011305164904" Rank="3" Units="ml">
              <Name>Inj human 100 u per ml</Name>
              <Brand ID="B01130516490402">
                <Name>Protaphane</Name>
                <Pack ID="P797146" Specified="true" OP="true" nzmt:ctpp_id="50116691000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>17.68</Subsidy>
                  <Price>17.68</Price>
                  <Alternate>17.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130516490425">
                <Name>Humulin NPH</Name>
                <Pack ID="P2207923" Specified="true" OP="true" nzmt:ctpp_id="50033061000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>17.68</Subsidy>
                  <Price>17.68</Price>
                  <Alternate>17.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113053882">
            <Name>Insulin lispro with insulin lispro protamine</Name>
            <Formulation ID="F011305388225" Rank="4" Units="inj" Statim="May">
              <Name>Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml</Name>
              <Brand ID="B01130538822525">
                <Name>Humalog Mix 25</Name>
                <Pack ID="P2011050" Specified="true" nzmt:ctpp_id="50001291000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.66</Subsidy>
                  <Price>42.66</Price>
                  <Alternate>42.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011305388226" Rank="4" Units="inj" Statim="May">
              <Name>Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml</Name>
              <Brand ID="B01130538822625">
                <Name>Humalog Mix 50</Name>
                <Pack ID="P2235854" Specified="true" nzmt:ctpp_id="50037571000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.66</Subsidy>
                  <Price>42.66</Price>
                  <Alternate>42.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113053982" Statim="May">
            <Name>Insulin aspart with insulin aspart protamine</Name>
            <Formulation ID="F011305398227" Rank="4" Units="inj">
              <Name>Inj 100 iu per ml, 3 ml prefilled pen</Name>
              <Brand ID="B01130539822725">
                <Name>NovoMix 30 FlexPen</Name>
                <Pack ID="P2404303" Specified="true" nzmt:ctpp_id="50134921000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>52.15</Subsidy>
                  <Price>52.15</Price>
                  <Alternate>52.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113056300" Statim="May">
            <Name>Insulin isophane with insulin neutral</Name>
            <Formulation ID="F011305630002" Rank="4" Units="inj" Weight="300">
              <Name>Inj human with neutral insulin 100 u per ml, 3 ml</Name>
              <Brand ID="B01130563000203">
                <Name>PenMix 30</Name>
                <Pack ID="P785733" Specified="true" nzmt:ctpp_id="50114161000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.66</Subsidy>
                  <Price>42.66</Price>
                  <Alternate>42.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130563000205">
                <Name>PenMix 50</Name>
                <Pack ID="P785768" Specified="true" nzmt:ctpp_id="50114181000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.66</Subsidy>
                  <Price>42.66</Price>
                  <Alternate>42.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130563000225">
                <Name>Humulin 30/70</Name>
                <Pack ID="P2207915" Specified="true" nzmt:ctpp_id="50033051000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.66</Subsidy>
                  <Price>42.66</Price>
                  <Alternate>42.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011305630003" Rank="3" Units="ml" Weight="100">
              <Name>Inj human with neutral insulin 100 u per ml</Name>
              <Brand ID="B01130563000307">
                <Name>Mixtard 30</Name>
                <Pack ID="P797189" Specified="true" OP="true" nzmt:ctpp_id="50116731000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>25.26</Subsidy>
                  <Price>25.26</Price>
                  <Alternate>25.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01130563000325">
                <Name>Humulin 30/70</Name>
                <Pack ID="P2207907" Specified="true" OP="true" nzmt:ctpp_id="50033041000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>25.26</Subsidy>
                  <Price>25.26</Price>
                  <Alternate>25.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011307">
          <Name>Insulin - Long-acting Preparations</Name>
          <Chemical ID="C0113073857" Statim="May">
            <Name>Insulin glargine</Name>
            <Formulation ID="F011307385725" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 u per ml, 3 ml</Name>
              <Brand ID="B01130738572525">
                <Name>Lantus</Name>
                <Pack ID="P2146754" Specified="true" nzmt:ctpp_id="50025291000117108">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>94.50</Subsidy>
                  <Price>94.50</Price>
                  <Alternate>94.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011307385726" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 u per ml, 10 ml</Name>
              <Brand ID="B01130738572625">
                <Name>Lantus</Name>
                <Pack ID="P2146746" Specified="true" nzmt:ctpp_id="50025281000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>63.00</Subsidy>
                  <Price>63.00</Price>
                  <Alternate>63.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011307385727" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 u per ml, 3 ml disposable pen</Name>
              <Brand ID="B01130738572725">
                <Name>Lantus SoloStar</Name>
                <Pack ID="P2275406" Specified="true" nzmt:ctpp_id="50043201000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>94.50</Subsidy>
                  <Price>94.50</Price>
                  <Alternate>94.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011309">
          <Name>Insulin - Rapid Acting Preparations</Name>
          <Chemical ID="C0113091192" Statim="May">
            <Name>Insulin lispro</Name>
            <Formulation ID="F011309119201" Rank="4" Units="inj" Weight="300">
              <Name>Inj 100 u per ml, 3 ml</Name>
              <Brand ID="B01130911920101">
                <Name>Humalog</Name>
                <Pack ID="P490865" Specified="true" nzmt:ctpp_id="50091781000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>59.52</Subsidy>
                  <Price>59.52</Price>
                  <Alternate>59.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011309119202" Rank="3" Units="ml">
              <Name>Inj 100 u per ml, 10 ml</Name>
              <Brand ID="B01130911920201">
                <Name>Humalog</Name>
                <Pack ID="P490857" Specified="true" OP="true" nzmt:ctpp_id="50091771000117106">
                  <Quantity>10</Quantity>
                  <Subsidy>34.92</Subsidy>
                  <Price>34.92</Price>
                  <Alternate>34.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113093783" Statim="May">
            <Name>Insulin aspart</Name>
            <Formulation ID="F011309378325" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 u per ml, 3 ml</Name>
              <Brand ID="B01130937832525">
                <Name>NovoRapid Penfill</Name>
                <Pack ID="P2105098" Specified="true" nzmt:ctpp_id="50018891000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>51.19</Subsidy>
                  <Price>51.19</Price>
                  <Alternate>51.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011309378326" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 u per ml, 10 ml</Name>
              <Brand ID="B01130937832625">
                <Name>NovoRapid</Name>
                <Pack ID="P2105101" Specified="true" nzmt:ctpp_id="50018901000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>30.03</Subsidy>
                  <Price>30.03</Price>
                  <Alternate>30.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011309378327" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 u per ml, 3 ml syringe</Name>
              <Brand ID="B01130937832725">
                <Name>NovoRapid FlexPen</Name>
                <Pack ID="P2469952" Specified="true" nzmt:ctpp_id="50216791000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>51.19</Subsidy>
                  <Price>51.19</Price>
                  <Alternate>51.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113093908" Statim="May">
            <Name>Insulin glulisine</Name>
            <Formulation ID="F011309390825" Rank="4" Units="inj">
              <Name>Inj 100 u per ml, 10 ml</Name>
              <Brand ID="B01130939082525">
                <Name>Apidra</Name>
                <Pack ID="P2317109" Specified="true" nzmt:ctpp_id="50048271000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>27.03</Subsidy>
                  <Price>27.03</Price>
                  <Alternate>27.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011309390826" Rank="4" Units="inj">
              <Name>Inj 100 u per ml, 3 ml disposable pen</Name>
              <Brand ID="B01130939082625">
                <Name>Apidra SoloStar</Name>
                <Pack ID="P2316870" Specified="true" nzmt:ctpp_id="50048231000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>46.07</Subsidy>
                  <Price>46.07</Price>
                  <Alternate>46.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011309390827" Rank="4" Units="inj">
              <Name>Inj 100 u per ml, 3 ml</Name>
              <Brand ID="B01130939082725">
                <Name>Apidra</Name>
                <Pack ID="P2361620" Specified="true" nzmt:ctpp_id="50000341000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>46.07</Subsidy>
                  <Price>46.07</Price>
                  <Alternate>46.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011311">
          <Name>Alpha Glucosidase Inhibitors</Name>
          <Chemical ID="C0113111247" Statim="Must">
            <Name>Acarbose</Name>
            <Formulation ID="F011311124701" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B01131112470125" PSS="2024-06-30">
                <Name>Accarb</Name>
                <Pack ID="P2402408" Specified="true" nzmt:ctpp_id="50145021000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>8.95</Subsidy>
                  <Price>8.95</Price>
                  <Alternate>8.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011311124702" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B01131112470225" PSS="2024-06-30">
                <Name>Accarb</Name>
                <Pack ID="P2402416" Specified="true" nzmt:ctpp_id="50145031000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>15.29</Subsidy>
                  <Price>15.29</Price>
                  <Alternate>15.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011312">
          <Name>Oral Hypoglycaemic Agents</Name>
          <Chemical ID="C0113121567" Statim="Must">
            <Name>Glibenclamide</Name>
            <Formulation ID="F011312156702" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B01131215670202" PSS="2024-06-30">
                <Name>Daonil</Name>
                <Pack ID="P203106" Specified="true" nzmt:ctpp_id="50005871000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>7.50</Subsidy>
                  <Price>7.50</Price>
                  <Alternate>7.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113121568" Statim="Must">
            <Name>Gliclazide</Name>
            <Formulation ID="F011312156801" Rank="1" Units="tab" Weight="80">
              <Name>Tab 80 mg</Name>
              <Brand ID="B01131215680127" PSS="2026-06-30">
                <Name>Glizide</Name>
                <Pack ID="P2280647" Specified="true" nzmt:ctpp_id="50209001000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>20.10</Subsidy>
                  <Price>20.10</Price>
                  <Alternate>20.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113121569" Statim="Must">
            <Name>Glipizide</Name>
            <Formulation ID="F011312156901" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B01131215690102" PSS="2024-06-30">
                <Name>Minidiab</Name>
                <Pack ID="P2091755" Specified="true" nzmt:ctpp_id="50017481000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>4.58</Subsidy>
                  <Price>4.58</Price>
                  <Alternate>4.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113121794" Statim="Must">
            <Name>Metformin hydrochloride</Name>
            <Formulation ID="F011312179401" Rank="1" Units="tab" Weight="500">
              <Name>Tab immediate-release 500 mg</Name>
              <Brand ID="B01131217940129" SoleSupply="2027-06-30">
                <Name>Metformin Viatris</Name>
                <Pack ID="P2628031" Specified="true" nzmt:ctpp_id="50291171000117103">
                  <Quantity>1000</Quantity>
                  <Subsidy>14.74</Subsidy>
                  <Price>14.74</Price>
                  <Alternate>14.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011312179402" Rank="1" Units="tab" Weight="850">
              <Name>Tab immediate-release 850 mg</Name>
              <Brand ID="B01131217940229" PSS="2027-06-30">
                <Name>Metformin Viatris</Name>
                <Pack ID="P2628058" Specified="true" nzmt:ctpp_id="50291341000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>11.28</Subsidy>
                  <Price>11.28</Price>
                  <Alternate>11.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113123800" Statim="Must">
            <Name>Pioglitazone</Name>
            <Formulation ID="F011312380025" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B01131238002527" PSS="2024-06-30">
                <Name>Vexazone</Name>
                <Pack ID="P2479435" Specified="true" nzmt:ctpp_id="50224121000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>6.80</Subsidy>
                  <Price>6.80</Price>
                  <Alternate>6.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011312380026" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Brand ID="B01131238002627" PSS="2024-06-30">
                <Name>Vexazone</Name>
                <Pack ID="P2479443" Specified="true" nzmt:ctpp_id="50224131000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>7.30</Subsidy>
                  <Price>7.30</Price>
                  <Alternate>7.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011312380027" Rank="1" Units="tab" Weight="45">
              <Name>Tab 45 mg</Name>
              <Brand ID="B01131238002727" PSS="2024-06-30">
                <Name>Vexazone</Name>
                <Pack ID="P2479451" Specified="true" nzmt:ctpp_id="50224141000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>12.25</Subsidy>
                  <Price>12.25</Price>
                  <Alternate>12.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113124103">
            <Name>Vildagliptin</Name>
            <Formulation ID="F011312410325" Rank="1" Units="tab">
              <Name>Tab 50 mg</Name>
              <Brand ID="B01131241032525">
                <Name>Galvus</Name>
                <Pack ID="P2455161" Specified="true" nzmt:ctpp_id="50201901000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>35.00</Subsidy>
                  <Price>35.00</Price>
                  <Alternate>35.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113124104">
            <Name>Vildagliptin with metformin hydrochloride</Name>
            <Formulation ID="F011312410425" Rank="1" Units="tab">
              <Name>Tab 50 mg with 850 mg metformin hydrochloride</Name>
              <Brand ID="B01131241042525">
                <Name>Galvumet</Name>
                <Pack ID="P2554801" Specified="true" nzmt:ctpp_id="50258071000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>35.00</Subsidy>
                  <Price>35.00</Price>
                  <Alternate>35.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011312410426" Rank="1" Units="tab">
              <Name>Tab 50 mg with 1,000 mg metformin hydrochloride</Name>
              <Brand ID="B01131241042625">
                <Name>Galvumet</Name>
                <Pack ID="P2554828" Specified="true" nzmt:ctpp_id="50258011000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>35.00</Subsidy>
                  <Price>35.00</Price>
                  <Alternate>35.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011315">
          <Name>GLP-1 Agonists</Name>
          <Chemical ID="C0113154149">
            <Name>Dulaglutide</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2284"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2284">
              <Title>
                <range>Dulaglutide</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has type 2 diabetes</ci>
                    <ci type="logical" class="Indication">Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of ALL of the following funded blood glucose lowering agents
                    for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin (see note a)*</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is MÄori or any Pacific ethnicity*</ci>
                      <ci type="logical" class="Indication">Patient has pre-existing cardiovascular disease or risk equivalent (see note b)*</ci>
                      <ci type="logical" class="Indication">Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment
                        calculator*</ci>
                      <ci type="logical" class="Indication">Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*</ci>
                      <ci type="logical" class="Indication">Patient has diabetic kidney disease (see note c)*</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>* Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.</p>
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>Due to the ongoing supply issues with GLP-1 agonists, we strongly urge all prescribers to consider initiating patients on other hypoglycaemic agents, provided they are not
                        contraindicated. Please also consider discontinuing GLP-1 agonist treatment where the patient is not receiving clinically meaningful benefit. </p>
                    </li>
                    <li>
                      <p>Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention,
                        coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.</p>
                    </li>
                    <li>
                      <p>Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month
                        period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause.</p>
                    </li>
                  </ol>
                </div>
              </Case>
            </Request>
            <Formulation ID="F011315414925" Rank="4" Units="inj">
              <Name>Inj 1.5mg per 0.5 ml prefilled pen</Name>
              <Brand ID="B01131541492525">
                <Name>Trulicity</Name>
                <Pack ID="P2617722" Specified="true" nzmt:ctpp_id="50278501000117100">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>115.23</Subsidy>
                  <Price>115.23</Price>
                  <Alternate>115.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113154173">
            <Name>Liraglutide</Name>
            <Rule Type="FormMax" Value="9" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: lower-alpha">
                <li>
                  <p>Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist.</p>
                </li>
                <li>
                  <p>Maximum of 1 pack of 3 (6 mg per ml, 3 ml) prefilled pens will be funded per month.</p>
                </li>
              </ol>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2285"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2285">
              <Title>
                <range>Liraglutide</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has type 2 diabetes</ci>
                    <ci type="logical" class="Indication">Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of ALL of the following funded blood glucose lowering agents
                    for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin (see note a)*</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is MÄori or any Pacific ethnicity*</ci>
                      <ci type="logical" class="Indication">Patient has pre-existing cardiovascular disease or risk equivalent (see note b)*</ci>
                      <ci type="logical" class="Indication">Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment
                        calculator*</ci>
                      <ci type="logical" class="Indication">Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*</ci>
                      <ci type="logical" class="Indication">Patient has diabetic kidney disease (see note c)*</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>* Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.</p>
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>Due to the ongoing supply issues with GLP-1 agonists, we strongly urge you to consider initiating patients on other hypoglycaemic agents, provided they are not contraindicated.
                        Please also consider discontinuing GLP-1 agonist treatment where the patient is not receiving clinically meaningful benefit.</p>
                    </li>
                    <li>
                      <p>Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention,
                        coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.</p>
                    </li>
                    <li>
                      <p>Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month
                        period) and/or eGFR less than 60 mL/min/1.73mÂ² in the presence of diabetes, without alternative cause.</p>
                    </li>
                  </ol>
                </div>
              </Case>
            </Request>
            <Formulation ID="F011315417325" Rank="4" Units="inj">
              <Name>Inj 6 mg per ml, 3 ml prefilled pen</Name>
              <Brand ID="B01131541732525">
                <Name>Victoza</Name>
                <Pack ID="P2653990" Specified="true" nzmt:ctpp_id="50245461000117105">
                  <Quantity>3</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>383.72</Subsidy>
                  <Price>383.72</Price>
                  <Alternate>383.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011318">
          <Name>SGLT2 Inhibitors</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA2068">
            <Title>
              <range>Empagliflozin</range>
              <range>Empagliflozin with metformin hydrochloride</range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Patient has previously received an initial
                    approval for a GLP-1 agonist</ci>
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has type 2 diabetes</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is MÄori or any Pacific
                            ethnicity*</ci>
                      <ci type="logical" class="Indication">Patient has pre-existing
                            cardiovascular disease or risk equivalent (see note a)*</ci>
                      <ci type="logical" class="Indication">Patient has an absolute 5-year
                            cardiovascular disease risk of 15% or greater according to a validated
                            cardiovascular risk assessment calculator*</ci>
                      <ci type="logical" class="Indication">Patient has a high lifetime
                            cardiovascular risk due to being diagnosed with type 2 diabetes during
                            childhood or as a young adult*</ci>
                      <ci type="logical" class="Indication">Patient has diabetic kidney disease
                            (see note b)*</ci>
                    </apply>
                    <ci type="logical" class="Indication">Target HbA1c (of 53 mmol/mol or less) has
                        not been achieved despite the regular use of at least one blood-glucose
                        lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3
                        months</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="patient's lifetime"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>* Criteria intended to describe patients at high risk of cardiovascular or renal
                complications of diabetes.</p>
                <ol style="list-style-type: lower-alpha">
                  <li>
                    <p>Pre-existing cardiovascular disease or risk equivalent defined as: prior
                        cardiovascular disease event (i.e. angina, myocardial infarction,
                        percutaneous coronary intervention, coronary artery bypass grafting,
                        transient ischaemic attack, ischaemic stroke, peripheral vascular disease),
                        congestive heart failure or familial hypercholesterolaemia.</p>
                  </li>
                  <li>
                    <p>Diabetic kidney disease defined as: persistent albuminuria
                        (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least
                        two out of three samples over a 3-6 month period) and/or eGFR less than 60
                        mL/min/1.73m2 in the presence of diabetes, without alternative cause.</p>
                  </li>
                </ol>
              </div>
            </Case>
          </Request>
          <Chemical ID="C0113184137" Statim="Must">
            <Name>Empagliflozin</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Not to be given in combination with a funded GLP-1 agonist.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2068"/>
            <Formulation ID="F011318413725" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B01131841372525">
                <Name>Jardiance</Name>
                <Pack ID="P2599694" Specified="true" nzmt:ctpp_id="50205351000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>58.56</Subsidy>
                  <Price>58.56</Price>
                  <Alternate>58.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011318413726" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B01131841372625">
                <Name>Jardiance</Name>
                <Pack ID="P2599708" Specified="true" nzmt:ctpp_id="50205371000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>58.56</Subsidy>
                  <Price>58.56</Price>
                  <Alternate>58.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0113184138" Statim="Must">
            <Name>Empagliflozin with metformin hydrochloride</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Not to be given in combination with a funded GLP-1 agonist.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2068"/>
            <Formulation ID="F011318413825" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg with 500 mg metformin hydrochloride</Name>
              <Brand ID="B01131841382525">
                <Name>Jardiamet</Name>
                <Pack ID="P2599716" Specified="true" nzmt:ctpp_id="50225021000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>58.56</Subsidy>
                  <Price>58.56</Price>
                  <Alternate>58.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011318413826" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg with 1,000 mg metformin hydrochloride</Name>
              <Brand ID="B01131841382625">
                <Name>Jardiamet</Name>
                <Pack ID="P2599724" Specified="true" nzmt:ctpp_id="50225041000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>58.56</Subsidy>
                  <Price>58.56</Price>
                  <Alternate>58.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011318413827" Rank="1" Units="tab" Weight="12.5">
              <Name>Tab 12.5 mg with 500 mg metformin hydrochloride</Name>
              <Brand ID="B01131841382725">
                <Name>Jardiamet</Name>
                <Pack ID="P2599732" Specified="true" nzmt:ctpp_id="50225051000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>58.56</Subsidy>
                  <Price>58.56</Price>
                  <Alternate>58.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011318413828" Rank="1" Units="tab" Weight="12.5">
              <Name>Tab 12.5 mg with 1,000 mg metformin hydrochloride</Name>
              <Brand ID="B01131841382825">
                <Name>Jardiamet</Name>
                <Pack ID="P2599740" Specified="true" nzmt:ctpp_id="50225071000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>58.56</Subsidy>
                  <Price>58.56</Price>
                  <Alternate>58.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0115">
        <Name>Diabetes Management</Name>
        <ATC3 ID="A011504">
          <Name>Ketone Testing</Name>
          <Chemical ID="C0115044090">
            <Name>Blood Ketone Diagnostic Test Strip</Name>
            <Rule Type="FormBan" Attribute="BSO"/>
            <Rule Type="FormMax" Value="20" Attribute="Rx"/>
            <Rule Type="FormMax" Value="10" Attribute="PSO"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Patient has any of the following:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>type 1 diabetes; or</p>
                </li>
                <li>
                  <p>permanent neonatal diabetes; or</p>
                </li>
                <li>
                  <p>undergone a pancreatectomy; or</p>
                </li>
                <li>
                  <p>cystic fibrosis-related diabetes; or</p>
                </li>
                <li>
                  <p>metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.</p>
                </li>
              </ol>
              <p>The prescription must be endorsed accordingly.</p>
            </div>
            <Formulation ID="F011504409025" Rank="10" Units="strip">
              <Name>Test strips</Name>
              <Brand ID="B01150440902525">
                <Name>KetoSens</Name>
                <Pack ID="P2535432" Specified="true" OP="true" nzmt:ctpp_id="50250981000117104">
                  <Quantity>10</Quantity>
                  <Subsidy>15.50</Subsidy>
                  <Price>15.50</Price>
                  <Alternate>15.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011505">
          <Name>Dual Blood Glucose and Blood Ketone Testing</Name>
          <Chemical ID="C0115054091">
            <Name>Dual blood glucose and blood ketone diagnostic test meter</Name>
            <Rule Type="FormMax" Value="1" Attribute="Rx"/>
            <Rule Type="FormMax" Value="1" Attribute="PSO"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>A dual blood glucose and blood ketone diagnostic test meter is subsidised for a patient who has:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>type 1 diabetes; or</p>
                </li>
                <li>
                  <p>permanent neonatal diabetes; or</p>
                </li>
                <li>
                  <p>undergone a pancreatectomy; or</p>
                </li>
                <li>
                  <p>cystic fibrosis-related diabetes; or</p>
                </li>
                <li>
                  <p>metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.</p>
                </li>
              </ol>
              <p>The prescription must be endorsed accordingly.</p>
              <p>Only 1 meter per patient will be subsidised (no repeat prescriptions).</p>
              <p>For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter. </p>
            </div>
            <Formulation ID="F011505409125" Rank="10" Units="pack">
              <Name>Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips</Name>
              <Brand ID="B01150540912525">
                <Name>CareSens Dual</Name>
                <Pack ID="P2535408" Specified="true" OP="true" nzmt:ctpp_id="50250991000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>20.00</Subsidy>
                  <Price>20.00</Price>
                  <Alternate>20.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011507">
          <Name>Blood Glucose Testing</Name>
          <Chemical ID="C0115073802">
            <Name>Blood glucose diagnostic test strip</Name>
            <Rule Type="FormMax" Value="50" Attribute="PSO"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>The number of test strips available on a prescription is restricted to 50 unless:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or</p>
                </li>
                <li>
                  <p>Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or</p>
                </li>
                <li>
                  <p>Prescribed for a pregnant woman with diabetes  and endorsed accordingly; or </p>
                </li>
                <li>
                  <p>Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or</p>
                </li>
                <li>
                  <p>Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F011507380225" Rank="10" Units="test">
              <Name>Test strips</Name>
              <Brand ID="B01150738022532">
                <Name>CareSens N</Name>
                <Pack ID="P2403153" Specified="true" OP="true" nzmt:ctpp_id="50143491000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>10.56</Subsidy>
                  <Price>10.56</Price>
                  <Alternate>10.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01150738022533">
                <Name>CareSens PRO</Name>
                <Pack ID="P2535424" Specified="true" OP="true" nzmt:ctpp_id="50250971000117102">
                  <Quantity>50</Quantity>
                  <Subsidy>10.56</Subsidy>
                  <Price>10.56</Price>
                  <Alternate>10.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115073807">
            <Name>Blood glucose diagnostic test meter</Name>
            <Rule Type="FormMax" Value="1" Attribute="Rx"/>
            <Rule Type="FormMax" Value="1" Attribute="PSO"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>A diagnostic blood glucose test meter is subsidised for a patient who:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>is receiving insulin or sulphonylurea therapy; or</p>
                </li>
                <li>
                  <p>is pregnant with diabetes; or</p>
                </li>
                <li>
                  <p>is on home TPN at risk of hypoglycaemia or hyperglycaemia; or</p>
                </li>
                <li>
                  <p>has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or
                    type 2 diabetes and metabolic syndrome.</p>
                </li>
              </ol>
              <p>The prescription must be endorsed accordingly.</p>
              <p>Only one CareSens meter per patient will be subsidised (no repeat prescriptions).</p>
              <p>Patients already using the CareSens N POP meter and CareSens N meter are not eligible for a new meter, unless they have:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>type 1 diabetes; or</p>
                </li>
                <li>
                  <p>permanent neonatal diabetes; or</p>
                </li>
                <li>
                  <p>undergone a pancreatectomy; or</p>
                </li>
                <li>
                  <p>cystic fibrosis-related diabetes.</p>
                </li>
              </ol>
              <p>For the avoidance of doubt patients who have previously received a funded meter, other than
            CareSens, are eligible for a funded CareSens meter.</p>
            </div>
            <Formulation ID="F011507380726" Rank="10" Units="pack">
              <Name>Meter with 50 lancets, a lancing device and 10 diagnostic test strips</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Note: Only 1 meter available per PSO</p>
              </div>
              <Brand ID="B01150738072625">
                <Name>CareSens N</Name>
                <Pack ID="P2403137" Specified="true" OP="true" nzmt:ctpp_id="50143391000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>10.00</Subsidy>
                  <Price>10.00</Price>
                  <Alternate>10.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01150738072626">
                <Name>CareSens N POP</Name>
                <Pack ID="P2403145" Specified="true" OP="true" nzmt:ctpp_id="50143401000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>10.00</Subsidy>
                  <Price>10.00</Price>
                  <Alternate>10.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01150738072628">
                <Name>CareSens N Premier</Name>
                <Pack ID="P2535416" Specified="true" OP="true" nzmt:ctpp_id="50250961000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>20.00</Subsidy>
                  <Price>20.00</Price>
                  <Alternate>20.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115073809" Update="+Subsidy">
            <Name>Blood glucose test strips (visually impaired)</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>The number of test strips available on a prescription is restricted to 50 unless:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or</p>
                </li>
                <li>
                  <p>Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or</p>
                </li>
                <li>
                  <p>Prescribed for a pregnant woman with diabetes  and endorsed accordingly; or </p>
                </li>
                <li>
                  <p>Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or</p>
                </li>
                <li>
                  <p>Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F011507380925" Rank="10" Units="test">
              <Name>Blood glucose test strips</Name>
              <Brand ID="B01150738092529">
                <Name>SensoCard</Name>
                <Pack ID="P2328410" Specified="true" OP="true" nzmt:ctpp_id="50049301000117109">
                  <Quantity>50</Quantity>
                  <Subsidy>31.20</Subsidy>
                  <Price>31.20</Price>
                  <Alternate>31.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011509">
          <Name>Insulin Syringes and Needles</Name>
          <Rule Type="SubRxF"/>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
            <p>Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on
    the same form as the one used for the supply of insulin or liraglutide or when prescribed for a
    patient and the prescription is endorsed accordingly. Pharmacists may annotate the prescription
    as endorsed where there exists a record of prior dispensing of insulin or liraglutide.</p>
          </div>
          <Chemical ID="C0115091110" Statim="Must">
            <Name>Insulin pen needles</Name>
            <Rule Type="FormMax" Value="200" Attribute="Rx"/>
            <Formulation ID="F011509111001" Rank="10" Units="dev" Weight="1">
              <Name>29 g x 12.7 mm</Name>
              <Brand ID="B01150911100101">
                <Name>B-D Micro-Fine</Name>
                <Pack ID="P2354837" Specified="true" nzmt:ctpp_id="50121241000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>10.95</Subsidy>
                  <Price>10.95</Price>
                  <Alternate>10.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509111002" Rank="10" Units="dev" Weight="1">
              <Name>31 g x 8 mm</Name>
              <Brand ID="B01150911100201">
                <Name>B-D Micro-Fine</Name>
                <Pack ID="P2181835" Specified="true" nzmt:ctpp_id="50029811000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>10.95</Subsidy>
                  <Price>10.95</Price>
                  <Alternate>10.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509111025" Rank="10" Units="dev" Weight="1">
              <Name>31 g x 5 mm</Name>
              <Brand ID="B01150911102525">
                <Name>B-D Micro-Fine</Name>
                <Pack ID="P433802" Specified="true" nzmt:ctpp_id="50085151000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>12.26</Subsidy>
                  <Price>12.26</Price>
                  <Alternate>12.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509111026" Rank="10" Units="dev" Weight="1">
              <Name>31 g x 6 mm</Name>
              <Brand ID="B01150911102626">
                <Name>Berpu</Name>
                <Pack ID="P2275384" Specified="true" nzmt:ctpp_id="50265591000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>9.50</Subsidy>
                  <Price>9.50</Price>
                  <Alternate>9.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509111027" Rank="10" Units="dev" Weight="1">
              <Name>32 g x 4 mm</Name>
              <Brand ID="B01150911102725">
                <Name>B-D Micro-Fine</Name>
                <Pack ID="P2375737" Specified="true" nzmt:ctpp_id="50120861000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>10.95</Subsidy>
                  <Price>10.95</Price>
                  <Alternate>10.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115096307" Statim="Must">
            <Name>Insulin syringes, disposable with attached needle</Name>
            <Rule Type="FormMax" Value="200" Attribute="Rx"/>
            <Formulation ID="F011509630702" Rank="10" Units="dev" Weight="3.29">
              <Name>Syringe 0.3 ml with 29 g x 12.7 mm needle</Name>
              <Brand ID="B01150963070201">
                <Name>B-D Ultra Fine</Name>
                <Pack ID="P788236" Specified="true" nzmt:ctpp_id="50114841000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>13.56</Subsidy>
                  <Price>13.56</Price>
                  <Alternate>13.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P799939" Specified="true" nzmt:ctpp_id="50117431000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>1.36</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.36</Alternate>
                  <Surcharge>0.06300</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509630704" Rank="10" Units="dev" Weight="5.29">
              <Name>Syringe 0.5 ml with 29 g x 12.7 mm needle</Name>
              <Brand ID="B01150963070401">
                <Name>B-D Ultra Fine</Name>
                <Pack ID="P788228" Specified="true" nzmt:ctpp_id="50114831000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>13.56</Subsidy>
                  <Price>13.56</Price>
                  <Alternate>13.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P799947" Specified="true" nzmt:ctpp_id="50117441000117105">
                  <Quantity>10</Quantity>
                  <Subsidy>1.36</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.36</Alternate>
                  <Surcharge>0.06300</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509630706" Rank="10" Units="dev" Weight="10.29">
              <Name>Syringe 1 ml with 29 g x 12.7 mm needle</Name>
              <Brand ID="B01150963070601">
                <Name>B-D Ultra Fine</Name>
                <Pack ID="P788244" Specified="true" nzmt:ctpp_id="50114851000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>13.56</Subsidy>
                  <Price>13.56</Price>
                  <Alternate>13.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P799955" Specified="true" nzmt:ctpp_id="50117451000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>1.36</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.36</Alternate>
                  <Surcharge>0.06300</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509630725" Rank="10" Units="dev" Weight="3.31">
              <Name>Syringe 0.3 ml with 31 g x 8 mm needle</Name>
              <Brand ID="B01150963072525">
                <Name>B-D Ultra Fine II</Name>
                <Pack ID="P2224216" Specified="true" nzmt:ctpp_id="50035631000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>13.56</Subsidy>
                  <Price>13.56</Price>
                  <Alternate>13.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2224348" Specified="true" nzmt:ctpp_id="50035671000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>1.30</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.30</Alternate>
                  <Surcharge>0.06900</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509630726" Rank="10" Units="dev" Weight="5.31">
              <Name>Syringe 0.5 ml with 31 g x 8 mm needle</Name>
              <Brand ID="B01150963072625">
                <Name>B-D Ultra Fine II</Name>
                <Pack ID="P2224208" Specified="true" nzmt:ctpp_id="50035621000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>13.56</Subsidy>
                  <Price>13.56</Price>
                  <Alternate>13.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2224321" Specified="true" nzmt:ctpp_id="50035661000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>1.36</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.36</Alternate>
                  <Surcharge>0.06300</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011509630727" Rank="10" Units="dev" Weight="10.31">
              <Name>Syringe 1 ml with 31 g x 8 mm needle</Name>
              <Brand ID="B01150963072725">
                <Name>B-D Ultra Fine II</Name>
                <Pack ID="P2224224" Specified="true" nzmt:ctpp_id="50035641000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>13.56</Subsidy>
                  <Price>13.56</Price>
                  <Alternate>13.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2224356" Specified="true" nzmt:ctpp_id="50035681000117105">
                  <Quantity>10</Quantity>
                  <Subsidy>1.36</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.36</Alternate>
                  <Surcharge>0.06300</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011512">
          <Name>Insulin Pumps</Name>
          <Chemical ID="C0115123968">
            <Name>Insulin pump</Name>
            <Rule Type="FormMax" Value="1" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 1 insulin pump per patient each four year period.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1603"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1603">
              <Title>
                <range>Insulin Pumps</range>
              </Title>
              <Case When="Initial application" Category="permanent neonatal diabetes">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has permanent neonatal diabetes</ci>
                    <ci type="logical" class="Indication">A MDI regimen trial is inappropriate</ci>
                    <ci type="logical" class="Indication">Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy</ci>
                    <ci type="logical" class="Indication">Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional)</ci>
                    <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
              <Case When="Renewal" Category="permanent neonatal diabetes" Form="SA1237 SA1603">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is continuing to derive benefit according to the treatment plan agreed at induction</ci>
                    <ci type="logical" class="Indication">Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician</ci>
                    <ci type="logical" class="Indication">It has been at least 4 years since the last insulin pump received by the patient or, in the case of patients qualifying under previous pump therapy for the initial application; the pump is due for replacement</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
              <Case When="Initial application" Category="severe unexplained hypoglycaemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes</ci>
                    <ci type="logical" class="Indication">Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional)</ci>
                    <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care</ci>
                    <ci type="logical" class="Indication">Has adhered to an intensive MDI regimen using analogue insulins for at least six months</ci>
                    <ci type="logical" class="Indication">Has had four severe unexplained hypoglycaemic episodes over a six month  period (severe as defined as requiring the assistance of another person)</ci>
                    <ci type="logical" class="Indication">Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol</ci>
                    <ci type="logical" class="Indication">Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
              <Case When="Renewal" Category="severe unexplained hypoglycaemia" Form="SA1237 SA1603">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events</ci>
                    <ci type="logical" class="Indication">HbA1c has not increased by more than 5 mmol/mol from baseline</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">It has been at least 4 years since the last insulin pump was received by the patient</ci>
                      <ci type="logical" class="Indication">The pump is due for replacement</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
              <Case When="Initial application" Category="HbA1c">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes</ci>
                    <ci type="logical" class="Indication">Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional)</ci>
                    <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care</ci>
                    <ci type="logical" class="Indication">Has adhered to an intensive MDI regimen using analogue insulins for at least six months</ci>
                    <ci type="logical" class="Indication">Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1</ci>
                    <ci type="logical" class="Indication">In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment</ci>
                    <ci type="logical" class="Indication">Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol</ci>
                    <ci type="logical" class="Indication">Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
              <Case When="Renewal" Category="HbA1c" Form="SA1237 SA1603">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol</ci>
                    <ci type="logical" class="Indication">The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">It has been at least 4 years since the last insulin pump was received by the patient</ci>
                      <ci type="logical" class="Indication">The pump is due for replacement</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
              <Case When="Initial application" Category="Previous use before 1 September 2012">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes</ci>
                    <ci type="logical" class="Indication">Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment</ci>
                    <ci type="logical" class="Indication">The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy</ci>
                    <ci type="logical" class="Indication">The patient is continuing to derive benefit from pump therapy</ci>
                    <ci type="logical" class="Indication">The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy</ci>
                    <ci type="logical" class="Indication">The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline</ci>
                    <ci type="logical" class="Indication">The patientâ€™s HbA1c has not deteriorated more than 5 mmol/mol from baseline</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">It has been at least 4 years since the last insulin pump was received by the patient</ci>
                      <ci type="logical" class="Indication">The pump is due for replacement</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
              <Case When="Renewal" Category="Previous use before 1 September 2012" Form="SA1603">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol</ci>
                    <ci type="logical" class="Indication">The patientâ€™s HbA1c has not deteriorated more than 5 mmol/mol from the time of commencing pump treatment</ci>
                    <ci type="logical" class="Indication">The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">It has been at least 4 years since the last insulin pump was received by the patient</ci>
                      <ci type="logical" class="Indication">The pump is due for replacement</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                      <ci type="logical" class="Indication">Applicant is a nurse practitioner working within their vocational scope</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>nurse practitioner</Applicant>
                <Term Measure="month">3</Term>
                <Lapse Measure="year">6</Lapse>
              </Case>
            </Request>
            <Formulation ID="F011512396840" Rank="10" Units="dev">
              <Name>Min basal rate 0.1 U/h</Name>
              <Brand ID="B01151239684026">
                <Name>Tandem t:slim X2 with Basal-IQ</Name>
                <Pack ID="P2598345" Specified="true" nzmt:ctpp_id="50280881000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>4500.00</Subsidy>
                  <Price>4500.00</Price>
                  <Alternate>4500.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011512396841" Rank="10" Units="dev">
              <Name>Min basal rate 0.025 U/h</Name>
              <Brand ID="B01151239684126">
                <Name>MiniMed 770G</Name>
                <Pack ID="P2619628" Specified="true" nzmt:ctpp_id="50291261000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>8800.00</Subsidy>
                  <Price>8800.00</Price>
                  <Alternate>8800.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A011515">
          <Name>Insulin Pump Consumables</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA1985">
            <Title>
              <range>Insulin Pump Consumables</range>
            </Title>
            <Case When="Initial application" Category="permanent neonatal diabetes">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient has permanent neonatal diabetes</ci>
                  <ci type="logical" class="Indication">A MDI regimen trial is inappropriate</ci>
                  <ci type="logical" class="Indication">Has been evaluated by the multidisciplinary
                    team for their suitability for insulin pump therapy</ci>
                  <ci type="logical" class="Indication">Patient/Parent/Guardian has undertaken
                    carbohydrate counting education (either a carbohydrate counting course or direct
                    education from an appropriate health professional)</ci>
                  <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team
                    experienced in the management of type 1 diabetes care</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="month">9</Term>
            </Case>
            <Case When="Renewal" Category="permanent neonatal diabetes" Form="SA1240 SA1604 SA1906 SA1985">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient is continuing to derive benefit
                    according to the treatment plan agreed at induction</ci>
                  <ci type="logical" class="Indication">Patient remains fully compliant and transition
                    to MDI is considered inappropriate by the treating physician</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Initial application" Category="severe unexplained hypoglycaemia">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient has type 1 diabetes or has undergone a
                    pancreatectomy or has cystic fibrosis-related diabetes</ci>
                  <ci type="logical" class="Indication">Has undertaken carbohydrate counting education
                    (either a carbohydrate counting course or direct education from an appropriate
                    health professional)</ci>
                  <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team
                    experienced in the management of type 1 diabetes care</ci>
                  <ci type="logical" class="Indication">Has adhered to an intensive MDI regimen using
                    analogue insulins for at least six months</ci>
                  <ci type="logical" class="Indication">Has had four severe unexplained hypoglycaemic
                    episodes over a six month period (severe as defined as requiring the assistance
                    of another person)</ci>
                  <ci type="logical" class="Indication">Has an average HbA1c between the following
                    range: equal to or greater than 53 mmol/mol and equal to or less than 90
                    mmol/mol</ci>
                  <ci type="logical" class="Indication">Has been evaluated by the multidisciplinary
                    team for their suitability for insulin pump therapy</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="month">9</Term>
            </Case>
            <Case When="Renewal" Category="severe unexplained hypoglycaemia" Form="SA1240 SA1604 SA1906 SA1985">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient is continuing to derive benefit
                    according to the treatment plan agreed at induction of at least a 50% reduction
                    from baseline in hypoglycaemic events</ci>
                  <ci type="logical" class="Indication">HbA1c has not increased by more than 5
                    mmol/mol from baseline</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Initial application" Category="HbA1c">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient has type 1 diabetes or has undergone a
                    pancreatectomy or has cystic fibrosis-related diabetes</ci>
                  <ci type="logical" class="Indication">Has undertaken carbohydrate counting education
                    (either a carbohydrate counting course or direct education from an appropriate
                    health professional)</ci>
                  <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team
                    experienced in the management of type 1 diabetes care</ci>
                  <ci type="logical" class="Indication">Has adhered to an intensive MDI regimen using
                    analogue insulins for at least six months</ci>
                  <ci type="logical" class="Indication">Has unpredictable and significant variability
                    in blood glucose including significant hypoglycaemia affecting the ability to
                    reduce HbA1</ci>
                  <ci type="logical" class="Indication">In the opinion of the treating clinician,
                    HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment</ci>
                  <ci type="logical" class="Indication">Has typical HbA1c results between the
                    following range: equal to or greater than 65 mmol/mol and equal to or less than
                    90 mmol/mol</ci>
                  <ci type="logical" class="Indication">Has been evaluated by the multidisciplinary
                    team for their suitability for insulin pump therapy</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="month">9</Term>
            </Case>
            <Case When="Renewal" Category="HbA1c" Form="SA1240 SA1604 SA1906 SA1985">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient is continuing to derive benefit
                    according to the treatment plan agreed at induction of achieving and maintaining
                    a reduction in HbA1c from baseline of 10 mmol/mol</ci>
                  <ci type="logical" class="Indication">The number of severe unexplained recurrent
                    hypoglycaemic episodes has not increased from baseline</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Initial application" Category="Previous use before 1 September 2012">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient has type 1 diabetes or has undergone a
                    pancreatectomy or has cystic fibrosis-related diabetes</ci>
                  <ci type="logical" class="Indication">Was already on pump treatment prior to 1
                    September 2012 and had been evaluated by the multidisciplinary team for their
                    suitability for insulin pump therapy at the time of initiating that pump
                    treatment and continues to benefit from pump treatment</ci>
                  <ci type="logical" class="Indication">The patient has adhered to an intensive MDI
                    regimen using analogue insulins for at least six months prior to initiating pump
                    therapy</ci>
                  <ci type="logical" class="Indication">The patient is continuing to derive benefit
                    from pump therapy</ci>
                  <ci type="logical" class="Indication">The patient had achieved and is maintaining a
                    HbA1c of equal to or less than 80 mmol/mol on pump therapy</ci>
                  <ci type="logical" class="Indication">The patient has had no increase in severe
                    unexplained hypoglycaemic episodes from baseline</ci>
                  <ci type="logical" class="Indication">The patientâ€™s HbA1c has not deteriorated more
                    than 5 mmol/mol from baseline</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Renewal" Category="Previous use before 1 September 2012" Form="SA1604 SA1906 SA1985">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The patient is continuing to derive benefit
                    according to the treatment plan and has maintained a HbA1c of equal to or less
                    than 80 mmol/mol</ci>
                  <ci type="logical" class="Indication">The patientâ€™s HbA1c has not deteriorated
                    more than 5 mmol/mol from initial application</ci>
                  <ci type="logical" class="Indication">The patient has not had an increase in
                    severe unexplained hypoglycaemic episodes from baseline</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Applicant is a relevant specialist</ci>
                    <ci type="logical" class="Indication">Applicant is a nurse practitioner working
                        within their vocational scope</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Applicant>nurse practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
          </Request>
          <Chemical ID="C0115153969">
            <Name>Insulin pump infusion set (steel cannula)</Name>
            <Rule Type="FormMax" Value="3" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 13 infusion sets will be funded per year.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1985"/>
            <Formulation ID="F011515396940" Rank="10" Units="set">
              <Name>6 mm steel needle; 60 cm tubing x 10</Name>
              <Brand ID="B01151539694025">
                <Name>MiniMed Sure-T MMT-864A</Name>
                <Pack ID="P2591685" Specified="true" OP="true" nzmt:ctpp_id="50277841000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515396941" Rank="10" Units="set">
              <Name>6 mm steel needle; 80 cm tubing x 10</Name>
              <Brand ID="B01151539694125">
                <Name>MiniMed Sure-T MMT-866A</Name>
                <Pack ID="P2591693" Specified="true" OP="true" nzmt:ctpp_id="50277851000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515396942" Rank="10" Units="set">
              <Name>8 mm steel needle; 60 cm tubing x 10</Name>
              <Brand ID="B01151539694225">
                <Name>MiniMed Sure-T MMT-874A</Name>
                <Pack ID="P2591707" Specified="true" OP="true" nzmt:ctpp_id="50277861000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515396943" Rank="10" Units="set">
              <Name>8 mm steel needle; 80 cm tubing x 10</Name>
              <Brand ID="B01151539694325">
                <Name>MiniMed Sure-T MMT-876A</Name>
                <Pack ID="P2591715" Specified="true" OP="true" nzmt:ctpp_id="50277911000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515396944" Rank="10" Units="set">
              <Name>10 mm steel needle; 60 cm tubing x 10</Name>
              <Brand ID="B01151539694425" ToBeDelisted="2024-07-01">
                <Name>MiniMed Sure-T MMT-884A</Name>
                <Pack ID="P2591723" Specified="true" OP="true" nzmt:ctpp_id="50277921000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515396945" Rank="10" Units="set">
              <Name>10 mm steel needle; 80 cm tubing x 10</Name>
              <Brand ID="B01151539694525" ToBeDelisted="2024-07-01">
                <Name>MiniMed Sure-T MMT-886A</Name>
                <Pack ID="P2591731" Specified="true" OP="true" nzmt:ctpp_id="50277931000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115153970">
            <Name>Insulin pump reservoir</Name>
            <Rule Type="FormMax" Value="3" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 13 packs of reservoir sets will be funded per year.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1985"/>
            <Formulation ID="F011515397026" Rank="10" Units="sets">
              <Name>10 x luer lock conversion cartridges 1.8 ml for Paradigm pumps</Name>
              <Brand ID="B01151539702625">
                <Name>ADR Cartridge 1.8</Name>
                <Pack ID="P2423065" Specified="true" OP="true" nzmt:ctpp_id="50143371000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>50.00</Subsidy>
                  <Price>50.00</Price>
                  <Alternate>50.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515397030" Rank="10" Units="sets">
              <Name>Cartridge for 7 series pump; 3.0 ml x 10</Name>
              <Brand ID="B01151539703025">
                <Name>MiniMed 3.0 Reservoir MMT-332A</Name>
                <Pack ID="P2430371" Specified="true" OP="true" nzmt:ctpp_id="50285071000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>50.00</Subsidy>
                  <Price>50.00</Price>
                  <Alternate>50.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115153984">
            <Name>Insulin pump infusion set (teflon cannula, straight insertion with insertion device)</Name>
            <Rule Type="FormMax" Value="3" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 13 infusion sets will be funded per year.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1985"/>
            <Formulation ID="F011515398447" Rank="10" Units="sets" Weight="6">
              <Name>6 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151539844725">
                <Name>AutoSoft 90</Name>
                <Pack ID="P2556804" Specified="true" OP="true" nzmt:ctpp_id="50259171000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>140.00</Subsidy>
                  <Price>140.00</Price>
                  <Alternate>140.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515398448" Rank="10" Units="sets" Weight="6">
              <Name>6 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151539844825">
                <Name>AutoSoft 90</Name>
                <Pack ID="P2556812" Specified="true" OP="true" nzmt:ctpp_id="50259181000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>140.00</Subsidy>
                  <Price>140.00</Price>
                  <Alternate>140.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515398449" Rank="10" Units="sets" Weight="9">
              <Name>9 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151539844925">
                <Name>AutoSoft 90</Name>
                <Pack ID="P2556820" Specified="true" OP="true" nzmt:ctpp_id="50259191000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>140.00</Subsidy>
                  <Price>140.00</Price>
                  <Alternate>140.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515398450" Rank="10" Units="sets" Weight="9">
              <Name>9 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151539845025">
                <Name>AutoSoft 90</Name>
                <Pack ID="P2556839" Specified="true" OP="true" nzmt:ctpp_id="50259201000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>140.00</Subsidy>
                  <Price>140.00</Price>
                  <Alternate>140.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115153986">
            <Name>Insulin pump infusion set (teflon cannula, angle insertion with insertion device)</Name>
            <Rule Type="FormMax" Value="3" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 13 infusion sets will be funded per year.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1985"/>
            <Formulation ID="F011515398643" Rank="10" Units="sets" Weight="13">
              <Name>13 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151539864325">
                <Name>AutoSoft 30</Name>
                <Pack ID="P2556847" Specified="true" OP="true" nzmt:ctpp_id="50259151000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>140.00</Subsidy>
                  <Price>140.00</Price>
                  <Alternate>140.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515398644" Rank="10" Units="sets" Weight="13">
              <Name>13 mm teflon cannula; angle insertion; insertion device; 110 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151539864425">
                <Name>AutoSoft 30</Name>
                <Pack ID="P2556855" Specified="true" OP="true" nzmt:ctpp_id="50259161000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>140.00</Subsidy>
                  <Price>140.00</Price>
                  <Alternate>140.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115154109">
            <Name>Insulin pump infusion set (steel cannula, straight insertion)</Name>
            <Rule Type="FormMax" Value="3" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 13 infusion sets will be funded per year.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1985"/>
            <Formulation ID="F011515410925" Rank="10" Units="sets" Weight="6">
              <Name>6 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151541092525">
                <Name>TruSteel</Name>
                <Pack ID="P2556863" Specified="true" OP="true" nzmt:ctpp_id="50259111000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515410927" Rank="10" Units="sets" Weight="8">
              <Name>8 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151541092725">
                <Name>TruSteel</Name>
                <Pack ID="P2556898" Specified="true" OP="true" nzmt:ctpp_id="50259131000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515410929" Rank="10" Units="set" Weight="6">
              <Name>6 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151541092925">
                <Name>TruSteel</Name>
                <Pack ID="P2616491" Specified="true" OP="true" nzmt:ctpp_id="50289201000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515410930" Rank="10" Units="set" Weight="8">
              <Name>8 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles</Name>
              <Brand ID="B01151541093025">
                <Name>TruSteel</Name>
                <Pack ID="P2612550" Specified="true" OP="true" nzmt:ctpp_id="50289211000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115154110">
            <Name>Insulin pump cartridge</Name>
            <Rule Type="FormMax" Value="3" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 13 packs of cartridge sets will be funded per year.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1985"/>
            <Formulation ID="F011515411025" Rank="10" Units="sets">
              <Name>Cartridge 300 U, t:lock x 10</Name>
              <Brand ID="B01151541102525">
                <Name>Tandem Cartridge</Name>
                <Pack ID="P2556790" Specified="true" OP="true" nzmt:ctpp_id="50259211000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>50.00</Subsidy>
                  <Price>50.00</Price>
                  <Alternate>50.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0115154128">
            <Name>Insulin pump infusion set (teflon cannula)</Name>
            <Rule Type="FormMax" Value="3" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of 13 infusion sets will be funded per year.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1985"/>
            <Formulation ID="F011515412825" Rank="10" Units="set">
              <Name>6 mm teflon needle, 45 cm pink tubing x 10</Name>
              <Brand ID="B01151541282525">
                <Name>MiniMed Mio MMT-921A</Name>
                <Pack ID="P2591758" Specified="true" OP="true" nzmt:ctpp_id="50277941000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412826" Rank="10" Units="set">
              <Name>6 mm teflon needle, 45 cm blue tubing x 10</Name>
              <Brand ID="B01151541282625">
                <Name>MiniMed Mio MMT-941A</Name>
                <Pack ID="P2591782" Specified="true" OP="true" nzmt:ctpp_id="50277971000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412827" Rank="10" Units="set">
              <Name>6 mm teflon needle, 60 cm pink tubing x 10</Name>
              <Brand ID="B01151541282725">
                <Name>MiniMed Mio MMT-923A</Name>
                <Pack ID="P2591766" Specified="true" OP="true" nzmt:ctpp_id="50277951000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412828" Rank="10" Units="set">
              <Name>6 mm teflon needle, 60 cm blue tubing x 10</Name>
              <Brand ID="B01151541282825">
                <Name>MiniMed Mio MMT-943A</Name>
                <Pack ID="P2591790" Specified="true" OP="true" nzmt:ctpp_id="50277981000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412829" Rank="10" Units="set">
              <Name>6 mm teflon needle, 60 cm tubing x 10</Name>
              <Brand ID="B01151541282925">
                <Name>MiniMed Quick-Set MMT-399A</Name>
                <Pack ID="P2591677" Specified="true" OP="true" nzmt:ctpp_id="50277831000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412830" Rank="10" Units="set">
              <Name>6 mm teflon needle, 80 cm pink tubing x 10</Name>
              <Brand ID="B01151541283025">
                <Name>MiniMed Mio MMT-925A</Name>
                <Pack ID="P2591774" Specified="true" OP="true" nzmt:ctpp_id="50277961000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412831" Rank="10" Units="set">
              <Name>6 mm teflon needle, 80 cm blue tubing</Name>
              <Brand ID="B01151541283125">
                <Name>MiniMed Mio MMT-945A</Name>
                <Pack ID="P2591804" Specified="true" OP="true" nzmt:ctpp_id="50277991000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412832" Rank="10" Units="set">
              <Name>6 mm teflon needle, 80 cm clear tubing x 10</Name>
              <Brand ID="B01151541283225">
                <Name>MiniMed Mio MMT-965A</Name>
                <Pack ID="P2591812" Specified="true" OP="true" nzmt:ctpp_id="50278001000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412833" Rank="10" Units="set">
              <Name>6 mm teflon needle, 80 cm tubing x 10</Name>
              <Brand ID="B01151541283325" ToBeDelisted="2024-07-01">
                <Name>MiniMed Quick-Set MMT-387A</Name>
                <Pack ID="P2591634" Specified="true" OP="true" nzmt:ctpp_id="50277791000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412834" Rank="10" Units="set">
              <Name>6 mm teflon needle, 110 cm tubing x 10</Name>
              <Brand ID="B01151541283425">
                <Name>MiniMed Quick-Set MMT-398A</Name>
                <Pack ID="P2591669" Specified="true" OP="true" nzmt:ctpp_id="50277821000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412835" Rank="10" Units="set">
              <Name>9 mm teflon needle, 60 cm tubing x 10</Name>
              <Brand ID="B01151541283525">
                <Name>MiniMed Quick-Set MMT-397A</Name>
                <Pack ID="P2591650" Specified="true" OP="true" nzmt:ctpp_id="50277811000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412836" Rank="10" Units="set">
              <Name>9 mm teflon needle, 80 cm clear tubing x 10</Name>
              <Brand ID="B01151541283625">
                <Name>MiniMed Mio MMT-975A</Name>
                <Pack ID="P2591820" Specified="true" OP="true" nzmt:ctpp_id="50278011000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412837" Rank="10" Units="set">
              <Name>9 mm teflon needle, 80 cm tubing x 10</Name>
              <Brand ID="B01151541283725" ToBeDelisted="2024-07-01">
                <Name>MiniMed Quick-Set MMT-386A</Name>
                <Pack ID="P2591626" Specified="true" OP="true" nzmt:ctpp_id="50277781000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412838" Rank="10" Units="set">
              <Name>9 mm teflon needle, 110 cm tubing x 10</Name>
              <Brand ID="B01151541283825">
                <Name>MiniMed Quick-Set MMT-396A</Name>
                <Pack ID="P2591642" Specified="true" OP="true" nzmt:ctpp_id="50277801000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412839" Rank="10" Units="set">
              <Name>13 mm teflon needle, 45 cm tubing x 10</Name>
              <Brand ID="B01151541283925" ToBeDelisted="2024-07-01">
                <Name>MiniMed Silhouette MMT-368A</Name>
                <Pack ID="P2591537" Specified="true" OP="true" nzmt:ctpp_id="50277701000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412840" Rank="10" Units="set">
              <Name>13 mm teflon needle, 60 cm tubing x 10</Name>
              <Brand ID="B01151541284025">
                <Name>MiniMed Silhouette MMT-381A</Name>
                <Pack ID="P2591561" Specified="true" OP="true" nzmt:ctpp_id="50277741000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412841" Rank="10" Units="set">
              <Name>13 mm teflon needle, 80 cm tubing x 10</Name>
              <Brand ID="B01151541284125" ToBeDelisted="2024-07-01">
                <Name>MiniMed Silhouette MMT-383A</Name>
                <Pack ID="P2591596" Specified="true" OP="true" nzmt:ctpp_id="50277761000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412842" Rank="10" Units="set">
              <Name>13 mm teflon needle, 110 cm tubing x 10</Name>
              <Brand ID="B01151541284225" ToBeDelisted="2024-07-01">
                <Name>MiniMed Silhouette MMT-382A</Name>
                <Pack ID="P2591588" Specified="true" OP="true" nzmt:ctpp_id="50277751000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412843" Rank="10" Units="set">
              <Name>17 mm teflon needle, 60 cm tubing x 10</Name>
              <Brand ID="B01151541284325">
                <Name>MiniMed Silhouette MMT-378A</Name>
                <Pack ID="P2591553" Specified="true" OP="true" nzmt:ctpp_id="50277731000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412844" Rank="10" Units="set">
              <Name>17 mm teflon needle, 80 cm tubing x 10</Name>
              <Brand ID="B01151541284425" ToBeDelisted="2024-07-01">
                <Name>MiniMed Silhouette MMT-384A</Name>
                <Pack ID="P2591618" Specified="true" OP="true" nzmt:ctpp_id="50277771000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F011515412845" Rank="10" Units="set">
              <Name>17 mm teflon needle, 110 cm tubing x 10</Name>
              <Brand ID="B01151541284525">
                <Name>MiniMed Silhouette MMT-377A</Name>
                <Pack ID="P2591545" Specified="true" OP="true" nzmt:ctpp_id="50277721000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0122">
        <Name>Digestives Including Enzymes</Name>
        <ATC3 ID="A012201">
          <Name>Digestives Including Enzymes</Name>
          <Chemical ID="C0122011126">
            <Name>Ursodeoxycholic acid</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1739"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1739">
              <Title>
                <range>Ursodeoxycholic Acid</range>
              </Title>
              <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci>
                    <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci>
                    <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
                    <ci type="logical" class="Indication">Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="Primary biliary cholangitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) &gt; 1:80, and raised cholestatic liver enzymes with or without
                    raised serum IgM or, if AMA is negative, by liver biopsy</ci>
                    <ci type="logical" class="Indication">Patient not requiring a liver transplant (bilirubin &gt; 100 umol/l; decompensated cirrhosis)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Pregnancy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient diagnosed with cholestasis of pregnancy</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Haematological Transplant">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone
                    marrow transplantation</ci>
                    <ci type="logical" class="Indication">Treatment for up to 13 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Total parenteral nutrition induced cholestasis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition
                    (TPN)</ci>
                    <ci type="logical" class="Indication">Liver function has not improved with modifying the TPN composition</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Chronic severe drug induced cholestatic liver injury" Form="SA0458 SA0841 SA0914 SA1003 SA1188 SA1383 SA1739">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient continues to benefit from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Pregnancy/Primary biliary cholangitis" Form="SA0458 SA0841 SA0914 SA1003 SA1188 SA1383 SA1739">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Renewal" Category="Total parenteral nutrition induced cholestasis" Form="SA0458 SA0841 SA0914 SA1003 SA1188 SA1383 SA1739">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F012201112625" Rank="2" Units="cap">
              <Name>Cap 250 mg</Name>
              <Brand ID="B01220111262525" PSS="2026-06-30">
                <Name>Ursosan</Name>
                <Pack ID="P2397528" Specified="true" nzmt:ctpp_id="50128171000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>33.95</Subsidy>
                  <Price>33.95</Price>
                  <Alternate>33.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0122011925">
            <Name>Pancreatic enzyme</Name>
            <Formulation ID="F012201192513" Rank="2" Units="cap" Weight="25000">
              <Name>Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) </Name>
              <Brand ID="B01220119251325" PSS="2024-06-30">
                <Name>Creon 25000</Name>
                <Pack ID="P2535319" Specified="true" nzmt:ctpp_id="50195611000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>94.38</Subsidy>
                  <Price>94.38</Price>
                  <Alternate>94.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012201192525" Rank="2" Units="cap" Weight="10000">
              <Name>Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) </Name>
              <Brand ID="B01220119252525" PSS="2024-06-30">
                <Name>Creon 10000</Name>
                <Pack ID="P2535300" Specified="true" nzmt:ctpp_id="50119241000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>34.93</Subsidy>
                  <Price>34.93</Price>
                  <Alternate>34.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012201192526" Rank="3" Units="g">
              <Name>Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph Eur U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U)</Name>
              <Brand ID="B01220119252625">
                <Name>Creon Micro</Name>
                <Pack ID="P2577550" Specified="true" OP="true" nzmt:ctpp_id="50201531000117106">
                  <Quantity>20</Quantity>
                  <Subsidy>34.93</Subsidy>
                  <Price>34.93</Price>
                  <Alternate>34.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0125">
        <Name>Laxatives</Name>
        <ATC3 ID="A012501">
          <Name>Bulk-forming Agents</Name>
          <Chemical ID="C0125012452" Statim="Must">
            <Name>Ispaghula (psyllium) husk</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F012501245202" Rank="3" Units="g">
              <Name>Powder for oral soln</Name>
              <Brand ID="B01250124520206" PSS="2026-06-30">
                <Name>Konsyl-D</Name>
                <Pack ID="P2358727" Specified="true" OP="true" nzmt:ctpp_id="50000351000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>20.00</Subsidy>
                  <Price>20.00</Price>
                  <Alternate>20.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A012504">
          <Name>Faecal Softeners</Name>
          <Chemical ID="C0125042429" Statim="Must">
            <Name>Docusate sodium</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F012504242901" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B01250424290101" PSS="2026-06-30">
                <Name>Coloxyl</Name>
                <Pack ID="P252832" Specified="true" nzmt:ctpp_id="50053561000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>3.20</Subsidy>
                  <Price>3.20</Price>
                  <Alternate>3.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012504242902" Rank="1" Units="tab" Weight="120">
              <Name>Tab 120 mg</Name>
              <Brand ID="B01250424290201" PSS="2026-06-30">
                <Name>Coloxyl</Name>
                <Pack ID="P252859" Specified="true" nzmt:ctpp_id="50053581000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>4.98</Subsidy>
                  <Price>4.98</Price>
                  <Alternate>4.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125042430" Statim="Must">
            <Name>Poloxamer</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Not funded for use in the ear.</p>
            </div>
            <Formulation ID="F012504243004" Rank="3" Units="ml">
              <Name>Oral drops 10%</Name>
              <Brand ID="B01250424300401" PSS="2026-06-30">
                <Name>Coloxyl</Name>
                <Pack ID="P252816" Specified="true" OP="true" nzmt:ctpp_id="50053541000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>4.17</Subsidy>
                  <Price>4.17</Price>
                  <Alternate>4.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125046304">
            <Name>Docusate sodium with sennosides</Name>
            <Formulation ID="F012504630401" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg with sennosides 8 mg</Name>
              <Brand ID="B01250463040125" PSS="2025-06-30">
                <Name>Laxsol</Name>
                <Pack ID="P2069482" Specified="true" nzmt:ctpp_id="50011761000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>3.50</Subsidy>
                  <Price>3.50</Price>
                  <Alternate>3.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A012505">
          <Name>Opioid Receptor Antagonists - Peripheral</Name>
          <Chemical ID="C0125054089">
            <Name>Methylnaltrexone bromide</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1691"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1691">
              <Title>
                <range>Methylnaltrexone bromide</range>
              </Title>
              <Case When="Initial application" Category="Opioid induced constipation">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="indication">The patient is receiving palliative care</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">Oral and rectal treatments for opioid induced constipation are ineffective</ci>
                      <ci type="logical" class="Trial">Oral and rectal treatments for opioid induced constipation are unable to be tolerated</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F012505408925" Rank="4" Units="inj" Weight="7">
              <Name>Inj 12 mg per 0.6 ml vial</Name>
              <Brand ID="B01250540892525">
                <Name>Relistor</Name>
                <Pack ID="P2536196" Specified="true" nzmt:ctpp_id="50186941000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>36.00</Subsidy>
                  <Price>36.00</Price>
                  <Alternate>36.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2536218" Specified="true" nzmt:ctpp_id="50186961000117101">
                  <Quantity>7</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>246.00</Subsidy>
                  <Price>246.00</Price>
                  <Alternate>246.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A012507">
          <Name>Osmotic Laxatives</Name>
          <Chemical ID="C0125071574" Statim="Must">
            <Name>Glycerol</Name>
            <Formulation ID="F012507157404" Rank="5" Units="supp">
              <Name>Suppos 2.8/4.0 g</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B01250715740402" PSS="2025-06-30">
                <Name>Lax-suppositories Glycerol</Name>
                <Pack ID="P2637103" Specified="true" nzmt:ctpp_id="50278581000117107">
                  <Quantity>20</Quantity>
                  <Subsidy>10.39</Subsidy>
                  <Price>10.39</Price>
                  <Alternate>10.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125072140">
            <Name>Sodium citrate with sodium lauryl sulphoacetate</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F012507214001" Rank="5" Units="en" Weight="450">
              <Name>Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml</Name>
              <Brand ID="B01250721400125" PSS="2025-06-30">
                <Name>Micolette</Name>
                <Pack ID="P2262673" Specified="true" nzmt:ctpp_id="50041551000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>35.89</Subsidy>
                  <Price>35.89</Price>
                  <Alternate>35.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01250721400126" S29="true">
                <Name>Micolette-S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2643367" Specified="true" nzmt:ctpp_id="50305011000117100">
                  <Quantity>50</Quantity>
                  <Subsidy>35.89</Subsidy>
                  <Price>35.89</Price>
                  <Alternate>35.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125072447" Statim="Must">
            <Name>Lactulose</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F012507244701" Rank="3" Units="ml">
              <Name>Oral liq 10 g per 15 ml</Name>
              <Brand ID="B01250724470102" PSS="2025-06-30">
                <Name>Laevolac</Name>
                <Pack ID="P2440210" Specified="true" nzmt:ctpp_id="50074861000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>3.61</Subsidy>
                  <Price>3.61</Price>
                  <Alternate>3.61</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125072462">
            <Name>Sodium acid phosphate</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F012507246202" Rank="5" Units="en" Weight="16">
              <Name>Enema 16% with sodium phosphate 8%</Name>
              <Brand ID="B01250724620202">
                <Name>Fleet Phosphate Enema</Name>
                <Pack ID="P267430" Specified="true" nzmt:ctpp_id="50059401000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>2.50</Subsidy>
                  <Price>2.50</Price>
                  <Alternate>2.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125073874">
            <Name>Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride</Name>
            <Formulation ID="F012507387425" Rank="2" Units="sach">
              <Name>Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg</Name>
              <Brand ID="B01250738742527" PSS="2026-06-30">
                <Name>Molaxole</Name>
                <Pack ID="P2519887" Specified="true" nzmt:ctpp_id="50192031000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>8.50</Subsidy>
                  <Price>8.50</Price>
                  <Alternate>8.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A012510">
          <Name>Stimulant Laxatives</Name>
          <Chemical ID="C0125102461" Statim="Must">
            <Name>Senna</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F012510246101" Rank="1" Units="tab">
              <Name>Tab, standardised</Name>
              <Brand ID="B01251024610101">
                <Name>Senokot</Name>
                <Pack ID="P267201" Specified="true" nzmt:ctpp_id="50059341000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>2.17</Subsidy>
                  <Price>8.21</Price>
                  <Alternate>2.17</Alternate>
                  <Surcharge>0.06040</Surcharge>
                </Pack>
                <Pack ID="P474436" Specified="true" nzmt:ctpp_id="50089391000117108">
                  <Quantity>20</Quantity>
                  <Subsidy>0.43</Subsidy>
                  <Price>2.06</Price>
                  <Alternate>0.43</Alternate>
                  <Surcharge>0.08150</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125102482" Statim="Must">
            <Name>Bisacodyl</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F012510248201" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B01251024820128" PSS="2025-06-30">
                <Name>Bisacodyl Viatris</Name>
                <Pack ID="P2631881" Specified="true" nzmt:ctpp_id="50299011000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>5.80</Subsidy>
                  <Price>5.80</Price>
                  <Alternate>5.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012510248203" Rank="5" Units="supp" Weight="10">
              <Name>Suppos 10 mg</Name>
              <Brand ID="B01251024820326" PSS="2024-06-30">
                <Name>Lax-Suppositories</Name>
                <Pack ID="P2485397" Specified="true" nzmt:ctpp_id="50278251000117103">
                  <Quantity>10</Quantity>
                  <Subsidy>3.69</Subsidy>
                  <Price>3.69</Price>
                  <Alternate>3.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0125104146">
            <Name>Sodium picosulfate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2053"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2053">
              <Title>
                <range>Sodium picosulfate</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient is a child with problematic
                    constipation despite an adequate trial of other oral pharmacotherapies including
                    macrogol where practicable</ci>
                    <ci type="logical" class="Indication">The patient would otherwise require a
                    high-volume bowel cleansing preparation or hospital admission</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2053">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F012510414625" Rank="3" Units="ml">
              <Name>Oral soln 7.5 mg per ml</Name>
              <Brand ID="B01251041462525">
                <Name>Dulcolax SP Drop</Name>
                <Pack ID="P2555611" Specified="true" OP="true" nzmt:ctpp_id="50225981000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>7.40</Subsidy>
                  <Price>7.40</Price>
                  <Alternate>7.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0128">
        <Name>Metabolic Disorder Agents</Name>
        <ATC3 ID="A012801">
          <Name>Metabolic Disorder Agents</Name>
          <Chemical ID="C0128014061">
            <Name>Galsulfase</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1988"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1988">
              <Title>
                <range>Galsulfase</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has been diagnosed with mucopolysaccharidosis VI</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency by either enzyme activity assay in leukocytes or skin fibroblasts</ci>
                      <ci type="logical" class="Indication">Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1593 SA1922 SA1988">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate for the patient and the patient is benefiting from treatment</ci>
                    <ci type="logical" class="Indication">Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates</ci>
                    <ci type="logical" class="Indication">Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT)</ci>
                    <ci type="logical" class="Indication">Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F012801406125" Rank="4" Units="inj" Weight="5">
              <Name>Inj 1 mg per ml, 5 ml vial</Name>
              <Brand ID="B01280140612525">
                <Name>Naglazyme</Name>
                <Pack ID="P2498715" Specified="true" nzmt:ctpp_id="50221641000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2234.00</Subsidy>
                  <Price>2234.00</Price>
                  <Alternate>2234.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014065">
            <Name>Sodium phenylbutyrate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1990"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1990">
              <Title>
                <range>Sodium phenylbutyrate</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient has a diagnosis of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1598 SA1924 SA1990">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F012801406525" Rank="3" Units="g">
              <Name>Grans 483 mg per g</Name>
              <Brand ID="B01280140652525">
                <Name>Pheburane</Name>
                <Pack ID="P2503484" Specified="true" OP="true" nzmt:ctpp_id="50223681000117100">
                  <Quantity>174</Quantity>
                  <Subsidy>2016.00</Subsidy>
                  <Price>2016.00</Price>
                  <Alternate>2016.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014066">
            <Name>Sodium benzoate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1599"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1599">
              <Title>
                <range>Sodium benzoate</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient has a diagnosis of a urea cycle disorder</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1599">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F012801406625" Rank="3" Units="ml">
              <Name>Soln 100 mg per ml</Name>
              <Brand ID="B01280140662525" S29="true">
                <Name>Amzoate</Name>
                <Pack ID="P2243628" Specified="true" CBS="true" nzmt:ctpp_id="50038561000117106">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014075">
            <Name>Alglucosidase alfa</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1986"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1986">
              <Title>
                <range>Alglucosidase Alfa</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient is aged up to 24 months at the
                    time of initial application and has been diagnosed with infantile Pompe
                    disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Diagnosis confirmed by documented
                        deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic
                        villus biopsies and/or cultured amniotic cells</ci>
                      <ci type="logical" class="Indication">Documented deficiency of acid
                        alpha-glucosidase, and urinary tetrasaccharide testing indicating a
                        diagnostic elevation of glucose tetrasaccharides</ci>
                      <ci type="logical" class="Indication">Documented deficiency of acid
                        alpha-glucosidase, and documented molecular genetic testing indicating a
                        disease-causing mutation in the acid alpha-glucosidase gene (GAA gene)</ci>
                      <ci type="logical" class="Indication">Documented urinary tetrasaccharide testing
                        indicating a diagnostic elevation of glucose tetrasaccharides, and molecular
                        genetic testing indicating a disease-causing mutation in the GAA gene</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has not required long-term invasive
                    ventilation for respiratory failure prior to starting enzyme replacement therapy
                    (ERT)</ci>
                    <ci type="logical" class="Indication">Patient does not have another life-threatening
                    or severe disease where the prognosis is unlikely to be influenced by ERT or
                    might be reasonably expected to compromise a response to ERT</ci>
                    <ci type="logical" class="Indication">Alglucosidase alfa to be administered at doses
                    no greater than 20 mg/kg every 2 weeks</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1622 SA1920 SA1986">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate for the
                    patient and the patient is benefiting from treatment</ci>
                    <ci type="logical" class="Indication">Alglucosidase alfa to be administered at doses
                    no greater than 20 mg/kg every 2 weeks</ci>
                    <ci type="logical" class="Indication">Patient has not had severe infusion-related
                    adverse reactions which were not preventable by appropriate pre-medication
                    and/or adjustment of infusion rates</ci>
                    <ci type="logical" class="Indication">Patient has not developed another life
                    threatening or severe disease where the long term prognosis is unlikely to be
                    influenced by ERT</ci>
                    <ci type="logical" class="Indication">Patient has not developed another medical
                    condition that might reasonably be expected to compromise a response to ERT</ci>
                    <ci type="logical" class="Indication">There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for &gt;14 days of invasive ventilation</ci>
                    <ci type="logical" class="Indication">There is no evidence of new or progressive cardiomyopathy</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F012801407525" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg vial</Name>
              <Brand ID="B01280140752525">
                <Name>Myozyme</Name>
                <Pack ID="P2500701" Specified="true" nzmt:ctpp_id="50187701000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1142.60</Subsidy>
                  <Price>1142.60</Price>
                  <Alternate>1142.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014076">
            <Name>Idursulfase</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1623"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1623">
              <Title>
                <range>Idursulfase</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts</ci>
                      <ci type="logical" class="Indication">Detection of a disease causing mutation in the iduronate 2-sulfatase gene</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant</ci>
                    <ci type="logical" class="Indication">Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT)</ci>
                    <ci type="logical" class="Indication">Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="week">24</Term>
              </Case>
            </Request>
            <Formulation ID="F012801407625" Rank="4" Units="inj" Weight="6">
              <Name>Inj 2 mg per ml, 3 ml vial</Name>
              <Brand ID="B01280140762525">
                <Name>Elaprase</Name>
                <Pack ID="P2336359" Specified="true" nzmt:ctpp_id="50181251000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4608.30</Subsidy>
                  <Price>4608.30</Price>
                  <Alternate>4608.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014092">
            <Name>Laronidase</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1695"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1695">
              <Title>
                <range>Laronidase</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has been diagnosed with Hurler Syndrome (mucopolysacchardosis I-H)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin
                        fibroblasts</ci>
                      <ci type="logical" class="Indication">Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be
                    bridging treatment to transplant</ci>
                    <ci type="logical" class="Indication">Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT)</ci>
                    <ci type="logical" class="Indication">Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every
                    week</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="week">24</Term>
              </Case>
            </Request>
            <Formulation ID="F012801409225" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 U per ml, 5 ml vial</Name>
              <Brand ID="B01280140922525">
                <Name>Aldurazyme</Name>
                <Pack ID="P2398362" Specified="true" nzmt:ctpp_id="50234481000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1335.16</Subsidy>
                  <Price>1335.16</Price>
                  <Alternate>1335.16</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014099">
            <Name>Betaine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1987"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1987">
              <Title>
                <range>Betaine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a confirmed diagnosis of homocystinuria</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">A cystathionine beta-synthase (CBS) deficiency</ci>
                      <ci type="logical" class="Indication">A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency</ci>
                      <ci type="logical" class="Indication">A disorder of intracellular cobalamin metabolism</ci>
                    </apply>
                    <ci type="logical" class="Indication">An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1727 SA1921 SA1987">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F012801409925" Rank="3" Units="g">
              <Name>Powder for oral soln</Name>
              <Brand ID="B01280140992525">
                <Name>Cystadane</Name>
                <Pack ID="P2536587" Specified="true" OP="true" nzmt:ctpp_id="50119231000117105">
                  <Quantity>180</Quantity>
                  <Subsidy>575.00</Subsidy>
                  <Price>575.00</Price>
                  <Alternate>575.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014111">
            <Name>Sapropterin dihydrochloride</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1989"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1989">
              <Title>
                <range>Sapropterin dihydrochloride</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant</ci>
                    <ci type="logical" class="Indication">Treatment with sapropterin is required to support management of PKU during pregnancy</ci>
                    <ci type="logical" class="Indication">Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg</ci>
                    <ci type="logical" class="Indication">Sapropterin to be used alone or in combination with PKU dietary management</ci>
                    <ci type="logical" class="Indication">Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Renewal" Form="SA1757 SA1923 SA1989">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy</ci>
                      <ci type="logical" class="Indication">On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient continues to be pregnant and treatment with sapropterin will not continue after delivery</ci>
                      <ci type="logical" class="Indication">Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin</ci>
                      <ci type="logical" class="Indication">Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy</ci>
                    </apply>
                    <ci type="logical" class="Indication">Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg</ci>
                    <ci type="logical" class="Indication">Sapropterin to be used alone or in combination with PKU dietary management</ci>
                    <ci type="logical" class="Indication">Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Applicant Referring="metabolic physician">any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <Lapse Measure="year">10</Lapse>
              </Case>
            </Request>
            <Formulation ID="F012801411125" Rank="1" Units="tab" Weight="100">
              <Name>Tab soluble 100 mg</Name>
              <Brand ID="B01280141112525">
                <Name>Kuvan</Name>
                <Pack ID="P2351676" Specified="true" OP="true" nzmt:ctpp_id="50123241000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>1452.70</Subsidy>
                  <Price>1452.70</Price>
                  <Alternate>1452.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014141">
            <Name>Coenzyme Q10</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2039"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2039">
              <Title>
                <range>Coenzyme Q10</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has a suspected inborn error of
                    metabolism that may respond to coenzyme Q10 supplementation</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2039">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a confirmed diagnosis of an inborn error of metabolism that responds to coenzyme Q10 supplementation</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F012801414125" Rank="2" Units="cap" Weight="120">
              <Name>Cap 120 mg</Name>
              <Brand ID="B01280141412525">
                <Name>Solgar</Name>
                <Pack ID="P2450364" Specified="true" CBS="true" nzmt:ctpp_id="50286221000117101">
                  <Quantity>30</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414126" Rank="2" Units="cap" Weight="160">
              <Name>Cap 160 mg</Name>
              <Brand ID="B01280141412625">
                <Name>Go Healthy</Name>
                <Pack ID="P2295253" Specified="true" CBS="true" nzmt:ctpp_id="50286951000117100">
                  <Quantity>60</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014142">
            <Name>Levocarnitine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2040"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2040">
              <Title>
                <range>Levocarnitine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has a suspected inborn error of metabolism that may respond to carnitine supplementation</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2040">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a confirmed diagnosis of an inborn error of metabolism that responds to carnitine supplementation</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F012801414225" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B01280141422525">
                <Name>Solgar</Name>
                <Pack ID="P2502151" Specified="true" CBS="true" nzmt:ctpp_id="50286961000117103">
                  <Quantity>30</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414226" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B01280141422625">
                <Name>Solgar</Name>
                <Pack ID="P2609274" Specified="true" CBS="true" nzmt:ctpp_id="50286911000117101">
                  <Quantity>30</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414227" Rank="2" Units="cap" Weight="500">
              <Name>Cap 500 mg</Name>
              <Brand ID="B01280141422725">
                <Name>Balance</Name>
                <Pack ID="P2609266" Specified="true" CBS="true" nzmt:ctpp_id="50286901000117104">
                  <Quantity>60</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414228" Rank="3" Units="ml" Weight="500">
              <Name>Oral liq 500 mg per 10 ml</Name>
              <Brand ID="B01280141422825">
                <Name>Balance</Name>
                <Pack ID="P2439816" Specified="true" CBS="true" nzmt:ctpp_id="50286971000117108">
                  <Quantity>300</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414229" Rank="3" Units="ml">
              <Name>Oral liq 1 g per 10 ml</Name>
              <Brand ID="B01280141422925" S29="true">
                <Name>Carnitor</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2569744" Specified="true" CBS="true" nzmt:ctpp_id="50303971000117105">
                  <Quantity>118</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B01280141422926" S29="true">
                <Name>Novitium Sugar Free</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2658216" Specified="true" CBS="true" nzmt:ctpp_id="50317411000117104">
                  <Quantity>118</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014143">
            <Name>Riboflavin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2041"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2041">
              <Title>
                <range>Riboflavin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Applicant>neurologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2041">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Applicant>neurologist</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F012801414325" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B01280141432525">
                <Name>Solgar</Name>
                <Pack ID="P2496402" Specified="true" CBS="true" nzmt:ctpp_id="50287011000117100">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414326" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B01280141432625">
                <Name>Country Life</Name>
                <Pack ID="P2211432" Specified="true" CBS="true" nzmt:ctpp_id="50286211000117107">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B01280141432626" S29="true">
                <Name>Puritan's Pride Vitamin B-2 100 mg</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2655977" Specified="true" CBS="true" nzmt:ctpp_id="50290571000117100">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014144">
            <Name>Arginine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2042"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2042">
              <Title>
                <range>Arginine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has a suspected inborn error of metabolism that may respond to arginine supplementation</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2042">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a confirmed diagnosis of an inborn error of metabolism that responds to arginine supplementation</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F012801414425" Rank="1" Units="tab" Weight="1000">
              <Name>Tab 1,000 mg</Name>
              <Brand ID="B01280141442525">
                <Name>Clinicians</Name>
                <Pack ID="P2400588" Specified="true" CBS="true" nzmt:ctpp_id="50286161000117100">
                  <Quantity>90</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414426" Rank="2" Units="cap" Weight="500">
              <Name>Cap 500 mg</Name>
              <Brand ID="B01280141442625">
                <Name>Solgar</Name>
                <Pack ID="P2609282" Specified="true" CBS="true" nzmt:ctpp_id="50286191000117106">
                  <Quantity>50</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414427" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B01280141442725">
                <Name>Biomed</Name>
                <Pack ID="P2393786" Specified="true" CBS="true" nzmt:ctpp_id="50145511000117106">
                  <Quantity>400</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0128014145">
            <Name>Taurine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2043"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2043">
              <Title>
                <range>Taurine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has a suspected specific mitochondrial disorder that may respond taurine supplementation</ci>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2043">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F012801414525" Rank="2" Units="cap" Weight="1000">
              <Name>Cap 1,000 mg</Name>
              <Brand ID="B01280141452525">
                <Name>Life Extension</Name>
                <Pack ID="P2609290" Specified="true" CBS="true" nzmt:ctpp_id="50286981000117106">
                  <Quantity>90</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414526" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B01280141452625">
                <Name>Life Extension</Name>
                <Pack ID="P2609304" Specified="true" CBS="true" nzmt:ctpp_id="50286201000117109">
                  <Quantity>300</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F012801414527" Rank="2" Units="cap">
              <Name>Cap 500 mg</Name>
              <Brand ID="B01280141452725">
                <Name>Solgar</Name>
                <Pack ID="P2557797" Specified="true" CBS="true" nzmt:ctpp_id="50290081000117105">
                  <Quantity>50</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A012802">
          <Name>Gaucher's Disease</Name>
          <Chemical ID="C0128024102">
            <Name>Taliglucerase alfa</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2137"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2137">
              <Title>
                <range>Taliglucerase alfa</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has a diagnosis of symptomatic type 1 or type 3*
                    Gaucher disease confirmed by the demonstration of specific deficiency of
                    glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic
                    analysis</ci>
                    <ci type="logical">Patient does not have another life-threatening or severe disease
                    where the prognosis is unlikely to be influenced by enzyme replacement therapy
                    (ERT) or the disease might be reasonably expected to compromise a response to
                    ERT</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has haematological complications of Gaucher
                        disease</ci>
                      <ci type="logical">Patient has skeletal complications of Gaucher disease</ci>
                      <ci type="logical">Patient has significant liver dysfunction or hepatomegaly
                        attributable to Gaucher disease</ci>
                      <ci type="logical">Patient has reduced vital capacity from clinically
                        significant or progressive pulmonary disease due to Gaucher disease</ci>
                      <ci type="logical">Patient is a child and has experienced growth failure with
                        significant decrease in percentile linear growth over a 6-12 month
                        period</ci>
                    </apply>
                    <ci type="logical">Taliglucerase alfa is to be administered at a dose no greater
                    than 30 unit/kg every other week rounded to the nearest whole vial (200
                    units)</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indication marked with * is an unapproved indication</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA2137">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started</ci>
                    <ci type="logical">Patient has demonstrated a clinically objective improvement or no
                    deterioration in haemoglobin levels, platelet counts and liver and spleen
                    size</ci>
                    <ci type="logical">Radiological (MRI) signs of bone activity performed at two years
                    since initiation of treatment, and five yearly thereafter, demonstrate no
                    deterioration shown by the MRI, compared with MRI taken immediately prior to
                    commencement of therapy or adjusted dose</ci>
                    <ci type="logical">Patient has not developed another medical condition that might
                    reasonably be expected to compromise a response to ERT</ci>
                    <ci type="logical">Patient is adherent with regular treatment and taliglucerase alfa
                    is to be administered at a dose no greater than 30 unit/kg every other week
                    rounded to the nearest whole vial (200 units)</ci>
                  </apply>
                </math>
                <Applicant>metabolic physician</Applicant>
                <Applicant Referring="metabolic physician">any relevant practitioner</Applicant>
                <Term Measure="year">3</Term>
              </Case>
            </Request>
            <Formulation ID="F012802410225" Rank="4" Units="inj">
              <Name>Inj 200 unit vial</Name>
              <Brand ID="B01280241022525">
                <Name>Elelyso</Name>
                <Pack ID="P2541106" Specified="true" nzmt:ctpp_id="50236221000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1072.00</Subsidy>
                  <Price>1072.00</Price>
                  <Alternate>1072.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0131">
        <Name>Mouth and Throat</Name>
        <ATC3 ID="A013101">
          <Name>Agents Used in Mouth Ulceration</Name>
          <Chemical ID="C0131011132">
            <Name>Benzydamine hydrochloride</Name>
            <Formulation ID="F013101113201" Rank="3" Units="ml">
              <Name>Soln 0.15%</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Additional subsidy by endorsement for a patient who has oral mucositis as a result of treatment for cancer, and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B01310111320101">
                <Name>Difflam</Name>
                <Pack ID="P538825" Specified="true" nzmt:ctpp_id="50095131000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>9.00</Subsidy>
                  <Price>21.73</Price>
                  <Alternate>21.73</Alternate>
                  <Surcharge>0.02546</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0131012133">
            <Name>Carmellose sodium with gelatin and pectin</Name>
            <Formulation ID="F013101213302" Rank="3" Units="g">
              <Name>Paste</Name>
              <Brand ID="B01310121330201">
                <Name>Orabase</Name>
                <Pack ID="P255599" Specified="true" OP="true" nzmt:ctpp_id="50055091000117101">
                  <Quantity>15</Quantity>
                  <Subsidy>4.55</Subsidy>
                  <Price>7.90</Price>
                  <Alternate>4.55</Alternate>
                  <Surcharge>0.22333</Surcharge>
                </Pack>
                <Pack ID="P765945" Specified="true" OP="true" nzmt:ctpp_id="50110591000117103">
                  <Quantity>5</Quantity>
                  <Subsidy>1.52</Subsidy>
                  <Price>3.60</Price>
                  <Alternate>1.52</Alternate>
                  <Surcharge>0.41600</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01310121330203">
                <Name>Stomahesive</Name>
                <Pack ID="P781398" Specified="true" OP="true" nzmt:ctpp_id="50113501000117100">
                  <Quantity>56</Quantity>
                  <Subsidy>17.20</Subsidy>
                  <Price>17.20</Price>
                  <Alternate>17.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013101213307" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B01310121330701">
                <Name>Stomahesive</Name>
                <Pack ID="P742570" Specified="true" OP="true" nzmt:ctpp_id="50107831000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>8.48</Subsidy>
                  <Price>10.95</Price>
                  <Alternate>8.48</Alternate>
                  <Surcharge>0.08821</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0131012389">
            <Name>Triamcinolone acetonide</Name>
            <Formulation ID="F013101238912" Rank="3" Units="g">
              <Name>Paste 0.1% </Name>
              <Brand ID="B01310123891225" PSS="2026-06-30">
                <Name>Kenalog in Orabase</Name>
                <Pack ID="P253790" Specified="true" OP="true" nzmt:ctpp_id="50054061000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>5.49</Subsidy>
                  <Price>5.49</Price>
                  <Alternate>5.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0131016014" Statim="Must">
            <Name>Choline salicylate with cetalkonium chloride</Name>
            <Formulation ID="F013101601401" Rank="3" Units="g">
              <Name>Adhesive gel 8.7% with cetalkonium chloride 0.01%</Name>
              <Brand ID="B01310160140101">
                <Name>Bonjela</Name>
                <Pack ID="P771473" Specified="true" OP="true" nzmt:ctpp_id="50111871000117108">
                  <Quantity>15</Quantity>
                  <Subsidy>2.06</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>2.06</Alternate>
                  <Surcharge>0.26267</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013107">
          <Name>Oropharyngeal Anti-infectives</Name>
          <Chemical ID="C0131071074">
            <Name>Amphotericin B</Name>
            <Formulation ID="F013107107401" Rank="1" Units="tab" Weight="10">
              <Name>Lozenges 10 mg</Name>
              <Brand ID="B01310710740101">
                <Name>Fungilin</Name>
                <Pack ID="P201960" Specified="true" nzmt:ctpp_id="50004271000117100">
                  <Quantity>20</Quantity>
                  <Subsidy>5.86</Subsidy>
                  <Price>5.86</Price>
                  <Alternate>5.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0131071825">
            <Name>Miconazole</Name>
            <Formulation ID="F013107182501" Rank="3" Units="g">
              <Name>Oral gel 20 mg per g</Name>
              <Brand ID="B01310718250125" PSS="2024-06-30">
                <Name>Decozol</Name>
                <Pack ID="P2405008" Specified="true" OP="true" nzmt:ctpp_id="50136621000117107">
                  <Quantity>40</Quantity>
                  <Subsidy>4.74</Subsidy>
                  <Price>4.74</Price>
                  <Alternate>4.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0131071881">
            <Name>Nystatin</Name>
            <Formulation ID="F013107188105" Rank="3" Units="ml" Weight="100000">
              <Name>Oral liq 100,000 u per ml</Name>
              <Brand ID="B01310718810502" PSS="2026-06-30">
                <Name>Nilstat</Name>
                <Pack ID="P254851" Specified="true" OP="true" nzmt:ctpp_id="50054691000117108">
                  <Quantity>24</Quantity>
                  <Subsidy>2.22</Subsidy>
                  <Price>2.22</Price>
                  <Alternate>2.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0137">
        <Name>Vitamins</Name>
        <ATC3 ID="A013704">
          <Name>Vitamin B</Name>
          <Chemical ID="C0137041624" Statim="Must">
            <Name>Hydroxocobalamin</Name>
            <Formulation ID="F013704162401" Rank="4" Units="inj" Weight="1">
              <Name>Inj 1 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="6" Attribute="PSO"/>
              <Brand ID="B01370416240129">
                <Name>Vita-B12</Name>
                <Pack ID="P2603055" Specified="true" nzmt:ctpp_id="50283401000117101">
                  <Quantity>3</Quantity>
                  <Subsidy>2.46</Subsidy>
                  <Price>2.46</Price>
                  <Alternate>2.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01370416240130" PSS="2024-06-30">
                <Name>Hydroxocobalamin Panpharma</Name>
                <Pack ID="P2637391" Specified="true" nzmt:ctpp_id="50251091000117105">
                  <Quantity>3</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2.46</Subsidy>
                  <Price>2.46</Price>
                  <Alternate>2.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01370416240131" S29="true">
                <Name>Cobal-B12</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2655241" Specified="true" nzmt:ctpp_id="50313211000117106">
                  <Quantity>3</Quantity>
                  <Subsidy>2.46</Subsidy>
                  <Price>2.46</Price>
                  <Alternate>2.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01370416240132" S29="true">
                <Name>Cobalin-H</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2656183" Specified="true" nzmt:ctpp_id="50315371000117107">
                  <Quantity>5</Quantity>
                  <Subsidy>4.10</Subsidy>
                  <Price>4.10</Price>
                  <Alternate>4.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01370416240134" S29="true">
                <Name>Neo-Cytamen S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2667924" Specified="true" nzmt:ctpp_id="50324121000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4.10</Subsidy>
                  <Price>4.10</Price>
                  <Alternate>4.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01370416240135" S29="true">
                <Name>Vitarubin Depot Injection</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2667916" Specified="true" nzmt:ctpp_id="50324111000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>8.20</Subsidy>
                  <Price>8.20</Price>
                  <Alternate>8.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0137042071">
            <Name>Pyridoxine hydrochloride</Name>
            <Rule Type="DoseSWt" Value="100"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F013704207102" Rank="1" Units="tab" Weight="25" Statim="Must">
              <Name>Tab 25 mg</Name>
              <Rule Type="MaxCoPayment" Value="0"/>
              <Brand ID="B01370420710227" PSS="2026-06-30">
                <Name>Vitamin B6 25</Name>
                <Pack ID="P2473534" Specified="true" nzmt:ctpp_id="50320741000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>3.43</Subsidy>
                  <Price>3.43</Price>
                  <Alternate>3.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013704207103" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab 50 mg</Name>
              <Brand ID="B01370420710304">
                <Name>Pyridoxine multichem</Name>
                <Pack ID="P2610582" Specified="true" nzmt:ctpp_id="50287641000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>23.45</Subsidy>
                  <Price>23.45</Price>
                  <Alternate>23.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0137042250" Statim="Must">
            <Name>Thiamine hydrochloride</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F013704225003" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B01370422500304" PSS="2025-06-30">
                <Name>Thiamine multichem</Name>
                <Pack ID="P2646552" Specified="true" nzmt:ctpp_id="50298141000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>4.65</Subsidy>
                  <Price>4.65</Price>
                  <Alternate>4.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0137042328" Statim="Must">
            <Name>Vitamin B complex</Name>
            <Formulation ID="F013704232802" Rank="1" Units="tab">
              <Name>Tab, strong, BPC</Name>
              <Brand ID="B01370423280226">
                <Name>Bplex</Name>
                <Pack ID="P2439700" Specified="true" nzmt:ctpp_id="50176651000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>11.25</Subsidy>
                  <Price>11.25</Price>
                  <Alternate>11.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013707">
          <Name>Vitamin C</Name>
          <Chemical ID="C0137071084" Statim="Must">
            <Name>Ascorbic acid</Name>
            <Rule Type="DoseSWt" Value="100"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F013707108401" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B01370710840127" PSS="2025-06-30">
                <Name>Cvite</Name>
                <Pack ID="P2642255" Specified="true" nzmt:ctpp_id="50176661000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>12.50</Subsidy>
                  <Price>12.50</Price>
                  <Alternate>12.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013710">
          <Name>Vitamin D</Name>
          <Chemical ID="C0137101020" Statim="Must">
            <Name>Alfacalcidol</Name>
            <Formulation ID="F013710102001" Rank="2" Units="cap" Weight="0.25">
              <Name>Cap 0.25 mcg</Name>
              <Brand ID="B01371010200101">
                <Name>One-Alpha</Name>
                <Pack ID="P203084" Specified="true" nzmt:ctpp_id="50005851000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>26.32</Subsidy>
                  <Price>26.32</Price>
                  <Alternate>26.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013710102002" Rank="2" Units="cap" Weight="1">
              <Name>Cap 1 mcg</Name>
              <Brand ID="B01371010200201">
                <Name>One-Alpha</Name>
                <Pack ID="P203092" Specified="true" nzmt:ctpp_id="50005861000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>87.98</Subsidy>
                  <Price>87.98</Price>
                  <Alternate>87.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01371010200202" S29="true">
                <Name>One-Alpha S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2640449" Specified="true" nzmt:ctpp_id="50303441000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>87.98</Subsidy>
                  <Price>87.98</Price>
                  <Alternate>87.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013710102003" Rank="3" Units="ml">
              <Name>Oral drops 2 mcg per ml</Name>
              <Brand ID="B01371010200301">
                <Name>One-Alpha</Name>
                <Pack ID="P315761" Specified="true" OP="true" nzmt:ctpp_id="50070701000117102">
                  <Quantity>20</Quantity>
                  <Subsidy>60.68</Subsidy>
                  <Price>60.68</Price>
                  <Alternate>60.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0137101187" Statim="Must">
            <Name>Colecalciferol</Name>
            <Formulation ID="F013710118725" Rank="2" Units="cap">
              <Name>Cap 1.25 mg (50,000 iu)</Name>
              <Rule Type="FormMax" Value="12" Attribute="Rx"/>
              <Brand ID="B01371011872525" ToBePSS="2024-06-01">
                <Name>Vit.D3</Name>
                <Pack ID="P2523590" Specified="true" nzmt:ctpp_id="50253791000117108">
                  <Quantity>12</Quantity>
                  <Subsidy>3.65</Subsidy>
                  <Price>3.65</Price>
                  <Alternate>3.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013710118726" Rank="3" Units="ml" Weight="188">
              <Name>Oral liq 188 mcg per ml (7,500 iu per ml)</Name>
              <Brand ID="B01371011872626">
                <Name>Clinicians</Name>
                <Pack ID="P2658429" Specified="true" OP="true" nzmt:ctpp_id="50320931000117108">
                  <Quantity>5</Quantity>
                  <Subsidy>9.00</Subsidy>
                  <Price>9.00</Price>
                  <Alternate>9.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0137101189" Statim="Must">
            <Name>Calcitriol</Name>
            <Formulation ID="F013710118901" Rank="2" Units="cap" Weight="0.25">
              <Name>Cap 0.25 mcg</Name>
              <Brand ID="B01371011890125" PSS="2025-06-30">
                <Name>Calcitriol-AFT</Name>
                <Pack ID="P2091038" Specified="true" nzmt:ctpp_id="50017291000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>7.89</Subsidy>
                  <Price>7.89</Price>
                  <Alternate>7.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013710118902" Rank="2" Units="cap" Weight="0.5">
              <Name>Cap 0.5 mcg</Name>
              <Brand ID="B01371011890225" PSS="2025-06-30">
                <Name>Calcitriol-AFT</Name>
                <Pack ID="P2091011" Specified="true" nzmt:ctpp_id="50017281000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>13.68</Subsidy>
                  <Price>13.68</Price>
                  <Alternate>13.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013719">
          <Name>Multivitamin Preparations</Name>
          <Chemical ID="C0137192330" Statim="Must">
            <Name>Vitamins</Name>
            <Formulation ID="F013719233001" Rank="1" Units="tab">
              <Name>Tab (BPC cap strength)</Name>
              <Brand ID="B01371923300127" PSS="2025-06-30">
                <Name>Mvite</Name>
                <Pack ID="P2642247" Specified="true" nzmt:ctpp_id="50176641000117104">
                  <Quantity>1000</Quantity>
                  <Subsidy>18.50</Subsidy>
                  <Price>18.50</Price>
                  <Alternate>18.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013719233025" Rank="2" Units="cap">
              <Name>Cap (fat soluble vitamins A, D, E, K)</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1720"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1720">
                <Title>
                  <range>Vitabdeck</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has cystic fibrosis with pancreatic insufficiency</ci>
                      <ci type="logical" class="Indication">Patient is an infant or child with liver disease or short gut syndrome</ci>
                      <ci type="logical" class="Indication">Patient has severe malabsorption syndrome</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="patient's lifetime"/>
                </Case>
              </Request>
              <Brand ID="B01371923302525">
                <Name>Vitabdeck</Name>
                <Pack ID="P2253801" Specified="true" nzmt:ctpp_id="50040251000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>23.40</Subsidy>
                  <Price>23.40</Price>
                  <Alternate>23.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0137192926" Statim="Must">
            <Name>Multivitamins</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1036"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1036">
              <Title>
                <range>Multivitamins<instance>Paediatric Seravit</instance></range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Renewal" Form="SA0600 SA0963 SA1036">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Patient has had a previous approval for multivitamins</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F013719292602" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B01371929260201">
                <Name>Paediatric Seravit</Name>
                <Pack ID="P2601435" Specified="true" OP="true" nzmt:ctpp_id="50284571000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>72.00</Subsidy>
                  <Price>72.00</Price>
                  <Alternate>72.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0137194049" Statim="Must">
            <Name>Multivitamin renal</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1546"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1546">
              <Title>
                <range>Multivitamin renal<instance>Clinicians Renal Vit</instance></range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis</ci>
                    <ci type="logical" class="Indication">The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of &lt; 15 ml/min/1.73 mÂ² body surface area (BSA)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F013719404925" Rank="2" Units="cap">
              <Name>Cap</Name>
              <Brand ID="B01371940492525">
                <Name>Clinicians Renal Vit</Name>
                <Pack ID="P2479168" Specified="true" nzmt:ctpp_id="50194501000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>6.49</Subsidy>
                  <Price>6.49</Price>
                  <Alternate>6.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0138">
        <Name>Minerals</Name>
        <ATC3 ID="A013810">
          <Name>Calcium</Name>
          <Chemical ID="C0138101191" Statim="Must">
            <Name>Calcium carbonate</Name>
            <Formulation ID="F013810119102" Rank="1" Units="tab" Weight="1250">
              <Name>Tab 1.25 g (500 mg elemental)</Name>
              <Brand ID="B01381011910225" PSS="2026-06-30">
                <Name>Calci-Tab 500</Name>
                <Pack ID="P2212269" Specified="true" nzmt:ctpp_id="50033651000117100">
                  <Quantity>250</Quantity>
                  <Subsidy>7.28</Subsidy>
                  <Price>7.28</Price>
                  <Alternate>7.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013810119128" Rank="1" Units="tab" Weight="1250">
              <Name>Tab eff 1.25 g (500 mg elemental)</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidy by endorsement â€“ Only when prescribed for paediatric patients (&lt;5 years) where calcium carbonate oral liquid is considered unsuitable.</p>
              </div>
              <Brand ID="B01381011912826" S29="true">
                <Name>Calcium 500 mg Hexal</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2633817" Specified="true" nzmt:ctpp_id="50300021000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>260.00</Subsidy>
                  <Price>260.00</Price>
                  <Alternate>260.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0138101199" Statim="Must">
            <Name>Calcium gluconate</Name>
            <Formulation ID="F013810119901" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10%, 10 ml ampoule</Name>
              <Brand ID="B01381011990126" S29="true">
                <Name>Max Health</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2559315" Specified="true" nzmt:ctpp_id="50260951000117100">
                  <Quantity>20</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>64.00</Subsidy>
                  <Price>64.00</Price>
                  <Alternate>64.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01381011990127" S29="true">
                <Name>Max Health - Hameln</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2591510" Specified="true" nzmt:ctpp_id="50277661000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>32.00</Subsidy>
                  <Price>32.00</Price>
                  <Alternate>32.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013825">
          <Name>Iodine</Name>
          <Chemical ID="C0138253907" Statim="Must">
            <Name>Potassium iodate</Name>
            <Formulation ID="F013825390726" Rank="1" Units="tab" Weight="253">
              <Name>Tab 253 mcg (150 mcg elemental iodine)</Name>
              <Brand ID="B01382539072625" PSS="2026-06-30">
                <Name>NeuroTabs</Name>
                <Pack ID="P2439964" Specified="true" nzmt:ctpp_id="50178331000117100">
                  <Quantity>90</Quantity>
                  <Subsidy>5.99</Subsidy>
                  <Price>5.99</Price>
                  <Alternate>5.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013830">
          <Name>Iron</Name>
          <Chemical ID="C0138301676" Statim="Must">
            <Name>Iron polymaltose</Name>
            <Formulation ID="F013830167601" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg per ml, 2 ml ampoule</Name>
              <Brand ID="B01383016760125">
                <Name>Ferrosig</Name>
                <Pack ID="P2135914" Specified="true" nzmt:ctpp_id="50023781000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>34.50</Subsidy>
                  <Price>34.50</Price>
                  <Alternate>34.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0138303293">
            <Name>Ferrous sulfate</Name>
            <Formulation ID="F013830329305" Rank="1" Units="tab" Weight="325" Statim="Must">
              <Name>Tab long-acting 325 mg (105 mg elemental)</Name>
              <Brand ID="B01383032930501" PSS="2025-06-30">
                <Name>Ferrograd</Name>
                <Pack ID="P2534819" Specified="true" nzmt:ctpp_id="50126231000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>2.55</Subsidy>
                  <Price>2.55</Price>
                  <Alternate>2.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013830329325" Rank="3" Units="ml" Weight="30" Statim="Must">
              <Name>Oral liq 30 mg (6 mg elemental) per 1 ml</Name>
              <Brand ID="B01383032932525" PSS="2025-06-30">
                <Name>Ferodan</Name>
                <Pack ID="P2259087" Specified="true" nzmt:ctpp_id="50040881000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>13.10</Subsidy>
                  <Price>13.10</Price>
                  <Alternate>13.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B01383032932526">
                <Name>Ferro-Liquid</Name>
                <Pack ID="P2664429" Specified="true" nzmt:ctpp_id="50029631000117109">
                  <Quantity>250</Quantity>
                  <Subsidy>9.25</Subsidy>
                  <Price>9.25</Price>
                  <Alternate>9.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0138303831" Statim="Must">
            <Name>Ferrous fumarate</Name>
            <Formulation ID="F013830383125" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg (65 mg elemental)</Name>
              <Brand ID="B01383038312525" PSS="2024-06-30">
                <Name>Ferro-tab</Name>
                <Pack ID="P2162156" Specified="true" nzmt:ctpp_id="50027441000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>3.04</Subsidy>
                  <Price>3.04</Price>
                  <Alternate>3.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0138303862" Statim="Must">
            <Name>Ferrous fumarate with folic acid</Name>
            <Formulation ID="F013830386225" Rank="1" Units="tab">
              <Name>Tab 310 mg (100 mg elemental) with folic acid 350 mcg</Name>
              <Brand ID="B01383038622525" PSS="2024-06-30">
                <Name>Ferro-F-Tabs</Name>
                <Pack ID="P2615584" Specified="true" nzmt:ctpp_id="50290911000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>5.98</Subsidy>
                  <Price>5.98</Price>
                  <Alternate>5.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0138304087">
            <Name>Iron (as ferric carboxymaltose)</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1840"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1840">
              <Title>
                <range>Ferric carboxymaltose</range>
              </Title>
              <Case When="Initial application" Category="serum ferritin less than or equal to 20 mcg/L">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has been compliant with oral iron treatment and treatment has proven ineffective</ci>
                      <ci type="logical" class="Indication">Treatment with oral iron has resulted in dose-limiting intolerance</ci>
                      <ci type="logical" class="Indication">Rapid correction of anaemia is required</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="serum ferritin less than or equal to 20 mcg/L" Form="SA1675 SA1840 SA1840">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L</ci>
                    <ci type="logical" class="Indication">A re-trial with oral iron is clinically inappropriate</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="iron deficiency anaemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with iron-deficiency anaemia</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has been compliant with oral iron treatment and treatment has proven ineffective</ci>
                      <ci type="logical" class="Indication">Treatment with oral iron has resulted in dose-limiting intolerance</ci>
                      <ci type="logical" class="Indication">Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is
                        unlikely to be effective</ci>
                      <ci type="logical" class="Indication">Rapid correction of anaemia is required</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>internal medicine physician</Applicant>
                <Applicant>obstetrician</Applicant>
                <Applicant>gynaecologist</Applicant>
                <Applicant>anaesthetist</Applicant>
                <Applicant Referring="internal medicine physician, obstetrician, gynaecologist or anaesthetist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="iron deficiency anaemia" Form="SA1675 SA1840">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient continues to have iron-deficiency anaemia</ci>
                    <ci type="logical" class="Indication">A re-trial with oral iron is clinically inappropriate</ci>
                  </apply>
                </math>
                <Applicant>internal medicine physician</Applicant>
                <Applicant>obstetrician</Applicant>
                <Applicant>gynaecologist</Applicant>
                <Applicant>anaesthetist</Applicant>
                <Applicant Referring="internal medicine physician, obstetrician, gynaecologist or anaesthetist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
            </Request>
            <Formulation ID="F013830408725" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg per ml, 10 ml vial</Name>
              <Brand ID="B01383040872525">
                <Name>Ferinject</Name>
                <Pack ID="P2401088" Specified="true" nzmt:ctpp_id="50131001000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>150.00</Subsidy>
                  <Price>150.00</Price>
                  <Alternate>150.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013840">
          <Name>Magnesium</Name>
          <Chemical ID="C0138402487">
            <Name>Magnesium hydroxide</Name>
            <Formulation ID="F013840248725" Rank="3" Units="ml">
              <Name>Suspension 8%</Name>
              <Brand ID="B01384024872526" S29="true">
                <Name>Phillips Milk of Magnesia</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2599953" Specified="true" nzmt:ctpp_id="50263101000117108">
                  <Quantity>355</Quantity>
                  <Subsidy>33.60</Subsidy>
                  <Price>33.60</Price>
                  <Alternate>33.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0138403329" Statim="Must">
            <Name>Magnesium sulphate</Name>
            <Formulation ID="F013840332903" Rank="4" Units="inj">
              <Name>Inj 2 mmol per ml, 5 ml ampoule</Name>
              <Brand ID="B01384033290325" ToBePSS="2024-06-01">
                <Name>Martindale</Name>
                <Pack ID="P2406438" Specified="true" nzmt:ctpp_id="50276951000117105">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>37.53</Subsidy>
                  <Price>37.53</Price>
                  <Alternate>37.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F013840332925" Rank="4" Units="inj" Weight="2">
              <Name>Inj 2 mmol per ml, 10 ml ampoule</Name>
              <Brand ID="B01384033292525" S29="true">
                <Name>Inresa</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2671093" Specified="true" nzmt:ctpp_id="50327411000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>75.06</Subsidy>
                  <Price>75.06</Price>
                  <Alternate>75.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A013850">
          <Name>Zinc</Name>
          <Chemical ID="C0138502354" Statim="Must">
            <Name>Zinc sulphate</Name>
            <Formulation ID="F013850235401" Rank="2" Units="cap" Weight="137.4">
              <Name>Cap 137.4 mg (50 mg elemental)</Name>
              <Brand ID="B01385023540101">
                <Name>Zincaps</Name>
                <Pack ID="P258253" Specified="true" nzmt:ctpp_id="50056211000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>11.00</Subsidy>
                  <Price>11.00</Price>
                  <Alternate>11.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A04">
      <Name>Blood and Blood Forming Organs</Name>
      <ATC2 ID="A0401">
        <Name>Antianaemics</Name>
        <ATC3 ID="A040101">
          <Name>Hypoplastic and Haemolytic</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA2266">
            <Title>
              <range>Hypoplastic and Haemolytic</range>
            </Title>
            <Case When="Initial application" Category="chronic renal failure">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient in chronic renal failure</ci>
                  <ci type="logical" class="Indication">Haemoglobin is less than or equal to 100g/L</ci>
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient does not have diabetes mellitus</ci>
                      <ci type="logical" class="Indication">Glomerular filtration rate is less than or equal to 30ml/min</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has diabetes mellitus</ci>
                      <ci type="logical" class="Indication">Glomerular filtration rate is less than or equal to 45ml/min</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is on haemodialysis or peritoneal dialysis</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Initial application" Category="myelodysplasia">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient has a confirmed diagnosis of myelodysplasia (MDS)*</ci>
                  <ci type="logical" class="Indication">Has had symptomatic anaemia with haemoglobin &lt;100g/L and is red cell transfusion-dependent</ci>
                  <ci type="logical" class="Indication">Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome
                    (WPSS)</ci>
                  <ci type="logical" class="Indication">Other causes of anaemia such as B12 and folate deficiency have been excluded</ci>
                  <ci type="logical" class="Indication">Patient has a serum epoetin level of &lt;500 IU/L</ci>
                  <ci type="logical" class="Indication">The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week</ci>
                </apply>
              </math>
              <Applicant>any specialist</Applicant>
              <Term Measure="month">2</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Indication marked with * is an unapproved indication</p>
              </div>
            </Case>
            <Case When="Renewal" Form="SA0922 SA1469 SA1775 SA2266" Category="chronic renal failure">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefiting from treatment</ci>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Renewal" Form="SA0922 SA1469 SA1775 SA2266" Category="myelodysplasia">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The patient's transfusion requirement continues to be reduced with erythropoietin treatment</ci>
                  <ci type="logical" class="Indication">Transformation to acute myeloid leukaemia has not occurred</ci>
                  <ci type="logical" class="Indication">The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week</ci>
                </apply>
              </math>
              <Applicant>any specialist</Applicant>
              <Term Measure="month">12</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Indication marked with * is an unapproved indication</p>
              </div>
            </Case>
          </Request>
          <Chemical ID="C0401012758">
            <Name>Epoetin alfa</Name>
            <Rule Type="Wastage"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2266"/>
            <Formulation ID="F040101275806" Rank="4" Units="inj" Weight="3000">
              <Name>Inj 3,000 iu in 0.3 ml, syringe</Name>
              <Brand ID="B04010127580602">
                <Name>Binocrit</Name>
                <Pack ID="P2559781" Specified="true" nzmt:ctpp_id="50133511000117109">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>150.00</Subsidy>
                  <Price>150.00</Price>
                  <Alternate>150.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275807" Rank="4" Units="inj" Weight="4000">
              <Name>Inj 4,000 iu in 0.4 ml, syringe</Name>
              <Brand ID="B04010127580702">
                <Name>Binocrit</Name>
                <Pack ID="P2559803" Specified="true" nzmt:ctpp_id="50133521000117103">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>96.50</Subsidy>
                  <Price>96.50</Price>
                  <Alternate>96.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275808" Rank="4" Units="inj" Weight="10000">
              <Name>Inj 10,000 iu in 1 ml, syringe</Name>
              <Brand ID="B04010127580802">
                <Name>Binocrit</Name>
                <Pack ID="P2559854" Specified="true" nzmt:ctpp_id="50133581000117104">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>197.50</Subsidy>
                  <Price>197.50</Price>
                  <Alternate>197.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275825" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 iu in 0.5 ml, syringe</Name>
              <Brand ID="B04010127582526">
                <Name>Binocrit</Name>
                <Pack ID="P2559765" Specified="true" nzmt:ctpp_id="50133501000117106">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>250.00</Subsidy>
                  <Price>250.00</Price>
                  <Alternate>250.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275826" Rank="4" Units="inj" Weight="5000">
              <Name>Inj 5,000 iu in 0.5 ml, syringe</Name>
              <Brand ID="B04010127582626">
                <Name>Binocrit</Name>
                <Pack ID="P2559811" Specified="true" nzmt:ctpp_id="50133531000117100">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>125.00</Subsidy>
                  <Price>125.00</Price>
                  <Alternate>125.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275827" Rank="4" Units="inj" Weight="6000">
              <Name>Inj 6,000 iu in 0.6 ml, syringe</Name>
              <Brand ID="B04010127582726">
                <Name>Binocrit</Name>
                <Pack ID="P2559838" Specified="true" nzmt:ctpp_id="50133541000117108">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>145.00</Subsidy>
                  <Price>145.00</Price>
                  <Alternate>145.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275828" Rank="4" Units="inj" Weight="8000">
              <Name>Inj 8,000 iu in 0.8 ml, syringe</Name>
              <Brand ID="B04010127582826">
                <Name>Binocrit</Name>
                <Pack ID="P2559846" Specified="true" nzmt:ctpp_id="50133561000117107">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>175.00</Subsidy>
                  <Price>175.00</Price>
                  <Alternate>175.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275829" Rank="4" Units="inj" Weight="40000">
              <Name>Inj 40,000 iu in 1 ml, syringe</Name>
              <Brand ID="B04010127582926">
                <Name>Binocrit</Name>
                <Pack ID="P2559862" Specified="true" nzmt:ctpp_id="50135731000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>250.00</Subsidy>
                  <Price>250.00</Price>
                  <Alternate>250.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040101275830" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2,000 iu in 1 ml, syringe</Name>
              <Brand ID="B04010127583025">
                <Name>Binocrit</Name>
                <Pack ID="P2559773" Specified="true" nzmt:ctpp_id="50133491000117100">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>100.00</Subsidy>
                  <Price>100.00</Price>
                  <Alternate>100.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A040104">
          <Name>Megaloblastic</Name>
          <Chemical ID="C0401041498">
            <Name>Folic acid</Name>
            <Formulation ID="F040104149801" Rank="1" Units="tab" Weight="5" Statim="Must">
              <Name>Tab 5 mg</Name>
              <Brand ID="B04010414980127" SoleSupply="2027-06-30">
                <Name>Folic Acid Viatris</Name>
                <Pack ID="P2633450" Specified="true" nzmt:ctpp_id="50292151000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>5.82</Subsidy>
                  <Price>5.82</Price>
                  <Alternate>5.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040104149803" Rank="3" Units="ml" Weight="50">
              <Name>Oral liq 50 mcg per ml</Name>
              <Brand ID="B04010414980301" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P344850" Specified="true" OP="true" nzmt:ctpp_id="50075821000117108">
                  <Quantity>25</Quantity>
                  <Subsidy>30.26</Subsidy>
                  <Price>30.26</Price>
                  <Alternate>30.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040104149825" Rank="1" Units="tab" Statim="Must">
              <Name>Tab 0.8 mg</Name>
              <Brand ID="B04010414982527">
                <Name>Folic Acid multichem</Name>
                <Pack ID="P2610566" Specified="true" nzmt:ctpp_id="50292241000117108">
                  <Quantity>1000</Quantity>
                  <Subsidy>26.60</Subsidy>
                  <Price>26.60</Price>
                  <Alternate>26.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0404">
        <Name>Antifibrinolytics, Haemostatics and Local Sclerosants</Name>
        <ATC3 ID="A040401">
          <Name>Antifibrinolytics, Haemostatics and Local Sclerosants</Name>
          <Chemical ID="C0404012164" Statim="Must">
            <Name>Sodium tetradecyl sulphate</Name>
            <Formulation ID="F040401216404" Rank="4" Units="inj" Weight="3">
              <Name>Inj 3% 2 ml</Name>
              <Brand ID="B04040121640401">
                <Name>Fibro-vein</Name>
                <Pack ID="P748781" Specified="true" nzmt:ctpp_id="50108321000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>28.50</Subsidy>
                  <Price>73.00</Price>
                  <Alternate>28.50</Alternate>
                  <Surcharge>8.90000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404012505">
            <Name>Tranexamic acid</Name>
            <Formulation ID="F040401250501" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B04040125050101">
                <Name>Cyklokapron</Name>
                <Pack ID="P461962" Specified="true" nzmt:ctpp_id="50087811000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>45.68</Subsidy>
                  <Price>45.68</Price>
                  <Alternate>45.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B04040125050102" PSS="2025-06-30">
                <Name>Mercury Pharma</Name>
                <Pack ID="P2574020" Specified="true" nzmt:ctpp_id="50126681000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>10.45</Subsidy>
                  <Price>10.45</Price>
                  <Alternate>10.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404013021">
            <Name>Octocog alfa [Recombinant factor VIII] (Advate)</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p>
            </div>
            <Formulation ID="F040401302125" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 iu vial</Name>
              <Brand ID="B04040130212525">
                <Name>Advate</Name>
                <Pack ID="P2292696" Specified="true" nzmt:ctpp_id="50044931000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>210.00</Subsidy>
                  <Price>210.00</Price>
                  <Alternate>210.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401302126" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 iu vial</Name>
              <Brand ID="B04040130212625">
                <Name>Advate</Name>
                <Pack ID="P2292718" Specified="true" nzmt:ctpp_id="50044941000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>420.00</Subsidy>
                  <Price>420.00</Price>
                  <Alternate>420.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401302127" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 iu vial</Name>
              <Brand ID="B04040130212725">
                <Name>Advate</Name>
                <Pack ID="P2292726" Specified="true" nzmt:ctpp_id="50044951000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>840.00</Subsidy>
                  <Price>840.00</Price>
                  <Alternate>840.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401302128" Rank="4" Units="inj" Weight="1500">
              <Name>Inj 1,500 iu vial</Name>
              <Brand ID="B04040130212825">
                <Name>Advate</Name>
                <Pack ID="P2292742" Specified="true" nzmt:ctpp_id="50044961000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1260.00</Subsidy>
                  <Price>1260.00</Price>
                  <Alternate>1260.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401302129" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2,000 iu vial</Name>
              <Brand ID="B04040130212925">
                <Name>Advate</Name>
                <Pack ID="P2292750" Specified="true" nzmt:ctpp_id="50044971000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1680.00</Subsidy>
                  <Price>1680.00</Price>
                  <Alternate>1680.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401302130" Rank="4" Units="inj" Weight="3000">
              <Name>Inj 3,000 iu vial</Name>
              <Brand ID="B04040130213025">
                <Name>Advate</Name>
                <Pack ID="P2292769" Specified="true" nzmt:ctpp_id="50044981000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2520.00</Subsidy>
                  <Price>2520.00</Price>
                  <Alternate>2520.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014018">
            <Name>Eptacog alfa [Recombinant factor VIIa]</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for &gt;14 days predicted use. Access to funded treatment for &gt;14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.</p>
            </div>
            <Formulation ID="F040401401825" Rank="4" Units="inj" Weight="1">
              <Name>Inj 1 mg syringe</Name>
              <Brand ID="B04040140182525">
                <Name>NovoSeven RT</Name>
                <Pack ID="P2404311" Specified="true" nzmt:ctpp_id="50178411000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1178.30</Subsidy>
                  <Price>1178.30</Price>
                  <Alternate>1178.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401401826" Rank="4" Units="inj" Weight="2">
              <Name>Inj 2 mg syringe</Name>
              <Brand ID="B04040140182625">
                <Name>NovoSeven RT</Name>
                <Pack ID="P2404338" Specified="true" nzmt:ctpp_id="50178421000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2356.60</Subsidy>
                  <Price>2356.60</Price>
                  <Alternate>2356.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401401827" Rank="4" Units="inj" Weight="5">
              <Name>Inj 5 mg syringe</Name>
              <Brand ID="B04040140182725">
                <Name>NovoSeven RT</Name>
                <Pack ID="P2404346" Specified="true" nzmt:ctpp_id="50178431000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5891.50</Subsidy>
                  <Price>5891.50</Price>
                  <Alternate>5891.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401401828" Rank="4" Units="inj" Weight="8">
              <Name>Inj 8 mg syringe</Name>
              <Brand ID="B04040140182825">
                <Name>NovoSeven RT</Name>
                <Pack ID="P2427184" Specified="true" nzmt:ctpp_id="50137201000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9426.40</Subsidy>
                  <Price>9426.40</Price>
                  <Alternate>9426.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014019">
            <Name>Moroctocog alfa [Recombinant factor VIII]</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.</p>
            </div>
            <Formulation ID="F040401401925" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 iu prefilled syringe</Name>
              <Brand ID="B04040140192525">
                <Name>Xyntha</Name>
                <Pack ID="P2424339" Specified="true" nzmt:ctpp_id="50158261000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>287.50</Subsidy>
                  <Price>287.50</Price>
                  <Alternate>287.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401401926" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 iu prefilled syringe</Name>
              <Brand ID="B04040140192625">
                <Name>Xyntha</Name>
                <Pack ID="P2424347" Specified="true" nzmt:ctpp_id="50158251000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>575.00</Subsidy>
                  <Price>575.00</Price>
                  <Alternate>575.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401401927" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 iu prefilled syringe</Name>
              <Brand ID="B04040140192725">
                <Name>Xyntha</Name>
                <Pack ID="P2424355" Specified="true" nzmt:ctpp_id="50158271000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1150.00</Subsidy>
                  <Price>1150.00</Price>
                  <Alternate>1150.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401401928" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2,000 iu prefilled syringe</Name>
              <Brand ID="B04040140192825">
                <Name>Xyntha</Name>
                <Pack ID="P2424363" Specified="true" nzmt:ctpp_id="50166001000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2300.00</Subsidy>
                  <Price>2300.00</Price>
                  <Alternate>2300.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401401929" Rank="4" Units="inj" Weight="3000">
              <Name>Inj 3,000 iu prefilled syringe</Name>
              <Brand ID="B04040140192925">
                <Name>Xyntha</Name>
                <Pack ID="P2424371" Specified="true" nzmt:ctpp_id="50178631000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3450.00</Subsidy>
                  <Price>3450.00</Price>
                  <Alternate>3450.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014021">
            <Name>Octocog alfa [Recombinant factor VIII] (Kogenate FS)</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.</p>
            </div>
            <Formulation ID="F040401402125" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 iu vial</Name>
              <Brand ID="B04040140212526">
                <Name>Kogenate FS</Name>
                <Pack ID="P2461366" Specified="true" nzmt:ctpp_id="50030561000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>237.50</Subsidy>
                  <Price>237.50</Price>
                  <Alternate>237.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401402126" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 iu vial</Name>
              <Brand ID="B04040140212626">
                <Name>Kogenate FS</Name>
                <Pack ID="P2461803" Specified="true" nzmt:ctpp_id="50030581000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>475.00</Subsidy>
                  <Price>475.00</Price>
                  <Alternate>475.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401402127" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 iu vial</Name>
              <Brand ID="B04040140212726">
                <Name>Kogenate FS</Name>
                <Pack ID="P2461811" Specified="true" nzmt:ctpp_id="50030571000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>950.00</Subsidy>
                  <Price>950.00</Price>
                  <Alternate>950.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401402129" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2,000 iu vial</Name>
              <Brand ID="B04040140212926">
                <Name>Kogenate FS</Name>
                <Pack ID="P2328534" Specified="true" nzmt:ctpp_id="50049311000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1900.00</Subsidy>
                  <Price>1900.00</Price>
                  <Alternate>1900.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401402130" Rank="4" Units="inj" Weight="3000">
              <Name>Inj 3,000 iu vial</Name>
              <Brand ID="B04040140213026">
                <Name>Kogenate FS</Name>
                <Pack ID="P2402882" Specified="true" nzmt:ctpp_id="50131741000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2850.00</Subsidy>
                  <Price>2850.00</Price>
                  <Alternate>2850.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014022">
            <Name>Factor eight inhibitor bypassing fraction</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia. Preferred Brand of bypassing agent for &gt;14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p>
            </div>
            <Formulation ID="F040401402225" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 U</Name>
              <Brand ID="B04040140222525">
                <Name>FEIBA NF</Name>
                <Pack ID="P2583992" Specified="true" nzmt:ctpp_id="50268721000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1315.00</Subsidy>
                  <Price>1315.00</Price>
                  <Alternate>1315.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401402226" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 U</Name>
              <Brand ID="B04040140222625">
                <Name>FEIBA NF</Name>
                <Pack ID="P2388804" Specified="true" nzmt:ctpp_id="50125351000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2630.00</Subsidy>
                  <Price>2630.00</Price>
                  <Alternate>2630.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401402227" Rank="4" Units="inj" Weight="2500">
              <Name>Inj 2,500 U</Name>
              <Brand ID="B04040140222725">
                <Name>FEIBA NF</Name>
                <Pack ID="P2487926" Specified="true" nzmt:ctpp_id="50210621000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>6575.00</Subsidy>
                  <Price>6575.00</Price>
                  <Alternate>6575.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014024">
            <Name>Eltrombopag</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1743"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1743">
              <Title>
                <range>Eltrombopag</range>
              </Title>
              <Case When="Initial application" Category="idiopathic thrombocytopenic purpura - post-splenectomy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has had a splenectomy</ci>
                    <ci type="logical" class="Indication">Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding</ci>
                      <ci type="logical" class="Indication">Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding</ci>
                      <ci type="logical" class="Indication">Patient has a platelet count of less than or equal to 10,000 platelets per microlitre</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="week">6</Term>
              </Case>
              <Case When="Initial application" Category="idiopathic thrombocytopenic purpura - preparation for splenectomy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient requires eltrombopag treatment as preparation for splenectomy</ci>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="week">6</Term>
              </Case>
              <Case When="Initial application" Category="idiopathic thrombocytopenic purpura contraindicated to splenectomy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a significant and well-documented contraindication to splenectomy for clinical reasons</ci>
                    <ci type="logical" class="Indication">Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter</ci>
                      <ci type="logical" class="Indication">Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="severe aplastic anaemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter</ci>
                      <ci type="logical" class="Indication">Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="idiopathic thrombocytopenic purpura - post-splenectomy" Form="SA1412 SA1418 SA1743">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required</ci>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Response to treatment is defined as a platelet count of &gt;30,000 platelets per microlitre.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="idiopathic thrombocytopenic purpura contraindicated to splenectomy" Form="SA1412 SA1418 SA1743">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patientâ€™s significant contraindication to splenectomy remains</ci>
                    <ci type="logical" class="Indication">The patient has obtained a response from treatment during the initial approval period</ci>
                    <ci type="logical" class="Indication">Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment</ci>
                    <ci type="logical" class="Indication">Further treatment with eltrombopag is required to maintain response</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="severe aplastic anaemia" Form="SA1412 SA1418 SA1743">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period</ci>
                    <ci type="logical" class="Indication">Platelet transfusion independence for a minimum of 8 weeks during the initial approval period</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F040401402425" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B04040140242525">
                <Name>Revolade</Name>
                <Pack ID="P2391406" Specified="true" nzmt:ctpp_id="50125751000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>1550.00</Subsidy>
                  <Price>1550.00</Price>
                  <Alternate>1550.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401402426" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B04040140242625">
                <Name>Revolade</Name>
                <Pack ID="P2391414" Specified="true" nzmt:ctpp_id="50125741000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>3100.00</Subsidy>
                  <Price>3100.00</Price>
                  <Alternate>3100.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014055">
            <Name>Nonacog gamma, [Recombinant Factor IX]</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p>
            </div>
            <Formulation ID="F040401405526" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 iu vial</Name>
              <Brand ID="B04040140552625">
                <Name>RIXUBIS</Name>
                <Pack ID="P2487942" Specified="true" nzmt:ctpp_id="50224571000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>435.00</Subsidy>
                  <Price>435.00</Price>
                  <Alternate>435.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401405527" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 iu vial</Name>
              <Brand ID="B04040140552725">
                <Name>RIXUBIS</Name>
                <Pack ID="P2487896" Specified="true" nzmt:ctpp_id="50224581000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>870.00</Subsidy>
                  <Price>870.00</Price>
                  <Alternate>870.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401405528" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2,000 iu vial</Name>
              <Brand ID="B04040140552825">
                <Name>RIXUBIS</Name>
                <Pack ID="P2487950" Specified="true" nzmt:ctpp_id="50224591000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1740.00</Subsidy>
                  <Price>1740.00</Price>
                  <Alternate>1740.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401405529" Rank="4" Units="inj" Weight="3000">
              <Name>Inj 3,000 iu vial</Name>
              <Brand ID="B04040140552925">
                <Name>RIXUBIS</Name>
                <Pack ID="P2487918" Specified="true" nzmt:ctpp_id="50224601000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2610.00</Subsidy>
                  <Price>2610.00</Price>
                  <Alternate>2610.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014116">
            <Name>Eftrenonacog alfa [Recombinant factor IX]</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.</p>
            </div>
            <Formulation ID="F040401411625" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 iu vial</Name>
              <Brand ID="B04040141162525">
                <Name>Alprolix</Name>
                <Pack ID="P2565846" Specified="true" nzmt:ctpp_id="50213551000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>612.50</Subsidy>
                  <Price>612.50</Price>
                  <Alternate>612.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411626" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 iu vial</Name>
              <Brand ID="B04040141162625">
                <Name>Alprolix</Name>
                <Pack ID="P2565854" Specified="true" nzmt:ctpp_id="50213561000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1225.00</Subsidy>
                  <Price>1225.00</Price>
                  <Alternate>1225.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411627" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 iu vial</Name>
              <Brand ID="B04040141162725">
                <Name>Alprolix</Name>
                <Pack ID="P2565862" Specified="true" nzmt:ctpp_id="50213571000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2450.00</Subsidy>
                  <Price>2450.00</Price>
                  <Alternate>2450.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411628" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2,000 iu vial</Name>
              <Brand ID="B04040141162825">
                <Name>Alprolix</Name>
                <Pack ID="P2565870" Specified="true" nzmt:ctpp_id="50213581000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4900.00</Subsidy>
                  <Price>4900.00</Price>
                  <Alternate>4900.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411629" Rank="4" Units="inj" Weight="3000">
              <Name>Inj 3,000 iu vial</Name>
              <Brand ID="B04040141162925">
                <Name>Alprolix</Name>
                <Pack ID="P2565889" Specified="true" nzmt:ctpp_id="50213591000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7350.00</Subsidy>
                  <Price>7350.00</Price>
                  <Alternate>7350.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411630" Rank="4" Units="inj" Weight="4000">
              <Name>Inj 4,000 iu vial</Name>
              <Brand ID="B04040141163025">
                <Name>Alprolix</Name>
                <Pack ID="P2636069" Specified="true" nzmt:ctpp_id="50274791000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9800.00</Subsidy>
                  <Price>9800.00</Price>
                  <Alternate>9800.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014117">
            <Name>Rurioctocog alfa pegol [Recombinant factor VIII]</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.</p>
            </div>
            <Formulation ID="F040401411725" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 iu vial</Name>
              <Brand ID="B04040141172525">
                <Name>Adynovate</Name>
                <Pack ID="P2561115" Specified="true" nzmt:ctpp_id="50234041000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>300.00</Subsidy>
                  <Price>300.00</Price>
                  <Alternate>300.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411726" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 iu vial</Name>
              <Brand ID="B04040141172625">
                <Name>Adynovate</Name>
                <Pack ID="P2561123" Specified="true" nzmt:ctpp_id="50234051000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>600.00</Subsidy>
                  <Price>600.00</Price>
                  <Alternate>600.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411727" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1,000 iu vial</Name>
              <Brand ID="B04040141172725">
                <Name>Adynovate</Name>
                <Pack ID="P2561131" Specified="true" nzmt:ctpp_id="50234061000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1200.00</Subsidy>
                  <Price>1200.00</Price>
                  <Alternate>1200.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401411728" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2,000 iu vial</Name>
              <Brand ID="B04040141172825">
                <Name>Adynovate</Name>
                <Pack ID="P2561158" Specified="true" nzmt:ctpp_id="50234071000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2400.00</Subsidy>
                  <Price>2400.00</Price>
                  <Alternate>2400.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0404014132">
            <Name>Emicizumab</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2272"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2272">
              <Title>
                <range>Emicizumab</range>
              </Title>
              <Case When="Initial application" Category="Severe Haemophilia A with or without FVIII inhibitors">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has severe congenital haemophilia A with a severe bleeding phenotype (endogenous factor VIII activity less than or equal to 2%)</ci>
                    <ci type="logical" class="Indication">Emicizumab is to be administered at a dose of no greater than 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F040401413225" Rank="4" Units="inj" Weight="30">
              <Name>Inj 30 mg in 1 ml vial</Name>
              <Brand ID="B04040141322525">
                <Name>Hemlibra</Name>
                <Pack ID="P2553511" Specified="true" nzmt:ctpp_id="50247471000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3570.00</Subsidy>
                  <Price>3570.00</Price>
                  <Alternate>3570.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401413226" Rank="4" Units="inj" Weight="60">
              <Name>Inj 60 mg in 0.4 ml vial</Name>
              <Brand ID="B04040141322625">
                <Name>Hemlibra</Name>
                <Pack ID="P2553546" Specified="true" nzmt:ctpp_id="50247481000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7138.00</Subsidy>
                  <Price>7138.00</Price>
                  <Alternate>7138.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401413227" Rank="4" Units="inj" Weight="105">
              <Name>Inj 105 mg in 0.7 ml vial</Name>
              <Brand ID="B04040141322725">
                <Name>Hemlibra</Name>
                <Pack ID="P2553554" Specified="true" nzmt:ctpp_id="50247491000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>12492.00</Subsidy>
                  <Price>12492.00</Price>
                  <Alternate>12492.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040401413228" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg in 1 ml vial</Name>
              <Brand ID="B04040141322825">
                <Name>Hemlibra</Name>
                <Pack ID="P2553538" Specified="true" nzmt:ctpp_id="50247501000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>17846.00</Subsidy>
                  <Price>17846.00</Price>
                  <Alternate>17846.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A040403">
          <Name>Vitamin K</Name>
          <Chemical ID="C0404031986">
            <Name>Phytomenadione</Name>
            <Formulation ID="F040403198603" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04040319860302">
                <Name>Konakion MM</Name>
                <Pack ID="P298204" Specified="true" nzmt:ctpp_id="50066441000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9.21</Subsidy>
                  <Price>9.21</Price>
                  <Alternate>9.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040403198625" Rank="4" Units="inj" Weight="2">
              <Name>Inj 2 mg per 0.2 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04040319862525">
                <Name>Konakion MM</Name>
                <Pack ID="P911828" Specified="true" nzmt:ctpp_id="50117821000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>8.00</Subsidy>
                  <Price>8.00</Price>
                  <Alternate>8.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0407">
        <Name>Antithrombotic Agents</Name>
        <ATC3 ID="A040701">
          <Name>Antiplatelet Agents</Name>
          <Chemical ID="C0407011087" Statim="Must">
            <Name>Aspirin</Name>
            <Formulation ID="F040701108725" Rank="1" Units="tab">
              <Name>Tab 100 mg</Name>
              <Brand ID="B04070110872525" ToBePSS="2024-06-01">
                <Name>Ethics Aspirin EC</Name>
                <Pack ID="P2213621" Specified="true" nzmt:ctpp_id="50034091000117104">
                  <Quantity>990</Quantity>
                  <Subsidy>12.65</Subsidy>
                  <Price>12.65</Price>
                  <Alternate>12.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0407011427" Statim="Must">
            <Name>Dipyridamole</Name>
            <Formulation ID="F040701142704" Rank="1" Units="tab" Weight="150">
              <Name>Tab long-acting 150 mg</Name>
              <Brand ID="B04070114270401">
                <Name>Pytazen SR</Name>
                <Pack ID="P750255" Specified="true" nzmt:ctpp_id="50108511000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>13.93</Subsidy>
                  <Price>13.93</Price>
                  <Alternate>13.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0407013860" Statim="Must">
            <Name>Clopidogrel</Name>
            <Formulation ID="F040701386025" Rank="1" Units="tab" Weight="75">
              <Name>Tab 75 mg</Name>
              <Brand ID="B04070138602528" PSS="2025-06-30">
                <Name>Arrow - Clopid</Name>
                <Pack ID="P2648954" Specified="true" nzmt:ctpp_id="50148141000117109">
                  <Quantity>84</Quantity>
                  <Subsidy>5.07</Subsidy>
                  <Price>5.07</Price>
                  <Alternate>5.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0407014008" Statim="Must">
            <Name>Ticagrelor</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1955"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1955">
              <Title>
                <range>Ticagrelor</range>
              </Title>
              <Case When="Initial application" Category="acute coronary syndrome">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci>
                    <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="thrombosis prevention neurological stenting">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has had a neurological stenting procedure* in the last 60 days</ci>
                      <ci type="logical" class="Indication">Patient is about to have a neurological stenting procedure performed*</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event</ci>
                        <ci type="logical" class="Indication">Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Percutaneous coronary intervention with stent deployment">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has undergone percutaneous coronary intervention</ci>
                    <ci type="logical" class="Indication">Patient has had a stent deployed in the previous 4 weeks</ci>
                    <ci type="logical" class="Indication">Patient is clopidogrel-allergic**</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Stent thrombosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382 SA1887 SA1955">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci>
                    <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="thrombosis prevention neurological stenting" Form="SA1382 SA1887 SA1955">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is continuing to benefit from treatment</ci>
                    <ci type="logical" class="Indication">Treatment continues to be clinically appropriate</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Percutaneous coronary intervention with stent deployment" Form="SA1382 SA1887 SA1955">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has undergone percutaneous coronary intervention</ci>
                    <ci type="logical" class="Indication">Patient has had a stent deployed in the previous 4 weeks</ci>
                    <ci type="logical" class="Indication">Patient is clopidogrel-allergic**</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>indications marked with * are unapproved indications.</p>
              </div>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.</p>
              </div>
            </Request>
            <Formulation ID="F040701400825" Rank="1" Units="tab" Weight="90">
              <Name>Tab 90 mg</Name>
              <Brand ID="B04070140082525">
                <Name>Brilinta</Name>
                <Pack ID="P2390922" Specified="true" nzmt:ctpp_id="50125811000117105">
                  <Quantity>56</Quantity>
                  <Subsidy>90.00</Subsidy>
                  <Price>90.00</Price>
                  <Alternate>90.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B04070140082526" PSS="2024-06-30">
                <Name>Ticagrelor Sandoz</Name>
                <Pack ID="P2638770" Specified="true" nzmt:ctpp_id="50270451000117104">
                  <Quantity>56</Quantity>
                  <Subsidy>23.85</Subsidy>
                  <Price>23.85</Price>
                  <Alternate>23.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A040704">
          <Name>Heparin and Antagonist Preparations</Name>
          <Chemical ID="C0407041589">
            <Name>Heparin sodium</Name>
            <Formulation ID="F040704158901" Rank="4" Units="inj">
              <Name>Inj 1,000 iu per ml, 5 ml ampoule</Name>
              <Brand ID="B04070415890125">
                <Name>Pfizer</Name>
                <Pack ID="P2339897" Specified="true" nzmt:ctpp_id="50049831000117105">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>86.11</Subsidy>
                  <Price>86.11</Price>
                  <Alternate>86.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704158903" Rank="4" Units="inj" Weight="500">
              <Name>Inj 5,000 iu per ml, 1 ml</Name>
              <Brand ID="B04070415890301">
                <Name>Hospira</Name>
                <Pack ID="P2034255" Specified="true" nzmt:ctpp_id="50006711000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>70.33</Subsidy>
                  <Price>70.33</Price>
                  <Alternate>70.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B04070415890303" S29="true">
                <Name>DBL Heparin Sodium</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2599902" Specified="true" nzmt:ctpp_id="50281671000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>32.66</Subsidy>
                  <Price>32.66</Price>
                  <Alternate>32.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704158906" Rank="4" Units="inj" Weight="2500">
              <Name>Inj 25,000 iu per ml, 0.2 ml</Name>
              <Brand ID="B04070415890601">
                <Name>Hospira</Name>
                <Pack ID="P333085" Specified="true">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>22.42</Subsidy>
                  <Price>22.42</Price>
                  <Alternate>22.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B04070415890628" S29="true">
                <Name>Heparin DBL</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2594781" Specified="true" nzmt:ctpp_id="50073941000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.40</Subsidy>
                  <Price>42.40</Price>
                  <Alternate>42.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2627884" Specified="true" nzmt:ctpp_id="50291691000117106">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>482.20</Subsidy>
                  <Price>482.20</Price>
                  <Alternate>482.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704158925" Rank="4" Units="inj">
              <Name>Inj 5,000 iu per ml, 5 ml vial</Name>
              <Brand ID="B04070415892525" PSS="2025-06-30">
                <Name>Heparin Sodium Panpharma</Name>
                <Pack ID="P2651815" Specified="true" nzmt:ctpp_id="50309411000117108">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>83.00</Subsidy>
                  <Price>83.00</Price>
                  <Alternate>83.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0407043893">
            <Name>Enoxaparin sodium</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2152"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2152">
              <Title>
                <range>Enoxaparin sodium</range>
              </Title>
              <Case When="Initial application" Category="Pregnancy, Malignancy or Haemodialysis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci>
                    <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci>
                    <ci type="logical" class="Treatment">For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">1</Term>
              </Case>
              <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment</ci>
                    <ci type="logical" class="Treatment">For the prophylaxis and treatment of venous thromboembolism in high risk surgery</ci>
                    <ci type="logical" class="Indication">To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery</ci>
                    <ci type="logical" class="Treatment">For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention</ci>
                    <ci type="logical" class="Treatment">To be used in association with cardioversion of atrial fibrillation</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Initial application" Category="Short-term use during treatment of COVID-19 with nirmatrelvir with ritonavir">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is receiving an anticoagulation treatment that has drug/drug interactions with ritonavir that increases risk of bleeding</ci>
                    <ci type="logical" class="Indication">Patient meets the Access Criteria for COVID-19 antivirals published on the Pharmac website*</ci>
                    <ci type="logical" class="Indication">Other antiviral treatments for COVID-19 have been considered and are not clinically suitable options</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="week">2</Term>
              </Case>
              <Case When="Renewal" Category="Pregnancy, Malignancy or Haemodialysis" Form="SA0975 SA1174 SA1646 SA2152">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patient's pregnancy</ci>
                    <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci>
                    <ci type="logical" class="Treatment">For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">1</Term>
              </Case>
              <Case When="Renewal" Category="Venous thromboembolism other than in pregnancy or malignancy" Form="SA0975 SA1174 SA1646 SA2152">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral
                anti-coagulation)</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
            </Request>
            <Formulation ID="F040704389325" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg in 0.2 ml syringe</Name>
              <Brand ID="B04070438932525">
                <Name>Clexane</Name>
                <Pack ID="P2581868" Specified="true" nzmt:ctpp_id="50116511000117109">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>31.28</Subsidy>
                  <Price>31.28</Price>
                  <Alternate>31.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704389326" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg in 0.4 ml syringe</Name>
              <Brand ID="B04070438932625">
                <Name>Clexane</Name>
                <Pack ID="P2581876" Specified="true" nzmt:ctpp_id="50116521000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.49</Subsidy>
                  <Price>42.49</Price>
                  <Alternate>42.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704389327" Rank="4" Units="inj" Weight="60">
              <Name>Inj 60 mg in 0.6 ml syringe</Name>
              <Brand ID="B04070438932725">
                <Name>Clexane</Name>
                <Pack ID="P2581884" Specified="true" nzmt:ctpp_id="50083481000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>60.67</Subsidy>
                  <Price>60.67</Price>
                  <Alternate>60.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704389328" Rank="4" Units="inj" Weight="80">
              <Name>Inj 80 mg in 0.8 ml syringe</Name>
              <Brand ID="B04070438932825">
                <Name>Clexane</Name>
                <Pack ID="P2581892" Specified="true" nzmt:ctpp_id="50083491000117102">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>80.89</Subsidy>
                  <Price>80.89</Price>
                  <Alternate>80.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704389329" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg in 1 ml syringe</Name>
              <Brand ID="B04070438932925">
                <Name>Clexane</Name>
                <Pack ID="P2581906" Specified="true" nzmt:ctpp_id="50083501000117108">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>101.30</Subsidy>
                  <Price>101.30</Price>
                  <Alternate>101.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704389330" Rank="4" Units="inj" Weight="120">
              <Name>Inj 120 mg in 0.8 ml syringe</Name>
              <Brand ID="B04070438933026">
                <Name>Clexane Forte</Name>
                <Pack ID="P2581914" Specified="true" nzmt:ctpp_id="50080661000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>125.87</Subsidy>
                  <Price>125.87</Price>
                  <Alternate>125.87</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040704389331" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg in 1 ml syringe</Name>
              <Brand ID="B04070438933126">
                <Name>Clexane Forte</Name>
                <Pack ID="P2581922" Specified="true" nzmt:ctpp_id="50080671000117108">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>143.86</Subsidy>
                  <Price>143.86</Price>
                  <Alternate>143.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0407046019">
            <Name>Heparinised saline</Name>
            <Formulation ID="F040704601901" Rank="4" Units="inj" Weight="50">
              <Name>Inj 10 iu per ml, 5 ml</Name>
              <Brand ID="B04070460190125">
                <Name>Pfizer</Name>
                <Pack ID="P2339919" Specified="true" nzmt:ctpp_id="50049851000117100">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>65.48</Subsidy>
                  <Price>65.48</Price>
                  <Alternate>65.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A040707">
          <Name>Oral Anticoagulants</Name>
          <Chemical ID="C0407072331" Statim="Must">
            <Name>Warfarin sodium</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Marevan and Coumadin are not interchangeable.</p>
            </div>
            <Formulation ID="F040707233101" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B04070723310101">
                <Name>Coumadin</Name>
                <Pack ID="P2586967" Specified="true" nzmt:ctpp_id="50116621000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>3.46</Subsidy>
                  <Price>3.46</Price>
                  <Alternate>3.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B04070723310102">
                <Name>Marevan</Name>
                <Pack ID="P210587" Specified="true" nzmt:ctpp_id="50018991000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>6.46</Subsidy>
                  <Price>6.46</Price>
                  <Alternate>6.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040707233103" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B04070723310301">
                <Name>Coumadin</Name>
                <Pack ID="P2586975" Specified="true" nzmt:ctpp_id="50110891000117100">
                  <Quantity>50</Quantity>
                  <Subsidy>4.31</Subsidy>
                  <Price>4.31</Price>
                  <Alternate>4.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040707233105" Rank="1" Units="tab" Weight="3">
              <Name>Tab 3 mg</Name>
              <Brand ID="B04070723310501">
                <Name>Marevan</Name>
                <Pack ID="P210595" Specified="true" nzmt:ctpp_id="50019041000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>10.03</Subsidy>
                  <Price>10.03</Price>
                  <Alternate>10.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040707233106" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B04070723310601">
                <Name>Coumadin</Name>
                <Pack ID="P2586983" Specified="true" nzmt:ctpp_id="50116631000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>5.93</Subsidy>
                  <Price>5.93</Price>
                  <Alternate>5.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B04070723310602">
                <Name>Marevan</Name>
                <Pack ID="P210609" Specified="true" nzmt:ctpp_id="50019061000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>11.48</Subsidy>
                  <Price>11.48</Price>
                  <Alternate>11.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0407073924">
            <Name>Rivaroxaban</Name>
            <Formulation ID="F040707392425" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Rule Type="DoseDMax" Value="1"/>
              <Brand ID="B04070739242525" PSS="2026-06-30">
                <Name>Xarelto</Name>
                <Pack ID="P2545152" Specified="true" nzmt:ctpp_id="50120191000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>15.60</Subsidy>
                  <Price>15.60</Price>
                  <Alternate>15.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040707392426" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Rule Type="FormMax" Value="14" Attribute="PSO"/>
              <Brand ID="B04070739242625" PSS="2026-06-30">
                <Name>Xarelto</Name>
                <Pack ID="P2425920" Specified="true" nzmt:ctpp_id="50147451000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>14.56</Subsidy>
                  <Price>14.56</Price>
                  <Alternate>14.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040707392427" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B04070739242725" PSS="2026-06-30">
                <Name>Xarelto</Name>
                <Pack ID="P2425947" Specified="true" nzmt:ctpp_id="50147471000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>14.56</Subsidy>
                  <Price>14.56</Price>
                  <Alternate>14.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0407073937">
            <Name>Dabigatran</Name>
            <Formulation ID="F040707393725" Rank="2" Units="cap" Weight="75">
              <Name>Cap 75 mg</Name>
              <Rule Type="DoseDMax" Value="2"/>
              <Brand ID="B04070739372525">
                <Name>Pradaxa</Name>
                <Pack ID="P2319586" Specified="true" nzmt:ctpp_id="50048601000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>27.99</Subsidy>
                  <Price>27.99</Price>
                  <Alternate>27.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040707393726" Rank="2" Units="cap" Weight="110">
              <Name>Cap 110 mg</Name>
              <Brand ID="B04070739372625">
                <Name>Pradaxa</Name>
                <Pack ID="P2319594" Specified="true" nzmt:ctpp_id="50048611000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>27.99</Subsidy>
                  <Price>27.99</Price>
                  <Alternate>27.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040707393727" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B04070739372725">
                <Name>Pradaxa</Name>
                <Pack ID="P2389673" Specified="true" nzmt:ctpp_id="50125241000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>27.99</Subsidy>
                  <Price>27.99</Price>
                  <Alternate>27.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0408">
        <Name>Blood Colony-stimulating Factors</Name>
        <ATC3 ID="A040803">
          <Name>Blood Colony-stimulating Factors</Name>
          <Chemical ID="C0408033974">
            <Name>Filgrastim</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1259"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1259">
              <Title>
                <range>Filgrastim</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%*)</ci>
                    <ci type="logical" class="Indication">Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation</ci>
                    <ci type="logical" class="Indication">Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation</ci>
                    <ci type="logical" class="Indication">Treatment of severe chronic neutropenia (ANC &lt; 0.5 Ã—<msup><mi>10</mi><mo>9</mo></msup>/L)</ci>
                    <ci type="logical" class="Indication">Treatment of drug-induced prolonged neutropenia (ANC &lt; 0.5 Ã—<msup><mi>10</mi><mo>9</mo></msup>/L)</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>vocationally registered general practitioner</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>*Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.</p>
              </div>
            </Request>
            <Formulation ID="F040803397425" Rank="4" Units="inj" Weight="300">
              <Name>Inj 300 mcg per 0.5 ml prefilled syringe</Name>
              <Brand ID="B04080339742526" PSS="2024-06-30">
                <Name>Nivestim</Name>
                <Pack ID="P2561956" Specified="true" nzmt:ctpp_id="50132241000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>96.22</Subsidy>
                  <Price>96.22</Price>
                  <Alternate>96.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F040803397426" Rank="4" Units="inj" Weight="480">
              <Name>Inj 480 mcg per 0.5 ml prefilled syringe</Name>
              <Brand ID="B04080339742626" PSS="2024-06-30">
                <Name>Nivestim</Name>
                <Pack ID="P2561964" Specified="true" nzmt:ctpp_id="50132221000117109">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>148.58</Subsidy>
                  <Price>148.58</Price>
                  <Alternate>148.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0408034009">
            <Name>Pegfilgrastim</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1912"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1912">
              <Title>
                <range>Pegfilgrastim</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Used for prevention of neutropenia in patients
                undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than
                or equal to 5%*)</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant>vocationally registered general practitioner</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>*Febrile neutropenia risk greater than or equal to 5% after taking into account other
            risk factors as defined by the European Organisation for Research and Treatment of
            Cancer (EORTC) guidelines.</p>
              </div>
            </Request>
            <Formulation ID="F040803400925" Rank="4" Units="inj">
              <Name>Inj 6 mg per 0.6 ml syringe</Name>
              <Brand ID="B04080340092526" PSS="2025-06-30">
                <Name>Ziextenzo</Name>
                <Pack ID="P2643340" Specified="true" nzmt:ctpp_id="50261371000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>65.00</Subsidy>
                  <Price>65.00</Price>
                  <Alternate>65.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0410">
        <Name>Fluids and Electrolytes</Name>
        <ATC3 ID="A041001">
          <Name>Intravenous Administration</Name>
          <Chemical ID="C0410011393" Statim="Must">
            <Name>Glucose [Dextrose]</Name>
            <Formulation ID="F041001139301" Rank="4" Units="inj" Weight="10">
              <Name>Inj 50%, 10 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04100113930125" PSS="2026-06-30">
                <Name>Biomed</Name>
                <Pack ID="P2243296" Specified="true" nzmt:ctpp_id="50038461000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>34.75</Subsidy>
                  <Price>34.75</Price>
                  <Alternate>34.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041001139325" Rank="4" Units="inj" Weight="90">
              <Name>Inj 50%, 90 ml bottle</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04100113932525" PSS="2026-06-30">
                <Name>Biomed</Name>
                <Pack ID="P2245833" Specified="true" nzmt:ctpp_id="50039251000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>17.50</Subsidy>
                  <Price>17.50</Price>
                  <Alternate>17.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410012016">
            <Name>Potassium chloride</Name>
            <Formulation ID="F041001201603" Rank="4" Units="inj" Weight="750" Statim="Must">
              <Name>Inj 75 mg per ml, 10 ml</Name>
              <Brand ID="B04100120160304">
                <Name>Juno</Name>
                <Pack ID="P2593785" Specified="true" nzmt:ctpp_id="50271801000117106">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>65.00</Subsidy>
                  <Price>65.00</Price>
                  <Alternate>65.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410012128">
            <Name>Sodium bicarbonate</Name>
            <Formulation ID="F041001212802" Rank="4" Units="inj" Weight="8.4">
              <Name>Inj 8.4%, 100 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B04100121280225" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P2244144" Specified="true" nzmt:ctpp_id="50038741000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>24.10</Subsidy>
                  <Price>24.10</Price>
                  <Alternate>24.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041001212826" Rank="4" Units="inj">
              <Name>Inj 8.4%, 50 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B04100121282625" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P2244152" Specified="true" nzmt:ctpp_id="50038751000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>23.52</Subsidy>
                  <Price>23.52</Price>
                  <Alternate>23.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410012135">
            <Name>Sodium chloride</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Not funded for use as a nasal drop. Not funded for nebuliser use except when used in conjunction with an antibiotic intended for nebuliser use.</p>
            </div>
            <Formulation ID="F041001213503" Rank="4" Units="inj" Weight="0.45">
              <Name>Inj 0.9%, 5 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04100121350327" PSS="2025-06-30">
                <Name>Fresenius Kabi</Name>
                <Pack ID="P2565749" Specified="true" nzmt:ctpp_id="50181141000117106">
                  <Quantity>20</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4.00</Subsidy>
                  <Price>4.00</Price>
                  <Alternate>4.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041001213504" Rank="4" Units="inj" Weight="0.9">
              <Name>Inj 0.9%, 10 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04100121350426" PSS="2025-06-30">
                <Name>Fresenius Kabi</Name>
                <Pack ID="P2565757" Specified="true" nzmt:ctpp_id="50181161000117105">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.25</Subsidy>
                  <Price>5.25</Price>
                  <Alternate>5.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041001213505" Rank="4" Units="inj" Weight="1.8">
              <Name>Inj 0.9%, 20 ml ampoule</Name>
              <Brand ID="B04100121350527" PSS="2025-06-30">
                <Name>Fresenius Kabi</Name>
                <Pack ID="P2565730" Specified="true" nzmt:ctpp_id="50181171000117100">
                  <Quantity>20</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.00</Subsidy>
                  <Price>5.00</Price>
                  <Alternate>5.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041001213509" Rank="3" Units="ml">
              <Name>Inj 0.9%, bag</Name>
              <Rule Type="FormMax" Value="2000" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)</p>
              </div>
              <Brand ID="B04100121350901">
                <Name>Baxter</Name>
                <Pack ID="P285153" Specified="true" nzmt:ctpp_id="50063991000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>1.33</Subsidy>
                  <Price>1.33</Price>
                  <Alternate>1.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P285161" Specified="true" nzmt:ctpp_id="50064001000117101">
                  <Quantity>1000</Quantity>
                  <Subsidy>1.36</Subsidy>
                  <Price>1.36</Price>
                  <Alternate>1.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041001213525" Rank="4" Units="inj">
              <Name>Inj 23.4% (4 mmol/ml), 20 ml ampoule</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
                <p xlink:type="simple" xlink:href="standard-formulae">For Sodium chloride oral liquid formulation refer Standard Formulae</p>
              </div>
              <Brand ID="B04100121352525">
                <Name>Biomed</Name>
                <Pack ID="P2089432" Specified="true" nzmt:ctpp_id="50016361000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>38.25</Subsidy>
                  <Price>38.25</Price>
                  <Alternate>38.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410012332">
            <Name>Water</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: decimal">
                <li>
                  <p>On a prescription or Practitionerâ€™s Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or</p>
                </li>
                <li>
                  <p>On a bulk supply order; or</p>
                </li>
                <li>
                  <p>When used in the extemporaneous compounding of eye drops; or</p>
                </li>
                <li>
                  <p>When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F041001233203" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04100123320325" PSS="2025-06-30">
                <Name>Multichem</Name>
                <Pack ID="P2208326" Specified="true" nzmt:ctpp_id="50307331000117101">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7.60</Subsidy>
                  <Price>7.60</Price>
                  <Alternate>7.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041001233204" Rank="4" Units="inj" Weight="20">
              <Name>Inj  20 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04100123320427" PSS="2025-06-30">
                <Name>Fresenius Kabi</Name>
                <Pack ID="P2565692" Specified="true" nzmt:ctpp_id="50180201000117109">
                  <Quantity>20</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.00</Subsidy>
                  <Price>5.00</Price>
                  <Alternate>5.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410012808">
            <Name>Total parenteral nutrition (TPN)</Name>
            <Formulation ID="F041001280801" Rank="10" Units="ea">
              <Name>Infusion</Name>
              <Brand ID="B04100128080101">
                <Name>TPN</Name>
                <Pack ID="P435031" Specified="true" OP="true" CBS="true" nzmt:ctpp_id="50085241000117109">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A041004">
          <Name>Oral Administration</Name>
          <Chemical ID="C0410041205">
            <Name>Calcium polystyrene sulphonate</Name>
            <Formulation ID="F041004120501" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B04100412050101">
                <Name>Calcium Resonium</Name>
                <Pack ID="P201510" Specified="true" OP="true" nzmt:ctpp_id="50002541000117100">
                  <Quantity>300</Quantity>
                  <Subsidy>169.85</Subsidy>
                  <Price>169.85</Price>
                  <Alternate>169.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410041394">
            <Name>Compound electrolytes with glucose [Dextrose]</Name>
            <Formulation ID="F041004139401" Rank="3" Units="ml">
              <Name>Soln with electrolytes</Name>
              <Brand ID="B04100413940127" ToBePSS="2024-05-01">
                <Name>Hydralyte - Lemonade</Name>
                <Pack ID="P2468255" Specified="true" OP="true" nzmt:ctpp_id="50208671000117101">
                  <Quantity>1000</Quantity>
                  <Subsidy>6.53</Subsidy>
                  <Price>6.53</Price>
                  <Alternate>6.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041004139425" Rank="3" Units="ml">
              <Name>Soln with electrolytes (2 x 500 ml)</Name>
              <Brand ID="B04100413942525" ToBeDelisted="2024-05-01">
                <Name>Pedialyte - Bubblegum</Name>
                <Pack ID="P2504308" Specified="true" OP="true" nzmt:ctpp_id="50236461000117102">
                  <Quantity>1000</Quantity>
                  <Subsidy>8.55</Subsidy>
                  <Price>8.55</Price>
                  <Alternate>8.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410041446">
            <Name>Compound electrolytes</Name>
            <Formulation ID="F041004144625" Rank="2" Units="sach" Weight="4.4">
              <Name>Powder for oral soln </Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B04100414462525" PSS="2025-06-30">
                <Name>Electral</Name>
                <Pack ID="P2576937" Specified="true" nzmt:ctpp_id="50181671000117107">
                  <Quantity>50</Quantity>
                  <Subsidy>9.53</Subsidy>
                  <Price>9.53</Price>
                  <Alternate>9.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410042013">
            <Name>Phosphorus</Name>
            <Formulation ID="F041004201301" Rank="1" Units="tab" Weight="300">
              <Name>Tab eff 500 mg (16 mmol)</Name>
              <Brand ID="B04100420130102">
                <Name>Phosphate Phebra</Name>
                <Pack ID="P2553325" Specified="true" nzmt:ctpp_id="50253861000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>82.50</Subsidy>
                  <Price>82.50</Price>
                  <Alternate>82.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410042016">
            <Name>Potassium chloride</Name>
            <Formulation ID="F041004201601" Rank="1" Units="tab" Weight="548" Statim="Must">
              <Name>Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)</Name>
              <Brand ID="B04100420160101">
                <Name>Chlorvescent</Name>
                <Pack ID="P405663" Specified="true" nzmt:ctpp_id="50082471000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>5.26</Subsidy>
                  <Price>17.10</Price>
                  <Alternate>5.26</Alternate>
                  <Surcharge>0.19733</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F041004201602" Rank="1" Units="tab" Weight="600" Statim="Must">
              <Name>Tab long-acting 600 mg (8 mmol)</Name>
              <Brand ID="B04100420160203">
                <Name>Span-K</Name>
                <Pack ID="P2144468" Specified="true" nzmt:ctpp_id="50024871000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>15.35</Subsidy>
                  <Price>15.35</Price>
                  <Alternate>15.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410042128">
            <Name>Sodium bicarbonate</Name>
            <Formulation ID="F041004212827" Rank="2" Units="cap">
              <Name>Cap 840 mg</Name>
              <Brand ID="B04100421282725">
                <Name>Sodibic</Name>
                <Pack ID="P2085992" Specified="true">
                  <Quantity>100</Quantity>
                  <Subsidy>8.52</Subsidy>
                  <Price>8.52</Price>
                  <Alternate>8.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2513447" Specified="true" nzmt:ctpp_id="50014371000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>8.52</Subsidy>
                  <Price>8.52</Price>
                  <Alternate>8.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0410042160">
            <Name>Sodium polystyrene sulphonate</Name>
            <Formulation ID="F041004216001" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B04100421600101">
                <Name>Resonium-A</Name>
                <Pack ID="P251089" Specified="true" OP="true" nzmt:ctpp_id="50052601000117109">
                  <Quantity>454</Quantity>
                  <Subsidy>84.65</Subsidy>
                  <Price>84.65</Price>
                  <Alternate>84.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A07">
      <Name>Cardiovascular System</Name>
      <ATC2 ID="A0704">
        <Name>Alpha-Adrenoceptor Blockers</Name>
        <ATC3 ID="A070401">
          <Name>Alpha Adrenoceptor Blockers</Name>
          <Chemical ID="C0704011966" Statim="Must">
            <Name>Phenoxybenzamine hydrochloride</Name>
            <Formulation ID="F070401196601" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B07040119660125" S29="true">
                <Name>BNM</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2457636" Specified="true" nzmt:ctpp_id="50202861000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>65.00</Subsidy>
                  <Price>65.00</Price>
                  <Alternate>65.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07040119660126" S29="true">
                <Name>Dibenzyline</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2541793" Specified="true" nzmt:ctpp_id="50048341000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>216.67</Subsidy>
                  <Price>216.67</Price>
                  <Alternate>216.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0704012031" Statim="Must">
            <Name>Prazosin</Name>
            <Formulation ID="F070401203102" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B07040120310202" S29="true">
                <Name>Minipress</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2672014" Specified="true" nzmt:ctpp_id="50054141000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>9.98</Subsidy>
                  <Price>9.98</Price>
                  <Alternate>9.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07040120310227" S29="true">
                <Name>Arrotex-Prazosin S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2625725" Specified="true" nzmt:ctpp_id="50292251000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>5.53</Subsidy>
                  <Price>5.53</Price>
                  <Alternate>5.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070401203103" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B07040120310302" S29="true">
                <Name>Minipress</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2672006" Specified="true" nzmt:ctpp_id="50054161000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>13.29</Subsidy>
                  <Price>13.29</Price>
                  <Alternate>13.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07040120310327" S29="true">
                <Name>Arrotex-Prazosin S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2625733" Specified="true" nzmt:ctpp_id="50292261000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070401203104" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07040120310402" S29="true">
                <Name>Minipress</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2671999" Specified="true" nzmt:ctpp_id="50054181000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>22.00</Subsidy>
                  <Price>22.00</Price>
                  <Alternate>22.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07040120310427" S29="true">
                <Name>Arrotex-Prazosin S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2625741" Specified="true" nzmt:ctpp_id="50292271000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>11.70</Subsidy>
                  <Price>11.70</Price>
                  <Alternate>11.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0704012515" Statim="Must">
            <Name>Doxazosin</Name>
            <Formulation ID="F070401251502" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B07040125150227">
                <Name>Doxazosin Clinect</Name>
                <Pack ID="P2608766" Specified="true" nzmt:ctpp_id="50287721000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>17.35</Subsidy>
                  <Price>17.35</Price>
                  <Alternate>17.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070401251503" Rank="1" Units="tab" Weight="4">
              <Name>Tab 4 mg</Name>
              <Brand ID="B07040125150327">
                <Name>Doxazosin Clinect</Name>
                <Pack ID="P2608774" Specified="true" nzmt:ctpp_id="50287751000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>20.94</Subsidy>
                  <Price>20.94</Price>
                  <Alternate>20.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0707">
        <Name>Agents Affecting the Renin-Angiotensin System</Name>
        <ATC3 ID="A070701">
          <Name>ACE Inhibitors</Name>
          <Chemical ID="C0707012711" Statim="Must">
            <Name>Enalapril maleate</Name>
            <Formulation ID="F070701271101" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07070127110128" PSS="2025-06-30">
                <Name>Acetec</Name>
                <Pack ID="P2636484" Specified="true" nzmt:ctpp_id="50300411000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>1.75</Subsidy>
                  <Price>1.75</Price>
                  <Alternate>1.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701271102" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07070127110228" PSS="2025-06-30">
                <Name>Acetec</Name>
                <Pack ID="P2636492" Specified="true" nzmt:ctpp_id="50300421000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>1.97</Subsidy>
                  <Price>1.97</Price>
                  <Alternate>1.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701271103" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07070127110328" PSS="2025-06-30">
                <Name>Acetec</Name>
                <Pack ID="P2636506" Specified="true" nzmt:ctpp_id="50300431000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>2.35</Subsidy>
                  <Price>2.35</Price>
                  <Alternate>2.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707012770">
            <Name>Cilazapril</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Subsidy by endorsement â€“ Subsidised for patients who were taking cilazapril prior to 1 May
        2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription
        as endorsed where there exists a record of prior dispensing of cilazapril. </p>
            </div>
            <Formulation ID="F070701277001" Rank="1" Units="tab" Weight="0.5" Statim="Must">
              <Name>Tab 0.5 mg</Name>
              <Brand ID="B07070127700125">
                <Name>Zapril</Name>
                <Pack ID="P2399059" Specified="true" nzmt:ctpp_id="50134061000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>2.69</Subsidy>
                  <Price>2.69</Price>
                  <Alternate>2.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701277002" Rank="1" Units="tab" Weight="2.5" Statim="Must">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B07070127700225">
                <Name>Zapril</Name>
                <Pack ID="P2379082" Specified="true" nzmt:ctpp_id="50122921000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>5.79</Subsidy>
                  <Price>5.79</Price>
                  <Alternate>5.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701277003" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07070127700325">
                <Name>Zapril</Name>
                <Pack ID="P2379090" Specified="true" nzmt:ctpp_id="50122931000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>10.05</Subsidy>
                  <Price>10.05</Price>
                  <Alternate>10.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707012772" Statim="Must">
            <Name>Quinapril</Name>
            <Formulation ID="F070701277201" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07070127720125" PSS="2024-06-30">
                <Name>Arrow-Quinapril 5</Name>
                <Pack ID="P2427877" Specified="true" nzmt:ctpp_id="50157741000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>5.97</Subsidy>
                  <Price>5.97</Price>
                  <Alternate>5.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701277202" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07070127720225" PSS="2024-06-30">
                <Name>Arrow-Quinapril 10</Name>
                <Pack ID="P2427885" Specified="true" nzmt:ctpp_id="50157771000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>5.18</Subsidy>
                  <Price>5.18</Price>
                  <Alternate>5.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701277203" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07070127720325" PSS="2024-06-30">
                <Name>Arrow-Quinapril 20</Name>
                <Pack ID="P2427893" Specified="true" nzmt:ctpp_id="50157781000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>7.95</Subsidy>
                  <Price>7.95</Price>
                  <Alternate>7.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707012797" Statim="Must">
            <Name>Lisinopril</Name>
            <Formulation ID="F070701279701" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07070127970126" PSS="2025-06-30">
                <Name>Ethics Lisinopril</Name>
                <Pack ID="P2352435" Specified="true" nzmt:ctpp_id="50226071000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>11.07</Subsidy>
                  <Price>11.07</Price>
                  <Alternate>11.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07070127970127" PSS="2025-06-30">
                <Name>Teva Lisinopril</Name>
                <Pack ID="P2643669" Specified="true" nzmt:ctpp_id="50304941000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>11.07</Subsidy>
                  <Price>11.07</Price>
                  <Alternate>11.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701279702" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07070127970226" PSS="2025-06-30">
                <Name>Ethics Lisinopril</Name>
                <Pack ID="P2352443" Specified="true" nzmt:ctpp_id="50226081000117104">
                  <Quantity>90</Quantity>
                  <Subsidy>11.67</Subsidy>
                  <Price>11.67</Price>
                  <Alternate>11.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07070127970227" PSS="2025-06-30">
                <Name>Teva Lisinopril</Name>
                <Pack ID="P2643677" Specified="true" nzmt:ctpp_id="50304951000117104">
                  <Quantity>90</Quantity>
                  <Subsidy>11.67</Subsidy>
                  <Price>11.67</Price>
                  <Alternate>11.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701279703" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07070127970326" PSS="2025-06-30">
                <Name>Ethics Lisinopril</Name>
                <Pack ID="P2352451" Specified="true" nzmt:ctpp_id="50226091000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>14.69</Subsidy>
                  <Price>14.69</Price>
                  <Alternate>14.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07070127970327" PSS="2025-06-30">
                <Name>Teva Lisinopril</Name>
                <Pack ID="P2643685" Specified="true" nzmt:ctpp_id="50304961000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>14.69</Subsidy>
                  <Price>14.69</Price>
                  <Alternate>14.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707012806" Statim="Must">
            <Name>Perindopril</Name>
            <Formulation ID="F070701280601" Rank="1" Units="tab" Weight="4">
              <Name>Tab 4 mg</Name>
              <Brand ID="B07070128060101" PSS="2024-06-30">
                <Name>Coversyl</Name>
                <Pack ID="P2603950" Specified="true" nzmt:ctpp_id="50114111000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>2.95</Subsidy>
                  <Price>2.95</Price>
                  <Alternate>2.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701280602" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B07070128060201" PSS="2024-06-30">
                <Name>Coversyl</Name>
                <Pack ID="P2603942" Specified="true" nzmt:ctpp_id="50075491000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>1.58</Subsidy>
                  <Price>1.58</Price>
                  <Alternate>1.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701280625" Rank="1" Units="tab" Weight="8">
              <Name>Tab 8 mg</Name>
              <Brand ID="B07070128062525">
                <Name>Coversyl</Name>
                <Pack ID="P2643316" Specified="true" nzmt:ctpp_id="50165771000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>5.02</Subsidy>
                  <Price>5.02</Price>
                  <Alternate>5.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707012841" Statim="Must">
            <Name>Captopril</Name>
            <Formulation ID="F070701284106" Rank="3" Units="ml" Weight="5">
              <Name>Oral liq 5 mg per ml</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Oral liquid restricted to children under 12 years of age.</p>
              </div>
              <Brand ID="B07070128410601" ToBeDelisted="2024-04-01">
                <Name>Capoten</Name>
                <Pack ID="P2055538" Specified="true" OP="true" nzmt:ctpp_id="50009941000117103">
                  <Quantity>95</Quantity>
                  <Subsidy>94.99</Subsidy>
                  <Price>94.99</Price>
                  <Alternate>94.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07070128410603" ToBePSS="2024-04-01">
                <Name>DP-Captopril</Name>
                <Pack ID="P2657775" Specified="true" OP="true" nzmt:ctpp_id="50305901000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>86.00</Subsidy>
                  <Price>86.00</Price>
                  <Alternate>86.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707014164" Statim="Must">
            <Name>Ramipril</Name>
            <Formulation ID="F070701416425" Rank="2" Units="cap" Weight="1.25">
              <Name>Cap 1.25 mg</Name>
              <Brand ID="B07070141642525" PSS="2024-06-30">
                <Name>Tryzan</Name>
                <Pack ID="P2635747" Specified="true" nzmt:ctpp_id="50298761000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>6.90</Subsidy>
                  <Price>6.90</Price>
                  <Alternate>6.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701416426" Rank="2" Units="cap" Weight="2.5">
              <Name>Cap 2.5 mg</Name>
              <Brand ID="B07070141642625" PSS="2024-06-30">
                <Name>Tryzan</Name>
                <Pack ID="P2635755" Specified="true" nzmt:ctpp_id="50298771000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>6.60</Subsidy>
                  <Price>6.60</Price>
                  <Alternate>6.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701416427" Rank="2" Units="cap" Weight="5">
              <Name>Cap 5 mg</Name>
              <Brand ID="B07070141642725" PSS="2024-06-30">
                <Name>Tryzan</Name>
                <Pack ID="P2635763" Specified="true" nzmt:ctpp_id="50298781000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>6.75</Subsidy>
                  <Price>6.75</Price>
                  <Alternate>6.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070701416428" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B07070141642825" PSS="2024-06-30">
                <Name>Tryzan</Name>
                <Pack ID="P2635771" Specified="true" nzmt:ctpp_id="50298791000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>7.05</Subsidy>
                  <Price>7.05</Price>
                  <Alternate>7.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A070702">
          <Name>ACE Inhibitors with Diuretics</Name>
          <Chemical ID="C0707023749">
            <Name>Quinapril with hydrochlorothiazide</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Subsidy by endorsement â€“ Subsidised for patients who were taking quinapril with hydrochlorothiazide prior to 1 May
        2022 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription
        as endorsed where there exists a record of prior dispensing of quinapril with hydrochlorothiazide. </p>
            </div>
            <Formulation ID="F070702374925" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg with hydrochlorothiazide 12.5 mg</Name>
              <Brand ID="B07070237492525" PSS="2024-06-30">
                <Name>Accuretic 10</Name>
                <Pack ID="P2022923" Specified="true" nzmt:ctpp_id="50004651000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>4.10</Subsidy>
                  <Price>4.10</Price>
                  <Alternate>4.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070702374926" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg with hydrochlorothiazide 12.5 mg</Name>
              <Brand ID="B07070237492625" PSS="2024-06-30">
                <Name>Accuretic 20</Name>
                <Pack ID="P2022931" Specified="true" nzmt:ctpp_id="50004661000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>5.25</Subsidy>
                  <Price>5.25</Price>
                  <Alternate>5.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A070703">
          <Name>Angiotensin II Antagonists</Name>
          <Chemical ID="C0707031061">
            <Name>Losartan potassium</Name>
            <Formulation ID="F070703106101" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab 50 mg</Name>
              <Brand ID="B07070310610126" PSS="2026-06-30">
                <Name>Losartan Actavis</Name>
                <Pack ID="P2466872" Specified="true" nzmt:ctpp_id="50211971000117101">
                  <Quantity>84</Quantity>
                  <Subsidy>2.86</Subsidy>
                  <Price>2.86</Price>
                  <Alternate>2.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070703106102" Rank="1" Units="tab" Weight="12.5" Statim="Must">
              <Name>Tab 12.5 mg</Name>
              <Brand ID="B07070310610226" PSS="2026-06-30">
                <Name>Losartan Actavis</Name>
                <Pack ID="P2466856" Specified="true" nzmt:ctpp_id="50211911000117108">
                  <Quantity>84</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.00</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070703106125" Rank="1" Units="tab" Weight="100" Statim="Must">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07070310612527" PSS="2026-06-30">
                <Name>Losartan Actavis</Name>
                <Pack ID="P2466880" Specified="true" nzmt:ctpp_id="50212001000117103">
                  <Quantity>84</Quantity>
                  <Subsidy>4.57</Subsidy>
                  <Price>4.57</Price>
                  <Alternate>4.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070703106126" Rank="1" Units="tab" Weight="25" Statim="Must">
              <Name>Tab 25 mg</Name>
              <Brand ID="B07070310612627" PSS="2026-06-30">
                <Name>Losartan Actavis</Name>
                <Pack ID="P2466864" Specified="true" nzmt:ctpp_id="50211941000117107">
                  <Quantity>84</Quantity>
                  <Subsidy>2.29</Subsidy>
                  <Price>2.29</Price>
                  <Alternate>2.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707031254" Statim="Must">
            <Name>Candesartan cilexetil</Name>
            <Formulation ID="F070703125401" Rank="1" Units="tab" Weight="4">
              <Name>Tab 4 mg</Name>
              <Brand ID="B07070312540125" PSS="2024-06-30">
                <Name>Candestar</Name>
                <Pack ID="P2380404" Specified="true" nzmt:ctpp_id="50125421000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.00</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070703125402" Rank="1" Units="tab" Weight="8">
              <Name>Tab 8 mg</Name>
              <Brand ID="B07070312540225" PSS="2024-06-30">
                <Name>Candestar</Name>
                <Pack ID="P2380412" Specified="true" nzmt:ctpp_id="50125431000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>2.28</Subsidy>
                  <Price>2.28</Price>
                  <Alternate>2.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070703125403" Rank="1" Units="tab" Weight="16">
              <Name>Tab 16 mg</Name>
              <Brand ID="B07070312540325" PSS="2024-06-30">
                <Name>Candestar</Name>
                <Pack ID="P2380420" Specified="true" nzmt:ctpp_id="50125441000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>3.31</Subsidy>
                  <Price>3.31</Price>
                  <Alternate>3.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070703125425" Rank="1" Units="tab" Weight="32">
              <Name>Tab 32 mg</Name>
              <Brand ID="B07070312542526" PSS="2024-06-30">
                <Name>Candestar</Name>
                <Pack ID="P2380439" Specified="true" nzmt:ctpp_id="50125451000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>5.26</Subsidy>
                  <Price>5.26</Price>
                  <Alternate>5.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A070705">
          <Name>Angiotensin II Antagonists with Diuretics</Name>
          <Chemical ID="C0707051068">
            <Name>Losartan potassium with hydrochlorothiazide</Name>
            <Formulation ID="F070705106805" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab 50 mg with hydrochlorothiazide 12.5 mg</Name>
              <Brand ID="B07070510680526" PSS="2025-06-30">
                <Name>Arrow-Losartan &amp; Hydrochlorothiazide</Name>
                <Pack ID="P2390620" Specified="true" nzmt:ctpp_id="50125521000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>4.00</Subsidy>
                  <Price>4.00</Price>
                  <Alternate>4.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0707054178" Statim="Must">
            <Name>Candesartan cilexetil with hydrochlorothiazide</Name>
            <Formulation ID="F070705417825" Rank="1" Units="Tab" Weight="16">
              <Name>Tab 16 mg with hydrochlorothiazide 12.5 mg</Name>
              <Brand ID="B07070541782525">
                <Name>APO-Candesartan HCTZ 16/12.5</Name>
                <Pack ID="P2653893" Specified="true" nzmt:ctpp_id="50303111000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>4.10</Subsidy>
                  <Price>4.10</Price>
                  <Alternate>4.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070705417826" Rank="1" Units="Tab" Weight="32">
              <Name>Tab 32 mg with hydrochlorothiazide 12.5 mg</Name>
              <Brand ID="B07070541782625">
                <Name>APO-Candesartan HCTZ 32/12.5</Name>
                <Pack ID="P2653907" Specified="true" nzmt:ctpp_id="50303121000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>5.25</Subsidy>
                  <Price>5.25</Price>
                  <Alternate>5.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A070710">
          <Name>Angiotensin II Antagonists with Neprilysin Inhibitors</Name>
          <Chemical ID="C0707104105">
            <Name>Sacubitril with valsartan</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2302"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2302">
              <Title>
                <range>Sacubitril with valsartan</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has heart failure</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is in NYHA/WHO functional class
                        II</ci>
                      <ci type="logical" class="Indication">Patient is in NYHA/WHO functional class
                        III</ci>
                      <ci type="logical" class="Indication">Patient is in NYHA/WHO functional class
                        IV</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a documented left ventricular
                        ejection fraction (LVEF) of less than or equal to 35%</ci>
                      <ci type="logical" class="Indication">An ECHO is not reasonably practical, and
                        in the opinion of the treating practitioner the patient would benefit from
                        treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is receiving concomitant optimal
                    standard chronic heart failure treatments</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F070710410525" Rank="1" Units="tab">
              <Name>Tab 24.3 mg with valsartan 25.7 mg</Name>
              <Brand ID="B07071041052525">
                <Name>Entresto 24/26</Name>
                <Pack ID="P2554720" Specified="true" nzmt:ctpp_id="50257661000117101">
                  <Quantity>56</Quantity>
                  <Subsidy>190.00</Subsidy>
                  <Price>190.00</Price>
                  <Alternate>190.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070710410526" Rank="1" Units="tab">
              <Name>Tab 48.6 mg with valsartan 51.4 mg</Name>
              <Brand ID="B07071041052625">
                <Name>Entresto 49/51</Name>
                <Pack ID="P2554739" Specified="true" nzmt:ctpp_id="50257671000117106">
                  <Quantity>56</Quantity>
                  <Subsidy>190.00</Subsidy>
                  <Price>190.00</Price>
                  <Alternate>190.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F070710410527" Rank="1" Units="tab">
              <Name>Tab 97.2 mg with valsartan 102.8 mg</Name>
              <Brand ID="B07071041052725">
                <Name>Entresto 97/103</Name>
                <Pack ID="P2554747" Specified="true" nzmt:ctpp_id="50257681000117109">
                  <Quantity>56</Quantity>
                  <Subsidy>190.00</Subsidy>
                  <Price>190.00</Price>
                  <Alternate>190.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0713">
        <Name>Antiarrhythmics</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A220101">For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local</p>
        </div>
        <ATC3 ID="A071301">
          <Name>Antiarrhythmics</Name>
          <Chemical ID="C0713011057">
            <Name>Amiodarone hydrochloride</Name>
            <Formulation ID="F071301105701" Rank="1" Units="tab" Weight="100" Statim="May">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07130110570102" PSS="2025-06-30">
                <Name>Aratac</Name>
                <Pack ID="P770620" Specified="true" nzmt:ctpp_id="50111671000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>3.49</Subsidy>
                  <Price>3.49</Price>
                  <Alternate>3.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301105702" Rank="1" Units="tab" Weight="200" Statim="May">
              <Name>Tab 200 mg</Name>
              <Brand ID="B07130110570202" PSS="2025-06-30">
                <Name>Aratac</Name>
                <Pack ID="P770639" Specified="true" nzmt:ctpp_id="50111681000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>4.49</Subsidy>
                  <Price>4.49</Price>
                  <Alternate>4.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301105703" Rank="4" Units="inj" Weight="150">
              <Name>Inj 50 mg per ml, 3 ml ampoule</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <Brand ID="B07130110570301">
                <Name>Cordarone-X</Name>
                <Pack ID="P2648520" Specified="true" nzmt:ctpp_id="50144331000117107">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9.12</Subsidy>
                  <Price>9.12</Price>
                  <Alternate>9.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07130110570326" PSS="2025-06-30">
                <Name>Max Health</Name>
                <Pack ID="P2565129" Specified="true" nzmt:ctpp_id="50231231000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>15.22</Subsidy>
                  <Price>15.22</Price>
                  <Alternate>15.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0713011097" Statim="Must">
            <Name>Atropine sulphate</Name>
            <Formulation ID="F071301109703" Rank="4" Units="inj" Weight="600">
              <Name>Inj 600 mcg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B07130110970303" PSS="2024-06-30">
                <Name>Martindale</Name>
                <Pack ID="P2528754" Specified="true" nzmt:ctpp_id="50226561000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>15.09</Subsidy>
                  <Price>15.09</Price>
                  <Alternate>15.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0713011412" Statim="Must">
            <Name>Digoxin</Name>
            <Formulation ID="F071301141201" Rank="1" Units="tab">
              <Name>Tab 62.5 mcg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B07130114120101" PSS="2025-06-30">
                <Name>Lanoxin PG</Name>
                <Pack ID="P2377012" Specified="true" nzmt:ctpp_id="50121671000117100">
                  <Quantity>240</Quantity>
                  <Subsidy>7.80</Subsidy>
                  <Price>7.80</Price>
                  <Alternate>7.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301141202" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mcg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B07130114120201" PSS="2025-06-30">
                <Name>Lanoxin</Name>
                <Pack ID="P2378078" Specified="true" nzmt:ctpp_id="50122551000117103">
                  <Quantity>240</Quantity>
                  <Subsidy>16.90</Subsidy>
                  <Price>16.90</Price>
                  <Alternate>16.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301141203" Rank="3" Units="ml" Weight="50">
              <Name>Oral liq 50 mcg per ml</Name>
              <Brand ID="B07130114120301">
                <Name>Lanoxin</Name>
                <Pack ID="P426490" Specified="true" nzmt:ctpp_id="50084571000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>16.60</Subsidy>
                  <Price>16.60</Price>
                  <Alternate>16.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07130114120325" S29="true">
                <Name>Lanoxin S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2527197" Specified="true" nzmt:ctpp_id="50245881000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>16.60</Subsidy>
                  <Price>16.60</Price>
                  <Alternate>16.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07130114120326">
                <Name>Lanoxin Paediatric Elixir</Name>
                <Pack ID="P2611562" Specified="true">
                  <Quantity>60</Quantity>
                  <Subsidy>16.60</Subsidy>
                  <Price>16.60</Price>
                  <Alternate>16.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0713011428" Statim="May">
            <Name>Disopyramide phosphate</Name>
            <Formulation ID="F071301142802" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B07130114280202">
                <Name>Rythmodan</Name>
                <Pack ID="P315699" Specified="true" nzmt:ctpp_id="50014281000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>23.87</Subsidy>
                  <Price>23.87</Price>
                  <Alternate>23.87</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07130114280203" S29="true">
                <Name>Rythmodan - Cheplafarm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2658062" Specified="true" nzmt:ctpp_id="50317321000117101">
                  <Quantity>84</Quantity>
                  <Subsidy>20.05</Subsidy>
                  <Price>20.05</Price>
                  <Alternate>20.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0713011510">
            <Name>Flecainide acetate</Name>
            <Formulation ID="F071301151001" Rank="1" Units="tab" Weight="50" Statim="May">
              <Name>Tab 50 mg</Name>
              <Brand ID="B07130115100104" PSS="2026-06-30">
                <Name>Flecainide BNM</Name>
                <Pack ID="P2567695" Specified="true" nzmt:ctpp_id="50177531000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>19.95</Subsidy>
                  <Price>19.95</Price>
                  <Alternate>19.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07130115100106" S29="true">
                <Name>Flecatab</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2666928" Specified="true" nzmt:ctpp_id="50323261000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>19.95</Subsidy>
                  <Price>19.95</Price>
                  <Alternate>19.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301151003" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 15 ml ampoule</Name>
              <Brand ID="B07130115100301">
                <Name>Tambocor</Name>
                <Pack ID="P2447363" Specified="true" nzmt:ctpp_id="50073641000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>104.00</Subsidy>
                  <Price>104.00</Price>
                  <Alternate>104.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301151004" Rank="2" Units="cap" Weight="100" Statim="May">
              <Name>Cap long-acting 100 mg</Name>
              <Brand ID="B07130115100402" PSS="2026-06-30">
                <Name>Flecainide Controlled Release Teva</Name>
                <Pack ID="P2567113" Specified="true" nzmt:ctpp_id="50264311000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>35.78</Subsidy>
                  <Price>35.78</Price>
                  <Alternate>35.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301151005" Rank="2" Units="cap" Weight="200" Statim="May">
              <Name>Cap long-acting 200 mg</Name>
              <Brand ID="B07130115100502" PSS="2026-06-30">
                <Name>Flecainide Controlled Release Teva</Name>
                <Pack ID="P2567121" Specified="true" nzmt:ctpp_id="50264351000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>54.28</Subsidy>
                  <Price>54.28</Price>
                  <Alternate>54.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0713011823" Statim="May">
            <Name>Mexiletine hydrochloride</Name>
            <Formulation ID="F071301182325" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B07130118232527" S29="true">
                <Name>Teva</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2605562" Specified="true" nzmt:ctpp_id="50285941000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>162.00</Subsidy>
                  <Price>162.00</Price>
                  <Alternate>162.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071301182326" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B07130118232626" S29="true">
                <Name>Teva</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2607263" Specified="true" nzmt:ctpp_id="50286091000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>202.00</Subsidy>
                  <Price>202.00</Price>
                  <Alternate>202.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0713012810" Statim="May">
            <Name>Propafenone hydrochloride</Name>
            <Formulation ID="F071301281001" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B07130128100101">
                <Name>Rytmonorm</Name>
                <Pack ID="P2534339" Specified="true" nzmt:ctpp_id="50115711000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>40.90</Subsidy>
                  <Price>40.90</Price>
                  <Alternate>40.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0715">
        <Name>Antihypotensives</Name>
        <ATC3 ID="A071501">
          <Name>Antihypotensives</Name>
          <Chemical ID="C0715011012">
            <Name>Midodrine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1474"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1474">
              <Title>
                <range>Midodrine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Patient has disabling orthostatic hypotension not due to drugs</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Renewal" Form="SA0934 SA1474">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F071501101201" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B07150110120102" PSS="2024-06-30">
                <Name>Midodrine Medsurge</Name>
                <Pack ID="P2632063" Specified="true" nzmt:ctpp_id="50277251000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>38.23</Subsidy>
                  <Price>38.23</Price>
                  <Alternate>38.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07150110120103" S29="true">
                <Name>MAR-Midodrine</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2667851" Specified="true" nzmt:ctpp_id="50324101000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>38.23</Subsidy>
                  <Price>38.23</Price>
                  <Alternate>38.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071501101202" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07150110120202" PSS="2024-06-30">
                <Name>Midodrine Medsurge</Name>
                <Pack ID="P2632071" Specified="true" nzmt:ctpp_id="50277131000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>59.98</Subsidy>
                  <Price>59.98</Price>
                  <Alternate>59.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0716">
        <Name>Beta-Adrenoceptor Blockers</Name>
        <ATC3 ID="A071601">
          <Name>Beta Adrenoceptor Blockers</Name>
          <Chemical ID="C0716011094" Statim="Must">
            <Name>Atenolol</Name>
            <Formulation ID="F071601109401" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B07160110940128" PSS="2024-06-30">
                <Name>Viatris</Name>
                <Pack ID="P2627140" Specified="true" nzmt:ctpp_id="50290831000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>9.33</Subsidy>
                  <Price>9.33</Price>
                  <Alternate>9.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601109402" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07160110940225" PSS="2024-06-30" ToBeDelisted="2024-07-01">
                <Name>Mylan Atenolol</Name>
                <Pack ID="P2279274" Specified="true" nzmt:ctpp_id="50217821000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>14.20</Subsidy>
                  <Price>14.20</Price>
                  <Alternate>14.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160110940227">
                <Name>Atenolol Viatris</Name>
                <Pack ID="P2627159" Specified="true" nzmt:ctpp_id="50290771000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>14.20</Subsidy>
                  <Price>14.20</Price>
                  <Alternate>14.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601109425" Rank="3" Units="ml">
              <Name>Oral liq 25 mg per 5 ml</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Restricted to children under 12 years of age.</p>
              </div>
              <Brand ID="B07160110942525">
                <Name>Atenolol AFT</Name>
                <Pack ID="P2403366" Specified="true" OP="true" nzmt:ctpp_id="50157821000117107">
                  <Quantity>300</Quantity>
                  <Subsidy>49.85</Subsidy>
                  <Price>49.85</Price>
                  <Alternate>49.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160110942526" S29="true">
                <Name>Atenolol AFT S29</Name>
                <Pack ID="P2586096" Specified="true" OP="true">
                  <Quantity>300</Quantity>
                  <Subsidy>21.25</Subsidy>
                  <Price>21.25</Price>
                  <Alternate>21.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160110942527" S29="true">
                <Name>Essential Generics</Name>
                <Pack ID="P2617838" Specified="true" OP="true" nzmt:ctpp_id="50289811000117102">
                  <Quantity>300</Quantity>
                  <Subsidy>38.20</Subsidy>
                  <Price>38.20</Price>
                  <Alternate>38.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716011699">
            <Name>Labetalol</Name>
            <Formulation ID="F071601169902" Rank="1" Units="tab" Weight="100" Statim="Must">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07160116990201" SoleSupply="2024-06-30">
                <Name>Trandate</Name>
                <Pack ID="P2582155" Specified="true" nzmt:ctpp_id="50025251000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601169903" Rank="1" Units="tab" Weight="200" Statim="Must">
              <Name>Tab 200 mg</Name>
              <Brand ID="B07160116990303" SoleSupply="2024-06-30">
                <Name>Trandate</Name>
                <Pack ID="P2582163" Specified="true" nzmt:ctpp_id="50019591000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>27.00</Subsidy>
                  <Price>27.00</Price>
                  <Alternate>27.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601169905" Rank="4" Units="inj" Weight="100" Statim="Must">
              <Name>Inj 5 mg per ml, 20 ml ampoule</Name>
              <Brand ID="B07160116990501">
                <Name>Trandate</Name>
                <Pack ID="P2604116" Specified="true">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>59.06</Subsidy>
                  <Price>88.60</Price>
                  <Alternate>59.06</Alternate>
                  <Surcharge>5.90800</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601169922" Rank="4" Units="inj" Weight="100" Statim="Must">
              <Name>inj 5 mg per ml, 20 ml vial</Name>
              <Brand ID="B07160116992202" S29="true">
                <Name>Alvogen</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2593769" Specified="true" nzmt:ctpp_id="50278951000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.29</Subsidy>
                  <Price>48.20</Price>
                  <Alternate>42.29</Alternate>
                  <Surcharge>5.91000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716011817" Statim="Must">
            <Name>Metoprolol succinate</Name>
            <Formulation ID="F071601181701" Rank="1" Units="tab" Weight="47.5">
              <Name>Tab long-acting 47.5 mg</Name>
              <Brand ID="B07160118170101" ToBeDelisted="2024-04-01">
                <Name>Betaloc CR</Name>
                <Pack ID="P599891" Specified="true" nzmt:ctpp_id="50098121000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>1.43</Subsidy>
                  <Price>1.43</Price>
                  <Alternate>1.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160118170126" ToBePSS="2024-04-01">
                <Name>Myloc CR</Name>
                <Pack ID="P2650703" Specified="true" nzmt:ctpp_id="50309201000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>3.65</Subsidy>
                  <Price>3.65</Price>
                  <Alternate>3.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601181702" Rank="1" Units="tab" Weight="95">
              <Name>Tab long-acting 95 mg</Name>
              <Brand ID="B07160118170201" ToBeDelisted="2024-04-01">
                <Name>Betaloc CR</Name>
                <Pack ID="P527858" Specified="true" nzmt:ctpp_id="50094401000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>2.15</Subsidy>
                  <Price>2.15</Price>
                  <Alternate>2.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160118170226" ToBePSS="2024-04-01">
                <Name>Myloc CR</Name>
                <Pack ID="P2650711" Specified="true" nzmt:ctpp_id="50309211000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>5.24</Subsidy>
                  <Price>5.24</Price>
                  <Alternate>5.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601181703" Rank="1" Units="tab" Weight="190">
              <Name>Tab long-acting 190 mg</Name>
              <Brand ID="B07160118170301" ToBeDelisted="2024-04-01">
                <Name>Betaloc CR</Name>
                <Pack ID="P599905" Specified="true" nzmt:ctpp_id="50098131000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>4.27</Subsidy>
                  <Price>4.27</Price>
                  <Alternate>4.27</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160118170326" ToBePSS="2024-04-01">
                <Name>Myloc CR</Name>
                <Pack ID="P2650738" Specified="true" nzmt:ctpp_id="50309221000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>9.76</Subsidy>
                  <Price>9.76</Price>
                  <Alternate>9.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601181725" Rank="1" Units="tab">
              <Name>Tab long-acting 23.75 mg</Name>
              <Brand ID="B07160118172525" ToBeDelisted="2024-04-01">
                <Name>Betaloc CR</Name>
                <Pack ID="P2026945" Specified="true" nzmt:ctpp_id="50005331000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>1.45</Subsidy>
                  <Price>1.45</Price>
                  <Alternate>1.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160118172527" ToBePSS="2024-04-01">
                <Name>Myloc CR</Name>
                <Pack ID="P2650681" Specified="true" nzmt:ctpp_id="50309191000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>4.20</Subsidy>
                  <Price>4.20</Price>
                  <Alternate>4.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716011818">
            <Name>Metoprolol tartrate</Name>
            <Formulation ID="F071601181801" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab 50 mg</Name>
              <Brand ID="B07160118180126" SoleSupply="2027-06-30">
                <Name>IPCA-Metoprolol</Name>
                <Pack ID="P2618672" Specified="true" nzmt:ctpp_id="50167631000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>5.66</Subsidy>
                  <Price>5.66</Price>
                  <Alternate>5.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601181802" Rank="1" Units="tab" Weight="100" Statim="Must">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07160118180226" SoleSupply="2027-06-30">
                <Name>IPCA-Metoprolol</Name>
                <Pack ID="P2618680" Specified="true" nzmt:ctpp_id="50167641000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>7.55</Subsidy>
                  <Price>7.55</Price>
                  <Alternate>7.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601181803" Rank="1" Units="tab" Weight="200" Statim="Must">
              <Name>Tab long-acting 200 mg</Name>
              <Brand ID="B07160118180301">
                <Name>Slow-Lopresor</Name>
                <Pack ID="P2108682" Specified="true" nzmt:ctpp_id="50019381000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>23.40</Subsidy>
                  <Price>23.40</Price>
                  <Alternate>23.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601181804" Rank="4" Units="inj" Weight="1" Statim="Must">
              <Name>Inj 1 mg per ml, 5 ml vial</Name>
              <Brand ID="B07160118180426">
                <Name>Metoprolol IV Mylan</Name>
                <Pack ID="P2550369" Specified="true" nzmt:ctpp_id="50227921000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>26.50</Subsidy>
                  <Price>26.50</Price>
                  <Alternate>26.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160118180427">
                <Name>Metoprolol IV Viatris</Name>
                <Pack ID="P2639777" Specified="true" nzmt:ctpp_id="50290851000117105">
                  <Quantity>5</Quantity>
                  <Subsidy>26.50</Subsidy>
                  <Price>26.50</Price>
                  <Alternate>26.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716011838" Statim="Must">
            <Name>Nadolol</Name>
            <Formulation ID="F071601183801" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B07160118380103" SoleSupply="2024-06-30">
                <Name>Nadolol BNM</Name>
                <Pack ID="P2621118" nzmt:ctpp_id="50291241000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>19.19</Subsidy>
                  <Price>19.19</Price>
                  <Alternate>19.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2647540" Specified="true" nzmt:ctpp_id="50297151000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>19.19</Subsidy>
                  <Price>19.19</Price>
                  <Alternate>19.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601183802" Rank="1" Units="tab" Weight="80">
              <Name>Tab 80 mg</Name>
              <Brand ID="B07160118380203" SoleSupply="2024-06-30">
                <Name>Nadolol BNM</Name>
                <Pack ID="P2621126" nzmt:ctpp_id="50291251000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>30.39</Subsidy>
                  <Price>30.39</Price>
                  <Alternate>30.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2647559" Specified="true" nzmt:ctpp_id="50297161000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>30.39</Subsidy>
                  <Price>30.39</Price>
                  <Alternate>30.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716012060">
            <Name>Propranolol</Name>
            <Formulation ID="F071601206001" Rank="1" Units="tab" Weight="10" Statim="Must">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07160120600126" SoleSupply="2027-06-30">
                <Name>Drofate</Name>
                <Pack ID="P2611414" Specified="true" nzmt:ctpp_id="50206991000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>7.04</Subsidy>
                  <Price>7.04</Price>
                  <Alternate>7.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601206002" Rank="1" Units="tab" Weight="40" Statim="Must">
              <Name>Tab 40 mg</Name>
              <Brand ID="B07160120600226" SoleSupply="2027-06-30">
                <Name>IPCA-Propranolol</Name>
                <Pack ID="P2618664" Specified="true" nzmt:ctpp_id="50207021000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>8.75</Subsidy>
                  <Price>8.75</Price>
                  <Alternate>8.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601206006" Rank="2" Units="cap" Weight="160" Statim="Must">
              <Name>Cap long-acting 160 mg</Name>
              <Brand ID="B07160120600602">
                <Name>Cardinol LA</Name>
                <Pack ID="P326070" Specified="true" nzmt:ctpp_id="50072421000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>18.17</Subsidy>
                  <Price>18.17</Price>
                  <Alternate>18.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601206025" Rank="3" Units="ml" Weight="4" Statim="Must">
              <Name>Oral liq 4 mg per ml</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1327"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1327">
                <Title>
                  <range>Propranolol</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only)</ci>
                      <ci type="logical" class="Indication">For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac  abnormalities</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="year">2</Term>
                </Case>
                <Case When="Renewal" Form="SA1327">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only)</ci>
                      <ci type="logical" class="Indication">For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac  abnormalities</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="year">2</Term>
                </Case>
              </Request>
              <Brand ID="B07160120602525" S29="true">
                <Name>Roxane-Propranolol</Name>
                <Pack ID="P2401894" Specified="true" CBS="true" nzmt:ctpp_id="50285831000117108">
                  <Quantity>500</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716012169" Statim="Must">
            <Name>Sotalol</Name>
            <Formulation ID="F071601216901" Rank="1" Units="tab" Weight="80">
              <Name>Tab 80 mg</Name>
              <Brand ID="B07160121690102" PSS="2025-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2127903" Specified="true" nzmt:ctpp_id="50022991000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>37.50</Subsidy>
                  <Price>37.50</Price>
                  <Alternate>37.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601216902" Rank="1" Units="tab" Weight="160">
              <Name>Tab 160 mg</Name>
              <Brand ID="B07160121690202" PSS="2025-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2127911" Specified="true" nzmt:ctpp_id="50023001000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>14.00</Subsidy>
                  <Price>14.00</Price>
                  <Alternate>14.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716013772" Statim="Must">
            <Name>Carvedilol</Name>
            <Formulation ID="F071601377225" Rank="1" Units="tab" Weight="6.25">
              <Name>Tab 6.25 mg</Name>
              <Brand ID="B07160137722527">
                <Name>Carvedilol Sandoz</Name>
                <Pack ID="P2527332" Specified="true" nzmt:ctpp_id="50192541000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>2.24</Subsidy>
                  <Price>2.24</Price>
                  <Alternate>2.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601377226" Rank="1" Units="tab" Weight="12.5">
              <Name>Tab 12.5 mg</Name>
              <Brand ID="B07160137722627">
                <Name>Carvedilol Sandoz</Name>
                <Pack ID="P2527324" Specified="true" nzmt:ctpp_id="50192561000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>2.30</Subsidy>
                  <Price>2.30</Price>
                  <Alternate>2.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601377227" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B07160137722727">
                <Name>Carvedilol Sandoz</Name>
                <Pack ID="P2527316" Specified="true" nzmt:ctpp_id="50192581000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>2.95</Subsidy>
                  <Price>2.95</Price>
                  <Alternate>2.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0716013949" Statim="Must">
            <Name>Bisoprolol fumarate</Name>
            <Formulation ID="F071601394925" Rank="1" Units="tab">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B07160139492526" ToBeDelisted="2024-04-01">
                <Name>Bisoprolol Mylan</Name>
                <Pack ID="P2588978" Specified="true" nzmt:ctpp_id="50234311000117104">
                  <Quantity>90</Quantity>
                  <Subsidy>1.84</Subsidy>
                  <Price>1.84</Price>
                  <Alternate>1.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160139492527" ToBeDelisted="2024-04-01">
                <Name>Bisoprolol Viatris</Name>
                <Pack ID="P2636158" Specified="true" nzmt:ctpp_id="50292461000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>1.84</Subsidy>
                  <Price>1.84</Price>
                  <Alternate>1.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160139492528" ToBePSS="2024-04-01">
                <Name>Ipca-Bisoprolol</Name>
                <Pack ID="P2660350" Specified="true" nzmt:ctpp_id="50319451000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>1.36</Subsidy>
                  <Price>1.36</Price>
                  <Alternate>1.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601394926" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07160139492626" ToBeDelisted="2024-04-01">
                <Name>Bisoprolol Mylan</Name>
                <Pack ID="P2589095" Specified="true" nzmt:ctpp_id="50234381000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>2.55</Subsidy>
                  <Price>2.55</Price>
                  <Alternate>2.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160139492627" ToBeDelisted="2024-04-01">
                <Name>Bisoprolol Viatris</Name>
                <Pack ID="P2636166" Specified="true" nzmt:ctpp_id="50292671000117100">
                  <Quantity>90</Quantity>
                  <Subsidy>2.55</Subsidy>
                  <Price>2.55</Price>
                  <Alternate>2.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160139492628" ToBePSS="2024-04-01">
                <Name>Ipca-Bisoprolol</Name>
                <Pack ID="P2660369" Specified="true" nzmt:ctpp_id="50319461000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>1.91</Subsidy>
                  <Price>1.91</Price>
                  <Alternate>1.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F071601394927" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07160139492726" ToBeDelisted="2024-04-01">
                <Name>Bisoprolol Mylan</Name>
                <Pack ID="P2589184" Specified="true" nzmt:ctpp_id="50234461000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>3.62</Subsidy>
                  <Price>3.62</Price>
                  <Alternate>3.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160139492727" ToBeDelisted="2024-04-01">
                <Name>Bisoprolol Viatris</Name>
                <Pack ID="P2636174" Specified="true" nzmt:ctpp_id="50292681000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>3.62</Subsidy>
                  <Price>3.62</Price>
                  <Alternate>3.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07160139492728" ToBePSS="2024-04-01">
                <Name>Ipca-Bisoprolol</Name>
                <Pack ID="P2660377" Specified="true" nzmt:ctpp_id="50319471000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>2.71</Subsidy>
                  <Price>2.71</Price>
                  <Alternate>2.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0722">
        <Name>Calcium Channel Blockers</Name>
        <ATC3 ID="A072201">
          <Name>Dihydropyridine Calcium Channel Blockers</Name>
          <Chemical ID="C0722011863" Statim="Must">
            <Name>Nifedipine</Name>
            <Formulation ID="F072201186301" Rank="1" Units="tab" Weight="10">
              <Name>Tab long-acting 10 mg</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised for patients who were taking nifedipine tab long-acting 10 mg  prior to 1 July 2023 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of nifedipine tab long-acting 10 mg.</p>
              </div>
              <Brand ID="B07220118630127" S29="true">
                <Name>Tensipine MR10</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2603217" Specified="true" nzmt:ctpp_id="50284411000117101">
                  <Quantity>56</Quantity>
                  <Subsidy>19.42</Subsidy>
                  <Price>19.42</Price>
                  <Alternate>19.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072201186302" Rank="1" Units="tab" Weight="20">
              <Name>Tab long-acting 20 mg</Name>
              <Brand ID="B07220118630203">
                <Name>Nyefax Retard</Name>
                <Pack ID="P529435" Specified="true" nzmt:ctpp_id="50094481000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>17.72</Subsidy>
                  <Price>17.72</Price>
                  <Alternate>17.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072201186303" Rank="1" Units="tab" Weight="30">
              <Name>Tab long-acting 30 mg</Name>
              <Brand ID="B07220118630327" S29="true">
                <Name>Mylan (24 hr release)</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2602911" Specified="true" nzmt:ctpp_id="50284271000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>34.10</Subsidy>
                  <Price>34.10</Price>
                  <Alternate>34.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07220118630328" S29="true">
                <Name>Mylan Italy (24 hr release)</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2618028" Specified="true" nzmt:ctpp_id="50291191000117102">
                  <Quantity>14</Quantity>
                  <Subsidy>4.78</Subsidy>
                  <Price>4.78</Price>
                  <Alternate>4.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07220118630329" S29="true">
                <Name>Nifedipine Viatris</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2669595" Specified="true" nzmt:ctpp_id="50325271000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>10.24</Subsidy>
                  <Price>10.24</Price>
                  <Alternate>10.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072201186304" Rank="1" Units="tab" Weight="60">
              <Name>Tab long-acting 60 mg</Name>
              <Brand ID="B07220118630427" S29="true">
                <Name>Mylan (24 hr release)</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2602938" Specified="true" nzmt:ctpp_id="50284281000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>52.81</Subsidy>
                  <Price>52.81</Price>
                  <Alternate>52.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0722012398" Statim="Must">
            <Name>Felodipine</Name>
            <Formulation ID="F072201239801" Rank="1" Units="tab" Weight="5">
              <Name>Tab long-acting 5 mg</Name>
              <Brand ID="B07220123980125" PSS="2024-06-30">
                <Name>Felo 5 ER</Name>
                <Pack ID="P2041510" Specified="true" nzmt:ctpp_id="50007951000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>4.07</Subsidy>
                  <Price>4.07</Price>
                  <Alternate>4.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072201239802" Rank="1" Units="tab" Weight="10">
              <Name>Tab long-acting 10 mg</Name>
              <Brand ID="B07220123980225" PSS="2024-06-30">
                <Name>Felo 10 ER</Name>
                <Pack ID="P2041499" Specified="true" nzmt:ctpp_id="50007931000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>4.32</Subsidy>
                  <Price>4.32</Price>
                  <Alternate>4.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072201239803" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab long-acting 2.5 mg</Name>
              <Brand ID="B07220123980301">
                <Name>Plendil ER</Name>
                <Pack ID="P353760" Specified="true" nzmt:ctpp_id="50077161000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>1.45</Subsidy>
                  <Price>1.45</Price>
                  <Alternate>1.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0722012793" Statim="Must">
            <Name>Amlodipine</Name>
            <Formulation ID="F072201279301" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07220127930128" PSS="2026-06-30">
                <Name>Vasorex</Name>
                <Pack ID="P2592517" Specified="true" nzmt:ctpp_id="50279001000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>1.21</Subsidy>
                  <Price>1.21</Price>
                  <Alternate>1.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072201279302" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07220127930228" PSS="2026-06-30">
                <Name>Vasorex</Name>
                <Pack ID="P2592525" Specified="true" nzmt:ctpp_id="50279041000117100">
                  <Quantity>90</Quantity>
                  <Subsidy>1.31</Subsidy>
                  <Price>1.31</Price>
                  <Alternate>1.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072201279325" Rank="1" Units="tab">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B07220127932527" PSS="2026-06-30">
                <Name>Vasorex</Name>
                <Pack ID="P2592509" Specified="true" nzmt:ctpp_id="50278961000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>1.45</Subsidy>
                  <Price>1.45</Price>
                  <Alternate>1.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A072202">
          <Name>Other Calcium Channel Blockers</Name>
          <Chemical ID="C0722021949" Statim="Must">
            <Name>Perhexiline maleate</Name>
            <Formulation ID="F072202194901" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07220219490125">
                <Name>Pexsig</Name>
                <Pack ID="P352713" Specified="true" nzmt:ctpp_id="50077101000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>62.90</Subsidy>
                  <Price>62.90</Price>
                  <Alternate>62.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0722022317" Statim="Must">
            <Name>Verapamil hydrochloride</Name>
            <Formulation ID="F072202231701" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B07220223170101">
                <Name>Isoptin</Name>
                <Pack ID="P2535327" Specified="true" nzmt:ctpp_id="50053891000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>7.01</Subsidy>
                  <Price>7.01</Price>
                  <Alternate>7.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072202231702" Rank="1" Units="tab" Weight="80">
              <Name>Tab 80 mg</Name>
              <Brand ID="B07220223170203">
                <Name>Isoptin</Name>
                <Pack ID="P2535335" Specified="true" nzmt:ctpp_id="50053901000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>11.74</Subsidy>
                  <Price>11.74</Price>
                  <Alternate>11.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072202231707" Rank="4" Units="inj" Weight="2.5">
              <Name>Inj 2.5 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B07220223170701">
                <Name>Isoptin</Name>
                <Pack ID="P2535351" Specified="true" nzmt:ctpp_id="50053881000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072202231709" Rank="1" Units="tab" Weight="120">
              <Name>Tab long-acting 120 mg</Name>
              <Brand ID="B07220223170901">
                <Name>Isoptin SR</Name>
                <Pack ID="P2571897" Specified="true" nzmt:ctpp_id="50110821000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>36.02</Subsidy>
                  <Price>36.02</Price>
                  <Alternate>36.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07220223170903" S29="true">
                <Name>Isoptin Retard</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2579391" Specified="true" nzmt:ctpp_id="50271721000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>36.02</Subsidy>
                  <Price>36.02</Price>
                  <Alternate>36.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072202231711" Rank="1" Units="tab" Weight="240">
              <Name>Tab long-acting 240 mg</Name>
              <Brand ID="B07220223171101">
                <Name>Isoptin SR</Name>
                <Pack ID="P2535343" Specified="true" nzmt:ctpp_id="50078791000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>15.12</Subsidy>
                  <Price>15.12</Price>
                  <Alternate>15.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0722022528">
            <Name>Diltiazem hydrochloride</Name>
            <Formulation ID="F072202252804" Rank="2" Units="cap" Weight="120" Statim="Must">
              <Name>Cap long-acting 120 mg</Name>
              <Brand ID="B07220225280426" PSS="2025-06-30">
                <Name>Diltiazem CD Clinect</Name>
                <Pack ID="P2648172" Specified="true" nzmt:ctpp_id="50299571000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>65.35</Subsidy>
                  <Price>65.35</Price>
                  <Alternate>65.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072202252805" Rank="2" Units="cap" Weight="180" Statim="Must">
              <Name>Cap long-acting 180 mg</Name>
              <Brand ID="B07220225280501" SoleSupply="2027-06-30">
                <Name>Cardizem CD</Name>
                <Pack ID="P254584" Specified="true" nzmt:ctpp_id="50054561000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072202252806" Rank="2" Units="cap" Weight="240" Statim="Must">
              <Name>Cap long-acting 240 mg</Name>
              <Brand ID="B07220225280601" SoleSupply="2027-06-30">
                <Name>Cardizem CD</Name>
                <Pack ID="P254592" Specified="true" nzmt:ctpp_id="50054571000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>9.30</Subsidy>
                  <Price>9.30</Price>
                  <Alternate>9.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0728">
        <Name>Centrally-Acting Agents</Name>
        <ATC3 ID="A072801">
          <Name>Centrally-Acting Agents</Name>
          <Chemical ID="C0728011317" Statim="Must">
            <Name>Clonidine</Name>
            <Formulation ID="F072801131702" Rank="9" Units="patch" Weight="2.5">
              <Name>Patch 2.5 mg, 100 mcg per day</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B07280113170225" PSS="2026-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2523078" Specified="true" nzmt:ctpp_id="50243581000117102">
                  <Quantity>4</Quantity>
                  <Subsidy>11.70</Subsidy>
                  <Price>11.70</Price>
                  <Alternate>11.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072801131703" Rank="9" Units="patch" Weight="5">
              <Name>Patch 5 mg, 200 mcg per day</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B07280113170325" PSS="2026-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2523086" Specified="true" nzmt:ctpp_id="50243591000117104">
                  <Quantity>4</Quantity>
                  <Subsidy>12.80</Subsidy>
                  <Price>12.80</Price>
                  <Alternate>12.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072801131704" Rank="9" Units="patch" Weight="7.5">
              <Name>Patch 7.5 mg, 300 mcg per day</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B07280113170425" PSS="2026-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2523094" Specified="true" nzmt:ctpp_id="50243601000117105">
                  <Quantity>4</Quantity>
                  <Subsidy>17.90</Subsidy>
                  <Price>17.90</Price>
                  <Alternate>17.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0728011318" Statim="Must">
            <Name>Clonidine hydrochloride</Name>
            <Formulation ID="F072801131801" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mcg</Name>
              <Brand ID="B07280113180101" PSS="2024-06-30">
                <Name>Catapres</Name>
                <Pack ID="P202274" Specified="true" nzmt:ctpp_id="50004611000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>37.07</Subsidy>
                  <Price>37.07</Price>
                  <Alternate>37.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072801131805" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mcg per ml, 1 ml ampoule</Name>
              <Brand ID="B07280113180502" PSS="2024-06-30">
                <Name>Medsurge</Name>
                <Pack ID="P2548445" Specified="true" nzmt:ctpp_id="50231191000117107">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>29.68</Subsidy>
                  <Price>29.68</Price>
                  <Alternate>29.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F072801131808" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mcg</Name>
              <Brand ID="B07280113180826" PSS="2025-06-30">
                <Name>Clonidine Teva</Name>
                <Pack ID="P2630249" Specified="true" nzmt:ctpp_id="50294351000117106">
                  <Quantity>112</Quantity>
                  <Subsidy>29.32</Subsidy>
                  <Price>29.32</Price>
                  <Alternate>29.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0728011806" Statim="Must">
            <Name>Methyldopa</Name>
            <Formulation ID="F072801180602" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B07280118060225" ToBeDelisted="2024-09-01">
                <Name>Methyldopa Mylan</Name>
                <Pack ID="P2500167">
                  <Quantity>100</Quantity>
                  <Subsidy>15.10</Subsidy>
                  <Price>15.10</Price>
                  <Alternate>15.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2603934" Specified="true" nzmt:ctpp_id="50234231000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>15.10</Subsidy>
                  <Price>15.10</Price>
                  <Alternate>15.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07280118060226" S29="true" ToBeDelisted="2024-09-01">
                <Name>Methyldopa Mylan  S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2567989" Specified="true" nzmt:ctpp_id="50265551000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>52.85</Subsidy>
                  <Price>52.85</Price>
                  <Alternate>52.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07280118060227">
                <Name>Methyldopa Viatris</Name>
                <Pack ID="P2644738" Specified="true" nzmt:ctpp_id="50294411000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>15.10</Subsidy>
                  <Price>15.10</Price>
                  <Alternate>15.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0731">
        <Name>Diuretics</Name>
        <ATC3 ID="A073101">
          <Name>Loop Diuretics</Name>
          <Chemical ID="C0731011171" Statim="Must">
            <Name>Bumetanide</Name>
            <Formulation ID="F073101117101" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B07310111710101">
                <Name>Burinex</Name>
                <Pack ID="P210323" Specified="true" nzmt:ctpp_id="50018591000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>16.36</Subsidy>
                  <Price>16.36</Price>
                  <Alternate>16.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07310111710102" S29="true">
                <Name>Burinex S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2588587" Specified="true" nzmt:ctpp_id="50277581000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>4.91</Subsidy>
                  <Price>4.91</Price>
                  <Alternate>4.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073101117102" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 500 mcg per ml, 4 ml vial</Name>
              <Brand ID="B07310111710201">
                <Name>Burinex</Name>
                <Pack ID="P704520" Specified="true" nzmt:ctpp_id="50103791000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7.95</Subsidy>
                  <Price>7.95</Price>
                  <Alternate>7.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731011544">
            <Name>Furosemide [Frusemide]</Name>
            <Formulation ID="F073101154401" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B07310115440108" SoleSupply="2024-06-30">
                <Name>IPCA-Frusemide</Name>
                <Pack ID="P2618699" Specified="true" nzmt:ctpp_id="50164111000117107">
                  <Quantity>1000</Quantity>
                  <Subsidy>8.00</Subsidy>
                  <Price>8.00</Price>
                  <Alternate>8.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073101154402" Rank="1" Units="tab" Weight="500" Statim="Must">
              <Name>Tab 500 mg</Name>
              <Brand ID="B07310115440225">
                <Name>Urex Forte</Name>
                <Pack ID="P2343444" Specified="true" nzmt:ctpp_id="50050091000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07310115440227" S29="true">
                <Name>Furosemid-Ratiopharm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2606763" Specified="true" nzmt:ctpp_id="50285981000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>89.48</Subsidy>
                  <Price>89.48</Price>
                  <Alternate>89.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2606771" Specified="true" nzmt:ctpp_id="50285991000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>169.96</Subsidy>
                  <Price>169.96</Price>
                  <Alternate>169.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073101154403" Rank="3" Units="ml" Statim="Must">
              <Name>Oral liq 10 mg per ml</Name>
              <Brand ID="B07310115440301">
                <Name>Lasix</Name>
                <Pack ID="P209945" OP="true">
                  <Quantity>30</Quantity>
                  <Subsidy>10.66</Subsidy>
                  <Price>10.66</Price>
                  <Alternate>10.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2489341" Specified="true" OP="true" nzmt:ctpp_id="50018351000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>11.20</Subsidy>
                  <Price>11.20</Price>
                  <Alternate>11.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073101154404" Rank="4" Units="inj" Weight="20" Statim="Must">
              <Name>Inj 10 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B07310115440426" PSS="2025-06-30">
                <Name>Furosemide-Baxter</Name>
                <Pack ID="P2599503" Specified="true" nzmt:ctpp_id="50281561000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2.40</Subsidy>
                  <Price>2.40</Price>
                  <Alternate>2.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073101154406" Rank="4" Units="inf" Weight="250" Statim="Must">
              <Name>Inj 10 mg per ml, 25 ml ampoule</Name>
              <Brand ID="B07310115440601">
                <Name>Lasix</Name>
                <Pack ID="P2482800" Specified="true" nzmt:ctpp_id="50218541000117109">
                  <Quantity>6</Quantity>
                  <Subsidy>60.65</Subsidy>
                  <Price>60.65</Price>
                  <Alternate>60.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073104">
          <Name>Potassium Sparing Diuretics</Name>
          <Chemical ID="C0731041050">
            <Name>Amiloride hydrochloride</Name>
            <Formulation ID="F073104105004" Rank="3" Units="ml">
              <Name>Oral liq 1 mg per ml</Name>
              <Brand ID="B07310410500401" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P344710" Specified="true" OP="true" nzmt:ctpp_id="50075781000117104">
                  <Quantity>25</Quantity>
                  <Subsidy>33.71</Subsidy>
                  <Price>33.71</Price>
                  <Alternate>33.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731042176">
            <Name>Spironolactone</Name>
            <Formulation ID="F073104217601" Rank="1" Units="tab" Weight="25" Statim="Must">
              <Name>Tab 25 mg</Name>
              <Brand ID="B07310421760125" PSS="2025-06-30">
                <Name>Spiractin</Name>
                <Pack ID="P2435179" Specified="true" nzmt:ctpp_id="50166411000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>3.68</Subsidy>
                  <Price>3.68</Price>
                  <Alternate>3.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073104217602" Rank="1" Units="tab" Weight="100" Statim="Must">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07310421760225" PSS="2025-06-30">
                <Name>Spiractin</Name>
                <Pack ID="P2435187" Specified="true" nzmt:ctpp_id="50166421000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>10.65</Subsidy>
                  <Price>10.65</Price>
                  <Alternate>10.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073104217603" Rank="3" Units="ml">
              <Name>Oral liq 5 mg per ml</Name>
              <Brand ID="B07310421760301" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P344877" Specified="true" OP="true" nzmt:ctpp_id="50075831000117106">
                  <Quantity>25</Quantity>
                  <Subsidy>34.65</Subsidy>
                  <Price>34.65</Price>
                  <Alternate>34.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731044100">
            <Name>Eplerenone</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1728"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1728">
              <Title>
                <range>Eplerenone</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has heart failure with ejection fraction less than 40%</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is intolerant to optimal dosing of spironolactone</ci>
                      <ci type="logical" class="Indication">Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F073104410025" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B07310441002525" PSS="2024-06-30">
                <Name>Inspra</Name>
                <Pack ID="P2619512" Specified="true" nzmt:ctpp_id="50048101000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>18.50</Subsidy>
                  <Price>18.50</Price>
                  <Alternate>18.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073104410026" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B07310441002625" PSS="2024-06-30">
                <Name>Inspra</Name>
                <Pack ID="P2555069">
                  <Quantity>30</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2619520" Specified="true" nzmt:ctpp_id="50258661000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073107">
          <Name>Potassium Sparing Combination Diuretics</Name>
          <Chemical ID="C0731071051" Statim="Must">
            <Name>Amiloride hydrochloride with furosemide</Name>
            <Formulation ID="F073107105101" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg with furosemide 40 mg</Name>
              <Brand ID="B07310710510101">
                <Name>Frumil</Name>
                <Pack ID="P2125536" Specified="true" nzmt:ctpp_id="50022761000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>8.63</Subsidy>
                  <Price>8.63</Price>
                  <Alternate>8.63</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731071053" Statim="Must">
            <Name>Amiloride hydrochloride with hydrochlorothiazide</Name>
            <Formulation ID="F073107105301" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg with hydrochlorothiazide 50 mg</Name>
              <Brand ID="B07310710530103">
                <Name>Moduretic</Name>
                <Pack ID="P2364433" Specified="true" nzmt:ctpp_id="50051091000117103">
                  <Quantity>50</Quantity>
                  <Subsidy>5.00</Subsidy>
                  <Price>5.00</Price>
                  <Alternate>5.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073110">
          <Name>Thiazide and Related Diuretics</Name>
          <Chemical ID="C0731101116" Statim="Must">
            <Name>Bendroflumethiazide [Bendrofluazide]</Name>
            <Formulation ID="F073110111601" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Rule Type="FormMax" Value="150" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>May be supplied on a PSO for reasons other than emergency.</p>
              </div>
              <Brand ID="B07311011160125" PSS="2026-06-30">
                <Name>Arrow-Bendrofluazide</Name>
                <Pack ID="P2351420" Specified="true" nzmt:ctpp_id="50050591000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>51.50</Subsidy>
                  <Price>51.50</Price>
                  <Alternate>51.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073110111602" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07311011160225" PSS="2026-06-30">
                <Name>Arrow-Bendrofluazide</Name>
                <Pack ID="P2351439" Specified="true" nzmt:ctpp_id="50050601000117105">
                  <Quantity>500</Quantity>
                  <Subsidy>61.00</Subsidy>
                  <Price>61.00</Price>
                  <Alternate>61.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731101282">
            <Name>Chlorothiazide</Name>
            <Formulation ID="F073110128202" Rank="3" Units="ml" Weight="50">
              <Name>Oral liq 50 mg per ml</Name>
              <Brand ID="B07311012820201" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P344818" Specified="true" OP="true" nzmt:ctpp_id="50075801000117100">
                  <Quantity>25</Quantity>
                  <Subsidy>29.21</Subsidy>
                  <Price>29.21</Price>
                  <Alternate>29.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731101290">
            <Name>Chlortalidone [Chlorthalidone]</Name>
            <Formulation ID="F073110129001" Rank="1" Units="tab" Weight="25" Statim="Must">
              <Name>Tab 25 mg</Name>
              <Brand ID="B07311012900101" PSS="2025-06-30">
                <Name>Hygroton</Name>
                <Pack ID="P2025779" Specified="true" nzmt:ctpp_id="50005061000117103">
                  <Quantity>50</Quantity>
                  <Subsidy>6.95</Subsidy>
                  <Price>6.95</Price>
                  <Alternate>6.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731101643" Statim="Must">
            <Name>Indapamide</Name>
            <Formulation ID="F073110164301" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B07311016430125" PSS="2026-06-30">
                <Name>Dapa-Tabs</Name>
                <Pack ID="P2356406" Specified="true" nzmt:ctpp_id="50050771000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>16.00</Subsidy>
                  <Price>16.00</Price>
                  <Alternate>16.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0731104006">
            <Name>Metolazone</Name>
            <Formulation ID="F073110400625" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07311040062525" S29="true">
                <Name>Metolazone</Name>
                <Pack ID="P2436108" Specified="true" CBS="true" nzmt:ctpp_id="50168741000117100">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B07311040062526" S29="true">
                <Name>Zaroxolyn</Name>
                <Pack ID="P2438232" Specified="true" CBS="true" nzmt:ctpp_id="50172781000117103">
                  <Quantity>50</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073114">
          <Name>Vasopressin receptor antagonists</Name>
          <Chemical ID="C0731144165">
            <Name>Tolvaptan</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2166"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2166">
              <Title>
                <range>Tolvaptan</range>
              </Title>
              <Case When="Initial application" Category="autosomal dominant polycystic kidney disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a confirmed diagnosis of autosomal
                    dominant polycystic kidney disease</ci>
                    <ci type="logical" class="Indication">Patient has an estimated glomerular filtration
                    rate (eGFR) of greater than or equal to 25 ml/min/1.73 mÂ² at treatment
                    initiation</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patientâ€™s disease is rapidly progressing, with a decline in
                        eGFR of greater than or equal to 5 mL/min/1.73 mÂ² within one-year</ci>
                      <ci type="logical">Patientâ€™s disease is rapidly progressing, with an average
                        decline in eGFR of greater than or equal to 2.5 mL/min/1.73 mÂ² per year over
                        a five-year period</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>renal physician</Applicant>
                <Applicant Referring="renal physician">any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="autosomal dominant polycystic kidney disease" Form="SA2166">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has not developed end-stage renal disease, defined as an
                    eGFR of less than 15 mL/min/1.73 mÂ²</ci>
                    <ci type="logical">Patient has not undergone a kidney transplant</ci>
                  </apply>
                </math>
                <Applicant>renal physician</Applicant>
                <Applicant Referring="renal physician">any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F073114416525" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B07311441652525">
                <Name>Jinarc</Name>
                <Pack ID="P2647494" Specified="true" OP="true" nzmt:ctpp_id="50253291000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>873.50</Subsidy>
                  <Price>873.50</Price>
                  <Alternate>873.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073114416526" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Brand ID="B07311441652625">
                <Name>Jinarc</Name>
                <Pack ID="P2647508" Specified="true" OP="true" nzmt:ctpp_id="50253301000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>873.50</Subsidy>
                  <Price>873.50</Price>
                  <Alternate>873.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073114416527" Rank="1" Units="tab" Weight="45">
              <Name>Tab 45 mg + 15 mg</Name>
              <Brand ID="B07311441652725">
                <Name>Jinarc</Name>
                <Pack ID="P2647451" Specified="true" OP="true" nzmt:ctpp_id="50253311000117101">
                  <Quantity>56</Quantity>
                  <Subsidy>1747.00</Subsidy>
                  <Price>1747.00</Price>
                  <Alternate>1747.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073114416528" Rank="1" Units="tab" Weight="60">
              <Name>Tab 60 mg + 30 mg</Name>
              <Brand ID="B07311441652825">
                <Name>Jinarc</Name>
                <Pack ID="P2647478" Specified="true" OP="true" nzmt:ctpp_id="50253321000117107">
                  <Quantity>56</Quantity>
                  <Subsidy>1747.00</Subsidy>
                  <Price>1747.00</Price>
                  <Alternate>1747.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073114416529" Rank="1" Units="tab" Weight="90">
              <Name>Tab 90 mg + 30 mg</Name>
              <Brand ID="B07311441652925">
                <Name>Jinarc</Name>
                <Pack ID="P2647486" Specified="true" OP="true" nzmt:ctpp_id="50253331000117105">
                  <Quantity>56</Quantity>
                  <Subsidy>1747.00</Subsidy>
                  <Price>1747.00</Price>
                  <Alternate>1747.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0732">
        <Name>Lipid-Modifying Agents</Name>
        <ATC3 ID="A073201">
          <Name>Fibrates</Name>
          <Chemical ID="C0732011151" Statim="Must">
            <Name>Bezafibrate</Name>
            <Formulation ID="F073201115101" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B07320111510101" PSS="2024-06-30">
                <Name>Bezalip</Name>
                <Pack ID="P474223" Specified="true" nzmt:ctpp_id="50089331000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>19.46</Subsidy>
                  <Price>19.46</Price>
                  <Alternate>19.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073201115102" Rank="1" Units="tab" Weight="400">
              <Name>Tab long-acting 400 mg</Name>
              <Brand ID="B07320111510201" PSS="2024-06-30">
                <Name>Bezalip Retard</Name>
                <Pack ID="P354333" Specified="true" nzmt:ctpp_id="50077271000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>21.21</Subsidy>
                  <Price>21.21</Price>
                  <Alternate>21.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073202">
          <Name>Other Lipid-Modifying Agents</Name>
          <Chemical ID="C0732022362" Statim="Must">
            <Name>Acipimox</Name>
            <Formulation ID="F073202236201" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B07320223620101">
                <Name>Olbetam</Name>
                <Pack ID="P609641" Specified="true">
                  <Quantity>30</Quantity>
                  <Subsidy>25.44</Subsidy>
                  <Price>25.44</Price>
                  <Alternate>25.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320223620125" S29="true">
                <Name>Olbetam S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2591936" Specified="true" nzmt:ctpp_id="50098841000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>21.56</Subsidy>
                  <Price>21.56</Price>
                  <Alternate>21.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073203">
          <Name>Resins</Name>
          <Chemical ID="C0732031345">
            <Name>Colestipol hydrochloride</Name>
            <Formulation ID="F073203134501" Rank="2" Units="sach">
              <Name>Grans for oral liq 5 g</Name>
              <Brand ID="B07320313450101" ToBeDelisted="2024-08-01">
                <Name>Colestid</Name>
                <Pack ID="P648450" Specified="true" nzmt:ctpp_id="50100351000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>32.89</Subsidy>
                  <Price>32.89</Price>
                  <Alternate>32.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0732034181">
            <Name>Colestyramine</Name>
            <Formulation ID="F073203418125" Rank="2" Units="sach">
              <Name>Powder for oral suspension 4 g sachet</Name>
              <Brand ID="B07320341812525" S29="true">
                <Name>Colestyramine - Mylan</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2662000" Specified="true" nzmt:ctpp_id="50320651000117109">
                  <Quantity>50</Quantity>
                  <Subsidy>61.50</Subsidy>
                  <Price>61.50</Price>
                  <Alternate>61.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320341812526" S29="true">
                <Name>Quantalan sugar free</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2577194" Specified="true" nzmt:ctpp_id="50282041000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>61.50</Subsidy>
                  <Price>61.50</Price>
                  <Alternate>61.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073204">
          <Name>HMG CoA Reductase Inhibitors (Statins)</Name>
          <Chemical ID="C0732041137" Statim="Must">
            <Name>Atorvastatin</Name>
            <Formulation ID="F073204113701" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07320411370129" PSS="2024-06-30">
                <Name>Lorstat</Name>
                <Pack ID="P2493586" Specified="true" nzmt:ctpp_id="50230471000117105">
                  <Quantity>500</Quantity>
                  <Subsidy>6.16</Subsidy>
                  <Price>6.16</Price>
                  <Alternate>6.16</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204113702" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07320411370229" PSS="2024-06-30">
                <Name>Lorstat</Name>
                <Pack ID="P2493594" Specified="true" nzmt:ctpp_id="50230501000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>9.24</Subsidy>
                  <Price>9.24</Price>
                  <Alternate>9.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204113703" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B07320411370329" PSS="2024-06-30">
                <Name>Lorstat</Name>
                <Pack ID="P2493608" Specified="true" nzmt:ctpp_id="50230531000117106">
                  <Quantity>500</Quantity>
                  <Subsidy>14.92</Subsidy>
                  <Price>14.92</Price>
                  <Alternate>14.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204113725" Rank="1" Units="tab" Weight="80">
              <Name>Tab 80 mg</Name>
              <Brand ID="B07320411372530" PSS="2024-06-30">
                <Name>Lorstat</Name>
                <Pack ID="P2493616" Specified="true" nzmt:ctpp_id="50230561000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>26.54</Subsidy>
                  <Price>26.54</Price>
                  <Alternate>26.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0732042513" Statim="Must">
            <Name>Simvastatin</Name>
            <Formulation ID="F073204251301" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07320425130128" PSS="2026-06-30">
                <Name>Simvastatin Mylan</Name>
                <Pack ID="P2520087" Specified="true" nzmt:ctpp_id="50247601000117104">
                  <Quantity>90</Quantity>
                  <Subsidy>1.68</Subsidy>
                  <Price>1.68</Price>
                  <Alternate>1.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320425130129">
                <Name>Simvastatin Viatris</Name>
                <Pack ID="P2643553" Specified="true" nzmt:ctpp_id="50295731000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>1.68</Subsidy>
                  <Price>1.68</Price>
                  <Alternate>1.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204251302" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07320425130229" PSS="2026-06-30">
                <Name>Simvastatin Viatris</Name>
                <Pack ID="P2643561" Specified="true" nzmt:ctpp_id="50295861000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>2.54</Subsidy>
                  <Price>2.54</Price>
                  <Alternate>2.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204251304" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B07320425130428" PSS="2026-06-30">
                <Name>Simvastatin Mylan</Name>
                <Pack ID="P2520109" Specified="true" nzmt:ctpp_id="50247621000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>4.11</Subsidy>
                  <Price>4.11</Price>
                  <Alternate>4.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320425130429">
                <Name>Simvastatin Viatris</Name>
                <Pack ID="P2643588" Specified="true" nzmt:ctpp_id="50295991000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>4.11</Subsidy>
                  <Price>4.11</Price>
                  <Alternate>4.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204251325" Rank="1" Units="tab" Weight="80">
              <Name>Tab 80 mg</Name>
              <Brand ID="B07320425132528" PSS="2026-06-30" ToBeDelisted="2024-09-01">
                <Name>Simvastatin Mylan</Name>
                <Pack ID="P2520117" Specified="true" nzmt:ctpp_id="50247631000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>8.81</Subsidy>
                  <Price>8.81</Price>
                  <Alternate>8.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320425132529">
                <Name>Simvastatin Viatris</Name>
                <Pack ID="P2643596" Specified="true" nzmt:ctpp_id="50296161000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>8.81</Subsidy>
                  <Price>8.81</Price>
                  <Alternate>8.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0732042780" Statim="Must">
            <Name>Pravastatin</Name>
            <Formulation ID="F073204278003" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07320427800328" ToBeDelisted="2024-05-01">
                <Name>Pravastatin Mylan</Name>
                <Pack ID="P2584948" Specified="true" nzmt:ctpp_id="50275611000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>2.11</Subsidy>
                  <Price>2.11</Price>
                  <Alternate>2.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320427800329" ToBeDelisted="2024-05-01">
                <Name>Pravastatin Viatris</Name>
                <Pack ID="P2631784" Specified="true" nzmt:ctpp_id="50291361000117106">
                  <Quantity>28</Quantity>
                  <Subsidy>2.11</Subsidy>
                  <Price>2.11</Price>
                  <Alternate>2.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320427800330" ToBePSS="2024-05-01">
                <Name>Clinect</Name>
                <Pack ID="P2665204" Specified="true" nzmt:ctpp_id="50301051000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>7.16</Subsidy>
                  <Price>7.16</Price>
                  <Alternate>7.16</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204278025" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B07320427802528" ToBeDelisted="2024-05-01">
                <Name>Pravastatin Mylan</Name>
                <Pack ID="P2584956" Specified="true" nzmt:ctpp_id="50275621000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>3.61</Subsidy>
                  <Price>3.61</Price>
                  <Alternate>3.61</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320427802529" ToBePSS="2024-05-01">
                <Name>Clinect</Name>
                <Pack ID="P2665212" Specified="true" nzmt:ctpp_id="50301091000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>12.25</Subsidy>
                  <Price>12.25</Price>
                  <Alternate>12.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0732044152" Statim="Must">
            <Name>Rosuvastatin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2093"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2093">
              <Title>
                <range>Rosuvastatin</range>
              </Title>
              <Case When="Initial application" Category="cardiovascular disease risk">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient is considered to be at risk of
            cardiovascular disease</ci>
                      <ci type="logical" class="Indication">Patient is MÄori or any Pacific ethnicity</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has a calculated risk of cardiovascular
            disease of at least 15% over 5 years</ci>
                      <ci type="logical" class="Indication">LDL cholesterol has not reduced to less than 1.8
            mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or
            simvastatin</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="familial hypercholesterolemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has familial hypercholesterolemia (defined as
          a Dutch Lipid Criteria score greater than or equal to 6)</ci>
                    <ci type="logical" class="Indication">LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="established cardiovascular disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has proven coronary artery disease
            (CAD)</ci>
                      <ci type="logical" class="Indication">Patient has proven peripheral artery disease
            (PAD)</ci>
                      <ci type="logical" class="Indication">Patient has experienced an ischaemic stroke</ci>
                    </apply>
                    <ci type="logical" class="Indication">LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or
          simvastatin</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="recurrent major cardiovascular events">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has experienced a recurrent major
          cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary
          revascularisation, hospitalisation for unstable angina) in the last 2 years</ci>
                    <ci type="logical" class="Indication">LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F073204415225" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07320441522525" ToBePSS="2024-10-01">
                <Name>Rosuvastatin Viatris</Name>
                <Pack ID="P2616742" nzmt:ctpp_id="50289661000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>1.29</Subsidy>
                  <Price>1.29</Price>
                  <Alternate>1.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2651130" Specified="true" nzmt:ctpp_id="50294161000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>1.29</Subsidy>
                  <Price>1.29</Price>
                  <Alternate>1.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204415226" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07320441522625" ToBePSS="2024-10-01">
                <Name>Rosuvastatin Viatris</Name>
                <Pack ID="P2616750" nzmt:ctpp_id="50289671000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>1.69</Subsidy>
                  <Price>1.69</Price>
                  <Alternate>1.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2651149" Specified="true" nzmt:ctpp_id="50294131000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>1.69</Subsidy>
                  <Price>1.69</Price>
                  <Alternate>1.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204415227" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07320441522725" ToBePSS="2024-04-01">
                <Name>Rosuvastatin Viatris</Name>
                <Pack ID="P2616769" nzmt:ctpp_id="50289681000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>2.71</Subsidy>
                  <Price>2.71</Price>
                  <Alternate>2.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2651157" Specified="true" nzmt:ctpp_id="50294141000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>2.71</Subsidy>
                  <Price>2.71</Price>
                  <Alternate>2.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073204415228" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B07320441522825" ToBePSS="2024-04-01">
                <Name>Rosuvastatin Viatris</Name>
                <Pack ID="P2616777" nzmt:ctpp_id="50289691000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>4.55</Subsidy>
                  <Price>4.55</Price>
                  <Alternate>4.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2651165" Specified="true" nzmt:ctpp_id="50294151000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>4.55</Subsidy>
                  <Price>4.55</Price>
                  <Alternate>4.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A073208">
          <Name>Selective Cholesterol Absorption Inhibitors</Name>
          <Chemical ID="C0732083799" Statim="Must">
            <Name>Ezetimibe</Name>
            <Formulation ID="F073208379925" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07320837992526">
                <Name>Ezemibe Viatris</Name>
                <Pack ID="P2488744" Specified="true" nzmt:ctpp_id="50218111000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>1.76</Subsidy>
                  <Price>1.76</Price>
                  <Alternate>1.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07320837992527" PSS="2026-06-30">
                <Name>Ezetimibe Sandoz</Name>
                <Pack ID="P2545861" Specified="true" nzmt:ctpp_id="50197101000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>1.76</Subsidy>
                  <Price>1.76</Price>
                  <Alternate>1.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0732083853">
            <Name>Ezetimibe with simvastatin</Name>
            <Formulation ID="F073208385325" Rank="1" Units="tab">
              <Name>Tab 10 mg with simvastatin 20 mg</Name>
              <Brand ID="B07320838532526">
                <Name>Zimybe</Name>
                <Pack ID="P2470691" Specified="true" nzmt:ctpp_id="50153511000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>6.15</Subsidy>
                  <Price>6.15</Price>
                  <Alternate>6.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073208385326" Rank="1" Units="tab">
              <Name>Tab 10 mg with simvastatin 40 mg</Name>
              <Brand ID="B07320838532626">
                <Name>Zimybe</Name>
                <Pack ID="P2470705" Specified="true" nzmt:ctpp_id="50153561000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>7.15</Subsidy>
                  <Price>7.15</Price>
                  <Alternate>7.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073208385327" Rank="1" Units="tab">
              <Name>Tab 10 mg with simvastatin 80 mg</Name>
              <Brand ID="B07320838532726">
                <Name>Zimybe</Name>
                <Pack ID="P2470713" Specified="true" nzmt:ctpp_id="50153591000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>8.15</Subsidy>
                  <Price>8.15</Price>
                  <Alternate>8.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073208385328" Rank="1" Units="tab">
              <Name>Tab 10 mg with simvastatin 10 mg</Name>
              <Brand ID="B07320838532826">
                <Name>Zimybe</Name>
                <Pack ID="P2470683" Specified="true" nzmt:ctpp_id="50153471000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>5.15</Subsidy>
                  <Price>5.15</Price>
                  <Alternate>5.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0734">
        <Name>Nitrates</Name>
        <ATC3 ID="A073401">
          <Name>Nitrates</Name>
          <Chemical ID="C0734011577" Statim="Must">
            <Name>Glyceryl trinitrate</Name>
            <Formulation ID="F073401157701" Rank="9" Units="patch" Weight="10">
              <Name>Patch 50 mg, 10 mg per day</Name>
              <Brand ID="B07340115770103">
                <Name>Nitroderm TTS</Name>
                <Pack ID="P750247" Specified="true" nzmt:ctpp_id="50108501000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>18.62</Subsidy>
                  <Price>18.62</Price>
                  <Alternate>18.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073401157705" Rank="9" Units="patch" Weight="5">
              <Name>Patch 25 mg, 5 mg per day</Name>
              <Brand ID="B07340115770502">
                <Name>Nitroderm TTS</Name>
                <Pack ID="P716790" Specified="true" nzmt:ctpp_id="50105141000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>15.73</Subsidy>
                  <Price>15.73</Price>
                  <Alternate>15.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073401157706" Rank="6" Units="dose">
              <Name>Oral pump spray, 400 mcg per dose</Name>
              <Rule Type="FormMax" Value="250" Attribute="PSO"/>
              <Brand ID="B07340115770601">
                <Name>Nitrolingual Pump Spray</Name>
                <Pack ID="P2017962" Specified="true" OP="true" nzmt:ctpp_id="50003521000117101">
                  <Quantity>250</Quantity>
                  <Subsidy>7.48</Subsidy>
                  <Price>7.48</Price>
                  <Alternate>7.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0734012836" Statim="Must">
            <Name>Isosorbide mononitrate</Name>
            <Formulation ID="F073401283601" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07340128360101" PSS="2026-06-30">
                <Name>Ismo 20</Name>
                <Pack ID="P214833" Specified="true" nzmt:ctpp_id="50025581000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>22.49</Subsidy>
                  <Price>22.49</Price>
                  <Alternate>22.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073401283602" Rank="1" Units="tab" Weight="40">
              <Name>Tab long-acting 40 mg</Name>
              <Brand ID="B07340128360225" PSS="2026-06-30">
                <Name>Ismo 40 Retard</Name>
                <Pack ID="P2447355" Specified="true" nzmt:ctpp_id="50196901000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>9.80</Subsidy>
                  <Price>9.80</Price>
                  <Alternate>9.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073401283603" Rank="1" Units="tab" Weight="60">
              <Name>Tab long-acting 60 mg</Name>
              <Brand ID="B07340128360304" PSS="2026-06-30">
                <Name>Duride</Name>
                <Pack ID="P2202964" Specified="true" nzmt:ctpp_id="50032091000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>13.50</Subsidy>
                  <Price>13.50</Price>
                  <Alternate>13.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0737">
        <Name>Sympathomimetics</Name>
        <ATC3 ID="A073701">
          <Name>Sympathomimetics</Name>
          <Chemical ID="C0737011015">
            <Name>Adrenaline</Name>
            <Formulation ID="F073701101501" Rank="4" Units="inj">
              <Name>Inj 1 in 1,000, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B07370110150101">
                <Name>DBL Adrenaline</Name>
                <Pack ID="P603341" Specified="true" nzmt:ctpp_id="50098491000117108">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>12.65</Subsidy>
                  <Price>12.65</Price>
                  <Alternate>12.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07370110150125">
                <Name>Aspen Adrenaline</Name>
                <Pack ID="P2309823" Specified="true" nzmt:ctpp_id="50046931000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4.98</Subsidy>
                  <Price>4.98</Price>
                  <Alternate>4.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F073701101502" Rank="4" Units="inj">
              <Name>Inj 1 in 10,000, 10 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B07370110150201">
                <Name>Hospira</Name>
                <Pack ID="P534196" Specified="true" nzmt:ctpp_id="50094741000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>27.00</Subsidy>
                  <Price>27.00</Price>
                  <Alternate>27.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07370110150225">
                <Name>Aspen Adrenaline</Name>
                <Pack ID="P2390949" Specified="true" nzmt:ctpp_id="50125901000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>49.00</Subsidy>
                  <Price>49.00</Price>
                  <Alternate>49.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A0740">
        <Name>Vasodilators</Name>
        <ATC3 ID="A074001">
          <Name>Vasodilators</Name>
          <Chemical ID="C0740011604" Statim="Must">
            <Name>Hydralazine hydrochloride</Name>
            <Formulation ID="F074001160401" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1321"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1321">
                <Title>
                  <range>Hydralazine</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci>
                      <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="patient's lifetime"/>
                </Case>
              </Request>
              <Brand ID="B07400116040125">
                <Name>Hydralazine</Name>
                <Pack ID="P2436116" Specified="true" CBS="true" nzmt:ctpp_id="50168761000117101">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B07400116040126" S29="true">
                <Name>Onelink</Name>
                <Pack ID="P2438224" Specified="true" CBS="true" nzmt:ctpp_id="50172791000117100">
                  <Quantity>56</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B07400116040127" S29="true">
                <Name>AMDIPHARM</Name>
                <Pack ID="P2176181" Specified="true" CBS="true" nzmt:ctpp_id="50241391000117105">
                  <Quantity>84</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B07400116040128" S29="true">
                <Name>Camber</Name>
                <Pack ID="P2656604" Specified="true" CBS="true" nzmt:ctpp_id="50319441000117109">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F074001160403" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg ampoule</Name>
              <Brand ID="B07400116040301">
                <Name>Apresoline</Name>
                <Pack ID="P274550">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>25.90</Subsidy>
                  <Price>25.90</Price>
                  <Alternate>25.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2446227" Specified="true" nzmt:ctpp_id="50060901000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>25.90</Subsidy>
                  <Price>25.90</Price>
                  <Alternate>25.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0740011928" Statim="Must">
            <Name>Papaverine hydrochloride</Name>
            <Formulation ID="F074001192801" Rank="4" Units="inj" Weight="120">
              <Name>Inj 12 mg per ml, 10 ml ampoule</Name>
              <Brand ID="B07400119280101">
                <Name>Hospira</Name>
                <Pack ID="P333328" Specified="true" nzmt:ctpp_id="50074101000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>257.12</Subsidy>
                  <Price>257.12</Price>
                  <Alternate>257.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0740012451" Statim="May">
            <Name>Minoxidil</Name>
            <Formulation ID="F074001245102" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07400124510201">
                <Name>Loniten</Name>
                <Pack ID="P300438" Specified="true" nzmt:ctpp_id="50066681000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>78.40</Subsidy>
                  <Price>78.40</Price>
                  <Alternate>78.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07400124510202" S29="true">
                <Name>Minoxidil Roma</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2662981" Specified="true" nzmt:ctpp_id="50320961000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>47.04</Subsidy>
                  <Price>47.04</Price>
                  <Alternate>47.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0740012455">
            <Name>Pentoxifylline [Oxpentifylline]</Name>
            <Formulation ID="F074001245501" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B07400124550101">
                <Name>Trental 400</Name>
                <Pack ID="P2111977" Specified="true" nzmt:ctpp_id="50019831000117100">
                  <Quantity>50</Quantity>
                  <Subsidy>42.26</Subsidy>
                  <Price>42.26</Price>
                  <Alternate>42.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0740013975" Statim="May">
            <Name>Nicorandil</Name>
            <Formulation ID="F074001397525" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07400139752525" ToBeDelisted="2024-05-01">
                <Name>Ikorel</Name>
                <Pack ID="P274143" Specified="true" nzmt:ctpp_id="50060801000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>25.57</Subsidy>
                  <Price>25.57</Price>
                  <Alternate>25.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07400139752526" ToBePSS="2024-05-01">
                <Name>Max Health</Name>
                <Pack ID="P2669242" Specified="true" nzmt:ctpp_id="50298331000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>21.73</Subsidy>
                  <Price>21.73</Price>
                  <Alternate>21.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F074001397526" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B07400139752625" ToBeDelisted="2024-05-01">
                <Name>Ikorel</Name>
                <Pack ID="P274151" Specified="true" nzmt:ctpp_id="50060811000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>32.28</Subsidy>
                  <Price>32.28</Price>
                  <Alternate>32.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B07400139752626" ToBePSS="2024-05-01">
                <Name>Max Health</Name>
                <Pack ID="P2669250" Specified="true" nzmt:ctpp_id="50298341000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>27.44</Subsidy>
                  <Price>27.44</Price>
                  <Alternate>27.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A074005">
          <Name>Endothelin Receptor Antagonists</Name>
          <Chemical ID="C0740053889">
            <Name>Bosentan</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2254"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2254">
              <Title>
                <range>Bosentan</range>
              </Title>
              <Case When="Initial application" Category="PAH monotherapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)*</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal
            lung disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Bosentan is to be used as PAH monotherapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has experienced intolerable side effects on sildenafil</ci>
                        <ci type="logical">Patient has an absolute contraindication to sildenafil</ci>
                        <ci type="logical">Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="PAH dual therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)*</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal
            lung disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures</ci>
                    </apply>
                    <ci type="logical">Bosentan is to be used as part of PAH dual therapy</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated
              risk stratification tool**</ci>
                      <ci type="logical">Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="PAH triple therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)*</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal
            lung disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Bosentan is to be used as part of PAH triple therapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient is on the lung transplant list</ci>
                        <ci type="logical">Patient is presenting in NYHA/WHO functional class IV</ci>
                        <apply>
                          <and/>
                          <ci type="logical">Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification
                tool**</ci>
                          <ci type="logical">Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1703 SA1712 SA1908 SA1991 SA2254">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Patient is continuing to derive benefit from bosentan treatment according to a validated PAH risk stratification tool**</ci>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>â€  The European Respiratory Journal Guidelines can be found here: <a href="https://erj.ersjournals.com/content/early/2022/08/25/13993003.00879-2022">2022 ECS/ERS Guidelines for the diagnosis and
        treatment of pulmonary hypertension PAH</a></p>
                <p>** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a
      validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.</p>
              </div>
            </Request>
            <Formulation ID="F074005388925" Rank="1" Units="tab">
              <Name>Tab 62.5 mg</Name>
              <Brand ID="B07400538892529" PSS="2024-06-30">
                <Name>Bosentan Dr Reddy's</Name>
                <Pack ID="P2550067" Specified="true" nzmt:ctpp_id="50230241000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>119.85</Subsidy>
                  <Price>119.85</Price>
                  <Alternate>119.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F074005388926" Rank="1" Units="tab" Weight="125">
              <Name>Tab 125 mg</Name>
              <Brand ID="B07400538892629" PSS="2024-06-30">
                <Name>Bosentan Dr Reddy's</Name>
                <Pack ID="P2550075" Specified="true" nzmt:ctpp_id="50230251000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>119.85</Subsidy>
                  <Price>119.85</Price>
                  <Alternate>119.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0740053904">
            <Name>Ambrisentan</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2253"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2253">
              <Title>
                <range>Ambrisentan</range>
              </Title>
              <Case When="Initial application" Category="PAH monotherapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see
                note below for link to these guidelines) â€ </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Ambrisentan is to be used as PAH monotherapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has experienced intolerable side effects with both sildenafil and bosentan</ci>
                        <ci type="logical">Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive
              or liver disease)</ci>
                        <ci type="logical">Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="PAH dual therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see
                note below for link to these guidelines) â€ </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Ambrisentan is to be used as PAH dual therapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has tried a PAH monotherapy (sildenafil or bosentan) for at least three months and has not experienced an acceptable response to treatment according to a
              validated risk stratification tool**</ci>
                        <ci type="logical">Patient has tried PAH dual therapy including bosentan and has experienced intolerable side effects on bosentan</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical">Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy</ci>
                        <ci type="logical">Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="PAH triple therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH 2022 (see
                note below for link to these guidelines) â€ </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Ambrisentan is to be used as PAH triple therapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient is on the lung transplant list</ci>
                        <apply>
                          <and/>
                          <ci type="logical">Patient is presenting in NYHA/WHO functional class IV</ci>
                          <ci type="logical">Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</ci>
                        </apply>
                        <apply>
                          <and/>
                          <ci type="logical">Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2253">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool**</ci>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>â€  The European Respiratory Journal Guidelines can be found here: <a href="https://erj.ersjournals.com/content/early/2022/08/25/13993003.00879-2022">2022 ECS/ERS Guidelines for the diagnosis and
        treatment of pulmonary hypertension PAH</a></p>
                <p>** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a
      validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.</p>
              </div>
            </Request>
            <Formulation ID="F074005390425" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B07400539042527" PSS="2026-06-30">
                <Name>Ambrisentan Viatris</Name>
                <Pack ID="P2626446" Specified="true" nzmt:ctpp_id="50290651000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>200.00</Subsidy>
                  <Price>200.00</Price>
                  <Alternate>200.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F074005390426" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B07400539042628" PSS="2026-06-30">
                <Name>Ambrisentan Viatris</Name>
                <Pack ID="P2626454" Specified="true" nzmt:ctpp_id="50290531000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>200.00</Subsidy>
                  <Price>200.00</Price>
                  <Alternate>200.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A074007">
          <Name>Phosphodiesterase Type 5 Inhibitors</Name>
          <Chemical ID="C0740073890">
            <Name>Sildenafil</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2255"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2255">
              <Title>
                <range>Sildenafil (Vedafil)</range>
              </Title>
              <Case When="Initial application" Category="Raynaud's Phenomenon*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has Raynaud's Phenomenon*</ci>
                    <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital
          ulcers; or gangrene)</ci>
                    <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of
          sympathomimetic drugs)</ci>
                    <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="Pulmonary arterial hypertension*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)*</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH is confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg</ci>
                        <ci type="logical">Pulmonary vascular resistance (PVR) of at least 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these
                guidelines) â€ </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal
            lung disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="erectile dysfunction due to spinal cord injury">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a documented history of traumatic or non-traumatic spinal cord injury</ci>
                    <ci type="logical" class="Indication">Patient has erectile dysfunction secondary to spinal cord injury requiring pharmacological treatment</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="erectile dysfunction due to spinal cord injury" Form="SA1738 SA1825 SA1909 SA1992 SA2255">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Note: Indications marked with * are Unapproved Indications.</p>
                <p>â€  The European Respiratory Journal Guidelines  can be found here: <a href="https://erj.ersjournals.com/content/early/2022/08/25/13993003.00879-2022">2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH</a></p>
                <p>** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a
      validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.</p>
              </div>
            </Request>
            <Formulation ID="F074007389025" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B07400738902527" PSS="2024-06-30">
                <Name>Vedafil</Name>
                <Pack ID="P2377764" Specified="true" nzmt:ctpp_id="50123901000117102">
                  <Quantity>4</Quantity>
                  <Subsidy>0.85</Subsidy>
                  <Price>0.85</Price>
                  <Alternate>0.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F074007389026" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B07400738902627" PSS="2024-06-30">
                <Name>Vedafil</Name>
                <Pack ID="P2377780" Specified="true" nzmt:ctpp_id="50123891000117101">
                  <Quantity>4</Quantity>
                  <Subsidy>1.70</Subsidy>
                  <Price>1.70</Price>
                  <Alternate>1.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F074007389027" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B07400738902727" PSS="2024-06-30">
                <Name>Vedafil</Name>
                <Pack ID="P2377810" Specified="true" nzmt:ctpp_id="50123881000117104">
                  <Quantity>12</Quantity>
                  <Subsidy>10.20</Subsidy>
                  <Price>10.20</Price>
                  <Alternate>10.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A074009">
          <Name>Prostacyclin Analogues</Name>
          <Chemical ID="C0740093891">
            <Name>Iloprost</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2257"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2257">
              <Title>
                <range>Iloprost</range>
              </Title>
              <Case When="Initial application" Category="PAH monotherapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures </ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Iloprost is to be used as PAH monotherapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)</ci>
                        <ci type="logical">Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="PAH dual therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures </ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil</ci>
                        <ci type="logical">Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</ci>
                        <ci type="logical">Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="PAH triple therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures </ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Iloprost is to be used as PAH triple therapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient is on the lung transplant list</ci>
                        <ci type="logical">Patient is presenting in NYHA/WHO functional class IV</ci>
                        <apply>
                          <and/>
                          <ci type="logical">Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification
                tool**</ci>
                          <ci type="logical">Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2257">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool**</ci>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>â€  The European Respiratory Journal Guidelines can be found here: <a href="https://erj.ersjournals.com/content/early/2022/08/25/13993003.00879-2022">2022 ECS/ERS Guidelines for the diagnosis and
        treatment of pulmonary hypertension PAH</a></p>
                <p>** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a
      validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.</p>
              </div>
            </Request>
            <Formulation ID="F074009389125" Rank="8" Units="neb" Weight="10">
              <Name>Nebuliser soln 10 mcg per ml, 2 ml</Name>
              <Brand ID="B07400938912526" PSS="2025-06-30">
                <Name>Vebulis</Name>
                <Pack ID="P2643006" Specified="true" nzmt:ctpp_id="50300961000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>185.03</Subsidy>
                  <Price>185.03</Price>
                  <Alternate>185.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C0740094093">
            <Name>Epoprostenol</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2256"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2256">
              <Title>
                <range>Epoprostenol</range>
              </Title>
              <Case When="Initial application" Category="PAH dual therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures </ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist</ci>
                      <ci type="logical">Patient is presenting in NYHA/WHO functional class IV</ci>
                      <ci type="logical">Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="PAH triple therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pulmonary arterial hypertension (PAH)</ci>
                    <ci type="logical">PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications</ci>
                    <ci type="logical">PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">PAH has been confirmed by right heart catheterisation</ci>
                        <ci type="logical">A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</ci>
                        <ci type="logical">A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</ci>
                        <ci type="logical">A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s <msup><mi>cm</mi><mo>-5</mo></msup>)</ci>
                        <apply>
                          <or/>
                          <ci type="logical">PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note
                below for link to these guidelines) â€  </ci>
                          <ci type="logical">Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</ci>
                          <ci type="logical">Patient has PAH other than idiopathic / heritable or drug-associated type</ci>
                        </apply>
                      </apply>
                      <ci type="logical">Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung
            disease</ci>
                      <ci type="logical">Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising
            of pulmonary/venous filling pressures </ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Epoprostenol is to be used as PAH triple therapy</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient is on the lung transplant list</ci>
                        <ci type="logical">Patient is presenting in NYHA/WHO functional class IV</ci>
                        <apply>
                          <and/>
                          <ci type="logical">Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification
                tool</ci>
                          <ci type="logical">Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA2256">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Patient is continuing to derive benefit from epoprostenol treatment according to a validated PAH risk stratification tool**</ci>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>cardiologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="respiratory specialist, cardiologist or rheumatologist">any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>â€  The European Respiratory Journal Guidelines can be found here: <a href="https://erj.ersjournals.com/content/early/2022/08/25/13993003.00879-2022">2022 ECS/ERS Guidelines for the diagnosis and
        treatment of pulmonary hypertension PAH</a></p>
                <p>** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a
      validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.</p>
              </div>
            </Request>
            <Formulation ID="F074009409325" Rank="4" Units="inj">
              <Name>Inj 500 mcg vial</Name>
              <Brand ID="B07400940932525">
                <Name>Veletri</Name>
                <Pack ID="P2488175" Specified="true" nzmt:ctpp_id="50201321000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>36.61</Subsidy>
                  <Price>36.61</Price>
                  <Alternate>36.61</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F074009409326" Rank="4" Units="inj" Weight="1">
              <Name>Inj 1.5 mg vial</Name>
              <Brand ID="B07400940932625">
                <Name>Veletri</Name>
                <Pack ID="P2488183" Specified="true" nzmt:ctpp_id="50201331000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>73.21</Subsidy>
                  <Price>73.21</Price>
                  <Alternate>73.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A10">
      <Name>Dermatologicals</Name>
      <ATC2 ID="A1001">
        <Name>Antiacne Preparations</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1603">For systemic antibacterials, refer to INFECTIONS, Antibacterials</p>
        </div>
        <ATC3 ID="A100101">
          <Name>Antiacne Preparations</Name>
          <Chemical ID="C1001011688">
            <Name>Isotretinoin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2023"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2023">
              <Title>
                <range>Isotretinoin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist,
          vocationally registered general practitioner, or nurse practitioner working in a relevant
          scope of practice</ci>
                    <ci type="logical" class="Indication">Applicant has an up to date knowledge of the safety
          issues around isotretinoin and is competent to prescribe isotretinoin</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is of child bearing potential and the
            possibility of pregnancy has been excluded prior to commencement of treatment and
            patient has been counselled and understands the risk of teratogenicity if isotretinoin
            is used during pregnancy and that they must not become pregnant during treatment and for
            a period of one month after the completion of treatment</ci>
                      <ci type="logical" class="Indication">Patient is not of child bearing potential</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">1</Term>
              </Case>
              <Case When="Renewal" Form="SA0955 SA1475 SA2023">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient is of child bearing potential and the
          possibility of pregnancy has been excluded prior to commencement of treatment and patient
          has been counselled and understands the risk of teratogenicity if isotretinoin is used
          during pregnancy and that they must not become pregnant during treatment and for a period
          of one month after the completion of treatment</ci>
                    <ci type="logical" class="Indication">Patient is not of child bearing potential</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">1</Term>
              </Case>
            </Request>
            <Formulation ID="F100101168801" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B10010116880125" PSS="2024-06-30">
                <Name>Oratane</Name>
                <Pack ID="P2400286" Specified="true" nzmt:ctpp_id="50133411000117108">
                  <Quantity>120</Quantity>
                  <Subsidy>18.75</Subsidy>
                  <Price>18.75</Price>
                  <Alternate>18.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F100101168802" Rank="2" Units="cap" Weight="20">
              <Name>Cap 20 mg</Name>
              <Brand ID="B10010116880202" PSS="2024-06-30">
                <Name>Oratane</Name>
                <Pack ID="P2400278" Specified="true" nzmt:ctpp_id="50133421000117102">
                  <Quantity>120</Quantity>
                  <Subsidy>26.73</Subsidy>
                  <Price>26.73</Price>
                  <Alternate>26.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F100101168825" Rank="2" Units="cap" Weight="5">
              <Name>Cap 5 mg</Name>
              <Brand ID="B10010116882525" PSS="2024-06-30">
                <Name>Oratane</Name>
                <Pack ID="P2339161" Specified="true" nzmt:ctpp_id="50122151000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>11.26</Subsidy>
                  <Price>11.26</Price>
                  <Alternate>11.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1001012286">
            <Name>Tretinoin</Name>
            <Formulation ID="F100101228626" Rank="3" Units="g">
              <Name>Crm 0.5 mg per g</Name>
              <Rule Type="FormMax" Value="50" Attribute="Rx"/>
              <Brand ID="B10010122862625" PSS="2024-06-30">
                <Name>ReTrieve</Name>
                <Pack ID="P2358751" Specified="true" OP="true" nzmt:ctpp_id="50050801000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>15.57</Subsidy>
                  <Price>15.57</Price>
                  <Alternate>15.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1001013915">
            <Name>Adapalene</Name>
            <Rule Type="FormMax" Value="30" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F100101391526" Rank="3" Units="g">
              <Name>Gel 0.1%</Name>
              <Brand ID="B10010139152625">
                <Name>Differin</Name>
                <Pack ID="P456160" Specified="true" OP="true" nzmt:ctpp_id="50086961000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>22.89</Subsidy>
                  <Price>22.89</Price>
                  <Alternate>22.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1004">
        <Name>Antibacterials Topical</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1603">For systemic antibacterials, refer to INFECTIONS, Antibacterials</p>
        </div>
        <ATC3 ID="A100401">
          <Name>Antibacterials Topical</Name>
          <Chemical ID="C1004011546">
            <Name>Sodium Fusidate [fusidic acid]</Name>
            <Formulation ID="F100401154608" Rank="3" Units="g">
              <Name>Crm 2%</Name>
              <Rule Type="FormMax" Value="5" Attribute="Rx"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10040115460825" PSS="2024-06-30">
                <Name>Foban</Name>
                <Pack ID="P2556170" Specified="true" OP="true" nzmt:ctpp_id="50162721000117107">
                  <Quantity>5</Quantity>
                  <Subsidy>1.59</Subsidy>
                  <Price>1.59</Price>
                  <Alternate>1.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F100401154609" Rank="3" Units="g">
              <Name>Oint 2%</Name>
              <Rule Type="FormMax" Value="5" Attribute="Rx"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10040115460925" PSS="2024-06-30">
                <Name>Foban</Name>
                <Pack ID="P2556189" Specified="true" OP="true" nzmt:ctpp_id="50162731000117105">
                  <Quantity>5</Quantity>
                  <Subsidy>1.59</Subsidy>
                  <Price>1.59</Price>
                  <Alternate>1.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1004011835">
            <Name>Mupirocin</Name>
            <Formulation ID="F100401183501" Rank="3" Units="g">
              <Name>Oint 2%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10040118350101">
                <Name>Bactroban</Name>
                <Pack ID="P523712" Specified="true" OP="true" nzmt:ctpp_id="50094101000117104">
                  <Quantity>15</Quantity>
                  <Subsidy>6.60</Subsidy>
                  <Price>11.50</Price>
                  <Alternate>6.60</Alternate>
                  <Surcharge>0.32667</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1004012114">
            <Name>Sulfadiazine Silver</Name>
            <Formulation ID="F100401211425" Rank="3" Units="g">
              <Name>Crm 1%</Name>
              <Rule Type="FormMax" Value="250" Attribute="PSO"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10040121142525">
                <Name>Flamazine</Name>
                <Pack ID="P2343851" Specified="true" OP="true" nzmt:ctpp_id="50050131000117105">
                  <Quantity>50</Quantity>
                  <Subsidy>10.80</Subsidy>
                  <Price>10.80</Price>
                  <Alternate>10.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1004013303" Statim="Must">
            <Name>Hydrogen peroxide</Name>
            <Formulation ID="F100401330325" Rank="3" Units="g">
              <Name>Crm 1%</Name>
              <Brand ID="B10040133032526">
                <Name>Crystaderm</Name>
                <Pack ID="P2399504" Specified="true" OP="true" nzmt:ctpp_id="50184561000117100">
                  <Quantity>10</Quantity>
                  <Subsidy>8.56</Subsidy>
                  <Price>8.56</Price>
                  <Alternate>8.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1007">
        <Name>Antifungals Topical</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1604">For systemic antifungals, refer to INFECTIONS, Antifungals</p>
        </div>
        <ATC3 ID="A100701">
          <Name>Antifungals Topical</Name>
          <Chemical ID="C1007011320" Statim="Must">
            <Name>Clotrimazole</Name>
            <Formulation ID="F100701132006" Rank="3" Units="ml">
              <Name>Soln 1%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10070113200601">
                <Name>Canesten</Name>
                <Pack ID="P202223" Specified="true" OP="true" nzmt:ctpp_id="50004481000117103">
                  <Quantity>20</Quantity>
                  <Subsidy>4.36</Subsidy>
                  <Price>7.55</Price>
                  <Alternate>4.36</Alternate>
                  <Surcharge>0.15950</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F100701132007" Rank="3" Units="g">
              <Name>Crm 1%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10070113200725" PSS="2025-06-30">
                <Name>Clomazol</Name>
                <Pack ID="P2184362" Specified="true" OP="true" nzmt:ctpp_id="50030181000117105">
                  <Quantity>20</Quantity>
                  <Subsidy>1.10</Subsidy>
                  <Price>1.10</Price>
                  <Alternate>1.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1007011443">
            <Name>Econazole nitrate</Name>
            <Formulation ID="F100701144307" Rank="10" Units="ea">
              <Name>Foaming soln 1%, 10 ml sachets</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10070114430701">
                <Name>Pevaryl</Name>
                <Pack ID="P383872" Specified="true" nzmt:ctpp_id="50080041000117108">
                  <Quantity>3</Quantity>
                  <Subsidy>9.89</Subsidy>
                  <Price>17.92</Price>
                  <Alternate>9.89</Alternate>
                  <Surcharge>2.67667</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F100701144310" Rank="3" Units="g">
              <Name>Crm 1%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10070114431002">
                <Name>Pevaryl</Name>
                <Pack ID="P2165953" Specified="true" OP="true" nzmt:ctpp_id="50027641000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>1.00</Subsidy>
                  <Price>7.78</Price>
                  <Alternate>1.00</Alternate>
                  <Surcharge>0.33900</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1007011620" Statim="Must">
            <Name>Miconazole nitrate</Name>
            <Formulation ID="F100701162001" Rank="3" Units="ml">
              <Name>Lotn 2%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10070116200101">
                <Name>Daktarin</Name>
                <Pack ID="P253278" Specified="true" OP="true" nzmt:ctpp_id="50053781000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>4.36</Subsidy>
                  <Price>10.03</Price>
                  <Alternate>4.36</Alternate>
                  <Surcharge>0.18900</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F100701162002" Rank="3" Units="ml">
              <Name>Tinct 2%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10070116200201">
                <Name>Daktarin</Name>
                <Pack ID="P253294" Specified="true" OP="true" nzmt:ctpp_id="50053801000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>4.36</Subsidy>
                  <Price>12.10</Price>
                  <Alternate>4.36</Alternate>
                  <Surcharge>0.25800</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F100701162003" Rank="3" Units="g">
              <Name>Crm 2%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="NotCombined"/>
              <Brand ID="B10070116200325" ToBePSS="2024-05-01">
                <Name>Multichem</Name>
                <Pack ID="P2184354" Specified="true" OP="true" nzmt:ctpp_id="50030171000117107">
                  <Quantity>15</Quantity>
                  <Subsidy>0.90</Subsidy>
                  <Price>0.90</Price>
                  <Alternate>0.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1007012832">
            <Name>Amorolfine</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="NotCombined"/>
            <Formulation ID="F100701283201" Rank="3" Units="ml">
              <Name>Nail soln 5%</Name>
              <Brand ID="B10070128320125" PSS="2026-06-30">
                <Name>MycoNail</Name>
                <Pack ID="P2461633" Specified="true" OP="true" nzmt:ctpp_id="50214811000117100">
                  <Quantity>5</Quantity>
                  <Subsidy>21.87</Subsidy>
                  <Price>21.87</Price>
                  <Alternate>21.87</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1008">
        <Name>Antipruritic Preparations</Name>
        <ATC3 ID="A100801">
          <Name>Antipruritic Preparations</Name>
          <Chemical ID="C1008011179">
            <Name>Calamine</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="NotCombined"/>
            <Formulation ID="F100801117901" Rank="3" Units="g">
              <Name>Crm, aqueous, BP</Name>
              <Brand ID="B10080111790126">
                <Name>healthE Calamine Aqueous</Name>
                <Pack ID="P2318628" Specified="true" nzmt:ctpp_id="50048441000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>3.45</Subsidy>
                  <Price>3.45</Price>
                  <Alternate>3.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1008011363">
            <Name>Crotamiton</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="NotCombined"/>
            <Formulation ID="F100801136301" Rank="3" Units="g">
              <Name>Crm 10%</Name>
              <Brand ID="B10080113630125" PSS="2024-06-30">
                <Name>Itch-Soothe</Name>
                <Pack ID="P2343614" Specified="true" OP="true" nzmt:ctpp_id="50050121000117107">
                  <Quantity>20</Quantity>
                  <Subsidy>3.29</Subsidy>
                  <Price>3.29</Price>
                  <Alternate>3.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1008013333">
            <Name>Menthol</Name>
            <Rule Type="Combined"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: decimal">
                <li>
                  <p>Only in combination with a dermatological base or proprietary Topical Corticosteriod â€“ Plain</p>
                </li>
                <li>
                  <p>With or without other dermatological galenicals.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F100801333301" Rank="3" Units="g">
              <Name>Crystals</Name>
              <Brand ID="B10080133330125">
                <Name>MidWest</Name>
                <Pack ID="P2018845" Specified="true" nzmt:ctpp_id="50003901000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>29.60</Subsidy>
                  <Price>29.60</Price>
                  <Alternate>29.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2377209" Specified="true" nzmt:ctpp_id="50121101000117103">
                  <Quantity>25</Quantity>
                  <Subsidy>6.92</Subsidy>
                  <Price>6.92</Price>
                  <Alternate>6.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1011">
        <Name>Corticosteroids Topical</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1407">For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS</p>
        </div>
        <ATC3 ID="A101101">
          <Name>Corticosteroids - Plain</Name>
          <Chemical ID="C1011011082">
            <Name>Methylprednisolone aceponate</Name>
            <Formulation ID="F101101108201" Rank="3" Units="g">
              <Name>Crm 0.1%</Name>
              <Brand ID="B10110110820101" PSS="2026-06-30">
                <Name>Advantan</Name>
                <Pack ID="P389439" Specified="true" OP="true" nzmt:ctpp_id="50080681000117106">
                  <Quantity>15</Quantity>
                  <Subsidy>4.95</Subsidy>
                  <Price>4.95</Price>
                  <Alternate>4.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101108202" Rank="3" Units="g">
              <Name>Oint 0.1%</Name>
              <Brand ID="B10110110820201" PSS="2026-06-30">
                <Name>Advantan</Name>
                <Pack ID="P388874" Specified="true" OP="true" nzmt:ctpp_id="50080561000117104">
                  <Quantity>15</Quantity>
                  <Subsidy>4.95</Subsidy>
                  <Price>4.95</Price>
                  <Alternate>4.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011011143">
            <Name>Betamethasone dipropionate</Name>
            <Formulation ID="F101101114312" Rank="3" Units="g">
              <Name>Crm 0.05%</Name>
              <Brand ID="B10110111431201">
                <Name>Diprosone</Name>
                <Pack ID="P201839" Specified="true" OP="true" nzmt:ctpp_id="50003631000117104">
                  <Quantity>15</Quantity>
                  <Subsidy>2.96</Subsidy>
                  <Price>2.96</Price>
                  <Alternate>2.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P210870" Specified="true" OP="true" nzmt:ctpp_id="50019401000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>36.00</Subsidy>
                  <Price>36.00</Price>
                  <Alternate>36.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101114313" Rank="3" Units="g">
              <Name>Oint 0.05%</Name>
              <Brand ID="B10110111431301">
                <Name>Diprosone</Name>
                <Pack ID="P210889" Specified="true" OP="true" nzmt:ctpp_id="50019481000117101">
                  <Quantity>15</Quantity>
                  <Subsidy>2.96</Subsidy>
                  <Price>2.96</Price>
                  <Alternate>2.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P210897" Specified="true" OP="true" nzmt:ctpp_id="50019501000117109">
                  <Quantity>50</Quantity>
                  <Subsidy>36.00</Subsidy>
                  <Price>36.00</Price>
                  <Alternate>36.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101114315" Rank="3" Units="g">
              <Name>Oint 0.05% in propylene glycol base</Name>
              <Brand ID="B10110111431525">
                <Name>Diprosone OV</Name>
                <Pack ID="P2062844" Specified="true" OP="true" nzmt:ctpp_id="50010971000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>4.33</Subsidy>
                  <Price>4.33</Price>
                  <Alternate>4.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011011309" Statim="Must">
            <Name>Clobetasol propionate</Name>
            <Formulation ID="F101101130903" Rank="3" Units="g">
              <Name>Crm 0.05%</Name>
              <Brand ID="B10110113090301" PSS="2025-06-30">
                <Name>Dermol</Name>
                <Pack ID="P229059" Specified="true" OP="true" nzmt:ctpp_id="50044571000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>2.40</Subsidy>
                  <Price>2.40</Price>
                  <Alternate>2.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101130904" Rank="3" Units="g">
              <Name>Oint 0.05%</Name>
              <Brand ID="B10110113090401" PSS="2025-06-30">
                <Name>Dermol</Name>
                <Pack ID="P229040" Specified="true" OP="true" nzmt:ctpp_id="50044501000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>2.33</Subsidy>
                  <Price>2.33</Price>
                  <Alternate>2.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011011310">
            <Name>Clobetasone butyrate</Name>
            <Formulation ID="F101101131002" Rank="3" Units="g">
              <Name>Crm 0.05%</Name>
              <Brand ID="B10110113100201">
                <Name>Eumovate</Name>
                <Pack ID="P713945" OP="true" nzmt:ctpp_id="50130931000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>5.38</Subsidy>
                  <Price>10.00</Price>
                  <Alternate>5.38</Alternate>
                  <Surcharge>0.15400</Surcharge>
                </Pack>
                <Pack ID="P2401096" Specified="true" OP="true" nzmt:ctpp_id="50223891000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>5.38</Subsidy>
                  <Price>10.00</Price>
                  <Alternate>5.38</Alternate>
                  <Surcharge>0.15400</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011011613">
            <Name>Hydrocortisone and paraffin liquid and lanolin</Name>
            <Formulation ID="F101101161301" Rank="3" Units="ml">
              <Name>Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B10110116130101" ToBePSS="2024-06-01">
                <Name>DP Lotn HC</Name>
                <Pack ID="P716294" Specified="true" nzmt:ctpp_id="50105041000117109">
                  <Quantity>250</Quantity>
                  <Subsidy>12.83</Subsidy>
                  <Price>12.83</Price>
                  <Alternate>12.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011011614">
            <Name>Hydrocortisone butyrate</Name>
            <Formulation ID="F101101161401" Rank="3" Units="g">
              <Name>Oint 0.1%</Name>
              <Brand ID="B10110116140101" PSS="2024-06-30">
                <Name>Locoid</Name>
                <Pack ID="P210382" Specified="true" OP="true" nzmt:ctpp_id="50018631000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>10.28</Subsidy>
                  <Price>10.28</Price>
                  <Alternate>10.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101161407" Rank="3" Units="g">
              <Name>Lipocream 0.1%</Name>
              <Brand ID="B10110116140701">
                <Name>Locoid Lipocream</Name>
                <Pack ID="P521957" Specified="true" OP="true" nzmt:ctpp_id="50093981000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>4.85</Subsidy>
                  <Price>4.85</Price>
                  <Alternate>4.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101161425" Rank="3" Units="ml">
              <Name>Milky emul 0.1%</Name>
              <Brand ID="B10110116142525" PSS="2024-06-30">
                <Name>Locoid Crelo</Name>
                <Pack ID="P2017458" Specified="true" OP="true" nzmt:ctpp_id="50003401000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>12.33</Subsidy>
                  <Price>12.33</Price>
                  <Alternate>12.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011011617" Statim="Must">
            <Name>Hydrocortisone</Name>
            <Formulation ID="F101101161706" Rank="3" Units="g">
              <Name>Powder</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Up to 5% in a dermatological base (not proprietary Topical Corticosteriod â€“ Plain) with or without other dermatological galenicals</p>
              </div>
              <Brand ID="B10110116170626">
                <Name>ABM</Name>
                <Pack ID="P2322420" Specified="true" nzmt:ctpp_id="50048881000117104">
                  <Quantity>25</Quantity>
                  <Subsidy>49.95</Subsidy>
                  <Price>49.95</Price>
                  <Alternate>49.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101161719" Rank="3" Units="g">
              <Name>Crm 1%</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B10110116171929" PSS="2025-06-30">
                <Name>Ethics</Name>
                <Pack ID="P2646587" Specified="true" OP="true" nzmt:ctpp_id="50183231000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>1.78</Subsidy>
                  <Price>1.78</Price>
                  <Alternate>1.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B10110116171930" PSS="2025-06-30">
                <Name>Noumed</Name>
                <Pack ID="P2645580" Specified="true" nzmt:ctpp_id="50306641000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>20.40</Subsidy>
                  <Price>20.40</Price>
                  <Alternate>20.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011012389">
            <Name>Triamcinolone acetonide</Name>
            <Formulation ID="F101101238908" Rank="3" Units="g">
              <Name>Crm 0.02%</Name>
              <Brand ID="B10110123890801" PSS="2026-06-30">
                <Name>Aristocort</Name>
                <Pack ID="P250066" Specified="true" OP="true" nzmt:ctpp_id="50052201000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>6.49</Subsidy>
                  <Price>6.49</Price>
                  <Alternate>6.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101238909" Rank="3" Units="g">
              <Name>Oint 0.02%</Name>
              <Brand ID="B10110123890901" PSS="2026-06-30">
                <Name>Aristocort</Name>
                <Pack ID="P250082" Specified="true" OP="true" nzmt:ctpp_id="50052221000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>6.54</Subsidy>
                  <Price>6.54</Price>
                  <Alternate>6.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011012716" Statim="Must">
            <Name>Betamethasone valerate</Name>
            <Formulation ID="F101101271608" Rank="3" Units="ml">
              <Name>Lotn 0.1%</Name>
              <Brand ID="B10110127160801" PSS="2024-06-30">
                <Name>Betnovate</Name>
                <Pack ID="P210110" Specified="true" OP="true" nzmt:ctpp_id="50018431000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101271609" Rank="3" Units="g">
              <Name>Crm 0.1%</Name>
              <Brand ID="B10110127160925" PSS="2024-06-30">
                <Name>Beta Cream</Name>
                <Pack ID="P2188740" Specified="true" OP="true" nzmt:ctpp_id="50030661000117105">
                  <Quantity>50</Quantity>
                  <Subsidy>4.53</Subsidy>
                  <Price>4.53</Price>
                  <Alternate>4.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101271610" Rank="3" Units="g">
              <Name>Oint 0.1%</Name>
              <Brand ID="B10110127161025" PSS="2024-06-30">
                <Name>Beta Ointment</Name>
                <Pack ID="P2188759" Specified="true" OP="true" nzmt:ctpp_id="50030671000117100">
                  <Quantity>50</Quantity>
                  <Subsidy>5.84</Subsidy>
                  <Price>5.84</Price>
                  <Alternate>5.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011012837">
            <Name>Mometasone furoate</Name>
            <Formulation ID="F101101283701" Rank="3" Units="ml">
              <Name>Lotn 0.1%</Name>
              <Brand ID="B10110128370101" PSS="2024-06-30">
                <Name>Elocon</Name>
                <Pack ID="P2177633" Specified="true" OP="true" nzmt:ctpp_id="50029201000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>4.50</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101283703" Rank="3" Units="g">
              <Name>Crm 0.1%</Name>
              <Brand ID="B10110128370301" PSS="2024-06-30">
                <Name>Elocon Alcohol Free</Name>
                <Pack ID="P218375" Specified="true" OP="true" nzmt:ctpp_id="50029991000117101">
                  <Quantity>15</Quantity>
                  <Subsidy>1.95</Subsidy>
                  <Price>1.95</Price>
                  <Alternate>1.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2395738" Specified="true" OP="true" nzmt:ctpp_id="50126471000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>3.10</Subsidy>
                  <Price>3.10</Price>
                  <Alternate>3.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101101283704" Rank="3" Units="g">
              <Name>Oint 0.1%</Name>
              <Brand ID="B10110128370401" PSS="2024-06-30">
                <Name>Elocon</Name>
                <Pack ID="P218383" Specified="true" OP="true" nzmt:ctpp_id="50030001000117102">
                  <Quantity>15</Quantity>
                  <Subsidy>1.95</Subsidy>
                  <Price>1.95</Price>
                  <Alternate>1.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2395746" Specified="true" OP="true" nzmt:ctpp_id="50126521000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>2.90</Subsidy>
                  <Price>2.90</Price>
                  <Alternate>2.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A101104">
          <Name>Corticosteroids - Combination</Name>
          <Chemical ID="C1011041148">
            <Name>Betamethasone valerate with sodium fusidate [fusidic acid]</Name>
            <Formulation ID="F101104114801" Rank="3" Units="g">
              <Name>Crm 0.1% with sodium fusidate (fusidic acid) 2%</Name>
              <Rule Type="FormMax" Value="15" Attribute="Rx"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B10110411480101">
                <Name>Fucicort</Name>
                <Pack ID="P629839" Specified="true" OP="true" nzmt:ctpp_id="50099811000117105">
                  <Quantity>15</Quantity>
                  <Subsidy>3.49</Subsidy>
                  <Price>10.45</Price>
                  <Alternate>3.49</Alternate>
                  <Surcharge>0.46400</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011041611" Statim="Must">
            <Name>Hydrocortisone with miconazole</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F101104161101" Rank="3" Units="g">
              <Name>Crm 1% with miconazole nitrate 2%</Name>
              <Brand ID="B10110416110101" PSS="2024-06-30">
                <Name>Micreme H</Name>
                <Pack ID="P704733" Specified="true" OP="true" nzmt:ctpp_id="50103821000117108">
                  <Quantity>15</Quantity>
                  <Subsidy>1.89</Subsidy>
                  <Price>1.89</Price>
                  <Alternate>1.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011041612">
            <Name>Hydrocortisone with natamycin and neomycin</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F101104161203" Rank="3" Units="g">
              <Name>Oint 1% with natamycin 1% and neomycin sulphate 0.5%</Name>
              <Brand ID="B10110416120301">
                <Name>Pimafucort</Name>
                <Pack ID="P260282" Specified="true" OP="true" nzmt:ctpp_id="50057061000117103">
                  <Quantity>15</Quantity>
                  <Subsidy>3.35</Subsidy>
                  <Price>3.35</Price>
                  <Alternate>3.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1011042387">
            <Name>Triamcinolone acetonide with gramicidin, neomycin and nystatin</Name>
            <Formulation ID="F101104238703" Rank="3" Units="g">
              <Name>Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B10110423870325">
                <Name>Viaderm KC</Name>
                <Pack ID="P2083078" Specified="true" OP="true" nzmt:ctpp_id="50013691000117102">
                  <Quantity>15</Quantity>
                  <Subsidy>3.49</Subsidy>
                  <Price>9.28</Price>
                  <Alternate>3.49</Alternate>
                  <Surcharge>0.38600</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1015">
        <Name>Barrier Creams and Emollients</Name>
        <ATC3 ID="A101502">
          <Name>Barrier Creams</Name>
          <Chemical ID="C1015021420" Statim="Must">
            <Name>Dimethicone</Name>
            <Formulation ID="F101502142025" Rank="3" Units="ml" Weight="5">
              <Name>Crm 5% pump bottle</Name>
              <Brand ID="B10150214202525" PSS="2025-06-30">
                <Name>healthE Dimethicone 5%</Name>
                <Pack ID="P2373319" Specified="true" OP="true" nzmt:ctpp_id="50196961000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>4.30</Subsidy>
                  <Price>4.30</Price>
                  <Alternate>4.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101502142026" Rank="3" Units="ml" Weight="10">
              <Name>Crm 10% pump bottle</Name>
              <Brand ID="B10150214202625">
                <Name>healthE Dimethicone 10%</Name>
                <Pack ID="P2373289" Specified="true" OP="true" nzmt:ctpp_id="50226321000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>4.52</Subsidy>
                  <Price>4.52</Price>
                  <Alternate>4.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015023431" Statim="Must">
            <Name>Zinc and castor oil</Name>
            <Formulation ID="F101502343101" Rank="3" Units="g">
              <Name>Oint</Name>
              <Brand ID="B10150234310107" SoleSupply="2025-06-30">
                <Name>Evara</Name>
                <Pack ID="P2658399" Specified="true" nzmt:ctpp_id="50297291000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>4.25</Subsidy>
                  <Price>4.25</Price>
                  <Alternate>4.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A101504">
          <Name>Emollients</Name>
          <Chemical ID="C1015042312" Statim="Must">
            <Name>Urea</Name>
            <Formulation ID="F101504231201" Rank="3" Units="g">
              <Name>Crm 10%</Name>
              <Brand ID="B10150423120125">
                <Name>healthE Urea Cream</Name>
                <Pack ID="P2444690" Specified="true" OP="true" nzmt:ctpp_id="50180301000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>1.37</Subsidy>
                  <Price>1.37</Price>
                  <Alternate>1.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015042339" Statim="Must">
            <Name>Wool fat with mineral oil</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F101504233919" Rank="3" Units="ml">
              <Name>Lotn hydrous 3% with mineral oil</Name>
              <Brand ID="B10150423391901">
                <Name>Alpha-Keri Lotion</Name>
                <Pack ID="P268070" Specified="true" nzmt:ctpp_id="50059561000117102">
                  <Quantity>1000</Quantity>
                  <Subsidy>5.60</Subsidy>
                  <Price>20.53</Price>
                  <Alternate>5.60</Alternate>
                  <Surcharge>0.01493</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B10150423391903">
                <Name>BK Lotion</Name>
                <Pack ID="P325295" Specified="true" OP="true" nzmt:ctpp_id="50072361000117101">
                  <Quantity>250</Quantity>
                  <Subsidy>1.40</Subsidy>
                  <Price>7.73</Price>
                  <Alternate>1.40</Alternate>
                  <Surcharge>0.02532</Surcharge>
                </Pack>
                <Pack ID="P325309" Specified="true" nzmt:ctpp_id="50072371000117106">
                  <Quantity>1000</Quantity>
                  <Subsidy>5.60</Subsidy>
                  <Price>23.91</Price>
                  <Alternate>5.60</Alternate>
                  <Surcharge>0.01831</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B10150423391904">
                <Name>DP Lotion</Name>
                <Pack ID="P619779" Specified="true" OP="true" nzmt:ctpp_id="50099641000117108">
                  <Quantity>250</Quantity>
                  <Subsidy>1.40</Subsidy>
                  <Price>5.87</Price>
                  <Alternate>1.40</Alternate>
                  <Surcharge>0.01788</Surcharge>
                </Pack>
                <Pack ID="P619787" Specified="true" nzmt:ctpp_id="50099651000117105">
                  <Quantity>1000</Quantity>
                  <Subsidy>5.60</Subsidy>
                  <Price>14.96</Price>
                  <Alternate>5.60</Alternate>
                  <Surcharge>0.00936</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015043213">
            <Name>Aqueous cream</Name>
            <Formulation ID="F101504321301" Rank="3" Units="g">
              <Name>Crm</Name>
              <Brand ID="B10150432130129">
                <Name>Evara</Name>
                <Pack ID="P2555115" Specified="true" nzmt:ctpp_id="50320251000117106">
                  <Quantity>500</Quantity>
                  <Subsidy>1.73</Subsidy>
                  <Price>1.73</Price>
                  <Alternate>1.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B10150432130133" PSS="2024-06-30">
                <Name>GEM Aqueous Cream</Name>
                <Pack ID="P2615592" Specified="true" nzmt:ctpp_id="50289551000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>1.73</Subsidy>
                  <Price>1.73</Price>
                  <Alternate>1.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B10150432130134">
                <Name>healthE Aqueous Cream SLS Free</Name>
                <Pack ID="P2321920" Specified="true" nzmt:ctpp_id="50154751000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>1.30</Subsidy>
                  <Price>1.30</Price>
                  <Alternate>1.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015043244" Statim="Must">
            <Name>Cetomacrogol</Name>
            <Formulation ID="F101504324401" Rank="3" Units="g">
              <Name>Crm BP</Name>
              <Brand ID="B10150432440126" PSS="2024-06-30">
                <Name>Cetomacrogol-AFT</Name>
                <Pack ID="P2615509" Specified="true" nzmt:ctpp_id="50293441000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>1.99</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015043282" Statim="Must">
            <Name>Emulsifying ointment</Name>
            <Formulation ID="F101504328201" Rank="3" Units="g">
              <Name>Oint BP</Name>
              <Brand ID="B10150432820126" ToBePSS="2024-05-01">
                <Name>Emulsifying Ointment ADE</Name>
                <Pack ID="P2597535" Specified="true" nzmt:ctpp_id="50280561000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>3.13</Subsidy>
                  <Price>3.13</Price>
                  <Alternate>3.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015043349">
            <Name>Paraffin</Name>
            <Formulation ID="F101504334925" Rank="3" Units="g">
              <Name>Oint liquid paraffin 50% with white soft paraffin 50%</Name>
              <Brand ID="B10150433492526" PSS="2025-06-30">
                <Name>White Soft Liquid Paraffin AFT</Name>
                <Pack ID="P2639106" Specified="true" OP="true" nzmt:ctpp_id="50307471000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>4.94</Subsidy>
                  <Price>4.94</Price>
                  <Alternate>4.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015043743" Statim="Must">
            <Name>Oil in water emulsion</Name>
            <Formulation ID="F101504374325" Rank="3" Units="g">
              <Name>Crm</Name>
              <Brand ID="B10150437432528" PSS="2024-06-30">
                <Name>Fatty Cream AFT</Name>
                <Pack ID="P2627426" Specified="true" nzmt:ctpp_id="50298701000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>2.04</Subsidy>
                  <Price>2.04</Price>
                  <Alternate>2.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1015044012">
            <Name>Cetomacrogol with glycerol</Name>
            <Formulation ID="F101504401225" Rank="3" Units="ml">
              <Name>Crm 90% with glycerol 10%</Name>
              <Brand ID="B10150440122529" PSS="2025-06-30">
                <Name>Evara</Name>
                <Pack ID="P2642778" Specified="true" OP="true" nzmt:ctpp_id="50296641000117105">
                  <Quantity>500</Quantity>
                  <Subsidy>2.13</Subsidy>
                  <Price>2.13</Price>
                  <Alternate>2.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2642786" Specified="true" OP="true" nzmt:ctpp_id="50296651000117107">
                  <Quantity>1000</Quantity>
                  <Subsidy>3.50</Subsidy>
                  <Price>3.50</Price>
                  <Alternate>3.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A101506">
          <Name>Other Dermatological Bases</Name>
          <Chemical ID="C1015063349">
            <Name>Paraffin</Name>
            <Formulation ID="F101506334903" Rank="3" Units="g">
              <Name>White soft</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid â€“ Plain.</p>
              </div>
              <Brand ID="B10150633490303" ToBeDelisted="2024-06-01">
                <Name>healthE</Name>
                <Pack ID="P2322080" Specified="true" nzmt:ctpp_id="50268191000117108">
                  <Quantity>2500</Quantity>
                  <Subsidy>19.99</Subsidy>
                  <Price>19.99</Price>
                  <Alternate>19.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2322099" Specified="true" nzmt:ctpp_id="50268201000117106">
                  <Quantity>450</Quantity>
                  <Subsidy>4.99</Subsidy>
                  <Price>4.99</Price>
                  <Alternate>4.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B10150633490304" ToBePSS="2024-06-01">
                <Name>EVARA White Soft Paraffin</Name>
                <Pack ID="P2664178" Specified="true" nzmt:ctpp_id="50321911000117107">
                  <Quantity>450</Quantity>
                  <Subsidy>4.74</Subsidy>
                  <Price>4.74</Price>
                  <Alternate>4.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2664186" Specified="true" nzmt:ctpp_id="50321921000117101">
                  <Quantity>2500</Quantity>
                  <Subsidy>19.00</Subsidy>
                  <Price>19.00</Price>
                  <Alternate>19.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1016">
        <Name>Minor Skin Infections</Name>
        <ATC3 ID="A101601">
          <Name>Minor Skin Infections</Name>
          <Chemical ID="C1016012385">
            <Name>Povidone iodine</Name>
            <Formulation ID="F101601238501" Rank="3" Units="g">
              <Name>Oint 10%</Name>
              <Rule Type="FormMax" Value="130" Attribute="Rx"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B10160123850101">
                <Name>Betadine</Name>
                <Pack ID="P2159252" Specified="true" OP="true" nzmt:ctpp_id="50027161000117100">
                  <Quantity>65</Quantity>
                  <Subsidy>7.40</Subsidy>
                  <Price>7.40</Price>
                  <Alternate>7.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101601238502" Rank="3" Units="ml">
              <Name>Antiseptic soln 10%</Name>
              <Brand ID="B10160123850204">
                <Name>Riodine</Name>
                <Pack ID="P994812" Specified="true" nzmt:ctpp_id="50119611000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>5.40</Subsidy>
                  <Price>5.40</Price>
                  <Alternate>5.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2013304" Specified="true" nzmt:ctpp_id="50001851000117109">
                  <Quantity>15</Quantity>
                  <Subsidy>3.83</Subsidy>
                  <Price>3.83</Price>
                  <Alternate>3.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101601238504" Rank="3" Units="ml">
              <Name>Skin preparation, povidone iodine 10% with 30% alcohol</Name>
              <Brand ID="B10160123850401">
                <Name>Betadine Skin Prep</Name>
                <Pack ID="P510327" Specified="true" nzmt:ctpp_id="50093411000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>1.63</Subsidy>
                  <Price>3.48</Price>
                  <Alternate>1.63</Alternate>
                  <Surcharge>0.01850</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101601238505" Rank="3" Units="ml">
              <Name>Skin preparation, povidone iodine 10% with 70% alcohol</Name>
              <Brand ID="B10160123850526">
                <Name>Pfizer</Name>
                <Pack ID="P2556286" Specified="true" nzmt:ctpp_id="50259341000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>1.63</Subsidy>
                  <Price>7.78</Price>
                  <Alternate>1.63</Alternate>
                  <Surcharge>0.06150</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101601238525" Rank="3" Units="ml">
              <Name>Antiseptic Solution 10%</Name>
              <Brand ID="B10160123852525" PSS="2024-06-30">
                <Name>Riodine</Name>
                <Pack ID="P777447" Specified="true" nzmt:ctpp_id="50112821000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>4.15</Subsidy>
                  <Price>4.15</Price>
                  <Alternate>4.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1017">
        <Name>Parasiticidal Preparations</Name>
        <ATC3 ID="A101701">
          <Name>Parasiticidal Preparations</Name>
          <Chemical ID="C1017011420" Statim="Must">
            <Name>Dimethicone</Name>
            <Formulation ID="F101701142027" Rank="3" Units="ml">
              <Name>Lotn 4%</Name>
              <Brand ID="B10170114202725" PSS="2025-06-30">
                <Name>healthE Dimethicone 4% Lotion</Name>
                <Pack ID="P2351293" Specified="true" OP="true" nzmt:ctpp_id="50242291000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>4.25</Subsidy>
                  <Price>4.25</Price>
                  <Alternate>4.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1017012828">
            <Name>Permethrin</Name>
            <Formulation ID="F101701282802" Rank="3" Units="ml">
              <Name>Lotn 5%</Name>
              <Brand ID="B10170128280225" PSS="2026-06-30">
                <Name>A-Scabies</Name>
                <Pack ID="P2332027" Specified="true" OP="true" nzmt:ctpp_id="50049481000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>4.28</Subsidy>
                  <Price>4.28</Price>
                  <Alternate>4.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1017013964">
            <Name>Ivermectin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2294"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2294">
              <Title>
                <range>Ivermectin</range>
              </Title>
              <Case When="Initial application" Category="Scabies">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The person has a severe scabies hyperinfestation
          (Crusted/ Norwegian scabies)</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The person has a confirmed diagnosis of scabies or
            is a close contact of a scabies case</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The person is unable to complete topical
              therapy</ci>
                        <ci type="logical" class="Indication">Previous treatment with topical therapy has been
              tried and not cleared the infestation</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Initial application" Category="Other parasitic infections">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">filariasis</ci>
                    <ci type="logical" class="Indication">cutaneous larva migrans (creeping eruption)</ci>
                    <ci type="logical" class="Indication">strongyloidiasis</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Renewal" Category="Scabies" Form="SA1225 SA2228 SA2294">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The person has a severe scabies hyperinfestation
          (Crusted/ Norwegian scabies)</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The person has a confirmed diagnosis of scabies or
            is a close contact of a scabies case</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The person is unable to complete topical
              therapy</ci>
                        <ci type="logical" class="Indication">Previous treatment with topical therapy has been
              tried and not cleared the infestation</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Renewal" Category="Other parasitic infections" Form="SA1225 SA2228 SA2294">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">filariasis</ci>
                    <ci type="logical" class="Indication">cutaneous larva migrans (creeping eruption)</ci>
                    <ci type="logical" class="Indication">strongyloidiasis</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
            </Request>
            <Formulation ID="F101701396425" Rank="1" Units="tab" Weight="3">
              <Name>Tab 3 mg</Name>
              <Rule Type="FormMax" Value="100" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.</p>
                  </li>
                  <li>
                    <p>Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.</p>
                  </li>
                  <li>
                    <p>For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or prisons.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B10170139642525">
                <Name>Stromectol</Name>
                <Pack ID="P2087057" Specified="true" nzmt:ctpp_id="50015351000117100">
                  <Quantity>4</Quantity>
                  <Subsidy>17.20</Subsidy>
                  <Price>17.20</Price>
                  <Alternate>17.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1019">
        <Name>Psoriasis and Eczema Preparations</Name>
        <ATC3 ID="A101901">
          <Name>Psoriasis and Eczema Preparations</Name>
          <Chemical ID="C1019011088">
            <Name>Tacrolimus</Name>
            <Formulation ID="F101901108827" Rank="3" Units="g">
              <Name>Oint 0.1%</Name>
              <Rule Type="FormMax" Value="30" Attribute="Rx"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Note: a maximum of 30 g per prescription and no more than one prescription per 12 weeks.</p>
              </div>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2074"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA2074">
                <Title>
                  <range>Tacrolimus Ointment</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has atopic dermatitis on the face</ci>
                      <ci type="logical" class="Indication">Patient has at least one of the following
                    contraindications to topical corticosteroids: periorificial dermatitis, rosacea,
                    documented epidermal atrophy or documented allergy to topical
                    corticosteroids</ci>
                    </apply>
                  </math>
                  <Applicant>dermatologist</Applicant>
                  <Applicant>paediatrician</Applicant>
                  <Applicant Referring="dermatologist, paediatrician, ">any relevant practitioner</Applicant>
                  <Term Measure="patient's lifetime"/>
                </Case>
              </Request>
              <Brand ID="B10190110882725" PSS="2026-06-30">
                <Name>Zematop</Name>
                <Pack ID="P2607646" Specified="true" OP="true" nzmt:ctpp_id="50269161000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>33.00</Subsidy>
                  <Price>33.00</Price>
                  <Alternate>33.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019011324">
            <Name>Coal tar with allantoin, menthol, phenol and sulphur</Name>
            <Formulation ID="F101901132401" Rank="3" Units="g">
              <Name>Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5%</Name>
              <Brand ID="B10190113240101">
                <Name>Egopsoryl TA</Name>
                <Pack ID="P201855" Specified="true" OP="true" nzmt:ctpp_id="50003651000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>3.43</Subsidy>
                  <Price>4.35</Price>
                  <Alternate>3.43</Alternate>
                  <Surcharge>0.03067</Surcharge>
                </Pack>
                <Pack ID="P201863" Specified="true" OP="true" nzmt:ctpp_id="50003681000117103">
                  <Quantity>75</Quantity>
                  <Subsidy>6.59</Subsidy>
                  <Price>8.00</Price>
                  <Alternate>6.59</Alternate>
                  <Surcharge>0.01880</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019012220" Statim="Must">
            <Name>Pine tar with trolamine laurilsulfate and fluorescein</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F101901222002" Rank="3" Units="ml">
              <Name>Soln 2.3% with trolamine laurilsulfate and fluorescein sodium</Name>
              <Brand ID="B10190122200201" PSS="2026-06-30">
                <Name>Pinetarsol</Name>
                <Pack ID="P307661" Specified="true" nzmt:ctpp_id="50068981000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>5.41</Subsidy>
                  <Price>5.41</Price>
                  <Alternate>5.41</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019012363">
            <Name>Acitretin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2024"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2024">
              <Title>
                <range>Acitretin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist,
          vocationally registered general practitioner, or nurse practitioner working in a relevant
          scope of practice</ci>
                    <ci type="logical" class="Indication">Applicant has an up to date knowledge of the safety
          issues around acitretin and is competent to prescribe acitretin</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is of child bearing potential and the
            possibility of pregnancy has been excluded prior to commencement of treatment and
            patient has been counselled and understands the risk of teratogenicity if acitretin
            is used during pregnancy and that they must not become pregnant during treatment and for
            a period of three years after the completion of treatment</ci>
                      <ci type="logical" class="Indication">Patient is not of child bearing potential</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">1</Term>
              </Case>
              <Case When="Renewal" Form="SA0946 SA0954 SA1476 SA2024">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient is of child bearing potential and the
          possibility of pregnancy has been excluded prior to commencement of treatment and patient
          has been counselled and understands the risk of teratogenicity if acitretin is used
          during pregnancy and that they must not become pregnant during treatment and for a period
          of three years after the completion of treatment</ci>
                    <ci type="logical" class="Indication">Patient is not of child bearing potential</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">1</Term>
              </Case>
            </Request>
            <Formulation ID="F101901236301" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B10190123630125">
                <Name>Novatretin</Name>
                <Pack ID="P2384167" Specified="true" nzmt:ctpp_id="50125951000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>26.20</Subsidy>
                  <Price>26.20</Price>
                  <Alternate>26.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101901236302" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B10190123630225">
                <Name>Novatretin</Name>
                <Pack ID="P2384175" Specified="true" nzmt:ctpp_id="50125961000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>57.37</Subsidy>
                  <Price>57.37</Price>
                  <Alternate>57.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019012796">
            <Name>Calcipotriol</Name>
            <Formulation ID="F101901279605" Rank="3" Units="g">
              <Name>Oint 50 mcg per g</Name>
              <Brand ID="B10190127960501">
                <Name>Daivonex</Name>
                <Pack ID="P2592673" Specified="true" OP="true" nzmt:ctpp_id="50272331000117100">
                  <Quantity>120</Quantity>
                  <Subsidy>40.00</Subsidy>
                  <Price>40.00</Price>
                  <Alternate>40.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019013264">
            <Name>Coal tar</Name>
            <Formulation ID="F101901326405" Rank="3" Units="ml">
              <Name>Soln BP</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>Up to 10% only in combination with a dermatological base or proprietary Topical Corticosteriod â€“ Plain</p>
                  </li>
                  <li>
                    <p>With or without other dermatological galenicals.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B10190132640525">
                <Name>Midwest</Name>
                <Pack ID="P2361671" Specified="true" nzmt:ctpp_id="50051021000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>36.25</Subsidy>
                  <Price>36.25</Price>
                  <Alternate>36.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019013385">
            <Name>Salicylic acid</Name>
            <Formulation ID="F101901338501" Rank="3" Units="g">
              <Name>Powder</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>Only in combination with a dermatological base or proprietary Topical Corticosteroid â€“ Plain or collodion flexible</p>
                  </li>
                  <li>
                    <p>With or without other dermatological galenicals.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B10190133850126">
                <Name>Midwest</Name>
                <Pack ID="P2574136" Specified="true" nzmt:ctpp_id="50268151000117104">
                  <Quantity>250</Quantity>
                  <Subsidy>18.88</Subsidy>
                  <Price>18.88</Price>
                  <Alternate>18.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019013411">
            <Name>Sulphur</Name>
            <Formulation ID="F101901341102" Rank="3" Units="g">
              <Name>Precipitated</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>Only in combination with a dermatological base or proprietary Topical Corticosteroid â€“ Plain</p>
                  </li>
                  <li>
                    <p>With or without other dermatological galenicals.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B10190134110226">
                <Name>Midwest</Name>
                <Pack ID="P2121158" Specified="true" nzmt:ctpp_id="50021991000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>6.35</Subsidy>
                  <Price>6.35</Price>
                  <Alternate>6.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019013776">
            <Name>Coal tar with salicylic acid and sulphur</Name>
            <Formulation ID="F101901377625" Rank="3" Units="g">
              <Name>Soln 12% with salicylic acid 2% and sulphur 4% oint</Name>
              <Brand ID="B10190137762526">
                <Name>Coco-Scalp</Name>
                <Pack ID="P2130017" Specified="true" OP="true" nzmt:ctpp_id="50023431000117109">
                  <Quantity>40</Quantity>
                  <Subsidy>7.95</Subsidy>
                  <Price>7.95</Price>
                  <Alternate>7.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2461617" Specified="true" OP="true" nzmt:ctpp_id="50204631000117107">
                  <Quantity>25</Quantity>
                  <Subsidy>4.97</Subsidy>
                  <Price>4.97</Price>
                  <Alternate>4.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019013941">
            <Name>Betamethasone dipropionate with calcipotriol</Name>
            <Formulation ID="F101901394125" Rank="3" Units="g">
              <Name>Oint 500 mcg with calcipotriol 50 mcg per g</Name>
              <Brand ID="B10190139412525" PSS="2024-06-30">
                <Name>Daivobet</Name>
                <Pack ID="P2170914" Specified="true" OP="true" nzmt:ctpp_id="50028761000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>15.90</Subsidy>
                  <Price>15.90</Price>
                  <Alternate>15.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101901394126" Rank="3" Units="g">
              <Name>Gel 500 mcg with calcipotriol 50 mcg per g</Name>
              <Brand ID="B10190139412625" PSS="2024-06-30">
                <Name>Daivobet</Name>
                <Pack ID="P2553015" Specified="true" OP="true" nzmt:ctpp_id="50179821000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>39.35</Subsidy>
                  <Price>39.35</Price>
                  <Alternate>39.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F101901394127" Rank="3" Units="g">
              <Name>Foam spray 500 mcg with calcipotriol 50 mcg per g</Name>
              <Brand ID="B10190139412725">
                <Name>Enstilar</Name>
                <Pack ID="P2582236" Specified="true" OP="true" nzmt:ctpp_id="50234121000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>59.95</Subsidy>
                  <Price>59.95</Price>
                  <Alternate>59.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1019014133">
            <Name>Pimecrolimus</Name>
            <Rule Type="FormMax" Value="15" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: a maximum of 15 g per prescription and no more than one prescription per 12 weeks.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1970"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1970">
              <Title>
                <range>Pimecrolimus</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has atopic dermatitis on the
                    eyelid</ci>
                    <ci type="logical" class="Indication">Patient has at least one of the following
                    contraindications to topical corticosteroids: periorificial dermatitis, rosacea,
                    documented epidermal atrophy, documented allergy to topical corticosteroids,
                    cataracts, glaucoma, or raised intraocular pressure</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Applicant>ophthalmologist</Applicant>
                <Applicant Referring="dermatologist, paediatrician or ophthalmologist">any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F101901413325" Rank="3" Units="g">
              <Name>Cream 1%</Name>
              <Brand ID="B10190141332525" PSS="2026-06-30">
                <Name>Elidel</Name>
                <Pack ID="P2098873" Specified="true" OP="true" nzmt:ctpp_id="50018251000117104">
                  <Quantity>15</Quantity>
                  <Subsidy>33.00</Subsidy>
                  <Price>33.00</Price>
                  <Alternate>33.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1022">
        <Name>Scalp Preparations</Name>
        <ATC3 ID="A102201">
          <Name>Scalp Preparations</Name>
          <Chemical ID="C1022011309" Statim="Must">
            <Name>Clobetasol propionate</Name>
            <Formulation ID="F102201130902" Rank="3" Units="ml">
              <Name>Scalp app 0.05%</Name>
              <Brand ID="B10220113090202" PSS="2025-06-30">
                <Name>Dermol</Name>
                <Pack ID="P772755" Specified="true" OP="true" nzmt:ctpp_id="50112111000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>6.26</Subsidy>
                  <Price>6.26</Price>
                  <Alternate>6.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1022011614">
            <Name>Hydrocortisone butyrate</Name>
            <Formulation ID="F102201161406" Rank="3" Units="ml">
              <Name>Scalp lotn 0.1%</Name>
              <Brand ID="B10220116140601" PSS="2024-06-30">
                <Name>Locoid</Name>
                <Pack ID="P210307" Specified="true" OP="true" nzmt:ctpp_id="50018581000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>6.57</Subsidy>
                  <Price>6.57</Price>
                  <Alternate>6.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1022011696">
            <Name>Ketoconazole</Name>
            <Formulation ID="F102201169603" Rank="3" Units="ml">
              <Name>Shampoo 2%</Name>
              <Rule Type="FormMax" Value="100" Attribute="Rx"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B10220116960302" ToBePSS="2024-05-01">
                <Name>Sebizole</Name>
                <Pack ID="P361410" Specified="true" OP="true" nzmt:ctpp_id="50078231000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>3.23</Subsidy>
                  <Price>3.23</Price>
                  <Alternate>3.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P461504" Specified="true" OP="true" nzmt:ctpp_id="50087681000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>4.09</Subsidy>
                  <Price>4.09</Price>
                  <Alternate>4.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1022012716" Statim="Must">
            <Name>Betamethasone valerate</Name>
            <Formulation ID="F102201271603" Rank="3" Units="ml">
              <Name>Scalp app 0.1%</Name>
              <Brand ID="B10220127160301" PSS="2024-06-30">
                <Name>Beta Scalp</Name>
                <Pack ID="P512877" Specified="true" OP="true" nzmt:ctpp_id="50093721000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>9.84</Subsidy>
                  <Price>9.84</Price>
                  <Alternate>9.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1025">
        <Name>Sunscreens</Name>
        <ATC3 ID="A102501">
          <Name>Sunscreens</Name>
          <Chemical ID="C1025012213">
            <Name>Sunscreens, proprietary</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F102501221325" Rank="3" Units="g">
              <Name>Lotn,</Name>
              <Brand ID="B10250122132526" PSS="2025-06-30">
                <Name>Marine Blue Lotion SPF 50+</Name>
                <Pack ID="P2454203" Specified="true" OP="true" nzmt:ctpp_id="50200001000117101">
                  <Quantity>200</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1028">
        <Name>Wart Preparations</Name>
        <ATC3 ID="A102801">
          <Name>Wart Preparations</Name>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
            <p xlink:type="simple" xlink:href="A1019">For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS</p>
          </div>
          <Chemical ID="C1028012516">
            <Name>Podophyllotoxin</Name>
            <Formulation ID="F102801251601" Rank="3" Units="ml">
              <Name>Soln 0.5%</Name>
              <Rule Type="FormMax" Value="3.5" Attribute="Rx"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B10280125160101">
                <Name>Condyline</Name>
                <Pack ID="P701610" Specified="true" OP="true" nzmt:ctpp_id="50103441000117101">
                  <Quantity>3.5</Quantity>
                  <Subsidy>33.60</Subsidy>
                  <Price>33.60</Price>
                  <Alternate>33.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1031">
        <Name>Other Skin Preparations</Name>
        <ATC3 ID="A103103">
          <Name>Antineoplastics</Name>
          <Chemical ID="C1031031528">
            <Name>Fluorouracil sodium</Name>
            <Formulation ID="F103103152801" Rank="3" Units="g">
              <Name>Crm 5%</Name>
              <Brand ID="B10310315280101" PSS="2024-06-30">
                <Name>Efudix</Name>
                <Pack ID="P253065" Specified="true" OP="true" nzmt:ctpp_id="50053671000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>6.95</Subsidy>
                  <Price>6.95</Price>
                  <Alternate>6.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A103105">
          <Name>Other Skin Preparations</Name>
          <Chemical ID="C1031053879">
            <Name>Imiquimod</Name>
            <Formulation ID="F103105387926" Rank="2" Units="sach" Weight="250">
              <Name>Crm 5%, 250 mg sachet</Name>
              <Brand ID="B10310538792626">
                <Name>Perrigo</Name>
                <Pack ID="P2543907" Specified="true" nzmt:ctpp_id="50195861000117100">
                  <Quantity>24</Quantity>
                  <Subsidy>21.72</Subsidy>
                  <Price>21.72</Price>
                  <Alternate>21.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A13">
      <Name>Genito-Urinary System</Name>
      <ATC2 ID="A1301">
        <Name>Contraceptives - Non-hormonal</Name>
        <Rule Type="MaxCoPayment" Value="5"/>
        <ATC3 ID="A130101">
          <Name>Condoms</Name>
          <Chemical ID="C1301016039" Statim="Must">
            <Name>Condoms</Name>
            <Formulation ID="F130101603903" Rank="10" Units="dev">
              <Name>53 mm</Name>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Brand ID="B13010160390327">
                <Name>Moments</Name>
                <Pack ID="P2575515" Specified="true" nzmt:ctpp_id="50267921000117108">
                  <Quantity>144</Quantity>
                  <Subsidy>11.64</Subsidy>
                  <Price>11.64</Price>
                  <Alternate>11.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2575523" Specified="true" nzmt:ctpp_id="50267931000117106">
                  <Quantity>10</Quantity>
                  <Subsidy>0.95</Subsidy>
                  <Price>0.95</Price>
                  <Alternate>0.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603925" Rank="10" Units="dev">
              <Name>49 mm</Name>
              <Rule Type="FormMax" Value="144" Attribute="PSO"/>
              <Brand ID="B13010160392528">
                <Name>Moments</Name>
                <Pack ID="P2575485" Specified="true" nzmt:ctpp_id="50267891000117104">
                  <Quantity>144</Quantity>
                  <Subsidy>11.42</Subsidy>
                  <Price>11.42</Price>
                  <Alternate>11.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603930" Rank="10" Units="dev">
              <Name>60 mm</Name>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Brand ID="B13010160393026">
                <Name>Gold Knight XL</Name>
                <Pack ID="P2583747" Specified="true" nzmt:ctpp_id="50282421000117103">
                  <Quantity>12</Quantity>
                  <Subsidy>1.82</Subsidy>
                  <Price>1.82</Price>
                  <Alternate>1.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2583755" Specified="true" nzmt:ctpp_id="50282431000117100">
                  <Quantity>144</Quantity>
                  <Subsidy>21.89</Subsidy>
                  <Price>21.89</Price>
                  <Alternate>21.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603932" Rank="10" Units="dev">
              <Name>56 mm</Name>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Brand ID="B13010160393228">
                <Name>Moments</Name>
                <Pack ID="P2575582" Specified="true" nzmt:ctpp_id="50269201000117102">
                  <Quantity>144</Quantity>
                  <Subsidy>11.64</Subsidy>
                  <Price>11.64</Price>
                  <Alternate>11.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2575590" Specified="true" nzmt:ctpp_id="50269191000117100">
                  <Quantity>10</Quantity>
                  <Subsidy>0.97</Subsidy>
                  <Price>0.97</Price>
                  <Alternate>0.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603933" Rank="10" Units="dev">
              <Name>53 mm, 0.05 mm thickness</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160393325">
                <Name>Moments</Name>
                <Pack ID="P2575493" Specified="true" nzmt:ctpp_id="50267901000117100">
                  <Quantity>144</Quantity>
                  <Subsidy>11.42</Subsidy>
                  <Price>11.42</Price>
                  <Alternate>11.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2575507" Specified="true" nzmt:ctpp_id="50267911000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>0.95</Subsidy>
                  <Price>0.95</Price>
                  <Alternate>0.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603934" Rank="10" Units="dev">
              <Name>53 mm, strawberry, red</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160393425">
                <Name>Moments</Name>
                <Pack ID="P2575566" Specified="true" nzmt:ctpp_id="50267991000117105">
                  <Quantity>144</Quantity>
                  <Subsidy>11.64</Subsidy>
                  <Price>11.64</Price>
                  <Alternate>11.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2575574" Specified="true" nzmt:ctpp_id="50268001000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>0.95</Subsidy>
                  <Price>0.95</Price>
                  <Alternate>0.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603935" Rank="10" Units="dev">
              <Name>53 mm, chocolate, brown</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160393525">
                <Name>Moments</Name>
                <Pack ID="P2575531" Specified="true" nzmt:ctpp_id="50267941000117103">
                  <Quantity>144</Quantity>
                  <Subsidy>11.64</Subsidy>
                  <Price>11.64</Price>
                  <Alternate>11.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2575558" Specified="true" nzmt:ctpp_id="50267971000117109">
                  <Quantity>10</Quantity>
                  <Subsidy>0.95</Subsidy>
                  <Price>0.95</Price>
                  <Alternate>0.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603936" Rank="10" Units="dev">
              <Name>56 mm, 0.08 mm thickness</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160393625">
                <Name>Moments</Name>
                <Pack ID="P2575604" Specified="true" nzmt:ctpp_id="50269221000117105">
                  <Quantity>144</Quantity>
                  <Subsidy>11.64</Subsidy>
                  <Price>11.64</Price>
                  <Alternate>11.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2575612" Specified="true" nzmt:ctpp_id="50269211000117104">
                  <Quantity>10</Quantity>
                  <Subsidy>0.97</Subsidy>
                  <Price>0.97</Price>
                  <Alternate>0.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603937" Rank="10" Units="dev">
              <Name>56 mm, 0.08 mm thickness, red</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160393725">
                <Name>Moments</Name>
                <Rule Type="FormMax" Value="60" Attribute="PSO"/>
                <Rule Type="FormMax" Value="60" Attribute="Rx"/>
                <Pack ID="P2575620" Specified="true" nzmt:ctpp_id="50269241000117100">
                  <Quantity>144</Quantity>
                  <Subsidy>11.64</Subsidy>
                  <Price>11.64</Price>
                  <Alternate>11.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2575639" Specified="true" nzmt:ctpp_id="50269231000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>0.97</Subsidy>
                  <Price>0.97</Price>
                  <Alternate>0.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603938" Rank="10" Units="dev">
              <Name>56 mm, 0.05 mm thickness</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160393825">
                <Name>Gold Knight</Name>
                <Pack ID="P2558440" Specified="true" nzmt:ctpp_id="50268091000117107">
                  <Quantity>144</Quantity>
                  <Subsidy>24.10</Subsidy>
                  <Price>24.10</Price>
                  <Alternate>24.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2558459" Specified="true" nzmt:ctpp_id="50268101000117103">
                  <Quantity>12</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.00</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603939" Rank="10" Units="dev">
              <Name>56 mm, chocolate</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160393925">
                <Name>Gold Knight</Name>
                <Pack ID="P2558408" Specified="true" nzmt:ctpp_id="50268131000117109">
                  <Quantity>144</Quantity>
                  <Subsidy>21.45</Subsidy>
                  <Price>21.45</Price>
                  <Alternate>21.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2558416" Specified="true" nzmt:ctpp_id="50268141000117101">
                  <Quantity>12</Quantity>
                  <Subsidy>1.79</Subsidy>
                  <Price>1.79</Price>
                  <Alternate>1.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603940" Rank="10" Units="dev">
              <Name>56 mm, strawberry</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Brand ID="B13010160394025">
                <Name>Gold Knight</Name>
                <Pack ID="P2558424" Specified="true" nzmt:ctpp_id="50268111000117100">
                  <Quantity>144</Quantity>
                  <Subsidy>21.45</Subsidy>
                  <Price>21.45</Price>
                  <Alternate>21.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2558432" Specified="true" nzmt:ctpp_id="50268121000117106">
                  <Quantity>12</Quantity>
                  <Subsidy>1.79</Subsidy>
                  <Price>1.79</Price>
                  <Alternate>1.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603941" Rank="10" Units="dev">
              <Name>60 mm (bulk pack)</Name>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Brand ID="B13010160394125">
                <Name>Gold Knight XL</Name>
                <Pack ID="P2583763" Specified="true" nzmt:ctpp_id="50282441000117108">
                  <Quantity>144</Quantity>
                  <Subsidy>17.78</Subsidy>
                  <Price>17.78</Price>
                  <Alternate>17.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130101603942" Rank="10" Units="dev">
              <Name>56 mm, 0.05mm thickness (bulk pack)</Name>
              <Rule Type="FormMax" Value="60" Attribute="Rx"/>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Brand ID="B13010160394225">
                <Name>Gold Knight</Name>
                <Pack ID="P2583739" Specified="true" nzmt:ctpp_id="50282401000117106">
                  <Quantity>144</Quantity>
                  <Subsidy>20.17</Subsidy>
                  <Price>20.17</Price>
                  <Alternate>20.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A130107">
          <Name>Contraceptive Devices</Name>
          <Chemical ID="C1301076038" Statim="Must">
            <Name>Intra-uterine device</Name>
            <Rule Type="FormMax" Value="40" Attribute="PSO"/>
            <Rule Type="FormReqd" Attribute="PSO"/>
            <Formulation ID="F130107603825" Rank="10" Units="dev">
              <Name>IUD 29.1 mm length x 23.2 mm width</Name>
              <Brand ID="B13010760382526" PSS="2025-06-30">
                <Name>Choice TT380 Short</Name>
                <Pack ID="P2467151" Specified="true" nzmt:ctpp_id="50212771000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>29.80</Subsidy>
                  <Price>29.80</Price>
                  <Alternate>29.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B13010760382527">
                <Name>7 MED NSHA Silver/Copper Short</Name>
                <Pack ID="P2643952" Specified="true" nzmt:ctpp_id="50305131000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>29.80</Subsidy>
                  <Price>29.80</Price>
                  <Alternate>29.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B13010760382528">
                <Name>Choice 380 7med Nsha Silver/copper Short</Name>
                <Pack ID="P2643758" Specified="true" nzmt:ctpp_id="50305141000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>29.80</Subsidy>
                  <Price>29.80</Price>
                  <Alternate>29.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130107603826" Rank="10" Units="dev">
              <Name>IUD 33.6 mm length x 29.9 mm width</Name>
              <Brand ID="B13010760382626" PSS="2025-06-30">
                <Name>Choice TT380 Standard</Name>
                <Pack ID="P2467178" Specified="true" nzmt:ctpp_id="50212761000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>29.80</Subsidy>
                  <Price>29.80</Price>
                  <Alternate>29.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130107603827" Rank="10" Units="dev">
              <Name>IUD 35.5 mm length x 19.6 mm width</Name>
              <Brand ID="B13010760382725" PSS="2025-06-30">
                <Name>Choice Load 375</Name>
                <Pack ID="P2497999" Specified="true" nzmt:ctpp_id="50232811000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>33.00</Subsidy>
                  <Price>33.00</Price>
                  <Alternate>33.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1308">
        <Name>Contraceptives - Hormonal</Name>
        <Rule Type="MaxCoPayment" Value="5"/>
        <ATC3 ID="A130802">
          <Name>Combined Oral Contraceptives</Name>
          <Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500">
            <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <apply>
                    <or/>
                    <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci>
                    <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci>
                  </apply>
                  <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci>
                </apply>
              </math>
              <Applicant>medical practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Renewal" Form="SA0265 SA0500">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci>
                  <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci>
                </apply>
              </math>
              <Applicant>medical practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.</p>
              <p>The additional subsidy will fund Mercilon and Marvelon up to the manufacturerâ€™s price for each of these products as identified on the Schedule at 1 November 1999.</p>
              <p>Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:</p>
              <ul>
                <li>
                  <p>on a Social Welfare benefit; or</p>
                </li>
                <li>
                  <p>have an income no greater than the benefit.</p>
                </li>
              </ul>
              <p>The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED</p>
            </div>
          </Request>
          <Chemical ID="C1308021475">
            <Name>Ethinyloestradiol with norethisterone</Name>
            <Formulation ID="F130802147509" Rank="1" Units="tab" Weight="35">
              <Name>Tab 35 mcg with norethisterone 500 mcg and 7 inert tab</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="84" Attribute="PSO"/>
              <Brand ID="B13080214750902">
                <Name>Norimin</Name>
                <Pack ID="P410691" Specified="true" nzmt:ctpp_id="50319191000117108">
                  <Quantity>84</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>21.99</Subsidy>
                  <Price>21.99</Price>
                  <Alternate>21.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2636077" Specified="true" nzmt:ctpp_id="50319201000117106">
                  <Quantity>112</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>29.32</Subsidy>
                  <Price>29.32</Price>
                  <Alternate>29.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130802147512" Rank="1" Units="tab" Weight="35" Statim="Must">
              <Name>Tab 35 mcg with norethisterone 1 mg and 7 inert tab</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="84" Attribute="PSO"/>
              <Brand ID="B13080214751201">
                <Name>Brevinor 1/28</Name>
                <Pack ID="P303542" Specified="true" nzmt:ctpp_id="50067671000117109">
                  <Quantity>84</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>12.25</Subsidy>
                  <Price>12.25</Price>
                  <Alternate>12.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B13080214751202">
                <Name>Brevinor-1 28 Day</Name>
                <Pack ID="P2656205" Specified="true" nzmt:ctpp_id="50275801000117108">
                  <Quantity>112</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>16.33</Subsidy>
                  <Price>16.33</Price>
                  <Alternate>16.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B13080214751203">
                <Name>Norimin-1 28 Day</Name>
                <Pack ID="P2656213" Specified="true" nzmt:ctpp_id="50314841000117106">
                  <Quantity>112</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>16.33</Subsidy>
                  <Price>16.33</Price>
                  <Alternate>16.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1308021477" Statim="Must">
            <Name>Ethinyloestradiol with desogestrel</Name>
            <Formulation ID="F130802147702" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mcg with desogestrel 150 mcg and 7 inert tab</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="84" Attribute="PSO"/>
              <Brand ID="B13080214770201">
                <Name>Mercilon 28</Name>
                <Pack ID="P682055" Specified="true" nzmt:ctpp_id="50101861000117100">
                  <Quantity>84</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>10.00</Subsidy>
                  <Price>10.00</Price>
                  <Alternate>10.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1308021718">
            <Name>Ethinyloestradiol with levonorgestrel</Name>
            <Formulation ID="F130802171808" Rank="1" Units="tab" Weight="150" Statim="Must">
              <Name>Tab 30 mcg with levonorgestrel 150 mcg</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="63" Attribute="PSO"/>
              <Rule Attribute="Special Authority" Type="Alternate" xlink:href="SA0500"/>
              <Brand ID="B13080217180801">
                <Name>Microgynon 30</Name>
                <Pack ID="P202770" Specified="true" nzmt:ctpp_id="50005431000117103">
                  <Quantity>63</Quantity>
                  <Multiple>21</Multiple>
                  <Subsidy>6.62</Subsidy>
                  <Price>16.50</Price>
                  <Alternate>15.00</Alternate>
                  <Surcharge>0.15683</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130802171809" Rank="1" Units="tab" Weight="150" Statim="Must">
              <Name>Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="84" Attribute="PSO"/>
              <Brand ID="B13080217180927" PSS="2025-06-30">
                <Name>Oralcon 30 ED</Name>
                <Pack ID="P2637138" Specified="true" nzmt:ctpp_id="50301271000117101">
                  <Quantity>84</Quantity>
                  <Subsidy>1.50</Subsidy>
                  <Price>1.50</Price>
                  <Alternate>1.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130802171812" Rank="1" Units="tab" Weight="100" Statim="Must">
              <Name>Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="84" Attribute="PSO"/>
              <Brand ID="B13080217181227" PSS="2025-06-30">
                <Name>Lo-Oralcon 20 ED</Name>
                <Pack ID="P2637111" Specified="true" nzmt:ctpp_id="50136121000117102">
                  <Quantity>84</Quantity>
                  <Subsidy>1.50</Subsidy>
                  <Price>1.50</Price>
                  <Alternate>1.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A130804">
          <Name>Progestogen-only Contraceptives</Name>
          <Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500">
            <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <apply>
                    <or/>
                    <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci>
                    <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci>
                  </apply>
                  <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci>
                </apply>
              </math>
              <Applicant>medical practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Renewal" Form="SA0265 SA0500">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci>
                  <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci>
                </apply>
              </math>
              <Applicant>medical practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.</p>
              <p>The additional subsidy will fund Mercilon and Marvelon up to the manufacturerâ€™s price for each of these products as identified on the Schedule at 1 November 1999.</p>
              <p>Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:</p>
              <ul>
                <li>
                  <p>on a Social Welfare benefit; or</p>
                </li>
                <li>
                  <p>have an income no greater than the benefit.</p>
                </li>
              </ul>
              <p>The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED</p>
            </div>
          </Request>
          <Chemical ID="C1308041724" Statim="Must">
            <Name>Levonorgestrel</Name>
            <Formulation ID="F130804172401" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mcg</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="84" Attribute="PSO"/>
              <Brand ID="B13080417240101">
                <Name>Microlut</Name>
                <Pack ID="P719803" Specified="true" nzmt:ctpp_id="50105531000117107">
                  <Quantity>84</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>16.50</Subsidy>
                  <Price>16.50</Price>
                  <Alternate>16.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2591839" Specified="true" nzmt:ctpp_id="50277541000117104">
                  <Quantity>112</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>22.00</Subsidy>
                  <Price>22.00</Price>
                  <Alternate>22.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F130804172428" Rank="10" Units="pack">
              <Name>Subdermal implant (2 x 75 mg rods)</Name>
              <Rule Type="FormMax" Value="3" Attribute="PSO"/>
              <Brand ID="B13080417242825" PSS="2026-06-30">
                <Name>Jadelle</Name>
                <Pack ID="P2265532" Specified="true" nzmt:ctpp_id="50041821000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>106.92</Subsidy>
                  <Price>106.92</Price>
                  <Alternate>106.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1308041766">
            <Name>Medroxyprogesterone acetate</Name>
            <Formulation ID="F130804176608" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg per ml, 1 ml syringe</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B13080417660801">
                <Name>Depo-Provera</Name>
                <Pack ID="P271691" Specified="true" nzmt:ctpp_id="50060491000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9.18</Subsidy>
                  <Price>9.18</Price>
                  <Alternate>9.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1308041871">
            <Name>Norethisterone</Name>
            <Formulation ID="F130804187101" Rank="1" Units="tab" Weight="0.35">
              <Name>Tab 350 mcg</Name>
              <Rule Type="Contraceptive" NonPrinting="true"/>
              <Rule Type="FormMax" Value="84" Attribute="PSO"/>
              <Brand ID="B13080418710101" PSS="2024-06-30">
                <Name>Noriday 28</Name>
                <Pack ID="P398322" Specified="true" nzmt:ctpp_id="50081781000117105">
                  <Quantity>84</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>12.25</Subsidy>
                  <Price>12.25</Price>
                  <Alternate>12.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A130805">
          <Name>Emergency Contraceptives</Name>
          <Chemical ID="C1308051724" Statim="Must">
            <Name>Levonorgestrel</Name>
            <Formulation ID="F130805172427" Rank="1" Units="tab" Weight="1500">
              <Name>Tab 1.5 mg</Name>
              <Rule Type="FormMax" Value="2" Attribute="Rx"/>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.</p>
              </div>
              <Rule Type="ProvAllow" Attribute="Pharmacist" NonPrinting="true"/>
              <Brand ID="B13080517242726" PSS="2025-06-30">
                <Name>Levonorgestrel BNM</Name>
                <Pack ID="P2645424" Specified="true" nzmt:ctpp_id="50264911000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>1.75</Subsidy>
                  <Price>1.75</Price>
                  <Alternate>1.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1309">
        <Name>Antiandrogen Oral Contraceptives</Name>
        <ATC3 ID="A130902">
          <Name>Antiandrogen Oral Contraceptives</Name>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
            <p>Prescribers may code prescriptions â€œcontraceptiveâ€ (code â€œOâ€) when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:</p>
            <ul>
              <li>
                <p>A maximum $5.00 prescription charge (patient co-payment) may apply.</p>
              </li>
              <li>
                <p>prescription may be written for up to six months supply.</p>
              </li>
            </ul>
            <p>Prescriptions coded in any other way are subject to any non contraceptive prescription charges that apply, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.</p>
          </div>
          <Chemical ID="C1309022706" Statim="Must">
            <Name>Cyproterone acetate with ethinyloestradiol</Name>
            <Formulation ID="F130902270602" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs</Name>
              <Rule Type="FormMax" Value="168" Attribute="PSO"/>
              <Brand ID="B13090227060227" PSS="2026-06-30">
                <Name>Ginet</Name>
                <Pack ID="P2455455" Specified="true" nzmt:ctpp_id="50198351000117102">
                  <Quantity>168</Quantity>
                  <Multiple>28</Multiple>
                  <Subsidy>5.08</Subsidy>
                  <Price>5.08</Price>
                  <Alternate>5.08</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1310">
        <Name>Gynaecological Anti-infectives</Name>
        <ATC3 ID="A131001">
          <Name>Gynaecological Anti-infectives</Name>
          <Chemical ID="C1310011006">
            <Name>Acetic acid with hydroxyquinoline and ricinoleic acid</Name>
            <Formulation ID="F131001100601" Rank="3" Units="g">
              <Name>Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator</Name>
              <Brand ID="B13100110060101">
                <Name>Aci-Jel</Name>
                <Pack ID="P536962" Specified="true" OP="true" nzmt:ctpp_id="50094981000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>8.43</Subsidy>
                  <Price>24.87</Price>
                  <Alternate>8.43</Alternate>
                  <Surcharge>0.16440</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1310011320" Statim="Must">
            <Name>Clotrimazole</Name>
            <Formulation ID="F131001132003" Rank="3" Units="g">
              <Name>Vaginal crm 1% with applicators</Name>
              <Brand ID="B13100113200325" PSS="2025-06-30">
                <Name>Clomazol</Name>
                <Pack ID="P2155656" Specified="true" OP="true" nzmt:ctpp_id="50026721000117107">
                  <Quantity>35</Quantity>
                  <Subsidy>3.50</Subsidy>
                  <Price>3.50</Price>
                  <Alternate>3.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F131001132004" Rank="3" Units="g">
              <Name>Vaginal crm 2% with applicators</Name>
              <Brand ID="B13100113200425" PSS="2025-06-30">
                <Name>Clomazol</Name>
                <Pack ID="P2249634" Specified="true" OP="true" nzmt:ctpp_id="50039611000117103">
                  <Quantity>20</Quantity>
                  <Subsidy>3.85</Subsidy>
                  <Price>3.85</Price>
                  <Alternate>3.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1310011620" Statim="Must">
            <Name>Miconazole nitrate</Name>
            <Formulation ID="F131001162006" Rank="3" Units="g">
              <Name>Vaginal crm 2% with applicator</Name>
              <Brand ID="B13100116200602">
                <Name>Micreme</Name>
                <Pack ID="P697648" Specified="true" OP="true" nzmt:ctpp_id="50102721000117108">
                  <Quantity>40</Quantity>
                  <Subsidy>6.89</Subsidy>
                  <Price>6.89</Price>
                  <Alternate>6.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1310011881">
            <Name>Nystatin</Name>
            <Formulation ID="F131001188109" Rank="3" Units="g">
              <Name>Vaginal crm 100,000 u per 5 g with applicator(s)</Name>
              <Brand ID="B13100118810901" PSS="2026-06-30">
                <Name>Nilstat</Name>
                <Pack ID="P254908" Specified="true" OP="true" nzmt:ctpp_id="50054711000117106">
                  <Quantity>75</Quantity>
                  <Subsidy>5.70</Subsidy>
                  <Price>5.70</Price>
                  <Alternate>5.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1314">
        <Name>Myometrial and Vaginal Hormone Preparations</Name>
        <ATC3 ID="A131402">
          <Name>Myometrial and Vaginal Hormone Preparations</Name>
          <Chemical ID="C1314021456">
            <Name>Ergometrine maleate</Name>
            <Formulation ID="F131402145601" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mcg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B13140214560101">
                <Name>DBL Ergometrine</Name>
                <Pack ID="P500372" Specified="true" nzmt:ctpp_id="50092921000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>160.00</Subsidy>
                  <Price>160.00</Price>
                  <Alternate>160.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1314021922">
            <Name>Oxytocin with ergometrine maleate</Name>
            <Rule Type="FormMax" Value="5" Attribute="PSO"/>
            <Formulation ID="F131402192203" Rank="4" Units="inj">
              <Name>Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule </Name>
              <Brand ID="B13140219220301" PSS="2025-06-30">
                <Name>Syntometrine</Name>
                <Pack ID="P256269" Specified="true" nzmt:ctpp_id="50055381000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>32.40</Subsidy>
                  <Price>32.40</Price>
                  <Alternate>32.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1314021923">
            <Name>Oxytocin</Name>
            <Rule Type="FormMax" Value="5" Attribute="PSO"/>
            <Formulation ID="F131402192301" Rank="4" Units="inj" Weight="5">
              <Name>Inj 5 iu per ml, 1 ml ampoule</Name>
              <Brand ID="B13140219230125" PSS="2025-06-30">
                <Name>Oxytocin BNM</Name>
                <Pack ID="P2448211" Specified="true" nzmt:ctpp_id="50128641000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4.98</Subsidy>
                  <Price>4.98</Price>
                  <Alternate>4.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F131402192302" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 iu per ml, 1 ml ampoule</Name>
              <Brand ID="B13140219230225" PSS="2025-06-30">
                <Name>Oxytocin BNM</Name>
                <Pack ID="P2577046" Specified="true" nzmt:ctpp_id="50128651000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.98</Subsidy>
                  <Price>5.98</Price>
                  <Alternate>5.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B13140219230227" S29="true">
                <Name>Oxytocin GH</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2649179" Specified="true" nzmt:ctpp_id="50308241000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.98</Subsidy>
                  <Price>5.98</Price>
                  <Alternate>5.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B13140219230228">
                <Name>Oxytocin Panpharma</Name>
                <Pack ID="P2658275" Specified="true" nzmt:ctpp_id="50317911000117106">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>11.96</Subsidy>
                  <Price>11.96</Price>
                  <Alternate>11.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1314022784" Statim="Must">
            <Name>Oestriol</Name>
            <Formulation ID="F131402278402" Rank="3" Units="g">
              <Name>Crm 1 mg per g with applicator</Name>
              <Brand ID="B13140227840201" PSS="2026-06-30">
                <Name>Ovestin</Name>
                <Pack ID="P767441" Specified="true" OP="true" nzmt:ctpp_id="50110991000117106">
                  <Quantity>15</Quantity>
                  <Subsidy>6.95</Subsidy>
                  <Price>6.95</Price>
                  <Alternate>6.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F131402278403" Rank="5" Units="pess">
              <Name>Pessaries 500 mcg</Name>
              <Brand ID="B13140227840301" PSS="2026-06-30">
                <Name>Ovestin</Name>
                <Pack ID="P767468" Specified="true" nzmt:ctpp_id="50216211000117109">
                  <Quantity>15</Quantity>
                  <Subsidy>7.55</Subsidy>
                  <Price>7.55</Price>
                  <Alternate>7.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1316">
        <Name>Pregnancy Tests - hCG Urine</Name>
        <ATC3 ID="A131602">
          <Name>Pregnancy Tests - hCG Urine</Name>
          <Chemical ID="C1316023000">
            <Name>Pregnancy tests - HCG urine</Name>
            <Rule Type="FormMax" Value="200" Attribute="PSO"/>
            <Rule Type="FormReqd" Attribute="PSO"/>
            <Formulation ID="F131602300002" Rank="10" Units="test">
              <Name>Cassette</Name>
              <Brand ID="B13160230000228">
                <Name>Smith BioMed Rapid Pregnancy Test</Name>
                <Pack ID="P2544873" Specified="true" OP="true" nzmt:ctpp_id="50255581000117101">
                  <Quantity>40</Quantity>
                  <Subsidy>12.00</Subsidy>
                  <Price>12.00</Price>
                  <Alternate>12.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B13160230000229">
                <Name>David One Step Cassette Pregnancy Test</Name>
                <Pack ID="P2602318" Specified="true" OP="true" nzmt:ctpp_id="50283781000117102">
                  <Quantity>40</Quantity>
                  <Subsidy>16.00</Subsidy>
                  <Price>16.00</Price>
                  <Alternate>16.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1319">
        <Name>Urinary Agents</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1622">For urinary tract Infections refer to INFECTIONS, Antibacterials</p>
        </div>
        <ATC3 ID="A131901">
          <Name>5-Alpha Reductase Inhibitors</Name>
          <Chemical ID="C1319013881" Statim="Must">
            <Name>Finasteride</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA0928"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA0928">
              <Title>
                <range>Finasteride</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci>
                      <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F131901388125" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B13190138812528" PSS="2026-06-30">
                <Name>Ricit</Name>
                <Pack ID="P2522756" Specified="true" nzmt:ctpp_id="50244211000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>4.79</Subsidy>
                  <Price>4.79</Price>
                  <Alternate>4.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A131902">
          <Name>Alpha-1A Adrenoreceptor Blockers</Name>
          <Chemical ID="C1319023910" Statim="Must">
            <Name>Tamsulosin hydrochloride</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1032"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1032">
              <Title>
                <range>Tamsulosin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci>
                    <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F131902391025" Rank="2" Units="cap">
              <Name>Cap 400 mcg</Name>
              <Brand ID="B13190239102525" PSS="2025-06-30">
                <Name>Tamsulosin-Rex</Name>
                <Pack ID="P2438526" Specified="true" nzmt:ctpp_id="50184831000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>22.31</Subsidy>
                  <Price>22.31</Price>
                  <Alternate>22.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A131904">
          <Name>Other Urinary Agents</Name>
          <Chemical ID="C1319041914" Statim="Must">
            <Name>Oxybutynin</Name>
            <Formulation ID="F131904191401" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B13190419140103">
                <Name>Alchemy Oxybutynin</Name>
                <Pack ID="P2627167" Specified="true" nzmt:ctpp_id="50296311000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>5.42</Subsidy>
                  <Price>5.42</Price>
                  <Alternate>5.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1319042142" Statim="Must">
            <Name>Sodium citro-tartrate</Name>
            <Formulation ID="F131904214201" Rank="2" Units="sach">
              <Name>Grans eff 4 g sachets</Name>
              <Brand ID="B13190421420102" PSS="2026-06-30">
                <Name>Ural</Name>
                <Pack ID="P298638" Specified="true" nzmt:ctpp_id="50066491000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>3.50</Subsidy>
                  <Price>3.50</Price>
                  <Alternate>3.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1319043370">
            <Name>Potassium citrate</Name>
            <Formulation ID="F131904337025" Rank="3" Units="ml" Weight="3">
              <Name>Oral liq 3 mmol per ml</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1083"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1083">
                <Title>
                  <range>Potassium Citrate</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has recurrent calcium oxalate urolithiasis</ci>
                      <ci type="logical" class="Trial">The patient has had more than two renal calculi in the two years prior to the application</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">12</Term>
                </Case>
                <Case When="Renewal" Form="SA1083">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="year">2</Term>
                </Case>
              </Request>
              <Brand ID="B13190433702525" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P2378728" Specified="true" OP="true" nzmt:ctpp_id="50121461000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>35.70</Subsidy>
                  <Price>35.70</Price>
                  <Alternate>35.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1319043902">
            <Name>Solifenacin succinate</Name>
            <Formulation ID="F131904390225" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B13190439022527" PSS="2024-06-30">
                <Name>Solifenacin Viatris</Name>
                <Pack ID="P2645319" Specified="true" nzmt:ctpp_id="50296261000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>2.05</Subsidy>
                  <Price>2.05</Price>
                  <Alternate>2.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F131904390226" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B13190439022627" PSS="2024-06-30">
                <Name>Solifenacin Viatris</Name>
                <Pack ID="P2645327" Specified="true" nzmt:ctpp_id="50296281000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>3.72</Subsidy>
                  <Price>3.72</Price>
                  <Alternate>3.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1322">
        <Name>Detection of Substances in Urine</Name>
        <ATC3 ID="A132201">
          <Name>Detection of Substances in Urine</Name>
          <Chemical ID="C1322011910" Statim="Must">
            <Name>Ortho-tolidine</Name>
            <Formulation ID="F132201191001" Rank="10" Units="test">
              <Name>Compound diagnostic sticks</Name>
              <Brand ID="B13220119100101">
                <Name>Hemastix</Name>
                <Pack ID="P250872" Specified="true" OP="true" nzmt:ctpp_id="50052531000117102">
                  <Quantity>50</Quantity>
                  <Subsidy>7.50</Subsidy>
                  <Price>8.25</Price>
                  <Alternate>7.50</Alternate>
                  <Surcharge>0.01500</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1322012238" Statim="Must">
            <Name>Tetrabromophenol</Name>
            <Formulation ID="F132201223801" Rank="10" Units="test">
              <Name>Blue diagnostic strips</Name>
              <Brand ID="B13220122380102">
                <Name>Albustix</Name>
                <Pack ID="P200190" Specified="true" OP="true" nzmt:ctpp_id="50000221000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>13.92</Subsidy>
                  <Price>13.92</Price>
                  <Alternate>13.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1325">
        <Name>Obstetric Preparations</Name>
        <ATC3 ID="A132501">
          <Name>Antiprogesterones</Name>
          <Chemical ID="C1325014129">
            <Name>Mifepristone</Name>
            <Formulation ID="F132501412925" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Rule Type="FormMax" Value="15" Attribute="PSO"/>
              <Brand ID="B13250141292525">
                <Name>Mifegyne</Name>
                <Pack ID="P2086522" Specified="true" nzmt:ctpp_id="50014861000117106">
                  <Quantity>3</Quantity>
                  <Subsidy>180.00</Subsidy>
                  <Price>180.00</Price>
                  <Alternate>180.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2603004" Specified="true" nzmt:ctpp_id="50278921000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>79.90</Subsidy>
                  <Price>79.90</Price>
                  <Alternate>79.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A14">
      <Name>Hormone Preparations - Systemic Excluding Contraceptive Hormones</Name>
      <ATC2 ID="A1404">
        <Name>Calcium Homeostasis</Name>
        <ATC3 ID="A140404">
          <Name>Calcium Homeostasis</Name>
          <Chemical ID="C1404041188" Statim="Must">
            <Name>Calcitonin</Name>
            <Formulation ID="F140404118802" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 iu per ml, 1 ml ampoule</Name>
              <Brand ID="B14040411880201">
                <Name>Miacalcic</Name>
                <Pack ID="P2548356" Specified="true" nzmt:ctpp_id="50056511000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>121.00</Subsidy>
                  <Price>121.00</Price>
                  <Alternate>121.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1404043913">
            <Name>Zoledronic acid</Name>
            <Formulation ID="F140404391326" Rank="4" Units="inj" Weight="4">
              <Name>Inj 4 mg per 5 ml, vial</Name>
              <Brand ID="B14040439132627" PSS="2024-06-30">
                <Name>Zoledronic acid Viatris</Name>
                <Pack ID="P2631830" Specified="true" nzmt:ctpp_id="50296231000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>18.00</Subsidy>
                  <Price>18.00</Price>
                  <Alternate>18.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1404044062">
            <Name>Cinacalcet</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2170"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2170">
              <Title>
                <range>Cinacalcet</range>
              </Title>
              <Case When="Initial application" Category="parathyroid carcinoma or calciphylaxis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has been diagnosed with a
                        parathyroid carcinoma (see Note)</ci>
                      <ci type="logical" class="Indication">The patient has persistent hypercalcaemia
                        (serum calcium greater than or equal to 3 mmol/L) despite previous
                        first-line treatments including sodium thiosulfate (where appropriate) and
                        bisphosphonates</ci>
                      <ci type="logical" class="Indication">The patient is symptomatic</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has been diagnosed with
                        calciphylaxis (calcific uraemic arteriolopathy)</ci>
                      <ci type="logical" class="Indication">The patient has symptomatic (e.g. painful
                        skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3
                        mmol/L)</ci>
                      <ci type="logical" class="Indication">The patient's condition has not responded
                        to previous first-line treatments including bisphosphonates and sodium
                        thiosulfate</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="parathyroid carcinoma or calciphylaxis" Form="SA1594 SA1618 SA2170">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient's serum calcium level has fallen
                    to &lt; 3mmol/L</ci>
                    <ci type="logical" class="Indication">The patient has experienced clinically
                    significant symptom improvement</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="patient's lifetime">1</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>This does not include parathyroid adenomas unless these have become malignant.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="primary hyperparathyroidism">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has primary hyperparathyroidism</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has hypercalcaemia of more than 3
                        mmol/L with or without symptoms</ci>
                      <ci type="logical" class="Indication">Patient has hypercalcaemia of more than
                        2.85 mmol/L with symptoms</ci>
                    </apply>
                    <ci type="logical" class="Indication">Surgery is not feasible or has failed</ci>
                    <ci type="logical" class="Indication">Patient has other comorbidities, severe bone
                    pain, or calciphylaxis</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime">1</Term>
              </Case>
              <Case When="Initial application" Category="secondary or tertiary hyperparathyroidism">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has tertiary hyperparathyroidism
                        and markedly elevated parathyroid hormone (PTH) with hypercalcaemia</ci>
                      <ci type="logical" class="Indication">Patient has symptomatic secondary
                        hyperparathyroidism and elevated PTH</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is on renal replacement therapy</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Residual parathyroid tissue has not been
                        localised despite repeat unsuccessful parathyroid explorations</ci>
                      <ci type="logical" class="Indication">Parathyroid tissue is surgically
                        inaccessible</ci>
                      <ci type="logical" class="Indication">Parathyroid surgery is not feasible</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="secondary or tertiary hyperparathyroidism" Form="SA1594 SA1618 SA2170">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has had a kidney transplant, and
                    following a treatment free interval of at least 12 weeks a clinically acceptable
                    parathyroid hormone (PTH) level to support ongoing cessation of treatment has
                    not been reached</ci>
                    <ci type="logical" class="Indication">The patient has not received a kidney
                    transplant and trial of withdrawal of cinacalcet is clinically
                    inappropriate</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F140404406225" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B14040440622526" PSS="2024-06-30">
                <Name>Cinacalet Devatis</Name>
                <Pack ID="P2615517" Specified="true" nzmt:ctpp_id="50268941000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>42.06</Subsidy>
                  <Price>42.06</Price>
                  <Alternate>42.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140404406226" Rank="1" Units="tab" Weight="60">
              <Name>Tab 60 mg</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B14040440622625" PSS="2024-06-30">
                <Name>Cinacalet Devatis</Name>
                <Pack ID="P2615525" Specified="true" nzmt:ctpp_id="50268951000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>84.12</Subsidy>
                  <Price>84.12</Price>
                  <Alternate>84.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1407">
        <Name>Corticosteroids and Related Agents for Systemic Use</Name>
        <ATC3 ID="A140701">
          <Name>Corticosteroids and Related Agents for Systemic Use</Name>
          <Chemical ID="C1407011383">
            <Name>Dexamethasone</Name>
            <Formulation ID="F140701138302" Rank="1" Units="tab" Weight="4" Statim="Must">
              <Name>Tab 4 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B14070113830225" PSS="2024-06-30">
                <Name>Dexmethsone</Name>
                <Pack ID="P2490226" Specified="true" nzmt:ctpp_id="50227441000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>2.65</Subsidy>
                  <Price>2.65</Price>
                  <Alternate>2.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701138305" Rank="3" Units="ml">
              <Name>Oral liq 1 mg per ml</Name>
              <Brand ID="B14070113830501" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P344842" Specified="true" OP="true" nzmt:ctpp_id="50075811000117102">
                  <Quantity>25</Quantity>
                  <Subsidy>52.80</Subsidy>
                  <Price>52.80</Price>
                  <Alternate>52.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701138325" Rank="1" Units="tab" Statim="Must">
              <Name>Tab 0.5 mg</Name>
              <Rule Type="FormMax" Value="60" Attribute="PSO"/>
              <Brand ID="B14070113832525" PSS="2024-06-30">
                <Name>Dexmethsone</Name>
                <Pack ID="P2490218" Specified="true" nzmt:ctpp_id="50227431000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>1.50</Subsidy>
                  <Price>1.50</Price>
                  <Alternate>1.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407011385" Statim="Must">
            <Name>Dexamethasone phosphate</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Dexamethasone phosphate injection will not be funded for oral use.</p>
            </div>
            <Formulation ID="F140701138501" Rank="4" Units="inj" Weight="4">
              <Name>Inj 4 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B14070113850125" PSS="2025-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2451689" Specified="true" nzmt:ctpp_id="50174641000117108">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7.86</Subsidy>
                  <Price>7.86</Price>
                  <Alternate>7.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701138502" Rank="4" Units="inj" Weight="8">
              <Name>Inj 4 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B14070113850225" PSS="2025-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2519143" Specified="true" nzmt:ctpp_id="50240001000117107">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>13.10</Subsidy>
                  <Price>13.10</Price>
                  <Alternate>13.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407011515" Statim="Must">
            <Name>Fludrocortisone acetate</Name>
            <Formulation ID="F140701151501" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mcg</Name>
              <Brand ID="B14070115150101" PSS="2025-06-30">
                <Name>Florinef</Name>
                <Pack ID="P204951" Specified="true" nzmt:ctpp_id="50009201000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>11.46</Subsidy>
                  <Price>11.46</Price>
                  <Alternate>11.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407011617" Statim="Must">
            <Name>Hydrocortisone</Name>
            <Formulation ID="F140701161701" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B14070116170101">
                <Name>Douglas</Name>
                <Pack ID="P205621" Specified="true" nzmt:ctpp_id="50010051000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>8.10</Subsidy>
                  <Price>8.10</Price>
                  <Alternate>8.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701161702" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B14070116170201">
                <Name>Douglas</Name>
                <Pack ID="P205648" Specified="true" nzmt:ctpp_id="50010111000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>20.32</Subsidy>
                  <Price>20.32</Price>
                  <Alternate>20.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701161716" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Rule Type="FormBan" Attribute="BSO"/>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B14070116171601" PSS="2024-06-30">
                <Name>Solu-Cortef</Name>
                <Pack ID="P265284" Specified="true" nzmt:ctpp_id="50058961000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4.38</Subsidy>
                  <Price>4.38</Price>
                  <Alternate>4.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407011810">
            <Name>Methylprednisolone acetate</Name>
            <Formulation ID="F140701181005" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per ml, 1 ml vial</Name>
              <Brand ID="B14070118100501">
                <Name>Depo-Medrol</Name>
                <Pack ID="P2454327" Specified="true" nzmt:ctpp_id="50149291000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>47.06</Subsidy>
                  <Price>47.06</Price>
                  <Alternate>47.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407011811" Statim="Must">
            <Name>Methylprednisolone</Name>
            <Formulation ID="F140701181101" Rank="1" Units="tab" Weight="4">
              <Name>Tab 4 mg</Name>
              <Brand ID="B14070118110101">
                <Name>Medrol</Name>
                <Pack ID="P210692" Specified="true" nzmt:ctpp_id="50019261000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>112.00</Subsidy>
                  <Price>112.00</Price>
                  <Alternate>112.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701181102" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B14070118110201">
                <Name>Medrol</Name>
                <Pack ID="P681776" Specified="true" nzmt:ctpp_id="50101831000117107">
                  <Quantity>20</Quantity>
                  <Subsidy>223.10</Subsidy>
                  <Price>223.10</Price>
                  <Alternate>223.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407011812">
            <Name>Methylprednisolone (as sodium succinate)</Name>
            <Formulation ID="F140701181201" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg vial</Name>
              <Brand ID="B14070118120101">
                <Name>Solu-Medrol-Act-O-Vial</Name>
                <Pack ID="P2394227" Specified="true" nzmt:ctpp_id="50126641000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>22.30</Subsidy>
                  <Price>22.30</Price>
                  <Alternate>22.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701181202" Rank="4" Units="inj" Weight="125">
              <Name>Inj 125 mg vial</Name>
              <Brand ID="B14070118120201">
                <Name>Solu-Medrol-Act-O-Vial</Name>
                <Pack ID="P2394219" Specified="true" nzmt:ctpp_id="50126631000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>34.10</Subsidy>
                  <Price>34.10</Price>
                  <Alternate>34.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701181204" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B14070118120401">
                <Name>Solu-Medrol-Act-O-Vial</Name>
                <Pack ID="P2394235" Specified="true" nzmt:ctpp_id="50126651000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>26.88</Subsidy>
                  <Price>26.88</Price>
                  <Alternate>26.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701181205" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g vial</Name>
              <Brand ID="B14070118120501">
                <Name>Solu-Medrol</Name>
                <Pack ID="P265357" Specified="true" nzmt:ctpp_id="50059021000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>32.84</Subsidy>
                  <Price>32.84</Price>
                  <Alternate>32.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407012034" Statim="Must">
            <Name>Prednisolone</Name>
            <Formulation ID="F140701203425" Rank="3" Units="ml" Weight="5">
              <Name>Oral liq 5 mg per ml</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Restricted to children under 12 years of age.</p>
              </div>
              <Brand ID="B14070120342525" PSS="2024-06-30">
                <Name>Redipred</Name>
                <Pack ID="P317659" Specified="true" OP="true" nzmt:ctpp_id="50071101000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407012038">
            <Name>Prednisone</Name>
            <Formulation ID="F140701203801" Rank="1" Units="tab" Weight="1" Statim="Must">
              <Name>Tab 1 mg</Name>
              <Brand ID="B14070120380126">
                <Name>Prednisone Clinect</Name>
                <Pack ID="P2608715" Specified="true" nzmt:ctpp_id="50287811000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>18.58</Subsidy>
                  <Price>18.58</Price>
                  <Alternate>18.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701203802" Rank="1" Units="tab" Weight="2.5" Statim="Must">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B14070120380205">
                <Name>Prednisone Clinect</Name>
                <Pack ID="P2608723" Specified="true" nzmt:ctpp_id="50287831000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>21.04</Subsidy>
                  <Price>21.04</Price>
                  <Alternate>21.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701203803" Rank="1" Units="tab" Weight="5" Statim="Must">
              <Name>Tab 5 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B14070120380305">
                <Name>Prednisone Clinect</Name>
                <Pack ID="P2608731" Specified="true" nzmt:ctpp_id="50287761000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>19.30</Subsidy>
                  <Price>19.30</Price>
                  <Alternate>19.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701203804" Rank="1" Units="tab" Weight="20" Statim="Must">
              <Name>Tab 20 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B14070120380405">
                <Name>Prednisone Clinect</Name>
                <Pack ID="P2608758" Specified="true" nzmt:ctpp_id="50287791000117105">
                  <Quantity>500</Quantity>
                  <Subsidy>50.51</Subsidy>
                  <Price>50.51</Price>
                  <Alternate>50.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407012239" Statim="Must">
            <Name>Tetracosactrin</Name>
            <Formulation ID="F140701223901" Rank="4" Units="inj" Weight="0.25">
              <Name>Inj 250 mcg per ml, 1 ml ampoule</Name>
              <Brand ID="B14070122390101">
                <Name>Synacthen</Name>
                <Pack ID="P2444836" Specified="true" nzmt:ctpp_id="50179841000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>86.25</Subsidy>
                  <Price>86.25</Price>
                  <Alternate>86.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14070122390104">
                <Name>UK Synacthen</Name>
                <Pack ID="P2587351" Specified="true" nzmt:ctpp_id="50277571000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>86.25</Subsidy>
                  <Price>86.25</Price>
                  <Alternate>86.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701223903" Rank="4" Units="inj" Weight="1">
              <Name>Inj 1 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B14070122390301">
                <Name>Synacthen Depot</Name>
                <Pack ID="P281956" Specified="true" nzmt:ctpp_id="50062571000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>690.00</Subsidy>
                  <Price>690.00</Price>
                  <Alternate>690.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14070122390302" S29="true">
                <Name>Synacthene Retard</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2560003" Specified="true" nzmt:ctpp_id="50261421000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>690.00</Subsidy>
                  <Price>690.00</Price>
                  <Alternate>690.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407012389">
            <Name>Triamcinolone acetonide</Name>
            <Formulation ID="F140701238901" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B14070123890101" PSS="2026-06-30">
                <Name>Kenacort-A 10</Name>
                <Pack ID="P282499" Specified="true" nzmt:ctpp_id="50062901000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>21.42</Subsidy>
                  <Price>21.42</Price>
                  <Alternate>21.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F140701238903" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B14070123890301" PSS="2026-06-30">
                <Name>Kenacort-A 40</Name>
                <Pack ID="P253766" Specified="true" nzmt:ctpp_id="50054031000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>52.63</Subsidy>
                  <Price>52.63</Price>
                  <Alternate>52.63</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1407012864" Statim="Must">
            <Name>Betamethasone sodium phosphate with betamethasone acetate</Name>
            <Formulation ID="F140701286401" Rank="4" Units="inj" Weight="3.9">
              <Name>Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml</Name>
              <Brand ID="B14070128640101">
                <Name>Celestone Chronodose</Name>
                <Pack ID="P733970" Specified="true" nzmt:ctpp_id="50107091000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>19.20</Subsidy>
                  <Price>36.96</Price>
                  <Alternate>19.20</Alternate>
                  <Surcharge>3.55200</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1410">
        <Name>Sex Hormones Non Contraceptive</Name>
        <ATC3 ID="A141001">
          <Name>Androgen Agonists and Antagonists</Name>
          <Chemical ID="C1410012707">
            <Name>Cyproterone acetate</Name>
            <Formulation ID="F141001270701" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B14100127070125" PSS="2024-06-30">
                <Name>Siterone</Name>
                <Pack ID="P2220482" Specified="true" nzmt:ctpp_id="50035001000117105">
                  <Quantity>50</Quantity>
                  <Subsidy>14.37</Subsidy>
                  <Price>14.37</Price>
                  <Alternate>14.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141001270725" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B14100127072525" PSS="2024-06-30">
                <Name>Siterone</Name>
                <Pack ID="P2235862" Specified="true" nzmt:ctpp_id="50037581000117102">
                  <Quantity>50</Quantity>
                  <Subsidy>28.03</Subsidy>
                  <Price>28.03</Price>
                  <Alternate>28.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1410012762">
            <Name>Testosterone cipionate</Name>
            <Formulation ID="F141001276201" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 100 mg per ml, 10 ml vial</Name>
              <Brand ID="B14100127620101">
                <Name>Depo-Testosterone</Name>
                <Pack ID="P741264" Specified="true" nzmt:ctpp_id="50107601000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>85.00</Subsidy>
                  <Price>85.00</Price>
                  <Alternate>85.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14100127620102" S29="true">
                <Name>Taro-Testosterone</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2645149" Specified="true" nzmt:ctpp_id="50305911000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>393.00</Subsidy>
                  <Price>393.00</Price>
                  <Alternate>393.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1410012764">
            <Name>Testosterone undecanoate</Name>
            <Formulation ID="F141001276401" Rank="2" Units="cap" Weight="40">
              <Name>Cap 40 mg</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidy by endorsement â€“ subsidised for patients who were taking testosterone undecanoate cap
        40mg prior to 1 November 2021 and the prescription is endorsed accordingly. Pharmacists may
        annotate the prescription as endorsed where there exists a record of prior dispensing of
        testosterone undecanoate cap 40 mg in the preceding 12 months.</p>
              </div>
              <Brand ID="B14100127640125">
                <Name>Andriol Testocaps</Name>
                <Pack ID="P2332620" Specified="true" nzmt:ctpp_id="50049501000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>21.00</Subsidy>
                  <Price>21.00</Price>
                  <Alternate>21.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14100127640127" S29="true">
                <Name>Steril-Gene</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2636840" Specified="true" nzmt:ctpp_id="50303451000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>35.00</Subsidy>
                  <Price>35.00</Price>
                  <Alternate>35.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141001276426" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 250 mg per ml, 4 ml vial</Name>
              <Brand ID="B14100127642625">
                <Name>Reandron 1000</Name>
                <Pack ID="P2472716" Specified="true" nzmt:ctpp_id="50196911000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>86.00</Subsidy>
                  <Price>86.00</Price>
                  <Alternate>86.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1410012765">
            <Name>Testosterone esters</Name>
            <Formulation ID="F141001276501" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 mg per ml, 1 ml</Name>
              <Brand ID="B14100127650125">
                <Name>Sustanon Ampoules</Name>
                <Pack ID="P2172011" Specified="true" nzmt:ctpp_id="50028911000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>12.98</Subsidy>
                  <Price>12.98</Price>
                  <Alternate>12.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1410013864">
            <Name>Testosterone</Name>
            <Formulation ID="F141001386426" Rank="9" Units="patch" Weight="5">
              <Name>Patch 5 mg per day</Name>
              <Brand ID="B14100138642625">
                <Name>Androderm</Name>
                <Pack ID="P2522403" Specified="true" nzmt:ctpp_id="50242631000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>225.00</Subsidy>
                  <Price>225.00</Price>
                  <Alternate>225.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1411">
        <Name>Hormone Replacement Therapy - Systemic</Name>
        <ATC3 ID="A141104">
          <Name>Oestrogens</Name>
          <Chemical ID="C1411041156">
            <Name>Oestradiol valerate</Name>
            <Formulation ID="F141104115601" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B14110411560101">
                <Name>Progynova</Name>
                <Pack ID="P2450453" Specified="true" nzmt:ctpp_id="50175551000117108">
                  <Quantity>84</Quantity>
                  <Subsidy>12.36</Subsidy>
                  <Price>12.36</Price>
                  <Alternate>12.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104115602" Rank="1" Units="tab" Weight="2" Statim="Must">
              <Name>Tab 2 mg</Name>
              <Brand ID="B14110411560201">
                <Name>Progynova</Name>
                <Pack ID="P2619423" Specified="true" nzmt:ctpp_id="50175561000117105">
                  <Quantity>84</Quantity>
                  <Subsidy>12.36</Subsidy>
                  <Price>12.36</Price>
                  <Alternate>12.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1411041886">
            <Name>Oestradiol</Name>
            <Formulation ID="F141104188605" Rank="9" Units="patch" Weight="25">
              <Name>Patch 25 mcg per day</Name>
              <Rule Type="DoseWMax" Value="2"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B14110418860525">
                <Name>Estradot</Name>
                <Pack ID="P2358840" Specified="true" nzmt:ctpp_id="50121471000117103">
                  <Quantity>8</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860526">
                <Name>Estradiol TDP Mylan</Name>
                <Pack ID="P2601583" Specified="true" nzmt:ctpp_id="50283011000117109">
                  <Quantity>8</Quantity>
                  <Subsidy>9.85</Subsidy>
                  <Price>9.85</Price>
                  <Alternate>9.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860527" S29="true">
                <Name>Estraderm MX</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2645475" Specified="true" nzmt:ctpp_id="50306551000117103">
                  <Quantity>8</Quantity>
                  <Subsidy>13.50</Subsidy>
                  <Price>13.50</Price>
                  <Alternate>13.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104188606" Rank="9" Units="patch" Weight="50">
              <Name>Patch 50 mcg per day</Name>
              <Rule Type="DoseWMax" Value="2"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B14110418860625">
                <Name>Estradot</Name>
                <Pack ID="P2358867" Specified="true" nzmt:ctpp_id="50050851000117105">
                  <Quantity>8</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860626">
                <Name>Estradiol TDP Mylan</Name>
                <Pack ID="P2601591" Specified="true">
                  <Quantity>8</Quantity>
                  <Subsidy>10.75</Subsidy>
                  <Price>10.75</Price>
                  <Alternate>10.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860627" S29="true">
                <Name>Estraderm MX</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2645483" Specified="true" nzmt:ctpp_id="50306541000117100">
                  <Quantity>8</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860628">
                <Name>Estradiol Viatris</Name>
                <Pack ID="P2661470" Specified="true" nzmt:ctpp_id="50283021000117103">
                  <Quantity>8</Quantity>
                  <Subsidy>10.75</Subsidy>
                  <Price>10.75</Price>
                  <Alternate>10.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104188607" Rank="9" Units="patch" Weight="100">
              <Name>Patch 100 mcg per day</Name>
              <Rule Type="DoseWMax" Value="2"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B14110418860725">
                <Name>Estradot</Name>
                <Pack ID="P2358883" Specified="true" nzmt:ctpp_id="50121501000117108">
                  <Quantity>8</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860726" S29="true">
                <Name>Estraderm MX</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2645491" Specified="true" nzmt:ctpp_id="50306561000117101">
                  <Quantity>8</Quantity>
                  <Subsidy>15.50</Subsidy>
                  <Price>15.50</Price>
                  <Alternate>15.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860727">
                <Name>Estradiol TDP Mylan</Name>
                <Pack ID="P2661497" Specified="true">
                  <Quantity>8</Quantity>
                  <Subsidy>12.95</Subsidy>
                  <Price>12.95</Price>
                  <Alternate>12.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418860728">
                <Name>Estradiol Viatris</Name>
                <Pack ID="P2662418" Specified="true" nzmt:ctpp_id="50315531000117100">
                  <Quantity>8</Quantity>
                  <Subsidy>12.95</Subsidy>
                  <Price>12.95</Price>
                  <Alternate>12.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104188610" Rank="1" Units="tab" Weight="2" Statim="Must">
              <Name>Tab 2 mg</Name>
              <Brand ID="B14110418861001">
                <Name>Estrofem</Name>
                <Pack ID="P327859" Specified="true" OP="true" nzmt:ctpp_id="50072721000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>4.12</Subsidy>
                  <Price>11.10</Price>
                  <Alternate>4.12</Alternate>
                  <Surcharge>0.24929</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104188611" Rank="1" Units="tab" Weight="1" Statim="Must">
              <Name>Tab 1 mg</Name>
              <Brand ID="B14110418861101">
                <Name>Estrofem</Name>
                <Pack ID="P258601" Specified="true" OP="true" nzmt:ctpp_id="50056371000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>4.12</Subsidy>
                  <Price>11.10</Price>
                  <Alternate>4.12</Alternate>
                  <Surcharge>0.24929</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104188625" Rank="9" Units="patch" Weight="75">
              <Name>Patch 75 mcg per day</Name>
              <Rule Type="DoseWMax" Value="2"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B14110418862525">
                <Name>Estradot</Name>
                <Pack ID="P2514346" Specified="true" nzmt:ctpp_id="50121491000117102">
                  <Quantity>8</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418862526">
                <Name>Estradiol TDP Mylan</Name>
                <Pack ID="P2605317" Specified="true">
                  <Quantity>8</Quantity>
                  <Subsidy>11.88</Subsidy>
                  <Price>11.88</Price>
                  <Alternate>11.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14110418862527">
                <Name>Estradiol Viatris</Name>
                <Pack ID="P2661489" Specified="true" nzmt:ctpp_id="50285461000117104">
                  <Quantity>8</Quantity>
                  <Subsidy>11.88</Subsidy>
                  <Price>11.88</Price>
                  <Alternate>11.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104188626" Rank="9" Units="patch">
              <Name>Patch 50 mcg per 24 hours</Name>
              <Rule Type="DoseWMax" Value="1"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B14110418862602">
                <Name>Climara</Name>
                <Pack ID="P371114" Specified="true" nzmt:ctpp_id="50078851000117109">
                  <Quantity>4</Quantity>
                  <Subsidy>7.04</Subsidy>
                  <Price>7.04</Price>
                  <Alternate>7.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1411041888" Statim="Must">
            <Name>Oestrogens</Name>
            <Formulation ID="F141104188801" Rank="1" Units="tab" Weight="0.3">
              <Name>Conjugated, equine tab 300 mcg</Name>
              <Brand ID="B14110418880102">
                <Name>Premarin</Name>
                <Pack ID="P2427478" Specified="true" nzmt:ctpp_id="50082971000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>3.01</Subsidy>
                  <Price>17.50</Price>
                  <Alternate>3.01</Alternate>
                  <Surcharge>0.51750</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141104188802" Rank="1" Units="tab" Weight="0.625">
              <Name>Conjugated, equine tab 625 mcg</Name>
              <Brand ID="B14110418880202">
                <Name>Premarin</Name>
                <Pack ID="P2427486" Specified="true" nzmt:ctpp_id="50082961000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>4.12</Subsidy>
                  <Price>17.50</Price>
                  <Alternate>4.12</Alternate>
                  <Surcharge>0.47786</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A141109">
          <Name>Progestogens</Name>
          <Chemical ID="C1411091766">
            <Name>Medroxyprogesterone acetate</Name>
            <Formulation ID="F141109176605" Rank="1" Units="tab" Weight="2.5" Statim="Must">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B14110917660501">
                <Name>Provera</Name>
                <Pack ID="P274186" Specified="true" nzmt:ctpp_id="50060821000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>4.69</Subsidy>
                  <Price>4.69</Price>
                  <Alternate>4.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2643979" Specified="true">
                  <Quantity>56</Quantity>
                  <Subsidy>8.75</Subsidy>
                  <Price>8.75</Price>
                  <Alternate>8.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141109176606" Rank="1" Units="tab" Weight="5" Statim="Must">
              <Name>Tab 5 mg</Name>
              <Brand ID="B14110917660601">
                <Name>Provera</Name>
                <Pack ID="P261130" Specified="true" nzmt:ctpp_id="50057481000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>17.50</Subsidy>
                  <Price>17.50</Price>
                  <Alternate>17.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2643987" Specified="true">
                  <Quantity>56</Quantity>
                  <Subsidy>9.80</Subsidy>
                  <Price>9.80</Price>
                  <Alternate>9.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141109176607" Rank="1" Units="tab" Weight="10" Statim="Must">
              <Name>Tab 10 mg</Name>
              <Brand ID="B14110917660701">
                <Name>Provera</Name>
                <Pack ID="P274135" Specified="true" nzmt:ctpp_id="50060791000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>8.94</Subsidy>
                  <Price>8.94</Price>
                  <Alternate>8.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A141114">
          <Name>Progestogen and Oestrogen Combined Preparations</Name>
          <Chemical ID="C1411142056" Statim="Must">
            <Name>Oestradiol with norethisterone</Name>
            <Formulation ID="F141114205602" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6)</Name>
              <Brand ID="B14111420560201">
                <Name>Trisequens</Name>
                <Pack ID="P767700" Specified="true" OP="true" nzmt:ctpp_id="50111101000117106">
                  <Quantity>28</Quantity>
                  <Subsidy>5.40</Subsidy>
                  <Price>18.10</Price>
                  <Alternate>5.40</Alternate>
                  <Surcharge>0.45357</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141114205603" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg with 1 mg norethisterone acetate</Name>
              <Brand ID="B14111420560301">
                <Name>Kliogest</Name>
                <Pack ID="P780227" Specified="true" OP="true" nzmt:ctpp_id="50113371000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>5.40</Subsidy>
                  <Price>18.10</Price>
                  <Alternate>5.40</Alternate>
                  <Surcharge>0.45357</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141114205604" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg with 0.5 mg norethisterone acetate</Name>
              <Brand ID="B14111420560401">
                <Name>Kliovance</Name>
                <Pack ID="P259772" Specified="true" OP="true" nzmt:ctpp_id="50056781000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>5.40</Subsidy>
                  <Price>18.10</Price>
                  <Alternate>5.40</Alternate>
                  <Surcharge>0.45357</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1412">
        <Name>Other Oestrogen Preparations</Name>
        <ATC3 ID="A141201">
          <Name>Other Oestrogen Preparations</Name>
          <Chemical ID="C1412012784" Statim="Must">
            <Name>Oestriol</Name>
            <Formulation ID="F141201278401" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B14120127840101" PSS="2026-06-30">
                <Name>Ovestin</Name>
                <Pack ID="P767476" Specified="true" nzmt:ctpp_id="50111011000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>7.70</Subsidy>
                  <Price>7.70</Price>
                  <Alternate>7.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1413">
        <Name>Other Progestogen Preparations</Name>
        <ATC3 ID="A141301">
          <Name>Other Progestogen Preparations</Name>
          <Chemical ID="C1413011724" Statim="Must">
            <Name>Levonorgestrel</Name>
            <Formulation ID="F141301172426" Rank="10" Units="dev">
              <Name>Intra-uterine device 52 mg</Name>
              <Brand ID="B14130117242625" SoleSupply="2024-10-31">
                <Name>Mirena</Name>
                <Pack ID="P2013908" Specified="true" nzmt:ctpp_id="50002091000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>269.50</Subsidy>
                  <Price>269.50</Price>
                  <Alternate>269.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141301172429" Rank="10" Units="dev" Weight="13">
              <Name>Intra-uterine device 13.5 mg</Name>
              <Brand ID="B14130117242925" SoleSupply="2024-10-31">
                <Name>Jaydess</Name>
                <Pack ID="P2474891" Specified="true" nzmt:ctpp_id="50185361000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>215.60</Subsidy>
                  <Price>215.60</Price>
                  <Alternate>215.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1413011766">
            <Name>Medroxyprogesterone acetate</Name>
            <Formulation ID="F141301176601" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B14130117660101">
                <Name>Provera HD</Name>
                <Pack ID="P261149" Specified="true" nzmt:ctpp_id="50057491000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>116.15</Subsidy>
                  <Price>116.15</Price>
                  <Alternate>116.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1413011871" Statim="Must">
            <Name>Norethisterone</Name>
            <Formulation ID="F141301187102" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B14130118710201">
                <Name>Primolut N</Name>
                <Pack ID="P2607441" Specified="true" nzmt:ctpp_id="50151071000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>5.49</Subsidy>
                  <Price>5.49</Price>
                  <Alternate>5.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1413012052">
            <Name>Progesterone</Name>
            <Formulation ID="F141301205225" Rank="2" Units="cap" Weight="100" Statim="Must">
              <Name>Cap 100 mg</Name>
              <Brand ID="B14130120522525" PSS="2025-06-30">
                <Name>Utrogestan</Name>
                <Pack ID="P2086905" Specified="true" nzmt:ctpp_id="50015211000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>14.85</Subsidy>
                  <Price>14.85</Price>
                  <Alternate>14.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1414">
        <Name>Thyroid and Antithyroid Agents</Name>
        <ATC3 ID="A141401">
          <Name>Thyroid and Antithyroid Agents</Name>
          <Chemical ID="C1414011221" Statim="Must">
            <Name>Carbimazole</Name>
            <Formulation ID="F141401122101" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B14140112210101" PSS="2025-06-30">
                <Name>Neo-Mercazole</Name>
                <Pack ID="P594423" Specified="true" nzmt:ctpp_id="50097891000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>7.56</Subsidy>
                  <Price>7.56</Price>
                  <Alternate>7.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1414012062">
            <Name>Propylthiouracil</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1199"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1199">
              <Title>
                <range>Propylthiouracil</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has hyperthyroidism</ci>
                    <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Renewal" Form="SA1199">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F141401206201" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B14140120620125" S29="true">
                <Name>PTU</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2010526" Specified="true" nzmt:ctpp_id="50130871000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>35.00</Subsidy>
                  <Price>35.00</Price>
                  <Alternate>35.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1414012263" Statim="Must">
            <Name>Levothyroxine</Name>
            <Formulation ID="F141401226301" Rank="1" Units="tab" Weight="0.05">
              <Name>Tab 50 mcg</Name>
              <Brand ID="B14140122630101">
                <Name>Eltroxin</Name>
                <Pack ID="P250287" Specified="true" nzmt:ctpp_id="50052321000117108">
                  <Quantity>1000</Quantity>
                  <Subsidy>64.28</Subsidy>
                  <Price>64.28</Price>
                  <Alternate>64.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14140122630125">
                <Name>Mercury Pharma</Name>
                <Pack ID="P2307766" Specified="true" nzmt:ctpp_id="50046271000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>1.71</Subsidy>
                  <Price>1.71</Price>
                  <Alternate>1.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14140122630126">
                <Name>Synthroid</Name>
                <Pack ID="P2534797" Specified="true" nzmt:ctpp_id="50125981000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>5.79</Subsidy>
                  <Price>5.79</Price>
                  <Alternate>5.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141401226302" Rank="1" Units="tab" Weight="0.1">
              <Name>Tab 100 mcg</Name>
              <Brand ID="B14140122630201">
                <Name>Eltroxin</Name>
                <Pack ID="P250295" Specified="true" nzmt:ctpp_id="50052331000117106">
                  <Quantity>1000</Quantity>
                  <Subsidy>66.78</Subsidy>
                  <Price>66.78</Price>
                  <Alternate>66.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14140122630225">
                <Name>Mercury Pharma</Name>
                <Pack ID="P2307758" Specified="true" nzmt:ctpp_id="50046261000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>1.78</Subsidy>
                  <Price>1.78</Price>
                  <Alternate>1.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14140122630226">
                <Name>Synthroid</Name>
                <Pack ID="P2534800" Specified="true" nzmt:ctpp_id="50125181000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>6.01</Subsidy>
                  <Price>6.01</Price>
                  <Alternate>6.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141401226325" Rank="1" Units="tab">
              <Name>Tab 25 mcg</Name>
              <Brand ID="B14140122632525">
                <Name>Synthroid</Name>
                <Pack ID="P2534789" Specified="true" nzmt:ctpp_id="50125971000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>5.55</Subsidy>
                  <Price>5.55</Price>
                  <Alternate>5.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1416">
        <Name>Trophic Hormones</Name>
        <ATC3 ID="A141602">
          <Name>Growth Hormones</Name>
          <Chemical ID="C1416022509" Statim="Must">
            <Name>Somatropin (Omnitrope)</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2032"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2032">
              <Title>
                <range>Somatropin</range>
              </Title>
              <Case When="Initial application" Category="growth hormone deficiency in children">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic
                    hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g.
                    cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at
                    least two random blood samples in the first 2 weeks of life, or from samples
                    during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a
                    laboratory device)</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for
                        age adjusted for bone age/pubertal status if appropriate over 6 or 12 months
                        using the standards of Tanner and Davies (1985)</ci>
                      <ci type="logical" class="Indication">A current bone age is &lt; 14 years
                        (female patients) or &lt; 16 years (male patients)</ci>
                      <ci type="logical" class="Indication">Peak growth hormone value of &lt; 5.0 mcg
                        per litre in response to two different growth hormone stimulation tests. In
                        children who are 5 years or older, GH testing with sex steroid priming is
                        required</ci>
                      <ci type="logical" class="Indication">If the patient has been treated for a
                        malignancy, they should be disease free for at least one year based upon
                        follow-up laboratory and radiological imaging appropriate for the
                        malignancy, unless there are strong medical reasons why this is either not
                        necessary or appropriate</ci>
                      <ci type="logical" class="Indication">Appropriate imaging of the pituitary gland
                        has been obtained</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="growth hormone deficiency in children" Form="SA1451 SA1629 SA2032">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">A current bone age is 14 years or under
                    (female patients) or 16 years or under (male patients)</ci>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to
                    25th percentile for age (adjusted for bone age/pubertal status if appropriate)
                    while on growth hormone treatment, as calculated over six months using the
                    standards of Tanner and Davis (1985)</ci>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to
                    2.0 cm per year, as calculated over 6 months</ci>
                    <ci type="logical" class="Indication">No serious adverse effect that the patients
                    specialist considers is likely to be attributable to growth hormone treatment
                    has occurred</ci>
                    <ci type="logical" class="Indication">No malignancy has developed since starting
                    growth hormone</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Turner syndrome">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a post-natal genotype
                    confirming Turner Syndrome</ci>
                    <ci type="logical" class="Indication">Height velocity is &lt; 25th percentile over
                    6-12 months using the standards of Tanner and Davies (1985)</ci>
                    <ci type="logical" class="Indication">A current bone age is &lt; 14 years</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="Turner syndrome" Form="SA1451 SA1629 SA2032">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to
                    50th percentile for age (while on growth hormone calculated over 6 to 12 months
                    using the Ranke's Turner Syndrome growth velocity charts)</ci>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to 2
                    cm per year, calculated over six months</ci>
                    <ci type="logical" class="Indication">A current bone age is 14 years or under </ci>
                    <ci type="logical" class="Indication">No serious adverse effect that the specialist
                    considers is likely to be attributable to growth hormone treatment has
                    occurred</ci>
                    <ci type="logical" class="Indication">No malignancy has developed since starting
                    growth hormone</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="short stature without growth hormone deficiency">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient's height is more than 3 standard
                    deviations below the mean for age or for bone age if there is marked growth
                    acceleration or delay</ci>
                    <ci type="logical" class="Indication">Height velocity is &lt; 25th percentile for
                    age (adjusted for bone age/pubertal status if appropriate), as calculated over 6
                    to 12 months using the standards of Tanner and Davies(1985)</ci>
                    <ci type="logical" class="Indication">A current bone age is &lt; 14 years or under
                    (female patients) or &lt; 16 years (male patients)</ci>
                    <ci type="logical" class="Indication">The patient does not have severe chronic
                    disease (including malignancy or recognized severe skeletal dysplasia) and is
                    not receiving medications known to impair height velocity</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="short stature without growth hormone deficiency" Form="SA1451 SA1629 SA2032">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to
                    50th percentile (adjusted for bone age/pubertal status if appropriate) as
                    calculated over 6 to 12 months using the standards of Tanner and Davies
                    (1985)</ci>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to 2
                    cm per year as calculated over six months</ci>
                    <ci type="logical" class="Indication">A current bone age is 14 years or under
                    (female patients) or 16 years or under (male patients)</ci>
                    <ci type="logical" class="Indication">No serious adverse effect that the patient's
                    specialist considers is likely to be attributable to growth hormone treatment
                    has occurred</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="short stature due to chronic renal insufficiency">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient's height is more than 2 standard
                    deviations below the mean</ci>
                    <ci type="logical" class="Indication">Height velocity is &lt; 25th percentile
                    (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to
                    12 months using the standards of Tanner and Davies (1985)</ci>
                    <ci type="logical" class="Indication">A current bone age is to 14 years or under
                    (female patients) or to 16 years or under (male patients)</ci>
                    <ci type="logical" class="Indication">The patient is metabolically stable, has no
                    evidence of metabolic bone disease and absence of any other severe chronic
                    disease</ci>
                    <ci type="logical" class="Indication">The patient is under the supervision of a
                    specialist with expertise in renal medicine</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has a GFR less than or equal
                        to 30 ml/min/1.73mÂ² as measured by the Schwartz method (Height(cm)/plasma
                        creatinine (umol/l)) x 40 = corrected GFR (ml/min/1.73mÂ²) in a child who may
                        or may not be receiving dialysis</ci>
                      <ci type="logical" class="Indication">The patient has received a renal
                        transplant and has received &lt; 5mg/ mÂ²/day of prednisone or equivalent for
                        at least 6 months.</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Applicant Referring="paediatric endocrinologist or endocrinologist">renal physician</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="short stature due to chronic renal insufficiency" Form="SA1451 SA1629 SA2032">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to
                    50th percentile (adjusted for bone age/pubertal status if appropriate) as
                    calculated over 6 to 12 months using the standards of Tanner and Davies
                    (1985)</ci>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to 2
                    cm per year as calculated over six months</ci>
                    <ci type="logical" class="Indication">A current bone age is 14 years or under
                    (female patients) or 16 years or under (male patients)</ci>
                    <ci type="logical" class="Indication">No serious adverse effect that the patients
                    specialist considers is likely to be attributable to growth hormone has
                    occurred</ci>
                    <ci type="logical" class="Indication">No malignancy has developed after growth
                    hormone therapy was commenced</ci>
                    <ci type="logical" class="Indication">The patient has not experienced significant
                    biochemical or metabolic deterioration confirmed by diagnostic results</ci>
                    <ci type="logical" class="Indication">The patient has not received renal
                    transplantation since starting growth hormone treatment</ci>
                    <ci type="logical" class="Indication">If the patient requires transplantation,
                    growth hormone prescription should cease before transplantation and a new
                    application should be made after transplantation based on the above
                    criteria</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Applicant Referring="paediatric endocrinologist or endocrinologist">renal physician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Prader-Willi syndrome">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a diagnosis of Prader-Willi
                    syndrome that has been confirmed by genetic testing or clinical scoring
                    criteria</ci>
                    <ci type="logical" class="Indication">The patient is aged six months or older</ci>
                    <ci type="logical" class="Indication">A current bone age is &lt; 14 years (female
                    patients) or &lt; 16 years (male patients)</ci>
                    <ci type="logical" class="Indication">Sleep studies or overnight oximetry have been
                    performed and there is no obstructive sleep disorder requiring treatment, or if
                    an obstructive sleep disorder is found, it has been adequately treated under the
                    care of a paediatric respiratory physician and/or ENT surgeon</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient is aged two years or
                            older</ci>
                        <ci type="logical" class="Indication">There is no evidence of type II
                            diabetes or uncontrolled obesity defined by BMI that has increased by
                            greater than or equal to 0.5 standard deviations in the preceding 12
                            months</ci>
                      </apply>
                      <ci type="logical" class="Indication">The patient is aged between six months and
                        two years and a thorough upper airway assessment is planned to be undertaken
                        prior to treatment commencement and at six to 12 weeks following treatment
                        initiation</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="Prader-Willi syndrome" Form="SA1451 SA1629 SA2032">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to
                    50th percentile (adjusted for bone age/pubertal status if appropriate) as
                    calculated over 6 to 12 months using the standards of Tanner and Davies
                    (1985)</ci>
                    <ci type="logical" class="Indication">Height velocity is greater than or equal to 2
                    cm per year as calculated over six months</ci>
                    <ci type="logical" class="Indication">A current bone age is 14 years or under
                    (female patients) or 16 years or under (male patients)</ci>
                    <ci type="logical" class="Indication">No serious adverse effect that the patient's
                    specialist considers is likely to be attributable to growth hormone treatment
                    has occurred</ci>
                    <ci type="logical" class="Indication">No malignancy has developed after growth
                    hormone therapy was commenced</ci>
                    <ci type="logical" class="Indication">The patient has not developed type II diabetes
                    or uncontrolled obesity as defined by BMI that has increased by greater than or
                    equal to 0.5 standard deviations in the preceding 12 months</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="adults and adolescents">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a medical condition that is
                    known to cause growth hormone deficiency (e.g. surgical removal of the pituitary
                    for treatment of a pituitary tumour)</ci>
                    <ci type="logical" class="Indication">The patient has undergone appropriate
                    treatment of other hormonal deficiencies and psychological illnesses</ci>
                    <ci type="logical" class="Indication">The patient has severe growth hormone
                    deficiency (see notes)</ci>
                    <ci type="logical" class="Indication">The patient's serum IGF-I is more than 1
                    standard deviation below the mean for age and sex</ci>
                    <ci type="logical" class="Indication">The patient has poor quality of life, as
                    defined by a score of 16 or more using the disease-specific quality of life
                    questionnaire for adult growth hormone deficiency (QoL-AGHDAÂ®)</ci>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">9</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>For the purposes of adults and adolescents, severe growth hormone deficiency is
                defined as a peak serum growth hormone level of less than or equal to 3 mcg per
                litre during an adequately performed insulin tolerance test (ITT) or glucagon
                stimulation test.</p>
                  <p>Patients with one or more additional anterior pituitary hormone deficiencies and a
                known structural pituitary lesion only require one test. Patients with isolated
                growth hormone deficiency require two growth hormone stimulation tests, of which,
                one should be ITT unless otherwise contraindicated. Where an additional test is
                required, an arginine provocation test can be used with a peak serum growth hormone
                level of less than or equal to 0.4 mcg per litre.</p>
                  <p>The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg
                monthly until the serum IGF-I is within 1 standard deviation of the mean normal
                value for age and sex; and</p>
                  <p>Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day
                for female patients.</p>
                  <p>At the commencement of treatment for hypopituitarism, patients must be monitored for
                any required adjustment in replacement doses of corticosteroid and
                levothyroxine.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="adults and adolescents" Form="SA1451 SA1629 SA2032">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has been treated with
                        somatropin for &lt; 12 months</ci>
                      <ci type="logical" class="Indication">There has been an improvement in Quality
                        of Life defined as a reduction of at least 8 points on the Quality of Life
                        Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDAÂ®) score from
                        baseline</ci>
                      <ci type="logical" class="Indication">Serum IGF-I levels have been increased
                        within Â±1SD of the mean of the normal range for age and sex</ci>
                      <ci type="logical" class="Indication">The dose of somatropin has not exceeded
                        0.7 mg per day for male patients, or 1 mg per day for female patients</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has been treated with
                        somatropin for more than 12 months</ci>
                      <ci type="logical" class="Indication">The patient has not had a deterioration in
                        Quality of Life defined as a 6 point or greater increase from their lowest
                        QoL-AGHDAÂ® score on treatment (other than due to obvious external factors
                        such as external stressors)</ci>
                      <ci type="logical" class="Indication">Serum IGF-I levels have continued to be
                        maintained within Â±1SD of the mean of the normal range for age and sex
                        (other than for obvious external factors)</ci>
                      <ci type="logical" class="Indication">The dose of somatropin has not exceeded
                        0.7 mg per day for male patients or 1 mg per day for female patients</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had a Special Authority
                        approval for somatropin for childhood deficiency in children and no longer
                        meets the renewal criteria under this indication</ci>
                      <ci type="logical" class="Indication">The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses</ci>
                      <ci type="logical" class="Indication">The patient has severe growth hormone deficiency (see notes)</ci>
                      <ci type="logical" class="Indication">The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex</ci>
                      <ci type="logical" class="Indication">The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDAÂ®)</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatric endocrinologist</Applicant>
                <Applicant>endocrinologist</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>For the purposes of adults and adolescents, severe growth hormone deficiency is
                defined as a peak serum growth hormone level of less than or equal to 3 mcg per
                litre during an adequately performed insulin tolerance test (ITT) or glucagon
                stimulation test.</p>
                  <p>Patients with one or more additional anterior pituitary hormone deficiencies and a
                known structural pituitary lesion only require one test. Patients with isolated
                growth hormone deficiency require two growth hormone stimulation tests, of which,
                one should be ITT unless otherwise contraindicated. Where an additional test is
                required, an arginine provocation test can be used with a peak serum growth hormone
                level of less than or equal to 0.4 mcg per litre.</p>
                  <p>The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg
                monthly until the serum IGF-I is within 1 standard deviation of the mean normal
                value for age and sex; and</p>
                  <p>Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day
                for female patients.</p>
                  <p>At the commencement of treatment for hypopituitarism, patients must be monitored for
                any required adjustment in replacement doses of corticosteroid and
                levothyroxine.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F141602250930" Rank="4" Units="inj" Weight="5">
              <Name>Inj 5 mg cartridge</Name>
              <Brand ID="B14160225093025" PSS="2024-06-30">
                <Name>Omnitrope</Name>
                <Pack ID="P2461536" Specified="true" nzmt:ctpp_id="50166511000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>69.75</Subsidy>
                  <Price>69.75</Price>
                  <Alternate>69.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14160225093026" S29="true">
                <Name>Omnitrope S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2648415" Specified="true" nzmt:ctpp_id="50307981000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>69.75</Subsidy>
                  <Price>69.75</Price>
                  <Alternate>69.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141602250931" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg cartridge</Name>
              <Brand ID="B14160225093125" PSS="2024-06-30">
                <Name>Omnitrope</Name>
                <Pack ID="P2461528" Specified="true" nzmt:ctpp_id="50166521000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>69.75</Subsidy>
                  <Price>69.75</Price>
                  <Alternate>69.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14160225093126" S29="true">
                <Name>Omnitrope S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2648407" Specified="true" nzmt:ctpp_id="50307991000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>69.75</Subsidy>
                  <Price>69.75</Price>
                  <Alternate>69.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141602250932" Rank="4" Units="inj" Weight="15">
              <Name>Inj 15 mg cartridge</Name>
              <Brand ID="B14160225093225" PSS="2024-06-30">
                <Name>Omnitrope</Name>
                <Pack ID="P2461501" Specified="true" nzmt:ctpp_id="50166531000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>139.50</Subsidy>
                  <Price>139.50</Price>
                  <Alternate>139.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14160225093226" S29="true">
                <Name>Omnitrope S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2648393" Specified="true" nzmt:ctpp_id="50308001000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>139.50</Subsidy>
                  <Price>139.50</Price>
                  <Alternate>139.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A141603">
          <Name>GnRH Analogues</Name>
          <Chemical ID="C1416031009">
            <Name>Leuprorelin</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Additional subsidy by endorsement where the patient is a child or adolescent and is unable to tolerate administration of goserelin and the prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F141603100929" Rank="4" Units="inj" Weight="3.75">
              <Name>Inj 3.75 mg prefilled dual chamber syringe</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B14160310092925">
                <Name>Lucrin Depot 1-month</Name>
                <Pack ID="P2330148" Specified="true" nzmt:ctpp_id="50049431000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>66.48</Subsidy>
                  <Price>221.60</Price>
                  <Alternate>221.60</Alternate>
                  <Surcharge>155.12000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141603100930" Rank="4" Units="inj" Weight="11.25">
              <Name>Inj 11.25 mg prefilled dual chamber syringe</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B14160310093025">
                <Name>Lucrin Depot 3-month</Name>
                <Pack ID="P2330156" Specified="true" nzmt:ctpp_id="50049441000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>177.50</Subsidy>
                  <Price>591.68</Price>
                  <Alternate>591.68</Alternate>
                  <Surcharge>414.18000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1416032540" Update="+Subsidy">
            <Name>Goserelin</Name>
            <Formulation ID="F141603254001" Rank="4" Units="inj" Weight="3.6">
              <Name>Implant 3.6 mg, syringe</Name>
              <Brand ID="B14160325400101" ToBePSS="2024-04-01">
                <Name>Zoladex</Name>
                <Pack ID="P678066" Specified="true" nzmt:ctpp_id="50101681000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>66.48</Subsidy>
                  <Price>66.48</Price>
                  <Alternate>66.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14160325400102" ToBeDelisted="2024-04-01">
                <Name>Teva</Name>
                <Pack ID="P2597527" Specified="true" nzmt:ctpp_id="50257321000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>91.50</Subsidy>
                  <Price>91.50</Price>
                  <Alternate>91.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141603254002" Rank="4" Units="inj" Weight="10.8">
              <Name>Implant 10.8 mg, syringe</Name>
              <Brand ID="B14160325400201" ToBePSS="2024-04-01">
                <Name>Zoladex</Name>
                <Pack ID="P362107" Specified="true" nzmt:ctpp_id="50078321000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>138.23</Subsidy>
                  <Price>138.23</Price>
                  <Alternate>138.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B14160325400202" ToBeDelisted="2024-04-01">
                <Name>Teva</Name>
                <Pack ID="P2597519" Specified="true" nzmt:ctpp_id="50257331000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>197.50</Subsidy>
                  <Price>197.50</Price>
                  <Alternate>197.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1419">
        <Name>Vasopressin Agonists</Name>
        <ATC3 ID="A141901">
          <Name>Vasopressin Agonists</Name>
          <Chemical ID="C1419012424">
            <Name>Desmopressin acetate</Name>
            <Formulation ID="F141901242403" Rank="4" Units="inj" Weight="4">
              <Name>Inj 4 mcg per ml, 1 ml</Name>
              <Brand ID="B14190124240301">
                <Name>Minirin</Name>
                <Pack ID="P338192" Specified="true" nzmt:ctpp_id="50074811000117101">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>67.18</Subsidy>
                  <Price>67.18</Price>
                  <Alternate>67.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141901242425" Rank="3" Units="ml" Weight="10" Statim="May">
              <Name>Nasal spray 10 mcg per dose</Name>
              <Brand ID="B14190124242525" PSS="2026-06-30">
                <Name>Desmopressin-PH&amp;T</Name>
                <Pack ID="P2198231" Specified="true" OP="true" nzmt:ctpp_id="50031711000117108">
                  <Quantity>6</Quantity>
                  <Subsidy>34.95</Subsidy>
                  <Price>34.95</Price>
                  <Alternate>34.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141901242426" Rank="1" Units="tab">
              <Name>Tab 100 mcg</Name>
              <Brand ID="B14190124242625">
                <Name>Minirin</Name>
                <Pack ID="P492620" Specified="true" nzmt:ctpp_id="50091971000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F141901242427" Rank="1" Units="tab">
              <Name>Tab 200 mcg</Name>
              <Brand ID="B14190124242725">
                <Name>Minirin</Name>
                <Pack ID="P492639" Specified="true" nzmt:ctpp_id="50091981000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>54.45</Subsidy>
                  <Price>54.45</Price>
                  <Alternate>54.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1419014134">
            <Name>Desmopressin</Name>
            <Formulation ID="F141901413425" Rank="1" Units="tab" Weight="120">
              <Name>Wafer 120 mcg</Name>
              <Brand ID="B14190141342525">
                <Name>Minirin Melt</Name>
                <Pack ID="P2603268" Specified="true" nzmt:ctpp_id="50128971000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>47.00</Subsidy>
                  <Price>47.00</Price>
                  <Alternate>47.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1421">
        <Name>Other Endocrine Agents</Name>
        <ATC3 ID="A142101">
          <Name>Other Endocrine Agents</Name>
          <Chemical ID="C1421011314">
            <Name>Clomifene citrate</Name>
            <Formulation ID="F142101131401" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B14210113140125" S29="true">
                <Name>Mylan Clomiphen</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2502666" Specified="true" nzmt:ctpp_id="50234241000117105">
                  <Quantity>10</Quantity>
                  <Subsidy>29.84</Subsidy>
                  <Price>29.84</Price>
                  <Alternate>29.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1421011822">
            <Name>Metyrapone</Name>
            <Formulation ID="F142101182201" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B14210118220101">
                <Name>Metopirone</Name>
                <Pack ID="P388130" Specified="true" nzmt:ctpp_id="50080411000117103">
                  <Quantity>50</Quantity>
                  <Subsidy>558.00</Subsidy>
                  <Price>558.00</Price>
                  <Alternate>558.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1421012865">
            <Name>Cabergoline</Name>
            <Request To="HealthPAC" For="Waiver of Rule" Form="SA2070">
              <Title>
                <range>Cabergoline</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Hyperprolactinemia</ci>
                    <ci type="logical" class="Indication">Acromegaly*</ci>
                    <ci type="logical" class="Indication">Inhibition of lactation</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Renewal" Category="for patients who have previously been funded under Special Authority form SA1031" Form="SA0175 SA1031 SA1370 SA2070">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient has previously held a valid Special
        Authority which has expired and the treatment remains appropriate and the patient is
        benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Indication marked with * is an unapproved indication.</p>
              </div>
            </Request>
            <Formulation ID="F142101286501" Rank="1" Units="tab" Weight="0.5">
              <Name>Tab 0.5 mg</Name>
              <Rule Type="FormMax" Value="2" Attribute="Rx" Waiver="Special" xlink:href="SA2070"/>
              <Brand ID="B14210128650101">
                <Name>Dostinex</Name>
                <Pack ID="P275824" Specified="true" nzmt:ctpp_id="50061131000117105">
                  <Quantity>2</Quantity>
                  <Subsidy>4.43</Subsidy>
                  <Price>4.43</Price>
                  <Alternate>4.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P275840" Specified="true" nzmt:ctpp_id="50061141000117102">
                  <Quantity>8</Quantity>
                  <Subsidy>17.94</Subsidy>
                  <Price>17.94</Price>
                  <Alternate>17.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A16">
      <Name>Infections - Agents for Systemic Use</Name>
      <ATC2 ID="A1601">
        <Name>Anthelmintics</Name>
        <ATC3 ID="A160101">
          <Name>Anthelmintics</Name>
          <Chemical ID="C1601011762">
            <Name>Mebendazole</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Formulation ID="F160101176201" Rank="3" Units="ml" Weight="20">
              <Name>Oral liq 100 mg per 5 ml</Name>
              <Brand ID="B16010117620101">
                <Name>Vermox</Name>
                <Pack ID="P239852" Specified="true" nzmt:ctpp_id="50051421000117106">
                  <Quantity>15</Quantity>
                  <Subsidy>2.18</Subsidy>
                  <Price>7.83</Price>
                  <Alternate>2.18</Alternate>
                  <Surcharge>0.37667</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160101176202" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B16010117620202" PSS="2024-06-30">
                <Name>Vermox</Name>
                <Pack ID="P258040" Specified="true" nzmt:ctpp_id="50056101000117102">
                  <Quantity>6</Quantity>
                  <Subsidy>7.97</Subsidy>
                  <Price>7.97</Price>
                  <Alternate>7.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1601013990">
            <Name>Albendazole</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1318"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1318">
              <Title>
                <range>Albendazole</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient has hydatids</ci>
                </math>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1318">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci>
                </math>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F160101399025" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B16010139902525" S29="true">
                <Name>Eskazole</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2429977" Specified="true" nzmt:ctpp_id="50168151000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>469.20</Subsidy>
                  <Price>469.20</Price>
                  <Alternate>469.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1601013991">
            <Name>Praziquantel</Name>
            <Formulation ID="F160101399125" Rank="1" Units="tab" Weight="600">
              <Name>Tab 600 mg</Name>
              <Brand ID="B16010139912525">
                <Name>Biltricide</Name>
                <Pack ID="P2028808" Specified="true" nzmt:ctpp_id="50005581000117103">
                  <Quantity>8</Quantity>
                  <Subsidy>68.00</Subsidy>
                  <Price>68.00</Price>
                  <Alternate>68.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1603">
        <Name>Antibacterials</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1004">For topical antibacterials, refer to DERMATOLOGICALS</p>
        </div>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A310301">For anti-infective eye preparations, refer to SENSORY ORGANS</p>
        </div>
        <ATC3 ID="A160301">
          <Name>Cephalosporins and Cephamycins</Name>
          <Chemical ID="C1603011081">
            <Name>Cefuroxime axetil</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F160301108102" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B16030110810202" S29="true">
                <Name>Ascend-Cefuroxime</Name>
                <Pack ID="P2658445" Specified="true" CBS="true" nzmt:ctpp_id="50318271000117106">
                  <Quantity>20</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603011228">
            <Name>Cefaclor monohydrate</Name>
            <Formulation ID="F160301122801" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B16030112280126" PSS="2025-06-30">
                <Name>Ranbaxy-Cefaclor</Name>
                <Pack ID="P2149389" Specified="true" nzmt:ctpp_id="50025801000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>25.85</Subsidy>
                  <Price>25.85</Price>
                  <Alternate>25.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160301122802" Rank="3" Units="ml" Weight="25">
              <Name>Grans for oral liq 125 mg per 5 ml</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B16030112280226" PSS="2025-06-30">
                <Name>Ranbaxy-Cefaclor</Name>
                <Pack ID="P471674" Specified="true" nzmt:ctpp_id="50088741000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>3.75</Subsidy>
                  <Price>3.75</Price>
                  <Alternate>3.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603011232">
            <Name>Ceftriaxone</Name>
            <Rule Type="FormMax" Value="10" Attribute="PSO"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningococcal disease, and the prescription or PSO is endorsed accordingly.</p>
            </div>
            <Formulation ID="F160301123202" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B16030112320228" PSS="2025-06-30">
                <Name>Ceftriaxone-AFT</Name>
                <Pack ID="P2400820" Specified="true" nzmt:ctpp_id="50085571000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.79</Subsidy>
                  <Price>0.79</Price>
                  <Alternate>0.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160301123203" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g vial</Name>
              <Brand ID="B16030112320329" PSS="2025-06-30">
                <Name>Ceftriaxone-AFT</Name>
                <Pack ID="P2428644" Specified="true" nzmt:ctpp_id="50133641000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3.59</Subsidy>
                  <Price>3.59</Price>
                  <Alternate>3.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603011234">
            <Name>Cefalexin</Name>
            <Formulation ID="F160301123402" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B16030112340225" PSS="2025-06-30">
                <Name>Cephalexin ABM</Name>
                <Pack ID="P2498871" Specified="true" nzmt:ctpp_id="50231821000117101">
                  <Quantity>20</Quantity>
                  <Subsidy>3.85</Subsidy>
                  <Price>3.85</Price>
                  <Alternate>3.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160301123403" Rank="3" Units="ml">
              <Name>Grans for oral liq 25 mg per ml</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B16030112340326" PSS="2024-06-30">
                <Name>Flynn</Name>
                <Pack ID="P2640481" Specified="true" nzmt:ctpp_id="50274621000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>7.88</Subsidy>
                  <Price>7.88</Price>
                  <Alternate>7.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160301123404" Rank="3" Units="ml">
              <Name>Grans for oral liq 50 mg per ml</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B16030112340425">
                <Name>Cefalexin Sandoz</Name>
                <Pack ID="P2332825" Specified="true" nzmt:ctpp_id="50049531000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>11.75</Subsidy>
                  <Price>11.75</Price>
                  <Alternate>11.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16030112340426" PSS="2024-06-30">
                <Name>Flynn</Name>
                <Pack ID="P2640503" Specified="true" nzmt:ctpp_id="50274631000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>10.38</Subsidy>
                  <Price>10.38</Price>
                  <Alternate>10.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160301123425" Rank="2" Units="cap" Weight="500">
              <Name>Cap 500 mg</Name>
              <Brand ID="B16030112342525" PSS="2025-06-30">
                <Name>Cephalexin ABM</Name>
                <Pack ID="P2361248" Specified="true" nzmt:ctpp_id="50050991000117107">
                  <Quantity>20</Quantity>
                  <Subsidy>5.85</Subsidy>
                  <Price>5.85</Price>
                  <Alternate>5.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603011236">
            <Name>Cefazolin</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only if prescribed for dialysis or cellulitis in accordance with a Te Whatu Ora Hospital approved protocol and the prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F160301123601" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B16030112360129" PSS="2026-06-30">
                <Name>Cefazolin-AFT</Name>
                <Pack ID="P2391325" Specified="true" nzmt:ctpp_id="50125781000117108">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3.39</Subsidy>
                  <Price>3.39</Price>
                  <Alternate>3.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160301123602" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g vial</Name>
              <Brand ID="B16030112360228" PSS="2026-06-30">
                <Name>Cefazolin-AFT</Name>
                <Pack ID="P2391317" Specified="true" nzmt:ctpp_id="50125771000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3.59</Subsidy>
                  <Price>3.59</Price>
                  <Alternate>3.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160301123625" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2 g vial</Name>
              <Brand ID="B16030112362525" PSS="2026-06-30">
                <Name>Cefazolin-AFT</Name>
                <Pack ID="P2662876" Specified="true" nzmt:ctpp_id="50228761000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>7.09</Subsidy>
                  <Price>7.09</Price>
                  <Alternate>7.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A160304">
          <Name>Macrolides</Name>
          <Chemical ID="C1603041178">
            <Name>Azithromycin</Name>
            <Request To="HealthPAC" For="Waiver of Rule" Form="SA1683">
              <Title>
                <range>Azithromycin</range>
              </Title>
              <Case When="Initial application" Category="bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*</ci>
                    <ci type="logical" class="Trial">Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*</ci>
                    <ci type="logical" class="Trial">Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas-related gram negative organisms*</ci>
                    <ci type="logical" class="Indication">Patient has an atypical Mycobacterium infection</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="non-cystic fibrosis bronchiectasis*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*</ci>
                    <ci type="logical" class="Trial">Patient is aged 18 and under</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period</ci>
                      <ci type="logical" class="Indication">Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="non-cystic fibrosis bronchiectasis*" Form="SA1648 SA1683">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis</ci>
                    <ci type="logical" class="Trial">Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a
                    further 12 months, unless considered clinically inappropriate to stop treatment</ci>
                    <ci type="logical" class="Indication">The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note)</ci>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Term Measure="month">12</Term>
                <History>
                  <Term Measure="patient's lifetime"/>
                  <Maximum>2</Maximum>
                </History>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are
                unapproved indications </p>
                </div>
              </Case>
            </Request>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised on Special Authority.</p>
            </div>
            <Rule Type="TreatMax" Value="5" Attribute="Rx" Waiver="Special" xlink:href="SA1683"/>
            <Formulation ID="F160304117801" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Rule Type="FormMax" Value="8" Attribute="PSO"/>
              <Brand ID="B16030411780101" SoleSupply="2024-06-30">
                <Name>Zithromax</Name>
                <Pack ID="P204218" Specified="true" nzmt:ctpp_id="50008131000117103">
                  <Quantity>2</Quantity>
                  <Subsidy>2.57</Subsidy>
                  <Price>2.57</Price>
                  <Alternate>2.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160304117825" Rank="3" Units="ml" Weight="600">
              <Name>Grans for oral liq 200 mg per 5 ml (40 mg per ml)</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B16030411782525">
                <Name>Zithromax</Name>
                <Pack ID="P2144042" Specified="true" nzmt:ctpp_id="50024771000117100">
                  <Quantity>15</Quantity>
                  <Subsidy>16.97</Subsidy>
                  <Price>16.97</Price>
                  <Alternate>16.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160304117826" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B16030411782625">
                <Name>Apo-Azithromycin</Name>
                <Pack ID="P2405296" Specified="true" nzmt:ctpp_id="50148261000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>8.19</Subsidy>
                  <Price>8.19</Price>
                  <Alternate>8.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603042790">
            <Name>Roxithromycin</Name>
            <Formulation ID="F160304279001" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B16030427900126" PSS="2026-06-30">
                <Name>Arrow-Roxithromycin</Name>
                <Pack ID="P2246236" Specified="true" nzmt:ctpp_id="50039301000117105">
                  <Quantity>50</Quantity>
                  <Subsidy>13.19</Subsidy>
                  <Price>13.19</Price>
                  <Alternate>13.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160304279002" Rank="1" Units="tab" Weight="300">
              <Name>Tab 300 mg</Name>
              <Brand ID="B16030427900226" PSS="2026-06-30">
                <Name>Arrow-Roxithromycin</Name>
                <Pack ID="P2246228" Specified="true" nzmt:ctpp_id="50039291000117109">
                  <Quantity>50</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603042809">
            <Name>Clarithromycin</Name>
            <Request To="HealthPAC" For="Waiver of Rule" Form="SA1857">
              <Title>
                <range>Clarithromycin</range>
              </Title>
              <Case When="Initial application" Category="Mycobacterial infections">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Atypical mycobacterial infection</ci>
                    <ci type="logical" class="Indication">Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents</ci>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Helicobacter pylori eradication">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">For the eradication of helicobacter pylori in a patient unable to swallow tablets</ci>
                    <ci type="logical" class="Indication">For use only in combination with omeprazole and amoxicillin as part of a triple therapy regimen</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="Prophylaxis of infective endocarditis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="Mycobacterial infections" Form="SA0070 SA0394 SA0443 SA0657 SA0988 SA1131 SA1857">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Rule Type="FormWt" Value="500" Attribute="Rx" Waiver="Special" xlink:href="SA1857"/>
            <Formulation ID="F160304280901" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B16030428090101" SoleSupply="2027-06-30">
                <Name>Klacid</Name>
                <Pack ID="P2606038" Specified="true" nzmt:ctpp_id="50122311000117108">
                  <Quantity>14</Quantity>
                  <Subsidy>8.53</Subsidy>
                  <Price>8.53</Price>
                  <Alternate>8.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160304280926" Rank="3" Units="ml" Weight="50">
              <Name>Grans for oral liq 250 mg per 5 ml</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B16030428092625">
                <Name>Klacid</Name>
                <Pack ID="P2535378" Specified="true" nzmt:ctpp_id="50231241000117107">
                  <Quantity>50</Quantity>
                  <Subsidy>192.00</Subsidy>
                  <Price>192.00</Price>
                  <Alternate>192.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603046026">
            <Name>Erythromycin ethyl succinate</Name>
            <Formulation ID="F160304602601" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Rule Type="FormMax" Value="20" Attribute="PSO"/>
              <Rule Type="RFPP" Value="2"/>
              <Brand ID="B16030460260102">
                <Name>E-Mycin</Name>
                <Pack ID="P243094" Specified="true" nzmt:ctpp_id="50051701000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>16.95</Subsidy>
                  <Price>16.95</Price>
                  <Alternate>16.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160304602603" Rank="3" Units="ml" Weight="40">
              <Name>Grans for oral liq 200 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="300" Attribute="PSO"/>
              <Rule Type="RFPP" Value="2"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030460260302">
                <Name>E-Mycin</Name>
                <Pack ID="P2618877" Specified="true" nzmt:ctpp_id="50051681000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>5.00</Subsidy>
                  <Price>5.00</Price>
                  <Alternate>5.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160304602605" Rank="3" Units="ml" Weight="80">
              <Name>Grans for oral liq 400 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030460260502">
                <Name>E-Mycin</Name>
                <Pack ID="P2618869" Specified="true" nzmt:ctpp_id="50051691000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>6.77</Subsidy>
                  <Price>6.77</Price>
                  <Alternate>6.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603046028">
            <Name>Erythromycin (as lactobionate)</Name>
            <Formulation ID="F160304602802" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g vial</Name>
              <Brand ID="B16030460280225" PSS="2025-06-30">
                <Name>Erythrocin IV</Name>
                <Pack ID="P2270234" Specified="true" nzmt:ctpp_id="50042201000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>10.00</Subsidy>
                  <Price>10.00</Price>
                  <Alternate>10.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A160307">
          <Name>Penicillins</Name>
          <Chemical ID="C1603071070">
            <Name>Amoxicillin with clavulanic acid</Name>
            <Formulation ID="F160307107001" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg with clavulanic acid 125 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16030710700126" PSS="2026-06-30">
                <Name>Curam Duo 500/125</Name>
                <Pack ID="P2602121" Specified="true" nzmt:ctpp_id="50135811000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>1.59</Subsidy>
                  <Price>1.59</Price>
                  <Alternate>1.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107002" Rank="3" Units="ml">
              <Name>Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25 mg per ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030710700201">
                <Name>Augmentin</Name>
                <Pack ID="P319473" Specified="true" nzmt:ctpp_id="50071531000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107004" Rank="3" Units="ml">
              <Name>Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 mg per ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Brand ID="B16030710700425">
                <Name>Curam</Name>
                <Pack ID="P2327945" Specified="true" OP="true" nzmt:ctpp_id="50049221000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>2.20</Subsidy>
                  <Price>2.20</Price>
                  <Alternate>2.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603071072">
            <Name>Amoxicillin</Name>
            <Formulation ID="F160307107202" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Rule Type="RFPP" Value="10"/>
              <Brand ID="B16030710720226" ToBeDelisted="2024-05-01">
                <Name>Alphamox</Name>
                <Pack ID="P2362716" Specified="true" nzmt:ctpp_id="50119781000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>43.45</Subsidy>
                  <Price>43.45</Price>
                  <Alternate>43.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16030710720227" ToBePSS="2024-05-01">
                <Name>Miro-Amoxicillin</Name>
                <Pack ID="P2669617" Specified="true" nzmt:ctpp_id="50309481000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>27.50</Subsidy>
                  <Price>27.50</Price>
                  <Alternate>27.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107203" Rank="2" Units="cap" Weight="500">
              <Name>Cap 500 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Rule Type="RFPP" Value="10"/>
              <Brand ID="B16030710720326" ToBeDelisted="2024-05-01">
                <Name>Alphamox</Name>
                <Pack ID="P2362724" Specified="true" nzmt:ctpp_id="50119791000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>66.44</Subsidy>
                  <Price>66.44</Price>
                  <Alternate>66.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16030710720327" ToBePSS="2024-05-01">
                <Name>Miro-Amoxicillin</Name>
                <Pack ID="P2669625" Specified="true" nzmt:ctpp_id="50309491000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>41.00</Subsidy>
                  <Price>41.00</Price>
                  <Alternate>41.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107205" Rank="3" Units="ml">
              <Name>Grans for oral liq 125 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030710720530" PSS="2026-06-30">
                <Name>Alphamox 125</Name>
                <Pack ID="P2503557" Specified="true" nzmt:ctpp_id="50209451000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>2.22</Subsidy>
                  <Price>2.22</Price>
                  <Alternate>2.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107206" Rank="3" Units="ml">
              <Name>Grans for oral liq 250 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="300" Attribute="PSO"/>
              <Rule Type="RFPP" Value="10"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030710720629" PSS="2026-06-30">
                <Name>Alphamox 250</Name>
                <Pack ID="P2503565" Specified="true" nzmt:ctpp_id="50209441000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>2.81</Subsidy>
                  <Price>2.81</Price>
                  <Alternate>2.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107208" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g vial</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B16030710720801">
                <Name>Ibiamox</Name>
                <Pack ID="P2272636" Specified="true" nzmt:ctpp_id="50042761000117101">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>21.64</Subsidy>
                  <Price>21.64</Price>
                  <Alternate>21.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107209" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B16030710720901">
                <Name>Ibiamox</Name>
                <Pack ID="P2272601" Specified="true" nzmt:ctpp_id="50042741000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>17.43</Subsidy>
                  <Price>17.43</Price>
                  <Alternate>17.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307107210" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 mg vial</Name>
              <Brand ID="B16030710721001">
                <Name>Ibiamox</Name>
                <Pack ID="P2272628" Specified="true" nzmt:ctpp_id="50042751000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>15.97</Subsidy>
                  <Price>15.97</Price>
                  <Alternate>15.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603071120">
            <Name>Benzathine benzylpenicillin</Name>
            <Formulation ID="F160307112002" Rank="4" Units="inj" Weight="1200000">
              <Name>Inj 900 mg (1.2 million units) in 2.3 ml syringe</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B16030711200225">
                <Name>Bicillin LA</Name>
                <Pack ID="P2258072" Specified="true" nzmt:ctpp_id="50040811000117107">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>375.97</Subsidy>
                  <Price>375.97</Price>
                  <Alternate>375.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603071136">
            <Name>Benzylpenicillin sodium [Penicillin G]</Name>
            <Formulation ID="F160307113601" Rank="4" Units="inj" Weight="600">
              <Name>Inj 600 mg (1 million units) vial</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B16030711360101" PSS="2026-06-30">
                <Name>Sandoz</Name>
                <Pack ID="P433748" Specified="true" nzmt:ctpp_id="50085141000117102">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>16.50</Subsidy>
                  <Price>16.50</Price>
                  <Alternate>16.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603071512">
            <Name>Flucloxacillin</Name>
            <Formulation ID="F160307151201" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16030715120125" PSS="2024-06-30">
                <Name>Flucloxacillin-AFT</Name>
                <Pack ID="P2335573" Specified="true" nzmt:ctpp_id="50049681000117107">
                  <Quantity>250</Quantity>
                  <Subsidy>15.79</Subsidy>
                  <Price>15.79</Price>
                  <Alternate>15.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307151202" Rank="2" Units="cap" Weight="500">
              <Name>Cap 500 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16030715120225" PSS="2024-06-30">
                <Name>Flucloxacillin-AFT</Name>
                <Pack ID="P2224186" Specified="true" nzmt:ctpp_id="50035611000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>52.99</Subsidy>
                  <Price>52.99</Price>
                  <Alternate>52.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307151203" Rank="3" Units="ml">
              <Name>Grans for oral liq 25 mg per ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030715120325" PSS="2024-06-30">
                <Name>AFT</Name>
                <Pack ID="P2072270" nzmt:ctpp_id="50012101000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>2.49</Subsidy>
                  <Price>2.49</Price>
                  <Alternate>2.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2431424" Specified="true" nzmt:ctpp_id="50157801000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>3.29</Subsidy>
                  <Price>3.29</Price>
                  <Alternate>3.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307151204" Rank="3" Units="ml">
              <Name>Grans for oral liq 50 mg per ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030715120425" PSS="2024-06-30">
                <Name>AFT</Name>
                <Pack ID="P2072262" nzmt:ctpp_id="50012091000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>3.25</Subsidy>
                  <Price>3.25</Price>
                  <Alternate>3.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2431432" Specified="true" nzmt:ctpp_id="50157811000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>3.68</Subsidy>
                  <Price>3.68</Price>
                  <Alternate>3.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307151205" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 mg vial</Name>
              <Brand ID="B16030715120502">
                <Name>Flucloxin</Name>
                <Pack ID="P331848" Specified="true" nzmt:ctpp_id="50073551000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>42.60</Subsidy>
                  <Price>42.60</Price>
                  <Alternate>42.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307151206" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B16030715120602">
                <Name>Flucloxin</Name>
                <Pack ID="P331856" Specified="true" nzmt:ctpp_id="50073561000117102">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>45.63</Subsidy>
                  <Price>45.63</Price>
                  <Alternate>45.63</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307151207" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g vial</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B16030715120726" PSS="2026-06-30">
                <Name>Flucil</Name>
                <Pack ID="P2523108" Specified="true" nzmt:ctpp_id="50197411000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603071970">
            <Name>Phenoxymethylpenicillin (Penicillin V)</Name>
            <Formulation ID="F160307197025" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16030719702525" PSS="2024-06-30">
                <Name>Cilicaine VK</Name>
                <Pack ID="P2602865" Specified="true" nzmt:ctpp_id="50009051000117102">
                  <Quantity>50</Quantity>
                  <Subsidy>3.84</Subsidy>
                  <Price>3.84</Price>
                  <Alternate>3.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307197026" Rank="2" Units="cap" Weight="500">
              <Name>Cap 500 mg</Name>
              <Rule Type="FormMax" Value="20" Attribute="PSO"/>
              <Rule Type="RFPP" Value="2"/>
              <Brand ID="B16030719702625" PSS="2024-06-30">
                <Name>Cilicaine VK</Name>
                <Pack ID="P2602873" Specified="true" nzmt:ctpp_id="50009061000117100">
                  <Quantity>50</Quantity>
                  <Subsidy>6.86</Subsidy>
                  <Price>6.86</Price>
                  <Alternate>6.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307197027" Rank="3" Units="ml" Weight="125">
              <Name>Grans for oral liq 125 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030719702725" PSS="2025-06-30">
                <Name>AFT</Name>
                <Pack ID="P2029219" Specified="true" nzmt:ctpp_id="50005731000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>3.40</Subsidy>
                  <Price>3.40</Price>
                  <Alternate>3.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160307197028" Rank="3" Units="ml" Weight="250">
              <Name>Grans for oral liq 250 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="300" Attribute="PSO"/>
              <Rule Type="RFPP" Value="2"/>
              <Rule Type="Wastage"/>
              <Brand ID="B16030719702825" PSS="2025-06-30">
                <Name>AFT</Name>
                <Pack ID="P2029227" Specified="true" nzmt:ctpp_id="50005741000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>4.24</Subsidy>
                  <Price>4.24</Price>
                  <Alternate>4.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A160310">
          <Name>Tetracyclines</Name>
          <Chemical ID="C1603101828" Statim="Must">
            <Name>Minocycline hydrochloride</Name>
            <Formulation ID="F160310182801" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Rule Attribute="Price" Type="Special" xlink:href="SA1355"/>
              <Request To="HealthPAC" For="Manufacturers Price" Form="SA1355">
                <Title>
                  <range>Minocycline hydrochloride Tab 50 mg</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The patient has rosacea</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="patient's lifetime"/>
                </Case>
              </Request>
              <Brand ID="B16031018280101">
                <Name>Mino-tabs</Name>
                <Pack ID="P472212" Specified="true" nzmt:ctpp_id="50088931000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>5.79</Subsidy>
                  <Price>12.05</Price>
                  <Alternate>12.05</Alternate>
                  <Surcharge>0.10433</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160310182802" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B16031018280201">
                <Name>Minomycin</Name>
                <Pack ID="P690805" Specified="true" nzmt:ctpp_id="50102081000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>19.32</Subsidy>
                  <Price>52.04</Price>
                  <Alternate>19.32</Alternate>
                  <Surcharge>0.32720</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603102529" Statim="Must">
            <Name>Doxycycline</Name>
            <Formulation ID="F160310252904" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16031025290401">
                <Name>Doxine</Name>
                <Pack ID="P2545136" Specified="true" nzmt:ctpp_id="50260471000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>64.43</Subsidy>
                  <Price>64.43</Price>
                  <Alternate>64.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603103999">
            <Name>Tetracycline</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1332"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1332">
              <Title>
                <range>Tetracycline</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci>
                    <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
            </Request>
            <Formulation ID="F160310399926" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B16031039992625" S29="true">
                <Name>Accord</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2587106" Specified="true" nzmt:ctpp_id="50275531000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>58.20</Subsidy>
                  <Price>58.20</Price>
                  <Alternate>58.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A160313">
          <Name>Other Antibiotics</Name>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
            <p xlink:type="simple" xlink:href="A1004">For topical antibiotics, refer to DERMATOLOGICALS</p>
          </div>
          <Chemical ID="C1603131303">
            <Name>Clindamycin</Name>
            <Formulation ID="F160313130301" Rank="2" Units="cap" Weight="150">
              <Name>Cap hydrochloride 150 mg</Name>
              <Brand ID="B16031313030101">
                <Name>Dalacin C</Name>
                <Pack ID="P2576392" Specified="true" nzmt:ctpp_id="50149351000117103">
                  <Quantity>24</Quantity>
                  <Subsidy>5.30</Subsidy>
                  <Price>5.30</Price>
                  <Alternate>5.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160313130303" Rank="4" Units="inj">
              <Name>Inj 150 mg per ml, 4 ml ampoule</Name>
              <Brand ID="B16031313030302" PSS="2025-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2646595" Specified="true" nzmt:ctpp_id="50288101000117100">
                  <Quantity>10</Quantity>
                  <Subsidy>35.10</Subsidy>
                  <Price>35.10</Price>
                  <Alternate>35.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603131346">
            <Name>Colistin sulphomethate</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F160313134601" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg</Name>
              <Brand ID="B16031313460125">
                <Name>Colistin-Link</Name>
                <Pack ID="P2245418" Specified="true" nzmt:ctpp_id="50039011000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>65.00</Subsidy>
                  <Price>65.00</Price>
                  <Alternate>65.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603131361" Statim="Must">
            <Name>Trimethoprim with sulphamethoxazole [Co-trimoxazole]</Name>
            <Formulation ID="F160313136101" Rank="3" Units="ml">
              <Name>Oral liq 8 mg sulphamethoxazole 40 mg per ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Brand ID="B16031313610125">
                <Name>Deprim</Name>
                <Pack ID="P2309718" Specified="true" nzmt:ctpp_id="50046921000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>2.97</Subsidy>
                  <Price>2.97</Price>
                  <Alternate>2.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160313136102" Rank="1" Units="tab" Weight="80">
              <Name>Tab trimethoprim 80 mg and sulphamethoxazole 400 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16031313610201" PSS="2024-06-30">
                <Name>Trisul</Name>
                <Pack ID="P283363" Specified="true" nzmt:ctpp_id="50063251000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>64.80</Subsidy>
                  <Price>64.80</Price>
                  <Alternate>64.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603131546">
            <Name>Sodium Fusidate [fusidic acid]</Name>
            <Formulation ID="F160313154601" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B16031315460101">
                <Name>Fucidin</Name>
                <Pack ID="P2621053" Specified="true" nzmt:ctpp_id="50053361000117105">
                  <Quantity>36</Quantity>
                  <Subsidy>135.70</Subsidy>
                  <Price>135.70</Price>
                  <Alternate>135.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603131554">
            <Name>Gentamicin sulphate</Name>
            <Formulation ID="F160313155401" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 1 ml ampoule</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B16031315540101">
                <Name>DBL Gentamicin</Name>
                <Pack ID="P619272" Specified="true" nzmt:ctpp_id="50099521000117102">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>95.00</Subsidy>
                  <Price>95.00</Price>
                  <Alternate>95.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160313155403" Rank="4" Units="inj" Weight="80">
              <Name>Inj 40 mg per ml, 2 ml ampoule</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B16031315540301">
                <Name>Pfizer</Name>
                <Pack ID="P771740" Specified="true" nzmt:ctpp_id="50111891000117109">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>18.38</Subsidy>
                  <Price>18.38</Price>
                  <Alternate>18.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2498588" Specified="true" nzmt:ctpp_id="50154141000117100">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>87.50</Subsidy>
                  <Price>87.50</Price>
                  <Alternate>87.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160313155425" Rank="4" Units="inj" Weight="20">
              <Name>Inj 10 mg per ml, 2 ml ampoule</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B16031315542525" S29="true">
                <Name>Teligent</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2584018" Specified="true" nzmt:ctpp_id="50274191000117107">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>182.00</Subsidy>
                  <Price>182.00</Price>
                  <Alternate>182.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16031315542526" S29="true">
                <Name>Wockhardt</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2619369" Specified="true" nzmt:ctpp_id="50257701000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>91.00</Subsidy>
                  <Price>91.00</Price>
                  <Alternate>91.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603132274">
            <Name>Tobramycin</Name>
            <Formulation ID="F160313227402" Rank="4" Units="inj" Weight="80">
              <Name>Inj 40 mg per ml, 2 ml vial</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B16031322740226" PSS="2024-06-30">
                <Name>Viatris</Name>
                <Pack ID="P2635690" Specified="true" nzmt:ctpp_id="50290891000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>18.50</Subsidy>
                  <Price>18.50</Price>
                  <Alternate>18.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160313227425" Rank="6" Units="dose">
              <Name>Solution for inhalation 60 mg per ml, 5 ml</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly.</p>
              </div>
              <Rule Type="Wastage"/>
              <Brand ID="B16031322742526" PSS="2026-06-30">
                <Name>Tobramycin BNM</Name>
                <Pack ID="P2601648" Specified="true" nzmt:ctpp_id="50257571000117107">
                  <Quantity>56</Quantity>
                  <Subsidy>395.00</Subsidy>
                  <Price>395.00</Price>
                  <Alternate>395.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603132300" Statim="Must">
            <Name>Trimethoprim</Name>
            <Formulation ID="F160313230002" Rank="1" Units="tab" Weight="300">
              <Name>Tab 300 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16031323000202" PSS="2024-06-30">
                <Name>TMP</Name>
                <Pack ID="P648507" Specified="true" nzmt:ctpp_id="50100371000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>18.55</Subsidy>
                  <Price>18.55</Price>
                  <Alternate>18.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603132314">
            <Name>Vancomycin</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F160313231403" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B16031323140325" PSS="2026-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2195267" Specified="true" nzmt:ctpp_id="50031261000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3.38</Subsidy>
                  <Price>3.38</Price>
                  <Alternate>3.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603132819">
            <Name>Ciprofloxacin</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Recommended for patients with any of the following:</p>
              <ol style="list-style-type: lower-roman">
                <li>
                  <p>microbiologically confirmed and clinically significant pseudomonas infection; or</p>
                </li>
                <li>
                  <p>prostatitis; or</p>
                </li>
                <li>
                  <p>pyelonephritis; or</p>
                </li>
                <li>
                  <p>gonorrhoea.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F160313281901" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B16031328190125">
                <Name>Cipflox</Name>
                <Pack ID="P2104997" Specified="true" nzmt:ctpp_id="50018831000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>2.42</Subsidy>
                  <Price>2.42</Price>
                  <Alternate>2.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16031328190127" S29="true">
                <Name>Ciprofloxacin - Torrent</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2672022" Specified="true" nzmt:ctpp_id="50328471000117101">
                  <Quantity>10</Quantity>
                  <Subsidy>3.85</Subsidy>
                  <Price>3.85</Price>
                  <Alternate>3.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160313281902" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B16031328190225" ToBeDelisted="2024-04-01">
                <Name>Cipflox</Name>
                <Pack ID="P2105004" Specified="true" nzmt:ctpp_id="50018841000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>3.40</Subsidy>
                  <Price>3.40</Price>
                  <Alternate>3.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16031328190227" S29="true">
                <Name>Ciprofloxacin - Torrent</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2664615" Specified="true">
                  <Quantity>10</Quantity>
                  <Subsidy>4.25</Subsidy>
                  <Price>4.25</Price>
                  <Alternate>4.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160313281903" Rank="1" Units="tab" Weight="750">
              <Name>Tab 750 mg</Name>
              <Brand ID="B16031328190325">
                <Name>Cipflox</Name>
                <Pack ID="P2105012" Specified="true" nzmt:ctpp_id="50018861000117103">
                  <Quantity>28</Quantity>
                  <Subsidy>5.95</Subsidy>
                  <Price>5.95</Price>
                  <Alternate>5.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603133925">
            <Name>Moxifloxacin</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1740"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1740">
              <Title>
                <range>Moxifloxacin</range>
              </Title>
              <Case When="Initial application" Category="Tuberculosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Active tuberculosis*</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Documented resistance to one or more first-line medications</ci>
                        <ci type="logical" class="Indication">Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as
                            part of regimen containing other second-line agents</ci>
                        <ci type="logical" class="Indication">Impaired visual acuity (considered to preclude ethambutol use)</ci>
                        <ci type="logical" class="Indication">Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications</ci>
                        <ci type="logical" class="Indication">Significant documented intolerance and/or side effects following a reasonable trial of first-line medications</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*</ci>
                    <ci type="logical" class="Indication">Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case</ci>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Term Measure="year">1</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1065 SA1358 SA1740">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Term Measure="year">1</Term>
              </Case>
              <Case When="Initial application" Category="Mycoplasma genitalium">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Has tried and failed to clear infection using azithromycin</ci>
                      <ci type="logical" class="Indication">Has laboratory confirmed azithromycin resistance</ci>
                    </apply>
                    <ci type="logical" class="Indication">Treatment is only for 7 days</ci>
                  </apply>
                </math>
                <Applicant>sexual health specialist</Applicant>
                <Applicant Referring="sexual health specialist">Practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Initial application" Category="Penetrating eye injury">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only</ci>
                </math>
                <Applicant>ophthalmologist</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Indications marked with * are unapproved indications.</p>
              </div>
            </Request>
            <Formulation ID="F160313392525" Rank="1" Units="tab">
              <Name>Tab 400 mg</Name>
              <Brand ID="B16031339252525">
                <Name>Avelox</Name>
                <Pack ID="P2022362" Specified="true" nzmt:ctpp_id="50004501000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>42.00</Subsidy>
                  <Price>42.00</Price>
                  <Alternate>42.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603133992">
            <Name>Pyrimethamine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1328"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1328">
              <Title>
                <range>Pyrimethamine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">For the treatment of toxoplasmosis in patients with HIV for a period of 3 months</ci>
                    <ci type="logical" class="Indication">For pregnant patients for the term of the pregnancy</ci>
                    <ci type="logical" class="Indication">For infants with congenital toxoplasmosis until 12 months of age</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F160313399225" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B16031339922525" S29="true">
                <Name>Daraprim</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2086883" Specified="true" nzmt:ctpp_id="50015191000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>48.00</Subsidy>
                  <Price>48.00</Price>
                  <Alternate>48.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603133993">
            <Name>Sulfadiazine sodium</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1331"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1331">
              <Title>
                <range>Sulfadiazine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">For the treatment of toxoplasmosis in patients with HIV for a period of 3 months</ci>
                    <ci type="logical" class="Indication">For pregnant patients for the term of the pregnancy</ci>
                    <ci type="logical" class="Indication">For infants with congenital toxoplasmosis until 12 months of age</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F160313399325" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B16031339932525" S29="true">
                <Name>Wockhardt</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2034441" Specified="true" nzmt:ctpp_id="50006851000117102">
                  <Quantity>56</Quantity>
                  <Subsidy>543.20</Subsidy>
                  <Price>543.20</Price>
                  <Alternate>543.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1603133998">
            <Name>Paromomycin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1689"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1689">
              <Title>
                <range>Paromomycin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient has confirmed cryptosporidium infection</ci>
                    <ci type="logical" class="Indication">For the eradication of Entamoeba histolyica carriage</ci>
                  </apply>
                </math>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Applicant>gastroenterologist</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Renewal" Form="SA1324 SA1689">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient has confirmed cryptosporidium infection</ci>
                    <ci type="logical" class="Indication">For the eradication of Entamoeba histolyica carriage</ci>
                  </apply>
                </math>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Applicant>gastroenterologist</Applicant>
                <Term Measure="month">1</Term>
              </Case>
            </Request>
            <Formulation ID="F160313399825" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B16031339982525" S29="true">
                <Name>Humatin</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2434652" Specified="true" nzmt:ctpp_id="50164581000117106">
                  <Quantity>16</Quantity>
                  <Subsidy>126.00</Subsidy>
                  <Price>126.00</Price>
                  <Alternate>126.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1604">
        <Name>Antifungals</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1007">For topical antifungals refer to DERMATOLOGICALS</p>
        </div>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1310">For topical antifungals refer to GENITO URINARY</p>
        </div>
        <ATC3 ID="A160401">
          <Name>Antifungals</Name>
          <Chemical ID="C1604011696">
            <Name>Ketoconazole</Name>
            <Formulation ID="F160401169601" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Rule Type="PCT"/>
              <Brand ID="B16040116960126" S29="true">
                <Name>Strides Shasun</Name>
                <Pack ID="P2592010" Specified="true" CBS="true" nzmt:ctpp_id="50277561000117100">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B16040116960127" S29="true">
                <Name>Taro</Name>
                <Pack ID="P2650924" Specified="true" CBS="true" nzmt:ctpp_id="50275381000117105">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B16040116960128" S29="true">
                <Name>Burel</Name>
                <Pack ID="P2652242" Specified="true" CBS="true" nzmt:ctpp_id="50310261000117103">
                  <Quantity>30</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B16040116960129" S29="true">
                <Name>Teva-Ketoconazole</Name>
                <Pack ID="P2168626" Specified="true" CBS="true" nzmt:ctpp_id="50320521000117101">
                  <Quantity>100</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1604011881">
            <Name>Nystatin</Name>
            <Formulation ID="F160401188125" Rank="1" Units="tab" Weight="500000">
              <Name>Tab 500,000 u</Name>
              <Brand ID="B16040118812502">
                <Name>Nilstat</Name>
                <Pack ID="P770752" Specified="true" nzmt:ctpp_id="50111711000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>14.16</Subsidy>
                  <Price>17.09</Price>
                  <Alternate>14.16</Alternate>
                  <Surcharge>0.05860</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401188126" Rank="2" Units="cap" Weight="500000">
              <Name>Cap 500,000 u</Name>
              <Brand ID="B16040118812601">
                <Name>Nilstat</Name>
                <Pack ID="P648345" Specified="true" nzmt:ctpp_id="50100311000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>12.81</Subsidy>
                  <Price>15.47</Price>
                  <Alternate>12.81</Alternate>
                  <Surcharge>0.05320</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1604012709">
            <Name>Fluconazole</Name>
            <Formulation ID="F160401270901" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B16040127090125" PSS="2026-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2149060" Specified="true" nzmt:ctpp_id="50025741000117107">
                  <Quantity>28</Quantity>
                  <Subsidy>4.10</Subsidy>
                  <Price>4.10</Price>
                  <Alternate>4.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401270902" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B16040127090225" PSS="2026-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2149079" Specified="true" nzmt:ctpp_id="50025751000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>0.45</Subsidy>
                  <Price>0.45</Price>
                  <Alternate>0.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401270903" Rank="2" Units="cap" Weight="200">
              <Name>Cap 200 mg</Name>
              <Brand ID="B16040127090325" PSS="2026-06-30">
                <Name>Mylan</Name>
                <Pack ID="P2149052" Specified="true" nzmt:ctpp_id="50025731000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>8.90</Subsidy>
                  <Price>8.90</Price>
                  <Alternate>8.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401270925" Rank="3" Units="ml">
              <Name>Powder for oral suspension 10 mg per ml</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1359"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1359">
                <Title>
                  <range>Fluconazole oral liquid</range>
                </Title>
                <Case When="Initial application" Category="Systemic candidiasis">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient requires prophylaxis for, or treatment of systemic candidiasis</ci>
                      <ci type="logical" class="Use">Patient is unable to swallow capsules</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="week">6</Term>
                </Case>
                <Case When="Initial application" Category="Immunocompromised">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient is immunocompromised</ci>
                      <ci type="logical" class="Indication">Patient is at moderate to high risk of invasive fungal infection</ci>
                      <ci type="logical" class="Indication">Patient is unable to swallow capsules</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
                <Case When="Renewal" Form="SA1148 SA1359" Category="Systemic candidiasis">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient requires prophylaxis for, or treatment of systemic candidiasis</ci>
                      <ci type="logical" class="Use">Patient is unable to swallow capsules</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="week">6</Term>
                </Case>
                <Case When="Renewal" Form="SA1148 SA1359" Category="Immunocompromised">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient remains immunocompromised</ci>
                      <ci type="logical" class="Indication">Patient remains at moderate to high risk of invasive fungal infection</ci>
                      <ci type="logical" class="Indication">Patient is unable to swallow capsules</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
              </Request>
              <Rule Type="Wastage"/>
              <Brand ID="B16040127092525">
                <Name>Diflucan</Name>
                <Pack ID="P950289" Specified="true" nzmt:ctpp_id="50118661000117107">
                  <Quantity>35</Quantity>
                  <Subsidy>129.02</Subsidy>
                  <Price>129.02</Price>
                  <Alternate>129.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1604012803">
            <Name>Itraconazole</Name>
            <Formulation ID="F160401280301" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B16040128030125">
                <Name>Itrazole</Name>
                <Pack ID="P2354322" Specified="true" nzmt:ctpp_id="50121121000117106">
                  <Quantity>15</Quantity>
                  <Subsidy>6.83</Subsidy>
                  <Price>6.83</Price>
                  <Alternate>6.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401280325" Rank="3" Units="ml" Weight="10">
              <Name>Oral liq 10 mg per ml</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1322"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1322">
                <Title>
                  <range>Itraconazole</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci>
                  </math>
                  <Applicant>infectious disease specialist</Applicant>
                  <Applicant>clinical microbiologist</Applicant>
                  <Applicant>clinical immunologist</Applicant>
                  <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
                <Case When="Renewal" Form="SA1322">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="month">6</Term>
                </Case>
              </Request>
              <Brand ID="B16040128032525">
                <Name>Sporanox</Name>
                <Pack ID="P485411" Specified="true" OP="true" nzmt:ctpp_id="50091121000117109">
                  <Quantity>150</Quantity>
                  <Subsidy>141.80</Subsidy>
                  <Price>141.80</Price>
                  <Alternate>141.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1604012830" Statim="Must">
            <Name>Terbinafine</Name>
            <Formulation ID="F160401283001" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B16040128300126" S29="true">
                <Name>Apo-Terbinafine</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2672537" Specified="true" nzmt:ctpp_id="50328721000117105">
                  <Quantity>42</Quantity>
                  <Subsidy>4.48</Subsidy>
                  <Price>4.48</Price>
                  <Alternate>4.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16040128300128" PSS="2026-06-30">
                <Name>Deolate</Name>
                <Pack ID="P2597160" Specified="true" nzmt:ctpp_id="50275841000117105">
                  <Quantity>84</Quantity>
                  <Subsidy>8.97</Subsidy>
                  <Price>8.97</Price>
                  <Alternate>8.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1604013978">
            <Name>Voriconazole</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1273"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1273">
              <Title>
                <range>Voriconazole</range>
              </Title>
              <Case When="Initial application" Category="invasive fungal infection">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is immunocompromised</ci>
                    <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci>
                      <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci>
                      <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci>
                      <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Form="SA1273" Category="invasive fungal infection">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is immunocompromised</ci>
                    <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient continues to require treatment for proven or probable invasive aspergillus infection</ci>
                      <ci type="logical" class="Indication">Patient continues to require treatment for possible invasive aspergillus infection</ci>
                      <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci>
                      <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
            </Request>
            <Formulation ID="F160401397825" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B16040139782526">
                <Name>Vttack</Name>
                <Pack ID="P2474867" Specified="true" nzmt:ctpp_id="50150701000117106">
                  <Quantity>56</Quantity>
                  <Subsidy>91.00</Subsidy>
                  <Price>91.00</Price>
                  <Alternate>91.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401397826" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B16040139782626">
                <Name>Vttack</Name>
                <Pack ID="P2474875" Specified="true" nzmt:ctpp_id="50150801000117100">
                  <Quantity>56</Quantity>
                  <Subsidy>350.00</Subsidy>
                  <Price>350.00</Price>
                  <Alternate>350.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401397827" Rank="3" Units="ml" Weight="40">
              <Name>Powder for oral suspension 40 mg per ml</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B16040139782725">
                <Name>Vfend</Name>
                <Pack ID="P2349639" Specified="true" nzmt:ctpp_id="50120351000117108">
                  <Quantity>70</Quantity>
                  <Subsidy>1523.22</Subsidy>
                  <Price>1523.22</Price>
                  <Alternate>1523.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1604013989">
            <Name>Posaconazole</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1285"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1285">
              <Title>
                <range>Posaconazole </range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci>
                    <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Term Measure="week">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1285">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci>
                    <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Term Measure="week">6</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>* Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.</p>
              </div>
            </Request>
            <Formulation ID="F160401398925" Rank="3" Units="ml" Weight="40">
              <Name>Oral liq 40 mg per ml</Name>
              <Brand ID="B16040139892526" PSS="2025-06-30">
                <Name>Devatis</Name>
                <Pack ID="P2645181" Specified="true" OP="true" nzmt:ctpp_id="50276851000117103">
                  <Quantity>105</Quantity>
                  <Subsidy>342.51</Subsidy>
                  <Price>342.51</Price>
                  <Alternate>342.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F160401398926" Rank="1" Units="tab" Weight="100">
              <Name>Tab modified-release 100 mg</Name>
              <Brand ID="B16040139892626" PSS="2025-06-30">
                <Name>Posaconazole Juno</Name>
                <Pack ID="P2631008" Specified="true" nzmt:ctpp_id="50281921000117100">
                  <Quantity>24</Quantity>
                  <Subsidy>206.00</Subsidy>
                  <Price>206.00</Price>
                  <Alternate>206.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1610">
        <Name>Antimalarials</Name>
        <ATC3 ID="A161001">
          <Name>Antimalarials</Name>
          <Chemical ID="C1610014002">
            <Name>Primaquine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1684"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1684">
              <Title>
                <range>Primaquine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci>
                    <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci>
                  </apply>
                </math>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Renewal" Form="SA1326 SA1684">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has relapsed vivax or ovale malaria</ci>
                    <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci>
                  </apply>
                </math>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>clinical microbiologist</Applicant>
                <Term Measure="month">1</Term>
              </Case>
            </Request>
            <Formulation ID="F161001400226" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B16100140022625" S29="true">
                <Name>Sanofi Primaquine</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2587637" Specified="true" nzmt:ctpp_id="50285771000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>400.00</Subsidy>
                  <Price>400.00</Price>
                  <Alternate>400.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1613">
        <Name>Antitrichomonal Agents</Name>
        <ATC3 ID="A161301">
          <Name>Antitrichomonal Agents</Name>
          <Chemical ID="C1613011820">
            <Name>Metronidazole</Name>
            <Formulation ID="F161301182001" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16130118200104">
                <Name>Metrogyl</Name>
                <Pack ID="P2580071" Specified="true" nzmt:ctpp_id="50257541000117101">
                  <Quantity>250</Quantity>
                  <Subsidy>33.15</Subsidy>
                  <Price>33.15</Price>
                  <Alternate>33.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161301182002" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Rule Type="FormMax" Value="15" Attribute="PSO"/>
              <Brand ID="B16130118200204">
                <Name>Metrogyl</Name>
                <Pack ID="P2580098" Specified="true" nzmt:ctpp_id="50257551000117104">
                  <Quantity>21</Quantity>
                  <Subsidy>5.23</Subsidy>
                  <Price>5.23</Price>
                  <Alternate>5.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161301182003" Rank="3" Units="ml" Weight="40">
              <Name>Oral liq benzoate 200 mg per 5 ml</Name>
              <Brand ID="B16130118200301">
                <Name>Flagyl-S</Name>
                <Pack ID="P729426" Specified="true" nzmt:ctpp_id="50106681000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161301182005" Rank="5" Units="supp" Weight="500">
              <Name>Suppos 500 mg</Name>
              <Brand ID="B16130118200501">
                <Name>Flagyl</Name>
                <Pack ID="P250511" Specified="true" nzmt:ctpp_id="50052391000117105">
                  <Quantity>10</Quantity>
                  <Subsidy>24.48</Subsidy>
                  <Price>24.48</Price>
                  <Alternate>24.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1613011906">
            <Name>Ornidazole</Name>
            <Formulation ID="F161301190601" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B16130119060125" PSS="2024-06-30">
                <Name>Arrow-Ornidazole</Name>
                <Pack ID="P2385325" Specified="true" nzmt:ctpp_id="50122911000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>36.16</Subsidy>
                  <Price>36.16</Price>
                  <Alternate>36.16</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1616">
        <Name>Antituberculotics and Antileprotics</Name>
        <ATC3 ID="A161601">
          <Name>Antituberculotics and Antileprotics</Name>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
            <p>Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status.</p>
          </div>
          <Chemical ID="C1616011312" Statim="Must">
            <Name>Clofazimine</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist.</p>
            </div>
            <Formulation ID="F161601131201" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B16160113120101" S29="true">
                <Name>Lamprene</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P654450" Specified="true" nzmt:ctpp_id="50100461000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>442.00</Subsidy>
                  <Price>442.00</Price>
                  <Alternate>442.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616011374">
            <Name>Dapsone</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist</p>
            </div>
            <Formulation ID="F161601137401" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B16160113740101">
                <Name>Dapsone</Name>
                <Pack ID="P712914" Specified="true" nzmt:ctpp_id="50104351000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>329.50</Subsidy>
                  <Price>329.50</Price>
                  <Alternate>329.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161601137425" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B16160113742525">
                <Name>Dapsone</Name>
                <Pack ID="P2212226" Specified="true" nzmt:ctpp_id="50033621000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>268.50</Subsidy>
                  <Price>268.50</Price>
                  <Alternate>268.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616011679" Statim="Must">
            <Name>Isoniazid</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician</p>
            </div>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F161601167901" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B16160116790101" PSS="2024-06-30">
                <Name>PSM</Name>
                <Pack ID="P267473" Specified="true" nzmt:ctpp_id="50059431000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>23.00</Subsidy>
                  <Price>23.00</Price>
                  <Alternate>23.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616011680" Statim="Must">
            <Name>Isoniazid with rifampicin</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician</p>
            </div>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F161601168002" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg with rifampicin 150 mg</Name>
              <Brand ID="B16160116800201" PSS="2024-06-30">
                <Name>Rifinah</Name>
                <Pack ID="P251232" Specified="true" nzmt:ctpp_id="50052701000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>89.82</Subsidy>
                  <Price>89.82</Price>
                  <Alternate>89.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161601168003" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg with rifampicin 300 mg</Name>
              <Brand ID="B16160116800301" PSS="2024-06-30">
                <Name>Rifinah</Name>
                <Pack ID="P251240" Specified="true" nzmt:ctpp_id="50052711000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>179.13</Subsidy>
                  <Price>179.13</Price>
                  <Alternate>179.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616012069" Statim="Must">
            <Name>Pyrazinamide</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician</p>
            </div>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F161601206901" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B16160120690125">
                <Name>AFT-Pyrazinamide</Name>
                <Pack ID="P2142023" Specified="true" nzmt:ctpp_id="50210191000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>64.95</Subsidy>
                  <Price>64.95</Price>
                  <Alternate>64.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616012088" Statim="Must">
            <Name>Rifampicin</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SubRxF" Waiver="SpecEnd"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For confirmed recurrent Staphylococcus aureus infection in combination with other effective anti-staphylococcal antimicrobial based on susceptibilities and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an internal medicine physician, clinical microbiologist, dermatologist, paediatrician, or public health physician.</p>
            </div>
            <Formulation ID="F161601208803" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B16160120880301" PSS="2026-06-30">
                <Name>Rifadin</Name>
                <Pack ID="P251186" Specified="true" nzmt:ctpp_id="50052651000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>58.54</Subsidy>
                  <Price>58.54</Price>
                  <Alternate>58.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161601208804" Rank="2" Units="cap" Weight="300">
              <Name>Cap 300 mg</Name>
              <Brand ID="B16160120880401" PSS="2026-06-30">
                <Name>Rifadin</Name>
                <Pack ID="P251194" Specified="true" nzmt:ctpp_id="50052661000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>122.06</Subsidy>
                  <Price>122.06</Price>
                  <Alternate>122.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16160120880402">
                <Name>Rifadin Sanofi</Name>
                <Pack ID="P2669838" Specified="true" nzmt:ctpp_id="50223041000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>122.06</Subsidy>
                  <Price>122.06</Price>
                  <Alternate>122.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161601208805" Rank="3" Units="ml">
              <Name>Oral liq 100 mg per 5 ml</Name>
              <Brand ID="B16160120880501" PSS="2026-06-30">
                <Name>Rifadin</Name>
                <Pack ID="P251208" Specified="true" nzmt:ctpp_id="50052671000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>12.60</Subsidy>
                  <Price>12.60</Price>
                  <Alternate>12.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616012854" Statim="Must">
            <Name>Rifabutin</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease physician, respiratory physician or gastroenterologist</p>
            </div>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F161601285401" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B16160128540101">
                <Name>Mycobutin</Name>
                <Pack ID="P219924" Specified="true" nzmt:ctpp_id="50031871000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>353.71</Subsidy>
                  <Price>353.71</Price>
                  <Alternate>353.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616013865">
            <Name>Ethambutol hydrochloride</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician</p>
            </div>
            <Formulation ID="F161601386525" Rank="1" Units="tab" Weight="56">
              <Name>Tab 400 mg</Name>
              <Brand ID="B16160138652525" S29="true">
                <Name>Myambutol</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2244969" Specified="true" nzmt:ctpp_id="50038861000117108">
                  <Quantity>56</Quantity>
                  <Subsidy>49.34</Subsidy>
                  <Price>49.34</Price>
                  <Alternate>49.34</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161601386526" Rank="1" Units="tab">
              <Name>Tab 100 mg</Name>
              <Brand ID="B16160138652626" S29="true">
                <Name>EMB Fatol</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2540746" Specified="true" nzmt:ctpp_id="50253281000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>85.73</Subsidy>
                  <Price>85.73</Price>
                  <Alternate>85.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616013994">
            <Name>Cycloserine</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.  </p>
            </div>
            <Formulation ID="F161601399425" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B16160139942526" S29="true">
                <Name>Cyclorin</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2566508" Specified="true" nzmt:ctpp_id="50291411000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>344.00</Subsidy>
                  <Price>344.00</Price>
                  <Alternate>344.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616014000">
            <Name>Para-amino salicylic acid</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician</p>
            </div>
            <Formulation ID="F161601400025" Rank="2" Units="sach" Weight="4">
              <Name>Grans for oral liq 4 g sachet</Name>
              <Brand ID="B16160140002525" S29="true">
                <Name>Paser</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2254921" Specified="true" nzmt:ctpp_id="50164571000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>280.00</Subsidy>
                  <Price>280.00</Price>
                  <Alternate>280.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616014001">
            <Name>Protionamide</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician</p>
            </div>
            <Formulation ID="F161601400125" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B16160140012525" S29="true">
                <Name>Peteha</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2086980" Specified="true">
                  <Quantity>100</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2434695" nzmt:ctpp_id="50164601000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616014179">
            <Name>Linezolid</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2234"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2234">
              <Title>
                <range>Linezolid</range>
              </Title>
              <Case When="Initial application" Category="multi-drug resistant tuberculosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The person has multi-drug resistant tuberculosis (MDR-TB)</ci>
                    <ci type="logical">ManatÅ« Hauora - Ministry of Healthâ€™s Tuberculosis Clinical Network has reviewed the individual case and recommends linezolid as part of the treatment regimen</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">18</Term>
              </Case>
            </Request>
            <Formulation ID="F161601417925" Rank="1" Units="Tab" Weight="600">
              <Name>Tab 600 mg</Name>
              <Brand ID="B16160141792525">
                <Name>Zyvox</Name>
                <Pack ID="P2058758" Specified="true" nzmt:ctpp_id="50010381000117104">
                  <Quantity>10</Quantity>
                  <Subsidy>276.89</Subsidy>
                  <Price>276.89</Price>
                  <Alternate>276.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161601417926" Rank="3" Units="ml" Weight="20">
              <Name>Oral liq 20 mg per ml</Name>
              <Brand ID="B16160141792625">
                <Name>Zyvox</Name>
                <Pack ID="P2058774" Specified="true" nzmt:ctpp_id="50010401000117104">
                  <Quantity>150</Quantity>
                  <Subsidy>1879.00</Subsidy>
                  <Price>1879.00</Price>
                  <Alternate>1879.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1616014180">
            <Name>Bedaquiline</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2244"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2244">
              <Title>
                <range>Bedaquiline</range>
              </Title>
              <Case When="Initial application" Category="multi-drug resistant tuberculosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The person has multi-drug resistant tuberculosis (MDR-TB)</ci>
                    <ci type="logical">ManatÅ« Hauora - Ministry of Healthâ€™s Tuberculosis Clinical Network has reviewed the individual case and recommends bedaquiline as part of the treatment regimen</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F161601418025" Rank="1" Units="Tab" Weight="100">
              <Name>Tab 100mg</Name>
              <Brand ID="B16160141802525">
                <Name>Sirturo</Name>
                <Pack ID="P2659956" Specified="true" OP="true" nzmt:ctpp_id="50304581000117103">
                  <Quantity>24</Quantity>
                  <Subsidy>3084.51</Subsidy>
                  <Price>3084.51</Price>
                  <Alternate>3084.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1619">
        <Name>Antivirals</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A310301">For eye preparations refer to Eye Preparations, Anti-Infective Preparations</p>
        </div>
        <ATC3 ID="A161905">
          <Name>Hepatitis B Treatment</Name>
          <Chemical ID="C1619052900">
            <Name>Lamivudine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1685"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1685">
              <Title>
                <range>Lamivudine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Used for the treatment or prevention of hepatitis B</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="year">1</Term>
              </Case>
              <Case When="Renewal" Form="SA0538 SA0772 SA0832 SA1360 SA1650 SA1685">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Used for the treatment or prevention of hepatitis B</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F161905290002" Rank="3" Units="ml">
              <Name>Oral liq 5 mg per ml</Name>
              <Brand ID="B16190529000225">
                <Name>Zeffix</Name>
                <Pack ID="P307696" Specified="true" OP="true" nzmt:ctpp_id="50068991000117102">
                  <Quantity>240</Quantity>
                  <Subsidy>270.00</Subsidy>
                  <Price>270.00</Price>
                  <Alternate>270.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161905290025" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B16190529002526" PSS="2026-06-30">
                <Name>Zetlam</Name>
                <Pack ID="P2399369" Specified="true" nzmt:ctpp_id="50145051000117103">
                  <Quantity>28</Quantity>
                  <Subsidy>12.06</Subsidy>
                  <Price>12.06</Price>
                  <Alternate>12.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1619053867" Statim="Must">
            <Name>Tenofovir disoproxil</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
              <p xlink:type="simple" xlink:href="A1620">Tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the
        purposes of Special Authority SA2139.</p>
            </div>
            <Formulation ID="F161905386727" Rank="1" Units="tab">
              <Name>Tab 245 mg (300 mg as a maleate)</Name>
              <Brand ID="B16190538672726" PSS="2025-06-30">
                <Name>Tenofovir Disoproxil Viatris</Name>
                <Pack ID="P2638061" Specified="true" nzmt:ctpp_id="50300001000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>15.00</Subsidy>
                  <Price>15.00</Price>
                  <Alternate>15.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1619053895" Statim="Must">
            <Name>Entecavir</Name>
            <Formulation ID="F161905389525" Rank="1" Units="tab">
              <Name>Tab 0.5 mg</Name>
              <Brand ID="B16190538952528" PSS="2026-06-30">
                <Name>Entecavir (Rex)</Name>
                <Pack ID="P2654431" Specified="true" nzmt:ctpp_id="50255601000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>12.04</Subsidy>
                  <Price>12.04</Price>
                  <Alternate>12.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A161907">
          <Name>Herpesvirus Treatments</Name>
          <Chemical ID="C1619071043">
            <Name>Valaciclovir</Name>
            <Formulation ID="F161907104301" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B16190710430125" PSS="2024-06-30">
                <Name>Vaclovir</Name>
                <Pack ID="P2483904" Specified="true" nzmt:ctpp_id="50229341000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161907104325" Rank="1" Units="tab" Weight="1000">
              <Name>Tab 1,000 mg</Name>
              <Brand ID="B16190710432525" PSS="2024-06-30">
                <Name>Vaclovir</Name>
                <Pack ID="P2483912" Specified="true" nzmt:ctpp_id="50220911000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>13.76</Subsidy>
                  <Price>13.76</Price>
                  <Alternate>13.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1619072483" Statim="Must">
            <Name>Aciclovir</Name>
            <Formulation ID="F161907248306" Rank="1" Units="tab" Weight="200">
              <Name>Tab dispersible 200 mg</Name>
              <Brand ID="B16190724830602" PSS="2025-06-30">
                <Name>Lovir</Name>
                <Pack ID="P471704" Specified="true" nzmt:ctpp_id="50088761000117108">
                  <Quantity>25</Quantity>
                  <Subsidy>1.78</Subsidy>
                  <Price>1.78</Price>
                  <Alternate>1.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161907248307" Rank="1" Units="tab" Weight="400">
              <Name>Tab dispersible 400 mg</Name>
              <Brand ID="B16190724830702" PSS="2025-06-30">
                <Name>Lovir</Name>
                <Pack ID="P471690" Specified="true" nzmt:ctpp_id="50088751000117106">
                  <Quantity>56</Quantity>
                  <Subsidy>5.81</Subsidy>
                  <Price>5.81</Price>
                  <Alternate>5.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F161907248308" Rank="1" Units="tab" Weight="800">
              <Name>Tab dispersible 800 mg</Name>
              <Brand ID="B16190724830810" PSS="2025-06-30">
                <Name>Lovir</Name>
                <Pack ID="P471712" Specified="true" nzmt:ctpp_id="50088771000117103">
                  <Quantity>35</Quantity>
                  <Subsidy>6.46</Subsidy>
                  <Price>6.46</Price>
                  <Alternate>6.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1619073979">
            <Name>Valganciclovir</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1993"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1993">
              <Title>
                <range>Valganciclovir</range>
              </Title>
              <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and
        requires valganciclovir for CMV prophylaxis</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Form="SA1274 SA1404 SA1993" Category="transplant cytomegalovirus prophylaxis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and
            received anti-thymocyte globulin and requires valganciclovir therapy for CMV
            prophylaxis</ci>
                      <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of
            valganciclovir prophylaxis following anti-thymocyte globulin</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has received pulse methylprednisolone for
            acute rejection and requires further valganciclovir therapy for CMV prophylaxis</ci>
                      <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of
            valganciclovir prophylaxis following pulse methylprednisolone</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="cytomegalovirus prophylaxis following anti-thymocyte globulin">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and
          received valganciclovir under Special Authority more than 2 years ago (27 months)</ci>
                    <ci type="logical" class="Indication">Patient has received anti-thymocyte globulin and
          requires valganciclovir for CMV prophylaxis</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Form="SA1274 SA1404 SA1993" Category="cytomegalovirus prophylaxis following anti-thymocyte globulin">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient has received a further course of
        anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="Lung transplant cytomegalovirus prophylaxis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has undergone a lung transplant</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The donor was cytomegalovirus positive and the
            patient is cytomegalovirus negative</ci>
                      <ci type="logical" class="Indication">The recipient is cytomegalovirus positive</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has a high risk of CMV disease</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Cytomegalovirus in immunocompromised patients">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is immunocompromised</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has cytomegalovirus syndrome or tissue
            invasive disease</ci>
                      <ci type="logical" class="Indication">Patient has rapidly rising plasma CMV DNA in absence
            of disease</ci>
                      <ci type="logical" class="Indication">Patient has cytomegalovirus retinitis</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Form="SA1274 SA1404 SA1993" Category="Cytomegalovirus in immunocompromised patients">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is immunocompromised</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has cytomegalovirus syndrome or tissue
            invasive disease</ci>
                      <ci type="logical" class="Indication">Patient has rapidly rising plasma CMV DNA in absence
            of disease</ci>
                      <ci type="logical" class="Indication">Patient has cytomegalovirus retinitis</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>for the purpose of this Special Authority "immunocompromised" includes transplant recipients,
      patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive
      treatment for other conditions.</p>
              </div>
            </Request>
            <Formulation ID="F161907397925" Rank="1" Units="tab" Weight="450">
              <Name>Tab 450 mg</Name>
              <Brand ID="B16190739792527" PSS="2024-06-30">
                <Name>Valganciclovir Viatris</Name>
                <Pack ID="P2635682" Specified="true" nzmt:ctpp_id="50291401000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>132.00</Subsidy>
                  <Price>132.00</Price>
                  <Alternate>132.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A161912">
          <Name>Hepatitis C Treatment</Name>
          <Chemical ID="C1619124070">
            <Name>Ledipasvir with sofosbuvir</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1605"/>
            <Request To="Hepatitis C Treatment Panel (HepCTP)" For="Subsidy" Form="SA1605">
              <Title>
                <range>Ledipasvir with sofosbuvir</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient is likely to benefit from  treatment</ci>
                </math>
                <Applicant>medical practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>By application to the Hepatitis C Treatment Panel (HepCTP).</p>
                <p>Applications will be considered by HepCTP and approved subject to confirmation of eligibility.</p>
                <p>Application details may be obtained from Pharmac's website <a href="http://pharmac.govt.nz/maviret">http://www.pharmac.govt.nz/maviret</a> or:</p>
                <p>The Coordinator, Hepatitis C Treatment Panel</p>
                <p>Pharmac, PO Box 10-254, WELLINGTON    Tel: (04) 460 4990,</p>
                <p>Email: <a href="mailto:hepcpanel@pharmac.govt.nz">hepcpanel@pharmac.govt.nz</a></p>
              </div>
            </Request>
            <Formulation ID="F161912407025" Rank="1" Units="tab">
              <Name>Tab 90 mg with sofosbuvir 400 mg</Name>
              <Brand ID="B16191240702525">
                <Name>Harvoni</Name>
                <Pack ID="P2504111" Specified="true" nzmt:ctpp_id="50203981000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>24363.46</Subsidy>
                  <Price>24363.46</Price>
                  <Alternate>24363.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1619124113">
            <Name>Glecaprevir with pibrentasvir</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note the supply of treatment is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website <a href="https://pharmac.govt.nz/maviret">https://pharmac.govt.nz/maviret</a></p>
            </div>
            <Formulation ID="F161912411325" Rank="1" Units="tab">
              <Name>Tab 100 mg with pibrentasvir 40 mg</Name>
              <Brand ID="B16191241132525">
                <Name>Maviret</Name>
                <Pack ID="P2552019" Specified="true" OP="true" nzmt:ctpp_id="50240831000117105">
                  <Quantity>84</Quantity>
                  <Subsidy>24750.00</Subsidy>
                  <Price>24750.00</Price>
                  <Alternate>24750.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A161916">
          <Name>HIV Prophylaxis and Treatment</Name>
          <Chemical ID="C1619163981" Statim="Must">
            <Name>Emtricitabine with tenofovir disoproxil</Name>
            <Request To="HealthPAC" For="Subsidy" Form="SA2138">
              <Title>
                <range>Emtricitabine with tenofovir disoproxil</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has tested HIV negative, does not have
                    signs or symptoms of acute HIV infection and has been assessed for HIV
                    seroconversion</ci>
                    <ci type="logical" class="Indication">The Practitioner considers the patient is at
                    elevated risk of HIV exposure and use of PrEP is clinically appropriate</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">24</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines:</p>
                  <p>https://ashm.org.au/HIV/PrEP/</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1714 SA1842 SA1904 SA1994 SA2138">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has tested HIV negative, does not have
                    signs or symptoms of acute HIV infection and has been assessed for HIV
                    seroconversion</ci>
                    <ci type="logical" class="Indication">The Practitioner considers the patient is at
                    elevated risk of HIV exposure and use of PrEP is clinically appropriate</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">24</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines:</p>
                  <p>https://ashm.org.au/HIV/PrEP/</p>
                </div>
              </Case>
            </Request>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Funding for emtricitabine with tenofovir disoproxil for use as PrEP, should be applied using Special Authority SA2138.</p>
            </div>
            <Rule Type="SubRxF" Waiver="Special" xlink:href="SA2138"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Endorsement for treatment of conditions approved via Special Authority SA2139
        (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure
        prophylaxis following exposure to HIV and percutaneous exposure): Prescription is deemed to
        be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another
        antiretroviral subsidised under Special Authority SA2139 and the prescription is annotated
        accordingly by the Pharmacist or endorsed by the prescriber.</p>
              <p/>
              <p>Note:</p>
              <p xlink:type="simple" xlink:href="A1620">Emtricitabine with tenofovir disoproxil prescribed
        under endorsement, for treatment of conditions approved via Special Authority SA2139
        (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure
        prophylaxis following exposure to HIV and percutaneous exposure), is included in the count
        of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the
        purposes of Special Authority SA2139</p>
              <p>There is an approval process to become a named specialist to prescribe antiretroviral therapy
        in New Zealand. Further information is available on the Pharmac website.</p>
            </div>
            <Formulation ID="F161916398127" Rank="1" Units="tab">
              <Name>Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate)</Name>
              <Brand ID="B16191639812726" PSS="2025-06-30">
                <Name>Tenofovir Disoproxil Emtricitabine Viatr</Name>
                <Pack ID="P2638088" Specified="true" nzmt:ctpp_id="50300051000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>15.45</Subsidy>
                  <Price>15.45</Price>
                  <Alternate>15.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A161917">
          <Name>COVID-19 Treatments</Name>
          <Chemical ID="C1619174156">
            <Name>Nirmatrelvir with ritonavir</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Treatment is funded only if patient meets access criteria for oral antiviral COVID-19
        treatments (as on <a href="https://pharmac.govt.nz/covid-oral-antivirals">Pharmacâ€™s
            website</a>) and has been endorsed accordingly by the prescriber. The supply of
        treatment is via Pharmacâ€™s approved distribution process. Refer to the Pharmac website for
        more information about this and stock availability. </p>
            </div>
            <Formulation ID="F161917415625" Rank="1" Units="tab" Weight="250">
              <Name>Tab 150 mg with ritonavir 100 mg</Name>
              <Brand ID="B16191741562525">
                <Name>Paxlovid</Name>
                <Pack ID="P2635143" Specified="true" nzmt:ctpp_id="50292521000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1619174157">
            <Name>Molnupiravir</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Treatment is funded only if patient meets access criteria for oral antiviral COVID-19
        treatments (as on <a href="https://pharmac.govt.nz/covid-oral-antivirals">Pharmacâ€™s
            website</a>) and has been endorsed accordingly by the prescriber. The supply of
        treatment is via Pharmacâ€™s approved distribution process. Refer to the Pharmac website for
        more information about this and stock availability. </p>
            </div>
            <Formulation ID="F161917415725" Rank="2" Units="cap" Weight="200">
              <Name>Cap 200 mg</Name>
              <Brand ID="B16191741572525">
                <Name>Lagevrio</Name>
                <Pack ID="P2635224" Specified="true" nzmt:ctpp_id="50296421000117103">
                  <Quantity>40</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1620">
        <Name>Antiretrovirals</Name>
        <Request To="HealthPAC" For="Subsidy" Form="SA2139" Confidential="true">
          <Title>
            <range>Antiretrovirals</range>
          </Title>
          <Case When="Initial application" Category="Confirmed HIV">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <ci type="logical" class="Indication">The patient has confirmed HIV infection</ci>
            </math>
            <Applicant>named specialist</Applicant>
            <Term Measure="patient's lifetime"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to
        4 subsidised antiretrovirals.</p>
              <p>Subsidies apply for a combination of up to four antiretroviral medications. The combination
        of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a
        combination product or separately) will be counted as one protease inhibitor for the purpose
        of accessing funding to antiretrovirals.</p>
            </div>
          </Case>
          <Case When="Renewal" Category="Confirmed HIV" Form="SA0556 SA0575 SA0754 SA0779 SA1021 SA1025 SA1364 SA1651 SA2139">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <ci type="logical" class="Indication">The treatment remains appropriate and the patient is
        benefiting from treatment</ci>
            </math>
            <Applicant>named specialist</Applicant>
            <Term Measure="patient's lifetime"/>
          </Case>
          <Case When="Initial application" Category="Prevention of maternal transmission">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <apply>
                <or/>
                <ci type="logical" class="Indication">Prevention of maternal foetal transmission</ci>
                <ci type="logical" class="Indication">Treatment of the newborn for up to eight weeks</ci>
              </apply>
            </math>
            <Applicant>named specialist</Applicant>
            <Term Measure="year">1</Term>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to
        4 subsidised antiretrovirals.</p>
              <p>Subsidies apply for a combination of up to four antiretroviral medications. The combination
        of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a
        combination product or separately) will be counted as one protease inhibitor for the purpose
        of accessing funding to antiretrovirals.</p>
              <p>Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners
        prescribing these medications should exercise their own skill, judgement, expertise and
        discretion, and make their own prescribing decisions with respect to the use of a
        Pharmaceutical for an indication for which it is not approved or contraindicated.</p>
            </div>
          </Case>
          <Case When="Initial application" Category="post-exposure prophylaxis following exposure to HIV">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <apply>
                <and/>
                <ci type="logical" class="Treatment">Treatment course to be initiated within 72 hours post
          exposure</ci>
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Patient has had condomless anal intercourse or
            receptive vaginal intercourse with a known HIV positive person with an unknown or
            detectable viral load greater than 200 copies per ml</ci>
                  <ci type="logical" class="Indication">Patient has shared intravenous injecting equipment
            with a known HIV positive person</ci>
                  <ci type="logical" class="Indication">Patient has had non-consensual intercourse and the
            clinician considers that the risk assessment indicates prophylaxis is required</ci>
                  <ci type="logical" class="Indication">Patient has had condomless anal intercourse with a
            person from a high HIV prevalence country or risk group whose HIV status is unknown</ci>
                </apply>
              </apply>
            </math>
            <Applicant>any relevant practitioner</Applicant>
            <Term Measure="week">4</Term>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to
        4 subsidised antiretrovirals.</p>
              <p>Subsidies apply for a combination of up to four antiretroviral medications. The combination
        of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a
        combination product or separately) will be counted as one protease inhibitor for the purpose
        of accessing funding to antiretrovirals.</p>
              <p>Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and
        Sexual Health Medicine clinical guidelines for PEP
        (https://www.ashm.org.au/hiv/hiv-management/pep/).</p>
            </div>
          </Case>
          <Case When="Renewal" Category="second or subsequent post-exposure prophylaxis" Form="SA0556 SA0575 SA0754 SA0779 SA1021 SA1025 SA1364 SA1651 SA2139">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <apply>
                <and/>
                <ci type="logical" class="Treatment">Treatment course to be initiated within 72 hours post
          exposure</ci>
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Patient has had condomless anal intercourse or
            receptive vaginal intercourse with a known HIV positive person with an unknown or
            detectable viral load greater than 200 copies per ml</ci>
                  <ci type="logical" class="Indication">Patient has shared intravenous injecting equipment
            with a known HIV positive person</ci>
                  <ci type="logical" class="Indication">Patient has had non-consensual intercourse and the
            clinician considers that the risk assessment indicates prophylaxis is required</ci>
                  <ci type="logical" class="Indication">Patient has had condomless anal intercourse with a
            person from a high HIV prevalence country or risk group whose HIV status is unknown</ci>
                </apply>
              </apply>
            </math>
            <Applicant>any relevant practitioner</Applicant>
            <Term Measure="week">4</Term>
          </Case>
          <Case When="Initial application" Category="Percutaneous exposure">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <ci type="logical" class="Indication">The patient has percutaneous exposure to blood known to
        be HIV positive</ci>
            </math>
            <Applicant>named specialist</Applicant>
            <Term Measure="week">6</Term>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to
        4 subsidised antiretrovirals.</p>
              <p>Subsidies apply for a combination of up to four antiretroviral medications. The combination
        of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a
        combination product or separately) will be counted as one protease inhibitor for the purpose
        of accessing funding to antiretrovirals.</p>
            </div>
          </Case>
          <Case When="Renewal" Category="Second or subsequent percutaneous exposure" Form="SA0556 SA0575 SA0754 SA0779 SA1021 SA1025 SA1364 SA1651 SA2139">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <ci type="logical" class="Indication">The patient has percutaneous exposure to blood known to
        be HIV positive</ci>
            </math>
            <Applicant>named specialist</Applicant>
            <Term Measure="week">6</Term>
          </Case>
        </Request>
        <ATC3 ID="A162001">
          <Name>Non-nucleosides Reverse Transcriptase Inhibitors</Name>
          <Chemical ID="C1620011170">
            <Name>Nevirapine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162001117001" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B16200111700125" PSS="2024-06-30" ToBeDelisted="2024-07-01">
                <Name>Nevirapine Alphapharm</Name>
                <Pack ID="P2404354" Specified="true" nzmt:ctpp_id="50147161000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>84.00</Subsidy>
                  <Price>84.00</Price>
                  <Alternate>84.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16200111700126">
                <Name>Nevirapine Viatris</Name>
                <Pack ID="P2640023" Specified="true" nzmt:ctpp_id="50290881000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>84.00</Subsidy>
                  <Price>84.00</Price>
                  <Alternate>84.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162001117025" Rank="3" Units="ml" Weight="10">
              <Name>Oral suspension 10 mg per ml</Name>
              <Brand ID="B16200111702525">
                <Name>Viramune Suspension</Name>
                <Pack ID="P2014947" Specified="true" OP="true" nzmt:ctpp_id="50002451000117104">
                  <Quantity>240</Quantity>
                  <Subsidy>203.55</Subsidy>
                  <Price>203.55</Price>
                  <Alternate>203.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620013732">
            <Name>Efavirenz</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162001373228" Rank="1" Units="tab" Weight="600">
              <Name>Tab 600 mg</Name>
              <Brand ID="B16200137322825">
                <Name>Stocrin</Name>
                <Pack ID="P2060094" Specified="true" nzmt:ctpp_id="50010681000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>63.38</Subsidy>
                  <Price>63.38</Price>
                  <Alternate>63.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162001373229" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B16200137322925">
                <Name>Stocrin</Name>
                <Pack ID="P2292483" Specified="true">
                  <Quantity>90</Quantity>
                  <Subsidy>190.15</Subsidy>
                  <Price>190.15</Price>
                  <Alternate>190.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620013918">
            <Name>Etravirine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162001391826" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B16200139182625">
                <Name>Intelence</Name>
                <Pack ID="P2426900" Specified="true" nzmt:ctpp_id="50147481000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>770.00</Subsidy>
                  <Price>770.00</Price>
                  <Alternate>770.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A162003">
          <Name>Nucleosides Reverse Transcriptase Inhibitors</Name>
          <Chemical ID="C1620031223">
            <Name>Zidovudine [AZT] with lamivudine</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162003122301" Rank="1" Units="tab" Weight="300">
              <Name>Tab 300 mg with lamivudine 150 mg</Name>
              <Brand ID="B16200312230125" ToBeDelisted="2024-07-01">
                <Name>Alphapharm</Name>
                <Pack ID="P2399377" Specified="true" nzmt:ctpp_id="50145241000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>92.40</Subsidy>
                  <Price>92.40</Price>
                  <Alternate>92.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16200312230126">
                <Name>Lamivudine/Zidovudine Viatris</Name>
                <Pack ID="P2645300" Specified="true" nzmt:ctpp_id="50290701000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>92.40</Subsidy>
                  <Price>92.40</Price>
                  <Alternate>92.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620032464">
            <Name>Zidovudine [AZT]</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162003246401" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B16200324640101">
                <Name>Retrovir</Name>
                <Pack ID="P552666" Specified="true" nzmt:ctpp_id="50095731000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>152.25</Subsidy>
                  <Price>152.25</Price>
                  <Alternate>152.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162003246402" Rank="3" Units="ml">
              <Name>Oral liq 10 mg per ml</Name>
              <Brand ID="B16200324640201">
                <Name>Retrovir</Name>
                <Pack ID="P818682" Specified="true" OP="true" nzmt:ctpp_id="50117731000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>30.45</Subsidy>
                  <Price>30.45</Price>
                  <Alternate>30.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620032900">
            <Name>Lamivudine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162003290001" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B16200329000126" PSS="2026-06-30">
                <Name>Lamivudine Viatris</Name>
                <Pack ID="P2638045" Specified="true" nzmt:ctpp_id="50293701000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>98.00</Subsidy>
                  <Price>98.00</Price>
                  <Alternate>98.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162003290026" Rank="3" Units="ml">
              <Name>Oral liq 10 mg per ml</Name>
              <Brand ID="B16200329002601">
                <Name>3TC</Name>
                <Pack ID="P474320" Specified="true" OP="true" nzmt:ctpp_id="50089351000117104">
                  <Quantity>240</Quantity>
                  <Subsidy>102.50</Subsidy>
                  <Price>102.50</Price>
                  <Alternate>102.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620033731">
            <Name>Abacavir sulphate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162003373125" Rank="1" Units="tab" Weight="300">
              <Name>Tab 300 mg</Name>
              <Brand ID="B16200337312525">
                <Name>Ziagen</Name>
                <Pack ID="P378038" Specified="true" nzmt:ctpp_id="50079501000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>180.00</Subsidy>
                  <Price>180.00</Price>
                  <Alternate>180.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162003373126" Rank="3" Units="ml">
              <Name>Oral liq 20 mg per ml</Name>
              <Brand ID="B16200337312625" ToBeDelisted="2024-07-01">
                <Name>Ziagen</Name>
                <Pack ID="P2014718" Specified="true" OP="true" nzmt:ctpp_id="50002401000117103">
                  <Quantity>240</Quantity>
                  <Subsidy>256.31</Subsidy>
                  <Price>256.31</Price>
                  <Alternate>256.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620033863">
            <Name>Abacavir sulphate with lamivudine</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: abacavir with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162003386325" Rank="1" Units="tab">
              <Name>Tab 600 mg with lamivudine 300 mg</Name>
              <Brand ID="B16200338632526" PSS="2025-06-30">
                <Name>Abacavir/Lamivudine Viatris</Name>
                <Pack ID="P2632365" Specified="true" nzmt:ctpp_id="50301251000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>29.50</Subsidy>
                  <Price>29.50</Price>
                  <Alternate>29.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620033866">
            <Name>Emtricitabine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162003386625" Rank="2" Units="cap" Weight="200">
              <Name>Cap 200 mg</Name>
              <Brand ID="B16200338662525">
                <Name>Emtriva</Name>
                <Pack ID="P2250063" Specified="true" nzmt:ctpp_id="50039681000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>307.20</Subsidy>
                  <Price>307.20</Price>
                  <Alternate>307.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620033980">
            <Name>Efavirenz with emtricitabine and tenofovir disoproxil</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Efavirenz with emtricitabine and tenofovir disoproxil counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162003398026" Rank="1" Units="tab">
              <Name>Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate)</Name>
              <Brand ID="B16200339802626">
                <Name>Viatris</Name>
                <Pack ID="P2644967" Specified="true" nzmt:ctpp_id="50292041000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>106.88</Subsidy>
                  <Price>106.88</Price>
                  <Alternate>106.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A162005">
          <Name>Protease Inhibitors</Name>
          <Chemical ID="C1620051086">
            <Name>Ritonavir</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162005108625" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B16200510862525">
                <Name>Norvir</Name>
                <Pack ID="P2379317" Specified="true" nzmt:ctpp_id="50122321000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>43.31</Subsidy>
                  <Price>43.31</Price>
                  <Alternate>43.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620053798">
            <Name>Lopinavir with ritonavir</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162005379827" Rank="1" Units="tab" Weight="250">
              <Name>Tab 200 mg with ritonavir 50 mg</Name>
              <Brand ID="B16200537982726" PSS="2024-06-30">
                <Name>Lopinavir/Ritonavir Mylan</Name>
                <Pack ID="P2613549" Specified="true" nzmt:ctpp_id="50218941000117103">
                  <Quantity>120</Quantity>
                  <Subsidy>295.00</Subsidy>
                  <Price>295.00</Price>
                  <Alternate>295.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162005379828" Rank="1" Units="tab" Weight="125">
              <Name>Tab 100 mg with ritonavir 25 mg</Name>
              <Brand ID="B16200537982826" PSS="2024-06-30">
                <Name>Lopinavir/Ritonavir Mylan</Name>
                <Pack ID="P2613530" Specified="true" nzmt:ctpp_id="50218911000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>150.00</Subsidy>
                  <Price>150.00</Price>
                  <Alternate>150.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620053861">
            <Name>Atazanavir sulphate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162005386125" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B16200538612527" PSS="2025-06-30">
                <Name>Atazanavir Mylan</Name>
                <Pack ID="P2640015" Specified="true" nzmt:ctpp_id="50239721000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>85.00</Subsidy>
                  <Price>85.00</Price>
                  <Alternate>85.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162005386126" Rank="2" Units="cap" Weight="200">
              <Name>Cap 200 mg</Name>
              <Brand ID="B16200538612627" PSS="2025-06-30">
                <Name>Atazanavir Mylan</Name>
                <Pack ID="P2642794" Specified="true" nzmt:ctpp_id="50302481000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>110.00</Subsidy>
                  <Price>110.00</Price>
                  <Alternate>110.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B16200538612628">
                <Name>Atazanavir Viatris</Name>
                <Pack ID="P2660024" Specified="true" nzmt:ctpp_id="50319321000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>110.00</Subsidy>
                  <Price>110.00</Price>
                  <Alternate>110.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620053919">
            <Name>Darunavir</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162005391926" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B16200539192627" PSS="2026-06-30">
                <Name>Darunavir Viatris</Name>
                <Pack ID="P2626462" Specified="true" nzmt:ctpp_id="50290581000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>150.00</Subsidy>
                  <Price>150.00</Price>
                  <Alternate>150.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162005391927" Rank="1" Units="tab" Weight="600">
              <Name>Tab 600 mg</Name>
              <Brand ID="B16200539192727" PSS="2026-06-30">
                <Name>Darunavir Viatris</Name>
                <Pack ID="P2626470" Specified="true" nzmt:ctpp_id="50290621000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>225.00</Subsidy>
                  <Price>225.00</Price>
                  <Alternate>225.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A162007">
          <Name>Strand Transfer Inhibitors</Name>
          <Chemical ID="C1620073900">
            <Name>Raltegravir potassium</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162007390025" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B16200739002525">
                <Name>Isentress</Name>
                <Pack ID="P2324059" Specified="true" nzmt:ctpp_id="50049001000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>1090.00</Subsidy>
                  <Price>1090.00</Price>
                  <Alternate>1090.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162007390026" Rank="1" Units="tab" Weight="600">
              <Name>Tab 600 mg</Name>
              <Brand ID="B16200739002625">
                <Name>Isentress HD</Name>
                <Pack ID="P2562960" Specified="true" nzmt:ctpp_id="50249791000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>1090.00</Subsidy>
                  <Price>1090.00</Price>
                  <Alternate>1090.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1620074073">
            <Name>Dolutegravir</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2139"/>
            <Formulation ID="F162007407325" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B16200740732525">
                <Name>Tivicay</Name>
                <Pack ID="P2510979" Specified="true" nzmt:ctpp_id="50197421000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>1090.00</Subsidy>
                  <Price>1090.00</Price>
                  <Alternate>1090.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1622">
        <Name>Immune Modulators</Name>
        <ATC3 ID="A162201">
          <Name>Immune Modulators</Name>
          <Chemical ID="C1622013787">
            <Name>Pegylated interferon alfa-2a</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Pharmac will consider funding ribavirin for the small group of patients who have a clinical need    
        for ribavirin and meet Special Authority criteria. Please contact the Hepatitis C Coordinator at   
        Pharmac on 0800-023-588 option 4.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2034"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2034">
              <Title>
                <range>Pegylated Interferon alfa-2A</range>
              </Title>
              <Case When="Initial application" Category="chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection</ci>
                      <ci type="logical" class="Indication">Patient has chronic hepatitis C and is co-infected with HIV</ci>
                      <ci type="logical" class="Indication">Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant</ci>
                    </apply>
                    <ci type="logical" class="Indication">Maximum of 48 weeks therapy</ci>
                  </apply>
                </math>
                <Applicant>any specialist</Applicant>
                <Term Measure="month">18</Term>
              </Case>
              <Case When="Renewal" Form="SA0692 SA0742 SA0802 SA0952 SA1134 SA1365 SA1400 SA1936 SA1972 SA1995 SA2034" Category="Chronic hepatitis C - genotype 1 infection">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has chronic hepatitis C, genotype 1</ci>
                    <ci type="logical" class="Indication">Patient has had previous treatment with pegylated interferon and ribavirin</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has responder relapsed</ci>
                      <ci type="logical" class="Indication">Patient was a partial responder</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is to be treated in combination with boceprevir</ci>
                    <ci type="logical" class="Indication">Maximum of 48 weeks therapy</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>general physician</Applicant>
                <Term Measure="month">18</Term>
              </Case>
              <Case When="Initial application" Category="Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has chronic hepatitis C, genotype 1</ci>
                    <ci type="logical" class="Indication">Patient has had previous treatment with pegylated interferon and ribavirin</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has responder relapsed</ci>
                      <ci type="logical" class="Indication">Patient was a partial responder</ci>
                      <ci type="logical" class="Indication">Patient received interferon treatment prior to 2004</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is to be treated in combination with boceprevir</ci>
                    <ci type="logical" class="Indication">Maximum of 48 weeks therapy</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>general physician</Applicant>
                <Term Measure="month">18</Term>
              </Case>
              <Case When="Initial application" Category="chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has chronic hepatitis C, genotype 2 or 3 infection</ci>
                    <ci type="logical" class="Indication">Maximum of 6 months therapy</ci>
                  </apply>
                </math>
                <Applicant>any specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Hepatitis B">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months)</ci>
                    <ci type="logical" class="Indication">Patient is Hepatitis B treatment-naive</ci>
                    <ci type="logical" class="Indication">ALT &gt; 2 times Upper Limit of Normal</ci>
                    <ci type="logical" class="Indication">HBV DNA &lt; 10 log10 IU/ml</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">HBeAg positive</ci>
                      <ci type="logical" class="Indication">serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis)</ci>
                    </apply>
                    <ci type="logical" class="Indication">Compensated liver disease</ci>
                    <ci type="logical" class="Indication">No continuing alcohol abuse or intravenous drug use</ci>
                    <ci type="logical" class="Indication">Not co-infected with HCV, HIV or HDV</ci>
                    <ci type="logical" class="Indication">Neither ALT nor AST &gt; 10 times upper limit of normal</ci>
                    <ci type="logical" class="Indication">No history of hypersensitivity or contraindications to pegylated interferon</ci>
                    <ci type="logical" class="Indication">Maximum of 48 weeks therapy</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant>infectious disease specialist</Applicant>
                <Applicant>general physician</Applicant>
                <Term Measure="month">18</Term>
              </Case>
              <Case When="Initial application" Category="myeloproliferative disorder or cutaneous T cell lymphoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient has a cutaneous T cell lymphoma*</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has a myeloproliferative disorder*</ci>
                      <ci type="logical" class="Indication">Patient is intolerant of hydroxyurea</ci>
                      <ci type="logical" class="Indication">Treatment with anagrelide and busulfan is not clinically appropriate</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has a myeloproliferative disorder</ci>
                      <ci type="logical" class="Indication">Patient is pregnant, planning pregnancy or lactating</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="myeloproliferative disorder or cutaneous T cell lymphoma" Form="SA0692 SA0742 SA0802 SA0952 SA1134 SA1365 SA1400 SA1936 SA1972 SA1995 SA2034">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and patient is benefitting from treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a cutaneous T cell lymphoma*</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has a myeloproliferative disorder*</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate</ci>
                          <ci type="logical" class="Indication">Patient is pregnant, planning pregnancy or lactating</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="post-allogenic bone marrow transplant">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="post-allogenic bone marrow transplant" Form="SA0692 SA0742 SA0802 SA0952 SA1134 SA1365 SA1400 SA1936 SA1972 SA1995 SA2034">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient is responding and ongoing treatment remains appropriate</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F162201378726" Rank="4" Units="inj" Weight="180">
              <Name>Inj 180 mcg prefilled syringe</Name>
              <Brand ID="B16220137872625">
                <Name>Pegasys</Name>
                <Pack ID="P2162806" Specified="true" nzmt:ctpp_id="50027531000117100">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>748.50</Subsidy>
                  <Price>748.50</Price>
                  <Alternate>748.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1623">
        <Name>Urinary Tract Infections</Name>
        <ATC3 ID="A162301">
          <Name>Urinary Tract Infections</Name>
          <Chemical ID="C1623011594" Statim="Must">
            <Name>Methenamine (hexamine) hippurate</Name>
            <Formulation ID="F162301159401" Rank="1" Units="tab">
              <Name>Tab 1 g</Name>
              <Brand ID="B16230115940101" PSS="2025-06-30">
                <Name>Hiprex</Name>
                <Pack ID="P209538" nzmt:ctpp_id="50017741000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>19.95</Subsidy>
                  <Price>19.95</Price>
                  <Alternate>19.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2671077" Specified="true">
                  <Quantity>100</Quantity>
                  <Subsidy>19.95</Subsidy>
                  <Price>19.95</Price>
                  <Alternate>19.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1623011867" Statim="Must">
            <Name>Nitrofurantoin</Name>
            <Formulation ID="F162301186701" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B16230118670101" PSS="2024-06-30">
                <Name>Nifuran</Name>
                <Pack ID="P254738" Specified="true" nzmt:ctpp_id="50054631000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>22.20</Subsidy>
                  <Price>22.20</Price>
                  <Alternate>22.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162301186702" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B16230118670201" PSS="2024-06-30">
                <Name>Nifuran</Name>
                <Pack ID="P254754" Specified="true" nzmt:ctpp_id="50054641000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>37.50</Subsidy>
                  <Price>37.50</Price>
                  <Alternate>37.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F162301186725" Rank="2" Units="cap" Weight="100">
              <Name>Cap modified-release 100 mg</Name>
              <Rule Type="FormMax" Value="15" Attribute="PSO"/>
              <Brand ID="B16230118672525" PSS="2026-06-30">
                <Name>Macrobid</Name>
                <Pack ID="P2493624" Specified="true" nzmt:ctpp_id="50221411000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>81.20</Subsidy>
                  <Price>81.20</Price>
                  <Alternate>81.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1623011874">
            <Name>Norfloxacin</Name>
            <Formulation ID="F162301187401" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B16230118740125">
                <Name>Arrow-Norfloxacin</Name>
                <Pack ID="P2204398" Specified="true" nzmt:ctpp_id="50032531000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>245.00</Subsidy>
                  <Price>245.00</Price>
                  <Alternate>245.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A19">
      <Name>Musculoskeletal System</Name>
      <ATC2 ID="A1901">
        <Name>Anticholinesterases</Name>
        <ATC3 ID="A190101">
          <Name>Anticholinesterases</Name>
          <Chemical ID="C1901011857">
            <Name>Neostigmine metilsulfate</Name>
            <Formulation ID="F190101185703" Rank="4" Units="inj" Weight="2">
              <Name>Inj 2.5 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B19010118570303" PSS="2024-06-30">
                <Name>Max Health</Name>
                <Pack ID="P2599996" Specified="true" nzmt:ctpp_id="50183201000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>33.81</Subsidy>
                  <Price>33.81</Price>
                  <Alternate>33.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1901012070" Statim="May">
            <Name>Pyridostigmine bromide</Name>
            <Formulation ID="F190101207001" Rank="1" Units="tab" Weight="60">
              <Name>Tab 60 mg</Name>
              <Brand ID="B19010120700101">
                <Name>Mestinon</Name>
                <Pack ID="P251011" Specified="true" nzmt:ctpp_id="50052591000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>50.28</Subsidy>
                  <Price>50.28</Price>
                  <Alternate>50.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1904">
        <Name>Non-Steroidal Anti-Inflammatory Drugs</Name>
        <ATC3 ID="A190401">
          <Name>Non-Steroidal Anti-Inflammatory Drugs</Name>
          <Chemical ID="C1904011401">
            <Name>Diclofenac sodium</Name>
            <Formulation ID="F190401140101" Rank="1" Units="tab" Weight="25" Statim="Must">
              <Name>Tab EC 25 mg</Name>
              <Brand ID="B19040114010126" PSS="2024-06-30">
                <Name>Diclofenac Sandoz</Name>
                <Pack ID="P2355981" Specified="true" nzmt:ctpp_id="50050751000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>1.99</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140102" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab EC 50 mg</Name>
              <Brand ID="B19040114010226" PSS="2024-06-30">
                <Name>Diclofenac Sandoz</Name>
                <Pack ID="P2356007" Specified="true" nzmt:ctpp_id="50050761000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>1.99</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140103" Rank="1" Units="tab" Weight="75" Statim="Must">
              <Name>Tab long-acting 75 mg</Name>
              <Brand ID="B19040114010302">
                <Name>Voltaren SR</Name>
                <Pack ID="P2140276" Specified="true" nzmt:ctpp_id="50024141000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>19.60</Subsidy>
                  <Price>19.60</Price>
                  <Alternate>19.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140105" Rank="4" Units="inj" Weight="75" Statim="Must">
              <Name>Inj 25 mg per ml, 3 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B19040114010501">
                <Name>Voltaren</Name>
                <Pack ID="P263486" Specified="true" nzmt:ctpp_id="50058331000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>13.20</Subsidy>
                  <Price>13.20</Price>
                  <Alternate>13.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140106" Rank="5" Units="supp" Weight="12.5" Statim="Must">
              <Name>Suppos 12.5 mg</Name>
              <Brand ID="B19040114010601">
                <Name>Voltaren</Name>
                <Pack ID="P645931" Specified="true" nzmt:ctpp_id="50100171000117109">
                  <Quantity>10</Quantity>
                  <Subsidy>2.04</Subsidy>
                  <Price>2.04</Price>
                  <Alternate>2.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140107" Rank="5" Units="supp" Weight="25" Statim="Must">
              <Name>Suppos 25 mg</Name>
              <Brand ID="B19040114010701">
                <Name>Voltaren</Name>
                <Pack ID="P645958" Specified="true" nzmt:ctpp_id="50100181000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>2.44</Subsidy>
                  <Price>2.44</Price>
                  <Alternate>2.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140108" Rank="5" Units="supp" Weight="50" Statim="Must">
              <Name>Suppos 50 mg</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <Brand ID="B19040114010801">
                <Name>Voltaren</Name>
                <Pack ID="P747742" Specified="true" nzmt:ctpp_id="50107991000117109">
                  <Quantity>10</Quantity>
                  <Subsidy>4.22</Subsidy>
                  <Price>4.22</Price>
                  <Alternate>4.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140109" Rank="5" Units="supp" Weight="100" Statim="Must">
              <Name>Suppos 100 mg</Name>
              <Brand ID="B19040114010901">
                <Name>Voltaren</Name>
                <Pack ID="P747750" Specified="true" nzmt:ctpp_id="50108001000117101">
                  <Quantity>10</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401140111" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab 50 mg dispersible</Name>
              <Brand ID="B19040114011101">
                <Name>Voltaren D</Name>
                <Pack ID="P269905" Specified="true" nzmt:ctpp_id="50059871000117105">
                  <Quantity>20</Quantity>
                  <Subsidy>1.50</Subsidy>
                  <Price>1.50</Price>
                  <Alternate>1.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1904011697" Statim="Must">
            <Name>Ketoprofen</Name>
            <Formulation ID="F190401169703" Rank="2" Units="cap" Weight="200">
              <Name>Cap long-acting 200 mg</Name>
              <Brand ID="B19040116970303">
                <Name>Oruvail SR</Name>
                <Pack ID="P397148" Specified="true" nzmt:ctpp_id="50081641000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>12.07</Subsidy>
                  <Price>12.07</Price>
                  <Alternate>12.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1904011769" Statim="Must">
            <Name>Mefenamic acid</Name>
            <Formulation ID="F190401176901" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B19040117690101">
                <Name>Ponstan</Name>
                <Pack ID="P616168" Specified="true" nzmt:ctpp_id="50099221000117100">
                  <Quantity>20</Quantity>
                  <Subsidy>0.50</Subsidy>
                  <Price>7.50</Price>
                  <Alternate>3.67</Alternate>
                  <Surcharge>0.35000</Surcharge>
                </Pack>
                <Pack ID="P2469499" Specified="true" nzmt:ctpp_id="50218561000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>1.25</Subsidy>
                  <Price>10.82</Price>
                  <Alternate>1.25</Alternate>
                  <Surcharge>0.19140</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1904012536" Statim="Must">
            <Name>Tenoxicam</Name>
            <Formulation ID="F190401253601" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B19040125360101" PSS="2025-06-30">
                <Name>Tilcotil</Name>
                <Pack ID="P2520559" Specified="true" nzmt:ctpp_id="50106671000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>18.50</Subsidy>
                  <Price>18.50</Price>
                  <Alternate>18.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401253626" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg vial</Name>
              <Brand ID="B19040125362625">
                <Name>AFT</Name>
                <Pack ID="P2307022" Specified="true" nzmt:ctpp_id="50046201000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9.95</Subsidy>
                  <Price>9.95</Price>
                  <Alternate>9.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1904012782" Statim="Must">
            <Name>Naproxen</Name>
            <Formulation ID="F190401278205" Rank="1" Units="tab" Weight="750">
              <Name>Tab long-acting 750 mg</Name>
              <Brand ID="B19040127820501" PSS="2024-06-30">
                <Name>Naprosyn SR 750</Name>
                <Pack ID="P2518627" Specified="true" nzmt:ctpp_id="50110911000117103">
                  <Quantity>28</Quantity>
                  <Subsidy>6.47</Subsidy>
                  <Price>6.47</Price>
                  <Alternate>6.47</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401278206" Rank="1" Units="tab" Weight="1000">
              <Name>Tab long-acting 1 g</Name>
              <Brand ID="B19040127820601" PSS="2024-06-30">
                <Name>Naprosyn SR 1000</Name>
                <Pack ID="P2518619" Specified="true" nzmt:ctpp_id="50110931000117107">
                  <Quantity>28</Quantity>
                  <Subsidy>8.62</Subsidy>
                  <Price>8.62</Price>
                  <Alternate>8.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401278209" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B19040127820904" PSS="2024-06-30">
                <Name>Noflam 250</Name>
                <Pack ID="P319333">
                  <Quantity>500</Quantity>
                  <Subsidy>32.69</Subsidy>
                  <Price>32.69</Price>
                  <Alternate>32.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2654458" Specified="true" nzmt:ctpp_id="50071471000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>32.69</Subsidy>
                  <Price>32.69</Price>
                  <Alternate>32.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401278211" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B19040127821103" PSS="2024-06-30">
                <Name>Noflam 500</Name>
                <Pack ID="P323071" nzmt:ctpp_id="50072121000117108">
                  <Quantity>250</Quantity>
                  <Subsidy>28.71</Subsidy>
                  <Price>28.71</Price>
                  <Alternate>28.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2654466" Specified="true">
                  <Quantity>250</Quantity>
                  <Subsidy>28.71</Subsidy>
                  <Price>28.71</Price>
                  <Alternate>28.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1904012798">
            <Name>Ibuprofen</Name>
            <Formulation ID="F190401279801" Rank="1" Units="tab" Weight="200" Statim="Must">
              <Name>Tab 200 mg</Name>
              <Brand ID="B19040127980129" SoleSupply="2026-06-30">
                <Name>Relieve</Name>
                <Pack ID="P2526212" Specified="true" nzmt:ctpp_id="50249431000117100">
                  <Quantity>1000</Quantity>
                  <Subsidy>21.40</Subsidy>
                  <Price>21.40</Price>
                  <Alternate>21.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401279804" Rank="1" Units="tab" Weight="800" Statim="Must">
              <Name>Tab long-acting 800 mg</Name>
              <Brand ID="B19040127980401" PSS="2024-06-30">
                <Name>Brufen SR</Name>
                <Pack ID="P2534320" Specified="true" nzmt:ctpp_id="50040471000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>3.05</Subsidy>
                  <Price>3.05</Price>
                  <Alternate>3.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190401279805" Rank="3" Units="ml" Weight="20" Statim="Must">
              <Name>Oral liq 20 mg per ml</Name>
              <Brand ID="B19040127980525">
                <Name>Fenpaed 100 mg per 5 ml</Name>
                <Pack ID="P2090864" Specified="true" nzmt:ctpp_id="50017201000117104">
                  <Quantity>200</Quantity>
                  <Subsidy>11.29</Subsidy>
                  <Price>11.29</Price>
                  <Alternate>11.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19040127980526" PSS="2024-06-30">
                <Name>Ethics</Name>
                <Pack ID="P2551985" Specified="true" nzmt:ctpp_id="50220601000117102">
                  <Quantity>200</Quantity>
                  <Subsidy>2.25</Subsidy>
                  <Price>2.25</Price>
                  <Alternate>2.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A190402">
          <Name>NSAIDs Other</Name>
          <Chemical ID="C1904024081">
            <Name>Celecoxib</Name>
            <Formulation ID="F190402408125" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B19040240812525" PSS="2025-06-30">
                <Name>Celecoxib Pfizer</Name>
                <Pack ID="P2521164" Specified="true" nzmt:ctpp_id="50241081000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>3.45</Subsidy>
                  <Price>3.45</Price>
                  <Alternate>3.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19040240812526">
                <Name>Celebrex</Name>
                <Pack ID="P2642433" Specified="true" nzmt:ctpp_id="50304311000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>3.45</Subsidy>
                  <Price>3.45</Price>
                  <Alternate>3.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190402408126" Rank="2" Units="cap" Weight="200">
              <Name>Cap 200 mg</Name>
              <Brand ID="B19040240812625" PSS="2025-06-30">
                <Name>Celecoxib Pfizer</Name>
                <Pack ID="P2521172" Specified="true" nzmt:ctpp_id="50241111000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>3.20</Subsidy>
                  <Price>3.20</Price>
                  <Alternate>3.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19040240812626">
                <Name>Celebrex</Name>
                <Pack ID="P2642441" Specified="true" nzmt:ctpp_id="50304341000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>3.20</Subsidy>
                  <Price>3.20</Price>
                  <Alternate>3.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1905">
        <Name>Topical Products for Joint and Muscular Pain</Name>
        <ATC3 ID="A190501">
          <Name>Topical Products for Joint and Muscular Pain</Name>
          <Chemical ID="C1905013854">
            <Name>Capsaicin</Name>
            <Formulation ID="F190501385426" Rank="3" Units="g">
              <Name>Crm 0.025%</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1289"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1289">
                <Title>
                  <range>Capsaicin</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="patient's lifetime"/>
                </Case>
              </Request>
              <Brand ID="B19050138542625">
                <Name>Zostrix</Name>
                <Pack ID="P472786" Specified="true" OP="true" nzmt:ctpp_id="50089091000117105">
                  <Quantity>45</Quantity>
                  <Subsidy>9.75</Subsidy>
                  <Price>9.75</Price>
                  <Alternate>9.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19050138542626" S29="true">
                <Name>Rugby Capsaicin Topical Cream</Name>
                <Pack ID="P2578409" Specified="true" OP="true" nzmt:ctpp_id="50271921000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>13.00</Subsidy>
                  <Price>13.00</Price>
                  <Alternate>13.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1907">
        <Name>Antirheumatoid Agents</Name>
        <ATC3 ID="A190701">
          <Name>Antirheumatoid Agents</Name>
          <Chemical ID="C1907011625" Statim="Must">
            <Name>Hydroxychloroquine</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Subsidised only if prescribed for rheumatoid arthritis, systemic or discoid lupus
        erythematosus, malaria treatment or suppression, relevant dermatological conditions
        (cutaneous forms of lupus and lichen planus, cutaneous vasculitides and mucosal
        ulceration)*, sarcoidosis (pulmonary and non-pulmonary)*, and the prescription is endorsed
        accordingly. Pharmacists may annotate the prescription as endorsed where there exists a
        record of prior dispensing of hydroxychloroquine.</p>
              <p>Note: Indication marked with a * is an unapproved indication.</p>
            </div>
            <Formulation ID="F190701162501" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B19070116250101">
                <Name>Plaquenil</Name>
                <Pack ID="P208264" Specified="true" nzmt:ctpp_id="50013571000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>8.78</Subsidy>
                  <Price>8.78</Price>
                  <Alternate>8.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1907011942">
            <Name>Penicillamine</Name>
            <Formulation ID="F190701194203" Rank="1" Units="tab" Weight="125">
              <Name>Tab 125 mg</Name>
              <Brand ID="B19070119420301">
                <Name>D-Penamine</Name>
                <Pack ID="P2125374" Specified="true" nzmt:ctpp_id="50022641000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>67.23</Subsidy>
                  <Price>67.23</Price>
                  <Alternate>67.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190701194204" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B19070119420401">
                <Name>D-Penamine</Name>
                <Pack ID="P2125382" Specified="true" nzmt:ctpp_id="50022651000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>110.12</Subsidy>
                  <Price>110.12</Price>
                  <Alternate>110.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1907013763">
            <Name>Leflunomide</Name>
            <Formulation ID="F190701376325" Rank="1" Units="tab" Weight="20" Statim="Must">
              <Name>Tab 20 mg</Name>
              <Brand ID="B19070137632525" PSS="2026-06-30">
                <Name>Arava</Name>
                <Pack ID="P369470" Specified="true" nzmt:ctpp_id="50078741000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190701376326" Rank="1" Units="tab" Weight="10" Statim="Must">
              <Name>Tab 10 mg</Name>
              <Brand ID="B19070137632625" PSS="2026-06-30">
                <Name>Arava</Name>
                <Pack ID="P306843" Specified="true" nzmt:ctpp_id="50068541000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1908">
        <Name>Drugs Affecting Bone Metabolism</Name>
        <ATC3 ID="A190802">
          <Name>Alendronate for Osteoporosis</Name>
          <Chemical ID="C1908021037" Statim="Must">
            <Name>Alendronate sodium</Name>
            <Formulation ID="F190802103725" Rank="1" Units="tab" Weight="70">
              <Name>Tab 70 mg</Name>
              <Brand ID="B19080210372525">
                <Name>Fosamax</Name>
                <Pack ID="P2022133" Specified="true" nzmt:ctpp_id="50004451000117109">
                  <Quantity>4</Quantity>
                  <Subsidy>3.10</Subsidy>
                  <Price>3.10</Price>
                  <Alternate>3.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1908023868" Statim="Must">
            <Name>Alendronate sodium with colecalciferol</Name>
            <Formulation ID="F190802386826" Rank="1" Units="tab">
              <Name>Tab 70 mg with colecalciferol 5,600 iu</Name>
              <Brand ID="B19080238682625">
                <Name>Fosamax Plus</Name>
                <Pack ID="P2337053" Specified="true" nzmt:ctpp_id="50049741000117107">
                  <Quantity>4</Quantity>
                  <Subsidy>1.99</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A190806">
          <Name>Other Treatments</Name>
          <Chemical ID="C1908063913">
            <Name>Zoledronic acid</Name>
            <Formulation ID="F190806391327" Rank="3" Units="ml">
              <Name>Inj 0.05 mg per ml, 100 ml, bag</Name>
              <Brand ID="B19080639132725" PSS="2025-06-30">
                <Name>Zoledronic Acid Viatris</Name>
                <Pack ID="P2636743" Specified="true" OP="true" nzmt:ctpp_id="50300801000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>22.53</Subsidy>
                  <Price>22.53</Price>
                  <Alternate>22.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1908063938" Statim="Must">
            <Name>Raloxifene hydrochloride</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1779"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1779">
              <Title>
                <range>Raloxifene</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to
                    2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes)</ci>
                    <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot
                    be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci>
                    <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci>
                    <ci type="logical" class="indication">Documented T-Score less than or equal to -3.0 (see Notes)</ci>
                    <ci type="logical" class="indication">A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which
                    incorporates BMD measurements (see Notes)</ci>
                    <ci type="logical" class="indication">Patient has had a Special Authority approval for zoledronic acid (Underlying cause â€“ Osteoporosis) or has had a Special Authority approval for
                    alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: lower-alpha">
                  <li>
                    <p>BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not
                    acceptable.</p>
                  </li>
                  <li>
                    <p>Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less
                    than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.</p>
                  </li>
                  <li>
                    <p>Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO
                    defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of
                    mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.</p>
                  </li>
                  <li>
                    <p>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or
                    greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</p>
                  </li>
                </ol>
              </div>
            </Request>
            <Formulation ID="F190806393825" Rank="1" Units="tab" Weight="60">
              <Name>Tab 60 mg</Name>
              <Brand ID="B19080639382525">
                <Name>Evista</Name>
                <Pack ID="P237523" Specified="true" nzmt:ctpp_id="50051191000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>53.76</Subsidy>
                  <Price>53.76</Price>
                  <Alternate>53.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1908063939">
            <Name>Teriparatide</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1139"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1139">
              <Title>
                <range>Teriparatide</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci>
                    <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci>
                    <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci>
                    <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 monthsâ€™ continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">18</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: lower-alpha">
                  <li>
                    <p>The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA).  Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable</p>
                  </li>
                  <li>
                    <p>Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year.  If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 monthsâ€™ continuous therapy.</p>
                  </li>
                  <li>
                    <p>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</p>
                  </li>
                  <li>
                    <p>A maximum of 18 months of treatment (18 cartridges) will be subsidised.</p>
                  </li>
                </ol>
              </div>
            </Request>
            <Formulation ID="F190806393925" Rank="4" Units="inj" Weight="250">
              <Name>Inj 250 mcg per ml, 2.4 ml</Name>
              <Brand ID="B19080639392525" ToBeDelisted="2024-06-01">
                <Name>Forteo</Name>
                <Pack ID="P2222906" nzmt:ctpp_id="50035421000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>490.00</Subsidy>
                  <Price>490.00</Price>
                  <Alternate>490.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2650908" Specified="true" nzmt:ctpp_id="50309431000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>490.00</Subsidy>
                  <Price>490.00</Price>
                  <Alternate>490.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19080639392526" ToBePSS="2024-06-01">
                <Name>Teriparatide - Teva</Name>
                <Pack ID="P2670399" Specified="true" nzmt:ctpp_id="50294581000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>195.00</Subsidy>
                  <Price>195.00</Price>
                  <Alternate>195.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1908064015">
            <Name>Risedronate sodium</Name>
            <Formulation ID="F190806401525" Rank="1" Units="tab" Weight="30">
              <Name>Tab 35 mg</Name>
              <Brand ID="B19080640152525" PSS="2025-06-30">
                <Name>Risedronate Sandoz</Name>
                <Pack ID="P2440202" Specified="true" nzmt:ctpp_id="50148021000117100">
                  <Quantity>4</Quantity>
                  <Subsidy>2.50</Subsidy>
                  <Price>2.50</Price>
                  <Alternate>2.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1908064101">
            <Name>Denosumab</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1777"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1777">
              <Title>
                <range>Denosumab</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">The patient has severe, established osteoporosis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">The patient is female and postmenopausal</ci>
                      <ci type="logical" class="Trial">The patient is male or non-binary</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5
                        standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note)</ci>
                      <ci type="logical" class="Trial">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be
                        performed because of major logistical, technical or pathophysiological reasons</ci>
                      <ci type="logical" class="Trial">History of two significant osteoporotic fractures demonstrated radiologically</ci>
                      <ci type="logical" class="Trial">Documented T-Score less than or equal to -3.0 (see Note)</ci>
                      <ci type="logical" class="Trial">A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which
                        incorporates BMD measurements (see Note)</ci>
                      <ci type="logical" class="Trial">Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special
                        Authority approval for raloxifene</ci>
                    </apply>
                    <ci type="logical" class="Therapy">Zoledronic acid is contraindicated because the patientâ€™s creatinine clearance is less than 35 mL/min</ci>
                    <ci type="logical" class="Therapy">The patient has experienced at least one symptomatic new fracture after at least 12 monthsâ€™ continuous therapy with a funded antiresorptive agent at
                    adequate doses (see Notes)</ci>
                    <ci type="logical" class="Therapy">The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: lower-alpha">
                  <li>
                    <p>BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not
                    acceptable</p>
                  </li>
                  <li>
                    <p>Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less
                    than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab</p>
                  </li>
                  <li>
                    <p>Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO
                    defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of
                    mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less</p>
                  </li>
                  <li>
                    <p>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or
                    greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>
                  </li>
                  <li>
                    <p>Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or
                    tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal
                    develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 monthsâ€™
                    continuous therapy</p>
                  </li>
                </ol>
              </div>
            </Request>
            <Formulation ID="F190806410125" Rank="4" Units="inj" Weight="60">
              <Name>Inj 60 mg prefilled syringe</Name>
              <Brand ID="B19080641012525">
                <Name>Prolia</Name>
                <Pack ID="P2406047" Specified="true" nzmt:ctpp_id="50253831000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>326.00</Subsidy>
                  <Price>326.00</Price>
                  <Alternate>326.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1908066033">
            <Name>Pamidronate disodium</Name>
            <Formulation ID="F190806603301" Rank="4" Units="inj" Weight="30">
              <Name>Inj 3 mg per ml, 10 ml vial</Name>
              <Brand ID="B19080660330125">
                <Name>Pamisol</Name>
                <Pack ID="P2034166" Specified="true" nzmt:ctpp_id="50020011000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>32.49</Subsidy>
                  <Price>32.49</Price>
                  <Alternate>32.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190806603326" Rank="4" Units="inj" Weight="60">
              <Name>Inj 6 mg per ml, 10 ml vial</Name>
              <Brand ID="B19080660332625">
                <Name>Pamisol</Name>
                <Pack ID="P2034174" Specified="true" nzmt:ctpp_id="50020031000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>88.11</Subsidy>
                  <Price>88.11</Price>
                  <Alternate>88.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F190806603327" Rank="4" Units="inj" Weight="90">
              <Name>Inj 9 mg per ml, 10 ml vial</Name>
              <Brand ID="B19080660332725">
                <Name>Pamisol</Name>
                <Pack ID="P2034190" Specified="true" nzmt:ctpp_id="50006641000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>94.34</Subsidy>
                  <Price>94.34</Price>
                  <Alternate>94.34</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1913">
        <Name>Hyperuricaemia and Antigout</Name>
        <ATC3 ID="A191301">
          <Name>Hyperuricaemia and Antigout</Name>
          <Chemical ID="C1913011026" Statim="Must">
            <Name>Allopurinol</Name>
            <Formulation ID="F191301102601" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B19130110260127" ToBeDelisted="2024-06-01">
                <Name>DP-Allopurinol</Name>
                <Pack ID="P2515849" Specified="true" nzmt:ctpp_id="50237531000117105">
                  <Quantity>500</Quantity>
                  <Subsidy>11.47</Subsidy>
                  <Price>11.47</Price>
                  <Alternate>11.47</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19130110260128" ToBePSS="2024-06-01">
                <Name>Ipca-Allopurinol</Name>
                <Pack ID="P2666855" Specified="true" nzmt:ctpp_id="50202431000117104">
                  <Quantity>1000</Quantity>
                  <Subsidy>17.99</Subsidy>
                  <Price>17.99</Price>
                  <Alternate>17.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F191301102602" Rank="1" Units="tab" Weight="300">
              <Name>Tab 300 mg</Name>
              <Brand ID="B19130110260228" ToBeDelisted="2024-06-01">
                <Name>DP-Allopurinol</Name>
                <Pack ID="P2515857" Specified="true" nzmt:ctpp_id="50240771000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>28.57</Subsidy>
                  <Price>28.57</Price>
                  <Alternate>28.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19130110260229" ToBePSS="2024-06-01">
                <Name>Ipca-Allopurinol</Name>
                <Pack ID="P2666863" Specified="true" nzmt:ctpp_id="50236381000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>22.50</Subsidy>
                  <Price>22.50</Price>
                  <Alternate>22.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1913011341" Statim="Must">
            <Name>Colchicine</Name>
            <Formulation ID="F191301134125" Rank="1" Units="tab">
              <Name>Tab 500 mcg</Name>
              <Brand ID="B19130113412525" PSS="2025-06-30">
                <Name>Colgout</Name>
                <Pack ID="P2200503" Specified="true" nzmt:ctpp_id="50031911000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1913012042" Statim="Must">
            <Name>Probenecid</Name>
            <Formulation ID="F191301204201" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B19130120420125">
                <Name>Probenecid-AFT</Name>
                <Pack ID="P2012499" Specified="true" nzmt:ctpp_id="50001631000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>66.95</Subsidy>
                  <Price>66.95</Price>
                  <Alternate>66.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1913014003">
            <Name>Benzbromarone</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1963"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1963">
              <Title>
                <range>Benzbromarone</range>
              </Title>
              <Case When="Renewal" Form="SA1319 SA1537 SA1963">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the
                    patient is benefitting from the treatment</ci>
                    <ci type="logical" class="Indication">There is no evidence of liver toxicity and
                    patient is continuing to receive regular (at least every three months) liver
                    function tests</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F191301400325" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B19130140032525" S29="true">
                <Name>Benzbromaron AL 100</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2434598" Specified="true" nzmt:ctpp_id="50164541000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>45.00</Subsidy>
                  <Price>45.00</Price>
                  <Alternate>45.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19130140032526" S29="true">
                <Name>Desuric</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2588366" Specified="true" nzmt:ctpp_id="50276531000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>13.50</Subsidy>
                  <Price>13.50</Price>
                  <Alternate>13.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19130140032527" S29="true">
                <Name>Urinorm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2588234" Specified="true" nzmt:ctpp_id="50276541000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>13.50</Subsidy>
                  <Price>13.50</Price>
                  <Alternate>13.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F191301400326" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B19130140032625" S29="true">
                <Name>Narcaricin mite</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2583194" Specified="true" nzmt:ctpp_id="50274141000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>32.00</Subsidy>
                  <Price>32.00</Price>
                  <Alternate>32.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1913014026">
            <Name>Febuxostat</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2054"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2054">
              <Title>
                <range>Febuxostat</range>
              </Title>
              <Case When="Initial application" Category="Gout">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with gout</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has a serum urate level
                        greater than 0.36 mmol/l despite treatment with allopurinol at doses of at
                        least 600 mg/day and addition of probenecid at doses of up to 2 g per day or
                        maximum tolerated dose</ci>
                      <ci type="logical" class="Indication">The patient has experienced intolerable
                        side effects from allopurinol such that treatment discontinuation is
                        required and serum urate remains greater than 0.36 mmol/l despite use of
                        probenecid at doses of up to 2 g per day or maximum tolerated dose</ci>
                      <ci type="logical" class="Indication">The patient has renal impairment such that
                        probenecid is contraindicated or likely to be ineffective and serum urate
                        remains greater than 0.36 mmol/l despite optimal treatment with allopurinol
                        (see Note)</ci>
                      <ci type="logical" class="Indication">The patient has previously had an initial
                        Special Authority approval for benzbromarone for treatment of gout.</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Tumour lysis syndrome">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome</ci>
                    <ci type="logical" class="Indication">Patient has a documented history of allopurinol intolerance</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>oncologist</Applicant>
                <Term Measure="week">6</Term>
              </Case>
              <Case When="Renewal" Category="Gout" Form="SA1431 SA1538 SA1931 SA1996 SA2054">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient
                is benefitting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Renewal" Category="Tumour lysis syndrome" Form="SA1431 SA1538 SA1931 SA1996 SA2054">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient
                is benefitting from treatment</ci>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>oncologist</Applicant>
                <Term Measure="week">6</Term>
              </Case>
            </Request>
            <Formulation ID="F191301402625" Rank="1" Units="tab" Weight="80">
              <Name>Tab 80 mg</Name>
              <Brand ID="B19130140262526" ToBeDelisted="2024-06-01">
                <Name>Febuxostat multichem</Name>
                <Pack ID="P2614170" Specified="true" nzmt:ctpp_id="50266271000117103">
                  <Quantity>28</Quantity>
                  <Subsidy>20.00</Subsidy>
                  <Price>20.00</Price>
                  <Alternate>20.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19130140262527" ToBePSS="2024-06-01">
                <Name>Febuxostat (Teva)</Name>
                <Pack ID="P2670356" Specified="true" nzmt:ctpp_id="50260241000117106">
                  <Quantity>28</Quantity>
                  <Subsidy>4.73</Subsidy>
                  <Price>4.73</Price>
                  <Alternate>4.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F191301402626" Rank="1" Units="tab" Weight="120">
              <Name>Tab 120 mg</Name>
              <Brand ID="B19130140262626" ToBeDelisted="2024-06-01">
                <Name>Febuxostat multichem</Name>
                <Pack ID="P2614189" Specified="true" nzmt:ctpp_id="50266261000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>20.00</Subsidy>
                  <Price>20.00</Price>
                  <Alternate>20.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19130140262627" ToBePSS="2024-06-01">
                <Name>Febuxostat (Teva)</Name>
                <Pack ID="P2670364" Specified="true" nzmt:ctpp_id="50260271000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>11.78</Subsidy>
                  <Price>11.78</Price>
                  <Alternate>11.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A1916">
        <Name>Muscle Relaxants</Name>
        <ATC3 ID="A191601">
          <Name>Muscle Relaxants</Name>
          <Chemical ID="C1916011373">
            <Name>Dantrolene</Name>
            <Formulation ID="F191601137301" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B19160113730101">
                <Name>Dantrium</Name>
                <Pack ID="P252409" Specified="true" nzmt:ctpp_id="50053311000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>112.13</Subsidy>
                  <Price>112.13</Price>
                  <Alternate>112.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B19160113730125" S29="true">
                <Name>Dantrium S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2512580" nzmt:ctpp_id="50237891000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>112.13</Subsidy>
                  <Price>112.13</Price>
                  <Alternate>112.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2648946" Specified="true" nzmt:ctpp_id="50313081000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>112.13</Subsidy>
                  <Price>112.13</Price>
                  <Alternate>112.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F191601137302" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B19160113730201">
                <Name>Dantrium</Name>
                <Pack ID="P252417" Specified="true" nzmt:ctpp_id="50053321000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>77.00</Subsidy>
                  <Price>77.00</Price>
                  <Alternate>77.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1916011908">
            <Name>Orphenadrine citrate</Name>
            <Formulation ID="F191601190801" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B19160119080101" PSS="2024-06-30">
                <Name>Norflex</Name>
                <Pack ID="P2645564" Specified="true" nzmt:ctpp_id="50290901000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>20.76</Subsidy>
                  <Price>20.76</Price>
                  <Alternate>20.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C1916012364">
            <Name>Baclofen</Name>
            <Formulation ID="F191601236401" Rank="1" Units="tab" Weight="10" Statim="Must">
              <Name>Tab 10 mg</Name>
              <Brand ID="B19160123640101">
                <Name>Pacifen</Name>
                <Pack ID="P403903" Specified="true" nzmt:ctpp_id="50082381000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>4.20</Subsidy>
                  <Price>4.20</Price>
                  <Alternate>4.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F191601236425" Rank="4" Units="inj">
              <Name>Inj 0.05 mg per ml, 1 ml ampoule</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B19160123642525">
                <Name>Lioresal Intrathecal</Name>
                <Pack ID="P2162334" Specified="true" nzmt:ctpp_id="50027491000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>11.55</Subsidy>
                  <Price>11.55</Price>
                  <Alternate>11.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F191601236426" Rank="4" Units="inj" Weight="2">
              <Name>Inj 2 mg per ml, 5 ml ampoule</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B19160123642626" PSS="2024-06-30">
                <Name>Medsurge</Name>
                <Pack ID="P2560054" Specified="true" nzmt:ctpp_id="50256691000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>306.82</Subsidy>
                  <Price>306.82</Price>
                  <Alternate>306.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A22">
      <Name>Nervous System</Name>
      <ATC2 ID="A2201">
        <Name>Agents for Parkinsonism and Related Disorders</Name>
        <ATC3 ID="A220101">
          <Name>Dopamine Agonists and Related Agents</Name>
          <Chemical ID="C2201011024" Statim="May">
            <Name>Apomorphine hydrochloride</Name>
            <Formulation ID="F220101102425" Rank="4" Units="inj">
              <Name>Inj 10 mg per ml, 2 ml ampoule</Name>
              <Brand ID="B22010110242527">
                <Name>Movapo</Name>
                <Pack ID="P2498723" Specified="true" nzmt:ctpp_id="50232801000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>59.50</Subsidy>
                  <Price>59.50</Price>
                  <Alternate>59.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101102426" Rank="4" Units="inj">
              <Name>Inj 10 mg per ml, 5 ml ampoule</Name>
              <Brand ID="B22010110242625">
                <Name>Movapo</Name>
                <Pack ID="P2581159" Specified="true" nzmt:ctpp_id="50232791000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>121.84</Subsidy>
                  <Price>121.84</Price>
                  <Alternate>121.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201011048" Statim="May">
            <Name>Amantadine hydrochloride</Name>
            <Formulation ID="F220101104801" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B22010110480101">
                <Name>Symmetrel</Name>
                <Pack ID="P204749" Specified="true" nzmt:ctpp_id="50149201000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>63.73</Subsidy>
                  <Price>63.73</Price>
                  <Alternate>63.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P788589" Specified="true" nzmt:ctpp_id="50115041000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>38.24</Subsidy>
                  <Price>38.24</Price>
                  <Alternate>38.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201011138" Statim="May">
            <Name>Tolcapone</Name>
            <Formulation ID="F220101113801" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22010111380101">
                <Name>Tasmar</Name>
                <Pack ID="P487236" Specified="true" nzmt:ctpp_id="50091491000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>152.38</Subsidy>
                  <Price>152.38</Price>
                  <Alternate>152.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201011717" Statim="Must">
            <Name>Levodopa with benserazide</Name>
            <Formulation ID="F220101171702" Rank="2" Units="cap" Weight="200">
              <Name>Cap 200 mg with benserazide 50 mg</Name>
              <Brand ID="B22010117170201">
                <Name>Madopar 250</Name>
                <Pack ID="P201448" Specified="true" nzmt:ctpp_id="50002321000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>26.25</Subsidy>
                  <Price>26.25</Price>
                  <Alternate>26.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101171706" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg with benserazide 25 mg</Name>
              <Brand ID="B22010117170601">
                <Name>Madopar 125</Name>
                <Pack ID="P201421" Specified="true" nzmt:ctpp_id="50002261000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>15.80</Subsidy>
                  <Price>15.80</Price>
                  <Alternate>15.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101171707" Rank="2" Units="cap" Weight="100">
              <Name>Cap long-acting 100 mg with benserazide 25 mg</Name>
              <Brand ID="B22010117170701">
                <Name>Madopar HBS</Name>
                <Pack ID="P693960" Specified="true" nzmt:ctpp_id="50102391000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>22.85</Subsidy>
                  <Price>22.85</Price>
                  <Alternate>22.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101171708" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg with benserazide 12.5 mg</Name>
              <Brand ID="B22010117170801">
                <Name>Madopar 62.5</Name>
                <Pack ID="P201413" Specified="true" nzmt:ctpp_id="50002221000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>13.75</Subsidy>
                  <Price>13.75</Price>
                  <Alternate>13.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101171709" Rank="1" Units="tab" Weight="50">
              <Name>Tab dispersible 50 mg with benserazide 12.5 mg</Name>
              <Brand ID="B22010117170901">
                <Name>Madopar Rapid</Name>
                <Pack ID="P635960" Specified="true" nzmt:ctpp_id="50133141000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>13.25</Subsidy>
                  <Price>13.25</Price>
                  <Alternate>13.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201011723">
            <Name>Levodopa with carbidopa</Name>
            <Formulation ID="F220101172301" Rank="1" Units="tab" Weight="100" Statim="Must">
              <Name>Tab 100 mg with carbidopa 25 mg</Name>
              <Brand ID="B22010117230102">
                <Name>Sinemet</Name>
                <Pack ID="P2429985" Specified="true" nzmt:ctpp_id="50058921000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>21.11</Subsidy>
                  <Price>21.11</Price>
                  <Alternate>21.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101172302" Rank="1" Units="tab" Weight="250" Statim="Must">
              <Name>Tab 250 mg with carbidopa 25 mg</Name>
              <Brand ID="B22010117230201">
                <Name>Sinemet</Name>
                <Pack ID="P2429993" Specified="true" nzmt:ctpp_id="50008781000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>38.39</Subsidy>
                  <Price>38.39</Price>
                  <Alternate>38.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101172303" Rank="1" Units="tab" Weight="200" Statim="Must">
              <Name>Tab long-acting 200 mg with carbidopa 50 mg</Name>
              <Brand ID="B22010117230301">
                <Name>Sinemet CR</Name>
                <Pack ID="P2430002" Specified="true" nzmt:ctpp_id="50102931000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>43.65</Subsidy>
                  <Price>43.65</Price>
                  <Alternate>43.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201013829" Statim="May">
            <Name>Entacapone</Name>
            <Formulation ID="F220101382925" Rank="1" Units="tab">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22010138292525" PSS="2024-06-30">
                <Name>Comtan</Name>
                <Pack ID="P2536471" Specified="true" nzmt:ctpp_id="50019691000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>18.04</Subsidy>
                  <Price>18.04</Price>
                  <Alternate>18.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201013830" Statim="May">
            <Name>Ropinirole hydrochloride</Name>
            <Formulation ID="F220101383025" Rank="1" Units="tab">
              <Name>Tab 0.25 mg</Name>
              <Brand ID="B22010138302526" PSS="2025-06-30">
                <Name>Ropin</Name>
                <Pack ID="P2310856" Specified="true" nzmt:ctpp_id="50047091000117107">
                  <Quantity>84</Quantity>
                  <Subsidy>4.05</Subsidy>
                  <Price>4.05</Price>
                  <Alternate>4.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101383026" Rank="1" Units="tab">
              <Name>Tab 1 mg</Name>
              <Brand ID="B22010138302626" PSS="2025-06-30">
                <Name>Ropin</Name>
                <Pack ID="P2310864" Specified="true" nzmt:ctpp_id="50047101000117103">
                  <Quantity>84</Quantity>
                  <Subsidy>4.95</Subsidy>
                  <Price>4.95</Price>
                  <Alternate>4.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101383027" Rank="1" Units="tab">
              <Name>Tab 2 mg</Name>
              <Brand ID="B22010138302726" PSS="2025-06-30">
                <Name>Ropin</Name>
                <Pack ID="P2310872" Specified="true" nzmt:ctpp_id="50047111000117100">
                  <Quantity>84</Quantity>
                  <Subsidy>6.48</Subsidy>
                  <Price>6.48</Price>
                  <Alternate>6.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101383028" Rank="1" Units="tab">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22010138302826" PSS="2025-06-30">
                <Name>Ropin</Name>
                <Pack ID="P2310880" Specified="true" nzmt:ctpp_id="50047121000117106">
                  <Quantity>84</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201013942" Statim="May">
            <Name>Pramipexole hydrochloride</Name>
            <Formulation ID="F220101394226" Rank="1" Units="tab" Weight="0.25">
              <Name>Tab 0.25 mg</Name>
              <Brand ID="B22010139422626" PSS="2025-06-30">
                <Name>Ramipex</Name>
                <Pack ID="P2450534" Specified="true" nzmt:ctpp_id="50192081000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>5.51</Subsidy>
                  <Price>5.51</Price>
                  <Alternate>5.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220101394228" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B22010139422826" PSS="2025-06-30">
                <Name>Ramipex</Name>
                <Pack ID="P2450542" Specified="true" nzmt:ctpp_id="50192101000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>18.66</Subsidy>
                  <Price>18.66</Price>
                  <Alternate>18.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201014148" Statim="Must">
            <Name>Rasagiline</Name>
            <Formulation ID="F220101414825" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B22010141482525" S29="true">
                <Name>Azilect</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2611449" Specified="true" nzmt:ctpp_id="50288211000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>53.50</Subsidy>
                  <Price>53.50</Price>
                  <Alternate>53.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220104">
          <Name>Anticholinergics</Name>
          <Chemical ID="C2201041130">
            <Name>Benzatropine mesylate</Name>
            <Formulation ID="F220104113001" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B22010411300125">
                <Name>Benztrop</Name>
                <Pack ID="P2123169" Specified="true" nzmt:ctpp_id="50022361000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>9.59</Subsidy>
                  <Price>9.59</Price>
                  <Alternate>9.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220104113002" Rank="4" Units="inj" Weight="2">
              <Name>Inj 1 mg per ml, 2 ml</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <Rule Type="FormReqd" Attribute="PSO"/>
              <Brand ID="B22010411300226">
                <Name>Phebra</Name>
                <Pack ID="P2580454" Specified="true" nzmt:ctpp_id="50269741000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>95.00</Subsidy>
                  <Price>95.00</Price>
                  <Alternate>95.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201042049">
            <Name>Procyclidine hydrochloride</Name>
            <Formulation ID="F220104204901" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22010420490101">
                <Name>Kemadrin</Name>
                <Pack ID="P264962" Specified="true" nzmt:ctpp_id="50058851000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>7.40</Subsidy>
                  <Price>7.40</Price>
                  <Alternate>7.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220107">
          <Name>Agents for Essential Tremor, Chorea and Related Disorders</Name>
          <Chemical ID="C2201072237">
            <Name>Tetrabenazine</Name>
            <Formulation ID="F220107223701" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22010722370126" PSS="2025-06-30">
                <Name>Motetis</Name>
                <Pack ID="P2394383" Specified="true" nzmt:ctpp_id="50128441000117103">
                  <Quantity>112</Quantity>
                  <Subsidy>106.59</Subsidy>
                  <Price>106.59</Price>
                  <Alternate>106.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2201074017">
            <Name>Riluzole</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1403"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1403">
              <Title>
                <range>Riluzole</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less</ci>
                    <ci type="logical" class="Indication">The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application</ci>
                    <ci type="logical" class="Indication">The patient has not undergone a tracheostomy</ci>
                    <ci type="logical" class="Indication">The patient has not experienced respiratory failure</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient is ambulatory</ci>
                      <ci type="logical" class="Indication">The patient is able to use upper limbs</ci>
                      <ci type="logical" class="Indication">The patient is able to swallow</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1403">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has not undergone a tracheostomy</ci>
                    <ci type="logical" class="Indication">The patient has not experienced respiratory failure</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient is ambulatory</ci>
                      <ci type="logical" class="Indication">The patient is able to use upper limbs</ci>
                      <ci type="logical" class="Indication">The patient is able to swallow</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">18</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F220107401725" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22010740172525" PSS="2024-06-30">
                <Name>Rilutek</Name>
                <Pack ID="P238732" Specified="true" nzmt:ctpp_id="50051311000117108">
                  <Quantity>56</Quantity>
                  <Subsidy>130.00</Subsidy>
                  <Price>130.00</Price>
                  <Alternate>130.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2202">
        <Name>Anaesthetics</Name>
        <ATC3 ID="A220201">
          <Name>Local</Name>
          <Chemical ID="C2202011719">
            <Name>Lidocaine [Lignocaine] hydrochloride</Name>
            <Formulation ID="F220201171907" Rank="4" Units="inj" Weight="20">
              <Name>Inj 1%, 20 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22020117190701">
                <Name>Xylocaine</Name>
                <Pack ID="P728128" Specified="true" nzmt:ctpp_id="50106521000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>12.00</Subsidy>
                  <Price>20.00</Price>
                  <Alternate>12.00</Alternate>
                  <Surcharge>1.60000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220201171910" Rank="4" Units="inj" Weight="5">
              <Name>Inj 1%, 5 ml ampoule</Name>
              <Rule Type="FormMax" Value="25" Attribute="PSO"/>
              <Brand ID="B22020117191001">
                <Name>Xylocaine</Name>
                <Pack ID="P311219" Specified="true" nzmt:ctpp_id="50069491000117102">
                  <Quantity>50</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>17.50</Subsidy>
                  <Price>35.00</Price>
                  <Alternate>17.50</Alternate>
                  <Surcharge>0.35000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22020117191026">
                <Name>Lidocaine-Baxter</Name>
                <Pack ID="P2599872" Specified="true" nzmt:ctpp_id="50276461000117104">
                  <Quantity>25</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9.50</Subsidy>
                  <Price>9.50</Price>
                  <Alternate>9.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220201171925" Rank="4" Units="inj" Weight="10">
              <Name>Inj 2%, 5 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22020117192527">
                <Name>Lidocaine-Baxter</Name>
                <Pack ID="P2599848" Specified="true" nzmt:ctpp_id="50276501000117104">
                  <Quantity>25</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9.00</Subsidy>
                  <Price>9.00</Price>
                  <Alternate>9.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220201171927" Rank="3" Units="ml">
              <Name>Oral (gel) soln 2%</Name>
              <Brand ID="B22020117192726">
                <Name>Mucosoothe</Name>
                <Pack ID="P2513307" Specified="true" nzmt:ctpp_id="50328161000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>44.00</Subsidy>
                  <Price>44.00</Price>
                  <Alternate>44.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220201171928" Rank="4" Units="inj" Weight="20">
              <Name>Inj 1%, 20 ml vial</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22020117192826">
                <Name>Lidocaine-Baxter</Name>
                <Pack ID="P2599856" Specified="true" nzmt:ctpp_id="50276481000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>6.85</Subsidy>
                  <Price>6.85</Price>
                  <Alternate>6.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220201171929" Rank="4" Units="inj" Weight="40">
              <Name>Inj 2%, 20 ml vial</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22020117192926">
                <Name>Lidocaine-Baxter</Name>
                <Pack ID="P2599864" Specified="true" nzmt:ctpp_id="50276521000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7.15</Subsidy>
                  <Price>7.15</Price>
                  <Alternate>7.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220201171930" Rank="4" Units="inj" Weight="500" Update="New Listing">
              <Name>Inj 10%, 5 ml ampoule</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised only for people receiving palliative care services where other analgesic agents haven't been effective.</p>
              </div>
              <Brand ID="B22020117193025" S29="true">
                <Name>Xylocard 500</Name>
                <Pack ID="P2674351" Specified="true" CBS="true" nzmt:ctpp_id="50329771000117103">
                  <Quantity>10</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2202013905">
            <Name>Lidocaine [Lignocaine]</Name>
            <Formulation ID="F220201390528" Rank="3" Units="ml" Weight="2">
              <Name>Gel 2%, tube</Name>
              <Rule Type="FormMax" Value="150" Attribute="PSO"/>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B22020139052825">
                <Name>Xylocaine 2% Jelly</Name>
                <Pack ID="P2285517" Specified="true" nzmt:ctpp_id="50043981000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>14.50</Subsidy>
                  <Price>14.50</Price>
                  <Alternate>14.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220201390529" Rank="10" Units="each">
              <Name>Gel 2%, 11 ml urethral syringe</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised only if prescribed for urethral, cervical or rectal administration and the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B22020139052925" PSS="2025-06-30">
                <Name>Instillagel Lido</Name>
                <Pack ID="P2580497" Specified="true" nzmt:ctpp_id="50246811000117103">
                  <Quantity>10</Quantity>
                  <Subsidy>59.50</Subsidy>
                  <Price>59.50</Price>
                  <Alternate>59.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220204">
          <Name>Topical Local Anaesthetics</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA0906">
            <Title>
              <range>Topical local anaesthetics<instance>EMLA</instance><instance>LMX4</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">the patient is a child with a chronic medical condition requiring frequent injections or venepuncture</ci>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Renewal" Form="SA0323 SA0906">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
          </Request>
          <Chemical ID="C2202041715">
            <Name>Lidocaine [Lignocaine] with prilocaine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA0906"/>
            <Formulation ID="F220204171501" Rank="3" Units="g" Weight="2.5">
              <Name>Crm 2.5% with prilocaine 2.5%</Name>
              <Brand ID="B22020417150101">
                <Name>EMLA</Name>
                <Pack ID="P719757" Specified="true" OP="true" nzmt:ctpp_id="50105491000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>45.00</Subsidy>
                  <Price>45.00</Price>
                  <Alternate>45.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220204171502" Rank="9" Units="tube" Weight="2.5">
              <Name>Crm 2.5% with prilocaine 2.5% (5 g tubes)</Name>
              <Brand ID="B22020417150201">
                <Name>EMLA</Name>
                <Pack ID="P657697" Specified="true" nzmt:ctpp_id="50100531000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>45.00</Subsidy>
                  <Price>45.00</Price>
                  <Alternate>45.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2202043905">
            <Name>Lidocaine [Lignocaine]</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA0906"/>
            <Formulation ID="F220204390526" Rank="3" Units="g">
              <Name>Crm 4%</Name>
              <Brand ID="B22020439052625">
                <Name>LMX4</Name>
                <Pack ID="P2396564" Specified="true" OP="true" nzmt:ctpp_id="50127631000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>27.00</Subsidy>
                  <Price>27.00</Price>
                  <Alternate>27.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2523248" Specified="true" OP="true" nzmt:ctpp_id="50127621000117107">
                  <Quantity>5</Quantity>
                  <Subsidy>5.40</Subsidy>
                  <Price>5.40</Price>
                  <Alternate>5.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2204">
        <Name>Analgesics</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1904">For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL</p>
        </div>
        <ATC3 ID="A220404">
          <Name>Non-opioid Analgesics</Name>
          <Chemical ID="C2204041087" Statim="Must">
            <Name>Aspirin</Name>
            <Formulation ID="F220404108701" Rank="1" Units="tab" Weight="300">
              <Name>Tab dispersible 300 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22040410870125" ToBePSS="2024-05-01">
                <Name>Ethics Aspirin</Name>
                <Pack ID="P2184338" Specified="true" nzmt:ctpp_id="50030151000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>5.65</Subsidy>
                  <Price>5.65</Price>
                  <Alternate>5.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204041849">
            <Name>Nefopam hydrochloride</Name>
            <Formulation ID="F220404184901" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Brand ID="B22040418490101">
                <Name>Acupan</Name>
                <Pack ID="P225665" Specified="true" nzmt:ctpp_id="50040641000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>23.40</Subsidy>
                  <Price>23.40</Price>
                  <Alternate>23.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204041929">
            <Name>Paracetamol</Name>
            <Formulation ID="F220404192902" Rank="3" Units="ml" Weight="24">
              <Name>Oral liq 120 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="600" Attribute="Rx" Waiver="SubRxF"/>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>Maximum of 200 ml per dispensing for non-endorsed patients. If quantities
                prescribed exceed 200 ml (for non-endorsed patients), then dispense in repeat
                dispensing not exceeding 200 ml per dispensing.</p>
                  </li>
                  <li>
                    <p>Subsidy by endorsement for higher quantities is available for patients with long
                term conditions who require regular daily dosing for one month or greater and the
                prescription is endorsed or annotated accordingly. Pharmacists may annotate the
                prescription as endorsed where dispensing history supports a long-term condition.</p>
                  </li>
                  <li>
                    <p>Note: 200 ml presentations of paracetamol oral liquid may be supplied on BSO to a Vaccinator under the provisions in Part I of Section A.</p>
                  </li>
                </ol>
              </div>
              <Rule Type="NotCombined"/>
              <Brand ID="B22040419290227">
                <Name>Avallon</Name>
                <Pack ID="P2643138" Specified="true" OP="true" nzmt:ctpp_id="50304001000117104">
                  <Quantity>200</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040419290228" PSS="2025-06-30">
                <Name>Paracetamol (Ethics)</Name>
                <Pack ID="P2650665" Specified="true" nzmt:ctpp_id="50207921000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>3.98</Subsidy>
                  <Price>3.98</Price>
                  <Alternate>3.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220404192903" Rank="3" Units="ml" Weight="50">
              <Name>Oral liq 250 mg per 5 ml</Name>
              <Rule Type="FormMax" Value="600" Attribute="Rx" Waiver="SubRxF"/>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>Maximum of 200 ml per dispensing for non-endorsed patients. If quantities
                prescribed exceed 200 ml (for non-endorsed patients), then dispense in repeat
                dispensing not exceeding 200 ml per dispensing.</p>
                  </li>
                  <li>
                    <p>Subsidy by endorsement for higher quantities is available for patients with long
                term conditions who require regular daily dosing for one month or greater and the
                prescription is endorsed or annotated accordingly. Pharmacists may annotate the
                prescription as endorsed where dispensing history supports a long-term condition.</p>
                  </li>
                  <li>
                    <p>Note: 200 ml presentations of paracetamol oral liquid may be supplied on BSO to a Vaccinator under the provisions in Part I of Section A.</p>
                  </li>
                </ol>
              </div>
              <Rule Type="NotCombined"/>
              <Brand ID="B22040419290301" PSS="2025-06-30">
                <Name>Pamol</Name>
                <Pack ID="P2643650" Specified="true" nzmt:ctpp_id="50307141000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>3.35</Subsidy>
                  <Price>3.35</Price>
                  <Alternate>3.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220404192904" Rank="5" Units="supp" Weight="125" Statim="Must">
              <Name>Suppos 125 mg</Name>
              <Brand ID="B22040419290425" PSS="2026-06-30">
                <Name>Gacet</Name>
                <Pack ID="P2482711" Specified="true" nzmt:ctpp_id="50206931000117109">
                  <Quantity>10</Quantity>
                  <Subsidy>4.29</Subsidy>
                  <Price>4.29</Price>
                  <Alternate>4.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220404192905" Rank="5" Units="supp" Weight="250" Statim="Must">
              <Name>Suppos 250 mg</Name>
              <Brand ID="B22040419290525" PSS="2026-06-30">
                <Name>Gacet</Name>
                <Pack ID="P2482738" Specified="true" nzmt:ctpp_id="50224181000117105">
                  <Quantity>10</Quantity>
                  <Subsidy>5.39</Subsidy>
                  <Price>5.39</Price>
                  <Alternate>5.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220404192906" Rank="5" Units="supp" Weight="500" Statim="Must">
              <Name>Suppos 500 mg</Name>
              <Brand ID="B22040419290626" PSS="2026-06-30">
                <Name>Gacet</Name>
                <Pack ID="P2552663" Specified="true" nzmt:ctpp_id="50196991000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>16.55</Subsidy>
                  <Price>16.55</Price>
                  <Alternate>16.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220404192908" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg - blister pack</Name>
              <Rule Type="FormMax" Value="300" Attribute="Rx" Waiver="SubRxF"/>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily
        dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition.</p>
                  </li>
                  <li>
                    <p>Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for
        non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B22040419290825" SoleSupply="2026-06-30">
                <Name>Pacimol</Name>
                <Pack ID="P2612712" Specified="true" nzmt:ctpp_id="50010991000117100">
                  <Quantity>1000</Quantity>
                  <Subsidy>19.75</Subsidy>
                  <Price>19.75</Price>
                  <Alternate>19.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220404192925" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg - bottle pack</Name>
              <Rule Type="FormMax" Value="300" Attribute="Rx" Waiver="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: decimal">
                  <li>
                    <p>Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily
        dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition.</p>
                  </li>
                  <li>
                    <p>Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for
        non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B22040419292527" SoleSupply="2026-06-30">
                <Name>Noumed Paracetamol</Name>
                <Pack ID="P2611430" Specified="true" nzmt:ctpp_id="50283311000117106">
                  <Quantity>1000</Quantity>
                  <Subsidy>17.92</Subsidy>
                  <Price>17.92</Price>
                  <Alternate>17.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204043854">
            <Name>Capsaicin</Name>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F220404385425" Rank="3" Units="g" Weight="1">
              <Name>Crm 0.075%</Name>
              <Brand ID="B22040438542525">
                <Name>Zostrix HP</Name>
                <Pack ID="P2022710" Specified="true" OP="true" nzmt:ctpp_id="50004591000117101">
                  <Quantity>45</Quantity>
                  <Subsidy>11.95</Subsidy>
                  <Price>11.95</Price>
                  <Alternate>11.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040438542526" S29="true">
                <Name>Rugby Capsaicin Topical Cream</Name>
                <Pack ID="P2582252" Specified="true" OP="true" nzmt:ctpp_id="50277551000117102">
                  <Quantity>57</Quantity>
                  <Subsidy>15.14</Subsidy>
                  <Price>15.14</Price>
                  <Alternate>15.14</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220407">
          <Name>Opioid Analgesics</Name>
          <Chemical ID="C2204071332">
            <Name>Codeine phosphate</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220407133201" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B22040713320104" PSS="2025-06-30">
                <Name>Noumed</Name>
                <Pack ID="P2643200" Specified="true" nzmt:ctpp_id="50302791000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>5.92</Subsidy>
                  <Price>5.92</Price>
                  <Alternate>5.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407133202" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Brand ID="B22040713320204">
                <Name>Aspen</Name>
                <Pack ID="P2643308" Specified="true" nzmt:ctpp_id="50304921000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>6.98</Subsidy>
                  <Price>6.98</Price>
                  <Alternate>6.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040713320205" PSS="2025-06-30">
                <Name>Noumed</Name>
                <Pack ID="P2643219" Specified="true" nzmt:ctpp_id="50302821000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>6.98</Subsidy>
                  <Price>6.98</Price>
                  <Alternate>6.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407133203" Rank="1" Units="tab" Weight="60">
              <Name>Tab 60 mg</Name>
              <Brand ID="B22040713320304" PSS="2025-06-30">
                <Name>Noumed</Name>
                <Pack ID="P2643227" Specified="true" nzmt:ctpp_id="50302851000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>13.89</Subsidy>
                  <Price>13.89</Price>
                  <Alternate>13.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204071795">
            <Name>Methadone hydrochloride</Name>
            <Rule Type="Controlled"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).</p>
            </div>
            <Rule Type="SafetyListMedicine"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
              <p xlink:type="simple" xlink:href="standard-formulae">For methadone hydrochloride oral liquid refer Standard Formulae</p>
            </div>
            <Formulation ID="F220407179501" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22040717950103" PSS="2025-06-30">
                <Name>Methadone BNM</Name>
                <Pack ID="P2639823" Specified="true" nzmt:ctpp_id="50256011000117105">
                  <Quantity>10</Quantity>
                  <Subsidy>1.45</Subsidy>
                  <Price>1.45</Price>
                  <Alternate>1.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407179502" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 1 ml</Name>
              <Brand ID="B22040717950201">
                <Name>AFT</Name>
                <Pack ID="P2265710" Specified="true" nzmt:ctpp_id="50041891000117108">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>68.90</Subsidy>
                  <Price>68.90</Price>
                  <Alternate>68.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407179505" Rank="3" Units="ml" Weight="2">
              <Name>Oral liq 2 mg per ml</Name>
              <Brand ID="B22040717950501" PSS="2024-06-30">
                <Name>Biodone</Name>
                <Pack ID="P361372" Specified="true" nzmt:ctpp_id="50078211000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>6.40</Subsidy>
                  <Price>6.40</Price>
                  <Alternate>6.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407179506" Rank="3" Units="ml" Weight="5">
              <Name>Oral liq 5 mg per ml</Name>
              <Brand ID="B22040717950602" PSS="2024-06-30">
                <Name>Biodone Forte</Name>
                <Pack ID="P412341" Specified="true" nzmt:ctpp_id="50083121000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>6.40</Subsidy>
                  <Price>6.40</Price>
                  <Alternate>6.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407179507" Rank="3" Units="ml" Weight="10">
              <Name>Oral liq 10 mg per ml</Name>
              <Brand ID="B22040717950701" PSS="2024-06-30">
                <Name>Biodone Extra Forte</Name>
                <Pack ID="P412325" Specified="true" nzmt:ctpp_id="50083111000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>7.50</Subsidy>
                  <Price>7.50</Price>
                  <Alternate>7.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204071830">
            <Name>Morphine hydrochloride</Name>
            <Rule Type="Controlled"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220407183001" Rank="3" Units="ml" Weight="1">
              <Name>Oral liq 1 mg per ml</Name>
              <Brand ID="B22040718300101">
                <Name>RA-Morph</Name>
                <Pack ID="P754285" Specified="true" nzmt:ctpp_id="50108931000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>11.98</Subsidy>
                  <Price>11.98</Price>
                  <Alternate>11.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183002" Rank="3" Units="ml" Weight="2">
              <Name>Oral liq 2 mg per ml</Name>
              <Brand ID="B22040718300201">
                <Name>RA-Morph</Name>
                <Pack ID="P754293" Specified="true" nzmt:ctpp_id="50108941000117103">
                  <Quantity>200</Quantity>
                  <Subsidy>16.24</Subsidy>
                  <Price>16.24</Price>
                  <Alternate>16.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183003" Rank="3" Units="ml" Weight="5">
              <Name>Oral liq 5 mg per ml</Name>
              <Brand ID="B22040718300301">
                <Name>RA-Morph</Name>
                <Pack ID="P754307" Specified="true" nzmt:ctpp_id="50108951000117101">
                  <Quantity>200</Quantity>
                  <Subsidy>19.44</Subsidy>
                  <Price>19.44</Price>
                  <Alternate>19.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040718300302" S29="true">
                <Name>Ordine</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2564378" Specified="true" nzmt:ctpp_id="50264481000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>19.44</Subsidy>
                  <Price>19.44</Price>
                  <Alternate>19.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183004" Rank="3" Units="ml" Weight="10">
              <Name>Oral liq 10 mg per ml</Name>
              <Brand ID="B22040718300401">
                <Name>RA-Morph</Name>
                <Pack ID="P754315" Specified="true" nzmt:ctpp_id="50108961000117104">
                  <Quantity>200</Quantity>
                  <Subsidy>27.74</Subsidy>
                  <Price>27.74</Price>
                  <Alternate>27.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040718300402" S29="true">
                <Name>Ordine</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2564386" Specified="true" nzmt:ctpp_id="50264491000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>27.74</Subsidy>
                  <Price>27.74</Price>
                  <Alternate>27.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204071831">
            <Name>Morphine sulphate</Name>
            <Rule Type="Controlled"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220407183107" Rank="4" Units="inj" Weight="5">
              <Name>Inj 5 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22040718310702" PSS="2025-06-30">
                <Name>Medsurge</Name>
                <Pack ID="P2602431" Specified="true" nzmt:ctpp_id="50266731000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.38</Subsidy>
                  <Price>5.38</Price>
                  <Alternate>5.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183108" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22040718310803" PSS="2025-06-30">
                <Name>Medsurge</Name>
                <Pack ID="P2602458" Specified="true" nzmt:ctpp_id="50266771000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4.68</Subsidy>
                  <Price>4.68</Price>
                  <Alternate>4.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183110" Rank="4" Units="inj" Weight="15">
              <Name>Inj 15 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22040718311003" PSS="2025-06-30">
                <Name>Medsurge</Name>
                <Pack ID="P2602466" Specified="true" nzmt:ctpp_id="50266801000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.53</Subsidy>
                  <Price>5.53</Price>
                  <Alternate>5.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183111" Rank="4" Units="inj" Weight="30">
              <Name>Inj 30 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22040718311103" PSS="2025-06-30">
                <Name>Medsurge</Name>
                <Pack ID="P2602474" Specified="true" nzmt:ctpp_id="50266831000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>6.28</Subsidy>
                  <Price>6.28</Price>
                  <Alternate>6.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183119" Rank="2" Units="cap" Weight="100">
              <Name>Cap long-acting 100 mg</Name>
              <Brand ID="B22040718311925" PSS="2025-06-30">
                <Name>m-Eslon</Name>
                <Pack ID="P2106507" Specified="true" nzmt:ctpp_id="50019191000117109">
                  <Quantity>10</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183120" Rank="1" Units="tab" Weight="10">
              <Name>Tab immediate-release 10 mg</Name>
              <Brand ID="B22040718312001">
                <Name>Sevredol</Name>
                <Pack ID="P2520990" Specified="true" nzmt:ctpp_id="50151981000117109">
                  <Quantity>10</Quantity>
                  <Subsidy>2.80</Subsidy>
                  <Price>2.80</Price>
                  <Alternate>2.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183121" Rank="1" Units="tab" Weight="20">
              <Name>Tab immediate-release 20 mg</Name>
              <Brand ID="B22040718312101">
                <Name>Sevredol</Name>
                <Pack ID="P2521008" Specified="true" nzmt:ctpp_id="50151991000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>5.52</Subsidy>
                  <Price>5.52</Price>
                  <Alternate>5.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183122" Rank="2" Units="cap" Weight="10">
              <Name>Cap long-acting 10 mg</Name>
              <Brand ID="B22040718312225" PSS="2025-06-30">
                <Name>m-Eslon</Name>
                <Pack ID="P2106469" Specified="true" nzmt:ctpp_id="50019151000117100">
                  <Quantity>10</Quantity>
                  <Subsidy>3.00</Subsidy>
                  <Price>3.00</Price>
                  <Alternate>3.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183126" Rank="2" Units="cap" Weight="30">
              <Name>Cap long-acting 30 mg</Name>
              <Brand ID="B22040718312625" PSS="2025-06-30">
                <Name>m-Eslon</Name>
                <Pack ID="P2106485" Specified="true" nzmt:ctpp_id="50019171000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>4.30</Subsidy>
                  <Price>4.30</Price>
                  <Alternate>4.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183127" Rank="2" Units="cap" Weight="60">
              <Name>Cap long-acting 60 mg</Name>
              <Brand ID="B22040718312725" PSS="2025-06-30">
                <Name>m-Eslon</Name>
                <Pack ID="P2106493" Specified="true" nzmt:ctpp_id="50019181000117106">
                  <Quantity>10</Quantity>
                  <Subsidy>9.00</Subsidy>
                  <Price>9.00</Price>
                  <Alternate>9.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407183128" Rank="3" Units="ml" Weight="100">
              <Name>Oral liq 2 mg per ml</Name>
              <Rule Type="Brandswitch" Value="2669986" Attribute="Wockhardt" xlink:href="A35"/>
              <Brand ID="B22040718312825" S29="true">
                <Name>Wockhardt</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2670070" Specified="true" nzmt:ctpp_id="50325471000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>16.31</Subsidy>
                  <Price>16.31</Price>
                  <Alternate>16.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204071931" Statim="Must">
            <Name>Paracetamol with codeine</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220407193101" Rank="1" Units="tab" Weight="500">
              <Name>Tab paracetamol 500 mg with codeine phosphate 8 mg</Name>
              <Brand ID="B22040719310127" PSS="2025-06-30">
                <Name>Paracetamol + Codeine (Relieve)</Name>
                <Pack ID="P2461234" Specified="true" nzmt:ctpp_id="50211441000117102">
                  <Quantity>1000</Quantity>
                  <Subsidy>27.50</Subsidy>
                  <Price>27.50</Price>
                  <Alternate>27.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204071953">
            <Name>Pethidine hydrochloride</Name>
            <Rule Type="Controlled"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220407195301" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22040719530103" PSS="2025-06-30">
                <Name>Noumed Pethidine</Name>
                <Pack ID="P2645599" Specified="true" nzmt:ctpp_id="50306661000117100">
                  <Quantity>10</Quantity>
                  <Subsidy>8.68</Subsidy>
                  <Price>8.68</Price>
                  <Alternate>8.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407195303" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22040719530301">
                <Name>DBL Pethidine Hydrochloride</Name>
                <Pack ID="P500429" Specified="true" nzmt:ctpp_id="50092941000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>29.88</Subsidy>
                  <Price>29.88</Price>
                  <Alternate>29.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407195305" Rank="4" Units="inj" Weight="100">
              <Name>Inj 50 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22040719530501">
                <Name>DBL Pethidine Hydrochloride</Name>
                <Pack ID="P394971" Specified="true" nzmt:ctpp_id="50081381000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>30.72</Subsidy>
                  <Price>30.72</Price>
                  <Alternate>30.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204072427">
            <Name>Dihydrocodeine tartrate</Name>
            <Formulation ID="F220407242701" Rank="1" Units="tab" Weight="60">
              <Name>Tab long-acting 60 mg</Name>
              <Brand ID="B22040724270101" PSS="2025-06-30">
                <Name>DHC Continus</Name>
                <Pack ID="P772887" Specified="true" nzmt:ctpp_id="50112121000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>8.60</Subsidy>
                  <Price>8.60</Price>
                  <Alternate>8.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204073801">
            <Name>Fentanyl</Name>
            <Rule Type="Controlled"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220407380115" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mcg per ml, 2 ml ampoule</Name>
              <Brand ID="B22040738011526" PSS="2024-06-30">
                <Name>Boucher and Muir</Name>
                <Pack ID="P2381176" Specified="true" nzmt:ctpp_id="50122561000117101">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3.75</Subsidy>
                  <Price>3.75</Price>
                  <Alternate>3.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407380116" Rank="4" Units="inj" Weight="500">
              <Name>Inj 50 mcg per ml, 10 ml ampoule</Name>
              <Brand ID="B22040738011626" PSS="2024-06-30">
                <Name>Boucher and Muir</Name>
                <Pack ID="P2381168" Specified="true" nzmt:ctpp_id="50122571000117106">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9.41</Subsidy>
                  <Price>9.41</Price>
                  <Alternate>9.41</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407380133" Rank="9" Units="patch" Weight="12">
              <Name>Patch 12.5 mcg per hour</Name>
              <Brand ID="B22040738013326" PSS="2024-06-30">
                <Name>Fentanyl Sandoz</Name>
                <Pack ID="P2472872" Specified="true" nzmt:ctpp_id="50175571000117100">
                  <Quantity>5</Quantity>
                  <Subsidy>6.99</Subsidy>
                  <Price>6.99</Price>
                  <Alternate>6.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407380134" Rank="9" Units="patch" Weight="25">
              <Name>Patch 25 mcg per hour</Name>
              <Brand ID="B22040738013426" PSS="2024-06-30">
                <Name>Fentanyl Sandoz</Name>
                <Pack ID="P2472880" Specified="true" nzmt:ctpp_id="50175581000117102">
                  <Quantity>5</Quantity>
                  <Subsidy>7.99</Subsidy>
                  <Price>7.99</Price>
                  <Alternate>7.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407380135" Rank="9" Units="patch" Weight="50">
              <Name>Patch 50 mcg per hour</Name>
              <Brand ID="B22040738013526" PSS="2024-06-30">
                <Name>Fentanyl Sandoz</Name>
                <Pack ID="P2472899" Specified="true" nzmt:ctpp_id="50175601000117105">
                  <Quantity>5</Quantity>
                  <Subsidy>9.49</Subsidy>
                  <Price>9.49</Price>
                  <Alternate>9.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407380136" Rank="9" Units="patch" Weight="75">
              <Name>Patch 75 mcg per hour</Name>
              <Brand ID="B22040738013626" PSS="2024-06-30">
                <Name>Fentanyl Sandoz</Name>
                <Pack ID="P2472902" Specified="true" nzmt:ctpp_id="50175611000117108">
                  <Quantity>5</Quantity>
                  <Subsidy>17.99</Subsidy>
                  <Price>17.99</Price>
                  <Alternate>17.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407380137" Rank="9" Units="patch" Weight="100">
              <Name>Patch 100 mcg per hour</Name>
              <Brand ID="B22040738013726" PSS="2024-06-30">
                <Name>Fentanyl Sandoz</Name>
                <Pack ID="P2472910" Specified="true" nzmt:ctpp_id="50175621000117102">
                  <Quantity>5</Quantity>
                  <Subsidy>18.59</Subsidy>
                  <Price>18.59</Price>
                  <Alternate>18.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204073822">
            <Name>Oxycodone hydrochloride</Name>
            <Rule Type="Controlled"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220407382225" Rank="2" Units="cap" Weight="5">
              <Name>Cap immediate-release 5 mg</Name>
              <Brand ID="B22040738222525" PSS="2024-06-30">
                <Name>OxyNorm</Name>
                <Pack ID="P2179741" Specified="true" nzmt:ctpp_id="50029531000117105">
                  <Quantity>20</Quantity>
                  <Subsidy>1.88</Subsidy>
                  <Price>1.88</Price>
                  <Alternate>1.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382226" Rank="2" Units="cap" Weight="10">
              <Name>Cap immediate-release 10 mg</Name>
              <Brand ID="B22040738222625" PSS="2024-06-30">
                <Name>OxyNorm</Name>
                <Pack ID="P2179768" Specified="true" nzmt:ctpp_id="50029541000117102">
                  <Quantity>20</Quantity>
                  <Subsidy>3.32</Subsidy>
                  <Price>3.32</Price>
                  <Alternate>3.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382227" Rank="2" Units="cap" Weight="20">
              <Name>Cap immediate-release 20 mg</Name>
              <Brand ID="B22040738222725" PSS="2024-06-30">
                <Name>OxyNorm</Name>
                <Pack ID="P2179776" Specified="true" nzmt:ctpp_id="50029551000117100">
                  <Quantity>20</Quantity>
                  <Subsidy>5.23</Subsidy>
                  <Price>5.23</Price>
                  <Alternate>5.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382228" Rank="1" Units="tab" Weight="10">
              <Name>Tab controlled-release 10 mg</Name>
              <Brand ID="B22040738222829" PSS="2024-06-30">
                <Name>Oxycodone Sandoz</Name>
                <Pack ID="P2559722" Specified="true" nzmt:ctpp_id="50223451000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>2.69</Subsidy>
                  <Price>2.69</Price>
                  <Alternate>2.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040738222830" S29="true">
                <Name>Oxycodone Sandoz S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2666456" Specified="true" nzmt:ctpp_id="50323751000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>3.77</Subsidy>
                  <Price>3.77</Price>
                  <Alternate>3.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382229" Rank="1" Units="tab" Weight="20">
              <Name>Tab controlled-release 20 mg</Name>
              <Brand ID="B22040738222929" PSS="2024-06-30">
                <Name>Oxycodone Sandoz</Name>
                <Pack ID="P2559730" Specified="true" nzmt:ctpp_id="50223511000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>3.49</Subsidy>
                  <Price>3.49</Price>
                  <Alternate>3.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382230" Rank="1" Units="tab" Weight="40">
              <Name>Tab controlled-release 40 mg</Name>
              <Brand ID="B22040738223029" PSS="2024-06-30">
                <Name>Oxycodone Sandoz</Name>
                <Pack ID="P2559749" Specified="true" nzmt:ctpp_id="50223571000117102">
                  <Quantity>20</Quantity>
                  <Subsidy>5.49</Subsidy>
                  <Price>5.49</Price>
                  <Alternate>5.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382231" Rank="1" Units="tab" Weight="80">
              <Name>Tab controlled-release 80 mg</Name>
              <Brand ID="B22040738223129" PSS="2024-06-30">
                <Name>Oxycodone Sandoz</Name>
                <Pack ID="P2559757" Specified="true" nzmt:ctpp_id="50223631000117101">
                  <Quantity>20</Quantity>
                  <Subsidy>12.99</Subsidy>
                  <Price>12.99</Price>
                  <Alternate>12.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382232" Rank="1" Units="tab" Weight="5">
              <Name>Tab controlled-release 5 mg</Name>
              <Brand ID="B22040738223225" S29="true">
                <Name>OxyContin</Name>
                <Pack ID="P2659980" Specified="true" nzmt:ctpp_id="50318971000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>4.04</Subsidy>
                  <Price>4.04</Price>
                  <Alternate>4.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040738223227" PSS="2024-06-30">
                <Name>Oxycodone Sandoz</Name>
                <Pack ID="P2559714" Specified="true" nzmt:ctpp_id="50223391000117108">
                  <Quantity>20</Quantity>
                  <Subsidy>2.69</Subsidy>
                  <Price>2.69</Price>
                  <Alternate>2.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22040738223228" S29="true">
                <Name>Oxycodone Sandoz S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2666448" Specified="true" nzmt:ctpp_id="50323731000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>3.77</Subsidy>
                  <Price>3.77</Price>
                  <Alternate>3.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382233" Rank="3" Units="ml" Weight="1">
              <Name>Oral liq 5 mg per 5 ml</Name>
              <Brand ID="B22040738223325" PSS="2024-06-30">
                <Name>OxyNorm</Name>
                <Pack ID="P2243687" Specified="true" nzmt:ctpp_id="50038601000117106">
                  <Quantity>250</Quantity>
                  <Subsidy>11.20</Subsidy>
                  <Price>11.20</Price>
                  <Alternate>11.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382234" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B22040738223427" PSS="2024-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2631172" Specified="true" nzmt:ctpp_id="50265931000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.82</Subsidy>
                  <Price>5.82</Price>
                  <Alternate>5.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382235" Rank="4" Units="inj" Weight="20">
              <Name>Inj 10 mg per ml, 2 ml ampoule</Name>
              <Brand ID="B22040738223527" PSS="2024-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2631180" Specified="true" nzmt:ctpp_id="50265941000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>11.49</Subsidy>
                  <Price>11.49</Price>
                  <Alternate>11.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407382236" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B22040738223626" PSS="2024-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2631199" Specified="true" nzmt:ctpp_id="50265951000117108">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>22.92</Subsidy>
                  <Price>22.92</Price>
                  <Alternate>22.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2204073906">
            <Name>Tramadol hydrochloride</Name>
            <Formulation ID="F220407390625" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B22040739062525" PSS="2026-06-30">
                <Name>Arrow-Tramadol</Name>
                <Pack ID="P2351889" Specified="true" nzmt:ctpp_id="50050611000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>3.33</Subsidy>
                  <Price>3.33</Price>
                  <Alternate>3.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407390626" Rank="1" Units="tab" Weight="100">
              <Name>Tab sustained-release 100 mg</Name>
              <Brand ID="B22040739062625" ToBePSS="2024-05-01">
                <Name>Tramal SR 100</Name>
                <Pack ID="P2149508" nzmt:ctpp_id="50025841000117102">
                  <Quantity>20</Quantity>
                  <Subsidy>1.95</Subsidy>
                  <Price>1.95</Price>
                  <Alternate>1.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2650959" Specified="true">
                  <Quantity>20</Quantity>
                  <Subsidy>1.95</Subsidy>
                  <Price>1.95</Price>
                  <Alternate>1.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407390627" Rank="1" Units="tab" Weight="150">
              <Name>Tab sustained-release 150 mg</Name>
              <Brand ID="B22040739062725" ToBePSS="2024-05-01">
                <Name>Tramal SR 150</Name>
                <Pack ID="P2149532" nzmt:ctpp_id="50025871000117108">
                  <Quantity>20</Quantity>
                  <Subsidy>2.95</Subsidy>
                  <Price>2.95</Price>
                  <Alternate>2.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2650967" Specified="true">
                  <Quantity>20</Quantity>
                  <Subsidy>2.95</Subsidy>
                  <Price>2.95</Price>
                  <Alternate>2.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220407390628" Rank="1" Units="tab" Weight="200">
              <Name>Tab sustained-release 200 mg</Name>
              <Brand ID="B22040739062825" ToBePSS="2024-05-01">
                <Name>Tramal SR 200</Name>
                <Pack ID="P2149524" nzmt:ctpp_id="50025861000117103">
                  <Quantity>20</Quantity>
                  <Subsidy>3.80</Subsidy>
                  <Price>3.80</Price>
                  <Alternate>3.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2650975" Specified="true">
                  <Quantity>20</Quantity>
                  <Subsidy>3.80</Subsidy>
                  <Price>3.80</Price>
                  <Alternate>3.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2205">
        <Name>Antidepressants</Name>
        <ATC3 ID="A220501">
          <Name>Cyclic and Related Agents</Name>
          <Chemical ID="C2205011059">
            <Name>Amitriptyline</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220501105901" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22050110590126" PSS="2026-06-30">
                <Name>Arrow-Amitriptyline</Name>
                <Pack ID="P2404451" Specified="true" nzmt:ctpp_id="50136081000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>2.99</Subsidy>
                  <Price>2.99</Price>
                  <Alternate>2.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501105902" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22050110590225" PSS="2026-06-30">
                <Name>Arrow-Amitriptyline</Name>
                <Pack ID="P2461250" Specified="true" nzmt:ctpp_id="50136051000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>1.99</Subsidy>
                  <Price>1.99</Price>
                  <Alternate>1.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501105903" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22050110590325" PSS="2026-06-30">
                <Name>Arrow-Amitriptyline</Name>
                <Pack ID="P2461269" Specified="true" nzmt:ctpp_id="50136011000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>3.14</Subsidy>
                  <Price>3.14</Price>
                  <Alternate>3.14</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205011315">
            <Name>Clomipramine hydrochloride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220501131501" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22050113150127" SoleSupply="2024-06-30">
                <Name>Clomipramine Teva</Name>
                <Pack ID="P2611392" Specified="true" nzmt:ctpp_id="50290061000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>10.17</Subsidy>
                  <Price>10.17</Price>
                  <Alternate>10.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501131502" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22050113150226" SoleSupply="2024-06-30">
                <Name>Clomipramine Teva</Name>
                <Pack ID="P2611406" Specified="true" nzmt:ctpp_id="50290071000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>11.99</Subsidy>
                  <Price>11.99</Price>
                  <Alternate>11.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501131525" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B22050113152525" S29="true">
                <Name>Clomipramine Teva</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2666901" Specified="true" nzmt:ctpp_id="50323281000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>11.19</Subsidy>
                  <Price>11.19</Price>
                  <Alternate>11.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501131526" Rank="2" Units="cap" Weight="10" Update="New Listing">
              <Name>Cap 10 mg</Name>
              <Brand ID="B22050113152625" S29="true">
                <Name>Clomipramine - Teva</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2674149" Specified="true" nzmt:ctpp_id="50329821000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>9.49</Subsidy>
                  <Price>9.49</Price>
                  <Alternate>9.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205011437">
            <Name>Dosulepin [Dothiepin] hydrochloride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Subsidy by endorsement â€“ Subsidised for patients who were taking dosulepin [dothiepin] hydrochloride prior to 1 June 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dosulepin [dothiepin] hydrochloride.</p>
            </div>
            <Formulation ID="F220501143701" Rank="1" Units="tab" Weight="75">
              <Name>Tab 75 mg</Name>
              <Brand ID="B22050114370104">
                <Name>Dosulepin Viatris</Name>
                <Pack ID="P2630885" Specified="true" nzmt:ctpp_id="50290681000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>3.85</Subsidy>
                  <Price>3.85</Price>
                  <Alternate>3.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501143702" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B22050114370203" S29="true">
                <Name>Dosulepin Mylan</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2578905" Specified="true" nzmt:ctpp_id="50271451000117107">
                  <Quantity>50</Quantity>
                  <Subsidy>7.83</Subsidy>
                  <Price>7.83</Price>
                  <Alternate>7.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22050114370204" S29="true">
                <Name>Dosulepin Viatris</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2636441" Specified="true" nzmt:ctpp_id="50300781000117102">
                  <Quantity>50</Quantity>
                  <Subsidy>7.83</Subsidy>
                  <Price>7.83</Price>
                  <Alternate>7.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205011642">
            <Name>Imipramine hydrochloride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220501164201" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22050116420125">
                <Name>Tofranil</Name>
                <Pack ID="P2015269" Specified="true" nzmt:ctpp_id="50002621000117109">
                  <Quantity>50</Quantity>
                  <Subsidy>5.48</Subsidy>
                  <Price>5.48</Price>
                  <Alternate>5.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2452804" Specified="true" nzmt:ctpp_id="50199371000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>10.96</Subsidy>
                  <Price>10.96</Price>
                  <Alternate>10.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501164202" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22050116420225">
                <Name>Tofranil</Name>
                <Pack ID="P2015250" Specified="true" nzmt:ctpp_id="50002611000117103">
                  <Quantity>50</Quantity>
                  <Subsidy>8.80</Subsidy>
                  <Price>8.80</Price>
                  <Alternate>8.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22050116420226" S29="true">
                <Name>Imipramine Crescent</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2669692" Specified="true" nzmt:ctpp_id="50325451000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>4.93</Subsidy>
                  <Price>4.93</Price>
                  <Alternate>4.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205011876">
            <Name>Nortriptyline hydrochloride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220501187601" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22050118760125" PSS="2025-06-30">
                <Name>Norpress</Name>
                <Pack ID="P2090678" Specified="true" nzmt:ctpp_id="50017121000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>2.46</Subsidy>
                  <Price>2.46</Price>
                  <Alternate>2.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220501187602" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22050118760202" PSS="2025-06-30">
                <Name>Norpress</Name>
                <Pack ID="P2312441" Specified="true" nzmt:ctpp_id="50047841000117107">
                  <Quantity>180</Quantity>
                  <Subsidy>6.29</Subsidy>
                  <Price>6.29</Price>
                  <Alternate>6.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220504">
          <Name>Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective</Name>
          <Chemical ID="C2205042285" Statim="Must">
            <Name>Tranylcypromine sulphate</Name>
            <Formulation ID="F220504228501" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22050422850101">
                <Name>Parnate</Name>
                <Pack ID="P2315076" Specified="true" nzmt:ctpp_id="50047991000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>22.94</Subsidy>
                  <Price>22.94</Price>
                  <Alternate>22.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220505">
          <Name>Monoamine-Oxidase Type A Inhibitors</Name>
          <Chemical ID="C2205052638">
            <Name>Moclobemide</Name>
            <Formulation ID="F220505263802" Rank="1" Units="tab" Weight="150" Statim="Must">
              <Name>Tab 150 mg</Name>
              <Brand ID="B22050526380201" PSS="2024-06-30">
                <Name>Aurorix</Name>
                <Pack ID="P2602385" Specified="true" nzmt:ctpp_id="50252531000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>11.80</Subsidy>
                  <Price>11.80</Price>
                  <Alternate>11.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220505263803" Rank="1" Units="tab" Weight="300" Statim="Must">
              <Name>Tab 300 mg</Name>
              <Brand ID="B22050526380301" PSS="2024-06-30">
                <Name>Aurorix</Name>
                <Pack ID="P2602393" Specified="true" nzmt:ctpp_id="50090581000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>19.25</Subsidy>
                  <Price>19.25</Price>
                  <Alternate>19.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220507">
          <Name>Selective Serotonin Reuptake Inhibitors</Name>
          <Chemical ID="C2205071193" Statim="Must">
            <Name>Citalopram hydrobromide</Name>
            <Formulation ID="F220507119301" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B22050711930129" PSS="2025-06-30">
                <Name>Celapram</Name>
                <Pack ID="P2638738" Specified="true" nzmt:ctpp_id="50161501000117102">
                  <Quantity>84</Quantity>
                  <Subsidy>2.86</Subsidy>
                  <Price>2.86</Price>
                  <Alternate>2.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205072636">
            <Name>Fluoxetine hydrochloride</Name>
            <Formulation ID="F220507263601" Rank="2" Units="cap" Weight="20">
              <Name>Cap 20 mg</Name>
              <Brand ID="B22050726360125" PSS="2025-06-30">
                <Name>Arrow-Fluoxetine</Name>
                <Pack ID="P2450860" Specified="true" nzmt:ctpp_id="50134501000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>3.13</Subsidy>
                  <Price>3.13</Price>
                  <Alternate>3.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22050726360126" S29="true">
                <Name>Brown &amp; Burk</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2653354" Specified="true" nzmt:ctpp_id="50310561000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>2.22</Subsidy>
                  <Price>2.22</Price>
                  <Alternate>2.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220507263602" Rank="1" Units="tab" Weight="20" Statim="Must">
              <Name>Tab dispersible 20 mg, scored</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised by endorsement</p>
                <ol style="list-style-type: decimal">
                  <li>
                    <p>When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or</p>
                  </li>
                  <li>
                    <p>When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B22050726360225" PSS="2025-06-30">
                <Name>Fluox</Name>
                <Pack ID="P2618575" Specified="true" nzmt:ctpp_id="50292131000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>2.50</Subsidy>
                  <Price>2.50</Price>
                  <Alternate>2.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205073926" Statim="Must">
            <Name>Escitalopram</Name>
            <Formulation ID="F220507392625" Rank="1" Units="tab">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22050739262529" ToBeDelisted="2024-04-01">
                <Name>Escitalopram (Ethics)</Name>
                <Pack ID="P2349310" Specified="true" nzmt:ctpp_id="50282351000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>1.07</Subsidy>
                  <Price>1.07</Price>
                  <Alternate>1.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22050739262530" ToBePSS="2024-04-01">
                <Name>Ipca-Escitalopram</Name>
                <Pack ID="P2661640" Specified="true" nzmt:ctpp_id="50223191000117106">
                  <Quantity>28</Quantity>
                  <Subsidy>0.79</Subsidy>
                  <Price>0.79</Price>
                  <Alternate>0.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220507392626" Rank="1" Units="tab">
              <Name>Tab 20 mg</Name>
              <Brand ID="B22050739262628" ToBeDelisted="2024-04-01">
                <Name>Escitalopram (Ethics)</Name>
                <Pack ID="P2349302" Specified="true" nzmt:ctpp_id="50282361000117103">
                  <Quantity>28</Quantity>
                  <Subsidy>1.92</Subsidy>
                  <Price>1.92</Price>
                  <Alternate>1.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22050739262629" ToBePSS="2024-04-01">
                <Name>Ipca-Escitalopram</Name>
                <Pack ID="P2661659" Specified="true" nzmt:ctpp_id="50223271000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>1.49</Subsidy>
                  <Price>1.49</Price>
                  <Alternate>1.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205073927" Statim="Must">
            <Name>Sertraline</Name>
            <Formulation ID="F220507392725" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22050739272528" PSS="2025-06-30">
                <Name>Setrona</Name>
                <Pack ID="P2570831" Specified="true" nzmt:ctpp_id="50168181000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>0.99</Subsidy>
                  <Price>0.99</Price>
                  <Alternate>0.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220507392726" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22050739272627" PSS="2025-06-30">
                <Name>Setrona</Name>
                <Pack ID="P2570858" Specified="true" nzmt:ctpp_id="50168171000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>1.74</Subsidy>
                  <Price>1.74</Price>
                  <Alternate>1.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205076009" Statim="Must">
            <Name>Paroxetine</Name>
            <Formulation ID="F220507600901" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B22050760090125" PSS="2025-06-30">
                <Name>Loxamine</Name>
                <Pack ID="P2626799" Specified="true" nzmt:ctpp_id="50176921000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>4.11</Subsidy>
                  <Price>4.11</Price>
                  <Alternate>4.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220509">
          <Name>Other Antidepressants</Name>
          <Chemical ID="C2205093785" Statim="Must">
            <Name>Venlafaxine</Name>
            <Formulation ID="F220509378525" Rank="2" Units="cap" Weight="75">
              <Name>Cap 75 mg</Name>
              <Brand ID="B22050937852526">
                <Name>Enlafax XR</Name>
                <Pack ID="P2509229" Specified="true" nzmt:ctpp_id="50237581000117106">
                  <Quantity>84</Quantity>
                  <Subsidy>10.32</Subsidy>
                  <Price>10.32</Price>
                  <Alternate>10.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220509378526" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B22050937852626">
                <Name>Enlafax XR</Name>
                <Pack ID="P2509237" Specified="true" nzmt:ctpp_id="50237601000117103">
                  <Quantity>84</Quantity>
                  <Subsidy>13.95</Subsidy>
                  <Price>13.95</Price>
                  <Alternate>13.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220509378527" Rank="2" Units="cap" Weight="37.5">
              <Name>Cap 37.5 mg</Name>
              <Brand ID="B22050937852726">
                <Name>Enlafax XR</Name>
                <Pack ID="P2509210" Specified="true" nzmt:ctpp_id="50237561000117103">
                  <Quantity>84</Quantity>
                  <Subsidy>8.29</Subsidy>
                  <Price>8.29</Price>
                  <Alternate>8.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2205093901">
            <Name>Mirtazapine</Name>
            <Formulation ID="F220509390125" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Brand ID="B22050939012527" SoleSupply="2024-06-30">
                <Name>Noumed</Name>
                <Pack ID="P2616084" Specified="true" nzmt:ctpp_id="50289071000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>2.60</Subsidy>
                  <Price>2.60</Price>
                  <Alternate>2.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220509390126" Rank="1" Units="tab" Weight="45">
              <Name>Tab 45 mg</Name>
              <Brand ID="B22050939012627" SoleSupply="2024-06-30">
                <Name>Noumed</Name>
                <Pack ID="P2616092" Specified="true" nzmt:ctpp_id="50289081000117101">
                  <Quantity>28</Quantity>
                  <Subsidy>3.45</Subsidy>
                  <Price>3.45</Price>
                  <Alternate>3.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2207">
        <Name>Antiepilepsy Drugs</Name>
        <ATC3 ID="A220701">
          <Name>Agents for Control of Status Epilepticus</Name>
          <Chemical ID="C2207011397">
            <Name>Diazepam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220701139704" Rank="9" Units="tube" Weight="5">
              <Name>Rectal tubes 5 mg</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22070113970401" PSS="2025-06-30">
                <Name>Stesolid</Name>
                <Pack ID="P425877" Specified="true" nzmt:ctpp_id="50084501000117105">
                  <Quantity>5</Quantity>
                  <Subsidy>54.58</Subsidy>
                  <Price>54.58</Price>
                  <Alternate>54.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220701139706" Rank="4" Units="inj" Weight="10">
              <Name>Inj 5 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Rule Type="FormReqd" Attribute="PSO"/>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>PSO must be endorsed â€œnot for anaesthetic proceduresâ€.</p>
              </div>
              <Brand ID="B22070113970601">
                <Name>Hospira</Name>
                <Pack ID="P399019" Specified="true" nzmt:ctpp_id="50081941000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>27.92</Subsidy>
                  <Price>27.92</Price>
                  <Alternate>27.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207011978">
            <Name>Phenytoin sodium</Name>
            <Formulation ID="F220701197806" Rank="4" Units="inj" Weight="100" Statim="Must">
              <Name>Inj 50 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22070119780625">
                <Name>Hospira</Name>
                <Pack ID="P391654" Specified="true" nzmt:ctpp_id="50081081000117108">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>104.58</Subsidy>
                  <Price>104.58</Price>
                  <Alternate>104.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220701197807" Rank="4" Units="inj" Weight="250" Statim="Must">
              <Name>Inj 50 mg per ml, 5 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22070119780725">
                <Name>Hospira</Name>
                <Pack ID="P391646" Specified="true" nzmt:ctpp_id="50081071000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>154.01</Subsidy>
                  <Price>154.01</Price>
                  <Alternate>154.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A220702">
          <Name>Control of Epilepsy</Name>
          <Chemical ID="C2207021002">
            <Name>Lamotrigine</Name>
            <Formulation ID="F220702100225" Rank="1" Units="tab" Weight="5" Statim="May">
              <Name>Tab dispersible 5 mg</Name>
              <Brand ID="B22070210022501">
                <Name>Lamictal</Name>
                <Pack ID="P2056143" Specified="true" nzmt:ctpp_id="50010041000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>50.00</Subsidy>
                  <Price>50.00</Price>
                  <Alternate>50.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702100226" Rank="1" Units="tab" Weight="25" Statim="Must">
              <Name>Tab dispersible 25 mg</Name>
              <Brand ID="B22070210022627">
                <Name>Logem</Name>
                <Pack ID="P2553376" Specified="true" nzmt:ctpp_id="50042601000117107">
                  <Quantity>56</Quantity>
                  <Subsidy>4.20</Subsidy>
                  <Price>4.20</Price>
                  <Alternate>4.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702100227" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab dispersible 50 mg</Name>
              <Brand ID="B22070210022727">
                <Name>Logem</Name>
                <Pack ID="P2553384" Specified="true" nzmt:ctpp_id="50042611000117105">
                  <Quantity>56</Quantity>
                  <Subsidy>5.11</Subsidy>
                  <Price>5.11</Price>
                  <Alternate>5.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702100228" Rank="1" Units="tab" Weight="100" Statim="Must">
              <Name>Tab dispersible 100 mg</Name>
              <Brand ID="B22070210022827">
                <Name>Logem</Name>
                <Pack ID="P2553392" Specified="true" nzmt:ctpp_id="50042621000117104">
                  <Quantity>56</Quantity>
                  <Subsidy>6.75</Subsidy>
                  <Price>6.75</Price>
                  <Alternate>6.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702100230" Rank="1" Units="tab" Weight="2" Statim="May">
              <Name>Tab dispersible 2 mg</Name>
              <Brand ID="B22070210023025">
                <Name>Lamictal</Name>
                <Pack ID="P2040034" Specified="true" nzmt:ctpp_id="50007681000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>55.00</Subsidy>
                  <Price>55.00</Price>
                  <Alternate>55.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021004" Statim="May">
            <Name>Vigabatrin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2088"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2088">
              <Title>
                <range>Vigabatrin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has infantile spasms</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has epilepsy</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">Seizures are not adequately
                                controlled with optimal treatment with other antiepilepsy
                                agents</ci>
                          <ci type="logical" class="Indication">Seizures are controlled adequately
                                but the patient has experienced unacceptable side effects from
                                optimal treatment with other antiepilepsy agents</ci>
                        </apply>
                      </apply>
                      <ci type="logical" class="Indication">Patient has tuberous sclerosis complex</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is, or will be, receiving regular
                        automated visual field testing (ideally before starting therapy and on a
                        6-monthly basis thereafter)</ci>
                      <ci type="logical" class="Indication">It is impractical or impossible (due to
                        comorbid conditions) to monitor the patientâ€™s visual fields.</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">15</Term>
              </Case>
              <Case When="Renewal" Form="SA0875 SA0937 SA1010 SA1072 SA1907 SA1997 SA2088">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Trial">The patient has demonstrated a significant and
                    sustained improvement in seizure rate or severity and or quality of life</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is receiving regular automated
                        visual field testing (ideally every 6 months) on an ongoing basis for
                        duration of treatment with vigabatrin</ci>
                      <ci type="logical" class="Indication">It is impractical or impossible (due to
                        comorbid conditions) to monitor the patientâ€™s visual fields.</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F220702100401" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B22070210040101">
                <Name>Sabril</Name>
                <Pack ID="P2144697" Specified="true" nzmt:ctpp_id="50024941000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>119.30</Subsidy>
                  <Price>119.30</Price>
                  <Alternate>119.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702100425" Rank="2" Units="sach" Weight="500">
              <Name>Powder for oral soln 500 mg per sachet</Name>
              <Brand ID="B22070210042525">
                <Name>Sabril</Name>
                <Pack ID="P2661683" Specified="true" nzmt:ctpp_id="50320421000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>71.58</Subsidy>
                  <Price>71.58</Price>
                  <Alternate>71.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021062" Statim="Must">
            <Name>Gabapentin</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Not subsidised in combination with subsidised pregabalin</p>
            </div>
            <Formulation ID="F220702106201" Rank="2" Units="cap" Weight="300">
              <Name>Cap 300 mg</Name>
              <Brand ID="B22070210620125" SoleSupply="2027-06-30">
                <Name>Nupentin</Name>
                <Pack ID="P2422778" Specified="true" nzmt:ctpp_id="50137511000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>8.45</Subsidy>
                  <Price>8.45</Price>
                  <Alternate>8.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702106202" Rank="2" Units="cap" Weight="400">
              <Name>Cap 400 mg</Name>
              <Brand ID="B22070210620225" SoleSupply="2027-06-30">
                <Name>Nupentin</Name>
                <Pack ID="P2422786" Specified="true" nzmt:ctpp_id="50137521000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>10.26</Subsidy>
                  <Price>10.26</Price>
                  <Alternate>10.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702106225" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B22070210622526" SoleSupply="2027-06-30">
                <Name>Nupentin</Name>
                <Pack ID="P2422751" Specified="true" nzmt:ctpp_id="50137501000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>6.45</Subsidy>
                  <Price>6.45</Price>
                  <Alternate>6.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021133" Statim="May">
            <Name>Topiramate</Name>
            <Formulation ID="F220702113301" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22070211330101">
                <Name>Topamax</Name>
                <Pack ID="P470988" Specified="true" nzmt:ctpp_id="50088551000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>26.04</Subsidy>
                  <Price>26.04</Price>
                  <Alternate>26.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330125">
                <Name>Arrow-Topiramate</Name>
                <Pack ID="P2350408" Specified="true" nzmt:ctpp_id="50050461000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>11.07</Subsidy>
                  <Price>11.07</Price>
                  <Alternate>11.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330126">
                <Name>Topiramate Actavis</Name>
                <Pack ID="P2465825" Specified="true" nzmt:ctpp_id="50203041000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>11.07</Subsidy>
                  <Price>11.07</Price>
                  <Alternate>11.07</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702113302" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22070211330201">
                <Name>Topamax</Name>
                <Pack ID="P470996" Specified="true" nzmt:ctpp_id="50088561000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>44.26</Subsidy>
                  <Price>44.26</Price>
                  <Alternate>44.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330225">
                <Name>Arrow-Topiramate</Name>
                <Pack ID="P2350416" Specified="true" nzmt:ctpp_id="50050471000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>18.81</Subsidy>
                  <Price>18.81</Price>
                  <Alternate>18.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330226">
                <Name>Topiramate Actavis</Name>
                <Pack ID="P2465833" Specified="true" nzmt:ctpp_id="50203101000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>18.81</Subsidy>
                  <Price>18.81</Price>
                  <Alternate>18.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702113303" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22070211330301">
                <Name>Topamax</Name>
                <Pack ID="P471003" Specified="true" nzmt:ctpp_id="50088571000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>75.25</Subsidy>
                  <Price>75.25</Price>
                  <Alternate>75.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330325">
                <Name>Arrow-Topiramate</Name>
                <Pack ID="P2350424" Specified="true" nzmt:ctpp_id="50050481000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>31.99</Subsidy>
                  <Price>31.99</Price>
                  <Alternate>31.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330326">
                <Name>Topiramate Actavis</Name>
                <Pack ID="P2465841" Specified="true" nzmt:ctpp_id="50202991000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>31.99</Subsidy>
                  <Price>31.99</Price>
                  <Alternate>31.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702113304" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22070211330401">
                <Name>Topamax</Name>
                <Pack ID="P471011" Specified="true" nzmt:ctpp_id="50088581000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>129.85</Subsidy>
                  <Price>129.85</Price>
                  <Alternate>129.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330425">
                <Name>Arrow-Topiramate</Name>
                <Pack ID="P2350432" Specified="true" nzmt:ctpp_id="50050491000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>55.19</Subsidy>
                  <Price>55.19</Price>
                  <Alternate>55.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070211330426">
                <Name>Topiramate Actavis</Name>
                <Pack ID="P2465868" Specified="true" nzmt:ctpp_id="50203151000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>55.19</Subsidy>
                  <Price>55.19</Price>
                  <Alternate>55.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702113325" Rank="2" Units="cap">
              <Name>Sprinkle cap 15 mg</Name>
              <Brand ID="B22070211332525">
                <Name>Topamax</Name>
                <Pack ID="P437212" Specified="true" nzmt:ctpp_id="50085741000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>20.84</Subsidy>
                  <Price>20.84</Price>
                  <Alternate>20.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702113326" Rank="2" Units="cap">
              <Name>Sprinkle cap 25 mg</Name>
              <Brand ID="B22070211332625">
                <Name>Topamax</Name>
                <Pack ID="P437239" Specified="true" nzmt:ctpp_id="50085751000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>26.04</Subsidy>
                  <Price>26.04</Price>
                  <Alternate>26.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021217" Statim="Must">
            <Name>Carbamazepine</Name>
            <Formulation ID="F220702121703" Rank="3" Units="ml" Weight="20">
              <Name>Oral liq 20 mg per ml</Name>
              <Brand ID="B22070212170301">
                <Name>Tegretol</Name>
                <Pack ID="P503649" Specified="true" nzmt:ctpp_id="50093111000117104">
                  <Quantity>250</Quantity>
                  <Subsidy>26.37</Subsidy>
                  <Price>26.37</Price>
                  <Alternate>26.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702121704" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22070212170402">
                <Name>Tegretol</Name>
                <Pack ID="P2291657" Specified="true" nzmt:ctpp_id="50044721000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>14.53</Subsidy>
                  <Price>14.53</Price>
                  <Alternate>14.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702121705" Rank="1" Units="tab" Weight="200">
              <Name>Tab long-acting 200 mg</Name>
              <Brand ID="B22070212170501">
                <Name>Tegretol CR</Name>
                <Pack ID="P715832" Specified="true" nzmt:ctpp_id="50104971000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>16.98</Subsidy>
                  <Price>16.98</Price>
                  <Alternate>16.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2649098" Specified="true" nzmt:ctpp_id="50308351000117105">
                  <Quantity>200</Quantity>
                  <Subsidy>33.96</Subsidy>
                  <Price>33.96</Price>
                  <Alternate>33.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702121706" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B22070212170602">
                <Name>Tegretol</Name>
                <Pack ID="P680931" Specified="true" nzmt:ctpp_id="50101801000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>34.58</Subsidy>
                  <Price>34.58</Price>
                  <Alternate>34.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702121707" Rank="1" Units="tab" Weight="400">
              <Name>Tab long-acting 400 mg</Name>
              <Brand ID="B22070212170701">
                <Name>Tegretol CR</Name>
                <Pack ID="P715840" Specified="true" nzmt:ctpp_id="50104981000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>39.17</Subsidy>
                  <Price>39.17</Price>
                  <Alternate>39.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021308">
            <Name>Clobazam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220702130801" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22070213080101">
                <Name>Frisium</Name>
                <Pack ID="P538620" Specified="true" nzmt:ctpp_id="50095121000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>9.12</Subsidy>
                  <Price>9.12</Price>
                  <Alternate>9.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021316">
            <Name>Clonazepam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F220702131603" Rank="3" Units="ml" Weight="2">
              <Name>Oral drops 2.5 mg per ml</Name>
              <Brand ID="B22070213160301">
                <Name>Rivotril</Name>
                <Pack ID="P204498" Specified="true" OP="true" nzmt:ctpp_id="50008411000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>7.38</Subsidy>
                  <Price>7.38</Price>
                  <Alternate>7.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021481">
            <Name>Ethosuximide</Name>
            <Formulation ID="F220702148101" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B22070214810101">
                <Name>Zarontin</Name>
                <Pack ID="P2489937" Specified="true" nzmt:ctpp_id="50227311000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>140.88</Subsidy>
                  <Price>140.88</Price>
                  <Alternate>140.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070214810102" S29="true">
                <Name>Essential Ethosuximide</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2641690" Specified="true" nzmt:ctpp_id="50303661000117105">
                  <Quantity>56</Quantity>
                  <Subsidy>78.89</Subsidy>
                  <Price>78.89</Price>
                  <Alternate>78.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702148102" Rank="3" Units="ml" Weight="50">
              <Name>Oral liq 250 mg per 5 ml</Name>
              <Brand ID="B22070214810201">
                <Name>Zarontin</Name>
                <Pack ID="P2106019" Specified="true" nzmt:ctpp_id="50019051000117104">
                  <Quantity>200</Quantity>
                  <Subsidy>56.35</Subsidy>
                  <Price>56.35</Price>
                  <Alternate>56.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207021978">
            <Name>Phenytoin sodium</Name>
            <Formulation ID="F220702197801" Rank="1" Units="tab" Weight="50" Statim="Must">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22070219780101">
                <Name>Dilantin Infatab</Name>
                <Pack ID="P2619474" Specified="true" nzmt:ctpp_id="50056381000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>75.00</Subsidy>
                  <Price>75.00</Price>
                  <Alternate>75.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702197802" Rank="2" Units="cap" Weight="30">
              <Name>Cap 30 mg</Name>
              <Brand ID="B22070219780201">
                <Name>Dilantin</Name>
                <Pack ID="P2619458" Specified="true" nzmt:ctpp_id="50258741000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>74.00</Subsidy>
                  <Price>74.00</Price>
                  <Alternate>74.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702197803" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B22070219780301">
                <Name>Dilantin</Name>
                <Pack ID="P2619431" Specified="true" nzmt:ctpp_id="50257591000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>37.00</Subsidy>
                  <Price>37.00</Price>
                  <Alternate>37.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702197804" Rank="3" Units="ml" Weight="6" Statim="Must">
              <Name>Oral liq 30 mg per 5 ml</Name>
              <Brand ID="B22070219780402">
                <Name>Dilantin Paediatric</Name>
                <Pack ID="P2619466" Specified="true" nzmt:ctpp_id="50056411000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>22.03</Subsidy>
                  <Price>22.03</Price>
                  <Alternate>22.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207022041" Statim="Must">
            <Name>Primidone</Name>
            <Formulation ID="F220702204101" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B22070220410127">
                <Name>Primidone Clinect</Name>
                <Pack ID="P2621746" Specified="true" nzmt:ctpp_id="50290421000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>37.35</Subsidy>
                  <Price>37.35</Price>
                  <Alternate>37.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207022166">
            <Name>Sodium valproate</Name>
            <Formulation ID="F220702216601" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22070221660101">
                <Name>Epilim Crushable</Name>
                <Pack ID="P539724" Specified="true" nzmt:ctpp_id="50095141000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>13.65</Subsidy>
                  <Price>13.65</Price>
                  <Alternate>13.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702216602" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg EC</Name>
              <Brand ID="B22070221660201">
                <Name>Epilim</Name>
                <Pack ID="P382175" Specified="true" nzmt:ctpp_id="50079921000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>27.44</Subsidy>
                  <Price>27.44</Price>
                  <Alternate>27.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702216603" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg EC</Name>
              <Brand ID="B22070221660301">
                <Name>Epilim</Name>
                <Pack ID="P316199" Specified="true" nzmt:ctpp_id="50070751000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>52.24</Subsidy>
                  <Price>52.24</Price>
                  <Alternate>52.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702216604" Rank="3" Units="ml" Weight="40" Statim="Must">
              <Name>Oral liq 200 mg per 5 ml</Name>
              <Brand ID="B22070221660401">
                <Name>Epilim S/F Liquid</Name>
                <Pack ID="P701017" Specified="true" nzmt:ctpp_id="50103311000117108">
                  <Quantity>300</Quantity>
                  <Subsidy>20.48</Subsidy>
                  <Price>20.48</Price>
                  <Alternate>20.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070221660402">
                <Name>Epilim Syrup</Name>
                <Pack ID="P701025" Specified="true" nzmt:ctpp_id="50103321000117102">
                  <Quantity>300</Quantity>
                  <Subsidy>20.48</Subsidy>
                  <Price>20.48</Price>
                  <Alternate>20.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702216605" Rank="4" Units="inj" Weight="400" Statim="Must">
              <Name>Inj 100 mg per ml, 4 ml</Name>
              <Brand ID="B22070221660501">
                <Name>Epilim IV</Name>
                <Pack ID="P710385" Specified="true" nzmt:ctpp_id="50104041000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>41.50</Subsidy>
                  <Price>41.50</Price>
                  <Alternate>41.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207023354">
            <Name>Phenobarbitone</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
              <p xlink:type="simple" xlink:href="standard-formulae">For phenobarbitone oral liquid refer Standard Formulae</p>
            </div>
            <Formulation ID="F220702335403" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B22070233540301" ToBeDelisted="2024-08-01">
                <Name>PSM</Name>
                <Pack ID="P765481" Specified="true" nzmt:ctpp_id="50302971000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>40.00</Subsidy>
                  <Price>40.00</Price>
                  <Alternate>40.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070233540302">
                <Name>Noumed Phenobarbitone</Name>
                <Pack ID="P2647524" Specified="true" nzmt:ctpp_id="50307081000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>248.50</Subsidy>
                  <Price>248.50</Price>
                  <Alternate>248.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702335404" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Brand ID="B22070233540402" PSS="2025-06-30">
                <Name>Noumed Phenobarbitone</Name>
                <Pack ID="P2647532" Specified="true" nzmt:ctpp_id="50307091000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>398.50</Subsidy>
                  <Price>398.50</Price>
                  <Alternate>398.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207023877">
            <Name>Levetiracetam</Name>
            <Formulation ID="F220702387726" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B22070238772626">
                <Name>Everet</Name>
                <Pack ID="P2479532" Specified="true" nzmt:ctpp_id="50229981000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>5.84</Subsidy>
                  <Price>5.84</Price>
                  <Alternate>5.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702387727" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B22070238772726">
                <Name>Everet</Name>
                <Pack ID="P2479540" Specified="true" nzmt:ctpp_id="50229991000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>10.51</Subsidy>
                  <Price>10.51</Price>
                  <Alternate>10.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702387728" Rank="1" Units="tab" Weight="750">
              <Name>Tab 750 mg</Name>
              <Brand ID="B22070238772826">
                <Name>Everet</Name>
                <Pack ID="P2479559" Specified="true" nzmt:ctpp_id="50230001000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>16.71</Subsidy>
                  <Price>16.71</Price>
                  <Alternate>16.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702387729" Rank="1" Units="tab" Weight="1000">
              <Name>Tab 1,000 mg</Name>
              <Brand ID="B22070238772925">
                <Name>Everet</Name>
                <Pack ID="P2479567" Specified="true" nzmt:ctpp_id="50230011000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>21.82</Subsidy>
                  <Price>21.82</Price>
                  <Alternate>21.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702387730" Rank="3" Units="ml" Weight="100">
              <Name>Oral liq 100 mg per ml</Name>
              <Brand ID="B22070238773025">
                <Name>Levetiracetam-AFT</Name>
                <Pack ID="P2472406" Specified="true" OP="true" nzmt:ctpp_id="50227941000117106">
                  <Quantity>300</Quantity>
                  <Subsidy>44.78</Subsidy>
                  <Price>44.78</Price>
                  <Alternate>44.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207023934" Statim="May">
            <Name>Lacosamide</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2267"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2267">
              <Title>
                <range>Lacosamide</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has focal epilepsy</ci>
                    <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">15</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1125 SA2223 SA2267">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Trial">The patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F220702393425" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22070239342525">
                <Name>Vimpat</Name>
                <Pack ID="P2378353" Specified="true" nzmt:ctpp_id="50122581000117109">
                  <Quantity>14</Quantity>
                  <Subsidy>25.04</Subsidy>
                  <Price>25.04</Price>
                  <Alternate>25.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702393426" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22070239342625">
                <Name>Vimpat</Name>
                <Pack ID="P2378388" Specified="true" nzmt:ctpp_id="50122591000117107">
                  <Quantity>14</Quantity>
                  <Subsidy>50.06</Subsidy>
                  <Price>50.06</Price>
                  <Alternate>50.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2378396" Specified="true" nzmt:ctpp_id="50122601000117101">
                  <Quantity>56</Quantity>
                  <Subsidy>200.24</Subsidy>
                  <Price>200.24</Price>
                  <Alternate>200.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702393427" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B22070239342725">
                <Name>Vimpat</Name>
                <Pack ID="P2378418" Specified="true" nzmt:ctpp_id="50122611000117103">
                  <Quantity>14</Quantity>
                  <Subsidy>75.10</Subsidy>
                  <Price>75.10</Price>
                  <Alternate>75.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2378426" Specified="true" nzmt:ctpp_id="50122621000117109">
                  <Quantity>56</Quantity>
                  <Subsidy>300.40</Subsidy>
                  <Price>300.40</Price>
                  <Alternate>300.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702393428" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22070239342825">
                <Name>Vimpat</Name>
                <Pack ID="P2378442" Specified="true" nzmt:ctpp_id="50122631000117107">
                  <Quantity>56</Quantity>
                  <Subsidy>400.55</Subsidy>
                  <Price>400.55</Price>
                  <Alternate>400.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207024004">
            <Name>Stiripentol</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2268"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2268">
              <Title>
                <range>Stiripentol</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has confirmed diagnosis of Dravet syndrome</ci>
                    <ci type="logical" class="Indication">Seizures have been inadequately controlled by appropriate courses of sodium valproate, 	clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet</ci>
                  </apply>
                </math>
                <Applicant>paediatric neurologist</Applicant>
                <Applicant Referring="paediatric neurologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate.</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1330 SA2217 SA2268">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F220702400425" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B22070240042525">
                <Name>Diacomit</Name>
                <Pack ID="P2434636" Specified="true" nzmt:ctpp_id="50164631000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>509.29</Subsidy>
                  <Price>509.29</Price>
                  <Alternate>509.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702400426" Rank="2" Units="sach" Weight="250">
              <Name>Powder for oral liq 250 mg sachet</Name>
              <Brand ID="B22070240042625">
                <Name>Diacomit</Name>
                <Pack ID="P2434644" Specified="true" nzmt:ctpp_id="50164641000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>509.29</Subsidy>
                  <Price>509.29</Price>
                  <Alternate>509.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2207024097">
            <Name>Pregabalin</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Not subsidised in combination with subsidised gabapentin</p>
            </div>
            <Formulation ID="F220702409725" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B22070240972525">
                <Name>Pregabalin Pfizer</Name>
                <Pack ID="P2534053" Specified="true" nzmt:ctpp_id="50248261000117100">
                  <Quantity>56</Quantity>
                  <Subsidy>2.25</Subsidy>
                  <Price>2.25</Price>
                  <Alternate>2.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070240972526" S29="true">
                <Name>Milpharm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2647605" Specified="true" nzmt:ctpp_id="50307161000117105">
                  <Quantity>56</Quantity>
                  <Subsidy>7.80</Subsidy>
                  <Price>7.80</Price>
                  <Alternate>7.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702409726" Rank="2" Units="cap" Weight="75" Statim="Must">
              <Name>Cap 75 mg</Name>
              <Brand ID="B22070240972625">
                <Name>Pregabalin Pfizer</Name>
                <Pack ID="P2534088" Specified="true" nzmt:ctpp_id="50248381000117100">
                  <Quantity>56</Quantity>
                  <Subsidy>2.65</Subsidy>
                  <Price>2.65</Price>
                  <Alternate>2.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070240972626" S29="true">
                <Name>Milpharm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2647591" Specified="true" nzmt:ctpp_id="50307171000117100">
                  <Quantity>56</Quantity>
                  <Subsidy>8.10</Subsidy>
                  <Price>8.10</Price>
                  <Alternate>8.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702409727" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B22070240972725">
                <Name>Pregabalin Pfizer</Name>
                <Pack ID="P2534096" Specified="true" nzmt:ctpp_id="50248541000117102">
                  <Quantity>56</Quantity>
                  <Subsidy>4.01</Subsidy>
                  <Price>4.01</Price>
                  <Alternate>4.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070240972726">
                <Name>Lyrica</Name>
                <Pack ID="P2602075" Specified="true" nzmt:ctpp_id="50037971000117106">
                  <Quantity>56</Quantity>
                  <Subsidy>4.01</Subsidy>
                  <Price>4.01</Price>
                  <Alternate>4.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22070240972727" S29="true">
                <Name>Milpharm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2651351" Specified="true" nzmt:ctpp_id="50309271000117100">
                  <Quantity>56</Quantity>
                  <Subsidy>12.44</Subsidy>
                  <Price>12.44</Price>
                  <Alternate>12.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F220702409728" Rank="2" Units="cap" Weight="300">
              <Name>Cap 300 mg</Name>
              <Brand ID="B22070240972825">
                <Name>Pregabalin Pfizer</Name>
                <Pack ID="P2534118" Specified="true" nzmt:ctpp_id="50248801000117102">
                  <Quantity>56</Quantity>
                  <Subsidy>7.38</Subsidy>
                  <Price>7.38</Price>
                  <Alternate>7.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2213">
        <Name>Antimigraine Preparations</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1904">For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL</p>
        </div>
        <ATC3 ID="A221301">
          <Name>Acute Migraine Treatment</Name>
          <Chemical ID="C2213012800">
            <Name>Sumatriptan</Name>
            <Formulation ID="F221301280002" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22130128000226" SoleSupply="2027-06-30">
                <Name>Sumagran</Name>
                <Pack ID="P2605848" Specified="true" nzmt:ctpp_id="50235041000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>14.41</Subsidy>
                  <Price>14.41</Price>
                  <Alternate>14.41</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221301280003" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22130128000326" SoleSupply="2027-06-30">
                <Name>Sumagran</Name>
                <Pack ID="P2605856" Specified="true" nzmt:ctpp_id="50235061000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>22.68</Subsidy>
                  <Price>22.68</Price>
                  <Alternate>22.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221301280025" Rank="4" Units="inj" Weight="6">
              <Name>Inj 12 mg per ml, 0.5 ml prefilled pen</Name>
              <Rule Type="FormMax" Value="10" Attribute="Rx"/>
              <Brand ID="B22130128002525" ToBePSS="2024-04-01">
                <Name>Clustran</Name>
                <Pack ID="P2647958" Specified="true" OP="true" nzmt:ctpp_id="50318621000117107">
                  <Quantity>2</Quantity>
                  <Subsidy>29.80</Subsidy>
                  <Price>29.80</Price>
                  <Alternate>29.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22130128002527" ToBeDelisted="2024-04-01">
                <Name>Imigran</Name>
                <Pack ID="P799661" Specified="true" OP="true" nzmt:ctpp_id="50117351000117102">
                  <Quantity>2</Quantity>
                  <Multiple>2</Multiple>
                  <Subsidy>34.00</Subsidy>
                  <Price>34.00</Price>
                  <Alternate>34.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2213013876">
            <Name>Rizatriptan</Name>
            <Formulation ID="F221301387625" Rank="1" Units="tab" Weight="10">
              <Name>Tab orodispersible 10 mg</Name>
              <Brand ID="B22130138762526" PSS="2026-06-30">
                <Name>Rizamelt </Name>
                <Pack ID="P2394634" Specified="true" nzmt:ctpp_id="50128451000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>4.84</Subsidy>
                  <Price>4.84</Price>
                  <Alternate>4.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A221304">
          <Name>Prophylaxis of Migraine</Name>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
            <p xlink:type="simple" xlink:href="A0716">For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM</p>
          </div>
          <Chemical ID="C2213042000" Statim="Must">
            <Name>Pizotifen</Name>
            <Formulation ID="F221304200001" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mcg</Name>
              <Brand ID="B22130420000101">
                <Name>Sandomigran</Name>
                <Pack ID="P2492954" Specified="true" nzmt:ctpp_id="50228651000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>23.21</Subsidy>
                  <Price>23.21</Price>
                  <Alternate>23.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2216">
        <Name>Antinausea and Vertigo Agents</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A0107">For Antispasmodics refer to ALIMENTARY TRACT</p>
        </div>
        <ATC3 ID="A221601">
          <Name>Antinausea and Vertigo Agents</Name>
          <Chemical ID="C2216011195" Statim="Must">
            <Name>Betahistine dihydrochloride</Name>
            <Formulation ID="F221601119501" Rank="1" Units="tab" Weight="16">
              <Name>Tab 16 mg</Name>
              <Brand ID="B22160111950101" PSS="2026-06-30">
                <Name>Serc</Name>
                <Pack ID="P2611376" Specified="true" nzmt:ctpp_id="50157851000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>3.70</Subsidy>
                  <Price>3.70</Price>
                  <Alternate>3.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216011436" Statim="Must">
            <Name>Domperidone</Name>
            <Formulation ID="F221601143601" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22160114360127" PSS="2025-06-30">
                <Name>Domperidone Viatris</Name>
                <Pack ID="P2631903" Specified="true" nzmt:ctpp_id="50301571000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>4.00</Subsidy>
                  <Price>4.00</Price>
                  <Alternate>4.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216011629">
            <Name>Hyoscine hydrobromide</Name>
            <Formulation ID="F221601162901" Rank="9" Units="patch">
              <Name>Patch 1 mg per 72 hours</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1998"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1998">
                <Title>
                  <range>Hyoscine (Scopolamine)</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Control of intractable nausea, vomiting, or
                    inability to swallow saliva in the treatment of malignancy or chronic disease
                    where the patient cannot tolerate or does not adequately respond to oral
                    anti-nausea agents</ci>
                      <ci type="logical" class="Indication">Control of clozapine-induced hypersalivation
                    where trials of at least two other alternative treatments have proven
                    ineffective</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="year">1</Term>
                </Case>
                <Case When="Renewal" Form="SA0051 SA0727 SA0939 SA1387 SA1927 SA1998">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient
                is benefiting from treatment</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="year">1</Term>
                </Case>
              </Request>
              <Brand ID="B22160116290101">
                <Name>Scopoderm TTS</Name>
                <Pack ID="P311472" Specified="true" nzmt:ctpp_id="50069661000117105">
                  <Quantity>2</Quantity>
                  <Subsidy>17.70</Subsidy>
                  <Price>17.70</Price>
                  <Alternate>17.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22160116290102" S29="true" Update="New Listing">
                <Name>Scopolamine - Mylan</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2674181" Specified="true" nzmt:ctpp_id="50329881000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>88.50</Subsidy>
                  <Price>88.50</Price>
                  <Alternate>88.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221601162903" Rank="4" Units="inj" Weight="400" Statim="Must">
              <Name>Inj 400 mcg per ml, 1 ml ampoule</Name>
              <Brand ID="B22160116290325" S29="true">
                <Name>Martindale</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2463563" Specified="true" nzmt:ctpp_id="50208021000117106">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>93.00</Subsidy>
                  <Price>93.00</Price>
                  <Alternate>93.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216011814" Statim="Must">
            <Name>Metoclopramide hydrochloride</Name>
            <Formulation ID="F221601181401" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22160118140125" PSS="2026-06-30">
                <Name>Metoclopramide Actavis 10</Name>
                <Pack ID="P2528878" Specified="true" nzmt:ctpp_id="50206281000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>1.57</Subsidy>
                  <Price>1.57</Price>
                  <Alternate>1.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221601181403" Rank="4" Units="inj" Weight="10">
              <Name>Inj 5 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22160118140327" PSS="2025-06-30">
                <Name>Baxter</Name>
                <Pack ID="P2625873" Specified="true" nzmt:ctpp_id="50273251000117107">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216012710">
            <Name>Ondansetron</Name>
            <Formulation ID="F221601271001" Rank="1" Units="tab" Weight="4" Statim="Must">
              <Name>Tab 4 mg</Name>
              <Brand ID="B22160127100128" PSS="2025-06-30">
                <Name>Periset</Name>
                <Pack ID="P2648024" Specified="true" nzmt:ctpp_id="50303721000117107">
                  <Quantity>50</Quantity>
                  <Subsidy>2.27</Subsidy>
                  <Price>2.27</Price>
                  <Alternate>2.27</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221601271003" Rank="1" Units="tab" Weight="8" Statim="Must">
              <Name>Tab 8 mg</Name>
              <Brand ID="B22160127100328" PSS="2025-06-30">
                <Name>Periset</Name>
                <Pack ID="P2648032" Specified="true" nzmt:ctpp_id="50303761000117103">
                  <Quantity>50</Quantity>
                  <Subsidy>4.10</Subsidy>
                  <Price>4.10</Price>
                  <Alternate>4.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221601271027" Rank="1" Units="tab" Weight="4">
              <Name>Tab disp 4 mg</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <Brand ID="B22160127102727" PSS="2026-06-30">
                <Name>Periset ODT</Name>
                <Pack ID="P2656868" Specified="true" nzmt:ctpp_id="50264581000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>0.56</Subsidy>
                  <Price>0.56</Price>
                  <Alternate>0.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221601271028" Rank="1" Units="tab" Weight="8">
              <Name>Tab disp 8 mg</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <Brand ID="B22160127102827" PSS="2026-06-30">
                <Name>Periset ODT</Name>
                <Pack ID="P2656876" Specified="true" nzmt:ctpp_id="50264601000117100">
                  <Quantity>10</Quantity>
                  <Subsidy>0.90</Subsidy>
                  <Price>0.90</Price>
                  <Alternate>0.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216013899">
            <Name>Aprepitant</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA0987"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA0987">
              <Title>
                <range>Aprepitant</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA0987">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F221601389925" Rank="2" Units="cap">
              <Name>Cap 2 x 80 mg and 1 x 125 mg</Name>
              <Brand ID="B22160138992525" PSS="2024-06-30">
                <Name>Emend Tri-Pack</Name>
                <Pack ID="P2244098" Specified="true" OP="true" nzmt:ctpp_id="50038731000117107">
                  <Quantity>3</Quantity>
                  <Subsidy>30.00</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>30.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216016010">
            <Name>Cyclizine hydrochloride</Name>
            <Formulation ID="F221601601001" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22160160100125" PSS="2024-06-30">
                <Name>Nausicalm</Name>
                <Pack ID="P2231220" Specified="true" nzmt:ctpp_id="50036891000117103">
                  <Quantity>10</Quantity>
                  <Subsidy>0.49</Subsidy>
                  <Price>0.49</Price>
                  <Alternate>0.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216016011">
            <Name>Cyclizine lactate</Name>
            <Formulation ID="F221601601101" Rank="4" Units="inj">
              <Name>Inj 50 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <Brand ID="B22160160110127" PSS="2025-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2595877" Specified="true" nzmt:ctpp_id="50260751000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>16.36</Subsidy>
                  <Price>16.36</Price>
                  <Alternate>16.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2216016012">
            <Name>Prochlorperazine</Name>
            <Formulation ID="F221601601201" Rank="1" Units="tab" Weight="3" Statim="Must">
              <Name>Tab 3 mg buccal</Name>
              <Brand ID="B22160160120101">
                <Name>Buccastem</Name>
                <Pack ID="P340537" Specified="true" nzmt:ctpp_id="50075091000117103">
                  <Quantity>50</Quantity>
                  <Subsidy>5.97</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>5.97</Alternate>
                  <Surcharge>0.48060</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22160160120102" S29="true">
                <Name>Max Health</Name>
                <Pack ID="P2658801" Specified="true" nzmt:ctpp_id="50318371000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>5.97</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>5.97</Alternate>
                  <Surcharge>0.48060</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221601601202" Rank="1" Units="tab" Weight="5" Statim="Must">
              <Name>Tab 5 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22160160120203" PSS="2026-06-30">
                <Name>Nausafix</Name>
                <Pack ID="P2528886" Specified="true" nzmt:ctpp_id="50205771000117103">
                  <Quantity>250</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22160160120205" S29="true">
                <Name>Nausafix - S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2670445" Specified="true" nzmt:ctpp_id="50325981000117100">
                  <Quantity>250</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F221601601206" Rank="4" Units="inj" Weight="12.5" Statim="Must">
              <Name>Inj 12.5 mg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22160160120601">
                <Name>Stemetil</Name>
                <Pack ID="P255335" Specified="true" nzmt:ctpp_id="50055021000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>25.81</Subsidy>
                  <Price>25.81</Price>
                  <Alternate>25.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2222">
        <Name>Antipsychotics</Name>
        <ATC3 ID="A222201">
          <Name>General</Name>
          <Chemical ID="C2222011011">
            <Name>Risperidone</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201101101" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B22220110110128" PSS="2026-06-30">
                <Name>Risperidone (Teva)</Name>
                <Pack ID="P2466902" Specified="true" nzmt:ctpp_id="50280931000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>2.44</Subsidy>
                  <Price>2.44</Price>
                  <Alternate>2.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201101102" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B22220110110228" PSS="2026-06-30">
                <Name>Risperidone (Teva)</Name>
                <Pack ID="P2466910" Specified="true" nzmt:ctpp_id="50280941000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>2.72</Subsidy>
                  <Price>2.72</Price>
                  <Alternate>2.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201101103" Rank="1" Units="tab" Weight="3">
              <Name>Tab 3 mg</Name>
              <Brand ID="B22220110110328" PSS="2026-06-30">
                <Name>Risperidone (Teva)</Name>
                <Pack ID="P2466929" Specified="true" nzmt:ctpp_id="50280951000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>4.50</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201101104" Rank="1" Units="tab" Weight="4">
              <Name>Tab 4 mg</Name>
              <Brand ID="B22220110110428" PSS="2026-06-30">
                <Name>Risperidone (Teva)</Name>
                <Pack ID="P2466937" Specified="true" nzmt:ctpp_id="50280961000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>6.25</Subsidy>
                  <Price>6.25</Price>
                  <Alternate>6.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201101105" Rank="3" Units="ml" Weight="1">
              <Name>Oral liq 1 mg per ml</Name>
              <Brand ID="B22220110110525" PSS="2026-06-30">
                <Name>Risperon</Name>
                <Pack ID="P2325640" Specified="true" nzmt:ctpp_id="50049071000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>10.29</Subsidy>
                  <Price>10.29</Price>
                  <Alternate>10.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2662396" Specified="true" nzmt:ctpp_id="50174301000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>17.80</Subsidy>
                  <Price>17.80</Price>
                  <Alternate>17.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201101125" Rank="1" Units="tab" Weight="0.5">
              <Name>Tab 0.5 mg</Name>
              <Brand ID="B22220110112529" PSS="2026-06-30">
                <Name>Risperidone (Teva)</Name>
                <Pack ID="P2466899" Specified="true" nzmt:ctpp_id="50280921000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>2.17</Subsidy>
                  <Price>2.17</Price>
                  <Alternate>2.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011078">
            <Name>Clozapine</Name>
            <Rule Type="Dispensary" Attribute="HP4" NonPrinting="true"/>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201107801" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22220110780101">
                <Name>Clozaril</Name>
                <Pack ID="P2534843">
                  <Quantity>50</Quantity>
                  <Subsidy>6.69</Subsidy>
                  <Price>6.69</Price>
                  <Alternate>6.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2534851" Specified="true" nzmt:ctpp_id="50048291000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>13.37</Subsidy>
                  <Price>13.37</Price>
                  <Alternate>13.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2633353" Specified="true" nzmt:ctpp_id="50086771000117102">
                  <Quantity>50</Quantity>
                  <Subsidy>6.69</Subsidy>
                  <Price>6.69</Price>
                  <Alternate>6.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22220110780125">
                <Name>Clopine</Name>
                <Pack ID="P2229153" Specified="true" nzmt:ctpp_id="50036711000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>13.37</Subsidy>
                  <Price>13.37</Price>
                  <Alternate>13.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2229773" Specified="true" nzmt:ctpp_id="50036761000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>6.69</Subsidy>
                  <Price>6.69</Price>
                  <Alternate>6.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201107802" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22220110780201">
                <Name>Clozaril</Name>
                <Pack ID="P2534878">
                  <Quantity>50</Quantity>
                  <Subsidy>17.33</Subsidy>
                  <Price>17.33</Price>
                  <Alternate>17.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2534886" Specified="true" nzmt:ctpp_id="50048281000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>34.65</Subsidy>
                  <Price>34.65</Price>
                  <Alternate>34.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2633361" Specified="true" nzmt:ctpp_id="50086781000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>17.33</Subsidy>
                  <Price>17.33</Price>
                  <Alternate>17.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22220110780225">
                <Name>Clopine</Name>
                <Pack ID="P2229161" Specified="true" nzmt:ctpp_id="50036721000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>34.65</Subsidy>
                  <Price>34.65</Price>
                  <Alternate>34.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2229811" Specified="true" nzmt:ctpp_id="50036781000117109">
                  <Quantity>50</Quantity>
                  <Subsidy>17.33</Subsidy>
                  <Price>17.33</Price>
                  <Alternate>17.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201107825" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22220110782525">
                <Name>Clopine</Name>
                <Pack ID="P2229137" Specified="true" nzmt:ctpp_id="50036691000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>17.33</Subsidy>
                  <Price>17.33</Price>
                  <Alternate>17.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2229781" Specified="true" nzmt:ctpp_id="50036771000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>8.67</Subsidy>
                  <Price>8.67</Price>
                  <Alternate>8.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201107826" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22220110782625">
                <Name>Clopine</Name>
                <Pack ID="P2229110" Specified="true" nzmt:ctpp_id="50036671000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>69.30</Subsidy>
                  <Price>69.30</Price>
                  <Alternate>69.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2229854" Specified="true" nzmt:ctpp_id="50036791000117107">
                  <Quantity>50</Quantity>
                  <Subsidy>34.65</Subsidy>
                  <Price>34.65</Price>
                  <Alternate>34.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201107827" Rank="3" Units="ml" Weight="100">
              <Name>Suspension 50 mg per ml</Name>
              <Brand ID="B22220110782726">
                <Name>Versacloz</Name>
                <Pack ID="P2604965" Specified="true" nzmt:ctpp_id="50269121000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>67.62</Subsidy>
                  <Price>67.62</Price>
                  <Alternate>67.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011140">
            <Name>Olanzapine</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201114001" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22220111400127">
                <Name>Zypine</Name>
                <Pack ID="P2439867" nzmt:ctpp_id="50183651000117103">
                  <Quantity>28</Quantity>
                  <Subsidy>1.58</Subsidy>
                  <Price>1.58</Price>
                  <Alternate>1.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2651084" Specified="true" nzmt:ctpp_id="50312971000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>1.93</Subsidy>
                  <Price>1.93</Price>
                  <Alternate>1.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201114002" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22220111400227">
                <Name>Zypine</Name>
                <Pack ID="P2439875" nzmt:ctpp_id="50183671000117106">
                  <Quantity>28</Quantity>
                  <Subsidy>2.01</Subsidy>
                  <Price>2.01</Price>
                  <Alternate>2.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2651092" Specified="true" nzmt:ctpp_id="50312981000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>1.93</Subsidy>
                  <Price>1.93</Price>
                  <Alternate>1.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201114003" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B22220111400327">
                <Name>Zypine</Name>
                <Pack ID="P2439859" nzmt:ctpp_id="50183661000117101">
                  <Quantity>28</Quantity>
                  <Subsidy>1.35</Subsidy>
                  <Price>1.35</Price>
                  <Alternate>1.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2651076" Specified="true" nzmt:ctpp_id="50312961000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>1.40</Subsidy>
                  <Price>1.40</Price>
                  <Alternate>1.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201114027" Rank="1" Units="tab" Weight="5">
              <Name>Tab orodispersible 5 mg</Name>
              <Brand ID="B22220111402727" PSS="2026-06-30">
                <Name>Zypine ODT</Name>
                <Pack ID="P2439832" Specified="true" nzmt:ctpp_id="50183641000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>2.42</Subsidy>
                  <Price>2.42</Price>
                  <Alternate>2.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201114028" Rank="1" Units="tab" Weight="10">
              <Name>Tab orodispersible 10 mg</Name>
              <Brand ID="B22220111402827" PSS="2026-06-30">
                <Name>Zypine ODT</Name>
                <Pack ID="P2439840" Specified="true" nzmt:ctpp_id="50183621000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>2.89</Subsidy>
                  <Price>2.89</Price>
                  <Alternate>2.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011183">
            <Name>Quetiapine</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201118301" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B22220111830125" PSS="2026-06-30">
                <Name>Quetapel</Name>
                <Pack ID="P2476266" Specified="true" nzmt:ctpp_id="50040161000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>2.36</Subsidy>
                  <Price>2.36</Price>
                  <Alternate>2.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201118302" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22220111830225" PSS="2026-06-30">
                <Name>Quetapel</Name>
                <Pack ID="P2252880" Specified="true" nzmt:ctpp_id="50040151000117103">
                  <Quantity>90</Quantity>
                  <Subsidy>6.40</Subsidy>
                  <Price>6.40</Price>
                  <Alternate>6.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201118303" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22220111830325" PSS="2026-06-30">
                <Name>Quetapel</Name>
                <Pack ID="P2252902" Specified="true" nzmt:ctpp_id="50040171000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>10.97</Subsidy>
                  <Price>10.97</Price>
                  <Alternate>10.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201118325" Rank="1" Units="tab" Weight="300">
              <Name>Tab 300 mg</Name>
              <Brand ID="B22220111832526" PSS="2026-06-30">
                <Name>Quetapel</Name>
                <Pack ID="P2476274" Specified="true" nzmt:ctpp_id="50040181000117109">
                  <Quantity>90</Quantity>
                  <Subsidy>15.83</Subsidy>
                  <Price>15.83</Price>
                  <Alternate>15.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011283">
            <Name>Chlorpromazine hydrochloride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201128301" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised for patients who were taking chlorpromazine hydrochloride 10 mg tablets prior to 1 August 2023 and
    the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed
    where there exists a record of prior dispensing of chlorpromazine 10 mg tablets in the preceding
    12 months.</p>
              </div>
              <Brand ID="B22220112830101" ToBeDelisted="2024-04-01">
                <Name>Largactil</Name>
                <Pack ID="P264539" Specified="true" nzmt:ctpp_id="50058691000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>14.83</Subsidy>
                  <Price>14.83</Price>
                  <Alternate>14.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201128302" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22220112830201">
                <Name>Largactil</Name>
                <Pack ID="P202576" Specified="true" nzmt:ctpp_id="50005051000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>15.62</Subsidy>
                  <Price>15.62</Price>
                  <Alternate>15.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201128304" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22220112830401">
                <Name>Largactil</Name>
                <Pack ID="P202592" Specified="true" nzmt:ctpp_id="50005121000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>36.73</Subsidy>
                  <Price>36.73</Price>
                  <Alternate>36.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201128306" Rank="4" Units="inj" Weight="50">
              <Name>Inj 25 mg per ml, 2 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220112830601">
                <Name>Largactil</Name>
                <Pack ID="P202525" Specified="true" nzmt:ctpp_id="50004951000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>30.79</Subsidy>
                  <Price>30.79</Price>
                  <Alternate>30.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011583">
            <Name>Haloperidol</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201158301" Rank="1" Units="tab" Weight="0.5">
              <Name>Tab 500 mcg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22220115830101">
                <Name>Serenace</Name>
                <Pack ID="P254320" Specified="true" nzmt:ctpp_id="50054391000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>6.23</Subsidy>
                  <Price>6.23</Price>
                  <Alternate>6.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201158302" Rank="1" Units="tab" Weight="1.5">
              <Name>Tab 1.5 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22220115830201">
                <Name>Serenace</Name>
                <Pack ID="P2143046" Specified="true" nzmt:ctpp_id="50024641000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>9.43</Subsidy>
                  <Price>9.43</Price>
                  <Alternate>9.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201158303" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B22220115830301">
                <Name>Serenace</Name>
                <Pack ID="P254355" Specified="true" nzmt:ctpp_id="50054421000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>29.72</Subsidy>
                  <Price>29.72</Price>
                  <Alternate>29.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2600099" Specified="true" nzmt:ctpp_id="50218521000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>14.86</Subsidy>
                  <Price>14.86</Price>
                  <Alternate>14.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201158304" Rank="3" Units="ml" Weight="2">
              <Name>Oral liq 2 mg per ml</Name>
              <Rule Type="FormMax" Value="200" Attribute="PSO"/>
              <Brand ID="B22220115830401">
                <Name>Serenace</Name>
                <Pack ID="P254290" Specified="true" nzmt:ctpp_id="50054381000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>23.84</Subsidy>
                  <Price>23.84</Price>
                  <Alternate>23.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201158306" Rank="4" Units="inj" Weight="5">
              <Name>Inj 5 mg per ml, 1 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220115830601">
                <Name>Serenace</Name>
                <Pack ID="P254258" Specified="true" nzmt:ctpp_id="50054351000117106">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>21.55</Subsidy>
                  <Price>21.55</Price>
                  <Alternate>21.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011798">
            <Name>Levomepromazine hydrochloride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201179803" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B22220117980325" PSS="2025-06-30">
                <Name>Wockhardt</Name>
                <Pack ID="P2501902" Specified="true" nzmt:ctpp_id="50213121000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>24.48</Subsidy>
                  <Price>24.48</Price>
                  <Alternate>24.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22220117980326" S29="true">
                <Name>Neuraxpharm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2640457" Specified="true" nzmt:ctpp_id="50303431000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>16.75</Subsidy>
                  <Price>16.75</Price>
                  <Alternate>16.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22220117980327" S29="true">
                <Name>Nozinan S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2642840" Specified="true" nzmt:ctpp_id="50304201000117108">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>16.75</Subsidy>
                  <Price>16.75</Price>
                  <Alternate>16.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011799">
            <Name>Levomepromazine</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201179901" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg as a maleate</Name>
              <Brand ID="B22220117990101">
                <Name>Nozinan</Name>
                <Pack ID="P258024" Specified="true" nzmt:ctpp_id="50056081000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>16.10</Subsidy>
                  <Price>16.10</Price>
                  <Alternate>16.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201179902" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg as a maleate</Name>
              <Brand ID="B22220117990201">
                <Name>Nozinan</Name>
                <Pack ID="P258032" Specified="true" nzmt:ctpp_id="50056091000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>41.75</Subsidy>
                  <Price>41.75</Price>
                  <Alternate>41.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201179925" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg (135 mg as a maleate)</Name>
              <Brand ID="B22220117992525">
                <Name>Nozinan (Swiss)</Name>
                <Pack ID="P2581779" Specified="true" nzmt:ctpp_id="50274451000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>41.75</Subsidy>
                  <Price>41.75</Price>
                  <Alternate>41.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201179926" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg (33.8 mg as a maleate)</Name>
              <Brand ID="B22220117992625">
                <Name>Nozinan (Swiss)</Name>
                <Pack ID="P2581760" Specified="true" nzmt:ctpp_id="50274441000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>16.10</Subsidy>
                  <Price>16.10</Price>
                  <Alternate>16.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222011950">
            <Name>Pericyazine</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201195001" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B22220119500101">
                <Name>Neulactil</Name>
                <Pack ID="P254665" Specified="true" nzmt:ctpp_id="50054601000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>12.49</Subsidy>
                  <Price>12.49</Price>
                  <Alternate>12.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2547422" Specified="true" nzmt:ctpp_id="50255981000117108">
                  <Quantity>84</Quantity>
                  <Subsidy>10.49</Subsidy>
                  <Price>10.49</Price>
                  <Alternate>10.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201195002" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22220119500201">
                <Name>Neulactil</Name>
                <Pack ID="P254673" Specified="true" nzmt:ctpp_id="50054611000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>44.45</Subsidy>
                  <Price>44.45</Price>
                  <Alternate>44.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2547430" Specified="true" nzmt:ctpp_id="50255991000117106">
                  <Quantity>84</Quantity>
                  <Subsidy>37.34</Subsidy>
                  <Price>37.34</Price>
                  <Alternate>37.34</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222012466">
            <Name>Lithium carbonate</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201246603" Rank="1" Units="tab" Weight="400">
              <Name>Tab long-acting 400 mg</Name>
              <Brand ID="B22220124660301" PSS="2024-06-30">
                <Name>Priadel</Name>
                <Pack ID="P260851" Specified="true" nzmt:ctpp_id="50057341000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>72.00</Subsidy>
                  <Price>72.00</Price>
                  <Alternate>72.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201246604" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B22220124660401">
                <Name>Douglas</Name>
                <Pack ID="P733393" Specified="true" nzmt:ctpp_id="50107021000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>22.36</Subsidy>
                  <Price>22.36</Price>
                  <Alternate>22.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222013873">
            <Name>Ziprasidone</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201387325" Rank="2" Units="cap" Weight="20">
              <Name>Cap 20 mg</Name>
              <Brand ID="B22220138732526">
                <Name>Zusdone</Name>
                <Pack ID="P2479575" Specified="true" nzmt:ctpp_id="50224261000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>17.90</Subsidy>
                  <Price>17.90</Price>
                  <Alternate>17.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201387326" Rank="2" Units="cap" Weight="40">
              <Name>Cap 40 mg</Name>
              <Brand ID="B22220138732626">
                <Name>Zusdone</Name>
                <Pack ID="P2479583" Specified="true" nzmt:ctpp_id="50224271000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>27.41</Subsidy>
                  <Price>27.41</Price>
                  <Alternate>27.41</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201387327" Rank="2" Units="cap" Weight="60">
              <Name>Cap 60 mg</Name>
              <Brand ID="B22220138732726">
                <Name>Zusdone</Name>
                <Pack ID="P2479591" Specified="true" nzmt:ctpp_id="50224281000117104">
                  <Quantity>60</Quantity>
                  <Subsidy>38.39</Subsidy>
                  <Price>38.39</Price>
                  <Alternate>38.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201387328" Rank="2" Units="cap" Weight="80">
              <Name>Cap 80 mg</Name>
              <Brand ID="B22220138732826">
                <Name>Zusdone</Name>
                <Pack ID="P2479605" Specified="true" nzmt:ctpp_id="50224291000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>46.55</Subsidy>
                  <Price>46.55</Price>
                  <Alternate>46.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222013878">
            <Name>Aripiprazole</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201387825" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22220138782526">
                <Name>Aripiprazole Sandoz</Name>
                <Pack ID="P2544539" Specified="true" nzmt:ctpp_id="50242531000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201387826" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B22220138782626">
                <Name>Aripiprazole Sandoz</Name>
                <Pack ID="P2544547" Specified="true" nzmt:ctpp_id="50242541000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201387827" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B22220138782726">
                <Name>Aripiprazole Sandoz</Name>
                <Pack ID="P2544555" Specified="true" nzmt:ctpp_id="50242551000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201387828" Rank="1" Units="tab" Weight="30">
              <Name>Tab 30 mg</Name>
              <Brand ID="B22220138782826">
                <Name>Aripiprazole Sandoz</Name>
                <Pack ID="P2544563" Specified="true" nzmt:ctpp_id="50242561000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201387829" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22220138782926">
                <Name>Aripiprazole Sandoz</Name>
                <Pack ID="P2544520" Specified="true" nzmt:ctpp_id="50242521000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22220138782928" S29="true">
                <Name>Ascend Aripiprazole</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2658259" Specified="true" nzmt:ctpp_id="50317501000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>10.50</Subsidy>
                  <Price>10.50</Price>
                  <Alternate>10.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222013884">
            <Name>Amisulpride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201388425" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22220138842526">
                <Name>Sulprix</Name>
                <Pack ID="P2609401" Specified="true" nzmt:ctpp_id="50176361000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>7.21</Subsidy>
                  <Price>7.21</Price>
                  <Alternate>7.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201388426" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22220138842626">
                <Name>Sulprix</Name>
                <Pack ID="P2609398" Specified="true" nzmt:ctpp_id="50176481000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>20.94</Subsidy>
                  <Price>20.94</Price>
                  <Alternate>20.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222201388427" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B22220138842726">
                <Name>Sulprix</Name>
                <Pack ID="P2609428" Specified="true" nzmt:ctpp_id="50176551000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>38.71</Subsidy>
                  <Price>38.71</Price>
                  <Alternate>38.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222013898">
            <Name>Zuclopenthixol hydrochloride</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222201389825" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22220138982525">
                <Name>Clopixol</Name>
                <Pack ID="P390372" Specified="true" nzmt:ctpp_id="50080941000117109">
                  <Quantity>100</Quantity>
                  <Subsidy>31.45</Subsidy>
                  <Price>31.45</Price>
                  <Alternate>31.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A222204">
          <Name>Depot Injections</Name>
          <Chemical ID="C2222041011">
            <Name>Risperidone</Name>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1427"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1427">
              <Title>
                <range>Risperidone microspheres</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has schizophrenia or other psychotic disorder</ci>
                      <ci type="logical" class="Trial">Has tried but failed to comply with treatment using oral atypical antipsychotic agents</ci>
                      <ci type="logical" class="Therapy">Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA0792 SA0926 SA1427">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F222204101126" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg vial</Name>
              <Brand ID="B22220410112625">
                <Name>Risperdal Consta</Name>
                <Pack ID="P2347652" Specified="true" nzmt:ctpp_id="50050331000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>135.98</Subsidy>
                  <Price>135.98</Price>
                  <Alternate>135.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204101127" Rank="4" Units="inj" Weight="37">
              <Name>Inj 37.5 mg vial</Name>
              <Brand ID="B22220410112725">
                <Name>Risperdal Consta</Name>
                <Pack ID="P2347644" Specified="true" nzmt:ctpp_id="50050321000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>178.71</Subsidy>
                  <Price>178.71</Price>
                  <Alternate>178.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204101128" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg vial</Name>
              <Brand ID="B22220410112825">
                <Name>Risperdal Consta</Name>
                <Pack ID="P2347660" Specified="true" nzmt:ctpp_id="50050341000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>217.56</Subsidy>
                  <Price>217.56</Price>
                  <Alternate>217.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222041140">
            <Name>Olanzapine</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note â€“ no new patients to be initiated on olanzapine.</p>
            </div>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1428"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1428">
              <Title>
                <range>Olanzapine depot injection</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="indication">The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="indication">The patient has schizophrenia</ci>
                      <ci type="logical" class="trial">The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents</ci>
                      <ci type="logical" class="indication">The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1146 SA1428">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="indication">The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F222204114015" Rank="4" Units="inj" Weight="210">
              <Name>Inj 210 mg vial</Name>
              <Brand ID="B22220411401525">
                <Name>Zyprexa Relprevv</Name>
                <Pack ID="P2337339" Specified="true" nzmt:ctpp_id="50122191000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>252.00</Subsidy>
                  <Price>252.00</Price>
                  <Alternate>252.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204114016" Rank="4" Units="inj" Weight="300">
              <Name>Inj 300 mg vial</Name>
              <Brand ID="B22220411401625">
                <Name>Zyprexa Relprevv</Name>
                <Pack ID="P2337347" Specified="true" nzmt:ctpp_id="50122181000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>414.00</Subsidy>
                  <Price>414.00</Price>
                  <Alternate>414.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204114017" Rank="4" Units="inj" Weight="405">
              <Name>Inj 405 mg vial</Name>
              <Brand ID="B22220411401725">
                <Name>Zyprexa Relprevv</Name>
                <Pack ID="P2337355" Specified="true" nzmt:ctpp_id="50122171000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>504.00</Subsidy>
                  <Price>504.00</Price>
                  <Alternate>504.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222041532">
            <Name>Flupenthixol decanoate</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222204153201" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220415320125">
                <Name>Fluanxol</Name>
                <Pack ID="P437298" Specified="true" nzmt:ctpp_id="50085771000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>13.14</Subsidy>
                  <Price>13.14</Price>
                  <Alternate>13.14</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204153202" Rank="4" Units="inj" Weight="40">
              <Name>Inj 20 mg per ml, 2 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220415320225">
                <Name>Fluanxol</Name>
                <Pack ID="P437301" Specified="true" nzmt:ctpp_id="50085781000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>20.90</Subsidy>
                  <Price>20.90</Price>
                  <Alternate>20.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204153203" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220415320325">
                <Name>Fluanxol</Name>
                <Pack ID="P437271" Specified="true" nzmt:ctpp_id="50085761000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>40.87</Subsidy>
                  <Price>40.87</Price>
                  <Alternate>40.87</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222042530">
            <Name>Haloperidol decanoate</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222204253001" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220425300101">
                <Name>Haldol</Name>
                <Pack ID="P714615" Specified="true" nzmt:ctpp_id="50104811000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>28.39</Subsidy>
                  <Price>28.39</Price>
                  <Alternate>28.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204253003" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220425300301">
                <Name>Haldol Concentrate</Name>
                <Pack ID="P768596" Specified="true" nzmt:ctpp_id="50111311000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>55.90</Subsidy>
                  <Price>55.90</Price>
                  <Alternate>55.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22220425300325" S29="true">
                <Name>Haldol Decanoas</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2503913" Specified="true" nzmt:ctpp_id="50234601000117106">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>55.90</Subsidy>
                  <Price>55.90</Price>
                  <Alternate>55.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222043803">
            <Name>Zuclopenthixol decanoate</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222204380325" Rank="4" Units="inj" Weight="200">
              <Name>Inj 200 mg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B22220438032525">
                <Name>Clopixol</Name>
                <Pack ID="P496189" Specified="true" nzmt:ctpp_id="50092801000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>19.80</Subsidy>
                  <Price>19.80</Price>
                  <Alternate>19.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222043878">
            <Name>Aripiprazole</Name>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2298"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2298">
              <Title>
                <range>Aripiprazole</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a current Special Authority approval for olanzapine depot injection, risperidone depot injection or paliperidone depot injection</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with olanzapine depot injection,
            risperidone depot injection or paliperidone depot injection</ci>
                      <ci type="logical" class="Indication">Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been
            initiated on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA2298">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The initiation of aripiprazole depot injection has been associated with fewer days of intensive intervention than prior to the initiation of an atypical
        antipsychotic depot injection</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F222204387831" Rank="4" Units="inj" Weight="300">
              <Name>Inj 300 mg vial</Name>
              <Brand ID="B22220438783125" S29="true">
                <Name>Abilify Maintena</Name>
                <Pack ID="P2670976" Specified="true" nzmt:ctpp_id="50212371000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>273.56</Subsidy>
                  <Price>273.56</Price>
                  <Alternate>273.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204387832" Rank="4" Units="inj" Weight="400">
              <Name>Inj 400 mg vial</Name>
              <Brand ID="B22220438783225" S29="true">
                <Name>Abilify Maintena</Name>
                <Pack ID="P2670984" Specified="true" nzmt:ctpp_id="50212381000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>341.96</Subsidy>
                  <Price>341.96</Price>
                  <Alternate>341.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222044025">
            <Name>Paliperidone</Name>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1429"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1429">
              <Title>
                <range>Paliperidone depot injection</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has schizophrenia or other psychotic disorder</ci>
                      <ci type="logical" class="Trial">Has tried but failed to comply with treatment using oral atypical antipsychotic agents</ci>
                      <ci type="logical" class="Therapy">Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1429">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F222204402525" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg syringe</Name>
              <Brand ID="B22220440252525">
                <Name>Invega Sustenna</Name>
                <Pack ID="P2426919" Specified="true" nzmt:ctpp_id="50134611000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>194.25</Subsidy>
                  <Price>194.25</Price>
                  <Alternate>194.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204402526" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg syringe</Name>
              <Brand ID="B22220440252625">
                <Name>Invega Sustenna</Name>
                <Pack ID="P2426927" Specified="true" nzmt:ctpp_id="50134631000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>271.95</Subsidy>
                  <Price>271.95</Price>
                  <Alternate>271.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204402527" Rank="4" Units="inj" Weight="75">
              <Name>Inj 75 mg syringe</Name>
              <Brand ID="B22220440252725">
                <Name>Invega Sustenna</Name>
                <Pack ID="P2426935" Specified="true" nzmt:ctpp_id="50134671000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>357.42</Subsidy>
                  <Price>357.42</Price>
                  <Alternate>357.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204402528" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg syringe</Name>
              <Brand ID="B22220440252825">
                <Name>Invega Sustenna</Name>
                <Pack ID="P2426943" Specified="true" nzmt:ctpp_id="50131131000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>435.12</Subsidy>
                  <Price>435.12</Price>
                  <Alternate>435.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204402529" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg syringe</Name>
              <Brand ID="B22220440252925">
                <Name>Invega Sustenna</Name>
                <Pack ID="P2426951" Specified="true" nzmt:ctpp_id="50134811000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>435.12</Subsidy>
                  <Price>435.12</Price>
                  <Alternate>435.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2222044166">
            <Name>Paliperidone palmitate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2167"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2167">
              <Title>
                <range>Paliperidone palmitate</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has schizophrenia</ci>
                    <ci type="logical" class="Indication">The patient has had an initial Special
                    Authority approval for paliperidone once-monthly depot injection</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA2167">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the initiation of paliperidone depot injection has
                been associated with fewer days of intensive intervention than was the case during a
                corresponding period of time prior to the initiation of an atypical antipsychotic
                depot injection</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F222204416625" Rank="4" Units="inj" Weight="175">
              <Name>Inj 175 mg syringe</Name>
              <Brand ID="B22220441662525">
                <Name>Invega Trinza</Name>
                <Pack ID="P2515202" Specified="true" nzmt:ctpp_id="50221911000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>815.85</Subsidy>
                  <Price>815.85</Price>
                  <Alternate>815.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204416626" Rank="4" Units="inj" Weight="263">
              <Name>Inj 263 mg syringe</Name>
              <Brand ID="B22220441662625">
                <Name>Invega Trinza</Name>
                <Pack ID="P2515210" Specified="true" nzmt:ctpp_id="50221921000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1072.26</Subsidy>
                  <Price>1072.26</Price>
                  <Alternate>1072.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204416627" Rank="4" Units="inj" Weight="350">
              <Name>Inj 350 mg syringe</Name>
              <Brand ID="B22220441662725">
                <Name>Invega Trinza</Name>
                <Pack ID="P2515229" Specified="true" nzmt:ctpp_id="50221931000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1305.36</Subsidy>
                  <Price>1305.36</Price>
                  <Alternate>1305.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222204416628" Rank="4" Units="inj" Weight="525">
              <Name>Inj 525 mg syringe</Name>
              <Brand ID="B22220441662825">
                <Name>Invega Trinza</Name>
                <Pack ID="P2515237" Specified="true" nzmt:ctpp_id="50221941000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1305.36</Subsidy>
                  <Price>1305.36</Price>
                  <Alternate>1305.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2225">
        <Name>Anxiolytics</Name>
        <ATC3 ID="A222501">
          <Name>Anxiolytics</Name>
          <Chemical ID="C2225011316">
            <Name>Clonazepam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222501131601" Rank="1" Units="tab" Weight="0.5">
              <Name>Tab 500 mcg</Name>
              <Brand ID="B22250113160125">
                <Name>Paxam</Name>
                <Pack ID="P2095483" Specified="true" nzmt:ctpp_id="50017781000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>5.64</Subsidy>
                  <Price>5.64</Price>
                  <Alternate>5.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222501131602" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B22250113160225">
                <Name>Paxam</Name>
                <Pack ID="P2095491" Specified="true" nzmt:ctpp_id="50017791000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>10.78</Subsidy>
                  <Price>10.78</Price>
                  <Alternate>10.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2225011397">
            <Name>Diazepam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222501139701" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B22250113970125" PSS="2026-06-30">
                <Name>Arrow-Diazepam</Name>
                <Pack ID="P2327996" Specified="true" nzmt:ctpp_id="50049241000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>95.00</Subsidy>
                  <Price>95.00</Price>
                  <Alternate>95.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222501139702" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22250113970225" PSS="2026-06-30">
                <Name>Arrow-Diazepam</Name>
                <Pack ID="P2328003" Specified="true" nzmt:ctpp_id="50049251000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>115.00</Subsidy>
                  <Price>115.00</Price>
                  <Alternate>115.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2225011730">
            <Name>Lorazepam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222501173002" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B22250117300201" PSS="2024-06-30">
                <Name>Ativan</Name>
                <Pack ID="P250120" Specified="true" nzmt:ctpp_id="50052251000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>12.50</Subsidy>
                  <Price>12.50</Price>
                  <Alternate>12.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222501173004" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B22250117300403" PSS="2024-06-30">
                <Name>Ativan</Name>
                <Pack ID="P2139022" Specified="true" nzmt:ctpp_id="50023961000117105">
                  <Quantity>250</Quantity>
                  <Subsidy>9.72</Subsidy>
                  <Price>9.72</Price>
                  <Alternate>9.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2225016006" Statim="Must">
            <Name>Buspirone hydrochloride</Name>
            <Formulation ID="F222501600601" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22250160060127" PSS="2024-06-30">
                <Name>Buspirone Viatris</Name>
                <Pack ID="P2615355" Specified="true" nzmt:ctpp_id="50289641000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>18.50</Subsidy>
                  <Price>18.50</Price>
                  <Alternate>18.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222501600602" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22250160060227" PSS="2024-06-30">
                <Name>Buspirone Viatris</Name>
                <Pack ID="P2615363" Specified="true" nzmt:ctpp_id="50289651000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>12.50</Subsidy>
                  <Price>12.50</Price>
                  <Alternate>12.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2226">
        <Name>Multiple Sclerosis Treatments</Name>
        <ATC3 ID="A222601">
          <Name>Multiple Sclerosis Treatments</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA2274">
            <Title>
              <range>Multiple Sclerosis</range>
            </Title>
            <Case When="Initial application" Category="Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Diagnosis of multiple sclerosis (MS) meets the
                    McDonald 2017 diagnostic criteria for MS and has been confirmed by a
                    neurologist</ci>
                    <ci type="logical" class="Indication">Patient has an EDSS score between 0 â€“
                    6.0</ci>
                    <ci type="logical" class="Indication">Patient has had at least one significant
                    attack of MS in the previous 12 months or two significant attacks in the past 24
                    months</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Each significant attack must be confirmed
                        by the applying neurologist or general physician (the patient may not
                        necessarily have been seen by them during the attack, but the
                        neurologist/physician must be satisfied that the clinical features were
                        characteristic)</ci>
                      <ci type="logical" class="Indication">Each significant attack is associated with
                        characteristic new symptom(s)/sign(s) or substantially worsening of
                        previously experienced symptoms(s)/sign(s)</ci>
                      <ci type="logical" class="Indication">Each significant attack has lasted at
                        least one week and has started at least one month after the onset of a
                        previous attack (where relevant)</ci>
                      <ci type="logical" class="Indication">Each significant attack can be
                        distinguished from the effects of general fatigue; and is not associated
                        with a fever (T&gt; 37.5Â°C)</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Each significant attack is severe
                            enough to change either the EDSS or at least one of the Kurtze
                            Functional System scores by at least 1 point</ci>
                        <ci type="logical" class="Indication">Each significant attack is a recurrent
                            paroxysmal symptom of multiple sclerosis (tonic seizures/spasms,
                            trigeminal neuralgia, Lhermitteâ€™s symptom)</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Evidence of new inflammatory activity on an
                    MRI scan within the past 24 months</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">A sign of that new inflammatory activity
                        on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing
                        lesion</ci>
                      <ci type="logical" class="Indication">A sign of that new inflammatory activity
                        is a lesion showing diffusion restriction</ci>
                      <ci type="logical" class="Indication">A sign of that new inflammatory is a T2
                        lesion with associated local swelling</ci>
                      <ci type="logical" class="Indication">A sign of that new inflammatory activity
                        is a prominent T2 lesion that clearly is responsible for the clinical
                        features of a recent attack that occurred within the last 2 years</ci>
                      <ci type="logical" class="Indication">A sign of that new inflammatory activity
                        is new T2 lesions compared with a previous MRI scan</ci>
                    </apply>
                  </apply>
                  <ci type="logical" class="Indication">Patient has an active approval for ocrelizumab and does not have primary progressive MS</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="month">12</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
              </div>
            </Case>
            <Case When="Renewal" Category="Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide" Form="SA2026 SA2051 SA2140 SA2176 SA2274">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">patient has had an EDSS score of 0 to 6.0
                (inclusive) with or without the use of unilateral or bilateral aids at any time in
                the last six months (ie the patient has walked 100 metres or more with or without
                aids in the last six months)</ci>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="month">12</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
              </div>
            </Case>
          </Request>
          <Chemical ID="C2226011248">
            <Name>Interferon beta-1-alpha</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2274"/>
            <Formulation ID="F222601124825" Rank="4" Units="inj">
              <Name>Inj 6 million iu prefilled syringe</Name>
              <Brand ID="B22260112482525">
                <Name>Avonex</Name>
                <Pack ID="P2261421" Specified="true" nzmt:ctpp_id="50041341000117105">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1170.00</Subsidy>
                  <Price>1170.00</Price>
                  <Alternate>1170.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222601124826" Rank="4" Units="inj">
              <Name>Injection 6 million iu per 0.5 ml pen injector</Name>
              <Brand ID="B22260112482625">
                <Name>Avonex Pen</Name>
                <Pack ID="P2431440" Specified="true" nzmt:ctpp_id="50155651000117106">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1170.00</Subsidy>
                  <Price>1170.00</Price>
                  <Alternate>1170.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2226013707">
            <Name>Interferon beta-1-beta</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2274"/>
            <Formulation ID="F222601370725" Rank="4" Units="inj" Weight="8000000">
              <Name>Inj 8 million iu per 1 ml</Name>
              <Brand ID="B22260137072525">
                <Name>Betaferon</Name>
                <Pack ID="P439169" Specified="true" nzmt:ctpp_id="50085941000117100">
                  <Quantity>15</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1322.89</Subsidy>
                  <Price>1322.89</Price>
                  <Alternate>1322.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2226013835">
            <Name>Glatiramer acetate</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2274"/>
            <Formulation ID="F222601383526" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg prefilled syringe</Name>
              <Brand ID="B22260138352625" PSS="2025-06-30">
                <Name>Copaxone</Name>
                <Pack ID="P2545349" Specified="true" nzmt:ctpp_id="50226651000117100">
                  <Quantity>12</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1137.48</Subsidy>
                  <Price>1137.48</Price>
                  <Alternate>1137.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2226014036">
            <Name>Fingolimod</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Type="Wastage"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2274"/>
            <Formulation ID="F222601403625" Rank="2" Units="cap">
              <Name>Cap 0.5 mg</Name>
              <Brand ID="B22260140362525">
                <Name>Gilenya</Name>
                <Pack ID="P2455153" Specified="true" nzmt:ctpp_id="50141011000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>2200.00</Subsidy>
                  <Price>2200.00</Price>
                  <Alternate>2200.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2226014045">
            <Name>Natalizumab</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2274"/>
            <Formulation ID="F222601404525" Rank="4" Units="inj">
              <Name>Inj 20 mg per ml, 15 ml vial</Name>
              <Brand ID="B22260140452525">
                <Name>Tysabri</Name>
                <Pack ID="P2467062" Specified="true" nzmt:ctpp_id="50130411000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1750.00</Subsidy>
                  <Price>1750.00</Price>
                  <Alternate>1750.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2226014053">
            <Name>Dimethyl fumarate</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Type="Wastage"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2274"/>
            <Formulation ID="F222601405325" Rank="2" Units="cap" Weight="120">
              <Name>Cap 120 mg</Name>
              <Brand ID="B22260140532525">
                <Name>Tecfidera</Name>
                <Pack ID="P2493004" Specified="true" nzmt:ctpp_id="50181461000117104">
                  <Quantity>14</Quantity>
                  <Subsidy>520.00</Subsidy>
                  <Price>520.00</Price>
                  <Alternate>520.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222601405326" Rank="2" Units="cap" Weight="240">
              <Name>Cap 240 mg</Name>
              <Brand ID="B22260140532625">
                <Name>Tecfidera</Name>
                <Pack ID="P2493012" Specified="true" nzmt:ctpp_id="50181491000117105">
                  <Quantity>56</Quantity>
                  <Subsidy>2000.00</Subsidy>
                  <Price>2000.00</Price>
                  <Alternate>2000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2226014054">
            <Name>Teriflunomide</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Type="Wastage"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2274"/>
            <Formulation ID="F222601405425" Rank="1" Units="tab" Weight="14">
              <Name>Tab 14 mg</Name>
              <Brand ID="B22260140542525">
                <Name>Aubagio</Name>
                <Pack ID="P2494418" Specified="true" nzmt:ctpp_id="50154071000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>659.90</Subsidy>
                  <Price>659.90</Price>
                  <Alternate>659.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A222604">
          <Name>Multiple Sclerosis Treatments - Other</Name>
          <Chemical ID="C2226044119">
            <Name>Ocrelizumab</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2273"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2273">
              <Title>
                <range>Ocrelizumab</range>
              </Title>
              <Case When="Initial application" Category="Multiple Sclerosis - ocrelizumab">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Diagnosis of multiple sclerosis (MS) meets the
                        McDonald 2017 diagnostic criteria for MS and has been confirmed by a
                        neurologist</ci>
                      <ci type="logical" class="Indication">Patient has an EDSS score between 0 â€“
                        6.0</ci>
                      <ci type="logical" class="Indication">Patient has had at least one significant
                        attack of MS in the previous 12 months or two significant attacks in the past 24
                        months</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Each significant attack must be confirmed
                            by the applying neurologist or general physician (the patient may not
                            necessarily have been seen by them during the attack, but the
                            neurologist/physician must be satisfied that the clinical features were
                            characteristic)</ci>
                        <ci type="logical" class="Indication">Each significant attack is associated with
                            characteristic new symptom(s)/sign(s) or substantially worsening of
                            previously experienced symptoms(s)/sign(s)</ci>
                        <ci type="logical" class="Indication">Each significant attack has lasted at
                            least one week and has started at least one month after the onset of a
                            previous attack (where relevant)</ci>
                        <ci type="logical" class="Indication">Each significant attack can be
                            distinguished from the effects of general fatigue; and is not associated
                            with a fever (T&gt; 37.5Â°C)</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">Each significant attack is severe
                                enough to change either the EDSS or at least one of the Kurtze
                                Functional System scores by at least 1 point</ci>
                          <ci type="logical" class="Indication">Each significant attack is a recurrent
                                paroxysmal symptom of multiple sclerosis (tonic seizures/spasms,
                                trigeminal neuralgia, Lhermitteâ€™s symptom)</ci>
                        </apply>
                      </apply>
                      <ci type="logical" class="Indication">Evidence of new inflammatory activity on an
                        MRI scan within the past 24 months</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">A sign of that new inflammatory activity
                            on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing
                            lesion</ci>
                        <ci type="logical" class="Indication">A sign of that new inflammatory activity
                            is a lesion showing diffusion restriction</ci>
                        <ci type="logical" class="Indication">A sign of that new inflammatory is a T2
                            lesion with associated local swelling</ci>
                        <ci type="logical" class="Indication">A sign of that new inflammatory activity
                            is a prominent T2 lesion that clearly is responsible for the clinical
                            features of a recent attack that occurred within the last 2 years</ci>
                        <ci type="logical" class="Indication">A sign of that new inflammatory activity
                            is new T2 lesions compared with a previous MRI scan</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Patient has an active Special Authority approval for either dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab or teriflunomide</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Multiple Sclerosis - ocrelizumab" Form="SA2273">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has had an EDSS score of 0 to 6.0
                (inclusive) with or without the use of unilateral or bilateral aids at any time in
                the last six months (ie the patient has walked 100 metres or more with or without
                aids in the last six months)</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Primary Progressive Multiple Sclerosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Diagnosis of primary progressive multiple sclerosis (PPMS) meets the 2017 McDonald criteria and has been confirmed by a neurologist</ci>
                    <ci type="logical" class="Indication">Patient has an EDSS 2.0 (score equal to or greater than 2 on pyramidal functions) to EDSS 6.5</ci>
                    <ci type="logical" class="Indication">Patient has no history of relapsing remitting multiple sclerosis</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Primary Progressive Multiple Sclerosis" Form="SA2273">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Patient has had an EDSS score of less than or equal to 6.5 at any time in the last six months (ie patient has walked 20 metres with bilateral assistance/aids, without rest in the last six months)</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F222604411925" Rank="4" Units="inj">
              <Name>Inj 30 mg per ml, 10 ml vial</Name>
              <Brand ID="B22260441192525">
                <Name>Ocrevus</Name>
                <Pack ID="P2540789" Specified="true" nzmt:ctpp_id="50235631000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9346.00</Subsidy>
                  <Price>9346.00</Price>
                  <Alternate>9346.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2228">
        <Name>Sedatives and Hypnotics</Name>
        <ATC3 ID="A222801">
          <Name>Sedatives and Hypnotics</Name>
          <Chemical ID="C2228011956">
            <Name>Phenobarbitone sodium</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1386"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1386">
              <Title>
                <range>Phenobarbitone</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci>
                    <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F222801195625" Rank="4" Units="inj">
              <Name>Inj 200 mg per ml, 1 ml ampoule</Name>
              <Brand ID="B22280119562525" S29="true">
                <Name>Max Health</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2437856" Specified="true" nzmt:ctpp_id="50166971000117109">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>113.37</Subsidy>
                  <Price>113.37</Price>
                  <Alternate>113.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2228012224">
            <Name>Temazepam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222801222425" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22280122242525" PSS="2026-06-30">
                <Name>Normison</Name>
                <Pack ID="P2184877" Specified="true" nzmt:ctpp_id="50030301000117100">
                  <Quantity>25</Quantity>
                  <Subsidy>1.40</Subsidy>
                  <Price>1.40</Price>
                  <Alternate>1.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2228012484">
            <Name>Zopiclone</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222801248401" Rank="1" Units="tab" Weight="7.5">
              <Name>Tab 7.5 mg</Name>
              <Brand ID="B22280124840126" PSS="2024-06-30">
                <Name>Zopiclone Actavis</Name>
                <Pack ID="P2480662" Specified="true" nzmt:ctpp_id="50220441000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>10.80</Subsidy>
                  <Price>10.80</Price>
                  <Alternate>10.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2228012539">
            <Name>Midazolam</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F222801253902" Rank="4" Units="inj" Weight="5">
              <Name>Inj 1 mg per ml, 5 ml ampoule</Name>
              <Brand ID="B22280125390228">
                <Name>Midazolam-Baxter</Name>
                <Pack ID="P2599279" Specified="true" nzmt:ctpp_id="50281291000117108">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>6.10</Subsidy>
                  <Price>6.10</Price>
                  <Alternate>6.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222801253903" Rank="4" Units="inj" Weight="15">
              <Name>Inj 5 mg per ml, 3 ml ampoule </Name>
              <Brand ID="B22280125390328">
                <Name>Midazolam-Baxter</Name>
                <Pack ID="P2599260" Specified="true" nzmt:ctpp_id="50281301000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5.00</Subsidy>
                  <Price>5.00</Price>
                  <Alternate>5.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222801253925" Rank="4" Units="inj" Weight="5">
              <Name>Inj 1 mg per ml, 5 ml plastic ampoule</Name>
              <Rule Type="FormMax" Value="10" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.</p>
              </div>
              <Brand ID="B22280125392525">
                <Name>Pfizer</Name>
                <Pack ID="P2263076" Specified="true" nzmt:ctpp_id="50041581000117107">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>17.28</Subsidy>
                  <Price>17.28</Price>
                  <Alternate>17.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F222801253926" Rank="4" Units="inj" Weight="15">
              <Name>Inj 5 mg per ml, 3 ml plastic ampoule </Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.</p>
              </div>
              <Brand ID="B22280125392625">
                <Name>Pfizer</Name>
                <Pack ID="P2263068" Specified="true" nzmt:ctpp_id="50041571000117109">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>13.09</Subsidy>
                  <Price>13.09</Price>
                  <Alternate>13.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2228014083">
            <Name>Melatonin</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1666"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1666">
              <Title>
                <range>Melatonin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to,
                    autism spectrum disorder or attention deficit hyperactivity disorder)*</ci>
                    <ci type="logical" class="Indication">Behavioural and environmental approaches have been tried and were unsuccessful, or are inappropriate</ci>
                    <ci type="logical" class="Indication">Funded modified-release melatonin is to be given at doses no greater than 10 mg per day</ci>
                    <ci type="logical" class="Indication">Patient is aged 18 years or under*</ci>
                  </apply>
                </math>
                <Applicant>psychiatrist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Applicant Referring="psychiatrist, paediatrician, neurologist or respiratory specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1666">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is aged 18 years or under*</ci>
                    <ci type="logical" class="Indication">Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined)</ci>
                    <ci type="logical" class="Indication">Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and
                    distressing insomnia</ci>
                    <ci type="logical" class="Indication">Funded modified-release melatonin is to be given at doses no greater than 10 mg per day</ci>
                  </apply>
                </math>
                <Applicant>psychiatrist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Applicant Referring="psychiatrist, paediatrician, neurologist or respiratory specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Indications marked with * are unapproved indications.</p>
              </div>
            </Request>
            <Formulation ID="F222801408325" Rank="1" Units="tab" Weight="2">
              <Name>Tab modified-release 2 mg</Name>
              <Rule Type="DoseDMax" Value="5"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Restricted to patients aged 18 years or under.</p>
              </div>
              <Brand ID="B22280140832526" PSS="2024-06-30">
                <Name>Vigisom</Name>
                <Pack ID="P2612593" Specified="true" nzmt:ctpp_id="50281501000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>11.50</Subsidy>
                  <Price>11.50</Price>
                  <Alternate>11.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2230">
        <Name>Spinal Muscular Atrophy</Name>
        <ATC3 ID="A223001">
          <Name>Spinal Muscular Atrophy</Name>
          <Chemical ID="C2230014168">
            <Name>Nusinersen</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2174"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2174">
              <Title>
                <range>Nusinersen</range>
              </Title>
              <Case When="Initial application" Category="spinal muscular atrophy (SMA)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation</ci>
                    <ci type="logical" class="Indication">Patient is 18 years of age or under</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient is pre-symptomatic</ci>
                        <ci type="logical" class="Indication">Patient has three or less copies of SMN2</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="spinal muscular atrophy (SMA)" Form="SA2174">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">There has been demonstrated maintenance of motor milestone function since treatment initiation</ci>
                    <ci type="logical" class="Indication">Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with nusinersen</ci>
                    <ci type="logical" class="Indication">Nusinersen not to be administered in combination other SMA disease modifying treatments or gene therapy</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F223001416825" Rank="4" Units="inj">
              <Name>Inj 12 mg per 5 ml vial</Name>
              <Brand ID="B22300141682525">
                <Name>Spinraza</Name>
                <Pack ID="P2648040" Specified="true" nzmt:ctpp_id="50249481000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>120000.00</Subsidy>
                  <Price>120000.00</Price>
                  <Alternate>120000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2230014176">
            <Name>Risdiplam</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: the supply of risdiplam is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website https://pharmac.govt.nz/risdiplam</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2203"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2203">
              <Title>
                <range>Risdiplam</range>
              </Title>
              <Case When="Initial application" Category="spinal muscular atrophy (SMA)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation</ci>
                    <ci type="logical">Patient is 18 years of age or under</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age</ci>
                      <apply>
                        <and/>
                        <ci type="logical">Patient is pre-symptomatic</ci>
                        <ci type="logical">Patient has three or less copies of SMN2</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="spinal muscular atrophy (SMA)" Form="SA2203">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">There has been demonstrated maintenance of motor milestone function since treatment initiation</ci>
                    <ci type="logical">Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam</ci>
                    <ci type="logical">Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F223001417625" Rank="3" Units="ml">
              <Name>Powder for oral soln 750 mcg per ml, 60 mg per bottle</Name>
              <Brand ID="B22300141762525">
                <Name>Evrysdi</Name>
                <Pack ID="P2649403" Specified="true" OP="true" nzmt:ctpp_id="50282411000117109">
                  <Quantity>80</Quantity>
                  <Subsidy>14100.00</Subsidy>
                  <Price>14100.00</Price>
                  <Alternate>14100.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2231">
        <Name>Stimulants/ADHD Treatments</Name>
        <ATC3 ID="A223101">
          <Name>Stimulants/ADHD Treatments</Name>
          <Chemical ID="C2231011389">
            <Name>Dexamfetamine sulfate</Name>
            <Rule Type="Controlled"/>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1149"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1149">
              <Title>
                <range>Dexamfetamine Sulfate</range>
              </Title>
              <Case When="Initial application" Category="ADHD in patients 5 or over">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over</ci>
                    <ci type="logical" class="Indication">Diagnosed according to DSM-IV or ICD 10 criteria</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a paediatrician or psychiatrist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">medical practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Initial application" Category="ADHD in patients under 5">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age</ci>
                    <ci type="logical" class="Indication">Diagnosed according to DSM-IV or ICD 10 criteria</ci>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Narcolepsy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient suffers from narcolepsy</ci>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Renewal" Category="ADHD in patients 5 or over" Form="SA0907 SA1073 SA1149">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a paediatrician or psychiatrist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">medical practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Renewal" Category="ADHD in patients under 5" Form="SA0907 SA1073 SA1149">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Narcolepsy" Form="SA0907 SA1073 SA1149">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F223101138901" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Rule Type="Brandswitch" Value="2673886" Attribute="BSF Noumed Dexamfetamine" xlink:href="A35"/>
              <Brand ID="B22310113890101" ToBeDelisted="2024-06-01">
                <Name>PSM</Name>
                <Pack ID="P2461374" Specified="true" nzmt:ctpp_id="50307061000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>21.00</Subsidy>
                  <Price>21.00</Price>
                  <Alternate>21.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310113890102" ToBeDelisted="2024-06-01">
                <Name>Aspen</Name>
                <Pack ID="P2642298" Specified="true" nzmt:ctpp_id="50315271000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>28.50</Subsidy>
                  <Price>28.50</Price>
                  <Alternate>28.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310113890103" ToBePSS="2024-06-01">
                <Name>Noumed Dexamfetamine</Name>
                <Pack ID="P2647516" Specified="true">
                  <Quantity>100</Quantity>
                  <Subsidy>29.80</Subsidy>
                  <Price>29.80</Price>
                  <Alternate>29.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2231011809">
            <Name>Methylphenidate hydrochloride</Name>
            <Rule Type="Controlled"/>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1964"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1964">
              <Title>
                <range>Methylphenidate Hydrochloride<instance>Rubifen</instance><instance>Rubifen SR</instance><instance>Ritalin</instance><instance>Ritalin SR</instance><instance>Methylphenidate ER - Teva</instance></range>
              </Title>
              <Case When="Initial application" Category="ADHD in patients 5 or over">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">ADHD (Attention Deficit and Hyperactivity Disorder)
          patients aged 5 years or over</ci>
                    <ci type="logical" class="Indication">Diagnosed according to DSM-IV or ICD 10 criteria</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a paediatrician or psychiatrist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a medical practitioner or nurse practitioner and confirms
            that a paediatrician or psychiatrist has been consulted within the last 2 years and has
            recommended treatment for the patient in writing</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">medical practitioner</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">nurse practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Initial application" Category="ADHD in patients under 5">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">ADHD (Attention Deficit and Hyperactivity Disorder)
          patients under 5 years of age</ci>
                    <ci type="logical" class="Indication">Diagnosed according to DSM-IV or ICD 10 criteria</ci>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Narcolepsy*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient suffers from narcolepsy</ci>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">24</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>*narcolepsy is not a registered indication for Methylphenidate ER â€“ Teva.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="ADHD in patients 5 or over" Form="SA0908 SA1074 SA1150 SA1964">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is
          benefiting from treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a paediatrician or psychiatrist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a medical practitioner or nurse practitioner and confirms
            that a paediatrician or psychiatrist has been consulted within the last 2 years and has
            recommended treatment for the patient in writing</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">medical practitioner</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">nurse practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Renewal" Category="ADHD in patients under 5" Form="SA0908 SA1074 SA1150 SA1964">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is
        benefiting from treatment</ci>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Narcolepsy*" Form="SA0908 SA1074 SA1150 SA1964">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is
        benefiting from treatment</ci>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">24</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>*narcolepsy is not a registered indication for Methylphenidate ER â€“ Teva.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F223101180901" Rank="1" Units="tab" Weight="10">
              <Name>Tab immediate-release 10 mg</Name>
              <Brand ID="B22310118090101">
                <Name>Ritalin</Name>
                <Pack ID="P2349329" Specified="true" nzmt:ctpp_id="50120341000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>3.00</Subsidy>
                  <Price>3.00</Price>
                  <Alternate>3.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310118090125">
                <Name>Rubifen</Name>
                <Pack ID="P437204" Specified="true" nzmt:ctpp_id="50085731000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>3.00</Subsidy>
                  <Price>3.00</Price>
                  <Alternate>3.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101180925" Rank="1" Units="tab" Weight="20">
              <Name>Tab sustained-release  20 mg</Name>
              <Brand ID="B22310118092526">
                <Name>Rubifen SR</Name>
                <Pack ID="P2116782" Specified="true" nzmt:ctpp_id="50020531000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>10.95</Subsidy>
                  <Price>10.95</Price>
                  <Alternate>10.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101180926" Rank="1" Units="tab" Weight="5">
              <Name>Tab immediate-release 5 mg</Name>
              <Brand ID="B22310118092625">
                <Name>Rubifen</Name>
                <Pack ID="P2227371" Specified="true" nzmt:ctpp_id="50036641000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>3.20</Subsidy>
                  <Price>3.20</Price>
                  <Alternate>3.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101180927" Rank="1" Units="tab" Weight="20">
              <Name>Tab immediate-release 20 mg</Name>
              <Brand ID="B22310118092725">
                <Name>Rubifen</Name>
                <Pack ID="P2227320" Specified="true" nzmt:ctpp_id="50036631000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>7.85</Subsidy>
                  <Price>7.85</Price>
                  <Alternate>7.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101180935" Rank="1" Units="tab" Weight="18">
              <Name>Tab extended-release 18 mg</Name>
              <Brand ID="B22310118093526">
                <Name>Methylphenidate ER - Teva</Name>
                <Pack ID="P2567091" Specified="true" nzmt:ctpp_id="50250351000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>7.75</Subsidy>
                  <Price>7.75</Price>
                  <Alternate>7.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101180936" Rank="1" Units="tab" Weight="36">
              <Name>Tab extended-release 36 mg</Name>
              <Brand ID="B22310118093626">
                <Name>Methylphenidate ER - Teva</Name>
                <Pack ID="P2562782" Specified="true" nzmt:ctpp_id="50250331000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>15.50</Subsidy>
                  <Price>15.50</Price>
                  <Alternate>15.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101180937" Rank="1" Units="tab" Weight="27">
              <Name>Tab extended-release 27 mg</Name>
              <Brand ID="B22310118093726">
                <Name>Methylphenidate ER - Teva</Name>
                <Pack ID="P2562774" Specified="true" nzmt:ctpp_id="50250341000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>11.45</Subsidy>
                  <Price>11.45</Price>
                  <Alternate>11.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101180938" Rank="1" Units="tab" Weight="54">
              <Name>Tab extended-release 54 mg</Name>
              <Brand ID="B22310118093826">
                <Name>Methylphenidate ER - Teva</Name>
                <Pack ID="P2562790" Specified="true" nzmt:ctpp_id="50250321000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>22.25</Subsidy>
                  <Price>22.25</Price>
                  <Alternate>22.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2231013880">
            <Name>Methylphenidate hydrochloride extended-release</Name>
            <Rule Type="Controlled"/>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2305"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2305">
              <Title>
                <range>Methylphenidate Hydrochloride Extended Release<instance>Concerta</instance><instance>Ritalin LA</instance></range>
              </Title>
              <Case When="Initial application" Category="ADHD">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">ADHD (Attention Deficit and Hyperactivity
          Disorder)</ci>
                    <ci type="logical" class="Indication">Diagnosed according to DSM-IV or ICD 10 criteria</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a paediatrician or psychiatrist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a medical practitioner or nurse practitioner and confirms
            that a paediatrician or psychiatrist has been consulted within the last 2 years and has
            recommended treatment for the patient in writing</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="trial">Patient is taking a currently subsidised formulation of
            methylphenidate hydrochloride (immediate-release or sustained-release) which has not
            been effective due to significant administration and/or difficulties with adherence</ci>
                      <ci type="logical" class="Endorsement">There is significant concern regarding the risk of
            diversion or abuse of immediate-release methylphenidate hydrochloride</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">medical practitioner</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">nurse practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Renewal" Category="ADHD" Form="SA0924 SA1151 SA1965 SA2278 SA2305">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is
          benefiting from treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a paediatrician or psychiatrist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a medical practitioner or nurse practitioner and confirms
            that a paediatrician or psychiatrist has been consulted within the last 2 years and has
            recommended treatment for the patient in writing</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>psychiatrist</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">medical practitioner</Applicant>
                <Applicant Referring="paediatrician or psychiatrist (in writing)">nurse practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F223101388025" Rank="1" Units="tab" Weight="18">
              <Name>Tab extended-release 18 mg</Name>
              <Brand ID="B22310138802525">
                <Name>Concerta</Name>
                <Pack ID="P2145065" Specified="true" nzmt:ctpp_id="50025041000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>58.96</Subsidy>
                  <Price>58.96</Price>
                  <Alternate>58.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388026" Rank="1" Units="tab" Weight="36">
              <Name>Tab extended-release 36 mg</Name>
              <Brand ID="B22310138802625">
                <Name>Concerta</Name>
                <Pack ID="P2145073" Specified="true" nzmt:ctpp_id="50025061000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>71.93</Subsidy>
                  <Price>71.93</Price>
                  <Alternate>71.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388027" Rank="1" Units="tab" Weight="27">
              <Name>Tab extended-release 27 mg</Name>
              <Brand ID="B22310138802725">
                <Name>Concerta</Name>
                <Pack ID="P2294524" Specified="true" nzmt:ctpp_id="50045281000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>65.44</Subsidy>
                  <Price>65.44</Price>
                  <Alternate>65.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388028" Rank="1" Units="tab" Weight="54">
              <Name>Tab extended-release 54 mg</Name>
              <Brand ID="B22310138802825">
                <Name>Concerta</Name>
                <Pack ID="P2145081" Specified="true" nzmt:ctpp_id="50025071000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>86.24</Subsidy>
                  <Price>86.24</Price>
                  <Alternate>86.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388029" Rank="2" Units="cap" Weight="20">
              <Name>Cap modified-release 20 mg</Name>
              <Brand ID="B22310138802925">
                <Name>Ritalin LA</Name>
                <Pack ID="P2274892" Specified="true" nzmt:ctpp_id="50043041000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>20.40</Subsidy>
                  <Price>20.40</Price>
                  <Alternate>20.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388030" Rank="2" Units="cap" Weight="30">
              <Name>Cap modified-release 30 mg</Name>
              <Brand ID="B22310138803025">
                <Name>Ritalin LA</Name>
                <Pack ID="P2274906" Specified="true" nzmt:ctpp_id="50043051000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>25.52</Subsidy>
                  <Price>25.52</Price>
                  <Alternate>25.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388031" Rank="2" Units="cap" Weight="40">
              <Name>Cap modified-release 40 mg</Name>
              <Brand ID="B22310138803125">
                <Name>Ritalin LA</Name>
                <Pack ID="P2274884" Specified="true" nzmt:ctpp_id="50043031000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>30.60</Subsidy>
                  <Price>30.60</Price>
                  <Alternate>30.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388032" Rank="2" Units="cap" Weight="10">
              <Name>Cap modified-release 10 mg</Name>
              <Brand ID="B22310138803225">
                <Name>Ritalin LA</Name>
                <Pack ID="P2346370" Specified="true" nzmt:ctpp_id="50050231000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>15.60</Subsidy>
                  <Price>15.60</Price>
                  <Alternate>15.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2231013887" Update="+Subsidy">
            <Name>Atomoxetine</Name>
            <Formulation ID="F223101388725" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B22310138872526" ToBeDelisted="2024-08-01">
                <Name>Generic Partners</Name>
                <Pack ID="P2566826" Specified="true" nzmt:ctpp_id="50232381000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>18.41</Subsidy>
                  <Price>18.41</Price>
                  <Alternate>18.41</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138872527" S29="true" ToBeDelisted="2024-08-01">
                <Name>APO-Atomoxetine S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2632497" Specified="true">
                  <Quantity>28</Quantity>
                  <Subsidy>18.41</Subsidy>
                  <Price>18.41</Price>
                  <Alternate>18.41</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138872528">
                <Name>APO-Atomoxetine</Name>
                <Pack ID="P2638517" Specified="true" nzmt:ctpp_id="50297781000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>43.02</Subsidy>
                  <Price>43.02</Price>
                  <Alternate>43.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388726" Rank="2" Units="cap" Weight="18">
              <Name>Cap 18 mg</Name>
              <Brand ID="B22310138872626" ToBeDelisted="2024-08-01">
                <Name>Generic Partners</Name>
                <Pack ID="P2566834" Specified="true" nzmt:ctpp_id="50232421000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>27.06</Subsidy>
                  <Price>27.06</Price>
                  <Alternate>27.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138872627">
                <Name>APO-Atomoxetine</Name>
                <Pack ID="P2637065" Specified="true" nzmt:ctpp_id="50301411000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>45.57</Subsidy>
                  <Price>45.57</Price>
                  <Alternate>45.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388727" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B22310138872726" ToBeDelisted="2024-08-01">
                <Name>Generic Partners</Name>
                <Pack ID="P2566842" Specified="true" nzmt:ctpp_id="50232471000117106">
                  <Quantity>28</Quantity>
                  <Subsidy>29.22</Subsidy>
                  <Price>29.22</Price>
                  <Alternate>29.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138872727">
                <Name>APO-Atomoxetine</Name>
                <Pack ID="P2637073" Specified="true" nzmt:ctpp_id="50301421000117103">
                  <Quantity>28</Quantity>
                  <Subsidy>44.30</Subsidy>
                  <Price>44.30</Price>
                  <Alternate>44.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388728" Rank="2" Units="cap" Weight="40">
              <Name>Cap 40 mg</Name>
              <Brand ID="B22310138872826" ToBeDelisted="2024-08-01">
                <Name>Generic Partners</Name>
                <Pack ID="P2566850" Specified="true" nzmt:ctpp_id="50232501000117101">
                  <Quantity>28</Quantity>
                  <Subsidy>29.22</Subsidy>
                  <Price>29.22</Price>
                  <Alternate>29.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138872827">
                <Name>APO-Atomoxetine</Name>
                <Pack ID="P2637081" Specified="true" nzmt:ctpp_id="50301431000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>46.21</Subsidy>
                  <Price>46.21</Price>
                  <Alternate>46.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388729" Rank="2" Units="cap" Weight="60">
              <Name>Cap 60 mg</Name>
              <Brand ID="B22310138872926" ToBeDelisted="2024-08-01">
                <Name>Generic Partners</Name>
                <Pack ID="P2566869" Specified="true" nzmt:ctpp_id="50232541000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>46.51</Subsidy>
                  <Price>46.51</Price>
                  <Alternate>46.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138872927" S29="true" ToBeDelisted="2024-08-01">
                <Name>APO-Atomoxetine S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2636050" Specified="true">
                  <Quantity>28</Quantity>
                  <Subsidy>46.51</Subsidy>
                  <Price>46.51</Price>
                  <Alternate>46.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138872928">
                <Name>APO-Atomoxetine</Name>
                <Pack ID="P2638525" Specified="true" nzmt:ctpp_id="50300341000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>51.31</Subsidy>
                  <Price>51.31</Price>
                  <Alternate>51.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388730" Rank="2" Units="cap" Weight="80">
              <Name>Cap 80 mg</Name>
              <Brand ID="B22310138873026" ToBeDelisted="2024-08-01">
                <Name>Generic Partners</Name>
                <Pack ID="P2566877" Specified="true" nzmt:ctpp_id="50232581000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>56.45</Subsidy>
                  <Price>56.45</Price>
                  <Alternate>56.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138873027" S29="true" ToBeDelisted="2024-08-01">
                <Name>APO-Atomoxetine S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2632500" Specified="true">
                  <Quantity>28</Quantity>
                  <Subsidy>56.45</Subsidy>
                  <Price>56.45</Price>
                  <Alternate>56.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138873028">
                <Name>APO-Atomoxetine</Name>
                <Pack ID="P2638533" Specified="true" nzmt:ctpp_id="50297791000117106">
                  <Quantity>28</Quantity>
                  <Subsidy>65.20</Subsidy>
                  <Price>65.20</Price>
                  <Alternate>65.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223101388731" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B22310138873126" ToBeDelisted="2024-08-01">
                <Name>Generic Partners</Name>
                <Pack ID="P2566885" Specified="true" nzmt:ctpp_id="50232621000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>58.48</Subsidy>
                  <Price>58.48</Price>
                  <Alternate>58.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138873127" S29="true" ToBeDelisted="2024-08-01">
                <Name>APO-Atomoxetine S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2632519" Specified="true">
                  <Quantity>28</Quantity>
                  <Subsidy>58.48</Subsidy>
                  <Price>58.48</Price>
                  <Alternate>58.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22310138873128">
                <Name>APO-Atomoxetine</Name>
                <Pack ID="P2638541" Specified="true" nzmt:ctpp_id="50297801000117107">
                  <Quantity>28</Quantity>
                  <Subsidy>65.71</Subsidy>
                  <Price>65.71</Price>
                  <Alternate>65.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2231013935">
            <Name>Modafinil</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1999"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1999">
              <Title>
                <range>Modafinil</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and
                    has excessive daytime sleepiness associated with narcolepsy occurring almost
                    daily for three months or more</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has a multiple sleep latency
                        test with a mean sleep latency of less than or equal to 10 minutes and 2 or
                        more sleep onset rapid eye movement periods</ci>
                      <ci type="logical" class="Indication">The patient has at least one of:
                        cataplexy, sleep paralysis or hypnagogic hallucinations</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">An effective dose of a subsidised
                        formulation of methylphenidate or dexamfetamine has been trialled and
                        discontinued because of intolerable side effects</ci>
                      <ci type="logical" class="Indication">Methylphenidate and dexamfetamine are
                        contraindicated</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Renewal" Form="SA1126 SA1932 SA1999">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient
                is benefiting from treatment</ci>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F223101393525" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B22310139352525" PSS="2024-06-30">
                <Name>Modavigil</Name>
                <Pack ID="P2560615" Specified="true" nzmt:ctpp_id="50018651000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>29.13</Subsidy>
                  <Price>29.13</Price>
                  <Alternate>29.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2232">
        <Name>Treatments for Dementia</Name>
        <ATC3 ID="A223201">
          <Name>Treatments for Dementia</Name>
          <Chemical ID="C2232013923" Statim="Must">
            <Name>Donepezil hydrochloride</Name>
            <Formulation ID="F223201392325" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B22320139232525" ToBeDelisted="2024-06-01">
                <Name>Donepezil-Rex</Name>
                <Pack ID="P2349159" Specified="true" nzmt:ctpp_id="50120691000117105">
                  <Quantity>90</Quantity>
                  <Subsidy>4.34</Subsidy>
                  <Price>4.34</Price>
                  <Alternate>4.34</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22320139232526" ToBePSS="2024-06-01">
                <Name>Ipca-Donepezil</Name>
                <Pack ID="P2666871" Specified="true" nzmt:ctpp_id="50206681000117104">
                  <Quantity>84</Quantity>
                  <Subsidy>3.70</Subsidy>
                  <Price>3.70</Price>
                  <Alternate>3.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223201392326" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B22320139232625" ToBeDelisted="2024-06-01">
                <Name>Donepezil-Rex</Name>
                <Pack ID="P2349140" Specified="true" nzmt:ctpp_id="50120681000117107">
                  <Quantity>90</Quantity>
                  <Subsidy>6.64</Subsidy>
                  <Price>6.64</Price>
                  <Alternate>6.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22320139232626" ToBePSS="2024-06-01">
                <Name>Ipca-Donepezil</Name>
                <Pack ID="P2666898" Specified="true" nzmt:ctpp_id="50206781000117108">
                  <Quantity>84</Quantity>
                  <Subsidy>5.50</Subsidy>
                  <Price>5.50</Price>
                  <Alternate>5.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2232014037">
            <Name>Rivastigmine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1488"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1488">
              <Title>
                <range>Rivastigmine patches</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has been diagnosed with
                    dementia</ci>
                    <ci type="logical" class="Indication">The patient has experienced intolerable nausea
                    and/or vomiting from donepezil tablets</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1488">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate</ci>
                    <ci type="logical" class="Indication">The patient has demonstrated a significant and
                    sustained benefit from treatment</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F223201403725" Rank="9" Units="patch" Weight="4">
              <Name>Patch 4.6 mg per 24 hour</Name>
              <Brand ID="B22320140372525">
                <Name>Exelon Patch 5</Name>
                <Pack ID="P2273616" Specified="true" nzmt:ctpp_id="50042961000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>90.00</Subsidy>
                  <Price>90.00</Price>
                  <Alternate>90.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22320140372527" PSS="2024-06-30">
                <Name>Rivastigmine Patch BNM 5</Name>
                <Pack ID="P2611570" Specified="true" nzmt:ctpp_id="50258711000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>38.00</Subsidy>
                  <Price>38.00</Price>
                  <Alternate>38.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223201403726" Rank="9" Units="patch" Weight="9">
              <Name>Patch 9.5 mg per 24 hour</Name>
              <Brand ID="B22320140372625">
                <Name>Exelon Patch 10</Name>
                <Pack ID="P2273608" Specified="true" nzmt:ctpp_id="50042951000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>90.00</Subsidy>
                  <Price>90.00</Price>
                  <Alternate>90.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22320140372627" PSS="2024-06-30">
                <Name>Rivastigmine Patch BNM 10</Name>
                <Pack ID="P2611589" Specified="true" nzmt:ctpp_id="50258721000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>38.00</Subsidy>
                  <Price>38.00</Price>
                  <Alternate>38.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2234">
        <Name>Treatments for Substance Dependence</Name>
        <ATC3 ID="A223401">
          <Name>Treatments for Substance Dependence</Name>
          <Chemical ID="C2234011432">
            <Name>Disulfiram</Name>
            <Formulation ID="F223401143201" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B22340114320101" PSS="2024-06-30">
                <Name>Antabuse</Name>
                <Pack ID="P524492" Specified="true" nzmt:ctpp_id="50094221000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>236.40</Subsidy>
                  <Price>236.40</Price>
                  <Alternate>236.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2234013722">
            <Name>Nicotine</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Nicotine will not be funded in amounts less than 4 weeks of treatment.</p>
            </div>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.</p>
            </div>
            <Rule Type="ProvAllow" Attribute="Pharmacist" NonPrinting="true"/>
            <Formulation ID="F223401372225" Rank="9" Units="patch" Weight="21">
              <Name>Patch 21 mg</Name>
              <Rule Type="FormMax" Value="28" Attribute="PSO"/>
              <Brand ID="B22340137222526">
                <Name>Habitrol</Name>
                <Pack ID="P2381400" Specified="true" nzmt:ctpp_id="50122491000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>24.12</Subsidy>
                  <Price>24.12</Price>
                  <Alternate>24.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372226" Rank="9" Units="patch" Weight="14">
              <Name>Patch 14 mg</Name>
              <Rule Type="FormMax" Value="28" Attribute="PSO"/>
              <Brand ID="B22340137222626">
                <Name>Habitrol</Name>
                <Pack ID="P2381397" Specified="true" nzmt:ctpp_id="50122481000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>21.05</Subsidy>
                  <Price>21.05</Price>
                  <Alternate>21.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372227" Rank="9" Units="patch" Weight="7">
              <Name>Patch 7 mg</Name>
              <Rule Type="FormMax" Value="28" Attribute="PSO"/>
              <Brand ID="B22340137222726">
                <Name>Habitrol</Name>
                <Pack ID="P2381389" Specified="true" nzmt:ctpp_id="50122471000117107">
                  <Quantity>28</Quantity>
                  <Subsidy>19.14</Subsidy>
                  <Price>19.14</Price>
                  <Alternate>19.14</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372228" Rank="10" Units="piece" Weight="2">
              <Name>Gum 2 mg (Fruit)</Name>
              <Rule Type="FormMax" Value="384" Attribute="PSO"/>
              <Brand ID="B22340137222826">
                <Name>Habitrol</Name>
                <Pack ID="P2640589" Specified="true" nzmt:ctpp_id="50315211000117107">
                  <Quantity>204</Quantity>
                  <Subsidy>21.42</Subsidy>
                  <Price>21.42</Price>
                  <Alternate>21.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372229" Rank="10" Units="piece" Weight="4">
              <Name>Gum 4 mg (Fruit)</Name>
              <Rule Type="FormMax" Value="384" Attribute="PSO"/>
              <Brand ID="B22340137222926">
                <Name>Habitrol</Name>
                <Pack ID="P2640597" Specified="true" nzmt:ctpp_id="50309181000117108">
                  <Quantity>204</Quantity>
                  <Subsidy>24.17</Subsidy>
                  <Price>24.17</Price>
                  <Alternate>24.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372234" Rank="10" Units="piece" Weight="2">
              <Name>Gum 2 mg (Mint)</Name>
              <Rule Type="FormMax" Value="384" Attribute="PSO"/>
              <Brand ID="B22340137223427">
                <Name>Habitrol</Name>
                <Pack ID="P2640562" Specified="true" nzmt:ctpp_id="50189591000117105">
                  <Quantity>204</Quantity>
                  <Subsidy>21.42</Subsidy>
                  <Price>21.42</Price>
                  <Alternate>21.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372235" Rank="10" Units="piece" Weight="4">
              <Name>Gum 4 mg (Mint)</Name>
              <Rule Type="FormMax" Value="384" Attribute="PSO"/>
              <Brand ID="B22340137223527">
                <Name>Habitrol</Name>
                <Pack ID="P2640570" Specified="true" nzmt:ctpp_id="50189491000117106">
                  <Quantity>204</Quantity>
                  <Subsidy>24.17</Subsidy>
                  <Price>24.17</Price>
                  <Alternate>24.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372237" Rank="10" Units="loz" Weight="1">
              <Name>Lozenge 1 mg</Name>
              <Rule Type="FormMax" Value="216" Attribute="PSO"/>
              <Brand ID="B22340137223725">
                <Name>Habitrol</Name>
                <Pack ID="P2381370" Specified="true" nzmt:ctpp_id="50122451000117104">
                  <Quantity>216</Quantity>
                  <Subsidy>19.76</Subsidy>
                  <Price>19.76</Price>
                  <Alternate>19.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372238" Rank="10" Units="loz" Weight="2">
              <Name>Lozenge 2 mg</Name>
              <Rule Type="FormMax" Value="216" Attribute="PSO"/>
              <Brand ID="B22340137223825">
                <Name>Habitrol</Name>
                <Pack ID="P2381362" Specified="true" nzmt:ctpp_id="50122461000117102">
                  <Quantity>216</Quantity>
                  <Subsidy>21.65</Subsidy>
                  <Price>21.65</Price>
                  <Alternate>21.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372239" Rank="9" Units="patch" Weight="21">
              <Name>Patch 21 mg for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137223925">
                <Name>Habitrol</Name>
                <Pack ID="P2179563" Specified="true" nzmt:ctpp_id="50029491000117105">
                  <Quantity>7</Quantity>
                  <Subsidy>10.93</Subsidy>
                  <Price>10.93</Price>
                  <Alternate>10.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372240" Rank="9" Units="patch" Weight="14">
              <Name>Patch 14 mg for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137224025">
                <Name>Habitrol</Name>
                <Pack ID="P2179555" Specified="true" nzmt:ctpp_id="50029481000117107">
                  <Quantity>7</Quantity>
                  <Subsidy>6.48</Subsidy>
                  <Price>6.48</Price>
                  <Alternate>6.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372241" Rank="9" Units="patch" Weight="7">
              <Name>Patch 7 mg for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137224125">
                <Name>Habitrol</Name>
                <Pack ID="P2179547" Specified="true" nzmt:ctpp_id="50029471000117109">
                  <Quantity>7</Quantity>
                  <Subsidy>4.13</Subsidy>
                  <Price>4.13</Price>
                  <Alternate>4.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372242" Rank="10" Units="piece" Weight="2">
              <Name>Gum 2 mg (Fruit) for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137224225">
                <Name>Habitrol</Name>
                <Pack ID="P2179504" Specified="true" nzmt:ctpp_id="50029431000117106">
                  <Quantity>96</Quantity>
                  <Subsidy>9.04</Subsidy>
                  <Price>9.04</Price>
                  <Alternate>9.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372243" Rank="10" Units="piece" Weight="4">
              <Name>Gum 4 mg (Fruit) for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137224325">
                <Name>Habitrol</Name>
                <Pack ID="P2179512" Specified="true" nzmt:ctpp_id="50029441000117103">
                  <Quantity>96</Quantity>
                  <Subsidy>10.47</Subsidy>
                  <Price>10.47</Price>
                  <Alternate>10.47</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372248" Rank="10" Units="piece" Weight="2">
              <Name>Gum 2 mg (Mint) for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137224825">
                <Name>Habitrol</Name>
                <Pack ID="P2179520" Specified="true" nzmt:ctpp_id="50029451000117101">
                  <Quantity>96</Quantity>
                  <Subsidy>9.04</Subsidy>
                  <Price>9.04</Price>
                  <Alternate>9.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372249" Rank="10" Units="piece" Weight="4">
              <Name>Gum 4 mg (Mint) for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137224925">
                <Name>Habitrol</Name>
                <Pack ID="P2179539" Specified="true" nzmt:ctpp_id="50029461000117104">
                  <Quantity>96</Quantity>
                  <Subsidy>10.47</Subsidy>
                  <Price>10.47</Price>
                  <Alternate>10.47</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372251" Rank="10" Units="loz" Weight="1">
              <Name>Lozenge 1 mg for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137225125">
                <Name>Habitrol</Name>
                <Pack ID="P2294370" Specified="true" nzmt:ctpp_id="50045181000117101">
                  <Quantity>36</Quantity>
                  <Subsidy>3.35</Subsidy>
                  <Price>3.35</Price>
                  <Alternate>3.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401372252" Rank="10" Units="loz" Weight="2">
              <Name>Lozenge 2 mg for direct distribution only</Name>
              <Rule Type="Dispensary" Attribute="Xpharm"/>
              <Brand ID="B22340137225225">
                <Name>Habitrol</Name>
                <Pack ID="P2294389" Specified="true" nzmt:ctpp_id="50045191000117103">
                  <Quantity>36</Quantity>
                  <Subsidy>3.40</Subsidy>
                  <Price>3.40</Price>
                  <Alternate>3.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2234013793">
            <Name>Naltrexone hydrochloride</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1408"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1408">
              <Title>
                <range>Naltrexone</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci>
                    <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to Te Whatu Ora or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is still unstable and requires further treatment</ci>
                      <ci type="logical" class="Indication">Patient achieved significant improvement but requires further treatment</ci>
                      <ci type="logical" class="Indication">Patient is well controlled but requires maintenance therapy</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F223401379325" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B22340137932526" PSS="2026-06-30">
                <Name>Naltraccord</Name>
                <Pack ID="P2380374" Specified="true" nzmt:ctpp_id="50122441000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>83.33</Subsidy>
                  <Price>83.33</Price>
                  <Alternate>83.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B22340137932527" S29="true">
                <Name>Naltrexone AOP</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2664941" Specified="true" nzmt:ctpp_id="50322261000117107">
                  <Quantity>28</Quantity>
                  <Subsidy>77.77</Subsidy>
                  <Price>77.77</Price>
                  <Alternate>77.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2234013892">
            <Name>Bupropion hydrochloride</Name>
            <Formulation ID="F223401389225" Rank="1" Units="tab">
              <Name>Tab modified-release 150 mg</Name>
              <Brand ID="B22340138922525" ToBePSS="2024-05-01">
                <Name>Zyban</Name>
                <Pack ID="P2439743" Specified="true" nzmt:ctpp_id="50080021000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>15.00</Subsidy>
                  <Price>15.00</Price>
                  <Alternate>15.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2234013920">
            <Name>Varenicline tartrate</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack</p>
            </div>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Varenicline will not be funded in amounts less than 4 weeks of treatment.</p>
            </div>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>The 6-month time period in which a patient can receive a funded 12-week course of varenicline tartrate starts from the date the Special Authority is approved.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1845"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1845">
              <Title>
                <range>Varenicline tartrate</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking</ci>
                    <ci type="logical" class="Use">The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse
                    monitoring</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included
                        the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy</ci>
                      <ci type="logical" class="Trial">The patient has tried but failed to quit smoking using bupropion or nortriptyline</ci>
                    </apply>
                    <ci type="logical" class="Use">The patient has not had a Special Authority for varenicline approved in the last 6 months</ci>
                    <ci type="logical" class="Use">Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this</ci>
                    <ci type="logical" class="Indication">The patient is not pregnant</ci>
                    <ci type="logical" class="Use">The patient will not be prescribed more than 12 weeks' funded varenicline (see note)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">5</Term>
              </Case>
              <Case When="Renewal" Form="SA1135 SA1054 SA1161 SA1575 SA1771 SA1845">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking</ci>
                    <ci type="logical" class="Use">The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse
                    monitoring</ci>
                    <ci type="logical" class="Use">It has been 6 months since the patientâ€™s previous Special Authority was approved</ci>
                    <ci type="logical" class="Use">Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this</ci>
                    <ci type="logical" class="Indication">The patient is not pregnant</ci>
                    <ci type="logical" class="Use">The patient will not be prescribed more than 12 weeks' funded varenicline (see note)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">5</Term>
                <History>
                  <Term Measure="month">6</Term>
                  <Maximum>1</Maximum>
                </History>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note" style="start">
                <p>a maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval.</p>
                <p>This includes the 4-week 'starter' pack.</p>
              </div>
            </Request>
            <Formulation ID="F223401392026" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B22340139202626" PSS="2024-06-30">
                <Name>Varenicline Pfizer</Name>
                <Pack ID="P2553163" Specified="true" nzmt:ctpp_id="50255041000117100">
                  <Quantity>56</Quantity>
                  <Subsidy>17.62</Subsidy>
                  <Price>17.62</Price>
                  <Alternate>17.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401392027" Rank="1" Units="tab">
              <Name>Tab 0.5 mg x 11 and 1 mg x 42</Name>
              <Brand ID="B22340139202725" PSS="2024-06-30">
                <Name>Varenicline Pfizer</Name>
                <Pack ID="P2553155" Specified="true" OP="true" nzmt:ctpp_id="50255031000117108">
                  <Quantity>53</Quantity>
                  <Subsidy>16.67</Subsidy>
                  <Price>16.67</Price>
                  <Alternate>16.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2234013950">
            <Name>Buprenorphine with naloxone</Name>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SafetyListMedicine"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1203"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1203">
              <Title>
                <range>Buprenorphine with naloxone</range>
              </Title>
              <Case When="Initial application" Category="Detoxification">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is opioid dependent</ci>
                    <ci type="logical" class="Indication">Patient is currently engaged with an opioid treatment service approved by the Ministry of Health</ci>
                    <ci type="logical" class="Treatment">Applicant works in an opioid treatment service approved by the Ministry of Health.</ci>
                  </apply>
                </math>
                <Applicant>medical practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Initial application" Category="Maintenance treatment">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is opioid dependent</ci>
                    <ci type="logical" class="Indication">Patient will not be receiving methadone</ci>
                    <ci type="logical" class="Indication">Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health</ci>
                    <ci type="logical" class="Treatment">Applicant works in an opioid treatment service approved by the Ministry of Health</ci>
                  </apply>
                </math>
                <Applicant>medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Detoxification" Form="SA1203">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is opioid dependent</ci>
                    <ci type="logical" class="Indication">Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned</ci>
                    <ci type="logical" class="Treatment">Patient is currently engaged with an opioid treatment service approved by the Ministry of Health</ci>
                    <ci type="logical" class="Indication">Applicant works in an opioid treatment service approved by the Ministry of Health</ci>
                  </apply>
                </math>
                <Applicant>medical practitioner</Applicant>
                <Term Measure="month">1</Term>
              </Case>
              <Case When="Renewal" Category="Maintenance treatment" Form="SA1203">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Treatment">Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone)</ci>
                    <ci type="logical" class="Treatment">Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health</ci>
                    <ci type="logical" class="Treatment">Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient</ci>
                  </apply>
                </math>
                <Applicant>medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Maintenance treatment where the patient has previously had an initial application for detoxification" Form="SA1203">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Treatment">Patient received but failed detoxification with buprenorphine with naloxone</ci>
                    <ci type="logical" class="Treatment">Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone)</ci>
                    <ci type="logical" class="Treatment">Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health</ci>
                    <ci type="logical" class="Treatment">Applicant works in an opioid treatment service approved by the Ministry of Health</ci>
                  </apply>
                </math>
                <Applicant>medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F223401395025" Rank="1" Units="tab">
              <Name>Tab sublingual 2 mg with naloxone 0.5 mg</Name>
              <Brand ID="B22340139502526" PSS="2025-06-30">
                <Name>Buprenorphine Naloxone BNM</Name>
                <Pack ID="P2574004" Specified="true" nzmt:ctpp_id="50244061000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>11.76</Subsidy>
                  <Price>11.76</Price>
                  <Alternate>11.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F223401395026" Rank="1" Units="tab">
              <Name>Tab sublingual 8 mg with naloxone 2 mg</Name>
              <Brand ID="B22340139502626" PSS="2025-06-30">
                <Name>Buprenorphine Naloxone BNM</Name>
                <Pack ID="P2574012" Specified="true" nzmt:ctpp_id="50244071000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>34.00</Subsidy>
                  <Price>34.00</Price>
                  <Alternate>34.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A25">
      <Name>Oncology Agents and Immunosuppressants</Name>
      <ATC2 ID="A2501">
        <Name>Chemotherapeutic Agents</Name>
        <ATC3 ID="A250101">
          <Name>Alkylating Agents</Name>
          <Chemical ID="C2501011173">
            <Name>Busulfan</Name>
            <Rule Type="PCT"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250101117301" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B25010111730101">
                <Name>Myleran</Name>
                <Pack ID="P201472" Specified="true" nzmt:ctpp_id="50002411000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>89.25</Subsidy>
                  <Price>89.25</Price>
                  <Alternate>89.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501011255">
            <Name>Chlorambucil</Name>
            <Rule Type="PCT"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250101125501" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B25010112550125">
                <Name>Leukeran FC</Name>
                <Pack ID="P2057409" Specified="true" nzmt:ctpp_id="50010301000117106">
                  <Quantity>25</Quantity>
                  <Subsidy>29.06</Subsidy>
                  <Price>29.06</Price>
                  <Alternate>29.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501011369">
            <Name>Cyclophosphamide</Name>
            <Formulation ID="F250101136901" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010113690127" PSS="2024-06-30">
                <Name>Cyclonex</Name>
                <Pack ID="P2611597" Specified="true" nzmt:ctpp_id="50286921000117107">
                  <Quantity>50</Quantity>
                  <Subsidy>145.00</Subsidy>
                  <Price>145.00</Price>
                  <Alternate>145.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101136902" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010113690201">
                <Name>Cytoxan</Name>
                <Pack ID="P785318" Specified="true" nzmt:ctpp_id="50114081000117102">
                  <Quantity>6</Quantity>
                  <Subsidy>127.80</Subsidy>
                  <Price>127.80</Price>
                  <Alternate>127.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010113690225">
                <Name>Endoxan</Name>
                <Pack ID="P2034212" Specified="true" nzmt:ctpp_id="50006661000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>35.65</Subsidy>
                  <Price>35.65</Price>
                  <Alternate>35.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101136925" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2 g vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010113692525">
                <Name>Endoxan</Name>
                <Pack ID="P2034220" Specified="true" nzmt:ctpp_id="50006671000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>71.25</Subsidy>
                  <Price>71.25</Price>
                  <Alternate>71.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101136926" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010113692625">
                <Name>Baxter</Name>
                <Pack ID="P2204266" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.04</Subsidy>
                  <Price>0.04</Price>
                  <Alternate>0.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501011773">
            <Name>Melphalan</Name>
            <Formulation ID="F250101177301" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010117730101">
                <Name>Alkeran</Name>
                <Pack ID="P200271" Specified="true" nzmt:ctpp_id="50000291000117108">
                  <Quantity>25</Quantity>
                  <Subsidy>40.70</Subsidy>
                  <Price>40.70</Price>
                  <Alternate>40.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101177325" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010117732525">
                <Name>Alkeran</Name>
                <Pack ID="P783781" Specified="true" nzmt:ctpp_id="50113801000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>67.80</Subsidy>
                  <Price>67.80</Price>
                  <Alternate>67.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010117732528" S29="true">
                <Name>Alkeran S29</Name>
                <Pack ID="P2617404" Specified="true" nzmt:ctpp_id="50275181000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>67.80</Subsidy>
                  <Price>67.80</Price>
                  <Alternate>67.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010117732529">
                <Name>Melpha</Name>
                <Pack ID="P2647699" Specified="true" nzmt:ctpp_id="50280261000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>48.25</Subsidy>
                  <Price>48.25</Price>
                  <Alternate>48.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501012257">
            <Name>Thiotepa</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250101225701" Rank="4" Units="inj" Weight="15">
              <Name>Inj 15 mg vial</Name>
              <Brand ID="B25010122570101" S29="true">
                <Name>THIO-TEPA</Name>
                <Pack ID="P256811" Specified="true" CBS="true" nzmt:ctpp_id="50055641000117102">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B25010122570125" S29="true">
                <Name>Bedford</Name>
                <Pack ID="P2300362" Specified="true" CBS="true" nzmt:ctpp_id="50045701000117107">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
              <Brand ID="B25010122570126">
                <Name>Tepadina</Name>
                <Pack ID="P2445700" CBS="true">
                  <Quantity>1</Quantity>
                </Pack>
                <Pack ID="P2487985" Specified="true" nzmt:ctpp_id="50180611000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>398.00</Subsidy>
                  <Price>398.00</Price>
                  <Alternate>398.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010122570127" S29="true">
                <Name>Max Health</Name>
                <Pack ID="P2603136" Specified="true" CBS="true" nzmt:ctpp_id="50291211000117101">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101225725" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25010122572525">
                <Name>Tepadina</Name>
                <Pack ID="P2487977" Specified="true" nzmt:ctpp_id="50125231000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>1800.00</Subsidy>
                  <Price>1800.00</Price>
                  <Alternate>1800.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010122572526" S29="true">
                <Name>Max Health</Name>
                <Pack ID="P2603144" Specified="true" CBS="true" nzmt:ctpp_id="50291201000117104">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501013819">
            <Name>Ifosfamide</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250101381925" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g</Name>
              <Brand ID="B25010138192525">
                <Name>Holoxan</Name>
                <Pack ID="P712736" Specified="true" nzmt:ctpp_id="50104251000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>96.00</Subsidy>
                  <Price>96.00</Price>
                  <Alternate>96.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101381926" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 2 g</Name>
              <Brand ID="B25010138192625">
                <Name>Holoxan</Name>
                <Pack ID="P712760" Specified="true" nzmt:ctpp_id="50104281000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>180.00</Subsidy>
                  <Price>180.00</Price>
                  <Alternate>180.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101381927" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010138192725">
                <Name>Baxter</Name>
                <Pack ID="P2204223" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.10</Subsidy>
                  <Price>0.10</Price>
                  <Alternate>0.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501013825">
            <Name>Carboplatin</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250101382526" Rank="4" Units="inj" Weight="450">
              <Name>Inj 10 mg per ml, 45 ml vial</Name>
              <Brand ID="B25010138252625">
                <Name>DBL Carboplatin</Name>
                <Pack ID="P2482517" Specified="true" nzmt:ctpp_id="50103501000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>32.59</Subsidy>
                  <Price>32.59</Price>
                  <Alternate>32.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010138252626">
                <Name>Carboplatin Ebewe</Name>
                <Pack ID="P2236524" Specified="true" nzmt:ctpp_id="50037621000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>45.20</Subsidy>
                  <Price>45.20</Price>
                  <Alternate>45.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010138252627">
                <Name>Carbaccord</Name>
                <Pack ID="P2424835" Specified="true" nzmt:ctpp_id="50146021000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>48.50</Subsidy>
                  <Price>48.50</Price>
                  <Alternate>48.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101382527" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010138252725">
                <Name>Baxter</Name>
                <Pack ID="P2204282" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.10</Subsidy>
                  <Price>0.10</Price>
                  <Alternate>0.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501013826">
            <Name>Cisplatin</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250101382625" Rank="4" Units="inj" Weight="50">
              <Name>Inj 1 mg per ml, 50 ml vial</Name>
              <Brand ID="B25010138262526">
                <Name>Cisplatin Ebewe</Name>
                <Pack ID="P2236532" Specified="true" nzmt:ctpp_id="50037631000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>15.00</Subsidy>
                  <Price>15.00</Price>
                  <Alternate>15.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101382626" Rank="4" Units="inj" Weight="100">
              <Name>Inj 1 mg per ml, 100 ml vial</Name>
              <Brand ID="B25010138262625">
                <Name>DBL Cisplatin</Name>
                <Pack ID="P528048" Specified="true" nzmt:ctpp_id="50094411000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>29.66</Subsidy>
                  <Price>29.66</Price>
                  <Alternate>29.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010138262626">
                <Name>Cisplatin Ebewe</Name>
                <Pack ID="P2236516" Specified="true" nzmt:ctpp_id="50037611000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>21.00</Subsidy>
                  <Price>21.00</Price>
                  <Alternate>21.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101382627" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010138262725">
                <Name>Baxter</Name>
                <Pack ID="P2204274" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.31</Subsidy>
                  <Price>0.31</Price>
                  <Alternate>0.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501013832">
            <Name>Oxaliplatin</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250101383226" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25010138322626">
                <Name>Oxaliplatin Ebewe</Name>
                <Pack ID="P2339013" Specified="true" nzmt:ctpp_id="50049791000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>110.00</Subsidy>
                  <Price>110.00</Price>
                  <Alternate>110.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010138322627">
                <Name>Oxaliplatin Actavis 100</Name>
                <Pack ID="P2400553" Specified="true" nzmt:ctpp_id="50129451000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>25.01</Subsidy>
                  <Price>25.01</Price>
                  <Alternate>25.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101383227" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010138322725">
                <Name>Baxter</Name>
                <Pack ID="P2207621" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.35</Subsidy>
                  <Price>0.35</Price>
                  <Alternate>0.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101383229" Rank="4" Units="inj" Weight="100">
              <Name>Inj 5 mg per ml, 20 ml vial</Name>
              <Brand ID="B25010138322926">
                <Name>Oxaliplatin Accord</Name>
                <Pack ID="P2571242" Specified="true" nzmt:ctpp_id="50262571000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>46.32</Subsidy>
                  <Price>46.32</Price>
                  <Alternate>46.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010138322927">
                <Name>Alchemy Oxaliplatin</Name>
                <Pack ID="P2654830" Specified="true" nzmt:ctpp_id="50291781000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>33.35</Subsidy>
                  <Price>33.35</Price>
                  <Alternate>33.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501013837">
            <Name>Carmustine</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250101383725" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25010138372525" PSS="2024-06-30">
                <Name>BiCNU</Name>
                <Pack ID="P2571234" Specified="true" nzmt:ctpp_id="50073841000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>710.00</Subsidy>
                  <Price>710.00</Price>
                  <Alternate>710.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101383726" Rank="10" Units="mg" Weight="100">
              <Name>Inj 100 mg for ECP</Name>
              <Brand ID="B25010138372625">
                <Name>Baxter</Name>
                <Pack ID="P2207648" Specified="true" OP="true">
                  <Quantity>100</Quantity>
                  <Subsidy>710.00</Subsidy>
                  <Price>710.00</Price>
                  <Alternate>710.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501013838">
            <Name>Lomustine</Name>
            <Rule Type="PCT"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250101383825" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B25010138382525">
                <Name>CeeNU</Name>
                <Pack ID="P332771" Specified="true" nzmt:ctpp_id="50073821000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>132.59</Subsidy>
                  <Price>132.59</Price>
                  <Alternate>132.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101383826" Rank="2" Units="cap" Weight="40">
              <Name>Cap 40 mg</Name>
              <Brand ID="B25010138382625">
                <Name>CeeNU</Name>
                <Pack ID="P332798" Specified="true" nzmt:ctpp_id="50073831000117107">
                  <Quantity>20</Quantity>
                  <Subsidy>399.15</Subsidy>
                  <Price>399.15</Price>
                  <Alternate>399.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501014084">
            <Name>Bendamustine hydrochloride</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2153"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2153">
              <Title>
                <range>Bendamustine hydrochloride</range>
              </Title>
              <Case When="Initial application" Category="treatment naive CLL">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment</ci>
                    <ci type="logical" class="Indication">The patient is chemotherapy treatment naive</ci>
                    <ci type="logical" class="Indication">The patient is unable to tolerate toxicity of full-dose FCR</ci>
                    <ci type="logical" class="Indication">Patient has ECOG performance status 0-2</ci>
                    <ci type="logical" class="Indication">Patient has a Cumulative Illness Rating Scale (CIRS) score of &lt;6</ci>
                    <ci type="logical" class="Indication">Bendamustine is to be administered at a maximum dose of 100 mg/mÂ² on days 1 and 2 every 4 weeks for a maximum of 6 cycles</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and
                supportive treatments.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Indolent, Low-grade lymphomas">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has indolent low grade NHL requiring treatment</ci>
                    <ci type="logical" class="Indication">Patient has a WHO performance status of 0-2</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient is treatment naive</ci>
                        <ci type="logical" class="Indication">Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+)</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen</ci>
                        <ci type="logical" class="Indication">Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient has not received prior bendamustine therapy</ci>
                        <ci type="logical" class="Indication">Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)</ci>
                        <ci type="logical" class="Indication">Patient has had a rituximab treatment-free interval of 12 months or more</ci>
                      </apply>
                      <ci type="logical" class="Indication">Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="Indolent, Low-grade lymphomas" Form="SA1667 SA2046 SA2153">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine</ci>
                      <ci type="logical" class="Indication">Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patients have not received a bendamustine regimen within the last 12 months</ci>
                      <apply>
                        <or/>
                        <apply>
                          <and/>
                          <ci type="logical" class="Indication">Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)</ci>
                          <ci type="logical" class="Indication">Patient has had a rituximab treatment-free interval of 12 months or more</ci>
                        </apply>
                        <ci type="logical" class="Indication">Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">9</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenstrom's macroglobulinaemia.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Hodgkin's lymphoma*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has Hodgkin's lymphoma requiring treatment</ci>
                    <ci type="logical" class="Indication">Patient has a ECOG performance status of 0-2</ci>
                    <ci type="logical" class="Indication">Patient has received one prior line of chemotherapy</ci>
                    <ci type="logical" class="Indication">Patient's disease relapsed or was refractory following prior chemotherapy</ci>
                    <ci type="logical" class="Indication">Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250101408425" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg vial</Name>
              <Brand ID="B25010140842525">
                <Name>Ribomustin</Name>
                <Pack ID="P2483807" Specified="true" nzmt:ctpp_id="50176951000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>77.00</Subsidy>
                  <Price>77.00</Price>
                  <Alternate>77.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101408426" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25010140842625">
                <Name>Ribomustin</Name>
                <Pack ID="P2483793" Specified="true" nzmt:ctpp_id="50126201000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>308.00</Subsidy>
                  <Price>308.00</Price>
                  <Alternate>308.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250101408427" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010140842725">
                <Name>Baxter</Name>
                <Pack ID="P2524058" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>3.23</Subsidy>
                  <Price>3.23</Price>
                  <Alternate>3.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250104">
          <Name>Antimetabolites</Name>
          <Chemical ID="C2501041198">
            <Name>Calcium folinate</Name>
            <Formulation ID="F250104119801" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010411980102">
                <Name>DBL Leucovorin Calcium</Name>
                <Pack ID="P701300" Specified="true" nzmt:ctpp_id="50125481000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>135.33</Subsidy>
                  <Price>135.33</Price>
                  <Alternate>135.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119802" Rank="4" Units="inj" Weight="3">
              <Name>Inj 3 mg per ml, 1 ml</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010411980201">
                <Name>Hospira</Name>
                <Pack ID="P333212" Specified="true" nzmt:ctpp_id="50074021000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>17.10</Subsidy>
                  <Price>17.10</Price>
                  <Alternate>17.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119804" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010411980426" S29="true">
                <Name>Leucovorin Pharmacia</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P296902" Specified="true" nzmt:ctpp_id="50066261000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>72.80</Subsidy>
                  <Price>72.80</Price>
                  <Alternate>72.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119825" Rank="4" Units="inj" Weight="300">
              <Name>Inj 300 mg</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010411982525" S29="true">
                <Name>Leucovorin DBL</Name>
                <Pack ID="P2034298" Specified="true" nzmt:ctpp_id="50006741000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>25.14</Subsidy>
                  <Price>25.14</Price>
                  <Alternate>25.14</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010411982526">
                <Name>Calcium Folinate Ebewe</Name>
                <Pack ID="P2216086" Specified="true" nzmt:ctpp_id="50034381000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>22.51</Subsidy>
                  <Price>22.51</Price>
                  <Alternate>22.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119826" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010411982625">
                <Name>Baxter</Name>
                <Pack ID="P2204290" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.06</Subsidy>
                  <Price>0.06</Price>
                  <Alternate>0.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119827" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010411982725">
                <Name>Calcium Folinate Ebewe</Name>
                <Pack ID="P2216078" Specified="true" nzmt:ctpp_id="50034371000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>7.33</Subsidy>
                  <Price>7.33</Price>
                  <Alternate>7.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010411982726" S29="true">
                <Name>Leucovorin Pharmacia</Name>
                <Pack ID="P297119" Specified="true" nzmt:ctpp_id="50296341000117102">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>94.90</Subsidy>
                  <Price>94.90</Price>
                  <Alternate>94.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119828" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 1 g</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010411982825">
                <Name>Calcium Folinate Ebewe</Name>
                <Pack ID="P2224887" Specified="true" nzmt:ctpp_id="50035871000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>67.51</Subsidy>
                  <Price>67.51</Price>
                  <Alternate>67.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119829" Rank="4" Units="inj" Weight="50">
              <Name>Inj 10 mg per ml, 5 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010411982925">
                <Name>Calcium Folinate Sandoz</Name>
                <Pack ID="P2539195" Specified="true" nzmt:ctpp_id="50235721000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7.28</Subsidy>
                  <Price>7.28</Price>
                  <Alternate>7.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010411982926" S29="true">
                <Name>Calcium Folinate Sandoz S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2611368" Specified="true" nzmt:ctpp_id="50287691000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>7.28</Subsidy>
                  <Price>7.28</Price>
                  <Alternate>7.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010411982927" S29="true">
                <Name>Eurofolic</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2655993" Specified="true" nzmt:ctpp_id="50315381000117105">
                  <Quantity>5</Quantity>
                  <Subsidy>36.48</Subsidy>
                  <Price>36.48</Price>
                  <Alternate>36.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119830" Rank="4" Units="inj" Weight="100">
              <Name>Inj 10 mg per ml, 10 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010411983025">
                <Name>Calcium Folinate Sandoz</Name>
                <Pack ID="P2539209" Specified="true" nzmt:ctpp_id="50235731000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>9.49</Subsidy>
                  <Price>9.49</Price>
                  <Alternate>9.49</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010411983026" S29="true">
                <Name>Eurofolic</Name>
                <Pack ID="P2655985" Specified="true" nzmt:ctpp_id="50315401000117105">
                  <Quantity>5</Quantity>
                  <Subsidy>47.45</Subsidy>
                  <Price>47.45</Price>
                  <Alternate>47.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119831" Rank="4" Units="inj" Weight="350">
              <Name>Inj 10 mg per ml, 35 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010411983125">
                <Name>Calcium Folinate Sandoz</Name>
                <Pack ID="P2539217" Specified="true" nzmt:ctpp_id="50235751000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>25.14</Subsidy>
                  <Price>25.14</Price>
                  <Alternate>25.14</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010411983126" S29="true">
                <Name>Calcium Folinate Sandoz S29</Name>
                <Pack ID="P2611341" Specified="true" nzmt:ctpp_id="50287651000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>25.14</Subsidy>
                  <Price>25.14</Price>
                  <Alternate>25.14</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104119832" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 10 mg per ml, 100 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010411983225">
                <Name>Calcium Folinate Sandoz</Name>
                <Pack ID="P2539225" Specified="true" nzmt:ctpp_id="50235771000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>72.00</Subsidy>
                  <Price>72.00</Price>
                  <Alternate>72.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501041371">
            <Name>Cytarabine</Name>
            <Formulation ID="F250104137101" Rank="4" Units="inj" Weight="100">
              <Name>Inj 20 mg per ml, 5 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010413710103">
                <Name>Pfizer</Name>
                <Pack ID="P786365" Specified="true" nzmt:ctpp_id="50114251000117101">
                  <Quantity>5</Quantity>
                  <Subsidy>472.00</Subsidy>
                  <Price>472.00</Price>
                  <Alternate>472.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104137102" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 100 mg per ml, 20 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010413710225">
                <Name>Pfizer</Name>
                <Pack ID="P2359537" Specified="true" nzmt:ctpp_id="50050901000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>48.80</Subsidy>
                  <Price>48.80</Price>
                  <Alternate>48.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104137126" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010413712625">
                <Name>Baxter</Name>
                <Pack ID="P2359413" Specified="true">
                  <Quantity>10</Quantity>
                  <Subsidy>0.29</Subsidy>
                  <Price>0.29</Price>
                  <Alternate>0.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104137127" Rank="10" Units="mg" Weight="100">
              <Name>Inj 100 mg intrathecal syringe for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010413712725">
                <Name>Baxter</Name>
                <Pack ID="P2204231" Specified="true" OP="true">
                  <Quantity>100</Quantity>
                  <Subsidy>94.40</Subsidy>
                  <Price>94.40</Price>
                  <Alternate>94.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501041529">
            <Name>Fluorouracil</Name>
            <Formulation ID="F250104152926" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 50 mg per ml, 20 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010415292627">
                <Name>Fluorouracil Accord</Name>
                <Pack ID="P2618435" Specified="true" nzmt:ctpp_id="50261271000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>10.51</Subsidy>
                  <Price>10.51</Price>
                  <Alternate>10.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104152927" Rank="4" Units="inj" Weight="2500">
              <Name>Inj 50 mg per ml, 50 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010415292727" Update="New Listing">
                <Name>Fluorouracil Accord</Name>
                <Pack ID="P2674092" Specified="true" nzmt:ctpp_id="50261281000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>14.72</Subsidy>
                  <Price>14.72</Price>
                  <Alternate>14.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104152928" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010415292825">
                <Name>Baxter</Name>
                <Pack ID="P2370123" Specified="true">
                  <Quantity>100</Quantity>
                  <Subsidy>0.62</Subsidy>
                  <Price>0.62</Price>
                  <Alternate>0.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104152930" Rank="4" Units="inj" Weight="5000">
              <Name>Inj 50 mg per ml, 100 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010415293026">
                <Name>Fluorouracil Accord</Name>
                <Pack ID="P2618427" Specified="true" nzmt:ctpp_id="50261301000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>29.44</Subsidy>
                  <Price>29.44</Price>
                  <Alternate>29.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501041781">
            <Name>Mercaptopurine</Name>
            <Formulation ID="F250104178102" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417810201" PSS="2025-06-30">
                <Name>Puri-nethol</Name>
                <Pack ID="P261270" Specified="true" nzmt:ctpp_id="50057571000117101">
                  <Quantity>25</Quantity>
                  <Subsidy>25.90</Subsidy>
                  <Price>25.90</Price>
                  <Alternate>25.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104178125" Rank="3" Units="ml" Weight="20">
              <Name>Oral suspension 20 mg per ml</Name>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1725"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1725">
                <Title>
                  <range>Mercaptopurine</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The patient requires a total dose of less than one full 50 mg tablet per day</ci>
                  </math>
                  <Applicant>paediatric haematologist</Applicant>
                  <Applicant>paediatric oncologist</Applicant>
                  <Term Measure="month">12</Term>
                </Case>
                <Case When="Renewal" Form="SA1725">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">Patient still requires a total dose of less than one full 50 mg tablet per day</ci>
                  </math>
                  <Applicant>paediatric haematologist</Applicant>
                  <Applicant>paediatric oncologist</Applicant>
                  <Term Measure="month">12</Term>
                </Case>
              </Request>
              <Brand ID="B25010417812525">
                <Name>Allmercap</Name>
                <Pack ID="P2545551" Specified="true" OP="true" nzmt:ctpp_id="50221241000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>428.00</Subsidy>
                  <Price>428.00</Price>
                  <Alternate>428.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501041797" Statim="Must">
            <Name>Methotrexate</Name>
            <Formulation ID="F250104179701" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417970125" PSS="2024-06-30">
                <Name>Trexate</Name>
                <Pack ID="P2537060" Specified="true" nzmt:ctpp_id="50252481000117108">
                  <Quantity>90</Quantity>
                  <Subsidy>9.98</Subsidy>
                  <Price>9.98</Price>
                  <Alternate>9.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179702" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417970225" PSS="2024-06-30">
                <Name>Trexate</Name>
                <Pack ID="P2537079" Specified="true" nzmt:ctpp_id="50252491000117106">
                  <Quantity>90</Quantity>
                  <Subsidy>33.71</Subsidy>
                  <Price>33.71</Price>
                  <Alternate>33.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179704" Rank="4" Units="inj" Weight="2.5">
              <Name>Inj 2.5 mg per ml, 2 ml</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417970402">
                <Name>Methotrexate DBL</Name>
                <Pack ID="P2599678" Specified="true">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>56.05</Subsidy>
                  <Price>56.05</Price>
                  <Alternate>56.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010417970403" S29="true">
                <Name>Methotrexate DBL S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2671980" Specified="true" nzmt:ctpp_id="50328461000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>56.05</Subsidy>
                  <Price>56.05</Price>
                  <Alternate>56.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179707" Rank="4" Units="inj" Weight="50">
              <Name>Inj 25 mg per ml, 2 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417970704">
                <Name>Methotrexate DBL Onco-Vial</Name>
                <Pack ID="P2599686" Specified="true" nzmt:ctpp_id="50281681000117107">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>30.00</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>30.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179710" Rank="4" Units="inj" Weight="500">
              <Name>Inj 25 mg per ml, 20 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417971001">
                <Name>DBL Methotrexate Onco-Vial</Name>
                <Pack ID="P333263" Specified="true" nzmt:ctpp_id="50074071000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>45.00</Subsidy>
                  <Price>45.00</Price>
                  <Alternate>45.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179711" Rank="4" Units="inj" Weight="5000">
              <Name>Inj 100 mg per ml, 50 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417971125">
                <Name>Methotrexate Ebewe</Name>
                <Pack ID="P2215683" Specified="true" nzmt:ctpp_id="50034321000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>67.99</Subsidy>
                  <Price>67.99</Price>
                  <Alternate>67.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179712" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 100 mg per ml, 10 ml</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010417971225">
                <Name>Methotrexate Ebewe</Name>
                <Pack ID="P2215675" Specified="true" nzmt:ctpp_id="50034311000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179725" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010417972525">
                <Name>Baxter</Name>
                <Pack ID="P2204134" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.06</Subsidy>
                  <Price>0.06</Price>
                  <Alternate>0.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179726" Rank="10" Units="mg" Weight="5">
              <Name>Inj 5 mg intrathecal syringe for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010417972625">
                <Name>Baxter</Name>
                <Pack ID="P2204126" Specified="true" OP="true">
                  <Quantity>5</Quantity>
                  <Subsidy>4.73</Subsidy>
                  <Price>4.73</Price>
                  <Alternate>4.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179729" Rank="4" Units="inj" Weight="7">
              <Name>Inj 7.5 mg prefilled syringe</Name>
              <Brand ID="B25010417972925">
                <Name>Methotrexate Sandoz</Name>
                <Pack ID="P2445832" Specified="true" nzmt:ctpp_id="50167731000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>14.61</Subsidy>
                  <Price>14.61</Price>
                  <Alternate>14.61</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179730" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg prefilled syringe</Name>
              <Brand ID="B25010417973025">
                <Name>Methotrexate Sandoz</Name>
                <Pack ID="P2445840" Specified="true" nzmt:ctpp_id="50167761000117100">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>14.66</Subsidy>
                  <Price>14.66</Price>
                  <Alternate>14.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179731" Rank="4" Units="inj" Weight="15">
              <Name>Inj 15 mg prefilled syringe</Name>
              <Brand ID="B25010417973125">
                <Name>Methotrexate Sandoz</Name>
                <Pack ID="P2445859" Specified="true" nzmt:ctpp_id="50167791000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>14.77</Subsidy>
                  <Price>14.77</Price>
                  <Alternate>14.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179732" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg prefilled syringe</Name>
              <Brand ID="B25010417973225">
                <Name>Methotrexate Sandoz</Name>
                <Pack ID="P2445867" Specified="true" nzmt:ctpp_id="50141461000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>14.88</Subsidy>
                  <Price>14.88</Price>
                  <Alternate>14.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179733" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg prefilled syringe</Name>
              <Brand ID="B25010417973325">
                <Name>Methotrexate Sandoz</Name>
                <Pack ID="P2445875" Specified="true" nzmt:ctpp_id="50141451000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>14.99</Subsidy>
                  <Price>14.99</Price>
                  <Alternate>14.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104179734" Rank="4" Units="inj" Weight="30">
              <Name>Inj 30 mg prefilled syringe</Name>
              <Brand ID="B25010417973425">
                <Name>Methotrexate Sandoz</Name>
                <Pack ID="P2445883" Specified="true" nzmt:ctpp_id="50141441000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>15.09</Subsidy>
                  <Price>15.09</Price>
                  <Alternate>15.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501042252">
            <Name>Thioguanine</Name>
            <Rule Type="PCT"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250104225201" Rank="1" Units="tab" Weight="40">
              <Name>Tab 40 mg</Name>
              <Brand ID="B25010422520101">
                <Name>Lanvis</Name>
                <Pack ID="P259713" Specified="true" nzmt:ctpp_id="50056741000117101">
                  <Quantity>25</Quantity>
                  <Subsidy>126.31</Subsidy>
                  <Price>126.31</Price>
                  <Alternate>126.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501043808">
            <Name>Capecitabine</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250104380825" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B25010438082529" PSS="2025-06-30">
                <Name>Capecitabine Viatris</Name>
                <Pack ID="P2634929" Specified="true" nzmt:ctpp_id="50302761000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>9.80</Subsidy>
                  <Price>9.80</Price>
                  <Alternate>9.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104380826" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B25010438082630" PSS="2025-06-30">
                <Name>Capecitabine Viatris</Name>
                <Pack ID="P2634937" Specified="true" nzmt:ctpp_id="50302771000117101">
                  <Quantity>120</Quantity>
                  <Subsidy>46.50</Subsidy>
                  <Price>46.50</Price>
                  <Alternate>46.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501043810">
            <Name>Fludarabine phosphate</Name>
            <Formulation ID="F250104381025" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010438102526">
                <Name>Fludarabine Ebewe</Name>
                <Pack ID="P2386933" Specified="true" nzmt:ctpp_id="50123471000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>634.00</Subsidy>
                  <Price>634.00</Price>
                  <Alternate>634.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104381026" Rank="10" Units="mg" Weight="50">
              <Name>Inj 50 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010438102625">
                <Name>Baxter</Name>
                <Pack ID="P2204169" Specified="true" OP="true">
                  <Quantity>50</Quantity>
                  <Subsidy>126.80</Subsidy>
                  <Price>126.80</Price>
                  <Alternate>126.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104381027" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010438102726">
                <Name>Fludara Oral</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2327988" Specified="true" nzmt:ctpp_id="50120021000117104">
                  <Quantity>20</Quantity>
                  <Subsidy>412.00</Subsidy>
                  <Price>412.00</Price>
                  <Alternate>412.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501043811">
            <Name>Irinotecan hydrochloride</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250104381126" Rank="4" Units="inj" Weight="100">
              <Name>Inj 20 mg per ml, 5 ml vial</Name>
              <Brand ID="B25010438112626">
                <Name>Irinotecan-Rex</Name>
                <Pack ID="P2351013" Specified="true" nzmt:ctpp_id="50050571000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>100.00</Subsidy>
                  <Price>100.00</Price>
                  <Alternate>100.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010438112627">
                <Name>Irinotecan Actavis 100</Name>
                <Pack ID="P2401916" Specified="true" nzmt:ctpp_id="50131031000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>71.44</Subsidy>
                  <Price>71.44</Price>
                  <Alternate>71.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010438112629">
                <Name>Accord</Name>
                <Pack ID="P2621177" Specified="true" nzmt:ctpp_id="50265431000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>52.57</Subsidy>
                  <Price>52.57</Price>
                  <Alternate>52.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104381127" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010438112725">
                <Name>Baxter</Name>
                <Pack ID="P2204142" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.54</Subsidy>
                  <Price>0.54</Price>
                  <Alternate>0.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501043840">
            <Name>Cladribine</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250104384025" Rank="4" Units="inj" Weight="10">
              <Name>Inj 1 mg per ml, 10 ml</Name>
              <Brand ID="B25010438402525">
                <Name>Leustatin</Name>
                <Pack ID="P2595788" Specified="true" nzmt:ctpp_id="50278241000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>749.96</Subsidy>
                  <Price>749.96</Price>
                  <Alternate>749.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104384026" Rank="10" Units="mg" Weight="10">
              <Name>Inj 10 mg for ECP</Name>
              <Brand ID="B25010438402625">
                <Name>Baxter</Name>
                <Pack ID="P2207540" Specified="true" OP="true">
                  <Quantity>10</Quantity>
                  <Subsidy>749.96</Subsidy>
                  <Price>749.96</Price>
                  <Alternate>749.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104384027" Rank="4" Units="inj">
              <Name>Inj 2 mg per ml, 5 ml</Name>
              <Brand ID="B25010438402725" S29="true">
                <Name>Litak</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2636220" Specified="true" nzmt:ctpp_id="50045001000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>749.96</Subsidy>
                  <Price>749.96</Price>
                  <Alternate>749.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501043842">
            <Name>Gemcitabine hydrochloride</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250104384226" Rank="4" Units="inj" Weight="1">
              <Name>Inj 1 g</Name>
              <Brand ID="B25010438422626">
                <Name>Gemcitabine Ebewe</Name>
                <Pack ID="P2320304" Specified="true" nzmt:ctpp_id="50048671000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>15.89</Subsidy>
                  <Price>15.89</Price>
                  <Alternate>15.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104384227" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010438422725">
                <Name>Baxter</Name>
                <Pack ID="P2207532" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.02</Subsidy>
                  <Price>0.02</Price>
                  <Alternate>0.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104384228" Rank="4" Units="inj">
              <Name>Inj 43.3 mg per ml (equivalent to 38 mg per ml gemcitabine), 26.3 ml vial</Name>
              <Brand ID="B25010438422825">
                <Name>DBL Gemcitabine</Name>
                <Pack ID="P2521423" Specified="true" nzmt:ctpp_id="50146891000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>18.94</Subsidy>
                  <Price>18.94</Price>
                  <Alternate>18.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501044034">
            <Name>Azacitidine</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2141"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2141">
              <Title>
                <range>Azacitidine</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome</ci>
                      <ci type="logical" class="Indication">The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder)</ci>
                      <ci type="logical" class="Indication">The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO)</ci>
                    </apply>
                    <ci type="logical" class="Indication">The patient has performance status (WHO/ECOG) grade 0-2</ci>
                    <ci type="logical" class="Indication">The patient has an estimated life expectancy of at least 3 months</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1467 SA2141">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and patient is benefitting from treatment</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250104403425" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25010440342526" PSS="2024-06-30">
                <Name>Azacitidine Dr Reddy's</Name>
                <Pack ID="P2550083" Specified="true" nzmt:ctpp_id="50232011000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>75.06</Subsidy>
                  <Price>75.06</Price>
                  <Alternate>75.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104403426" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010440342625">
                <Name>Baxter</Name>
                <Pack ID="P2465884" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.83</Subsidy>
                  <Price>0.83</Price>
                  <Alternate>0.83</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501044088">
            <Name>Pemetrexed</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1679"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1679" Confidential="true">
              <Title>
                <range>Pemetrexed</range>
              </Title>
              <Case When="Initial application" Category="mesothelioma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with mesothelioma</ci>
                    <ci type="logical" class="Indication">Pemetrexed to be administered at a dose of 500 mg/mÂ² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">8</Term>
              </Case>
              <Case When="Renewal" Category="mesothelioma" Form="SA1679">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from treatment</ci>
                    <ci type="logical" class="Indication">Pemetrexed to be administered at a dose of 500mg/mÂ² every 21 days for a maximum of 6 cycles</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">8</Term>
              </Case>
              <Case When="Initial application" Category="non-small cell lung carcinoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has chemotherapy-naÃ¯ve disease</ci>
                        <ci type="logical" class="Indication">Pemetrexed is to be administered at a dose of 500 mg/mÂ² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has had first-line treatment with platinum based chemotherapy</ci>
                        <ci type="logical" class="Indication">Patient has not received prior funded treatment with pemetrexed</ci>
                        <ci type="logical" class="Indication">Pemetrexed is to be administered at a dose of 500 mg/mÂ² every 21 days for a maximum of 6 cycles</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">8</Term>
              </Case>
              <Case When="Renewal" Category="non-small cell lung carcinoma" Form="SA1679">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from treatment</ci>
                    <ci type="logical" class="Indication">Pemetrexed is to be administered at a dose of 500mg/mÂ² every 21 days</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">8</Term>
              </Case>
            </Request>
            <Formulation ID="F250104408825" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25010440882525">
                <Name>Juno Pemetrexed</Name>
                <Pack ID="P2524619" Specified="true" nzmt:ctpp_id="50229141000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>60.89</Subsidy>
                  <Price>60.89</Price>
                  <Alternate>60.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104408826" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B25010440882625">
                <Name>Juno Pemetrexed</Name>
                <Pack ID="P2524627" Specified="true" nzmt:ctpp_id="50229131000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>217.77</Subsidy>
                  <Price>217.77</Price>
                  <Alternate>217.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250104408827" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010440882725">
                <Name>Baxter</Name>
                <Pack ID="P2532387" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.55</Subsidy>
                  <Price>0.55</Price>
                  <Alternate>0.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250107">
          <Name>Other Cytotoxic Agents</Name>
          <Chemical ID="C2501071626">
            <Name>Hydroxyurea [hydroxycarbamide]</Name>
            <Rule Type="PCT"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250107162601" Rank="2" Units="cap" Weight="500">
              <Name>Cap 500 mg</Name>
              <Brand ID="B25010716260102" PSS="2026-06-30">
                <Name>Devatis</Name>
                <Pack ID="P2593246" Specified="true" nzmt:ctpp_id="50265131000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>20.72</Subsidy>
                  <Price>20.72</Price>
                  <Alternate>20.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501072047">
            <Name>Procarbazine hydrochloride</Name>
            <Rule Type="PCT"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250107204701" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B25010720470101" S29="true">
                <Name>Natulan</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P336548" Specified="true" nzmt:ctpp_id="50074521000117109">
                  <Quantity>50</Quantity>
                  <Subsidy>980.00</Subsidy>
                  <Price>980.00</Price>
                  <Alternate>980.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501072286">
            <Name>Tretinoin</Name>
            <Formulation ID="F250107228625" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010722862525">
                <Name>Vesanoid</Name>
                <Pack ID="P235229" Specified="true" nzmt:ctpp_id="50050631000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>479.50</Subsidy>
                  <Price>479.50</Price>
                  <Alternate>479.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501072319">
            <Name>Vinblastine sulphate</Name>
            <Formulation ID="F250107231901" Rank="4" Units="inj" Weight="10">
              <Name>Inj 1 mg per ml, 10 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010723190102">
                <Name>Hospira</Name>
                <Pack ID="P779989" Specified="true" nzmt:ctpp_id="50113271000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>270.37</Subsidy>
                  <Price>270.37</Price>
                  <Alternate>270.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107231925" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010723192525">
                <Name>Baxter</Name>
                <Pack ID="P2204061" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501072320" Update="-Subsidy">
            <Name>Vincristine sulphate</Name>
            <Formulation ID="F250107232001" Rank="4" Units="inj" Weight="1">
              <Name>Inj 1 mg per ml, 1 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010723200101">
                <Name>DBL Vincristine Sulfate</Name>
                <Pack ID="P604585" Specified="true" nzmt:ctpp_id="50098581000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>51.37</Subsidy>
                  <Price>51.37</Price>
                  <Alternate>51.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107232002" Rank="4" Units="inj" Weight="2">
              <Name>Inj 1 mg per ml, 2 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010723200201">
                <Name>DBL Vincristine Sulfate</Name>
                <Pack ID="P604593" Specified="true" nzmt:ctpp_id="50098591000117107">
                  <Quantity>5</Quantity>
                  <Subsidy>102.73</Subsidy>
                  <Price>102.73</Price>
                  <Alternate>102.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107232025" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010723202525">
                <Name>Baxter</Name>
                <Pack ID="P2204053" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>12.60</Subsidy>
                  <Price>12.60</Price>
                  <Alternate>12.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501072433">
            <Name>Etoposide</Name>
            <Formulation ID="F250107243301" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010724330101">
                <Name>Vepesid</Name>
                <Pack ID="P332690" Specified="true" nzmt:ctpp_id="50073781000117100">
                  <Quantity>20</Quantity>
                  <Subsidy>340.73</Subsidy>
                  <Price>340.73</Price>
                  <Alternate>340.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107243302" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010724330201">
                <Name>Vepesid</Name>
                <Pack ID="P332704" Specified="true" nzmt:ctpp_id="50073791000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>340.73</Subsidy>
                  <Price>340.73</Price>
                  <Alternate>340.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107243303" Rank="4" Units="inj" Weight="100">
              <Name>Inj 20 mg per ml, 5 ml vial</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010724330325">
                <Name>Rex Medical</Name>
                <Pack ID="P2480913" Specified="true" nzmt:ctpp_id="50225401000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>7.90</Subsidy>
                  <Price>7.90</Price>
                  <Alternate>7.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107243325" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010724332525">
                <Name>Baxter</Name>
                <Pack ID="P2204118" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.09</Subsidy>
                  <Price>0.09</Price>
                  <Alternate>0.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073812">
            <Name>Bleomycin sulphate</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107381225" Rank="4" Units="inj" Weight="15000">
              <Name>Inj 15,000 iu, vial</Name>
              <Brand ID="B25010738122526">
                <Name>DBL Bleomycin Sulfate</Name>
                <Pack ID="P2343207" Specified="true" nzmt:ctpp_id="50050051000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>185.16</Subsidy>
                  <Price>185.16</Price>
                  <Alternate>185.16</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381226" Rank="10" Units="iu" Weight="1000">
              <Name>Inj 1,000 iu for ECP</Name>
              <Brand ID="B25010738122625">
                <Name>Baxter</Name>
                <Pack ID="P2204215" Specified="true">
                  <Quantity>1000</Quantity>
                  <Subsidy>14.32</Subsidy>
                  <Price>14.32</Price>
                  <Alternate>14.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073813">
            <Name>Doxorubicin hydrochloride</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107381326" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010738132625">
                <Name>Baxter</Name>
                <Pack ID="P2204185" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.35</Subsidy>
                  <Price>0.35</Price>
                  <Alternate>0.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381327" Rank="4" Units="inj" Weight="10">
              <Name>Inj 2 mg per ml, 5 ml vial</Name>
              <Brand ID="B25010738132725">
                <Name>Doxorubicin Ebewe</Name>
                <Pack ID="P2224070" Specified="true" nzmt:ctpp_id="50035531000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>10.00</Subsidy>
                  <Price>10.00</Price>
                  <Alternate>10.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381328" Rank="4" Units="inj" Weight="100">
              <Name>Inj 2 mg per ml, 50 ml vial</Name>
              <Brand ID="B25010738132825">
                <Name>Doxorubicin Ebewe</Name>
                <Pack ID="P2224097" Specified="true" nzmt:ctpp_id="50035551000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>23.00</Subsidy>
                  <Price>23.00</Price>
                  <Alternate>23.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381329" Rank="4" Units="inj" Weight="200">
              <Name>Inj 2 mg per ml, 100 ml vial </Name>
              <Brand ID="B25010738132925">
                <Name>Doxorubicin Ebewe</Name>
                <Pack ID="P2224100" Specified="true" nzmt:ctpp_id="50035561000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>69.99</Subsidy>
                  <Price>69.99</Price>
                  <Alternate>69.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738132927">
                <Name>Arrow-Doxorubicin</Name>
                <Pack ID="P2427214" Specified="true" nzmt:ctpp_id="50152591000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>65.00</Subsidy>
                  <Price>65.00</Price>
                  <Alternate>65.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738132928" S29="true">
                <Name>Accord</Name>
                <Pack ID="P2655446" Specified="true" nzmt:ctpp_id="50314131000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>69.99</Subsidy>
                  <Price>69.99</Price>
                  <Alternate>69.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381330" Rank="4" Units="inj" Weight="50">
              <Name>Inj 2 mg per ml, 25 ml vial</Name>
              <Brand ID="B25010738133026">
                <Name>Doxorubicin Ebewe</Name>
                <Pack ID="P2224089" Specified="true" nzmt:ctpp_id="50035541000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>11.50</Subsidy>
                  <Price>11.50</Price>
                  <Alternate>11.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738133028">
                <Name>Arrow-Doxorubicin</Name>
                <Pack ID="P2427222" Specified="true" nzmt:ctpp_id="50152561000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>17.00</Subsidy>
                  <Price>17.00</Price>
                  <Alternate>17.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073814">
            <Name>Epirubicin hydrochloride</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107381425" Rank="4" Units="inj" Weight="10">
              <Name>Inj 2 mg per ml, 5 ml vial</Name>
              <Brand ID="B25010738142526">
                <Name>Epirubicin Ebewe</Name>
                <Pack ID="P2224119" Specified="true" nzmt:ctpp_id="50035571000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>25.00</Subsidy>
                  <Price>25.00</Price>
                  <Alternate>25.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381426" Rank="4" Units="inj" Weight="50">
              <Name>Inj 2 mg per ml, 25 ml vial</Name>
              <Brand ID="B25010738142626">
                <Name>Epirubicin Ebewe</Name>
                <Pack ID="P2224127" Specified="true" nzmt:ctpp_id="50035581000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>30.00</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>30.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381427" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010738142725">
                <Name>Baxter</Name>
                <Pack ID="P2204177" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.50</Subsidy>
                  <Price>0.50</Price>
                  <Alternate>0.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381429" Rank="4" Units="inj" Weight="200">
              <Name>Inj 2 mg per ml, 100 ml vial</Name>
              <Brand ID="B25010738142925">
                <Name>Epirubicin Ebewe</Name>
                <Pack ID="P2224143" Specified="true" nzmt:ctpp_id="50035601000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>99.99</Subsidy>
                  <Price>99.99</Price>
                  <Alternate>99.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073815" Update="-Subsidy">
            <Name>Paclitaxel</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107381525" Rank="4" Units="inj" Weight="100">
              <Name>Inj 6 mg per ml, 16.7 ml vial</Name>
              <Brand ID="B25010738152526">
                <Name>Paclitaxel Ebewe</Name>
                <Pack ID="P2207664" Specified="true" nzmt:ctpp_id="50032921000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>24.00</Subsidy>
                  <Price>24.00</Price>
                  <Alternate>24.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738152527">
                <Name>Paclitaxel Actavis</Name>
                <Pack ID="P2394561" Specified="true" nzmt:ctpp_id="50126211000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>91.67</Subsidy>
                  <Price>91.67</Price>
                  <Alternate>91.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738152528" Update="New Listing">
                <Name>Anzatax</Name>
                <Pack ID="P2271834" Specified="true" nzmt:ctpp_id="50042651000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>19.59</Subsidy>
                  <Price>19.59</Price>
                  <Alternate>19.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381526" Rank="4" Units="inj" Weight="30">
              <Name>Inj 30 mg</Name>
              <Brand ID="B25010738152626">
                <Name>Paclitaxel Ebewe</Name>
                <Pack ID="P2316978" Specified="true" nzmt:ctpp_id="50048251000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>47.30</Subsidy>
                  <Price>47.30</Price>
                  <Alternate>47.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381527" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010738152725">
                <Name>Baxter</Name>
                <Pack ID="P2204088" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.17</Subsidy>
                  <Price>0.17</Price>
                  <Alternate>0.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381528" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg</Name>
              <Brand ID="B25010738152825">
                <Name>Paclitaxel Ebewe</Name>
                <Pack ID="P2207672" Specified="true" nzmt:ctpp_id="50032931000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>26.69</Subsidy>
                  <Price>26.69</Price>
                  <Alternate>26.69</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738152826">
                <Name>Anzatax</Name>
                <Pack ID="P2271826" Specified="true" nzmt:ctpp_id="50042641000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>137.50</Subsidy>
                  <Price>137.50</Price>
                  <Alternate>137.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738152827">
                <Name>Paclitaxel Actavis</Name>
                <Pack ID="P2394588" Specified="true" nzmt:ctpp_id="50126241000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>137.50</Subsidy>
                  <Price>137.50</Price>
                  <Alternate>137.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381529" Rank="4" Units="inj" Weight="300">
              <Name>Inj 6 mg per ml, 50 ml vial</Name>
              <Brand ID="B25010738152925">
                <Name>Paclitaxel Ebewe</Name>
                <Pack ID="P2207680" Specified="true" nzmt:ctpp_id="50032941000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>44.00</Subsidy>
                  <Price>44.00</Price>
                  <Alternate>44.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738152926">
                <Name>Anzatax</Name>
                <Pack ID="P2271818" Specified="true" nzmt:ctpp_id="50042631000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>37.89</Subsidy>
                  <Price>37.89</Price>
                  <Alternate>37.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738152927">
                <Name>Paclitaxel Actavis</Name>
                <Pack ID="P2394596" Specified="true" nzmt:ctpp_id="50126251000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>275.00</Subsidy>
                  <Price>275.00</Price>
                  <Alternate>275.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073816">
            <Name>Vinorelbine</Name>
            <Formulation ID="F250107381625" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg per ml, 1 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738162525" ToBeDelisted="2024-10-01">
                <Name>Navelbine</Name>
                <Pack ID="P2087111" Specified="true" nzmt:ctpp_id="50015401000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>12.00</Subsidy>
                  <Price>12.00</Price>
                  <Alternate>12.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738162526">
                <Name>Vinorelbine Ebewe</Name>
                <Pack ID="P2236613" Specified="true" nzmt:ctpp_id="50037711000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>42.00</Subsidy>
                  <Price>42.00</Price>
                  <Alternate>42.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381626" Rank="4" Units="inj" Weight="50">
              <Name>Inj 10 mg per ml, 5 ml vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738162625" ToBeDelisted="2024-10-01">
                <Name>Navelbine</Name>
                <Pack ID="P2087103" Specified="true" nzmt:ctpp_id="50015391000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>56.00</Subsidy>
                  <Price>56.00</Price>
                  <Alternate>56.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738162626">
                <Name>Vinorelbine Ebewe</Name>
                <Pack ID="P2236605" Specified="true" nzmt:ctpp_id="50037701000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>210.00</Subsidy>
                  <Price>210.00</Price>
                  <Alternate>210.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738162627" S29="true">
                <Name>Sagent</Name>
                <Pack ID="P2618621" Specified="true" nzmt:ctpp_id="50290091000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>328.65</Subsidy>
                  <Price>328.65</Price>
                  <Alternate>328.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738162628" S29="true">
                <Name>Navelbine S29</Name>
                <Pack ID="P2663260" Specified="true" nzmt:ctpp_id="50321031000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>168.00</Subsidy>
                  <Price>168.00</Price>
                  <Alternate>168.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381627" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738162725">
                <Name>Baxter</Name>
                <Pack ID="P2204045" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>3.80</Subsidy>
                  <Price>3.80</Price>
                  <Alternate>3.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381629" Rank="2" Units="cap" Weight="80">
              <Name>Cap 80 mg</Name>
              <Brand ID="B25010738162925" PSS="2025-06-30">
                <Name>Vinorelbine Te Arai</Name>
                <Pack ID="P2651920" Specified="true" nzmt:ctpp_id="50255731000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>60.00</Subsidy>
                  <Price>60.00</Price>
                  <Alternate>60.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381630" Rank="2" Units="cap" Weight="30">
              <Name>Cap 30 mg</Name>
              <Brand ID="B25010738163025" PSS="2025-06-30">
                <Name>Vinorelbine Te Arai</Name>
                <Pack ID="P2547880" Specified="true" nzmt:ctpp_id="50255721000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>40.00</Subsidy>
                  <Price>40.00</Price>
                  <Alternate>40.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107381631" Rank="2" Units="cap" Weight="20">
              <Name>Cap 20 mg</Name>
              <Brand ID="B25010738163125" PSS="2025-06-30">
                <Name>Vinorelbine Te Arai</Name>
                <Pack ID="P2651912" Specified="true" nzmt:ctpp_id="50255711000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>30.00</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>30.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073820">
            <Name>Mesna</Name>
            <Formulation ID="F250107382025" Rank="4" Units="inj" Weight="400">
              <Name>Inj 100 mg per ml, 4 ml ampoule</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738202525">
                <Name>Uromitexan</Name>
                <Pack ID="P712744" Specified="true" nzmt:ctpp_id="50123281000117100">
                  <Quantity>15</Quantity>
                  <Subsidy>177.45</Subsidy>
                  <Price>177.45</Price>
                  <Alternate>177.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382026" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 100 mg per ml, 10 ml ampoule</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738202625">
                <Name>Uromitexan</Name>
                <Pack ID="P712752" Specified="true" nzmt:ctpp_id="50104271000117106">
                  <Quantity>15</Quantity>
                  <Subsidy>407.40</Subsidy>
                  <Price>407.40</Price>
                  <Alternate>407.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382027" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010738202725">
                <Name>Uromitexan</Name>
                <Pack ID="P2085887" Specified="true" nzmt:ctpp_id="50014261000117107">
                  <Quantity>50</Quantity>
                  <Subsidy>314.00</Subsidy>
                  <Price>314.00</Price>
                  <Alternate>314.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382028" Rank="1" Units="tab" Weight="600">
              <Name>Tab 600 mg</Name>
              <Rule Type="PCT"/>
              <Rule Type="SpecEnd" Attribute="Retail"/>
              <Brand ID="B25010738202825">
                <Name>Uromitexan</Name>
                <Pack ID="P2087189" Specified="true" nzmt:ctpp_id="50015441000117108">
                  <Quantity>50</Quantity>
                  <Subsidy>448.50</Subsidy>
                  <Price>448.50</Price>
                  <Alternate>448.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382029" Rank="10" Units="mg">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738202925">
                <Name>Baxter</Name>
                <Pack ID="P2370131" Specified="true">
                  <Quantity>100</Quantity>
                  <Subsidy>2.96</Subsidy>
                  <Price>2.96</Price>
                  <Alternate>2.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073821">
            <Name>Mitozantrone</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107382125" Rank="4" Units="inj" Weight="20">
              <Name>Inj 2 mg per ml, 10 ml vial</Name>
              <Brand ID="B25010738212526">
                <Name>Mitozantrone Ebewe</Name>
                <Pack ID="P2270463" Specified="true" nzmt:ctpp_id="50042391000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>97.50</Subsidy>
                  <Price>97.50</Price>
                  <Alternate>97.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382127" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010738212725">
                <Name>Baxter</Name>
                <Pack ID="P2204096" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>5.51</Subsidy>
                  <Price>5.51</Price>
                  <Alternate>5.51</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073827">
            <Name>Dacarbazine</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107382725" Rank="4" Units="inj" Weight="200">
              <Name>Inj 200 mg vial</Name>
              <Brand ID="B25010738272525">
                <Name>DBL Dacarbazine</Name>
                <Pack ID="P299308" Specified="true" nzmt:ctpp_id="50066551000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>72.11</Subsidy>
                  <Price>72.11</Price>
                  <Alternate>72.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738272526" S29="true">
                <Name>Dacarbazine APP</Name>
                <Pack ID="P2539446" Specified="true" nzmt:ctpp_id="50252291000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>580.60</Subsidy>
                  <Price>580.60</Price>
                  <Alternate>580.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382726" Rank="10" Units="mg" Weight="200">
              <Name>Inj 200 mg for ECP</Name>
              <Brand ID="B25010738272625">
                <Name>Baxter</Name>
                <Pack ID="P2204207" Specified="true" OP="true">
                  <Quantity>200</Quantity>
                  <Subsidy>72.11</Subsidy>
                  <Price>72.11</Price>
                  <Alternate>72.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073828">
            <Name>Daunorubicin</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107382826" Rank="10" Units="mg" Weight="20">
              <Name>Inj 20 mg for ECP</Name>
              <Brand ID="B25010738282625">
                <Name>Baxter</Name>
                <Pack ID="P2204193" Specified="true" OP="true">
                  <Quantity>20</Quantity>
                  <Subsidy>171.93</Subsidy>
                  <Price>171.93</Price>
                  <Alternate>171.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382827" Rank="4" Units="inj">
              <Name>Inj 2 mg per ml, 10 ml</Name>
              <Brand ID="B25010738282725">
                <Name>Pfizer</Name>
                <Pack ID="P2325500" Specified="true" nzmt:ctpp_id="50049051000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>171.93</Subsidy>
                  <Price>171.93</Price>
                  <Alternate>171.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107382828" Rank="4" Units="inj">
              <Name>Inj 20 mg vial</Name>
              <Brand ID="B25010738282825" S29="true">
                <Name>Daunorubicin Zentiva</Name>
                <Pack ID="P2636476" Specified="true" nzmt:ctpp_id="50300791000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1495.00</Subsidy>
                  <Price>1495.00</Price>
                  <Alternate>1495.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073834">
            <Name>Docetaxel</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107383425" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg</Name>
              <Brand ID="B25010738342527">
                <Name>Docetaxel Sandoz</Name>
                <Pack ID="P2428148" Specified="true" nzmt:ctpp_id="50168801000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>48.75</Subsidy>
                  <Price>48.75</Price>
                  <Alternate>48.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107383426" Rank="4" Units="inj" Weight="80">
              <Name>Inj 80 mg</Name>
              <Brand ID="B25010738342627">
                <Name>Docetaxel Sandoz</Name>
                <Pack ID="P2428156" Specified="true" nzmt:ctpp_id="50168841000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>195.00</Subsidy>
                  <Price>195.00</Price>
                  <Alternate>195.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107383427" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010738342725">
                <Name>Baxter</Name>
                <Pack ID="P2207559" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.35</Subsidy>
                  <Price>0.35</Price>
                  <Alternate>0.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107383429" Rank="4" Units="inj" Weight="80">
              <Name>Inj 20 mg per ml, 4 ml vial</Name>
              <Brand ID="B25010738342926" S29="true">
                <Name>Docetaxel Accord</Name>
                <Pack ID="P2571161" Specified="true" nzmt:ctpp_id="50266051000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>26.95</Subsidy>
                  <Price>26.95</Price>
                  <Alternate>26.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107383431" Rank="4" Units="inj" Weight="80">
              <Name>Inj 10 mg per ml, 8 ml vial</Name>
              <Brand ID="B25010738343125">
                <Name>DBL Docetaxel</Name>
                <Pack ID="P2440830" Specified="true" nzmt:ctpp_id="50142051000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>24.91</Subsidy>
                  <Price>24.91</Price>
                  <Alternate>24.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073843">
            <Name>Anagrelide hydrochloride</Name>
            <Rule Type="PCT"/>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Formulation ID="F250107384325" Rank="2" Units="cap" Weight="0.5">
              <Name>Cap 0.5 mg</Name>
              <Brand ID="B25010738432527">
                <Name>Agrylin</Name>
                <Pack ID="P2583054" Specified="true" nzmt:ctpp_id="50242281000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>1175.87</Subsidy>
                  <Price>1175.87</Price>
                  <Alternate>1175.87</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073844">
            <Name>Arsenic trioxide</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107384426" Rank="4" Units="inj" Weight="10">
              <Name>Inj 1 mg per ml, 10 ml vial</Name>
              <Brand ID="B25010738442625">
                <Name>Phenasen</Name>
                <Pack ID="P2560518" Specified="true" nzmt:ctpp_id="50262111000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>4817.00</Subsidy>
                  <Price>4817.00</Price>
                  <Alternate>4817.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384427" Rank="10" Units="mg" Weight="10">
              <Name>Inj 10 mg for ECP</Name>
              <Brand ID="B25010738442725">
                <Name>Baxter</Name>
                <Pack ID="P2568675" Specified="true" OP="true">
                  <Quantity>10</Quantity>
                  <Subsidy>481.70</Subsidy>
                  <Price>481.70</Price>
                  <Alternate>481.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073845">
            <Name>Thalidomide</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1124"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1124">
              <Title>
                <range>Thalidomide</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="indication">The patient has multiple myeloma</ci>
                    <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1124 SA0817 SA0882">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.</p>
                <p>Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.</p>
                <p>Indication marked with * is an unapproved indication.</p>
              </div>
            </Request>
            <Formulation ID="F250107384525" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B25010738452526">
                <Name>Thalomid</Name>
                <Pack ID="P2381125" Specified="true" nzmt:ctpp_id="50122501000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>378.00</Subsidy>
                  <Price>378.00</Price>
                  <Alternate>378.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384526" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B25010738452625">
                <Name>Thalomid</Name>
                <Pack ID="P2381133" Specified="true" nzmt:ctpp_id="50122651000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>756.00</Subsidy>
                  <Price>756.00</Price>
                  <Alternate>756.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073846">
            <Name>Dactinomycin [Actinomycin D]</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107384625" Rank="4" Units="inj" Weight="0.5">
              <Name>Inj 0.5 mg vial</Name>
              <Brand ID="B25010738462525">
                <Name>Cosmegen</Name>
                <Pack ID="P203343" Specified="true" nzmt:ctpp_id="50006341000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>255.00</Subsidy>
                  <Price>255.00</Price>
                  <Alternate>255.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384626" Rank="10" Units="mg" Weight="0.5">
              <Name>Inj 0.5 mg for ECP</Name>
              <Brand ID="B25010738462625">
                <Name>Baxter</Name>
                <Pack ID="P2207583" Specified="true" OP="true">
                  <Quantity>0.5</Quantity>
                  <Subsidy>255.00</Subsidy>
                  <Price>255.00</Price>
                  <Alternate>255.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073847">
            <Name>Etoposide phosphate</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107384725" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg (of etoposide base)</Name>
              <Brand ID="B25010738472525">
                <Name>Etopophos</Name>
                <Pack ID="P493953" Specified="true" nzmt:ctpp_id="50092311000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>40.00</Subsidy>
                  <Price>40.00</Price>
                  <Alternate>40.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384726" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg (of etoposide base) for ECP</Name>
              <Brand ID="B25010738472625">
                <Name>Baxter</Name>
                <Pack ID="P2207613" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>0.47</Subsidy>
                  <Price>0.47</Price>
                  <Alternate>0.47</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073848">
            <Name>Idarubicin hydrochloride</Name>
            <Formulation ID="F250107384827" Rank="4" Units="inj" Weight="5">
              <Name>Inj 5 mg vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738482725">
                <Name>Zavedos</Name>
                <Pack ID="P784443" Specified="true" nzmt:ctpp_id="50113921000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>109.74</Subsidy>
                  <Price>109.74</Price>
                  <Alternate>109.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384828" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg vial</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738482825">
                <Name>Zavedos</Name>
                <Pack ID="P784451" Specified="true" nzmt:ctpp_id="50113931000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>233.64</Subsidy>
                  <Price>233.64</Price>
                  <Alternate>233.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384829" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Rule Type="PCT" Attribute="only"/>
              <Rule Type="SpecEnd" Attribute="Hospital"/>
              <Brand ID="B25010738482925">
                <Name>Baxter</Name>
                <Pack ID="P2207575" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>25.77</Subsidy>
                  <Price>25.77</Price>
                  <Alternate>25.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073849">
            <Name>Mitomycin C</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107384927" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010738492725">
                <Name>Baxter</Name>
                <Pack ID="P2207605" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>269.85</Subsidy>
                  <Price>269.85</Price>
                  <Alternate>269.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384928" Rank="4" Units="inj" Weight="5">
              <Name>Inj 5 mg vial</Name>
              <Brand ID="B25010738492826" S29="true">
                <Name>Accord</Name>
                <Pack ID="P2137844" Specified="true" nzmt:ctpp_id="50182211000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>641.70</Subsidy>
                  <Price>641.70</Price>
                  <Alternate>641.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107384929" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg vial</Name>
              <Brand ID="B25010738492925" S29="true">
                <Name>Omegapharm</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2580160" Specified="true" nzmt:ctpp_id="50272261000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>1250.00</Subsidy>
                  <Price>1250.00</Price>
                  <Alternate>1250.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738492926">
                <Name>Teva</Name>
                <Pack ID="P2601761" Specified="true" nzmt:ctpp_id="50264951000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>1250.00</Subsidy>
                  <Price>1250.00</Price>
                  <Alternate>1250.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073850">
            <Name>Pentostatin [Deoxycoformycin]</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107385025" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mg</Name>
              <Brand ID="B25010738502525" S29="true">
                <Name>Nipent</Name>
                <Pack ID="P2063859" CBS="true">
                  <Quantity>1</Quantity>
                </Pack>
                <Pack ID="P2580713" Specified="true" CBS="true" nzmt:ctpp_id="50011151000117101">
                  <Quantity>1</Quantity>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073856">
            <Name>Temozolomide</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2275"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2275">
              <Title>
                <range>Temozolomide</range>
              </Title>
              <Case When="Initial application" Category="gliomas">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="indication">the patient has a glioma</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="gliomas" Form="SA1063 SA1610 SA1616 SA1741 SA2275">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">treatment remains appropriate and patient is benefitting from treatment</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="neuroendocrine tumours">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*</ci>
                    <ci type="logical" class="Indication">Temozolomide is to be given in combination with capecitabine</ci>
                    <ci type="logical" class="Indication">Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/mÂ² per day</ci>
                    <ci type="logical" class="Indication">Temozolomide to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="neuroendocrine tumours" Form="SA1063 SA1610 SA1616 SA1741 SA2275">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from treatment</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="ewing's sarcoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient has relapsed/refractory Ewingâ€™s sarcoma</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="ewing's sarcoma" Form="SA1063 SA1610 SA1616 SA1741 SA2275">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from treatment</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.</p>
              </div>
            </Request>
            <Formulation ID="F250107385625" Rank="2" Units="cap" Weight="5">
              <Name>Cap 5 mg</Name>
              <Brand ID="B25010738562526">
                <Name>Temaccord</Name>
                <Pack ID="P2388278" Specified="true" nzmt:ctpp_id="50127391000117103">
                  <Quantity>5</Quantity>
                  <Subsidy>9.13</Subsidy>
                  <Price>9.13</Price>
                  <Alternate>9.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107385626" Rank="2" Units="cap" Weight="20">
              <Name>Cap 20 mg</Name>
              <Brand ID="B25010738562626">
                <Name>Temaccord</Name>
                <Pack ID="P2388251" Specified="true" nzmt:ctpp_id="50127411000117103">
                  <Quantity>5</Quantity>
                  <Subsidy>16.38</Subsidy>
                  <Price>16.38</Price>
                  <Alternate>16.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738562629">
                <Name>Apo-Temozolomide</Name>
                <Pack ID="P2572311" Specified="true" nzmt:ctpp_id="50201841000117101">
                  <Quantity>5</Quantity>
                  <Subsidy>18.30</Subsidy>
                  <Price>18.30</Price>
                  <Alternate>18.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107385627" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B25010738562726">
                <Name>Temaccord</Name>
                <Pack ID="P2388243" Specified="true" nzmt:ctpp_id="50127421000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>35.98</Subsidy>
                  <Price>35.98</Price>
                  <Alternate>35.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25010738562728">
                <Name>Apo-Temozolomide</Name>
                <Pack ID="P2572338" Specified="true" nzmt:ctpp_id="50201851000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>40.20</Subsidy>
                  <Price>40.20</Price>
                  <Alternate>40.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107385628" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B25010738562826">
                <Name>Temaccord</Name>
                <Pack ID="P2388235" Specified="true" nzmt:ctpp_id="50127441000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>86.34</Subsidy>
                  <Price>86.34</Price>
                  <Alternate>86.34</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107385629" Rank="2" Units="cap" Weight="140">
              <Name>Cap 140 mg</Name>
              <Brand ID="B25010738562926">
                <Name>Temaccord</Name>
                <Pack ID="P2566044" Specified="true" nzmt:ctpp_id="50182161000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>50.12</Subsidy>
                  <Price>50.12</Price>
                  <Alternate>50.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107385630" Rank="2" Units="cap" Weight="180">
              <Name>Cap 180 mg</Name>
              <Brand ID="B25010738563025" S29="true">
                <Name>Accord</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2579499" Specified="true" nzmt:ctpp_id="50271841000117108">
                  <Quantity>14</Quantity>
                  <Subsidy>620.00</Subsidy>
                  <Price>620.00</Price>
                  <Alternate>620.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073897">
            <Name>Amsacrine</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250107389725" Rank="4" Units="inj" Weight="75">
              <Name>Inj 75 mg</Name>
              <Brand ID="B25010738972526" S29="true">
                <Name>AmsaLyo</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2473542" Specified="true" nzmt:ctpp_id="50220341000117108">
                  <Quantity>5</Quantity>
                  <Subsidy>1250.00</Subsidy>
                  <Price>1250.00</Price>
                  <Alternate>1250.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107389726" Rank="4" Units="inj" Weight="75">
              <Name>Inj 50 mg per ml, 1.5 ml ampoule</Name>
              <Brand ID="B25010738972625" S29="true">
                <Name>Amsidine</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2318725" Specified="true">
                  <Quantity>6</Quantity>
                  <Subsidy>1500.00</Subsidy>
                  <Price>1500.00</Price>
                  <Alternate>1500.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2577437" Specified="true" nzmt:ctpp_id="50045751000117106">
                  <Quantity>6</Quantity>
                  <Subsidy>4736.00</Subsidy>
                  <Price>4736.00</Price>
                  <Alternate>4736.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501073936">
            <Name>Bortezomib</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1889"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1889">
              <Title>
                <range>Bortezomib</range>
              </Title>
              <Case When="Initial application" Category="multiple myeloma/amyloidosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has symptomatic multiple myeloma</ci>
                    <ci type="logical" class="Indication">The patient has symptomatic systemic AL amyloidosis *</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250107393625" Rank="4" Units="inj" Weight="3.5">
              <Name>Inj 3.5 mg vial</Name>
              <Brand ID="B25010739362529">
                <Name>DBL Bortezomib</Name>
                <Pack ID="P2647583" Specified="true" nzmt:ctpp_id="50249241000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>74.93</Subsidy>
                  <Price>74.93</Price>
                  <Alternate>74.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107393626" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25010739362626">
                <Name>Baxter</Name>
                <Pack ID="P2583976" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>22.26</Subsidy>
                  <Price>22.26</Price>
                  <Alternate>22.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501074005">
            <Name>Pegaspargase</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1979"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1979">
              <Title>
                <range>Pegaspargase</range>
              </Title>
              <Case When="Initial application" Category="Acute lymphoblastic leukaemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci>
                    <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment 	protocol</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Lymphoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient has lymphoma requiring L-asparaginase containing protocols (e.g. SMILE)</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Acute lymphoblastic leukaemia" Form="SA1325 SA1979">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci>
                    <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250107400526" Rank="4" Units="inj">
              <Name>Inj 750 iu per ml, 5 ml vial</Name>
              <Brand ID="B25010740052625" S29="true">
                <Name>Oncaspar LYO</Name>
                <Pack ID="P2578158" Specified="true" nzmt:ctpp_id="50271741000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>3455.00</Subsidy>
                  <Price>3455.00</Price>
                  <Alternate>3455.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501074035">
            <Name>Lenalidomide</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2047"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2047">
              <Title>
                <range>Lenalidomide</range>
              </Title>
              <Case When="Initial application" Category="Relapsed/refractory disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has relapsed or refractory multiple myeloma with progressive disease</ci>
                    <ci type="logical" class="Indication">Patient has not previously been treated with lenalidomide</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Lenalidomide to be used as third line* treatment for multiple myeloma</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Lenalidomide to be used as second line treatment for multiple myeloma</ci>
                        <ci type="logical" class="Indication">The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Maintenance following first-line autologous stem cell transplant (SCT)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation</ci>
                    <ci type="logical" class="Indication">Patient has at least a stable disease response in the first 100 days after transplantation</ci>
                    <ci type="logical" class="Indication">Lenalidomide maintenance is to be commenced within 6 months of transplantation</ci>
                    <ci type="logical" class="Indication">Lenalidomide to be administered at a maximum dose of 15 mg/day</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1468 SA1897 SA2047" Category="Relapsed/refractory disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and patient is benefitting from treatment</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1468 SA1897 SA2047" Category="Maintenance following first line autologous SCT">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and patient is benefitting from treatment</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.</p>
              </div>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250107403525" Rank="2" Units="cap" Weight="10">
              <Name>Cap 10 mg</Name>
              <Brand ID="B25010740352525">
                <Name>Revlimid</Name>
                <Pack ID="P2293390" Specified="true" nzmt:ctpp_id="50045051000117108">
                  <Quantity>21</Quantity>
                  <Subsidy>4655.25</Subsidy>
                  <Price>4655.25</Price>
                  <Alternate>4655.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2586312" Specified="true" nzmt:ctpp_id="50259661000117107">
                  <Quantity>28</Quantity>
                  <Subsidy>6207.00</Subsidy>
                  <Price>6207.00</Price>
                  <Alternate>6207.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107403526" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B25010740352625">
                <Name>Revlimid</Name>
                <Pack ID="P2331209" Specified="true" nzmt:ctpp_id="50126541000117101">
                  <Quantity>21</Quantity>
                  <Subsidy>7627.00</Subsidy>
                  <Price>7627.00</Price>
                  <Alternate>7627.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107403527" Rank="2" Units="cap" Weight="15">
              <Name>Cap 15 mg</Name>
              <Brand ID="B25010740352725">
                <Name>Revlimid</Name>
                <Pack ID="P2369478" Specified="true" nzmt:ctpp_id="50124471000117101">
                  <Quantity>21</Quantity>
                  <Subsidy>5429.39</Subsidy>
                  <Price>5429.39</Price>
                  <Alternate>5429.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2586320" Specified="true" nzmt:ctpp_id="50259671000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>7239.18</Subsidy>
                  <Price>7239.18</Price>
                  <Alternate>7239.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107403528" Rank="2" Units="cap" Weight="5">
              <Name>Cap 5 mg</Name>
              <Brand ID="B25010740352825">
                <Name>Revlimid</Name>
                <Pack ID="P2586339" Specified="true" nzmt:ctpp_id="50259651000117105">
                  <Quantity>28</Quantity>
                  <Subsidy>5122.76</Subsidy>
                  <Price>5122.76</Price>
                  <Alternate>5122.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501074120">
            <Name>Venetoclax</Name>
            <Rule Type="SpecEnd"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1868"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1868">
              <Title>
                <range>Venetoclax</range>
              </Title>
              <Case When="Initial application" Category="relapsed/refractory chronic lymphocytic leukaemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has chronic lymphocytic leukaemia requiring treatment</ci>
                    <ci type="logical" class="Indication">Patient has received at least one prior therapy for chronic lymphocytic leukaemia</ci>
                    <ci type="logical" class="Indication">Patient has not previously received funded venetoclax</ci>
                    <ci type="logical" class="Indication">The patientâ€™s disease has relapsed within 36 months of previous treatment</ci>
                    <ci type="logical" class="Indication">Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax</ci>
                    <ci type="logical" class="Indication">Patient has an ECOG performance status of 0-2</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">7</Term>
              </Case>
              <Case When="Renewal" Category="relapsed/refractory chronic lymphocytic leukaemia" Form="SA1868">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment</ci>
                    <ci type="logical" class="Indication">Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is
                    required due to disease progression or unacceptable toxicity</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has previously untreated chronic lymphocytic leukaemia</ci>
                    <ci type="logical" class="Indication">There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing</ci>
                    <ci type="logical" class="Indication">Patient has an ECOG performance status of 0-2</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*" Form="SA1868">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>â€˜Chronic lymphocytic leukaemia (CLL)â€™ includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.</p>
              </div>
            </Request>
            <Formulation ID="F250107412025" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B25010741202525">
                <Name>Venclexta</Name>
                <Pack ID="P2635054" Specified="true" OP="true" nzmt:ctpp_id="50285391000117102">
                  <Quantity>2</Quantity>
                  <Subsidy>13.68</Subsidy>
                  <Price>13.68</Price>
                  <Alternate>13.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107412026" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B25010741202625">
                <Name>Venclexta</Name>
                <Pack ID="P2555654" Specified="true" OP="true" nzmt:ctpp_id="50240861000117103">
                  <Quantity>7</Quantity>
                  <Subsidy>239.44</Subsidy>
                  <Price>239.44</Price>
                  <Alternate>239.44</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107412027" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Rule Type="Wastage"/>
              <Brand ID="B25010741202725">
                <Name>Venclexta</Name>
                <Pack ID="P2555662" Specified="true" nzmt:ctpp_id="50240901000117108">
                  <Quantity>120</Quantity>
                  <Subsidy>8209.41</Subsidy>
                  <Price>8209.41</Price>
                  <Alternate>8209.41</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107412028" Rank="1" Units="tab">
              <Name>Tab 14 x 10 mg, 7 x 50 mg, 21 x 100 mg</Name>
              <Brand ID="B25010741202825">
                <Name>Venclexta</Name>
                <Pack ID="P2555638" Specified="true" OP="true" nzmt:ctpp_id="50240911000117106">
                  <Quantity>42</Quantity>
                  <Subsidy>1771.86</Subsidy>
                  <Price>1771.86</Price>
                  <Alternate>1771.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501074123">
            <Name>Olaparib</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2163"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2163">
              <Title>
                <range>Olaparib</range>
              </Title>
              <Case When="Initial application" Category="Ovarian cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer</ci>
                    <ci type="logical" class="Indication">There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has newly diagnosed, advanced disease</ci>
                        <ci type="logical" class="Indication">Patient has received one line** of previous treatment with platinum-based chemotherapy</ci>
                        <ci type="logical" class="Indication">Patientâ€™s disease must have experienced a partial or complete response to the first-line platinum-based regimen</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has received at least two lines** of previous treatment with platinum-based chemotherapy</ci>
                        <ci type="logical" class="Indication">Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy</ci>
                        <ci type="logical" class="Indication">Patientâ€™s disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen</ci>
                        <ci type="logical" class="Indication">Patient has not previously received funded olaparib treatment</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Treatment will be commenced within 12 weeks of the patientâ€™s last dose of the immediately preceding platinum-based regimen</ci>
                    <ci type="logical" class="Indication">Treatment to be administered as maintenance treatment</ci>
                    <ci type="logical" class="Indication">Treatment not to be administered in combination with other chemotherapy</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Ovarian cancer" Form="SA1883 SA2148 SA2163">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Treatment remains clinically appropriate and patient is benefitting from treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">No evidence of progressive disease</ci>
                      <ci type="logical" class="Indication">Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinicianâ€™s opinion</ci>
                    </apply>
                    <ci type="logical" class="Indication">Treatment to be administered as maintenance treatment</ci>
                    <ci type="logical" class="Indication">Treatment not to be administered in combination with other chemotherapy</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has received one line** of previous treatment with platinum-based chemotherapy</ci>
                        <ci type="logical" class="Indication">Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years</ci>
                      </apply>
                      <ci type="logical" class="Indication">Patient has received at least two lines** of previous treatment with platinum-based chemotherapy</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>*Note â€œhigh-grade serousâ€ includes tumours with high-grade serous features or a high-grade serous component.</p>
                <p>**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.</p>
              </div>
            </Request>
            <Formulation ID="F250107412326" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B25010741232625">
                <Name>Lynparza</Name>
                <Pack ID="P2578441" Specified="true" nzmt:ctpp_id="50249561000117108">
                  <Quantity>56</Quantity>
                  <Subsidy>3701.00</Subsidy>
                  <Price>3701.00</Price>
                  <Alternate>3701.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107412327" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B25010741232725">
                <Name>Lynparza</Name>
                <Pack ID="P2578468" Specified="true" nzmt:ctpp_id="50249551000117106">
                  <Quantity>56</Quantity>
                  <Subsidy>3701.00</Subsidy>
                  <Price>3701.00</Price>
                  <Alternate>3701.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501074167">
            <Name>Ibrutinib</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2168"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2168">
              <Title>
                <range>Ibrutinib</range>
              </Title>
              <Case When="Initial application" Category="chronic lymphocytic leukaemia (CLL)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has chronic lymphocytic leukaemia
                    (CLL) requiring therapy</ci>
                    <ci type="logical" class="Indication">Patient has not previously received funded
                    ibrutinib</ci>
                    <ci type="logical" class="Indication">Ibrutinib is to be used as monotherapy</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">There is documentation confirming that patient has 17p
                            deletion or TP53 mutation</ci>
                        <ci type="logical">Patient has experienced intolerable side effects with
                            venetoclax monotherapy</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical">Patient has received at least one prior
                            immunochemotherapy for CLL</ci>
                        <ci type="logical">Patientâ€™s CLL has relapsed within 36 months of previous
                            treatment</ci>
                        <ci type="logical">Patient has experienced intolerable side effects with
                            venetoclax in combination with rituximab regimen</ci>
                      </apply>
                      <ci type="logical">Patientâ€™s CLL is refractory to or has relapsed within 36
                        months of a venetoclax regimen</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="chronic lymphocytic leukaemia (CLL)" Form="SA2168">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">No evidence of clinical disease progression</ci>
                    <ci type="logical">The treatment remains appropriate and the patient is benefitting
                    from treatment</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>â€˜Chronic lymphocytic leukaemia (CLL)â€™ includes small lymphocytic lymphoma (SLL) and
            B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved
            indications.</p>
              </div>
            </Request>
            <Formulation ID="F250107416725" Rank="1" Units="tab" Weight="140">
              <Name>Tab 140 mg</Name>
              <Brand ID="B25010741672525">
                <Name>Imbruvica</Name>
                <Pack ID="P2606402" Specified="true" nzmt:ctpp_id="50257041000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>3217.00</Subsidy>
                  <Price>3217.00</Price>
                  <Alternate>3217.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250107416726" Rank="1" Units="tab" Weight="420">
              <Name>Tab 420 mg</Name>
              <Brand ID="B25010741672625">
                <Name>Imbruvica</Name>
                <Pack ID="P2606410" Specified="true" nzmt:ctpp_id="50257061000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>9652.00</Subsidy>
                  <Price>9652.00</Price>
                  <Alternate>9652.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250109">
          <Name>Protein-tyrosine Kinase Inhibitors</Name>
          <Chemical ID="C2501093780">
            <Name>Imatinib mesilate</Name>
            <Formulation ID="F250109378025" Rank="2" Units="cap" Weight="100" Statim="Must">
              <Name>Cap 100 mg</Name>
              <Brand ID="B25010937802527" PSS="2026-06-30">
                <Name>Imatinib-Rex</Name>
                <Pack ID="P2594315" Specified="true" nzmt:ctpp_id="50245691000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>44.93</Subsidy>
                  <Price>44.93</Price>
                  <Alternate>44.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109378027" Rank="2" Units="cap" Weight="400" Statim="Must">
              <Name>Cap 400 mg</Name>
              <Brand ID="B25010937802726" PSS="2026-06-30">
                <Name>Imatinib-Rex</Name>
                <Pack ID="P2594323" Specified="true" nzmt:ctpp_id="50245701000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>69.76</Subsidy>
                  <Price>69.76</Price>
                  <Alternate>69.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501093894">
            <Name>Dasatinib</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1805"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1805">
              <Title>
                <range>Dasatinib</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase</ci>
                      <ci type="logical" class="Indication">Maximum dose of 140 mg/day</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL)</ci>
                      <ci type="logical" class="Indication">Maximum dose of 140 mg/day</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has a diagnosis of CML in chronic phase</ci>
                      <ci type="logical" class="Indication">Maximum dose of 100 mg/day</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has documented treatment failure* with imatinib</ci>
                        <ci type="logical" class="Indication">Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib</ci>
                        <ci type="logical" class="Indication">Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system</ci>
                        <ci type="logical" class="Indication">Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1805" Break="before">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Lack of treatment failure while on dasatinib*</ci>
                    <ci type="logical" class="Indication">Dasatinib treatment remains appropriate and the patient is benefiting from treatment</ci>
                    <ci type="logical" class="Indication">Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>*treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/</p>
                </div>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250109389425" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B25010938942525">
                <Name>Sprycel</Name>
                <Pack ID="P2258048" Specified="true" nzmt:ctpp_id="50040781000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>3774.06</Subsidy>
                  <Price>3774.06</Price>
                  <Alternate>3774.06</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109389426" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B25010938942625">
                <Name>Sprycel</Name>
                <Pack ID="P2258056" Specified="true" nzmt:ctpp_id="50040791000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>6214.20</Subsidy>
                  <Price>6214.20</Price>
                  <Alternate>6214.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109389427" Rank="1" Units="tab" Weight="70">
              <Name>Tab 70 mg</Name>
              <Brand ID="B25010938942725">
                <Name>Sprycel</Name>
                <Pack ID="P2258064" Specified="true" nzmt:ctpp_id="50040801000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>7692.58</Subsidy>
                  <Price>7692.58</Price>
                  <Alternate>7692.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501093916">
            <Name>Erlotinib</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2115"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2115">
              <Title>
                <range>Erlotinib</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci>
                    <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is treatment naive</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient has discontinued gefitinib due to intolerance</ci>
                        <ci type="logical" class="Indication">The cancer did not progress while on gefitinib</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Erlotinib is to be given for a maximum of 3 months</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Form="SA1044 SA1411 SA1519 SA1577 SA1641 SA1653 SA1915 SA2000 SA2115">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">radiological assessment (preferably including CT scan) indicates NSCLC has not progressed</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1044 SA1411 SA1519 SA1577 SA1641 SA1653 SA1915 SA2000 SA2115" Category="pandemic circumstances">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient is clinically benefiting from
                    treatment and continued treatment remains appropriate</ci>
                    <ci type="logical" class="Indication">Erlotinib to be discontinued at progression</ci>
                    <ci type="logical" class="Indication">The regular Special Authority renewal
                    requirements cannot be met due to COVID-19 constraints on the health sector</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250109391625" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B25010939162526">
                <Name>Alchemy</Name>
                <Pack ID="P2641569" Specified="true" nzmt:ctpp_id="50280501000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>329.70</Subsidy>
                  <Price>329.70</Price>
                  <Alternate>329.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109391626" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B25010939162626">
                <Name>Alchemy</Name>
                <Pack ID="P2641550" Specified="true" nzmt:ctpp_id="50280511000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>569.70</Subsidy>
                  <Price>569.70</Price>
                  <Alternate>569.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501093921">
            <Name>Sunitinib</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2117"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2117">
              <Title>
                <range>Sunitinib</range>
              </Title>
              <Case When="Initial application" Category="RCC">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has metastatic renal cell
                    carcinoma</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">The patient is treatment naive</ci>
                      <ci type="logical" class="Trial">The patient has only received prior cytokine
                        treatment</ci>
                      <ci type="logical" class="Trial">The patient has only received prior treatment
                        with an investigational agent within the confines of a bona fide clinical
                        trial which has Ethics Committee approval</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Trial">The patient has discontinued pazopanib
                            within 3 months of starting treatment due to intolerance</ci>
                        <ci type="logical" class="Trial">The cancer did not progress whilst on
                            pazopanib</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">The patient has good performance status
                    (WHO/ECOG grade 0-2)</ci>
                    <ci type="logical" class="Indication">The disease is of predominant clear cell
                    histology</ci>
                    <mi class="heading">The patient has intermediate or poor prognosis defined as:</mi>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Lactate dehydrogenase level &gt; 1.5 times upper
                        limit of normal</ci>
                      <ci type="logical" class="Use">Haemoglobin level &lt; lower limit of normal</ci>
                      <ci type="logical" class="Use">Corrected serum calcium level &gt; 10 mg/dL (2.5
                        mmol/L)</ci>
                      <ci type="logical" class="Use">Interval of &lt; 1 year from original diagnosis
                        to the start of systemic therapy</ci>
                      <ci type="logical" class="Use">Karnofsky performance score of less than or equal
                        to 70</ci>
                      <ci type="logical" class="Use">2 or more sites of organ metastasis</ci>
                    </apply>
                    <ci type="logical" class="Use">Sunitinib to be used for a maximum of 2 cycles</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="GIST">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has unresectable or metastatic
                    malignant gastrointestinal stromal tumour (GIST)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">The patient's disease has progressed following
                        treatment with imatinib</ci>
                      <ci type="logical" class="Trial">The patient has documented treatment-limiting
                        intolerance, or toxicity to, imatinib</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="RCC" Form="SA1055 SA1162 SA1200 SA1266 SA1917 SA2002 SA2117">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Trial">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the
                    patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Sunitinib treatment should be stopped if disease progresses.</p>
                  <p>Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6.
                Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6</p>
                </div>
              </Case>
              <Case When="Renewal" Category="GIST" Form="SA1055 SA1162 SA1200 SA1266 SA1917 SA2002 SA2117">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <mi class="heading">The patient has responded to treatment or has stable disease as
                    determined by Choi's modified CT response evaluation criteria as follows:</mi>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has had a complete response
                        (disappearance of all lesions and no new lesions)</ci>
                      <ci type="logical" class="Indication">The patient has had a partial response (a
                        decrease in size of 10% or more or decrease in tumour density in Hounsfield
                        Units (HU) of 15% or more on CT and no new lesions and no obvious
                        progression of non measurable disease)</ci>
                      <ci type="logical" class="Indication">The patient has stable disease (does not
                        meet criteria the two above) and does not have progressive disease and no
                        symptomatic deterioration attributed to tumour progression</ci>
                    </apply>
                    <ci type="logical" class="Trial">The treatment remains appropriate and the patient
                    is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>It is recommended that response to treatment be assessed using Choi's modified CT
                response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease
                is defined as either: an increase in tumour size of 10% or more and not meeting
                criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or
                new intratumoral nodules, or increase in the size of the existing intratumoral
                nodules.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="GIST pandemic circumstances" Form="SA1055 SA1162 SA1200 SA1266 SA1917 SA2002 SA2117">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has unresectable or metastatic malignant gastrointestinal stromal (GIST)</ci>
                    <ci type="logical" class="Indication">The patient is clinically benifiting from treatment and continued treatment remains appropriate</ci>
                    <ci type="logical" class="Indication">Sunitinib is to be discontinued at progression</ci>
                    <ci type="logical" class="Indication">The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250109392125" Rank="2" Units="cap">
              <Name>Cap 12.5 mg</Name>
              <Brand ID="B25010939212526" PSS="2024-06-30">
                <Name>Sunitinib Pfizer</Name>
                <Pack ID="P2630303" Specified="true" nzmt:ctpp_id="50282531000117101">
                  <Quantity>28</Quantity>
                  <Subsidy>208.38</Subsidy>
                  <Price>208.38</Price>
                  <Alternate>208.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109392126" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B25010939212626" PSS="2024-06-30">
                <Name>Sunitinib Pfizer</Name>
                <Pack ID="P2630311" Specified="true" nzmt:ctpp_id="50282541000117109">
                  <Quantity>28</Quantity>
                  <Subsidy>416.77</Subsidy>
                  <Price>416.77</Price>
                  <Alternate>416.77</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109392127" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B25010939212726" PSS="2024-06-30">
                <Name>Sunitinib Pfizer</Name>
                <Pack ID="P2630338" Specified="true" nzmt:ctpp_id="50282561000117108">
                  <Quantity>28</Quantity>
                  <Subsidy>694.62</Subsidy>
                  <Price>694.62</Price>
                  <Alternate>694.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501093943">
            <Name>Pazopanib</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1190"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1190">
              <Title>
                <range>Pazopanib</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient is treatment naive</ci>
                      <ci type="logical" class="Indication">The patient has only received prior cytokine treatment</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance</ci>
                        <ci type="logical" class="Indication">The cancer did not progress whilst on sunitinib</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">The patient has good performance status (WHO/ECOG grade 0-2)</ci>
                    <ci type="logical" class="Indication">The disease is of predominant clear cell histology</ci>
                    <mi class="heading">The patient has intermediate or poor prognosis defined as:</mi>
                    <apply>
                      <or style="The patient has intermediate or poor prognosis defined as "/>
                      <ci type="logical" class="Indication">Lactate dehydrogenase level &gt; 1.5 times upper limit of normal</ci>
                      <ci type="logical" class="Indication">Haemoglobin level &lt; lower limit of normal</ci>
                      <ci type="logical" class="Indication">Corrected serum calcium level &gt; 10 mg/dL (2.5 mmol/L)</ci>
                      <ci type="logical" class="Indication">Interval of &lt; 1 year from original diagnosis to the start of systemic therapy</ci>
                      <ci type="logical" class="Indication">Karnofsky performance score of less than or equal to 70</ci>
                      <ci type="logical" class="Indication">2 or more sites of organ metastasis</ci>
                    </apply>
                    <ci type="logical" class="Indication">Pazopanib to be used for a maximum of 3 months</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Form="SA1190">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of disease progression</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Pazopanib treatment should be stopped if disease progresses.</p>
                <p>Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.</p>
              </div>
            </Request>
            <Formulation ID="F250109394325" Rank="1" Units="tab" Weight="200">
              <Name>Tab 200 mg</Name>
              <Brand ID="B25010939432525">
                <Name>Votrient</Name>
                <Pack ID="P2386127" Specified="true" nzmt:ctpp_id="50123631000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>1334.70</Subsidy>
                  <Price>1334.70</Price>
                  <Alternate>1334.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109394326" Rank="1" Units="tab" Weight="400">
              <Name>Tab 400 mg</Name>
              <Brand ID="B25010939432625">
                <Name>Votrient</Name>
                <Pack ID="P2386135" Specified="true" nzmt:ctpp_id="50123641000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>2669.40</Subsidy>
                  <Price>2669.40</Price>
                  <Alternate>2669.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501093966">
            <Name>Gefitinib</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2116"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2116">
              <Title>
                <range>Gefitinib</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is treatment naive</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient has discontinued erlotinib due to intolerance</ci>
                        <ci type="logical" class="Indication">The cancer did not progress whilst on erlotinib</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase</ci>
                    <ci type="logical" class="Indication">Gefitinib is to be given for a maximum of 3 months</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Form="SA1226 SA1520 SA1578 SA1654 SA1916 SA2001 SA2116">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="pandemic circumstances" Form="SA1226 SA1520 SA1578 SA1654 SA1916 SA2001 SA2116">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient is clinically benefiting from
                    treatment and continued treatment remains appropriate</ci>
                    <ci type="logical" class="Indication">Gefitinib to be discontinued at progression</ci>
                    <ci type="logical" class="Indication">The regular Special Authority renewal
                    requirements cannot be met due to COVID-19 constraints on the health sector</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250109396625" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B25010939662525">
                <Name>Iressa</Name>
                <Pack ID="P2146541" Specified="true" nzmt:ctpp_id="50025241000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>918.00</Subsidy>
                  <Price>918.00</Price>
                  <Alternate>918.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501094038">
            <Name>Nilotinib</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2301"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2301">
              <Title>
                <range>Nilotinib</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic phase, or in chronic phase</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI)</ci>
                      <ci type="logical" class="Trial">Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) precluding further treatment</ci>
                    </apply>
                    <ci type="logical" class="Use">Maximum nilotinib dose of 800 mg/day</ci>
                    <ci type="logical" class="Use">Subsidised for use as monotherapy only</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note" style="start">
                  <p>*treatment failure as defined by Leukaemia Net Guidelines.</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1489 SA2301">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines</ci>
                    <ci type="logical" class="Use">Nilotinib treatment remains appropriate and the patient is benefiting from treatment</ci>
                    <ci type="logical" class="Use">Maximum nilotinib dose of 800 mg/day</ci>
                    <ci type="logical" class="Use">Subsidised for use as monotherapy only</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250109403825" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B25010940382525">
                <Name>Tasigna</Name>
                <Pack ID="P2468115" Specified="true" nzmt:ctpp_id="50214821000117106">
                  <Quantity>120</Quantity>
                  <Subsidy>4680.00</Subsidy>
                  <Price>4680.00</Price>
                  <Alternate>4680.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109403826" Rank="2" Units="cap" Weight="200">
              <Name>Cap 200 mg</Name>
              <Brand ID="B25010940382625">
                <Name>Tasigna</Name>
                <Pack ID="P2439360" Specified="true" nzmt:ctpp_id="50141131000117107">
                  <Quantity>120</Quantity>
                  <Subsidy>6532.00</Subsidy>
                  <Price>6532.00</Price>
                  <Alternate>6532.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501094106">
            <Name>Ruxolitinib</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1890"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1890">
              <Title>
                <range>Ruxolitinib</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has primary myelofibrosis or
                    post-polycythemia vera myelofibrosis or post-essential thrombocythemia
                    myelofibrosis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">A classification of risk of intermediate-2 or
                        high-risk myelofibrosis according to either the International Prognostic Scoring
                        System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the
                        Age-Adjusted DIPSS</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS</ci>
                        <ci type="logical" class="Indication">Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">A maximum dose of 20 mg twice daily is to
                    be given</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1753 SA1890">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the
                    patient is benefiting from treatment</ci>
                    <ci type="logical" class="Indication">A maximum dose of 20 mg twice daily is to be
                    given</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250109410625" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B25010941062525">
                <Name>Jakavi</Name>
                <Pack ID="P2554763" Specified="true" nzmt:ctpp_id="50219001000117105">
                  <Quantity>56</Quantity>
                  <Subsidy>2500.00</Subsidy>
                  <Price>2500.00</Price>
                  <Alternate>2500.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109410626" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B25010941062625">
                <Name>Jakavi</Name>
                <Pack ID="P2554771" Specified="true" nzmt:ctpp_id="50219071000117101">
                  <Quantity>56</Quantity>
                  <Subsidy>5000.00</Subsidy>
                  <Price>5000.00</Price>
                  <Alternate>5000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109410627" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B25010941062725">
                <Name>Jakavi</Name>
                <Pack ID="P2554798" Specified="true" nzmt:ctpp_id="50219141000117106">
                  <Quantity>56</Quantity>
                  <Subsidy>5000.00</Subsidy>
                  <Price>5000.00</Price>
                  <Alternate>5000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109410628" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10mg</Name>
              <Brand ID="B25010941062825">
                <Name>Jakavi</Name>
                <Pack ID="P2627817" Specified="true" nzmt:ctpp_id="50244541000117108">
                  <Quantity>56</Quantity>
                  <Subsidy>5000.00</Subsidy>
                  <Price>5000.00</Price>
                  <Alternate>5000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501094121">
            <Name>Alectinib</Name>
            <Rule Type="SpecEnd"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1870"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1870">
              <Title>
                <range>Alectinib</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer</ci>
                    <ci type="logical" class="Treatment">There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test</ci>
                    <ci type="logical" class="Treatment">Patient has an ECOG performance score of 0-2</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1870">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">No evidence of progressive disease according to RECIST criteria</ci>
                    <ci type="logical" class="Treatment">The patient is benefitting from and tolerating treatment</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250109412125" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B25010941212525">
                <Name>Alecensa</Name>
                <Pack ID="P2574152" Specified="true" nzmt:ctpp_id="50242371000117101">
                  <Quantity>224</Quantity>
                  <Subsidy>7935.00</Subsidy>
                  <Price>7935.00</Price>
                  <Alternate>7935.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2501094125">
            <Name>Palbociclib</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1894"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1894">
              <Title>
                <range>Palbociclib (Ibrance)</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has unresectable locally advanced or metastatic breast cancer</ci>
                    <ci type="logical">There is documentation confirming disease is hormone-receptor positive and HER2-negative</ci>
                    <ci type="logical">Patient has an ECOG performance score of 0-2</ci>
                    <apply>
                      <or/>
                      <mi class="heading">second or subsequent line setting</mi>
                      <ci type="logical">Disease has relapsed or progressed during prior endocrine therapy</ci>
                      <apply>
                        <and/>
                        <mi class="heading">first line setting</mi>
                        <ci type="logical">Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal state</ci>
                        <apply>
                          <or/>
                          <ci type="logical">Patient has not received prior systemic treatment for metastatic disease</ci>
                          <apply>
                            <and/>
                            <ci type="logical">Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020</ci>
                            <ci type="logical">Patient has not received prior systemic endocrine treatment for metastatic disease</ci>
                            <ci type="logical">There is no evidence of progressive disease</ci>
                          </apply>
                        </apply>
                      </apply>
                    </apply>
                    <ci type="logical">Treatment must be used in combination with an endocrine partner</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="Medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1894">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Treatment must be used in combination with an endocrine partner</ci>
                    <ci type="logical">No evidence of progressive disease</ci>
                    <ci type="logical">The treatment remains appropriate and the patient is benefitting from treatment</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="Medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250109412528" Rank="1" Units="tab" Weight="75">
              <Name>Tab 75 mg</Name>
              <Brand ID="B25010941252825">
                <Name>Ibrance</Name>
                <Pack ID="P2611635" Specified="true" nzmt:ctpp_id="50280071000117106">
                  <Quantity>21</Quantity>
                  <Subsidy>4000.00</Subsidy>
                  <Price>4000.00</Price>
                  <Alternate>4000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109412529" Rank="1" Units="tab" Weight="100">
              <Name>Tab 100 mg</Name>
              <Brand ID="B25010941252925">
                <Name>Ibrance</Name>
                <Pack ID="P2611643" Specified="true" nzmt:ctpp_id="50280081000117109">
                  <Quantity>21</Quantity>
                  <Subsidy>4000.00</Subsidy>
                  <Price>4000.00</Price>
                  <Alternate>4000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250109412530" Rank="1" Units="tab" Weight="125">
              <Name>Tab 125 mg</Name>
              <Brand ID="B25010941253025">
                <Name>Ibrance</Name>
                <Pack ID="P2611651" Specified="true" nzmt:ctpp_id="50280091000117107">
                  <Quantity>21</Quantity>
                  <Subsidy>4000.00</Subsidy>
                  <Price>4000.00</Price>
                  <Alternate>4000.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2504">
        <Name>Endocrine Therapy</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
          <p xlink:type="simple" xlink:href="A1416">For GnRH ANALOGUES â€“ refer to HORMONE PREPARATIONS, Trophic Hormones</p>
        </div>
        <ATC3 ID="A250401">
          <Name>Endocrine Therapy</Name>
          <Chemical ID="C2504011537">
            <Name>Flutamide</Name>
            <Formulation ID="F250401153701" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B25040115370103">
                <Name>Flutamin</Name>
                <Pack ID="P259985" Specified="true" nzmt:ctpp_id="50056921000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>119.50</Subsidy>
                  <Price>119.50</Price>
                  <Alternate>119.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040115370126" S29="true">
                <Name>Prostacur</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2612232" Specified="true" nzmt:ctpp_id="50287941000117100">
                  <Quantity>90</Quantity>
                  <Subsidy>107.55</Subsidy>
                  <Price>107.55</Price>
                  <Alternate>107.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504012218" Statim="Must">
            <Name>Tamoxifen citrate</Name>
            <Formulation ID="F250401221801" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B25040122180107" PSS="2026-06-30">
                <Name>Tamoxifen Sandoz</Name>
                <Pack ID="P2556944" Specified="true" nzmt:ctpp_id="50255141000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>15.00</Subsidy>
                  <Price>15.00</Price>
                  <Alternate>15.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250401221802" Rank="1" Units="tab" Weight="20">
              <Name>Tab 20 mg</Name>
              <Brand ID="B25040122180225" PSS="2026-06-30">
                <Name>Tamoxifen Sandoz</Name>
                <Pack ID="P2556952" Specified="true" nzmt:ctpp_id="50048541000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>5.32</Subsidy>
                  <Price>5.32</Price>
                  <Alternate>5.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504012511">
            <Name>Octreotide</Name>
            <Formulation ID="F250401251103" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mcg per ml, 1 ml ampoule</Name>
              <Brand ID="B25040125110327" S29="true">
                <Name>Octreotide GH</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2595893" Specified="true" nzmt:ctpp_id="50280421000117104">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>113.10</Subsidy>
                  <Price>113.10</Price>
                  <Alternate>113.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040125110328" PSS="2024-06-30">
                <Name>Max Health</Name>
                <Pack ID="P2629526" Specified="true" nzmt:ctpp_id="50275171000117105">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>113.10</Subsidy>
                  <Price>113.10</Price>
                  <Alternate>113.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040125110329" S29="true">
                <Name>Sun Pharma</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2669390" Specified="true" nzmt:ctpp_id="50275121000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>113.10</Subsidy>
                  <Price>113.10</Price>
                  <Alternate>113.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250401251129" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mcg per ml, 1 ml ampoule</Name>
              <Brand ID="B25040125112925" S29="true">
                <Name>Octreotide GH</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2595885" Specified="true" nzmt:ctpp_id="50279711000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>32.71</Subsidy>
                  <Price>32.71</Price>
                  <Alternate>32.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040125112926" PSS="2024-06-30">
                <Name>Max Health</Name>
                <Pack ID="P2629518" Specified="true" nzmt:ctpp_id="50275161000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>32.71</Subsidy>
                  <Price>32.71</Price>
                  <Alternate>32.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040125112927" S29="true">
                <Name>Sun Pharma</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2669382" Specified="true" nzmt:ctpp_id="50325481000117108">
                  <Quantity>5</Quantity>
                  <Subsidy>32.71</Subsidy>
                  <Price>32.71</Price>
                  <Alternate>32.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250401251130" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mcg per ml, 1 ml ampoule</Name>
              <Brand ID="B25040125113025" S29="true">
                <Name>Octreotide GH</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2595907" Specified="true" nzmt:ctpp_id="50280901000117101">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>27.58</Subsidy>
                  <Price>27.58</Price>
                  <Alternate>27.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040125113026" PSS="2024-06-30">
                <Name>Max Health</Name>
                <Pack ID="P2629534" Specified="true" nzmt:ctpp_id="50275151000117102">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>27.58</Subsidy>
                  <Price>27.58</Price>
                  <Alternate>27.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504012512">
            <Name>Octreotide long-acting</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2119"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2119">
              <Title>
                <range>Octreotide long-acting</range>
              </Title>
              <Case When="Initial application" Category="Malignant Bowel Obstruction">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has nausea* and vomiting* due to
                    malignant bowel obstruction*</ci>
                    <ci type="logical" class="Trial">Treatment with antiemetics, rehydration,
                    antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has
                    failed</ci>
                    <ci type="logical" class="Treatment">Octreotide to be given at a maximum dose 1500
                    mcg daily for up to 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">2</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Malignant Bowel Obstruction" Form="SA0099 SA0445 SA0563 SA1016 SA1918 SA2004 SA2072 SA2119">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient
                is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="Acromegaly">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has acromegaly</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">Treatment with surgery, radiotherapy and a
                        dopamine agonist has failed</ci>
                      <ci type="logical" class="Trial">Treatment with octreotide is for an interim
                        period while awaiting the effects of radiotherapy and a dopamine agonist has
                        failed</ci>
                      <ci type="logical" class="Indication">The patient is unwilling, or unable, to
                        undergo surgery and/or radiotherapy</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="Acromegaly" Form="SA0099 SA0445 SA0563 SA1016 SA1918 SA2004 SA2072 SA2119">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">IGF1 levels have decreased since starting
                    octreotide</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the
                    patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="year">2</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>In patients with Acromegaly octreotide treatment should be discontinued if IGF1
                levels have not decreased after 3 months treatment. In patients treated with
                radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month,
                for assessment of remission. Octreotide treatment should be stopped where there is
                biochemical evidence of remission (normal IGF1 levels) following octreotide
                treatment withdrawal for at least 4 weeks</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Acromegaly - pandemic circumstances" Form="SA0099 SA0445 SA0563 SA1016 SA1918 SA2004 SA2072 SA2119">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has acromegaly</ci>
                    <ci type="logical" class="Indication">The patient is clinically benefiting from treatment and continued treatment remains appropriate</ci>
                    <ci type="logical" class="Indication">The regular Special Authority renewal
                    requirements cannot be met due to COVID-19 constraints on the health sector</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Other Indications">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">VIPomas and Glucagonomas - for patients who
                    are seriously ill in order to improve their clinical state prior to definitive
                    surgery</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Gastrinoma</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Trial">Patient has failed surgery</ci>
                        <ci type="logical" class="Trial">Patient in metastatic disease after H2
                            antagonists (or proton pump inhibitors) have failed</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Insulinomas</ci>
                      <ci type="logical" class="Trial">Surgery is contraindicated or has failed</ci>
                    </apply>
                    <ci type="logical" class="Indication">For pre-operative control of hypoglycaemia and
                    for maintenance therapy</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Carcinoid syndrome (diagnosed by tissue
                        pathology and/or urinary 5HIAA analysis)</ci>
                      <ci type="logical" class="Trial">Disabling symptoms not controlled by maximal
                        medical therapy</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="year">2</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous
                diarrhoea and hypotension will not be funded as a Special Authority item</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Other Indications" Form="SA0099 SA0445 SA0563 SA1016 SA1918 SA2004 SA2072 SA2119">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient
                is benefiting from treatment</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="pre-operative acromegaly">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has acromegaly</ci>
                    <ci type="logical" class="Trial">Patient has a large pituitary tumour, greater than 10 mm at its widest</ci>
                    <ci type="logical" class="Treatment">Patient is scheduled to undergo pituitary surgery in the next six months</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250401251225" Rank="10" Units="vial" Weight="10">
              <Name>Inj depot 10 mg prefilled syringe</Name>
              <Brand ID="B25040125122525">
                <Name>Sandostatin LAR</Name>
                <Pack ID="P2150832" Specified="true" nzmt:ctpp_id="50026161000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>1152.00</Subsidy>
                  <Price>1152.00</Price>
                  <Alternate>1152.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040125122526" PSS="2024-06-30">
                <Name>Octreotide Depot Teva</Name>
                <Pack ID="P2615320" Specified="true" nzmt:ctpp_id="50265481000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>439.97</Subsidy>
                  <Price>439.97</Price>
                  <Alternate>439.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250401251226" Rank="10" Units="vial" Weight="20">
              <Name>Inj depot 20 mg prefilled syringe</Name>
              <Brand ID="B25040125122625">
                <Name>Sandostatin LAR</Name>
                <Pack ID="P2150840" Specified="true" nzmt:ctpp_id="50026171000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>1539.00</Subsidy>
                  <Price>1539.00</Price>
                  <Alternate>1539.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040125122626" PSS="2024-06-30">
                <Name>Octreotide Depot Teva</Name>
                <Pack ID="P2615339" Specified="true" nzmt:ctpp_id="50265491000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>647.03</Subsidy>
                  <Price>647.03</Price>
                  <Alternate>647.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250401251227" Rank="10" Units="vial" Weight="30">
              <Name>Inj depot 30 mg prefilled syringe</Name>
              <Brand ID="B25040125122726" PSS="2024-06-30">
                <Name>Octreotide Depot Teva</Name>
                <Pack ID="P2615347" Specified="true" nzmt:ctpp_id="50265501000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>718.55</Subsidy>
                  <Price>718.55</Price>
                  <Alternate>718.55</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504013883">
            <Name>Bicalutamide</Name>
            <Formulation ID="F250401388325" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B25040138832527" PSS="2026-06-30">
                <Name>Binarex</Name>
                <Pack ID="P2523655" Specified="true" nzmt:ctpp_id="50198471000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>4.18</Subsidy>
                  <Price>4.18</Price>
                  <Alternate>4.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B25040138832529" S29="true">
                <Name>Apo-Bicalutamide</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2672111" Specified="true" nzmt:ctpp_id="50328761000117101">
                  <Quantity>28</Quantity>
                  <Subsidy>4.18</Subsidy>
                  <Price>4.18</Price>
                  <Alternate>4.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504014048">
            <Name>Abiraterone acetate</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2118"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2118">
              <Title>
                <range>Abiraterone acetate</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has prostate cancer</ci>
                    <ci type="logical" class="Treatment">Patient has metastases</ci>
                    <ci type="logical" class="Indication">Patient's disease is castration resistant</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient is symptomatic</ci>
                        <ci type="logical" class="Treatment">Patient has disease progression (rising serum PSA) after second line anti-androgen therapy</ci>
                        <ci type="logical" class="Indication">Patient has ECOG performance score of 0-1</ci>
                        <ci type="logical" class="Treatment">Patient has not had prior treatment with taxane chemotherapy</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Treatment">Patient's disease has progressed following prior chemotherapy containing a taxane</ci>
                        <ci type="logical" class="Treatment">Patient has ECOG performance score of 0-2</ci>
                        <ci type="logical" class="Treatment">Patient has not had prior treatment with abiraterone</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant>radiation oncologist</Applicant>
                <Applicant>urologist</Applicant>
                <Applicant Referring="medical oncologist, radiation oncologist or urologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="abiraterone acetate" Form="SA1515 SA1767 SA1914 SA2003 SA2118">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Significant decrease in serum PSA from baseline</ci>
                    <ci type="logical" class="Indication">No evidence of clinical disease progression</ci>
                    <ci type="logical" class="Indication">No initiation of taxane chemotherapy with abiraterone</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant>radiation oncologist</Applicant>
                <Applicant>urologist</Applicant>
                <Applicant Referring="medical oncologist, radiation oncologist or urologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="pandemic circumstances" Form="SA1515 SA1767 SA1914 SA2003 SA2118">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient is clinically benefiting from treatment and continued treatment remains appropriate</ci>
                    <ci type="logical" class="Indication">Abiraterone acetate to be discontinued at progression</ci>
                    <ci type="logical" class="Indication">No initiation of taxane chemotherapy with abiraterone</ci>
                    <ci type="logical" class="Indication">The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250401404825" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B25040140482525">
                <Name>Zytiga</Name>
                <Pack ID="P2453517" Specified="true" nzmt:ctpp_id="50143741000117101">
                  <Quantity>120</Quantity>
                  <Subsidy>4276.19</Subsidy>
                  <Price>4276.19</Price>
                  <Alternate>4276.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504014126">
            <Name>Fulvestrant</Name>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1895"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1895">
              <Title>
                <range>Fulvestrant</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer</ci>
                    <ci type="logical" class="Treatment">Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease</ci>
                    <ci type="logical" class="Treatment">Treatment to be given at a dose of 500 mg monthly following loading doses</ci>
                    <ci type="logical" class="Treatment">Treatment to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1895">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Treatment remains appropriate and patient is benefitting from treatment</ci>
                    <ci type="logical" class="Treatment">Treatment to be given at a dose of 500 mg monthly</ci>
                    <ci type="logical" class="Treatment">There is no evidence of disease progression</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250401412625" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg per ml, 5 ml prefilled syringe</Name>
              <Brand ID="B25040141262525">
                <Name>Faslodex</Name>
                <Pack ID="P2586371" Specified="true" nzmt:ctpp_id="50260581000117104">
                  <Quantity>2</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1068.00</Subsidy>
                  <Price>1068.00</Price>
                  <Alternate>1068.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250404">
          <Name>Aromatase Inhibitors</Name>
          <Chemical ID="C2504041158" Statim="Must">
            <Name>Anastrozole</Name>
            <Formulation ID="F250404115801" Rank="1" Units="tab" Weight="1">
              <Name>Tab 1 mg</Name>
              <Brand ID="B25040411580128" PSS="2026-06-30">
                <Name>Anatrole</Name>
                <Pack ID="P2520079" Specified="true" nzmt:ctpp_id="50281611000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>4.39</Subsidy>
                  <Price>4.39</Price>
                  <Alternate>4.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504041181" Statim="Must">
            <Name>Letrozole</Name>
            <Formulation ID="F250404118101" Rank="1" Units="tab" Weight="2.5">
              <Name>Tab 2.5 mg</Name>
              <Brand ID="B25040411810127" PSS="2024-06-30">
                <Name>Letrole</Name>
                <Pack ID="P2474425">
                  <Quantity>30</Quantity>
                  <Subsidy>5.84</Subsidy>
                  <Price>5.84</Price>
                  <Alternate>5.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2656655" Specified="true" nzmt:ctpp_id="50227451000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>5.84</Subsidy>
                  <Price>5.84</Price>
                  <Alternate>5.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2504043872" Statim="Must">
            <Name>Exemestane</Name>
            <Formulation ID="F250404387225" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B25040438722526" SoleSupply="2026-06-30">
                <Name>Pfizer Exemestane</Name>
                <Pack ID="P2500647" Specified="true" nzmt:ctpp_id="50228741000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>9.86</Subsidy>
                  <Price>9.86</Price>
                  <Alternate>9.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2507">
        <Name>Immunosuppressants</Name>
        <ATC3 ID="A250701">
          <Name>Cytotoxic Immunosuppressants</Name>
          <Chemical ID="C2507011034">
            <Name>Mycophenolate mofetil</Name>
            <Formulation ID="F250701103401" Rank="2" Units="cap" Weight="250">
              <Name>Cap 250 mg</Name>
              <Brand ID="B25070110340101">
                <Name>Cellcept</Name>
                <Pack ID="P350516" Specified="true" nzmt:ctpp_id="50076851000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>35.90</Subsidy>
                  <Price>35.90</Price>
                  <Alternate>35.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250701103426" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B25070110342625">
                <Name>Cellcept</Name>
                <Pack ID="P2093774" Specified="true" nzmt:ctpp_id="50017601000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>35.90</Subsidy>
                  <Price>35.90</Price>
                  <Alternate>35.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250701103427" Rank="3" Units="ml">
              <Name>Powder for oral liq 1 g per 5 ml</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.</p>
              </div>
              <Brand ID="B25070110342725">
                <Name>Cellcept</Name>
                <Pack ID="P2124912" Specified="true" OP="true" nzmt:ctpp_id="50022571000117100">
                  <Quantity>165</Quantity>
                  <Subsidy>187.25</Subsidy>
                  <Price>187.25</Price>
                  <Alternate>187.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507011100" Statim="Must">
            <Name>Azathioprine</Name>
            <Formulation ID="F250701110001" Rank="1" Units="tab" Weight="50">
              <Name>Tab 50 mg</Name>
              <Brand ID="B25070111000102" PSS="2025-06-30">
                <Name>Azamun</Name>
                <Pack ID="P390003" Specified="true" nzmt:ctpp_id="50080791000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>8.10</Subsidy>
                  <Price>8.10</Price>
                  <Alternate>8.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250701110025" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B25070111002525" PSS="2025-06-30">
                <Name>Azamun</Name>
                <Pack ID="P2465345" Specified="true" nzmt:ctpp_id="50208701000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>7.36</Subsidy>
                  <Price>7.36</Price>
                  <Alternate>7.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250702">
          <Name>Fusion Proteins</Name>
          <Chemical ID="C2507023786">
            <Name>Etanercept</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2103"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2103">
              <Title>
                <range>Etanercept</range>
              </Title>
              <Case When="Initial application" Category="adult-onset Still's disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has had an initial Special
                            Authority approval for adalimumab for adult-onset Still's disease
                            (AOSD)</ci>
                        <ci type="logical" class="Indication">The patient has been started on
                            tocilizumab for AOSD in a Te Whatu Ora Hospital</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab and/or tocilizumab</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient
                            benefit from at least a three-month trial of adalimumab and/or
                            tocilizumab such that they do not meet the renewal criteria for
                            AOSD</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient diagnosed with AOSD according to
                        the Yamaguchi criteria (J Rheumatol 1992;19:424-430)</ci>
                      <ci type="logical" class="Indication">Patient has tried and not responded to at
                        least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg,
                        non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate</ci>
                      <ci type="logical" class="Indication">Patient has persistent symptoms of
                        disabling poorly controlled and active disease</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="adult-onset Still's disease" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a rheumatologist</ci>
                      <ci type="logical" class="Indication">Applicant is a Practitioner and confirms
                        that a rheumatologist has provided a letter, email or fax recommending that
                        the patient continues with etanercept treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">The patient has a sustained improvement in
                    inflammatory markers and functional status</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="ankylosing spondylitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab for ankylosing spondylitis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient
                            benefit from adalimumab to meet the renewal criteria for adalimumab for
                            ankylosing spondylitis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has a confirmed diagnosis of
                        ankylosing spondylitis present for more than six months</ci>
                      <ci type="logical" class="Indication">Patient has low back pain and stiffness
                        that is relieved by exercise but not by rest</ci>
                      <ci type="logical" class="Indication">Patient has bilateral sacroiliitis
                        demonstrated by plain radiographs, CT or MRI scan</ci>
                      <ci type="logical" class="Trial">Patient's ankylosing spondylitis has not
                        responded adequately to treatment with two or more non-steroidal
                        anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if
                        indicated, while patient was undergoing at least 3 months of a regular
                        exercise regimen for ankylosing spondylitis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has limitation of motion of
                            the lumbar spine in the sagittal and the frontal planes as determined by
                            the following Bath Ankylosing Spondylitis Metrology Index (BASMI)
                            measures: a modified Schober's test of less than or equal to 4 cm and
                            lumbar side flexion measurement of less than or equal to 10 cm (mean of
                            left and right)</ci>
                        <ci type="logical" class="Indication">Patient has limitation of chest
                            expansion by at least 2.5 cm below the average normal values corrected
                            for age and gender (see Notes)</ci>
                      </apply>
                      <ci type="logical" class="Indication">A Bath Ankylosing Spondylitis Disease
                        Activity Index (BASDAI) of at least 6 on a 0-10 scale</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>The BASDAI must have been determined at the completion of the 3 month exercise trial,
                but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1
                month old at the time of initial application.</p>
                  <p>Average normal chest expansion corrected for age and gender:</p>
                  <p>18-24 years - Male: 7.0 cm; Female: 5.5 cm</p>
                  <p>25-34 years - Male: 7.5 cm; Female: 5.5 cm</p>
                  <p>35-44 years - Male: 6.5 cm; Female: 4.5 cm</p>
                  <p>45-54 years - Male: 6.0 cm; Female: 5.0 cm</p>
                  <p>55-64 years - Male: 5.5 cm; Female: 4.0 cm</p>
                  <p>65-74 years - Male: 4.0 cm; Female: 4.0 cm</p>
                  <p>75+ years - Male: 3.0 cm; Female: 2.5 cm</p>
                </div>
              </Case>
              <Case When="Renewal" Category="ankylosing spondylitis" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a rheumatologist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a Practitioner and confirms
                        that a rheumatologist has provided a letter, email or fax recommending that
                        the patient continues with etanercept treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">Following 12 weeksâ€™ initial treatment and for
                    subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or
                    more points from pre-treatment baseline on a 10 point scale, or an improvement
                    in BASDAI of 50%, whichever is less</ci>
                    <ci type="logical" class="Indication">Physician considers that the patient has
                    benefited from treatment and that continued treatment is appropriate</ci>
                    <ci type="logical" class="Endorsement">Etanercept to be administered at doses no
                    greater than 50 mg every 7 days</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="polyarticular course juvenile idiopathic arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab for polyarticular course juvenile
                        idiopathic arthritis (JIA)</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient
                            benefit from adalimumab to meet the renewal criteria for adalimumab for
                            polyarticular course JIA</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">To be used as an adjunct to methotrexate
                        therapy or monotherapy where use of methotrexate is limited by toxicity or
                        intolerance</ci>
                      <ci type="logical" class="Indication">Patient has had polyarticular course JIA
                        for 6 months duration or longer</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">At least 5 active joints and at least
                            3 joints with limited range of motion, pain or tenderness after a
                            3-month trial of methotrexate (at the maximum tolerated dose)</ci>
                        <ci type="logical" class="Indication">Moderate or high disease activity
                            (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate
                            (at the maximum tolerated dose)</ci>
                        <ci type="logical" class="Indication">Low disease activity (cJADAS10 score
                            between 1.1 and 2.5) after a 6-month trial of methotrexate</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="polyarticular course juvenile idiopathic arthritis" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Subsidised as an adjunct to methotrexate
                    therapy or monotherapy where use of methotrexate is limited by toxicity or
                    intolerance</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 months' initial
                        treatment, the patient has at least a 50% decrease in active joint count and
                        an improvement in physician's global assessment from baseline</ci>
                      <ci type="logical" class="Indication">On subsequent reapplications, the patient
                        demonstrates at least a continuing 30% improvement in active joint count and
                        continued improvement in physician's global assessment from baseline</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="oligoarticular course juvenile idiopathic arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab for oligoarticular course juvenile
                        idiopathic arthritis (JIA)</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient
                            benefit from adalimumab to meet the renewal criteria for adalimumab for
                            oligoarticular course JIA</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">To be used as an adjunct to methotrexate
                        therapy or monotherapy where use of methotrexate is limited by toxicity or
                        intolerance</ci>
                      <ci type="logical" class="Indication">Patient has had oligoarticular course JIA
                        for 6 months duration or longer</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">At least 2 active joints with limited
                            range of motion, pain or tenderness after a 3-month trial of
                            methotrexate (at the maximum tolerated dose)</ci>
                        <ci type="logical" class="Indication">Moderate or high disease activity
                            (cJADAS10 score greater than 1.5) with poor prognostic features after a
                            3-month trial of methotrexate (at the maximum tolerated dose)</ci>
                        <ci type="logical" class="Indication">High disease activity (cJADAS10 score
                            greater than 4) after a 6-month trial of methotrexate</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="oligoarticular course juvenile idiopathic arthritis" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Subsidised as an adjunct to methotrexate
                    therapy or monotherapy where use of methotrexate is limited by toxicity or
                    intolerance</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 months' initial
                        treatment, the patient has at least a 50% decrease in active joint count and
                        an improvement in physician's global assessment from baseline</ci>
                      <ci type="logical" class="Indication">On subsequent reapplications, the patient
                        demonstrates at least a continuing 30% improvement in active joint count and
                        continued improvement in physician's global assessment from baseline</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="psoriatic arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab or secukinumab for psoriatic
                        arthritis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab or secukinumab</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient
                            benefit from adalimumab or secukinumab to meet the renewal criteria for
                            adalimumab or secukinumab for psoriatic arthritis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has had severe active psoriatic
                        arthritis for six months duration or longer</ci>
                      <ci type="logical" class="Trial">Patient has tried and not responded to at least
                        three months of oral or parenteral methotrexate at a dose of at least 20 mg
                        weekly or a maximum tolerated dose</ci>
                      <ci type="logical" class="Trial">Patient has tried and not responded to at least
                        three months of sulfasalazine at a dose of at least 2 g per day or
                        leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses)</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has persistent symptoms of
                            poorly controlled and active disease in at least 15 swollen, tender
                            joints</ci>
                        <ci type="logical" class="Indication">Patient has persistent symptoms of
                            poorly controlled and active disease in at least four joints from the
                            following: wrist, elbow, knee, ankle, and either shoulder or hip</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has a C-reactive protein level
                            greater than 15 mg/L measured no more than one month prior to the date
                            of this application</ci>
                        <ci type="logical" class="Indication">Patient has an elevated erythrocyte
                            sedimentation rate (ESR) greater than 25 mm per hour</ci>
                        <ci type="logical" class="Indication">ESR and CRP not measured as patient is
                            currently receiving prednisone therapy at a dose of greater than 5 mg
                            per day and has done so for more than three months</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="psoriatic arthritis" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a rheumatologist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a Practitioner and confirms
                        that a rheumatologist has provided a letter, email or fax recommending that
                        the patient continues with etanercept treatment</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 months' initial
                        treatment, the patient has at least a 50% decrease in active joint count
                        from baseline and a clinically significant response to treatment in the
                        opinion of the physician</ci>
                      <ci type="logical" class="Indication">The patient demonstrates at least a
                        continuing 30% improvement in active joint count from baseline and a
                        clinically significant response to prior etanercept treatment in the opinion
                        of the treating physician</ci>
                    </apply>
                    <ci type="logical" class="Endorsement">Etanercept to be administered at doses no
                    greater than 50 mg every 7 days</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="pyoderma gangrenosum">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has pyoderma gangrenosum*</ci>
                    <ci type="logical" class="Indication">Patient has received three months of
                    conventional therapy including a minimum of three pharmaceuticals (e.g.
                    prednisone, ciclosporine, azathioprine, or methotrexate) and not received an
                    adequate response</ci>
                    <ci type="logical" class="Indication">A maximum of 8 doses</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">4</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="pyoderma gangrenosum" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has shown clinical improvement</ci>
                    <ci type="logical" class="Indication">Patient continues to require treatment</ci>
                    <ci type="logical" class="Treatment">A maximum of 8 doses</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis - rheumatoid ">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab for rheumatoid arthritis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient
                            benefit to meet the renewal criteria for rheumatoid arthritis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has had rheumatoid arthritis
                        (either confirmed by radiology imaging, or the patient is cyclic
                        citrullinated peptide (CCP) antibody positive) for six months duration or
                        longer</ci>
                      <ci type="logical" class="Treatment">Treatment is to be used as an adjunct to
                        methotrexate therapy or monotherapy where use of methotrexate is limited by
                        toxicity or intolerance</ci>
                      <ci type="logical" class="Trial">Patient has tried and not responded to at least
                        three months of methotrexate at a maximum tolerated dose (unless
                        contraindicated)</ci>
                      <ci type="logical" class="Trial">Patient has tried and not responded to at least
                        three months of methotrexate in combination with sulfasalazine and
                        hydroxychloroquine sulphate (at maximum tolerated doses unless
                        contraindicated)</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Trial">Patient has tried and not responded to at
                            least three months of methotrexate in combination
                            with the maximum tolerated dose of ciclosporin</ci>
                        <ci type="logical" class="Trial">Patient has tried and not responded to at
                            least three months of therapy at the maximum tolerated dose of
                            leflunomide alone or in combination with methotrexate</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has persistent symptoms of
                            poorly controlled and active disease in at least 15 swollen joints</ci>
                        <ci type="logical" class="Indication">Patient has persistent symptoms of
                            poorly controlled and active disease in at least four joints from the
                            following: wrist, elbow, knee, ankle, and either shoulder or hip</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis - rheumatoid" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Treatment">Treatment is to be used as an adjunct to
                    methotrexate therapy or monotherapy where use of methotrexate is limited by
                    toxicity or intolerance</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">Following initial treatment, the
                        patient has at least a 50% decrease in active joint count from baseline and
                        a clinically significant response to treatment in the opinion of the
                        physician</ci>
                      <ci type="logical" class="Trial">On subsequent reapplications, the patient
                        demonstrates at least a continuing 30% improvement in active joint count
                        from baseline and a clinically significant response to treatment in the
                        opinion of the physician</ci>
                    </apply>
                    <ci type="logical" class="Endorsement">Etanercept to be administered at doses no
                    greater than 50 mg every 7 days</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="severe chronic plaque psoriasis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab for severe chronic plaque psoriasis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient
                            benefit from adalimumab to meet the renewal criteria for adalimumab for
                            severe chronic plaque psoriasis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has "whole body" severe
                            chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI)
                            score of greater than 10, where lesions have been present for at least 6
                            months from the time of initial diagnosis</ci>
                        <ci type="logical" class="Trial">Patient has severe chronic plaque psoriasis
                            of the face, or palm of a hand or sole of a foot, where the plaque or
                            plaques have been present for at least 6 months from the time of initial
                            diagnosis</ci>
                      </apply>
                      <ci type="logical" class="Trial">Patient has tried, but had an inadequate
                        response (see Note) to, or has experienced intolerable side effects from, at
                        least three of the following (at maximum tolerated doses unless
                        contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin</ci>
                      <ci type="logical" class="Test">A PASI assessment or Dermatology Quality of Life
                        Index (DLQI) assessment has been completed for at least the most recent
                        prior treatment course (but preferably all prior treatment courses),
                        preferably while still on treatment but no longer than 1 month following
                        cessation of each prior treatment course</ci>
                      <ci type="logical" class="Test">The most recent PASI or DLQI assessment is no
                        more than 1 month old at the time of application</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">4</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>"Inadequate response" is defined as: for whole body severe chronic plaque psoriasis,
                a PASI score of greater than 10, as assessed preferably while still on treatment but
                no longer than 1 month following cessation of the most recent prior treatment; for
                severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI
                symptom subscores for erythema, thickness and scaling are rated as severe or very
                severe, and the skin area affected is 30% or more of the face, palm of a hand or
                sole of a foot, as assessed preferably while still on treatment but no longer than 1
                month following cessation of the most recent prior treatment.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="severe chronic plaque psoriasis" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Endorsement">Applicant is a dermatologist</ci>
                      <ci type="logical" class="Endorsement">Applicant is a Practitioner and confirms
                        that a dermatologist has provided a letter, email or fax recommending that
                        the patient continues with etanercept treatment</ci>
                    </apply>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient had "whole body" severe
                            chronic plaque psoriasis at the start of treatment</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">Following each prior etanercept
                                treatment course the patient has a PASI score which is reduced by
                                75% or more, or is sustained at this level, when compared with the
                                pre-treatment baseline value</ci>
                          <ci type="logical" class="Indication">Following each prior etanercept
                                treatment course the patient has a Dermatology Quality of Life Index
                                (DLQI) improvement of 5 or more, when compared with the
                                pre-treatment baseline value</ci>
                        </apply>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient had severe chronic plaque
                            psoriasis of the face, or palm of a hand or sole of a foot at the start
                            of treatment</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">Following each prior etanercept
                                treatment course the patient has a reduction in the PASI symptom
                                subscores for all 3 of erythema, thickness and scaling, to slight or
                                better, or sustained at this level, as compared to the treatment
                                course baseline values</ci>
                          <ci type="logical" class="Indication">Following each prior etanercept
                                treatment course the patient has a reduction of 75% or more in the
                                skin area affected, or sustained at this level, as compared to the
                                pre-treatment baseline value</ci>
                        </apply>
                      </apply>
                    </apply>
                    <ci type="logical" class="Endorsement">Etanercept to be administered at doses no
                    greater than 50 mg every 7 days</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>A treatment course is defined as a minimum of 12 weeks of etanercept treatment</p>
                </div>
              </Case>
              <Case When="Initial application" Category="undifferentiated spondyloarthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has undifferentiated peripheral
                    spondyloarthritis* with active peripheral joint arthritis in at least four
                    joints from the following: wrist, elbow, knee, ankle, and either shoulder or
                    hip</ci>
                    <ci type="logical" class="Indication">Patient has tried and not responded to at
                    least three months of oral or parenteral methotrexate at a dose of at least 20
                    mg weekly or a maximum tolerated dose</ci>
                    <ci type="logical" class="Indication">Patient has tried and not responded to at
                    least three months of sulfasalazine at a dose of at least 2 g per day (or
                    maximum tolerated dose)</ci>
                    <ci type="logical" class="Indication">Patient has tried and not responded to at
                    least three months of leflunomide at a dose of up to 20 mg daily (or maximum
                    tolerated dose)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a C-reactive protein level
                        greater than 15 mg/L measured no more than one month prior to the date of
                        this application</ci>
                      <ci type="logical" class="Indication">Patient has an elevated erythrocyte
                        sedimentation rate (ESR) greater than 25 mm per hour measured no more than
                        one month prior to the date of this application</ci>
                      <ci type="logical" class="Indication">ESR and CRP not measured as patient is
                        currently receiving prednisone therapy at a dose of greater than 5 mg per
                        day and has done so for more than three months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="undifferentiated spondyloarthritis" Form="SA0667 SA0868 SA1060 SA1157 SA1372 SA1450 SA1478 SA1620 SA1812 SA1891 SA1949 SA1974 SA2048 SA2103">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a rheumatologist</ci>
                      <ci type="logical" class="Indication">Applicant is a Practitioner and confirms
                        that a rheumatologist has provided a letter, email or fax recommending that
                        the patient continues with etanercept treatment</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 monthsâ€™ initial
                        treatment, the patient has at least a 50% decrease in active joint count
                        from baseline and a clinically significant response to treatment in the
                        opinion of the physician</ci>
                      <ci type="logical" class="Indication">The patient demonstrates at least a
                        continuing 30% improvement in active joint count from baseline and a
                        clinically significant response to prior etanercept treatment in the opinion
                        of the treating physician</ci>
                    </apply>
                    <ci type="logical" class="Indication">Etanercept to be administered at doses no
                    greater than 50 mg dose every 7 days</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250702378625" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg</Name>
              <Brand ID="B25070237862525" SoleSupply="2024-06-30">
                <Name>Enbrel</Name>
                <Pack ID="P2006561" Specified="true" nzmt:ctpp_id="50000651000117101">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>690.00</Subsidy>
                  <Price>690.00</Price>
                  <Alternate>690.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250702378626" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg autoinjector</Name>
              <Brand ID="B25070237862625" SoleSupply="2024-06-30">
                <Name>Enbrel</Name>
                <Pack ID="P2510456" Specified="true" nzmt:ctpp_id="50120621000117108">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1050.00</Subsidy>
                  <Price>1050.00</Price>
                  <Alternate>1050.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250702378627" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg prefilled syringe</Name>
              <Brand ID="B25070237862725" SoleSupply="2024-06-30">
                <Name>Enbrel</Name>
                <Pack ID="P2382113" Specified="true" nzmt:ctpp_id="50122421000117106">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1050.00</Subsidy>
                  <Price>1050.00</Price>
                  <Alternate>1050.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250702378628" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg autoinjector</Name>
              <Brand ID="B25070237862825" SoleSupply="2024-06-30">
                <Name>Enbrel</Name>
                <Pack ID="P2602113" Specified="true" nzmt:ctpp_id="50305921000117105">
                  <Quantity>4</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>690.00</Subsidy>
                  <Price>690.00</Price>
                  <Alternate>690.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250703">
          <Name>Immune Modulators</Name>
          <Chemical ID="C2507033841">
            <Name>Antithymocyte globulin (equine)</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250703384125" Rank="4" Units="inj" Weight="250">
              <Name>Inj 50 mg per ml, 5 ml</Name>
              <Brand ID="B25070338412525">
                <Name>ATGAM</Name>
                <Pack ID="P765651" Specified="true" nzmt:ctpp_id="50110581000117101">
                  <Quantity>5</Quantity>
                  <Subsidy>2774.48</Subsidy>
                  <Price>2774.48</Price>
                  <Alternate>2774.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507033922">
            <Name>Bacillus Calmette-Guerin (BCG) vaccine</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Subsidised only for bladder cancer.</p>
            </div>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Formulation ID="F250703392225" Rank="4" Units="inj">
              <Name>Inj 2-8 x 100 million CFU</Name>
              <Brand ID="B25070339222525">
                <Name>OncoTICE</Name>
                <Pack ID="P799629" Specified="true" nzmt:ctpp_id="50117311000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>149.37</Subsidy>
                  <Price>149.37</Price>
                  <Alternate>149.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250703392226" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per ml, vial</Name>
              <Brand ID="B25070339222625" S29="true">
                <Name>SII-Onco-BCG</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2474239" Specified="true" nzmt:ctpp_id="50220721000117104">
                  <Quantity>3</Quantity>
                  <Subsidy>176.90</Subsidy>
                  <Price>176.90</Price>
                  <Alternate>176.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250704">
          <Name>Monoclonal Antibodies</Name>
          <Chemical ID="C2507043817">
            <Name>Rituximab (Mabthera)</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1976"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1976">
              <Title>
                <range>Rituximab<instance>Mabthera</instance></range>
              </Title>
              <Case When="Initial application" Category="rheumatoid arthritis - TNF inhibitors contraindicated">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Use">Treatment with a Tumour Necrosis Factor alpha
                    inhibitor is contraindicated</ci>
                    <ci type="logical" class="Use">Patient has had severe and active erosive rheumatoid
                    arthritis (either confirmed by radiology imaging, or the patient is cyclic
                    citrullinated peptide (CCP) antibody positive) for six months duration or
                    longer</ci>
                    <ci type="logical" class="Use">Patient has tried and not responded to at least three
                    months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or
                    a maximum tolerated dose</ci>
                    <ci type="logical" class="Use">Patient has tried and not responded to at least three
                    months of oral or parenteral methotrexate in combination with sulfasalazine and
                    hydroxychloroquine sulphate (at maximum tolerated doses)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has tried and not responded to at least
                        three months of oral or parenteral methotrexate in combination with the
                        maximum tolerated dose of ciclosporin</ci>
                      <ci type="logical" class="Use">Patient has tried and not responded to at least
                        three months of oral or parenteral methotrexate in combination with
                        intramuscular gold</ci>
                      <ci type="logical" class="Use">Patient has tried and not responded to at least
                        three months of therapy at the maximum tolerated dose of leflunomide alone
                        or in combination with oral or parenteral methotrexate</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has persistent symptoms of poorly
                        controlled and active disease in at least 20 swollen, tender joints</ci>
                      <ci type="logical" class="Use">Patient has persistent symptoms of poorly
                        controlled and active disease in at least four joints from the following:
                        wrist, elbow, knee, ankle, and either shoulder or hip</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has a C-reactive protein level greater
                        than 15 mg/L measured no more than one month prior to the date of this
                        application</ci>
                      <ci type="logical" class="Use">C-reactive protein levels not measured as patient
                        is currently receiving prednisone therapy at a dose of greater than 5 mg per
                        day and has done so for more than three months</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Rituximab to be used as an adjunct to
                        methotrexate or leflunomide therapy</ci>
                      <ci type="logical" class="Use">Patient is contraindicated to both methotrexate
                        and leflunomide, requiring rituximab monotherapy to be used</ci>
                    </apply>
                    <ci type="logical" class="Indication">Maximum of two 1,000 mg infusions of rituximab
                    given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="rheumatoid arthritis - prior TNF inhibitor use">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Use">The patient has had an initial community Special
                        Authority approval for at least one of etanercept and/or adalimumab for
                        rheumatoid arthritis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Use">The patient has experienced intolerable side
                            effects from a reasonable trial of adalimumab and/or etanercept</ci>
                        <ci type="logical" class="Use">Following at least a four month trial of
                            adalimumab and/or etanercept, the patient did not meet the renewal
                            criteria for adalimumab and/or etanercept for rheumatoid arthritis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Rituximab to be used as an adjunct to
                        methotrexate or leflunomide therapy</ci>
                      <ci type="logical" class="Use">Patient is contraindicated to both methotrexate
                        and leflunomide, requiring rituximab monotherapy to be used</ci>
                    </apply>
                    <ci type="logical" class="Indication">Maximum of two 1,000 mg infusions of rituximab
                    given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="rheumatoid arthritis - re-treatment in 'partial responders' to rituximab" Form="SA0777 SA0884 SA0961 SA1050 SA1152 SA1631 SA1655 SA1686 SA1783 SA1818 SA1861 SA1884 SA1901 SA1976">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">At 4 months following the initial course of
                        rituximab infusions the patient had between a 30% and 50% decrease in active
                        joint count from baseline and a clinically significant response to treatment
                        in the opinion of the physician</ci>
                      <ci type="logical" class="Use">At 4 months following the second course of
                        rituximab infusions the patient had at least a 50% decrease in active joint
                        count from baseline and a clinically significant response to treatment in
                        the opinion of the physician</ci>
                      <ci type="logical" class="Use">At 4 months following the third and subsequent
                        courses of rituximab infusions, the patient demonstrates at least a
                        continuing 30% improvement in active joint count from baseline and a
                        clinically significant response to treatment in the opinion of the
                        physician</ci>
                    </apply>
                    <ci type="logical" class="Indication">Rituximab re-treatment not to be given within
                    6 months of the previous course of treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Rituximab to be used as an adjunct to
                        methotrexate or leflunomide therapy</ci>
                      <ci type="logical" class="Use">Patient is contraindicated to both methotrexate
                        and leflunomide, requiring rituximab monotherapy to be used</ci>
                    </apply>
                    <ci type="logical" class="Indication">Maximum of two 1,000 mg infusions of rituximab
                    given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="rheumatoid arthritis - re-treatment in 'responders' to rituximab" Form="SA0777 SA0884 SA0961 SA1050 SA1152 SA1631 SA1655 SA1686 SA1783 SA1818 SA1861 SA1884 SA1901 SA1976">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">At 4 months following the initial course of
                        rituximab infusions the patient had at least a 50% decrease in active joint
                        count from baseline and a clinically significant response to treatment in
                        the opinion of the physician</ci>
                      <ci type="logical" class="Use">At 4 months following the second and subsequent
                        courses of rituximab infusions, the patient demonstrates at least a
                        continuing 30% improvement in active joint count from baseline and a
                        clinically significant response to treatment in the opinion of the
                        physician</ci>
                    </apply>
                    <ci type="logical" class="Indication">Rituximab re-treatment not to be given within
                    6 months of the previous course of treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Rituximab to be used as an adjunct to
                        methotrexate or leflunomide therapy</ci>
                      <ci type="logical" class="Use">Patient is contraindicated to both methotrexate
                        and leflunomide, requiring rituximab monotherapy to be used</ci>
                    </apply>
                    <ci type="logical" class="Indication">Maximum of two 1,000 mg infusions of rituximab
                    given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
            </Request>
            <Formulation ID="F250704381725" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg per 10 ml vial</Name>
              <Brand ID="B25070438172525">
                <Name>Mabthera</Name>
                <Pack ID="P307785" Specified="true" nzmt:ctpp_id="50069021000117105">
                  <Quantity>2</Quantity>
                  <Subsidy>1075.50</Subsidy>
                  <Price>1075.50</Price>
                  <Alternate>1075.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704381726" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg per 50 ml vial</Name>
              <Brand ID="B25070438172625">
                <Name>Mabthera</Name>
                <Pack ID="P307831" Specified="true" nzmt:ctpp_id="50069031000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>2688.30</Subsidy>
                  <Price>2688.30</Price>
                  <Alternate>2688.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704381727" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070438172725">
                <Name>Baxter (Mabthera)</Name>
                <Pack ID="P2204037" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>5.64</Subsidy>
                  <Price>5.64</Price>
                  <Alternate>5.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507043818">
            <Name>Trastuzumab (Herceptin)</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2287"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2287">
              <Title>
                <range>Trastuzumab (Herceptin)</range>
              </Title>
              <Case When="Renewal" Category="early breast cancer*" Form="SA0778 SA0871 SA0885 SA1017 SA1163 SA1192 SA1521 SA1632 SA2277 SA2287">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci>
                    <ci type="logical" class="Indication">The patient received prior adjuvant trastuzumab treatment for early breast cancer</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due
                            to intolerable side effects</ci>
                        <ci type="logical" class="Indication">The cancer did not progress whilst on lapatinib</ci>
                      </apply>
                      <ci type="logical" class="Indication">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Trastuzumab will not be given in combination with pertuzumab</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Trastuzumab to be administered in combination with pertuzumab</ci>
                        <ci type="logical" class="Indication">Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between
                            prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer</ci>
                        <ci type="logical" class="Indication">The patient has good performance status (ECOG grade 0-1)</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci>
                    <ci type="logical" class="Indication">Trastuzumab to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>* For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="metastatic breast cancer" Form="SA0778 SA0871 SA0885 SA1017 SA1163 SA1192 SA1521 SA1632 SA2277 SA2287">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci>
                    <ci type="logical" class="Indication">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab</ci>
                    <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci>
                    <ci type="logical" class="Indication">Trastuzumab to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250704381825" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg vial</Name>
              <Brand ID="B25070438182525" ToBeDelisted="2024-06-01">
                <Name>Herceptin</Name>
                <Pack ID="P2060396" Specified="true" nzmt:ctpp_id="50010741000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>1350.00</Subsidy>
                  <Price>1350.00</Price>
                  <Alternate>1350.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704381826" Rank="4" Units="inj" Weight="440">
              <Name>Inj 440 mg vial</Name>
              <Brand ID="B25070438182625" ToBeDelisted="2024-06-01">
                <Name>Herceptin</Name>
                <Pack ID="P2053314" Specified="true" nzmt:ctpp_id="50009531000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>3875.00</Subsidy>
                  <Price>3875.00</Price>
                  <Alternate>3875.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704381827" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070438182725" ToBeDelisted="2024-06-01">
                <Name>Baxter</Name>
                <Pack ID="P2204029" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>9.36</Subsidy>
                  <Price>9.36</Price>
                  <Alternate>9.36</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507043836">
            <Name>Adalimumab (Humira - Alternative brand)</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2157"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2157">
              <Title>
                <range>Adalimumab (Humira - Alternative brand)</range>
              </Title>
              <Case When="Initial application" Category="Behcetâ€™s disease â€“ severe">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Behcetâ€™s disease â€“ severe" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has had a good clinical response to treatment with
               measurably improved quality of life</ci>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Hidradenitis suppurativa">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 7 days. Fortnightly dosing has been considered</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Hidradenitis suppurativa" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has a reduction in active lesions (e.g. inflammatory
               nodules, abscesses, draining fistulae) of 25% or more from baseline</ci>
                    <ci type="logical">The patient has a Dermatology Quality of Life Index improvement of 4
               or more from baseline</ci>
                    <ci type="logical">Adalimumab is to be administered at doses no greater than 40mg every
               7 days. Fortnightly dosing has been considered</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Psoriasis - severe chronic plaque">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Psoriasis - severe chronic plaque" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">Patient had "whole body" severe chronic plaque psoriasis at the
                     start of treatment</ci>
                        <apply>
                          <or/>
                          <ci type="logical">Following each prior adalimumab treatment course the patient
                        has a PASI score which is reduced by 75% or more, or is sustained at this
                        level, when compared with the pre-adalimumab treatment baseline value</ci>
                          <ci type="logical">Following each prior adalimumab treatment course the patient
                        has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more,
                        when compared with the pre-treatment baseline value</ci>
                        </apply>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical">Patient had severe chronic plaque psoriasis of the face, or
                     palm of a hand or sole of a foot at the start of treatment</ci>
                        <apply>
                          <or/>
                          <ci type="logical">Following each prior adalimumab treatment course the patient
                        has a reduction in the PASI symptom subscores for all 3 of erythema,
                        thickness and scaling, to slight or better, or sustained at this level, as
                        compared to the treatment course baseline values</ci>
                          <ci type="logical">Following each prior adalimumab treatment course the patient
                        has a reduction of 75% or more in the skin area affected, or sustained at
                        this level, as compared to the pre-adalimumab treatment baseline value</ci>
                        </apply>
                      </apply>
                    </apply>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Pyoderma gangrenosum">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">A maximum of 8 doses</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Pyoderma gangrenosum" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has demonstrated clinical improvement and continues to
               require treatment</ci>
                    <ci type="logical">A maximum of 8 doses</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Crohnâ€™s disease - adult">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6
                  months treatment with Amgevitat</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with
                  Amgevita and clinician attributes this loss of disease response to a change in
                  treatment regimen</ci>
                      <ci type="logical">Patient has Crohnâ€™s and is considered to be at risk of disease
                  destabilisation if there were to be a change to current treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohnâ€™s disease - adult" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">CDAI score has reduced by 100 points from the CDAI score when the
                  patient was initiated on adalimumab</ci>
                      <ci type="logical">CDAI score is 150 or less</ci>
                      <ci type="logical">The patient has demonstrated an adequate response to treatment,
                  but CDAI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Crohnâ€™s disease - children">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6
                  months treatment with Amgevita</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with
                  Amgevita and clinician attributes this loss of disease response to a change in
                  treatment regimen</ci>
                      <ci type="logical">Patient has Crohnâ€™s and is considered to be at risk of disease
                  destabilisation if there were to be a change to current treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohnâ€™s disease - children" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">PCDAI score has reduced by 10 points from the PCDAI score when the
                  patient was initiated on adalimumab</ci>
                      <ci type="logical">PCDAI score is 15 or less</ci>
                      <ci type="logical">The patient has demonstrated an adequate response to treatment,
                  but PCDAI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Crohnâ€™s disease - fistulising">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6
                  months treatment with Amgevita</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with
                  Amgevita and clinician attributes this loss of disease response to a change in
                  treatment regimen</ci>
                      <ci type="logical">Patient has Crohnâ€™s and is considered to be at risk of disease
                  destabilisation if there were to be a change to current treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohnâ€™s disease - fistulising" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The number of open draining fistulae have decreased from baseline
                  by at least 50%</ci>
                      <ci type="logical">There has been a marked reduction in drainage of all fistula(e)
                  from baseline as demonstrated by a reduction in the Fistula Assessment score,
                  together with less induration and patient-reported pain</ci>
                    </apply>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Ocular inflammation â€“ chronic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6
                  months treatment with Amgevita</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months
                  treatment with Amgevita and clinician attributes this loss of disease response to
                  a change in treatment regimen</ci>
                      <ci type="logical">Patient has uveitis and is considered to be at risk of vision loss
                  if they were to change treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Ocular inflammation â€“ chronic" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has had a good clinical response following 12 weeks'
                  initial treatment</ci>
                      <ci type="logical">Following each 12-month treatment period, the patient has had a
                  sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN)
                  criteria &lt; Â½+ anterior chamber or vitreous cells, absence of active vitreous or
                  retinal lesions, or resolution of uveitic cystoid macular oedema)</ci>
                      <ci type="logical">Following each 12-month treatment period, the patient has a
                  sustained steroid sparing effect, allowing reduction in prednisone to &lt; 10mg
                  daily, or steroid drops less than twice daily if under 18 years old</ci>
                    </apply>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Ocular inflammation â€“ severe">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6
                  months treatment with Amgevita</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months
                  treatment with Amgevita and clinician attributes this loss of disease response to
                  a change in treatment regimen</ci>
                      <ci type="logical">Patient has uveitis and is considered to be at risk of vision loss
                  if they were to change treatment</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Ocular inflammation â€“ severe" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has had a good clinical response following 3 initial
                  doses</ci>
                      <ci type="logical">Following each 12-month treatment period, the patient has had a
                  sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN)
                  criteria &lt;Â½+ anterior chamber or vitreous cells, absence of active vitreous or
                  retinal lesions, or resolution of uveitic cystoid macular oedema)</ci>
                      <ci type="logical">Following each 12-month treatment period, the patient has a
                  sustained steroid sparing effect, allowing reduction in prednisone to &lt; 10mg
                  daily, or steroid drops less than twice daily if under 18 years old</ci>
                    </apply>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="ankylosing spondylitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita)</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="ankylosing spondylitis" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Treatment has resulted in an improvement in BASDAI of 4 or more
               points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI
               of 50%, whichever is less</ci>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis â€“ oligoarticular course juvenile idiopathic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis â€“ oligoarticular course juvenile idiopathic" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">the patient demonstrates at least a continuing 30% improvement in active
            joint count and continued improvement in physician's global assessment from
            baseline</ci>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis - polyarticular course juvenile idiopathic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis - polyarticular course juvenile idiopathic" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">the patient demonstrates at least a continuing 30% improvement in active
            joint count and continued improvement in physician's global assessment from
            baseline</ci>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis - psoriatic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <ci type="logical" class="Indication">Adalimumab to be administered at doses no greater
               than 40 mg every 14 days</ci>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis - psoriatic" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient demonstrates at least a continuing 30% improvement in
               active joint count from baseline and a clinically significant response to prior
               adalimumab treatment in the opinion of the treating physician</ci>
                    <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every 14
               days</ci>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="named specialist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis â€“ rheumatoid">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every
                  14 days</ci>
                      <ci type="logical">Patient cannot take concomitant methotrexate and requires doses of
                  adalimumab higher than 40 mg every 14 days to maintain an adequate response</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis â€“ rheumatoid" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient demonstrates at least a continuing 30% improvement in
               active joint count from baseline and a clinically significant response to prior
               adalimumab treatment in the opinion of the treating physician</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Adalimumab to be administered at doses no greater than 40 mg every
                  14 days</ci>
                      <ci type="logical">Patient cannot take concomitant methotrexate and requires doses of
                  adalimumab higher than 40 mg every 14 days to maintain an adequate response</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Still's disease â€“ adult-onset (AOSD)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced intolerable side effects from
                  adalimumab (Amgevita) following a minimum of 4 weeks treatment</ci>
                      <ci type="logical">Patient has developed symptoms of loss of disease control
                  following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician
                  attributes this loss of disease response to a change in treatment regimen</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has received a maximum of 6 months
               treatment with Amgevita</ci>
                    <ci type="logical" class="Indication">Patient has previously had a Special Authority
               approval for the Humira brand of adalimumab for this indication</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Still's disease â€“ adult-onset (AOSD)" Form="SA2157">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">the patient has demonstrated a sustained improvement in inflammatory
            markers and functional status</ci>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250704383629" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg per 0.2 ml prefilled syringe</Name>
              <Brand ID="B25070438362925">
                <Name>Humira</Name>
                <Pack ID="P2635062" Specified="true" nzmt:ctpp_id="50245271000117104">
                  <Quantity>2</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1599.96</Subsidy>
                  <Price>1599.96</Price>
                  <Alternate>1599.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704383630" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per 0.4 ml prefilled syringe</Name>
              <Brand ID="B25070438363025">
                <Name>Humira</Name>
                <Pack ID="P2635038" Specified="true" nzmt:ctpp_id="50231751000117104">
                  <Quantity>2</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1599.96</Subsidy>
                  <Price>1599.96</Price>
                  <Alternate>1599.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704383631" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per 0.4 ml prefilled pen</Name>
              <Brand ID="B25070438363125">
                <Name>HumiraPen</Name>
                <Pack ID="P2635011" Specified="true" nzmt:ctpp_id="50231791000117108">
                  <Quantity>2</Quantity>
                  <Subsidy>1599.96</Subsidy>
                  <Price>1599.96</Price>
                  <Alternate>1599.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044039">
            <Name>Omalizumab</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1744"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1744">
              <Title>
                <range>Omalizumab</range>
              </Title>
              <Case When="Initial application" Category="severe asthma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">Patient must be aged 6 years or older</ci>
                    <ci type="logical" class="Use">Patient has a diagnosis of severe asthma</ci>
                    <ci type="logical" class="Use">Past or current evidence of atopy, documented by skin prick testing or RAST</ci>
                    <ci type="logical" class="Use">Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline</ci>
                    <ci type="logical" class="Use">Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Therapy">Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated</ci>
                      <ci type="logical" class="Use">Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids</ci>
                    </apply>
                    <ci type="logical" class="Use">Patient has an Asthma Control Test (ACT) score of 10 or less</ci>
                    <ci type="logical" class="Use">Baseline measurements of the patientâ€™s asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment</ci>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>clinical immunologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="severe chronic spontaneous urticaria">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">Patient must be aged 12 years or older</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Therapy">Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above</ci>
                        <ci type="logical" class="Use">Patient has a Dermatology life quality index (DLQI) of 10 or greater</ci>
                      </apply>
                      <ci type="logical" class="Therapy">Patient has a Urticaria Control Test (UCT) of 8 or less</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Therapy">Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (&gt;3 mg/kg day) for at least 6 weeks</ci>
                      <ci type="logical" class="Use">Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (&gt;20 mg prednisone per day for at least 5 days) in the previous 6 months</ci>
                      <ci type="logical" class="Use">Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Therapy">Treatment to be stopped if inadequate response* following 4 doses</ci>
                      <ci type="logical" class="Use">Complete response* to 6 doses of omalizumab</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>clinical immunologist</Applicant>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="severe asthma" Form="SA1490 SA1744">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">An increase in the Asthma Control Test (ACT) score of at least 5 from baseline</ci>
                    <ci type="logical" class="Use">A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline</ci>
                  </apply>
                </math>
                <Applicant>clinical immunologist</Applicant>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Renewal" Category="severe chronic spontaneous urticaria" Form="SA1490 SA1744">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Therapy">Patient has previously adequately responded* to 6 doses of omalizumab</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Therapy">Patient has previously had a complete response* to 6 doses of omalizumab</ci>
                      <ci type="logical" class="Use">Patient has relapsed after cessation of omalizumab therapy</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>clinical immunologist</Applicant>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>*Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.</p>
              </div>
            </Request>
            <Formulation ID="F250704403925" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg vial</Name>
              <Brand ID="B25070440392525">
                <Name>Xolair</Name>
                <Pack ID="P2243369" Specified="true" nzmt:ctpp_id="50038491000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>450.00</Subsidy>
                  <Price>450.00</Price>
                  <Alternate>450.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704403926" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg prefilled syringe</Name>
              <Brand ID="B25070440392625">
                <Name>Xolair</Name>
                <Pack ID="P2555042" Specified="true" nzmt:ctpp_id="50246061000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>450.00</Subsidy>
                  <Price>450.00</Price>
                  <Alternate>450.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044064">
            <Name>Siltuximab</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1596"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1596">
              <Title>
                <range>Siltuximab</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease</ci>
                    <ci type="logical" class="Indication">Treatment with an adequate trial of corticosteroids has proven ineffective</ci>
                    <ci type="logical" class="Treatment">Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1596">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status</ci>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250704406425" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25070440642525">
                <Name>Sylvant</Name>
                <Pack ID="P2500663" Specified="true" nzmt:ctpp_id="50206061000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>770.57</Subsidy>
                  <Price>770.57</Price>
                  <Alternate>770.57</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704406426" Rank="4" Units="inj" Weight="400">
              <Name>Inj 400 mg vial</Name>
              <Brand ID="B25070440642625">
                <Name>Sylvant</Name>
                <Pack ID="P2500655" Specified="true" nzmt:ctpp_id="50206071000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3082.33</Subsidy>
                  <Price>3082.33</Price>
                  <Alternate>3082.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044077">
            <Name>Pertuzumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2276"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2276">
              <Title>
                <range>Pertuzumab</range>
              </Title>
              <Case When="Initial application" Category="metastatic breast cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is chemotherapy treatment naÃ¯ve</ci>
                      <ci type="logical" class="Indication">Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer</ci>
                    </apply>
                    <ci type="logical" class="Indication">The patient has good performance status (ECOG grade 0-1)</ci>
                    <ci type="logical" class="Indication">Pertuzumab to be administered in combination with trastuzumab</ci>
                    <ci type="logical" class="Indication">Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks</ci>
                    <ci type="logical" class="Indication">Pertuzumab to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="metastatic breast cancer" Form="SA1606 SA2276">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci>
                      <ci type="logical" class="Indication">The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has previously discontinued treatment with pertuzumab and trastuzumab for reasons other than severe toxicity or disease progression</ci>
                      <ci type="logical" class="Indication">Patient has signs of disease progression</ci>
                      <ci type="logical" class="Indication">Disease has not progressed during previous treatment with pertuzumab and trastuzumab</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250704407725" Rank="4" Units="inj" Weight="30">
              <Name>Inj 30 mg per ml, 14 ml vial</Name>
              <Brand ID="B25070440772525">
                <Name>Perjeta</Name>
                <Pack ID="P2444208" Specified="true" nzmt:ctpp_id="50149421000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>3927.00</Subsidy>
                  <Price>3927.00</Price>
                  <Alternate>3927.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704407727" Rank="10" Units="mg" Weight="420">
              <Name>Inj 420 mg for ECP</Name>
              <Brand ID="B25070440772725">
                <Name>Baxter</Name>
                <Pack ID="P2555328" Specified="true" OP="true">
                  <Quantity>420</Quantity>
                  <Subsidy>3927.00</Subsidy>
                  <Price>3927.00</Price>
                  <Alternate>3927.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044078">
            <Name>Obinutuzumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2155"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2155">
              <Title>
                <range>Obinutuzumab</range>
              </Title>
              <Case When="Initial application" Category="chronic lymphocytic leukaemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has progressive Binet stage A, B
                    or C CD20+ chronic lymphocytic leukaemia requiring treatment</ci>
                    <ci type="logical" class="Indication">The patient is obinutuzumab treatment
                    naive</ci>
                    <ci type="logical" class="Indication">The patient is not eligible for full dose FCR
                    due to comorbidities with a score &gt; 6 on the Cumulative Illness Rating Scale
                    (CIRS) or reduced renal function (creatinine clearance &lt;70mL/min)</ci>
                    <ci type="logical" class="Indication">Patient has adequate neutrophil and platelet
                    counts* unless the cytopenias are a consequence of marrow infiltration by
                    CLL</ci>
                    <ci type="logical" class="Indication">Patient has good performance status</ci>
                    <ci type="logical" class="Indication">Obinutuzumab to be administered at a maximum
                    cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum
                    of 6 cycles</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers
                only to illness/impairment other than CLL induced illness/impairment in the patient.
                'Good performance status' means ECOG score of 0-1, however, in patients temporarily
                debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where
                treatment with obinutuzumab is expected to improve symptoms and improve ECOG score
                to &lt;2.</p>
                  <p>* Neutrophil greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater
                than or equal to 75 x 10<sup>9</sup>/L.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="follicular / marginal zone lymphoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has follicular lymphoma</ci>
                      <ci type="logical" class="Indication">Patient has marginal zone lymphoma</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen*</ci>
                    <ci type="logical" class="Indication">Patient has an ECOG performance status of 0-2</ci>
                    <ci type="logical" class="Indication">Patient has been previously treated with no more than four chemotherapy regimens</ci>
                    <ci type="logical" class="Indication">Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy*</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">9</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>* includes unapproved indications</p>
                </div>
              </Case>
              <Case When="Renewal" Category="follicular / marginal zone lymphoma" Form="SA2155">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has no evidence of disease progression following obinutuzumab induction therapy</ci>
                    <ci type="logical" class="Indication">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years</ci>
                    <ci type="logical" class="Indication">Obinutuzumab to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
            </Request>
            <Formulation ID="F250704407825" Rank="4" Units="inj" Weight="25">
              <Name>Inj 25 mg per ml, 40 ml vial</Name>
              <Brand ID="B25070440782525">
                <Name>Gazyva</Name>
                <Pack ID="P2471981" Specified="true" nzmt:ctpp_id="50184011000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>5910.00</Subsidy>
                  <Price>5910.00</Price>
                  <Alternate>5910.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704407826" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070440782625">
                <Name>Baxter</Name>
                <Pack ID="P2514184" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>6.21</Subsidy>
                  <Price>6.21</Price>
                  <Alternate>6.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044094">
            <Name>Cetuximab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1697"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1697">
              <Title>
                <range>Cetuximab</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck</ci>
                    <ci type="logical" class="Indication">Patient is contraindicated to, or is intolerant of, cisplatin</ci>
                    <ci type="logical" class="Indication">Patient has good performance status</ci>
                    <ci type="logical" class="Indication">To be administered in combination with radiation therapy</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250704409425" Rank="4" Units="inj" Weight="100">
              <Name>Inj 5 mg per ml, 20 ml vial</Name>
              <Brand ID="B25070440942525">
                <Name>Erbitux</Name>
                <Pack ID="P2304457" Specified="true" nzmt:ctpp_id="50045981000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>364.00</Subsidy>
                  <Price>364.00</Price>
                  <Alternate>364.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704409426" Rank="4" Units="inj" Weight="500">
              <Name>Inj 5 mg per ml, 100 ml vial</Name>
              <Brand ID="B25070440942625">
                <Name>Erbitux</Name>
                <Pack ID="P2304465" Specified="true" nzmt:ctpp_id="50045991000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>1820.00</Subsidy>
                  <Price>1820.00</Price>
                  <Alternate>1820.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704409427" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070440942725">
                <Name>Baxter</Name>
                <Pack ID="P2537958" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>3.82</Subsidy>
                  <Price>3.82</Price>
                  <Alternate>3.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044098">
            <Name>Aflibercept</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1772"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1772">
              <Title>
                <range>Aflibercept</range>
              </Title>
              <Case When="Initial application" Category="wet age related macular degeneration">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Wet age-related macular degeneration (wet AMD)</ci>
                        <ci type="logical" class="Indication">Polypoidal choroidal vasculopathy</ci>
                        <ci type="logical" class="Indication">Choroidal neovascular membrane from causes other than wet AMD</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab</ci>
                        <ci type="logical" class="Indication">There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart</ci>
                      </apply>
                      <ci type="logical" class="Indication">There is no structural damage to the central fovea of the treated eye</ci>
                      <ci type="logical" class="Indication">Patient has not previously been treated with ranibizumab for longer than 3 months</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months</ci>
                      <ci type="logical" class="Trial">Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>ophthalmologist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Initial application" Category="diabetic macular oedema">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has centre involving diabetic macular oedema (DMO)</ci>
                    <ci type="logical" class="Indication">Patientâ€™s disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly</ci>
                    <ci type="logical" class="Indication">Patient has reduced visual acuity between 6/9 â€“ 6/36 with functional awareness of reduction in vision</ci>
                    <ci type="logical" class="Indication">Patient has DMO within central OCT (ocular coherence tomography) subfield &gt;350 micrometers</ci>
                    <ci type="logical" class="Indication">There is no centre-involving sub-retinal fibrosis or foveal atrophy</ci>
                  </apply>
                </math>
                <Applicant>ophthalmologist</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="wet age related macular degeneration" Form="SA1726 SA1772">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Documented benefit must be demonstrated to continue</ci>
                    <ci type="logical" class="Indication">Patientâ€™s vision is 6/36 or better on the Snellen visual acuity score</ci>
                    <ci type="logical" class="Indication">There is no structural damage to the central fovea of the treated eye</ci>
                  </apply>
                </math>
                <Applicant>ophthalmologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="diabetic macular oedema" Form="SA1726 SA1772">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">There is stability or two lines of Snellen visual acuity gain</ci>
                    <ci type="logical" class="Indication">There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid)</ci>
                    <ci type="logical" class="Indication">Patientâ€™s vision is 6/36 or better on the Snellen visual acuity score</ci>
                    <ci type="logical" class="Indication">There is no centre-involving sub-retinal fibrosis or foveal atrophy</ci>
                    <ci type="logical" class="Indication">After each consecutive 12 months treatment with (2nd line anti-VEGF agent), patient has retrialled with at least one injection of bevacizumab and
                    had no response</ci>
                  </apply>
                </math>
                <Applicant>ophthalmologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250704409825" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per ml, 0.1 ml vial</Name>
              <Brand ID="B25070440982525">
                <Name>Eylea</Name>
                <Pack ID="P2441195" Specified="true" nzmt:ctpp_id="50140231000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1250.00</Subsidy>
                  <Price>1250.00</Price>
                  <Alternate>1250.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044107">
            <Name>Secukinumab</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2084"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2084">
              <Title>
                <range>Secukinumab</range>
              </Title>
              <Case When="Initial application" Category="severe chronic plaque psoriasis â€“ second-line biologic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has had an initial Special
                    Authority approval for adalimumab or etanercept, or has trialled infliximab in a
                    Te Whatu Ora Hospital, for severe chronic plaque psoriasis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has experienced intolerable
                        side effects from adalimumab, etanercept or infliximab</ci>
                      <ci type="logical" class="Indication">The patient has received insufficient
                        benefit from adalimumab, etanercept or infliximab</ci>
                    </apply>
                    <ci type="logical" class="Indication">A Psoriasis Area and Severity Index (PASI)
                    assessment or Dermatology Quality of Life Index (DLQI) assessment has been
                    completed for at least the most recent prior treatment course, preferably while
                    still on treatment but no longer than 1 month following cessation of each prior
                    treatment course</ci>
                    <ci type="logical" class="Indication">The most recent PASI or DQLI assessment is no
                    more than 1 month old at the time of application</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="severe chronic plaque psoriasis â€“ first-line biologic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has "whole body" severe chronic
                        plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of
                        greater than 10, where lesions have been present for at least 6 months from
                        the time of initial diagnosis</ci>
                      <ci type="logical" class="Indication">Patient has severe chronic plaque
                        psoriasis of the face, or palm of a hand or sole of a foot, where the plaque
                        or plaques have been present for at least 6 months from the time of initial
                        diagnosis</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has tried, but had an inadequate
                    response (see Note) to, or has experienced intolerable side effects from, at
                    least three of the following (at maximum tolerated doses unless
                    contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin</ci>
                    <ci type="logical" class="Indication">A PASI assessment or Dermatology Quality of
                    Life Index (DLQI) assessment has been completed for at least the most recent
                    prior treatment course, preferably while still on treatment but no longer than 1
                    month following cessation of each prior treatment course</ci>
                    <ci type="logical" class="Indication">The most recent PASI or DQLI assessment is no
                    more than 1 month old at the time of application</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">4</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate
                response" is defined as: for whole body severe chronic plaque psoriasis, a PASI
                score of greater than 10, as assessed preferably while still on treatment but no
                longer than 1 month following cessation of the most recent prior treatment; for
                severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI
                symptom sub scores for erythema, thickness and scaling are rated as severe or very
                severe, and the skin area affected is 30% or more of the face, palm of a hand or
                sole of a foot, as assessed preferably while still on treatment but no longer than 1
                month following cessation of the most recent prior treatment.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="severe chronic plaque psoriasis â€“ first and second-line biologic" Form="SA1754 SA2044 SA2084">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patientâ€™s PASI score has reduced by 75% or
                        more (PASI 75) as compared to baseline PASI prior to commencing
                        secukinumab</ci>
                      <ci type="logical" class="Indication">Patient has a Dermatology Quality of Life
                        Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to
                        commencing secukinumab</ci>
                    </apply>
                    <ci type="logical" class="Indication">Secukinumab to be administered at a maximum
                    dose of 300 mg monthly</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="ankylosing spondylitis â€“ second-line biologic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has had an initial Special
                    Authority approval for adalimumab and/or etanercept for ankylosing
                    spondylitis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has experienced intolerable
                        side effects from a reasonable trial of adalimumab and/or etanercept</ci>
                      <ci type="logical" class="Indication">Following 12 weeks of adalimumab and/or
                        etanercept treatment, the patient did not meet the renewal criteria for
                        adalimumab and/or etanercept for ankylosing spondylitis</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="ankylosing spondylitis â€“ second-line biologic" Form="SA1754 SA2044 SA2084">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Following 12 weeks initial treatment of
                    secukinumab treatment, BASDAI has improved by 4 or more points from
                    pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less</ci>
                    <ci type="logical" class="Indication">Physician considers that the patient has
                    benefitted from treatment and that continued treatment is appropriate</ci>
                    <ci type="logical" class="Indication">Secukinumab to be administered at doses no
                    greater than 150 mg monthly</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="psoriatic arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has had an initial Special
                        Authority approval for adalimumab, etanercept or infliximab for psoriatic
                        arthritis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has experienced intolerable
                            side effects from adalimumab, etanercept or infliximab</ci>
                        <ci type="logical" class="Indication">Patient has received
                            insufficient benefit from adalimumab, etanercept or infliximab to meet
                            the renewal criteria for adalimumab, etanercept or infliximab for
                            psoriatic arthritis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has had severe active psoriatic
                        arthritis for six months duration or longer</ci>
                      <ci type="logical" class="Indication">Patient has tried and not responded to at
                        least three months of oral or parenteral methotrexate at a dose of at least
                        20 mg weekly or a maximum tolerated dose</ci>
                      <ci type="logical" class="Indication">Patient has tried and not responded to at
                        least three months of sulfasalazine at a dose of at least 2 g per day or
                        leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses)</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has persistent symptoms of
                            poorly controlled and active disease in at least 15 swollen, tender
                            joints</ci>
                        <ci type="logical" class="Indication">Patient has persistent symptoms of
                            poorly controlled and active disease in at least four joints from the
                            following: wrist, elbow, knee, ankle, and either shoulder or hip</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has a C-reactive protein level
                            greater than 15 mg/L measured no more than one month prior to the date
                            of this application</ci>
                        <ci type="logical" class="Indication">Patient has an elevated erythrocyte
                            sedimentation rate (ESR) greater than 25 mm per hour</ci>
                        <ci type="logical" class="Indication">ESR and CRP not measured as patient is
                            currently receiving prednisone therapy at a dose of greater than 5 mg
                            per day and has done so for more than three months</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="psoriatic arthritis" Form="SA1754 SA2044 SA2084">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 months' initial
                        treatment, the patient has at least a 50% decrease in active joint count
                        from baseline and a clinically significant response to treatment in the
                        opinion of the physician</ci>
                      <ci type="logical" class="Indication">The patient demonstrates at least a
                        continuing 30% improvement in active joint count from baseline and a
                        clinically significant response to prior secukinumab treatment in the
                        opinion of the treating physician</ci>
                    </apply>
                    <ci type="logical" class="Indication">Secukinumab to be administered at doses no
                    greater than 300 mg monthly</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250704410725" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg per ml, 1 ml prefilled syringe</Name>
              <Brand ID="B25070441072525">
                <Name>Cosentyx</Name>
                <Pack ID="P2554712" Specified="true" nzmt:ctpp_id="50230961000117108">
                  <Quantity>2</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1599.00</Subsidy>
                  <Price>1599.00</Price>
                  <Alternate>1599.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2609665" Specified="true" nzmt:ctpp_id="50230971000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>799.50</Subsidy>
                  <Price>799.50</Price>
                  <Alternate>799.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044114">
            <Name>Infliximab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2179"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2179">
              <Title>
                <range>Infliximab</range>
              </Title>
              <Case When="Initial application" Category="Crohn's disease (adults)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has active Crohn's disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a CDAI score of greater than
                        or equal to 300 or HBI score of greater than or equal to 10</ci>
                      <ci type="logical" class="Use">Patient has extensive small intestine disease
                        affecting more than 50 cm of the small intestine</ci>
                      <ci type="logical" class="Use">Patient has evidence of short gut syndrome or
                        would be at risk of short gut syndrome with further bowel resection</ci>
                      <ci type="logical" class="Use">Patient has an ileostomy or colostomy, and has
                        intestinal inflammation</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has tried but has experienced an
                    inadequate response to, or intolerable side effects from, prior therapy with
                    immunomodulators and corticosteroids</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohn's disease (adults)" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">CDAI score has reduced by 100 points from
                        the CDAI score, or HBI score has reduced by 3 points, from when the patient
                        was initiated on infliximab</ci>
                      <ci type="logical" class="Use">CDAI score is 150 or less, or HBI is 4 or
                        less</ci>
                      <ci type="logical" class="Use">The patient has demonstrated an adequate response
                        to treatment but CDAI score and/or HBI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses up to 5
                    mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used
                    for up to 3 doses if required for secondary non-response to treatment for
                    re-induction. Another re-induction may be considered sixteen weeks after
                    completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or
                    equivalent) may be used for patients treated with this dose prior to 1 February
                    2019</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Crohn's disease (children)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Paediatric patient has active Crohn's
                    disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a PCDAI score of greater than
                        or equal to 30</ci>
                      <ci type="logical" class="Use">Patient has extensive small intestine
                        disease</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has tried but experienced an
                    inadequate response to, or intolerable side effects from, prior therapy with
                    immunomodulators and corticosteroids</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohn's disease (children)" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">PCDAI score has reduced by 10 points from
                        the PCDAI score when the patient was initiated on infliximab</ci>
                      <ci type="logical" class="Use">PCDAI score is 15 or less</ci>
                      <ci type="logical" class="Use">The patient has demonstrated an adequate response
                        to treatment but PCDAI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses up to 5
                    mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used
                    for up to 3 doses if required for secondary non-response to treatment for
                    re-induction. Another re-induction may be considered sixteen weeks after
                    completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or
                    equivalent) may be used for patients treated with this dose prior to 1 February
                    2019</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Graft vs host disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has steroid-refractory acute graft vs.
                host disease of the gut</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="Pulmonary sarcoidosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">patient has life-threatening pulmonary sarcoidosis
                diagnosed by a multidisciplinary team that is refractory to other treatments</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="acute fulminant ulcerative colitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has acute, fulminant ulcerative
                    colitis</ci>
                    <ci type="logical" class="Indication">Treatment with intravenous or high dose oral
                    corticosteroids has not been successful</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="week">6</Term>
              </Case>
              <Case When="Initial application" Category="ankylosing spondylitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has had an initial Special
                    Authority approval for adalimumab and/or etanercept for ankylosing
                    spondylitis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has experienced intolerable
                        side effects from a reasonable trial of adalimumab and/or etanercept</ci>
                      <ci type="logical" class="Use">Following 12 weeks of adalimumab and/or
                        etanercept treatment, the patient did not meet the renewal criteria for
                        adalimumab and/or etanercept for ankylosing spondylitis</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="ankylosing spondylitis" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Following 12 weeks of infliximab treatment,
                    BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10
                    point scale, or by 50%, whichever is less</ci>
                    <ci type="logical" class="Indication">Physician considers that the patient has
                    benefited from treatment and that continued treatment is appropriate</ci>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses no
                    greater than 5 mg/kg every 6-8 weeks</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="chronic ocular inflammation">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab for chronic ocular inflammation</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab</ci>
                        <ci type="logical" class="Use">The patient has received insufficient benefit
                            from adalimumab to meet the renewal criteria for adalimumab for chronic
                            ocular inflammation</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has severe uveitis uncontrolled
                        with treatment of steroids and other immunosuppressants with a severe risk
                        of vision loss</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient is 18 years or older and
                            treatment with at least two other immunomodulatory agents has proven
                            ineffective</ci>
                        <ci type="logical" class="Use">Patient is under 18 years and treatment with
                            methotrexate has proven ineffective or is not tolerated at a therapeutic
                            dose</ci>
                        <ci type="logical" class="Use">Patient is under 8 years and treatment with
                            steroids or methotrexate has proven ineffective or is not tolerated at a
                            therapeutic dose; or disease requires control to prevent irreversible
                            vision loss prior to achieving a therapeutic dose of methotrexate</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="chronic ocular inflammation" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has had a good clinical response
                    following 3 initial doses</ci>
                    <ci type="logical" class="Use">Following each 12 month treatment period, the patient
                    has had a sustained reduction in inflammation (Standardisation of Uveitis
                    Nomenclature (SUN) criteria &lt; Â½+ anterior chamber or vitreous cells, absence
                    of active vitreous or retinal lesions, or resolution of uveitic cystoid macular
                    oedema)</ci>
                    <ci type="logical" class="Use">Following each 12 month treatment period, the patient
                    has a sustained steroid sparing effect, allowing reduction in prednisone to
                    &lt;10mg daily, or steroid drops less than twice daily if under 18 years
                    old</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>A trial withdrawal should be considered after every 24 months of stability, unless
                the patient is deemed to have extremely high risk of irreversible vision loss if
                infliximab is withdrawn.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="fistulising Crohn's disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has confirmed Crohn's disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has one or more complex externally
                        draining enterocutaneous fistula(e)</ci>
                      <ci type="logical" class="Use">Patient has one or more rectovaginal
                        fistula(e)</ci>
                      <ci type="logical" class="Use">Patent has complex peri-anal fistula</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="fistulising Crohn's disease" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">The number of open draining fistulae have
                        decreased from baseline by at least 50%</ci>
                      <ci type="logical" class="Use">There has been a marked reduction in drainage of
                        all fistula(e) from baseline (in the case of adult patients, as demonstrated
                        by a reduction in the Fistula Assessment score), together with less
                        induration and patient reported pain</ci>
                    </apply>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses up to 5
                    mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used
                    for up to 3 doses if required for secondary non-response to treatment for
                    re-induction. Another re-induction may be considered sixteen weeks after
                    completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or
                    equivalent) may be used for patients treated with this dose prior to 1 February
                    2019</ci>
                  </apply>
                </math>
                <Applicant>gastroenterologist</Applicant>
                <Applicant Referring="gastroenterologist">Practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="neurosarcoidosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with
                    neurosarcoiosis by a multidisciplinary team</ci>
                    <ci type="logical" class="Indication">Patient has CNS involvement</ci>
                    <ci type="logical" class="Indication">Patient has steroid-refractory disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">IV cyclophosphamide has been tried</ci>
                      <ci type="logical" class="Indication">Treatment with IV cyclophosphamide is
                        clinically inappropriate</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">Practitioner</Applicant>
                <Term Measure="month">18</Term>
              </Case>
              <Case When="Renewal" Category="neurosarcoidosis" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">A withdrawal period has been tried and the
                    patient has relapsed</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">A withdrawal period has been considered
                        but would not be clinically appropriate</ci>
                      <ci type="logical" class="Indication">There has been a marked reduction in
                        prednisone dose</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">There has been an improvement in MRI
                            appearances</ci>
                        <ci type="logical" class="Indication">Marked improvement in other
                            symptomology</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">Practitioner</Applicant>
                <Term Measure="month">18</Term>
              </Case>
              <Case When="Initial application" Category="plaque psoriasis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab, etanercept or secukinumab for severe
                        chronic plaque psoriasis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has experienced intolerable
                            side effects from adalimumab, etanercept or secukinumab</ci>
                        <ci type="logical" class="Indication">Patient has received insufficient
                            benefit from adalimumab, etanercept or secukinumab to meet the renewal
                            criteria for adalimumab, etanercept or secukinumab for severe chronic
                            plaque psoriasis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has "whole body" severe
                            chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI)
                            score of greater than 10, where lesions have been present for at least 6
                            months from the time of initial diagnosis</ci>
                        <ci type="logical" class="Indication">Patient has severe chronic plaque
                            psoriasis of the face, or palm of a hand or sole of a foot, where the
                            plaque or plaques have been present for at least 6 months from the time
                            of initial diagnosis</ci>
                      </apply>
                      <ci type="logical" class="Indication">Patient has tried, but had an inadequate
                        response (see Note) to, or has experienced intolerable side effects from, at
                        least three of the following (at maximum tolerated doses unless
                        contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin</ci>
                      <ci type="logical" class="Indication">A PASI assessment has been completed for
                        at least the most recent prior treatment course (but preferably all prior
                        treatment courses), preferably while still on treatment but no longer than 1
                        month following cessation of each prior treatment course</ci>
                      <ci type="logical" class="Indication">The most recent PASI assessment is no more
                        than 1 month old at the time of initiation</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">3</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>"Inadequate response" is defined as: for whole body severe chronic plaque psoriasis,
                a PASI score of greater than 10, as assessed preferably while still on treatment but
                no longer than 1 month following cessation of the most recent prior treatment; for
                severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI
                symptom subscores for erythema, thickness and scaling are rated as severe or very
                severe, and the skin area affected is 30% or more of the face, palm of a hand or
                sole of a foot, as assessed preferably while still on treatment but no longer than 1
                month following cessation of the most recent prior treatment.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="plaque psoriasis" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient had "whole body" severe
                            chronic plaque psoriasis at the start of treatment</ci>
                        <ci type="logical" class="Indication">Following each prior infliximab
                            treatment course the patient has a PASI score which is reduced by 75% or
                            more, or is sustained at this level, when compared with the
                            pre-infliximab treatment baseline value</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient had severe chronic plaque
                            psoriasis of the face, or palm of a hand or sole of a foot at the start
                            of treatment</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">Following each prior infliximab
                                treatment course the patient has a reduction in the PASI symptom
                                subscores for all 3 of erythema, thickness and scaling, to slight or
                                better, or sustained at this level, as compared to the treatment
                                course baseline values</ci>
                          <ci type="logical" class="Indication">Following each prior infliximab
                                treatment course the patient has a reduction of 75% or more in the
                                skin area affected, or sustained at this level, as compared to the
                                pre-infliximab treatment baseline value</ci>
                        </apply>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses no
                    greater than 5 mg/kg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="previous use">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient was being treated with infliximab
                    prior to 1 February 2019</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Rheumatoid arthritis</ci>
                      <ci type="logical" class="Indication">Ankylosing spondylitis</ci>
                      <ci type="logical" class="Indication">Psoriatic arthritis</ci>
                      <ci type="logical" class="Indication">Severe ocular inflammation</ci>
                      <ci type="logical" class="Indication">Chronic ocular inflammation</ci>
                      <ci type="logical" class="Indication">Crohnâ€™s disease (adults)</ci>
                      <ci type="logical" class="Indication">Crohnâ€™s disease (children)</ci>
                      <ci type="logical" class="Indication">Fistulising Crohnâ€™s disease</ci>
                      <ci type="logical" class="Indication">Severe fulminant ulcerative colitis</ci>
                      <ci type="logical" class="Indication">Severe ulcerative colitis</ci>
                      <ci type="logical" class="Indication">Plaque psoriasis</ci>
                      <ci type="logical" class="Indication">Neurosarcoidosis</ci>
                      <ci type="logical" class="Indication">Severe Behcetâ€™s disease</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="psoriatic arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has had an initial Special
                    Authority approval for adalimumab and/or etanercept and/or secukinumab for
                    psoriatic arthritis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has experienced intolerable
                        side effects from adalimumab and/or etanercept and/or secukinumab</ci>
                      <ci type="logical" class="Use">Following 3-4 months' initial treatment with
                        adalimumab and/or etanercept and/or secukinumab, the patient did not meet
                        the renewal criteria for adalimumab and/or etanercept and/or secukinumab for
                        psoriatic arthritis</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="psoriatic arthritis" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 months' initial
                        treatment, the patient has at least a 50% decrease in active joint count
                        from baseline and a clinically significant response to treatment in the
                        opinion of the physician</ci>
                      <ci type="logical" class="Use">The patient demonstrates at least a continuing
                        30% improvement in active joint count from baseline and a clinically
                        significant response to prior infliximab treatment in the opinion of the
                        treating physician</ci>
                    </apply>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses no
                    greater than 5 mg/kg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="rheumatoid arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has had an initial Special
                    Authority approval for adalimumab and/or etanercept for rheumatoid
                    arthritis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has experienced intolerable
                        side effects from a reasonable trial of adalimumab and/or etanercept</ci>
                      <ci type="logical" class="Use">Following at least a four month trial of
                        adalimumab and/or etanercept, the patient did not meet the renewal criteria
                        for adalimumab and/or etanercept</ci>
                    </apply>
                    <ci type="logical" class="Indication">Treatment is to be used as an adjunct to
                    methotrexate therapy or monotherapy where use of methotrexate is limited by
                    toxicity or intolerance</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="rheumatoid arthritis" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Treatment is to be used as an adjunct to
                    methotrexate therapy or monotherapy where use of methotrexate is limited by
                    toxicity or intolerance</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 months' initial
                        treatment, the patient has at least a 50% decrease in active joint count
                        from baseline and a clinically significant response to treatment in the
                        opinion of the physician</ci>
                      <ci type="logical" class="Use">The patient demonstrates at least a continuing
                        30% improvement in active joint count from baseline and a clinically
                        significant response to treatment in the opinion of the physician</ci>
                    </apply>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses no
                    greater than 3 mg/kg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="severe Behcet's disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has severe Behcet's disease which
                    is significantly impacting the patientâ€™s quality of life (see Notes)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has severe ocular,
                        neurological and/or vasculitic symptoms and has not responded adequately to
                        one or more treatment(s) appropriate for the particular symptom(s) (see
                        Notes)</ci>
                      <ci type="logical" class="Indication">The patient has severe gastrointestinal,
                        rheumatologic and/or mucocutaneous symptoms and has not responded adequately
                        to two or more treatment appropriate for the particular symptom(s) (see
                        Notes)</ci>
                    </apply>
                    <ci type="logical" class="Indication">The patient is experiencing significant loss
                    of quality of life</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Behcetâ€™s disease diagnosed according to the International Study Group for Behcetâ€™s
                Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an
                appropriate quality of life scale such as that published in Gilworth et al J
                Rheumatol. 2004;31:931-7.</p>
                  <p>Treatments appropriate for the particular symptoms are those that are considered
                standard conventional treatments for these symptoms, for example intravenous/oral
                steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids,
                thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and
                colchicine, steroids and methotrexate for rheumatological symptoms.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="severe Behcet's disease" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has had a good clinical response to
                    initial treatment with measurably improved quality of life</ci>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses no
                    greater than 5 mg/kg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="fulminant ulcerative colitis" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Where maintenance treatment is considered
                    appropriate, infliximab should be used in combination with immunomodulators and
                    reassessed every 6 months</ci>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses up to 5
                    mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used
                    for up to 3 doses if required for secondary non-response to treatment for
                    re-induction. Another re-induction may be considered sixteen weeks after
                    completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or
                    equivalent) may be used for patients treated with this dose prior to 1 February
                    2019</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="severe ocular inflammation">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special
                        Authority approval for adalimumab for severe ocular inflammation</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced
                            intolerable side effects from adalimumab</ci>
                        <ci type="logical" class="Use">The patient has received insufficient benefit
                            from adalimumab to meet the renewal criteria for adalimumab for severe
                            ocular inflammation</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has severe, vision-threatening
                        ocular inflammation requiring rapid control</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Treatment with high-dose steroids
                            (intravenous methylprednisolone) followed by high dose oral steroids has
                            proven ineffective at controlling symptoms</ci>
                        <ci type="logical" class="Use">Patient developed new inflammatory symptoms
                            while receiving high dose steroids</ci>
                        <ci type="logical" class="Use">Patient is aged under 8 years and treatment
                            with high dose oral steroids and other immunosuppressants has proven
                            ineffective at controlling symptoms</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="severe ocular inflammation" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has had a good clinical response
                    following 3 initial doses</ci>
                    <ci type="logical" class="Indication">Following each 12 month treatment period, the
                    patient has had a sustained reduction in inflammation (Standardisation of
                    Uveitis Nomenclature (SUN) criteria &lt; Â½+ anterior chamber or vitreous cells,
                    absence of active vitreous or retinal lesions, or resolution of uveitic cystoid
                    macular oedema)</ci>
                    <ci type="logical" class="Indication">Following each 12 month treatment period, the
                    patient has a sustained steroid sparing effect, allowing reduction in prednisone
                    to &lt;10mg daily, or steroid drops less than twice daily if under 18 years
                    old</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>A trial withdrawal should be considered after every 24 months of stability, unless
                the patient is deemed to have extremely high risk of irreversible vision loss if
                infliximab is withdrawn.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="ulcerative colitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has active ulcerative colitis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patients SCCAI is greater than or equal to
                        4</ci>
                      <ci type="logical" class="Indication">Patients PUCAI score is greater than or
                        equal to 20</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient has tried but has experienced an
                    inadequate response to, or has experienced intolerable side effects from, prior
                    therapy with immunomodulators and systemic corticosteroids</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="ulcerative colitis" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The SCCAI score has reduced by 2 points or
                        more from the SCCAI score when the patient was initiated on infliximab</ci>
                      <ci type="logical" class="Indication">The PUCAI score has reduced by 10 points
                        or more from the PUCAI score when the patient was initiated on
                        infliximab</ci>
                    </apply>
                    <ci type="logical" class="Indication">Infliximab to be administered at doses up to 5
                    mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used
                    for up to 3 doses if required for secondary non-response to treatment for
                    re-induction. Another re-induction may be considered sixteen weeks after
                    completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or
                    equivalent) may be used for patients treated with this dose prior to 1 February
                    2019</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="pyoderma gangrenosum">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has pyoderma gangrenosum*</ci>
                    <ci type="logical" class="Indication">Patient has received three months of
                    conventional therapy including a minimum of three pharmaceuticals (e.g.
                    prednisone, ciclosporine, azathioprine, or methotrexate) and not received an
                    adequate response</ci>
                    <ci type="logical" class="Indication">A maximum of 8 doses</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">4</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Note: Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="pyoderma gangrenosum" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has shown clinical improvement</ci>
                    <ci type="logical" class="Indication">Patient continues to require treatment</ci>
                    <ci type="logical" class="Treatment">A maximum of 8 doses</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant Referring="dermatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="inflammatory bowel arthritis â€“ axial">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a diagnosis of active ulcerative
                    colitis or active Crohnâ€™s disease</ci>
                    <ci type="logical" class="Indication">Patient has had axial inflammatory pain for
                    six months or more</ci>
                    <ci type="logical" class="Indication">Patient is unable to take NSAIDs</ci>
                    <ci type="logical" class="Indication">Patient has unequivocal sacroiliitis
                    demonstrated by radiological imaging or MRI</ci>
                    <ci type="logical" class="Indication">Patientâ€™s disease has not responded adequately
                    to prior treatment consisting of at least 3 months of an exercise regime
                    supervised by a physiotherapist</ci>
                    <ci type="logical" class="Indication">Patient has a BASDAI of at least 6 on a 0 - 10
                    scale completed after the 3 month exercise trial, but prior to ceasing any
                    previous pharmacological treatment </ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="inflammatory bowel arthritis â€“ axial" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">treatment has resulted in an improvement in
                    BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or
                    an improvement in BASDAI of 50%, whichever is less</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="inflammatory bowel arthritis â€“ peripheral">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a diagnosis of active ulcerative
                    colitis or active Crohnâ€™s disease</ci>
                    <ci type="logical" class="Indication">Patient has active arthritis in at least four
                    joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist,
                    elbow, shoulder, sternoclavicular</ci>
                    <ci type="logical" class="Indication">Patient has tried and not experienced a
                    response to at least three months of methotrexate or azathioprine at a maximum
                    tolerated dose (unless contraindicated)</ci>
                    <ci type="logical" class="Indication">Patient has tried and not experienced a
                    response to at least three months of sulfasalazine at a maximum tolerated dose
                    (unless contraindicated)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a CRP level greater than 15
                        mg/L measured no more than one month prior to the date of this
                        application</ci>
                      <ci type="logical" class="Indication">Patient has an ESR greater than 25 mm per
                        hour measured no more than one month prior to the date of this
                        application</ci>
                      <ci type="logical" class="Indication">ESR and CRP not measured as patient is
                        currently receiving prednisone therapy at a dose of greater than 5 mg per
                        day and has done so for more than three months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="inflammatory bowel arthritis â€“ peripheral" Form="SA1778 SA1831 SA1951 SA1982 SA2050 SA2082 SA2179">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Following initial treatment, patient has
                    experienced at least a 50% decrease in active joint count from baseline and a
                    clinically significant response to treatment in the opinion of the
                    physician</ci>
                    <ci type="logical" class="Indication">Patient has experienced at least a continuing
                    30% improvement in active joint count from baseline in the opinion of the
                    treating physician</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F250704411425" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg</Name>
              <Brand ID="B25070441142525">
                <Name>Remicade</Name>
                <Pack ID="P2016710" Specified="true" nzmt:ctpp_id="50003171000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>428.00</Subsidy>
                  <Price>428.00</Price>
                  <Alternate>428.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704411426" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070441142625">
                <Name>Baxter</Name>
                <Pack ID="P2478420" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>4.40</Subsidy>
                  <Price>4.40</Price>
                  <Alternate>4.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044115">
            <Name>Tocilizumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2159"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2159">
              <Title>
                <range>Tocilizumab</range>
              </Title>
              <Case When="Initial application" Category="cytokine release syndrome">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Use">The patient is enrolled in the Children's Oncology Group
            AALL1731 trial</ci>
                      <ci type="logical" class="Use">The patient has developed grade 3 or 4 cytokine release
            syndrome associated with the administration of blinatumomab for the treatment of acute
            lymphoblastic leukaemia</ci>
                      <ci type="logical" class="Use">Tocilizumab is to be administered at doses no greater than
            8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg)</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient is enrolled in the Malaghan Institute of
            Medical Research Phase I ENABLE trial</ci>
                      <ci type="logical" class="Indication">The patient has developed CRS or CAR T-Cell Related
            Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy
            for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma</ci>
                      <ci type="logical" class="Indication">Tocilizumab is to be administered according to the
            consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev
            Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3
            doses</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="previous use">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Use">Patient was being treated with tocilizumab prior to 1
          February 2019</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">rheumatoid arthritis</ci>
                      <ci type="logical" class="Use">systemic juvenile idiopathic arthritis</ci>
                      <ci type="logical" class="Use">adult-onset Still's disease</ci>
                      <ci type="logical" class="Use">polyarticular juvenile idiopathic arthritis</ci>
                      <ci type="logical" class="Use">idiopathic multicentric Castleman's disease</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Use">The patient has had an initial Special Authority approval for
          adalimumab and/or etanercept for rheumatoid arthritis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has experienced intolerable side effects
            from adalimumab and/or etanercept</ci>
                      <ci type="logical" class="Use">The patient has received insufficient benefit from at least
            a three-month trial of adalimumab and/or etanercept such that they do not meet the
            renewal criteria for rheumatoid arthritis</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient is seronegative for both anti-cyclic
            citrullinated peptide (CCP) antibodies and rheumatoid factor</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient has been started on rituximab for
              rheumatoid arthritis in a Te Whatu Ora Hospital</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">The patient has experienced intolerable side
                effects from rituximab</ci>
                          <ci type="logical" class="Use">At four months following the initial course of
                rituximab the patient has received insufficient benefit such that they do not meet
                the renewal criteria for rheumatoid arthritis</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Rheumatoid Arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid
          arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated
          peptide (CCP) antibody positive) for six months duration or longer</ci>
                    <ci type="logical" class="Indication">Tocilizumab is to be used as monotherapy</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Treatment with methotrexate is contraindicated</ci>
                      <ci type="logical" class="Use">Patient has tried and did not tolerate oral and/or
            parenteral methotrexate</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has tried and not responded to at least
            three months therapy at the maximum tolerated dose of ciclosporin alone or in
            combination with another agent</ci>
                      <ci type="logical" class="Use">Patient has tried and not responded to at least three
            months therapy at the maximum tolerated dose of leflunomide alone or in combination with
            another agent</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has persistent symptoms of poorly controlled
            and active disease in at least 20 active, swollen, tender joints</ci>
                      <ci type="logical" class="Use">Patient has persistent symptoms of poorly controlled and
            active disease in at least four active joints from the following: wrist, elbow, knee,
            ankle, and either shoulder or hip</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a C-reactive protein level greater than
            15 mg/L measured no more than one month prior to the date of this application</ci>
                      <ci type="logical" class="Use">C-reactive protein levels not measured as patient is
            currently receiving prednisone therapy at a dose of greater than 5 mg per day and has
            done so for more than three months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="systemic juvenile idiopathic arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient diagnosed with systemic juvenile idiopathic
          arthritis</ci>
                    <ci type="logical" class="Indication">Patient has tried and not responded to a reasonable
          trial of all of the following, either alone or in combination: oral or parenteral
          methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic
          corticosteroids</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="adult-onset Still's disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has had an initial Special Authority
              approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD)</ci>
                        <ci type="logical" class="Indication">The patient has been started on tocilizumab for
              AOSD in a Te Whatu Ora Hospital</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has experienced intolerable side
              effects from adalimumab and/or etanercept</ci>
                        <ci type="logical" class="Indication">The patient has received insufficient benefit from
              at least a three-month trial of adalimumab and/or etanercept such that they do not
              meet the renewal criteria for AOSD</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient diagnosed with AOSD according to the
            Yamaguchi criteria (J Rheumatol 1992;19:424-430)</ci>
                      <ci type="logical" class="Indication">Patient has tried and not responded to at least 6
            months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal
            antiinflammatory drugs (NSAIDs) and methotrexate</ci>
                      <ci type="logical" class="Indication">Patient has persistent symptoms of disabling poorly
            controlled and active disease</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="polyarticular juvenile idiopathic arthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has had an initial Special Authority
            approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic
            arthritis (JIA)</ci>
                      <ci type="logical" class="Indication">The patient has experienced intolerable side
            effects, or has received insufficient benefit from, both etanercept and adalimumab</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Treatment with a tumour necrosis factor alpha
            inhibitor is contraindicated</ci>
                      <ci type="logical" class="Indication">Patient has had polyarticular course JIA for 6
            months duration or longer</ci>
                      <ci type="logical" class="Indication">To be used as an adjunct to methotrexate therapy or
            monotherapy where use of methotrexate is limited by toxicity or intolerance</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">At least 5 active joints and at least 3 joints
              with limited range of motion, pain or tenderness after a 3-month trial of methotrexate
              (at the maximum tolerated dose)</ci>
                        <ci type="logical" class="Indication">Moderate or high disease activity (cJADAS10 score
              of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated
              dose)</ci>
                        <ci type="logical" class="Indication">Low disease activity (cJADAS10 score between 1.1
              and 2.5) after a 6-month trial of methotrexate</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="idiopathic multicentric Castleman's disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has severe HHV-8 negative idiopathic
          multicentric Castleman's disease</ci>
                    <ci type="logical" class="Indication">Treatment with an adequate trial of corticosteroids
          has proven ineffective</ci>
                    <ci type="logical" class="Indication">Tocilizumab to be administered at doses no greater
          than 8 mg/kg IV every 3-4 weeks</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="haematologist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="moderate to severe COVID-19">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has confirmed (or probable) COVID-19</ci>
                    <ci type="logical" class="Indication">Oxygen saturation of &lt;92% on room air, or requiring
          supplemental oxygen</ci>
                    <ci type="logical" class="Indication">Patient is receiving adjunct systemic corticosteroids,
          or systemic corticosteroids are contraindicated</ci>
                    <ci type="logical" class="Indication">Tocilizumab is to be administered at doses no greater
          than 8mg/kg IV for a maximum of one dose</ci>
                    <ci type="logical" class="Indication">Tocilizumab is not to be administered in combination
          with barcitinib</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="week">4</Term>
              </Case>
              <Case When="Renewal" Category="Rheumatoid Arthritis" Form="SA1781 SA1858 SA1977 SA2078 SA2100 SA2159">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Following 6 months' initial treatment, the patient has
          at least a 50% decrease in active joint count from baseline and a clinically significant
          response to treatment in the opinion of the physician</ci>
                    <ci type="logical" class="Indication">On subsequent reapplications, the patient demonstrates
          at least a continuing 30% improvement in active joint count from baseline and a clinically
          significant response to treatment in the opinion of the physician</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="systemic juvenile idiopathic arthritis" Form="SA1781 SA1858 SA1977 SA2078 SA2100 SA2159">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Following up to 6 months' initial treatment, the
          patient has achieved at least an American College of Rheumatology paediatric 30%
          improvement criteria (ACR Pedi 30) response from baseline</ci>
                    <ci type="logical" class="Indication">On subsequent reapplications, the patient demonstrates
          at least a continuing ACR Pedi 30 response from baseline</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="adult-onset Still's disease" Form="SA1781 SA1858 SA1977 SA2078 SA2100 SA2159">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the patient has a sustained improvement in inflammatory
        markers and functional status</ci>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="polyarticular juvenile idiopathic arthritis" Form="SA1781 SA1858 SA1977 SA2078 SA2100 SA2159">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Treatment is to be used as an adjunct to methotrexate
          therapy or monotherapy where use of methotrexate is limited by toxicity or
          intolerance</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Following 3 to 4 months' initial treatment, the
            patient has at least a 50% decrease in active joint count and an improvement in
            physician's global assessment from baseline</ci>
                      <ci type="logical" class="Indication">On subsequent reapplications, the patient
            demonstrates at least a continuing 30% improvement in active joint count and continued
            improvement in physician's global assessment from baseline</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="idiopathic multicentric Castleman's disease" Form="SA1781 SA1858 SA1977 SA2078 SA2100 SA2159">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient has a
        sustained improvement in inflammatory markers and functional status</ci>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="haematologist or rheumatologist">Practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250704411525" Rank="4" Units="inj" Weight="80">
              <Name>Inj 20 mg per ml, 4 ml vial</Name>
              <Brand ID="B25070441152525">
                <Name>Actemra</Name>
                <Pack ID="P2337983" Specified="true" nzmt:ctpp_id="50120251000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>220.00</Subsidy>
                  <Price>220.00</Price>
                  <Alternate>220.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704411526" Rank="4" Units="inj" Weight="200">
              <Name>Inj 20 mg per ml, 10 ml vial</Name>
              <Brand ID="B25070441152625">
                <Name>Actemra</Name>
                <Pack ID="P2337991" Specified="true" nzmt:ctpp_id="50120261000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>550.00</Subsidy>
                  <Price>550.00</Price>
                  <Alternate>550.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704411527" Rank="4" Units="inj" Weight="400">
              <Name>Inj 20 mg per ml, 20 ml vial</Name>
              <Brand ID="B25070441152725">
                <Name>Actemra</Name>
                <Pack ID="P2440571" Specified="true" nzmt:ctpp_id="50176811000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>1100.00</Subsidy>
                  <Price>1100.00</Price>
                  <Alternate>1100.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704411528" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070441152825">
                <Name>Baxter</Name>
                <Pack ID="P2478439" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>2.85</Subsidy>
                  <Price>2.85</Price>
                  <Alternate>2.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044122">
            <Name>Trastuzumab emtansine</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2144"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2144">
              <Title>
                <range>Trastuzumab emtansine</range>
              </Title>
              <Case When="Initial application" Category="early breast cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has early breast cancer expressing
                    HER2 IHC3+ or ISH+</ci>
                    <ci type="logical" class="Indication">Documentation of pathological invasive
                    residual disease in the breast and/or auxiliary lymph nodes following completion
                    of surgery</ci>
                    <ci type="logical" class="Indication">Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery</ci>
                    <ci type="logical" class="Indication">Disease has not progressed during neoadjuvant therapy</ci>
                    <ci type="logical" class="Indication">Patient has left ventricular ejection fraction of 45% or greater</ci>
                    <ci type="logical" class="Indication">Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery</ci>
                    <ci type="logical" class="Indication">Trastuzumab emtansine to be discontinued at disease progression</ci>
                    <ci type="logical" class="Indication">Total adjuvant treatment duration must not exceed 42 weeks (14 cycles)</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="metastatic breast cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has metastatic breast cancer
                    expressing HER-2 IHC 3+ or ISH+ (including FISH or other current
                    technology)</ci>
                    <ci type="logical" class="Treatment">Patient has previously received trastuzumab and
                    chemotherapy, separately or in combination</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has received prior therapy for
                        metastatic disease*</ci>
                      <ci type="logical" class="Treatment">The patient developed disease recurrence
                        during, or within six months of completing adjuvant therapy*</ci>
                    </apply>
                    <ci type="logical" class="Treatment">Patient has a good performance status (ECOG
                    0-1)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient does not have symptomatic brain
                        metastases</ci>
                      <ci type="logical" class="Treatment">Patient has brain metastases and has
                        received prior local CNS therapy</ci>
                    </apply>
                    <ci type="logical" class="Treatment">Patient has not received prior funded trastuzumab emtansine treatment</ci>
                    <ci type="logical" class="Treatment">Treatment to be discontinued at disease
                    progression</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="metastatic breast cancer" Form="SA1871 SA2144">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The cancer has not progressed at any time
                    point during the previous approval period whilst on trastuzumab emtansine</ci>
                    <ci type="logical" class="Treatment">Treatment to be discontinued at disease
                    progression</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note" style="start">
                  <p>Prior or adjuvant therapy includes anthracycline, other chemotherapy,
                biological drugs, or endocrine therapy.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250704412225" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25070441222525">
                <Name>Kadcyla</Name>
                <Pack ID="P2444186" Specified="true" nzmt:ctpp_id="50149361000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>2320.00</Subsidy>
                  <Price>2320.00</Price>
                  <Alternate>2320.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704412226" Rank="4" Units="inj" Weight="160">
              <Name>Inj 160 mg vial</Name>
              <Brand ID="B25070441222625">
                <Name>Kadcyla</Name>
                <Pack ID="P2444194" Specified="true" nzmt:ctpp_id="50149481000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>3712.00</Subsidy>
                  <Price>3712.00</Price>
                  <Alternate>3712.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704412227" Rank="10" Units="mg">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070441222725">
                <Name>Baxter</Name>
                <Pack ID="P2579111" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>24.52</Subsidy>
                  <Price>24.52</Price>
                  <Alternate>24.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044124">
            <Name>Rituximab (Riximyo)</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2233"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2233">
              <Title>
                <range>Rituximab<instance>Riximyo</instance></range>
              </Title>
              <Case When="Initial application" Category="ABO-incompatible organ transplant">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">patient is to undergo an ABO-incompatible solid organ transplant*</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="ANCA associated vasculitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has been diagnosed with ANCA associated vasculitis*</ci>
                    <ci type="logical">The total rituximab dose would not exceed the equivalent of 375 mg/mÂ² of body-surface area per week for a total of 4 weeks</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months</ci>
                      <ci type="logical">Patient has previously had a cumulative dose of cyclophosphamide &gt;15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose &gt;15 g</ci>
                      <ci type="logical">Cyclophosphamide and methotrexate are contraindicated</ci>
                      <ci type="logical">Patient is a female of child-bearing potential</ci>
                      <ci type="logical">Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="ANCA associated vasculitis" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has been diagnosed with ANCA associated vasculitis*</ci>
                    <ci type="logical">Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis</ci>
                    <ci type="logical">The total rituximab dose would not exceed the equivalent of 375 mg/mÂ² of body-surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Antibody-mediated organ transplant rejection">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">patient has been diagnosed with antibody-mediated organ transplant rejection*</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Chronic lymphocytic leukaemia">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical">The patient is rituximab treatment naive</ci>
                      <apply>
                        <or/>
                        <ci type="logical">The patient is chemotherapy treatment naive</ci>
                        <apply>
                          <and/>
                          <ci type="logical">The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment</ci>
                          <ci type="logical">The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy</ci>
                        </apply>
                      </apply>
                      <ci type="logical">The patientâ€™s disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax</ci>
                    </apply>
                    <ci type="logical">The patient has good performance status</ci>
                    <apply>
                      <or/>
                      <ci type="logical">The patient does not have chromosome 17p deletion CLL</ci>
                      <ci type="logical">Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia</ci>
                    </apply>
                    <ci type="logical">Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles</ci>
                    <ci type="logical">It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <Lapse Measure="year">10</Lapse>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to &lt;2.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Chronic lymphocytic leukaemia" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">The patientâ€™s disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax</ci>
                      <apply>
                        <and/>
                        <ci type="logical">The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL</ci>
                        <ci type="logical">The patient has had an interval of 36 months or more since commencement of initial rituximab treatment</ci>
                        <ci type="logical">The patient does not have chromosome 17p deletion CLL</ci>
                        <ci type="logical">It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine</ci>
                      </apply>
                    </apply>
                    <ci type="logical">Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <Lapse Measure="year">10</Lapse>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Neuromyelitis Optica Spectrum Disorder(NMOSD)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks</ci>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD)</ci>
                      <apply>
                        <and/>
                        <ci type="logical">The patient has experienced a breakthrough attack of NMOSD</ci>
                        <ci type="logical">The patient is receiving treatment with mycophenolate</ci>
                        <ci type="logical">The patients is receiving treatment with corticosteroids</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Neuromyelitis Optica Spectrum Disorder" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks</ci>
                    <ci type="logical">The patients has responded to the most recent course of rituximab</ci>
                    <ci type="logical">The patient has not received rituximab in the previous 6 months</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Post-transplant">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has B-cell post-transplant lymphoproliferative disorder*</ci>
                    <ci type="logical">To be used for a maximum of 8 treatment cycles</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Post-transplant" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has had a rituximab treatment-free interval of 12 months or more</ci>
                    <ci type="logical">The patient has B-cell post-transplant lymphoproliferative disorder*</ci>
                    <ci type="logical">To be used for no more than 6 treatment cycles</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">9</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Severe Refractory Myasthenia Gravis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective</ci>
                      <apply>
                        <and/>
                        <ci type="logical">Treatment with at least one other immunosuppressant for a period of at least 12 months</ci>
                        <ci type="logical">Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">medical practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Renewal" Category="Severe Refractory Myasthenia Gravis" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart</ci>
                    <ci type="logical">An initial response lasting at least 12 months was demonstrated</ci>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months</ci>
                      <apply>
                        <and/>
                        <ci type="logical">The patientâ€™s myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months</ci>
                        <ci type="logical">Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">medical practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient is a child with SDNS* or FRNS*</ci>
                    <ci type="logical">Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity</ci>
                    <ci type="logical">Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects</ci>
                    <ci type="logical">Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/mÂ² of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="nephrologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient who was previously treated with rituximab for nephrotic syndrome*</ci>
                    <ci type="logical">Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/mÂ² of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="nephrologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Steroid resistant nephrotic syndrome (SRNS)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective</ci>
                    <ci type="logical">Treatment with tacrolimus for at least 3 months has been ineffective</ci>
                    <ci type="logical">Genetic causes of nephrotic syndrome have been excluded</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/mÂ² of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="nephrologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Steroid resistant nephrotic syndrome (SRNS)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient who was previously treated with rituximab for nephrotic syndrome*</ci>
                    <ci type="logical">Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/mÂ² of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="nephrologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="aggressive CD20 positive NHL">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has treatment naive aggressive CD20 positive NHL</ci>
                      <ci type="logical">To be used with a multi-agent chemotherapy regimen given with curative intent</ci>
                      <ci type="logical">To be used for a maximum of 8 treatment cycles</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy</ci>
                      <ci type="logical">To be used for a maximum of 6 treatment cycles</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia</p>
                </div>
              </Case>
              <Case When="Renewal" Category="aggressive CD20 positive NHL" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has had a rituximab treatment-free interval of 12 months or more</ci>
                    <ci type="logical">The patient has relapsed refractory/aggressive CD20 positive NHL</ci>
                    <ci type="logical">To be used with a multi-agent chemotherapy regimen given with curative intent</ci>
                    <ci type="logical">To be used for a maximum of 4 treatment cycles</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia</p>
                </div>
              </Case>
              <Case When="Initial application" Category="haemophilia with inhibitors">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Patient has mild congenital haemophilia complicated by inhibitors</ci>
                    <ci type="logical">Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy</ci>
                    <ci type="logical">Patient has acquired haemophilia</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="haemophilia with inhibitors" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient was previously treated with rituximab for haemophilia with inhibitors</ci>
                    <ci type="logical">An initial response lasting at least 12 months was demonstrated</ci>
                    <ci type="logical">Patient now requires repeat treatment</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="immune thrombocytopenic purpura (ITP)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre</ci>
                      <ci type="logical">Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical">Treatment with steroids and splenectomy have been ineffective</ci>
                      <ci type="logical">Treatment with steroids has been ineffective and splenectomy is an absolute contraindication</ci>
                      <ci type="logical">Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy)</ci>
                    </apply>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="immune thrombocytopenic purpura (ITP)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/mÂ² weekly for 4 weeks) is now planned</ci>
                    <apply>
                      <and/>
                      <ci type="logical">Patient was previously treated with rituximab for immune thrombocytopenic purpura*</ci>
                      <ci type="logical">An initial response lasting at least 12 months was demonstrated</ci>
                      <ci type="logical">Patient now requires repeat treatment</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="indolent, low-grade lymphomas or hairy cell leukaemia*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy</ci>
                      <ci type="logical">To be used for a maximum of 6 treatment cycles</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy</ci>
                      <ci type="logical">To be used for a maximum of 6 treatment cycles</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">9</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="indolent, low-grade lymphomas or hairy cell leukaemia*" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has had a rituximab treatment-free interval of 12 months or more</ci>
                    <ci type="logical">The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy</ci>
                    <ci type="logical">To be used for no more than 6 treatment cycles</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="pure red cell aplasia (PRCA)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder</ci>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="pure red cell aplasia (PRCA)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months</ci>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="severe cold haemagglutinin disease (CHAD)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has cold haemagglutinin disease*</ci>
                    <ci type="logical">Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="severe cold haemagglutinin disease (CHAD)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/mÂ² weekly for 4 weeks) is now planned</ci>
                    <apply>
                      <and/>
                      <ci type="logical">Patient was previously treated with rituximab for severe cold haemagglutinin disease*</ci>
                      <ci type="logical">An initial response lasting at least 12 months was demonstrated</ci>
                      <ci type="logical">Patient now requires repeat treatment</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="thrombotic thrombocytopenic purpura (TTP)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange</ci>
                      <ci type="logical">Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="thrombotic thrombocytopenic purpura (TTP)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*</ci>
                    <ci type="logical">An initial response lasting at least 12 months was demonstrated</ci>
                    <ci type="logical">Patient now requires repeat treatment</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="treatment refractory systemic lupus erythematosus (SLE)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has severe, immediately life- or organ-threatening SLE*</ci>
                    <ci type="logical">The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg</ci>
                    <ci type="logical">The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated</ci>
                    <ci type="logical">Maximum of four 1000 mg infusions of rituximab</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="rheumatologist or nephrologist">Practitioner</Applicant>
                <Term Measure="month">7</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="treatment refractory systemic lupus erythematosus (SLE)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patientâ€™s SLE* achieved at least a partial response to the previous round of prior rituximab treatment</ci>
                    <ci type="logical">The disease has subsequently relapsed</ci>
                    <ci type="logical">Maximum of two 1000 mg infusions of rituximab</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="rheumatologist or nephrologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="warm autoimmune haemolytic anaemia (warm AIHA)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has warm autoimmune haemolytic anaemia*</ci>
                    <ci type="logical">One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to &gt;5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="warm autoimmune haemolytic anaemia (warm AIHA)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/mÂ² weekly for 4 weeks) is now planned</ci>
                    <apply>
                      <and/>
                      <ci type="logical">Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*</ci>
                      <ci type="logical">An initial response lasting at least 12 months was demonstrated</ci>
                      <ci type="logical">Patient now requires repeat treatment</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant Referring="haematologist">Practitioner</Applicant>
                <Term Measure="week">8</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="severe antisynthetase syndrome">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has confirmed antisynthetase syndrome</ci>
                    <ci type="logical">Patient has severe, immediately life or organ threatening disease, including interstitial lung disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease</ci>
                      <ci type="logical">Rapid treatment is required due to life threatening complications</ci>
                    </apply>
                    <ci type="logical">Maximum of four 1,000mg infusions of rituximab</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="severe antisynthetase syndrome" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patientâ€™s disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function</ci>
                    <ci type="logical">The patient has not received rituximab in the previous 6 months</ci>
                    <ci type="logical">Maximum of two cycles of 2 x 1,000mg infusions of rituximab given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="graft versus host disease">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has refractory graft versus host disease following transplant</ci>
                    <ci type="logical">Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease</ci>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/mÂ² of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="severe chronic inflammatory demyelinating polyneuropathy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD)</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease</ci>
                        <ci type="logical">At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease</ci>
                      </apply>
                      <ci type="logical">Rapid treatment is required due to life threatening complications</ci>
                    </apply>
                    <ci type="logical">One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="severe chronic inflammatory demyelinating polyneuropathy" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patientâ€™s disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline</ci>
                    <ci type="logical">The patient has not received rituximab in the previous 6 months</ci>
                    <ci type="logical">One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="anti-NMDA receptor autoimmune encephalitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has severe anti-NMDA receptor autoimmune encephalitis</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical">Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease</ci>
                        <ci type="logical">At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease</ci>
                      </apply>
                      <ci type="logical">Rapid treatment is required due to life threatening complications</ci>
                    </apply>
                    <ci type="logical">One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="anti-NMDA receptor autoimmune encephalitis" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patientâ€™s disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function</ci>
                    <ci type="logical">The patient has not received rituximab in the previous 6 months</ci>
                    <ci type="logical">The patient has experienced a relapse and now requires further treatment</ci>
                    <ci type="logical">One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant Referring="neurologist">medical practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="CD20+ low grade or follicular B-cell NHL">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy</ci>
                      <ci type="logical">To be used for a maximum of 6 treatment cycles</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy</ci>
                      <ci type="logical">To be used for a maximum of 6 treatment cycles</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Renewal" Category="CD20+ low grade or follicular B-cell NHL" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy</ci>
                    <ci type="logical">Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of 12 cycles)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">24</Term>
              </Case>
              <Case When="Initial application" Category="Membranous nephropathy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has biopsy-proven primary/idiopathic membranous nephropathy*</ci>
                      <ci type="logical">Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of &gt;60ml/min/1.73m2</ci>
                    </apply>
                    <ci type="logical">Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note)</ci>
                    <ci type="logical">The total rituximab dose would not exceed the equivalent of 375mg/m2 of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="nephrologist">any relevant practitioner</Applicant>
                <Term Measure="week">6</Term>
              </Case>
              <Case When="Renewal" Category="Membranous nephropathy" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient was previously treated with rituximab for membranous nephropathy*</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment</ci>
                      <ci type="logical">Patient achieved partial response to treatment and requires repeat treatment (see Note)</ci>
                    </apply>
                    <ci type="logical">The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant Referring="nephrologist">any relevant practitioner</Applicant>
                <Term Measure="week">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>Indications marked with * are unapproved indications.</p>
                    </li>
                    <li>
                      <p>High risk of progression to end-stage kidney disease defined as &gt;5g/day proteinuria.</p>
                    </li>
                    <li>
                      <p>Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.</p>
                    </li>
                    <li>
                      <p>Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.</p>
                    </li>
                  </ol>
                </div>
              </Case>
              <Case When="Initial application" Category="B-cell acute lymphoblastic leukaemia/lymphoma*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*</ci>
                    <ci type="logical">Treatment must be in combination with an intensive chemotherapy protocol with curative intent</ci>
                    <ci type="logical">The total rituximab dose would not exceed the equivalent of 375 mg/mÂ² per dose for a maximum of 18 doses</ci>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Applicant Referring="relevant specialist">medical practitioner</Applicant>
                <Term Measure="year">2</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="desensisation prior to transplant">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient requires desensitisation prior to mismatched allogenic stem cell transplant*</ci>
                    <ci type="logical">Patient would receive no more than two doses at 375 mg/m2 of body-surface area</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="week">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="pemiphigus*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has severe rapidly progressive pemphigus</ci>
                      <ci type="logical">Is used in combination with systemic corticosteroids (20 mg/day)</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Skin involvement is at least 5% body surface area</ci>
                        <ci type="logical">Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions</ci>
                        <ci type="logical">Involvement of two or more mucosal sites</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has pemphigus</ci>
                      <ci type="logical">Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="pemiphigus*" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement</ci>
                    <ci type="logical">Patient has not received rituximab in the previous 6 months</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="immunoglobulin G4-related disease (IgG4-RD*)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has confirmed diagnosis of IgG4-RD*</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse</ci>
                      <ci type="logical">Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance</ci>
                    </apply>
                    <ci type="logical">Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="week">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="immunoglobulin G4-related disease (IgG4-RD*)" Form="SA1885 SA1902 SA1937 SA2028 SA2061 SA2083 SA2114 SA2233">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">Treatment with rituximab for IgG4-RD* was previously successful and patientâ€™s disease has demonstrated sustained response, but the condition has relapsed</ci>
                      <ci type="logical">Patient is receiving maintenance treatment for IgG4-RD*</ci>
                    </apply>
                    <ci type="logical">Rituximab re-treatment not to be given within 6 months of previous course of treatment</ci>
                    <ci type="logical">Maximum of two 1000 mg infusions of rituximab given two weeks apart</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250704412425" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070441242525">
                <Name>Baxter (Riximyo)</Name>
                <Pack ID="P2583984" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>1.38</Subsidy>
                  <Price>1.38</Price>
                  <Alternate>1.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704412426" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg per 10 ml vial</Name>
              <Brand ID="B25070441242625">
                <Name>Riximyo</Name>
                <Pack ID="P2583917" Specified="true" nzmt:ctpp_id="50250031000117104">
                  <Quantity>2</Quantity>
                  <Subsidy>275.33</Subsidy>
                  <Price>275.33</Price>
                  <Alternate>275.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704412427" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg per 50 ml vial</Name>
              <Brand ID="B25070441242725">
                <Name>Riximyo</Name>
                <Pack ID="P2583909" Specified="true" nzmt:ctpp_id="50250041000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>688.20</Subsidy>
                  <Price>688.20</Price>
                  <Alternate>688.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044127">
            <Name>Mepolizumab</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2154"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2154">
              <Title>
                <range>Mepolizumab</range>
              </Title>
              <Case When="Initial application" Category="Severe eosinophilic asthma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient must be aged 12 years or older</ci>
                    <ci type="logical" class="Indication">Patient must have a diagnosis of severe
                    eosinophilic asthma documented by a respiratory physician or clinical
                    immunologist</ci>
                    <ci type="logical" class="Indication">Conditions that mimic asthma eg. vocal cord
                    dysfunction, central airway obstruction, bronchiolitis etc. have been
                    excluded</ci>
                    <ci type="logical" class="Treatment">Patient has a blood eosinophil count of greater
                    than 0.5 x 10^9 cells/L in the last 12 months</ci>
                    <ci type="logical" class="Treatment">Patient must be adherent to optimised asthma
                    therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per
                    day of fluticasone propionate) plus long acting beta-2 agonist, or
                    budesonide/formoterol as part of the single maintenance and reliever therapy
                    regimen, unless contraindicated or not tolerated</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has had at least 4 exacerbations needing systemic
                        corticosteroids in the previous 12 months, where an exacerbation is defined
                        as either documented use of oral corticosteroids for at least 3 days or
                        parenteral corticosteroids</ci>
                      <ci type="logical">Patient has received continuous oral corticosteroids of at
                        least the equivalent of 10 mg per day over the previous 3 months</ci>
                    </apply>
                    <ci type="logical">Treatment is not to be used in combination with subsidised
                    benralizumab</ci>
                    <ci type="logical">Patient has an Asthma Control Test (ACT) score of 10 or less.
                    Baseline measurements of the patientâ€™s asthma control using the ACT and oral
                    corticosteroid dose must be made at the time of application, and again at around
                    52 weeks after the first dose to assess response to treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has not previously received an
                        anti-IL5 biological therapy for their severe eosinophilic asthma</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient was refractory or intolerant
                            to previous anti-IL5 biological therapy</ci>
                        <ci type="logical" class="Indication">Patient was not eligible to continue
                            treatment with previous anti-IL5 biological therapy and discontinued
                            within 12 months of commencing treatment</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory physician</Applicant>
                <Applicant>clinical immunologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1896 SA2154" Category="Severe eosinophilic asthma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">An increase in the Asthma Control Test (ACT) score of at least 5 from baseline</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab</ci>
                      <ci type="logical">Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory physician</Applicant>
                <Applicant>clinical immunologist</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F250704412725" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg vial</Name>
              <Brand ID="B25070441272525" ToBeDelisted="2024-08-01">
                <Name>Nucala</Name>
                <Pack ID="P2534460" Specified="true" nzmt:ctpp_id="50232951000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1638.00</Subsidy>
                  <Price>1638.00</Price>
                  <Alternate>1638.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704412726" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg prefilled pen</Name>
              <Brand ID="B25070441272625">
                <Name>Nucala</Name>
                <Pack ID="P2606836" Specified="true" nzmt:ctpp_id="50276021000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>1638.00</Subsidy>
                  <Price>1638.00</Price>
                  <Alternate>1638.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044154">
            <Name>Casirivimab and imdevimab</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2096"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2096">
              <Title>
                <range>Casirivimab and imdevimab</range>
              </Title>
              <Case When="Initial application" Category="Treatment of profoundly immunocompromised patients">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has confirmed (or probable) COVID-19</ci>
                    <ci type="logical" class="Indication">The patient is in the community with mild to moderate
          disease severity*</ci>
                    <ci type="logical" class="Indication">Patient is profoundly immunocompromised** and is at
          risk of not having mounted an adequate response to vaccination against COVID-19 or is
          unvaccinated</ci>
                    <ci type="logical" class="Indication">Patientâ€™s symptoms started within the last 10
          days</ci>
                    <ci type="logical" class="Indication">Patient is not receiving high flow oxygen or
          assisted/mechanical ventilation</ci>
                    <ci type="logical" class="Indication">Casirivimab and imdevimab is to be administered at a
          maximum dose of no greater than 2,400 mg</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="week">2</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>* Mild to moderate disease severity as described on the <a href="https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-information-health-professionals/covid-19-advice-all-health-professionals#adult-management">Ministry of Health Website</a></p>
                  <p>** Examples include B-cell depletive illnesses or patients receiving treatment that is
        B-Cell depleting.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250704415425" Rank="4" Units="inj" Weight="120">
              <Name>Inj 120 mg per ml casirivimab, 11.1 ml vial (1) and inj 120 mg per ml imdevimab, 11.1 ml vial (1)</Name>
              <Brand ID="B25070441542525">
                <Name>Ronapreve</Name>
                <Pack ID="P2630923" Specified="true" OP="true" nzmt:ctpp_id="50290861000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044155">
            <Name>Adalimumab (Amgevita)</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2178"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2178">
              <Title>
                <range>Adalimumab (Amgevita)</range>
              </Title>
              <Case When="Initial application" Category="Behcet's disease - severe">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has severe Behcet's disease* that is significantly
               impacting the patient's quality of life</ci>
                    <apply>
                      <or/>
                      <ci type="logical">The patient has severe ocular, neurological, and/or vasculitic
                  symptoms and has not responded adequately to one or more treatment(s) appropriate
                  for the particular symptom(s)</ci>
                      <ci type="logical">The patient has severe gastrointestinal, rheumatological, and/or
                  mucocutaneous symptoms and has not responded adequately to two or more treatments
                  appropriate for the particular symptom(s)</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Hidradenitis suppurativa">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage
               III lesions in distinct anatomic areas</ci>
                    <ci type="logical">Patient has tried, but had an inadequate response to at least a 90
               day trial of systemic antibiotics or has demonstrated intolerance to or has
               contraindications for systemic antibiotics</ci>
                    <ci type="logical">Patient has 3 or more active lesions</ci>
                    <ci type="logical">The patient has a DLQI of 10 or more and the assessment is no more
               than 1 month old at time of application</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="Hidradenitis suppurativa" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">The patient has a reduction in active lesions (e.g. inflammatory
               nodules, abscesses, draining fistulae) of 25% or more from baseline</ci>
                    <ci type="logical">The patient has a DLQI improvement of 4 or more from baseline</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Plaque psoriasis - severe chronic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has had an initial Special Authority approval for
                  etanercept for severe chronic plaque psoriasis</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has experienced intolerable side effects</ci>
                        <ci type="logical">Patient has received insufficient benefit to meet the renewal
                     criteria for etanercept for severe chronic plaque psoriasis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has "whole body" severe chronic plaque psoriasis with a
                     PASI score of greater than 10, where lesions have been present for at least 6
                     months from the time of initial diagnosis</ci>
                        <ci type="logical">Patient has severe chronic plaque psoriasis of the face, or
                     palm of a hand or sole of a foot, where the plaque or plaques have been present
                     for at least 6 months from the time of initial diagnosis</ci>
                      </apply>
                      <ci type="logical">Patient has tried, but had an inadequate response to, or has
                  experienced intolerable side effects from, at least three of the following (at
                  maximum tolerated doses unless contraindicated): phototherapy, methotrexate,
                  ciclosporin, or acitretin</ci>
                      <ci type="logical">A PASI assessment or DLQI assessment has been completed for at
                  least the most recent prior treatment course but no longer than 1 month following
                  cessation of each prior treatment course and is no more than 1 month old at the
                  time of application</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="Plaque psoriasis - severe chronic" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">Patient had "whole body" severe chronic plaque psoriasis at the
                  start of treatment</ci>
                      <apply>
                        <or/>
                        <ci type="logical">The patient has a PASI score which is reduced by 75% or more,
                     or is sustained at this level, when compared with the pre treatment baseline
                     value</ci>
                        <ci type="logical">The patient has a DLQI improvement of 5 or more, when compared
                     with the pre-treatment baseline value</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient had severe chronic plaque psoriasis of the face, or palm
                  of a hand or sole of a foot at the start of treatment</ci>
                      <apply>
                        <or/>
                        <ci type="logical">The patient has a reduction in the PASI symptom subscores for
                     all 3 of erythema, thickness and scaling, to slight or better, or sustained at
                     this level, as compared to the treatment course baseline values</ci>
                        <ci type="logical">The patient has a reduction of 75% or more in the skin area
                     affected, or sustained at this level, as compared to the pre treatment baseline
                     value</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="pyoderma gangrenosum">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has pyoderma gangrenosum*</ci>
                    <ci type="logical">Patient has received three months of conventional therapy including a
               minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or
               methotrexate) and has not received an adequate response</ci>
                  </apply>
                </math>
                <Applicant>dermatologist</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="Crohn's disease - adults">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has active Crohn's disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has a CDAI score of greater than or equal to 300, or HBI
                  score of greater than or equal to 10</ci>
                      <ci type="logical">Patient has extensive small intestine disease affecting more than
                  50 cm of the small intestine</ci>
                      <ci type="logical">Patient has evidence of short gut syndrome or would be at risk of
                  short gut syndrome with further bowel resection</ci>
                      <ci type="logical">Patient has an ileostomy or colostomy and has intestinal
                  inflammation</ci>
                    </apply>
                    <ci type="logical">Patient has tried but had an inadequate response to, or has
               experienced intolerable side effects from, prior therapy with immunomodulators and
               corticosteroids</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohn's disease - adults" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">CDAI score has reduced by 100 points from the CDAI score, or HBI
               score has reduced by 3 points, from when the patient was initiated on adalimumab</ci>
                    <ci type="logical">CDAI score is 150 or less, or HBI is 4 or less</ci>
                    <ci type="logical">The patient has demonstrated an adequate response to treatment, but
               CDAI score and/or HBI score cannot be assessed</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Crohn's disease - children">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Paediatric patient has active Crohn's disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has a PCDAI score of greater than or equal to 30</ci>
                      <ci type="logical">Patient has extensive small intestine disease</ci>
                    </apply>
                    <ci type="logical">Patient has tried but had an inadequate response to, or has
               experienced intolerable side effects from, prior therapy with immunomodulators and
               corticosteroids</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohn's disease - children" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">PCDAI score has reduced by 10 points from the PCDAI score when the
               patient was initiated on adalimumab</ci>
                    <ci type="logical">PCDAI score is 15 or less</ci>
                    <ci type="logical">The patient has demonstrated an adequate response to treatment but
               PCDAI score cannot be assessed</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Crohn's disease - fistulising">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has confirmed Crohn's disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has one or more complex externally draining
                  enterocutaneous fistula(e)</ci>
                      <ci type="logical">Patient has one or more rectovaginal fistula(e)</ci>
                      <ci type="logical">Patient has complex peri-anal fistula</ci>
                    </apply>
                    <ci type="logical">A Baseline Fistula Assessment has been completed and is no more than
               1 month old at the time of application</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohn's disease - fistulising" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">The number of open draining fistulae have decreased from baseline by
               at least 50%</ci>
                    <ci type="logical">There has been a marked reduction in drainage of all fistula(e) from
               baseline as demonstrated by a reduction in the Fistula Assessment score, together
               with less induration and patient-reported pain</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Ocular inflammation - chronic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">The patient has had an initial Special Authority approval for
               infliximab for chronic ocular inflammation</ci>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has severe uveitis uncontrolled with treatment of steroids
                  and other immunosuppressants with a severe risk of vision loss</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient is 18 years or older and treatment with at least two
                     other immunomodulatory agents has proven ineffective</ci>
                        <ci type="logical">Patient is under 18 years and treatment with methotrexate has
                     proven ineffective or is not tolerated at a therapeutic dose</ci>
                        <ci type="logical">Patient is under 8 years and treatment with steroids or
                     methotrexate has proven ineffective or is not tolerated at a therapeutic dose;
                     or disease requires control to prevent irreversible vision loss prior to
                     achieving a therapeutic dose of methotrexate</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="Ocular inflammation - chronic" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">The patient has had a good clinical response following 12 weeks'
               initial treatment</ci>
                    <ci type="logical">Following each 2 year treatment period, the patient has had a
               sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN)
               criteria &lt; Â½+ anterior chamber or vitreous cells, absence of active vitreous or
               retinal lesions, or resolution of uveitic cystoid macular oedema)</ci>
                    <ci type="logical">Following each 2 year treatment period, the patient has a sustained
               steroid sparing effect, allowing reduction in prednisone to &lt; 10mg daily, or
               steroid drops less than twice daily if under 18 years old</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Ocular inflammation - severe">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Patient has had an initial Special Authority approval for infliximab
               for severe ocular inflammation</ci>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has severe, vision-threatening ocular inflammation
                  requiring rapid control</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Treatment with high-dose steroids (intravenous
                     methylprednisolone) followed by high dose oral steroids has proven ineffective
                     at controlling symptoms</ci>
                        <ci type="logical">Patient developed new inflammatory symptoms while receiving
                     high dose steroids</ci>
                        <ci type="logical">Patient is aged under 8 years and treatment with high dose oral
                     steroids and other immunosuppressants has proven ineffective at controlling
                     symptoms</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="Ocular inflammation - severe" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">The patient has had a good clinical response following 3 initial
               doses</ci>
                    <ci type="logical">Following each 2 year treatment period, the patient has had a
               sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN)
               criteria &lt;Â½+ anterior chamber or vitreous cells, absence of active vitreous or
               retinal lesions, or resolution of uveitic cystoid macular oedema)</ci>
                    <ci type="logical">Following each 2 year treatment period, the patient has a sustained
               steroid sparing effect, allowing reduction in prednisone to &lt; 10mg daily, or
               steroid drops less than twice daily if under 18 years old</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="ankylosing spondylitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has had an initial Special Authority approval for
                  etanercept for ankylosing spondylitis</ci>
                      <apply>
                        <or/>
                        <ci type="logical">The patient has experienced intolerable side effects</ci>
                        <ci type="logical">The patient has received insufficient benefit to meet the
                     renewal criteria for ankylosing spondylitis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has a confirmed diagnosis of ankylosing spondylitis for
                  more than six months</ci>
                      <ci type="logical">Patient has low back pain and stiffness that is relieved by
                  exercise but not by rest</ci>
                      <ci type="logical">Patient has bilateral sacroiliitis demonstrated by radiology
                  imaging</ci>
                      <ci type="logical">Patient has not responded adequately to treatment with two or more
                  NSAIDs, while patient was undergoing at least 3 months of a regular exercise
                  regimen for ankylosing spondylitis</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has limitation of motion of the lumbar spine in the
                     sagittal and the frontal planes as determined by the following BASMI measures:
                     a modified Schober's test of less than or equal to 4 cm and lumbar side flexion
                     measurement of less than or equal to 10 cm (mean of left and right)</ci>
                        <ci type="logical">Patient has limitation of chest expansion by at least 2.5 cm
                     below the average normal values corrected for age and gender</ci>
                      </apply>
                      <ci type="logical">A BASDAI of at least 6 on a 0-10 scale completed after the 3 month
                  exercise trial, but prior to ceasing any previous pharmacological treatment and is
                  no more than 1 month old at the time of application</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="ankylosing spondylitis" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">treatment has resulted in an improvement in BASDAI of 4 or more points
            from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%,
            whichever is less</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis - oligoarticular course juvenile idiopathic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has had an initial Special Authority approval for
                  etanercept for oligoarticular course juvenile idiopathic arthritis (JIA)</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has experienced intolerable side effects</ci>
                        <ci type="logical">Patient has received insufficient benefit to meet the renewal
                     criteria for oligoarticular course JIA</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">To be used as an adjunct to methotrexate therapy or monotherapy
                  where use of methotrexate is limited by toxicity or intolerance</ci>
                      <ci type="logical">Patient has had oligoarticular course JIA for 6 months duration or
                  longer</ci>
                      <apply>
                        <or/>
                        <ci type="logical">At least 2 active joints with limited range of motion, pain or
                     tenderness after a 3-month trial of methotrexate (at the maximum tolerated
                     dose)</ci>
                        <ci type="logical">Moderate or high disease activity (cJADAS10 score greater than
                     1.5) with poor prognostic features after a 3-month trial of methotrexate (at
                     the maximum tolerated dose)</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis - oligoarticular course juvenile idiopathic" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Following initial treatment, the patient has at least a 50% decrease
               in active joint count and an improvement in physician's global assessment from
               baseline</ci>
                    <ci type="logical">On subsequent reapplications, the patient demonstrates at least a
               continuing 30% improvement in active joint count and continued improvement in
               physician's global assessment from baseline</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis - polyarticular course juvenile idiopathic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has had an initial Special Authority approval for
                  etanercept for polyarticular course juvenile idiopathic arthritis (JIA)</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has experienced intolerable side effects</ci>
                        <ci type="logical">Patient has received insufficient benefit to meet the renewal
                     criteria for polyarticular course JIA</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">To be used as an adjunct to methotrexate therapy or monotherapy
                  where use of methotrexate is limited by toxicity or intolerance</ci>
                      <ci type="logical">Patient has had polyarticular course JIA for 6 months duration or
                  longer</ci>
                      <apply>
                        <or/>
                        <ci type="logical">At least 5 active joints and at least 3 joints with limited
                     range of motion, pain or tenderness after a 3-month trial of methotrexate (at
                     the maximum tolerated dose)</ci>
                        <ci type="logical">Moderate or high disease activity (cJADAS10 score of at least
                     2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose)</ci>
                        <ci type="logical">Low disease activity (cJADAS10 score between 1.1 and 2.5) after
                     a 6-month trial of methotrexate</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>named specialist</Applicant>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis - polyarticular course juvenile idiopathic" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Following initial treatment, the patient has at least a 50% decrease
               in active joint count and an improvement in physician's global assessment from
               baseline</ci>
                    <ci type="logical">On subsequent reapplications, the patient demonstrates at least a
               continuing 30% improvement in active joint count and continued improvement in
               physician's global assessment from baseline</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis - psoriatic">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has had an initial Special Authority approval for
                  etanercept or secukinumab for psoriatic arthritis</ci>
                      <apply>
                        <or/>
                        <ci type="logical">The patient has experienced intolerable side effects</ci>
                        <ci type="logical">The patient has received insufficient benefit from to meet the
                     renewal criteria for psoriatic arthritis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has had active psoriatic arthritis for six months duration
                  or longer</ci>
                      <ci type="logical">Patient has tried and not responded to at least three months of
                  methotrexate at a maximum tolerated dose (unless contraindicated)</ci>
                      <ci type="logical">Patient has tried and not responded to at least three months of
                  sulfasalazine or leflunomide at maximum tolerated doses (unless
                  contraindicated)</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has persistent symptoms of poorly controlled and active
                     disease in at least 15 swollen joints</ci>
                        <ci type="logical">Patient has persistent symptoms of poorly controlled and active
                     disease in at least four joints from the following: wrist, elbow, knee, ankle,
                     and either shoulder or hip</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has a CRP level greater than 15 mg/L measured no more
                     than one month prior to the date of this application</ci>
                        <ci type="logical">Patient has an ESR greater than 25 mm per hour</ci>
                        <ci type="logical">ESR and CRP not measured as patient is currently receiving
                     prednisone therapy at a dose of greater than 5 mg per day and has done so for
                     more than three months</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis - psoriatic" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Following initial treatment, the patient has at least a 50% decrease
               in swollen joint count from baseline and a clinically significant response in the
               opinion of the physician</ci>
                    <ci type="logical">Patient demonstrates at least a continuing 30% improvement in swollen
               joint count from baseline and a clinically significant response in the opinion of the
               treating physician</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Arthritis - rheumatoid">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has had an initial Special Authority approval for
                  etanercept for rheumatoid arthritis</ci>
                      <apply>
                        <or/>
                        <ci type="logical">The patient has experienced intolerable side effects</ci>
                        <ci type="logical">The patient has received insufficient benefit from etanercept
                     to meet the renewal criteria for rheumatoid arthritis</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has had rheumatoid arthritis (either confirmed by
                  radiology imaging, or the patient is CCP antibody positive) for six months
                  duration or longer</ci>
                      <ci type="logical">Treatment is to be used as an adjunct to methotrexate therapy or
                  monotherapy where use of methotrexate is limited by toxicity or intolerance</ci>
                      <ci type="logical">Patient has tried and not responded to at least three months of
                  methotrexate at a maximum tolerated dose (unless contraindicated)</ci>
                      <ci type="logical">Patient has tried and not responded to at least three months of
                  methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at
                  maximum tolerated doses (unless contraindicated)</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has tried and not responded to at least three months of
                     methotrexate in combination with the maximum tolerated dose of ciclosporin</ci>
                        <ci type="logical">Patient has tried and not responded to at least three months of
                     therapy at the maximum tolerated dose of leflunomide alone or in combination
                     with methotrexate</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has persistent symptoms of poorly controlled and active
                     disease in at least 15 swollen joints</ci>
                        <ci type="logical">Patient has persistent symptoms of poorly controlled and active
                     disease in at least four joints from the following: wrist, elbow, knee, ankle,
                     and either shoulder or hip</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Arthritis - rheumatoid" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Following initial treatment, the patient has at least a 50% decrease
               in active joint count from baseline and a clinically significant response to
               treatment in the opinion of the physician</ci>
                    <ci type="logical">On subsequent reapplications, the patient demonstrates at least a
               continuing 30% improvement in active joint count from baseline and a clinically
               significant response to treatment in the opinion of the physician</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Still's disease - adult-onset (AOSD)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical">The patient has had an initial Special Authority approval for
                  etanercept and/or tocilizumab for AOSD</ci>
                      <apply>
                        <or/>
                        <ci type="logical">Patient has experienced intolerable side effects from
                     etanercept and/or tocilizumab</ci>
                        <ci type="logical">Patient has received insufficient benefit from at least a
                     three-month trial of etanercept and/or tocilizumab</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient diagnosed with AOSD according to the Yamaguchi
                  criteria</ci>
                      <ci type="logical">Patient has tried and not responded to at least 6 months of
                  glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate</ci>
                      <ci type="logical">Patient has persistent symptoms of disabling poorly controlled and
                  active disease</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
              <Case When="Initial application" Category="ulcerative colitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has active ulcerative colitis</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patientâ€™s SCCAI score is greater than or equal to 4</ci>
                      <ci type="logical">Patientâ€™s PUCAI score is greater than or equal to 20</ci>
                    </apply>
                    <ci type="logical">Patient has tried but had an inadequate response to, or has
               experienced intolerable side effects from prior therapy with immunomodulators and
               systemic corticosteroids</ci>
                    <ci type="logical">Surgery (or further surgery) is considered to be clinically
               inappropriate</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="ulcerative colitis" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">The SCCAI score has reduced by 2 points or more from the SCCAI score
               when the patient was initiated on biologic therapy</ci>
                    <ci type="logical">The PUCAI score has reduced by 10 points or more from the PUCAI score
               when the patient was initiation on biologic therapy</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="undifferentiated spondyloarthritis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has undifferentiated peripheral spondyloarthritis* with
               active peripheral joint arthritis in at least four joints from the following: wrist,
               elbow, knee, ankle, and either shoulder or hip</ci>
                    <ci type="logical">Patient has tried and not responded to at least three months of each
               of methotrexate, sulfasalazine and leflunomide, at maximum tolerated doses (unless
               contraindicated)</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has a CRP level greater than 15 mg/L measured no more than
                  one month prior to the date of this application</ci>
                      <ci type="logical">Patient has an ESR greater than 25 mm per hour measured no more
                  than one month prior to the date of this application</ci>
                      <ci type="logical">ESR and CRP not measured as patient is currently receiving
                  prednisone therapy at a dose of greater than 5 mg per day and has done so for more
                  than three months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications</p>
                </div>
              </Case>
              <Case When="Renewal" Category="undifferentiated spondyloarthritis" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Following initial treatment, the patient has at least a 50% decrease
               in active joint count from baseline and a clinically significant response to
               treatment in the opinion of the physician</ci>
                    <ci type="logical">The patient demonstrates at least a continuing 30% improvement in
               active joint count from baseline and a clinically significant response in the opinion
               of the treating physician</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="inflammatory bowel arthritis â€“ axial">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has a diagnosis of active ulcerative colitis or active
               Crohnâ€™s disease</ci>
                    <ci type="logical">Patient has axial inflammatory pain for six months or more</ci>
                    <ci type="logical">Patient is unable to take NSAIDs</ci>
                    <ci type="logical">Patient has unequivocal sacroiliitis demonstrated by radiological
               imaging or MRI</ci>
                    <ci type="logical">Patient has not responded adequately to prior treatment consisting of
               at least 3 months of an exercise regime supervised by a physiotherapist</ci>
                    <ci type="logical">A BASDAI of at least 6 on a 0-10 scale completed after the 3 month
               exercise trial, but prior to ceasing any previous pharmacological treatment</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="inflammatory bowel arthritis â€“ axial" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical">Treatment has resulted in an improvement in BASDAI of 4 or more points
            from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%,
            whichever is less</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="inflammatory bowel arthritis â€“ peripheral">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has a diagnosis of active ulcerative colitis or active
               Crohnâ€™s disease</ci>
                    <ci type="logical">Patient has active arthritis in at least four joints from the
               following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder,
               sternoclavicular</ci>
                    <ci type="logical">Patient has tried and not experienced a response to at least three
               months of methotrexate, or azathioprine at a maximum tolerated dose (unless
               contraindicated)</ci>
                    <ci type="logical">Patient has tried and not experienced a response to at least three
               months of sulfasalazine at a maximum tolerated dose (unless contraindicated)</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has a CRP level greater than 15 mg/L measured no more than
                  one month prior to the date of this application</ci>
                      <ci type="logical">Patient has an ESR greater than 25 mm per hour measured no more
                  than one month prior to the date of this application</ci>
                      <ci type="logical">ESR and CRP not measured as patient is currently receiving
                  prednisone therapy at a dose of greater than 5 mg per day and has done so for more
                  than three months</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="inflammatory bowel arthritis â€“ peripheral" Form="SA2102 SA2142 SA2177 SA2178">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical">Following initial treatment, patient has at least a 50% decrease in
               active joint count from baseline and a clinically significant response to treatment
               in the opinion of the physician</ci>
                    <ci type="logical">Patient has experienced at least a continuing 30% improvement in
               active joint count from baseline in the opinion of the treating physician</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F250704415525" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per 0.8 ml prefilled pen</Name>
              <Brand ID="B25070441552525" PSS="2026-07-31">
                <Name>Amgevita</Name>
                <Pack ID="P2631105" Specified="true" nzmt:ctpp_id="50252821000117106">
                  <Quantity>2</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>375.00</Subsidy>
                  <Price>375.00</Price>
                  <Alternate>375.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704415526" Rank="4" Units="inj" Weight="40">
              <Name>Inj 40 mg per 0.8 ml prefilled syringe</Name>
              <Brand ID="B25070441552625" PSS="2026-07-31">
                <Name>Amgevita</Name>
                <Pack ID="P2631113" Specified="true" nzmt:ctpp_id="50252771000117100">
                  <Quantity>2</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>375.00</Subsidy>
                  <Price>375.00</Price>
                  <Alternate>375.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704415527" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mg per 0.4 ml prefilled syringe</Name>
              <Brand ID="B25070441552725" PSS="2026-07-31">
                <Name>Amgevita</Name>
                <Pack ID="P2631121" Specified="true" nzmt:ctpp_id="50252741000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>190.00</Subsidy>
                  <Price>190.00</Price>
                  <Alternate>190.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044159">
            <Name>Gemtuzumab ozogamicin</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2269"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2269">
              <Title>
                <range>Gemtuzumab ozogamicin</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has not received prior chemotherapy for this condition</ci>
                    <ci type="logical">Patient has de novo CD33-positive acute myeloid leukaemia</ci>
                    <ci type="logical">Patient does not have acute promyelocytic leukaemia</ci>
                    <ci type="logical">Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC)</ci>
                    <ci type="logical">Patient is being treated with curative intent</ci>
                    <ci type="logical">Patientâ€™s disease risk has been assessed by cytogenetic testing to be good or intermediate</ci>
                    <ci type="logical">Patient must be considered eligible for standard intensive remission induction chemotherapy with standard anthracycline and cytarabine (AraC)</ci>
                    <ci type="logical">Gemtuzumab ozogamicin to be funded for one course only (one dose at 3 mg per mÂ² body surface area or up to 2 vials of 5 mg as separate doses)</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Applicant>paediatric haematologist</Applicant>
                <Applicant>paediatric oncologist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (eg myelodysplasia or myeloproliferative disorder).</p>
              </div>
            </Request>
            <Formulation ID="F250704415925" Rank="4" Units="inj">
              <Name>Inj 5 mg vial</Name>
              <Brand ID="B25070441592525">
                <Name>Mylotarg</Name>
                <Pack ID="P2611678" Specified="true">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>12973.00</Subsidy>
                  <Price>12973.00</Price>
                  <Alternate>12973.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044160">
            <Name>Tixagevimab with cilgavimab</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Treatment is funded only if patient meets access criteria for tixagevimab with cilgavimab (as
        per https://pharmac.govt.nz/Evusheld) and has been endorsed accordingly by the prescriber.
        The supply of treatment is via Pharmacâ€™s approved distribution process. Refer to the Pharmac
        website for more information about this and stock availability.</p>
            </div>
            <Formulation ID="F250704416025" Rank="4" Units="inj" Weight="100">
              <Name>Inj 100 mg per ml, 1.5 ml vial with cilgavimab 100 mg per ml,1.5 ml vial</Name>
              <Brand ID="B25070441602525">
                <Name>Evusheld</Name>
                <Pack ID="P2639750" Specified="true" nzmt:ctpp_id="50299311000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044163">
            <Name>Benralizumab</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2151"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2151">
              <Title>
                <range>Benralizumab</range>
              </Title>
              <Case When="Initial application" Category="Severe eosinophilic asthma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient must be aged 12 years or older</ci>
                    <ci type="logical" class="Indication">Patient must have a diagnosis of severe
                    eosinophilic asthma documented by a respiratory physician or clinical
                    immunologist</ci>
                    <ci type="logical" class="Indication">Conditions that mimic asthma eg. vocal cord
                    dysfunction, central airway obstruction, bronchiolitis etc. have been
                    excluded</ci>
                    <ci type="logical" class="Indication">Patient has a blood eosinophil count of
                    greater than 0.5 Ã— 10^9 cells/L in the last 12 months</ci>
                    <ci type="logical" class="Indication">Patient must be adherent to optimised asthma
                    therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per
                    day of fluticasone propionate) plus long-acting beta-2 agonist, or
                    budesonide/formoterol as part of the anti-inflammatory reliever therapy plus
                    maintenance regimen, unless contraindicated or not tolerated</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has had at least 4 exacerbations
                        needing systemic corticosteroids in the previous 12 months, where an
                        exacerbation is defined as either documented use of oral corticosteroids for
                        at least 3 days or parenteral corticosteroids</ci>
                      <ci type="logical" class="Indication">Patient has received continuous oral
                        corticosteroids of at least the equivalent of 10 mg per day over the
                        previous 3 months</ci>
                    </apply>
                    <ci type="logical" class="Indication">Treatment is not to be used in combination
                    with subsidised mepolizumab</ci>
                    <ci type="logical" class="Indication">Patient has an Asthma Control Test (ACT) score
                    of 10 or less. Baseline measurements of the patientâ€™s asthma control using the
                    ACT and oral corticosteroid dose must be made at the time of application, and
                    again at around 52 weeks after the first dose to assess response to
                    treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has not previously received an
                        anti-IL5 biological therapy for their severe eosinophilic asthma</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient was refractory or intolerant
                            to previous anti-IL5 biological therapy</ci>
                        <ci type="logical" class="Indication">Patient was not eligible to continue
                            treatment with previous anti-IL5 biological therapy and discontinued
                            within 12 months of commencing treatment</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory physician</Applicant>
                <Applicant>clinical immunologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="Severe eosinophilic asthma" Form="SA2151">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">An increase in the Asthma Control Test (ACT)
                    score of at least 5 from baseline</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Exacerbations have been reduced from
                        baseline by 50% as a result of treatment with benralizumab</ci>
                      <ci type="logical" class="Indication">Reduction in continuous oral
                        corticosteroid use by 50% or by 10 mg/day while maintaining or improving
                        asthma control</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory physician</Applicant>
                <Applicant>clinical immunologist</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Formulation ID="F250704416325" Rank="4" Units="inj">
              <Name>Inj 30 mg per ml, 1 ml prefilled pen</Name>
              <Brand ID="B25070441632525">
                <Name>Fasenra</Name>
                <Pack ID="P2638746" Specified="true" nzmt:ctpp_id="50284831000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>3539.00</Subsidy>
                  <Price>3539.00</Price>
                  <Alternate>3539.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044171">
            <Name>Ustekinumab</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2182"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2182">
              <Title>
                <range>Ustekinumab</range>
              </Title>
              <Case When="Initial application" Category="Crohn's disease - adults">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient is currently on treatment with
                    ustekinumab commenced prior to 1 February 2023 and met all remaining criteria
                    (criterion 2) below at the time of commencing treatment</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has active Crohn's disease</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has had an initial approval
                            for prior biologic therapy for Crohnâ€™s disease and has experienced
                            intolerable side effects or insufficient benefit to meet renewal
                            criteria</ci>
                        <apply>
                          <and/>
                          <ci type="logical" class="Indication">Patient meets the initiation
                                criteria for prior biologic therapies for Crohnâ€™s disease</ci>
                          <ci type="logical" class="Indication">Other biologics for Crohnâ€™s
                                disease are contraindicated</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohn's disease - adults" Form="SA2182">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">CDAI score has reduced by 100 points, or HBI
                        score has reduced by 3 points, from when the patient was initiated on
                        biologic therapy</ci>
                      <ci type="logical" class="Use">CDAI score is 150 or less, or HBI is 4 or
                        less</ci>
                      <ci type="logical" class="Use">The patient has experienced an adequate response
                        to treatment, but CDAI score and/or HBI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical" class="Use">Ustekinumab to be administered at a dose no greater
                    than 90 mg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="Crohn's disease - children*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient is currently on treatment with
                    ustekinumab commenced prior to 1 February 2023 and met all remaining criteria
                    (criterion 2) below at the time of commencing treatment</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has active Crohn's disease</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has had an initial approval
                            for prior biologic therapy and has experienced intolerable side effects
                            or insufficient benefit to meet renewal criteria</ci>
                        <apply>
                          <and/>
                          <ci type="logical" class="Indication">Patient meets the initiation
                                criteria for prior biologic therapies for Crohnâ€™s disease</ci>
                          <ci type="logical" class="Indication">Other biologics for Crohnâ€™s
                                disease are contraindicated</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indication marked with * is an unapproved indication.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Crohn's disease - children*" Form="SA2182">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">PCDAI score has reduced by 10 points from when
                        the patient was initiated on biologic therapy</ci>
                      <ci type="logical" class="Use">PCDAI score is 15 or less</ci>
                      <ci type="logical" class="Use">The patient has experienced an adequate response
                        to treatment, but CDAI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical" class="Indication">Ustekinumab to administered at a dose no
                    greater than 90 mg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indication marked with * is an unapproved indication.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="ulcerative colitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient is currently on treatment with
                    ustekinumab commenced prior to 1 February 2023 and met all remaining criteria
                    (criterion 2) below at the time of commencing treatment</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has active ulcerative colitis</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient has had an initial approval
                            for prior biologic therapy for ulcerative colitis and has experienced
                            intolerable side effects or insufficient benefit to meet renewal
                            criteria</ci>
                        <apply>
                          <and/>
                          <ci type="logical" class="Indication">Patient meets the initiation criteria for prior biologic therapies for ulcerative colitis</ci>
                          <ci type="logical" class="Indication">Other biologics for ulcerative colitis are contraindicated</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="ulcerative colitis" Form="SA2182">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy</ci>
                      <ci type="logical" class="Use">PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy*</ci>
                    </apply>
                    <ci type="logical" class="Indication">Ustekinumab will be used at a dose no greater than 90 mg intravenously every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Criterion marked with * is for an unapproved indication.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250704417125" Rank="4" Units="inj">
              <Name>Inj 90 mg per ml, 1 ml pre-filled syringe</Name>
              <Brand ID="B25070441712525">
                <Name>Stelara</Name>
                <Pack ID="P2455544" Specified="true" nzmt:ctpp_id="50201311000117106">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>4162.00</Subsidy>
                  <Price>4162.00</Price>
                  <Alternate>4162.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044172">
            <Name>Vedolizumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2183"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2183">
              <Title>
                <range>Vedolizumab</range>
              </Title>
              <Case When="Initial application" Category="Crohn's disease - adults">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has active Crohn's disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated)</ci>
                      <ci type="logical" class="Use">Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10</ci>
                      <ci type="logical" class="Use">Patient has extensive small intestine disease affecting more than 50 cm of the small intestine</ci>
                      <ci type="logical" class="Use">Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection</ci>
                      <ci type="logical" class="Use">Patient has an ileostomy or colostomy, and has intestinal inflammation</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids</ci>
                      <ci type="logical" class="Use">Patient has experienced intolerable side effects from immunomodulators and corticosteroids</ci>
                      <ci type="logical" class="Use">Immunomodulators and corticosteroids are contraindicated</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Crohn's disease - adults" Form="SA2183">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy</ci>
                      <ci type="logical" class="Use">CDAI score is 150 or less, or HBI is 4 or less</ci>
                      <ci type="logical" class="Use">The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical" class="Use">Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Initial application" Category="Crohn's disease - children*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Paediatric patient has active Crohnâ€™s disease</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated)</ci>
                      <ci type="logical" class="Use">Patient has a Paediatric Crohnâ€™s Disease Activity Index (PCDAI) score of greater than or equal to 30</ci>
                      <ci type="logical" class="Use">Patient has extensive small intestine disease</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids</ci>
                      <ci type="logical" class="Use">Patient has experienced intolerable side effects from immunomodulators and corticosteroids</ci>
                      <ci type="logical" class="Use">Immunomodulators and corticosteroids are contraindicated</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indication marked with * is an unapproved indication.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="Crohn's disease - children*" Form="SA2183">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Use">PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy</ci>
                      <ci type="logical" class="Use">PCDAI score is 15 or less</ci>
                      <ci type="logical" class="Use">The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed</ci>
                    </apply>
                    <ci type="logical" class="Indication">Vedolizumab to administered at a dose no greater than 300mg every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indication marked with * is an unapproved indication.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="ulcerative colitis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has active ulcerative colitis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated)</ci>
                      <ci type="logical" class="Indication">Patient has a SCCAI score is greater than or equal to 4</ci>
                      <ci type="logical" class="Indication">Patientâ€™s PUCAI score is greater than or equal to 20*</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids</ci>
                      <ci type="logical" class="Indication">Patient has experienced intolerable side effects from immunomodulators and corticosteroids</ci>
                      <ci type="logical" class="Indication">Immunomodulators and corticosteroids are contraindicated</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indication marked with * is an unapproved indication.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="ulcerative colitis" Form="SA2183">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy</ci>
                      <ci type="logical" class="Indication">The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy *</ci>
                    </apply>
                    <ci type="logical" class="Indication">Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="year">2</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indication marked with * is an unapproved indication.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250704417225" Rank="4" Units="inj">
              <Name>Inj 300 mg vial</Name>
              <Brand ID="B25070441722525">
                <Name>Entyvio</Name>
                <Pack ID="P2649144" Specified="true" nzmt:ctpp_id="50276411000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>3313.00</Subsidy>
                  <Price>3313.00</Price>
                  <Alternate>3313.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044182">
            <Name>Brentuximab Vedotin</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2289"/>
            <Request Form="SA2289" To="HealthPAC" For="Subsidy">
              <Title>
                <range>Brentuximab</range>
              </Title>
              <Case When="Initial application" Category="relapsed/refractory Hodgkin lymphoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has relapsed/refractory CD30-positive Hodgkin lymphoma after two or more lines of chemotherapy</ci>
                        <ci type="logical" class="Indication">Patient is ineligible for autologous stem cell transplant</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient has relapsed/refractory CD30-positive Hodgkin lymphoma</ci>
                        <ci type="logical" class="Indication">Patient has previously undergone autologous stem cell transplant</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Patient has not previously received funded brentuximab vedotin</ci>
                    <ci type="logical" class="Indication">Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles</ci>
                    <ci type="logical" class="Indication">Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="relapsed/refractory Hodgkin lymphoma" Form="SA2289">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles</ci>
                    <ci type="logical" class="Indication">Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated</ci>
                    <ci type="logical" class="Indication">Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">9</Term>
              </Case>
              <Case When="Initial application" Category="anaplastic large cell lymphoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has relapsed/refractory CD30-positive systemic anaplastic large cell lymphoma</ci>
                    <ci type="logical" class="Indication">Patient has an ECOG performance status of 0-1</ci>
                    <ci type="logical" class="Indication">Patient has not previously received brentuximab vedotin</ci>
                    <ci type="logical" class="Indication">Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles</ci>
                    <ci type="logical" class="Indication">Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="anaplastic large cell lymphoma" Form="SA2289">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles</ci>
                    <ci type="logical" class="Indication">Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated</ci>
                    <ci type="logical" class="Indication">Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">9</Term>
              </Case>
            </Request>
            <Formulation ID="F250704418225" Rank="4" Units="inj" Weight="50">
              <Name>Inj 50 mg vial</Name>
              <Brand ID="B25070441822525">
                <Name>Adcetris</Name>
                <Pack ID="P2649152" Specified="true" nzmt:ctpp_id="50208141000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>5275.18</Subsidy>
                  <Price>5275.18</Price>
                  <Alternate>5275.18</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507044183">
            <Name>Trastuzumab (Herzuma)</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2293"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2293">
              <Title>
                <range>Trastuzumab (Herzuma)</range>
              </Title>
              <Case When="Initial application" Category="early breast cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology)</ci>
                    <ci type="logical" class="Indication">Maximum cumulative dose of 106 mg/kg (12 months' treatment)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">15</Term>
              </Case>
              <Case When="Renewal" Category="early breast cancer*" Form="SA2293">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci>
                      <ci type="logical" class="Indication">The patient received prior adjuvant trastuzumab treatment for early breast cancer</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer</ci>
                        <ci type="logical" class="Indication">The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib</ci>
                        <ci type="logical" class="Indication">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab</ci>
                      </apply>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Trastuzumab will not be given in combination with pertuzumab</ci>
                        <apply>
                          <and/>
                          <ci type="logical" class="Indication">Trastuzumab to be administered in combination with pertuzumab</ci>
                          <ci type="logical" class="Indication">Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior
                (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer</ci>
                          <ci type="logical" class="Indication">The patient has good performance status (ECOG grade 0-1)</ci>
                        </apply>
                      </apply>
                      <ci type="logical" class="Indication">Trastuzumab to be discontinued at disease progression</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease
            progression</ci>
                      <ci type="logical" class="Indication">Patient has signs of disease progression</ci>
                      <ci type="logical" class="Indication">Disease has not progressed during previous treatment with trastuzumab</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>* For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer</p>
                </div>
              </Case>
              <Case When="Initial application" Category="metastatic breast cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer</ci>
                      <ci type="logical" class="Indication">The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Trastuzumab will not be given in combination with pertuzumab</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Trastuzumab to be administered in combination with pertuzumab</ci>
                        <ci type="logical" class="Indication">Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior
              (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer</ci>
                        <ci type="logical" class="Indication">The patient has good performance status (ECOG grade 0-1)</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Trastuzumab to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="metastatic breast cancer" Form="SA2293">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci>
                      <ci type="logical" class="Indication">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab</ci>
                      <ci type="logical" class="Indication">Trastuzumab to be discontinued at disease progression</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression</ci>
                      <ci type="logical" class="Indication">Patient has signs of disease progression</ci>
                      <ci type="logical" class="Indication">Disease has not progressed during previous treatment with trastuzumab</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Initial application" Category="gastric, gastro-oesophageal junction and oesophageal cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other
          current technology)</ci>
                    <ci type="logical" class="Indication">Patient has an ECOG score of 0-2</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="gastric, gastro-oesophageal junction and oesophageal cancer" Form="SA2293">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab</ci>
                    <ci type="logical" class="Indication">Trastuzumab to be discontinued at disease progression</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F250704418325" Rank="4" Units="inj" Weight="150">
              <Name>Inj 150 mg vial</Name>
              <Brand ID="B25070441832525" ToBePSS="2024-06-01">
                <Name>Herzuma</Name>
                <Pack ID="P2670127" Specified="true" nzmt:ctpp_id="50243261000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>100.00</Subsidy>
                  <Price>100.00</Price>
                  <Alternate>100.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704418326" Rank="4" Units="inj" Weight="440">
              <Name>Inj 440 mg vial</Name>
              <Brand ID="B25070441832625" ToBePSS="2024-06-01">
                <Name>Herzuma</Name>
                <Pack ID="P2670135" Specified="true" nzmt:ctpp_id="50243301000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>293.35</Subsidy>
                  <Price>293.35</Price>
                  <Alternate>293.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250704418327" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070441832725">
                <Name>Baxter</Name>
                <Pack ID="P2669994" Specified="true">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.70</Subsidy>
                  <Price>0.70</Price>
                  <Alternate>0.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250705">
          <Name>Programmed Cell Death-1 (PD-1) Inhibitors</Name>
          <Chemical ID="C2507054069">
            <Name>Nivolumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2306"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2306">
              <Title>
                <range>Nivolumab</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has metastatic or unresectable melanoma (excluding uveal)
                    stage III or IV</ci>
                    <ci type="logical">Baseline measurement of overall tumour burden is documented clinically and radiologically</ci>
                    <ci type="logical">The patient has ECOG performance score of 0-2</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has not received funded pembrolizumab</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Trial">Patient has received an initial Special
                            Authority approval for pembrolizumab and has discontinued pembrolizumab 
                            within 12 weeks of starting treatment due to intolerance</ci>
                        <ci type="logical" class="Trial">The cancer did not progress while the
                            patient was on pembrolizumab</ci>
                      </apply>
                    </apply>
                    <ci type="logical">Documentation confirming that the patient has been informed and
                    acknowledges that funded treatment with nivolumab will not be continued if their
                    disease progresses</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="less than 24 months on treatment" Form="SA1911 SA2006 SA2120 SA2306">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical">Patient's disease has had a complete response to
                            treatment</ci>
                        <ci type="logical">Patient's disease has had a partial response to treatment</ci>
                        <ci type="logical">Patient has stable disease</ci>
                      </apply>
                      <ci type="logical">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period</ci>
                      <ci type="logical">The treatment remains clinically appropriate and the patient
                        is benefitting from the treatment</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has previously discontinued treatment with nivolumab
                        for reasons other than severe toxicity or disease progression</ci>
                      <ci type="logical">Patient has signs of disease progression</ci>
                      <ci type="logical">Disease has not progressed during previous treatment with
                        nivolumab</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="more than 24 months on treatment" Form="SA1911 SA2006 SA2120 SA2306">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has been on treatment for more than 24 months</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <apply>
                          <or/>
                          <ci type="logical">Patient's disease has had a complete response to treatment</ci>
                          <ci type="logical">Patient's disease has had a partial response to treatment</ci>
                          <ci type="logical">Patient has stable disease</ci>
                        </apply>
                        <ci type="logical">Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period</ci>
                        <ci type="logical">The treatment remains clinically appropriate and the patient is benefitting from the treatment</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical">Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression</ci>
                        <ci type="logical">Patient has signs of disease progression</ci>
                        <ci type="logical">Disease has not progressed during previous treatment with nivolumab</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
            </Request>
            <Formulation ID="F250705406925" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070540692525">
                <Name>Baxter</Name>
                <Pack ID="P2503476" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>27.62</Subsidy>
                  <Price>27.62</Price>
                  <Alternate>27.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250705406926" Rank="4" Units="inj" Weight="40">
              <Name>Inj 10 mg per ml, 4 ml vial</Name>
              <Brand ID="B25070540692625">
                <Name>Opdivo</Name>
                <Pack ID="P2504138" Specified="true" nzmt:ctpp_id="50229151000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>1051.98</Subsidy>
                  <Price>1051.98</Price>
                  <Alternate>1051.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250705406927" Rank="4" Units="inj" Weight="100">
              <Name>Inj 10 mg per ml, 10 ml vial</Name>
              <Brand ID="B25070540692725">
                <Name>Opdivo</Name>
                <Pack ID="P2504146" Specified="true" nzmt:ctpp_id="50229161000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>2629.96</Subsidy>
                  <Price>2629.96</Price>
                  <Alternate>2629.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507054072">
            <Name>Pembrolizumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2307"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2307">
              <Title>
                <range>Pembrolizumab</range>
              </Title>
              <Case When="Initial application" Category="unresectable or metastatic melanoma">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has metastatic or unresectable melanoma (excluding uveal)
                    stage III or IV</ci>
                    <ci type="logical">Baseline measurement of overall tumour burden is documented clinically and radiologically</ci>
                    <ci type="logical">The patient has ECOG performance score of 0-2</ci>
                    <apply>
                      <or/>
                      <ci type="logical">Patient has not received funded nivolumab</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Trial">Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within
                            12 weeks of starting treatment due to intolerance</ci>
                        <ci type="logical" class="Trial">The cancer did not progress while the
                            patient was on nivolumab</ci>
                      </apply>
                    </apply>
                    <ci type="logical">Documentation confirming that the patient has been informed and
                    acknowledges that funded treatment with pembrolizumab will not be continued if
                    their disease progresses</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="unresectable or metastatic melanoma, less than 24 months on treatment" Form="SA1615 SA1657 SA1862 SA1910 SA2007 SA2121 SA2197 SA2241 SA2265 SA2307">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <apply>
                        <or/>
                        <ci type="logical">Patient's disease has had a complete response to treatment</ci>
                        <ci type="logical">Patient's disease has had a partial response to treatment</ci>
                        <ci type="logical">Patient has stable disease</ci>
                      </apply>
                      <ci type="logical">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period</ci>
                      <ci type="logical">The treatment remains clinically appropriate and the patient is benefitting from the treatment</ci>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical">Patient has previously discontinued treatment with
                        pembrolizumab for reasons other than severe toxicity or disease
                        progression</ci>
                      <ci type="logical">Patient has signs of disease progression</ci>
                      <ci type="logical">Disease has not progressed during previous treatment with
                        pembrolizumab</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="unresectable or metastatic melanoma, more than 24 months on treatment" Form="SA1615 SA1657 SA1862 SA1910 SA2007 SA2121 SA2197 SA2241 SA2265 SA2307">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has been on treatment for more than 24 months</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <apply>
                          <or/>
                          <ci type="logical">Patient's disease has had a complete response to treatment</ci>
                          <ci type="logical">Patient's disease has had a partial response to treatment</ci>
                          <ci type="logical">Patient has stable disease</ci>
                        </apply>
                        <ci type="logical">Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period</ci>
                        <ci type="logical">The treatment remains clinically appropriate and the patient is benefitting from the treatment</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical">Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression</ci>
                        <ci type="logical">Patient has signs of disease progression</ci>
                        <ci type="logical">Disease has not progressed during previous treatment with pembrolizumab</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="non-small cell lung cancer first-line monotherapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has locally advanced or metastatic, unresectable,
                    non-small cell lung cancer</ci>
                    <ci type="logical">Patient has not had chemotherapy for their disease in the
                    palliative setting</ci>
                    <ci type="logical">Patient has not received prior funded treatment with an immune
                    checkpoint inhibitor for NSCLC</ci>
                    <ci type="logical">For patients with non-squamous histology there is documentation confirming that the disease does not
                    express activating mutations of EGFR or ALK tyrosine kinase unless not possible
                    to ascertain</ci>
                    <ci type="logical">Pembrolizumab to be used as monotherapy</ci>
                    <apply>
                      <or/>
                      <ci type="logical">There is documentation confirming the disease expresses PD-L1
                        at a level greater than or equal to 50% as determined by a validated test
                        unless not possible to ascertain</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Trial">There is documentation confirming the
                            disease expresses PD-L1 at a level greater than or equal to 1% as
                            determined by a validated test unless not possible to ascertain</ci>
                        <ci type="logical" class="Trial">Chemotherapy is determined to be not in the
                            best interest of the patient based on clinician assessment</ci>
                      </apply>
                    </apply>
                    <ci type="logical">Patient has an ECOG 0-2</ci>
                    <ci type="logical">Pembrolizumab to be used at a maximum dose of 200 mg every three
                    weeks (or equivalent) for a maximum of 16 weeks</ci>
                    <ci type="logical">Baseline measurement of overall tumour burden is documented
                    clinically and radiologically</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="non-small cell lung cancer first line monotherapy" Form="SA1615 SA1657 SA1862 SA1910 SA2007 SA2121 SA2197 SA2241 SA2265 SA2307">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">Patientâ€™s disease has had a complete response to
                        treatment</ci>
                      <ci type="logical">Patientâ€™s disease has had a partial response to
                        treatment</ci>
                      <ci type="logical">Patient has stable disease</ci>
                    </apply>
                    <ci type="logical">Response to treatment in target lesions has been determined by
                    comparable radiologic assessment following the most recent treatment period</ci>
                    <ci type="logical">No evidence of disease progression</ci>
                    <ci type="logical">The treatment remains clinically appropriate and patient is
                    benefitting from treatment</ci>
                    <ci type="logical">Pembrolizumab to be used at a maximum dose of 200 mg every three
                    weeks (or equivalent)</ci>
                    <ci type="logical">Treatment with pembrolizumab to cease after a total duration of
                    24 months from commencement (or equivalent of 35 cycles dosed every 3
                    weeks)</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Initial application" Category="non-small cell lung cancer first-line combination therapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has locally advanced or metastatic, unresectable,
                    non-small cell lung cancer</ci>
                    <ci type="logical">The patient has not had chemotherapy for their disease in the
                    palliative setting</ci>
                    <ci type="logical">Patient has not received prior funded treatment with an immune
                    checkpoint inhibitor for NSCLC</ci>
                    <ci type="logical">For patients with non-squamous histology there is documentation confirming that the disease does not
                    express activating mutations of EGFR or ALK tyrosine kinase unless not possible
                    to ascertain</ci>
                    <ci type="logical">Pembrolizumab to be used in combination with platinum-based
                    chemotherapy</ci>
                    <ci type="logical">Patient has an ECOG 0-2</ci>
                    <ci type="logical">Pembrolizumab to be used at a maximum dose of 200 mg every three
                    weeks (or equivalent) for a maximum of 16 weeks</ci>
                    <ci type="logical">Baseline measurement of overall tumour burden is documented
                    clinically and radiologically</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="non-small cell lung cancer first line combination therapy" Form="SA1615 SA1657 SA1862 SA1910 SA2007 SA2121 SA2197 SA2241 SA2265 SA2307">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">Patientâ€™s disease has had a complete response to
                        treatment</ci>
                      <ci type="logical">Patientâ€™s disease has had a partial response to
                        treatment</ci>
                      <ci type="logical">Patient has stable disease</ci>
                    </apply>
                    <ci type="logical">Response to treatment in target lesions has been determined by
                    comparable radiologic assessment following the most recent treatment period</ci>
                    <ci type="logical">No evidence of disease progression</ci>
                    <ci type="logical">The treatment remains clinically appropriate and patient is
                    benefitting from treatment</ci>
                    <ci type="logical">Pembrolizumab to be used at a maximum dose of 200 mg every three
                    weeks (or equivalent)</ci>
                    <ci type="logical">Treatment with pembrolizumab to cease after a total duration of
                    24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
            </Request>
            <Formulation ID="F250705407226" Rank="10" Units="mg" Weight="1">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070540722625">
                <Name>Baxter</Name>
                <Pack ID="P2508427" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>47.74</Subsidy>
                  <Price>47.74</Price>
                  <Alternate>47.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250705407227" Rank="4" Units="inj" Weight="100">
              <Name>Inj 25 mg per ml, 4 ml vial</Name>
              <Brand ID="B25070540722725">
                <Name>Keytruda</Name>
                <Pack ID="P2547996" Specified="true" nzmt:ctpp_id="50231951000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>4680.00</Subsidy>
                  <Price>4680.00</Price>
                  <Alternate>4680.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507054161">
            <Name>Durvalumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2164"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2164">
              <Title>
                <range>Durvalumab</range>
              </Title>
              <Case When="Initial application" Category="Non-small cell lung cancer">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC)</ci>
                    <ci type="logical" class="Indication">Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy</ci>
                    <ci type="logical" class="Indication">Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment</ci>
                    <ci type="logical" class="Indication">Patient has a ECOG performance status of 0 or 1</ci>
                    <ci type="logical" class="Indication">Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab</ci>
                    <ci type="logical" class="Indication">Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks</ci>
                      <ci type="logical" class="Indication">Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks</ci>
                    </apply>
                    <ci type="logical" class="Indication">Treatment with durvalumab to cease upon signs of disease progression</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Category="Non-small cell lung cancer" Form="SA2147 SA2164">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">The treatment remains clinically appropriate and the patient is benefitting from treatment</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks</ci>
                      <ci type="logical" class="Indication">Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks</ci>
                    </apply>
                    <ci type="logical" class="Indication">Treatment with durvalumab to cease upon signs of disease progression</ci>
                    <ci type="logical" class="Indication">Total continuous treatment duration must not exceed 12 months</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">medical practitioner</Applicant>
                <Term Measure="month">3</Term>
              </Case>
            </Request>
            <Formulation ID="F250705416125" Rank="4" Units="inj">
              <Name>Inj 50 mg per ml, 2.4 ml vial</Name>
              <Brand ID="B25070541612525">
                <Name>Imfinzi</Name>
                <Pack ID="P2578425" Specified="true" nzmt:ctpp_id="50259971000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>1128.00</Subsidy>
                  <Price>1128.00</Price>
                  <Alternate>1128.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250705416126" Rank="4" Units="inj">
              <Name>Inj 50 mg per ml, 10 ml vial</Name>
              <Brand ID="B25070541612625">
                <Name>Imfinzi</Name>
                <Pack ID="P2578433" Specified="true" nzmt:ctpp_id="50259981000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>4700.00</Subsidy>
                  <Price>4700.00</Price>
                  <Alternate>4700.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250705416127" Rank="10" Units="mg">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070541612725">
                <Name>Baxter</Name>
                <Pack ID="P2642166" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>9.59</Subsidy>
                  <Price>9.59</Price>
                  <Alternate>9.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507054174">
            <Name>Atezolizumab</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2264"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2264">
              <Title>
                <range>Atezolizumab</range>
              </Title>
              <Case When="Initial application" Category="non-small cell lung cancer second line monotherapy">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical">Patient has locally advanced or metastatic non-small cell lung
                    cancer</ci>
                    <ci type="logical">Patient has not received prior funded treatment with an immune
                    checkpoint inhibitor for NSCLC</ci>
                    <ci type="logical">For patients with non-squamous histology there is documentation confirming that the disease does not
                    express activating mutations of EGFR or ALK tyrosine kinase unless not possible
                    to ascertain</ci>
                    <ci type="logical">Patient has an ECOG 0-2</ci>
                    <ci type="logical">Patient has documented disease progression following treatment
                    with at least two cycles of platinum-based chemotherapy</ci>
                    <ci type="logical">Atezolizumab is to be used as monotherapy at a dose of 1200 mg
                    every three weeks (or equivalent) for a maximum of 16 weeks</ci>
                    <ci type="logical">Baseline measurement of overall tumour burden is documented
                    clinically and radiologically</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
              <Case When="Renewal" Category="non-small cell lung cancer second line monotherapy" Form="SA2195 SA2240 SA2264">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical">Patientâ€™s disease has had a complete response to
                        treatment</ci>
                      <ci type="logical">Patientâ€™s disease has had a partial response to
                        treatment</ci>
                      <ci type="logical">Patient has stable disease</ci>
                    </apply>
                    <ci type="logical">Response to treatment in target lesions has been determined by
                    comparable radiologic assessment following the most recent treatment period</ci>
                    <ci type="logical">No evidence of disease progression</ci>
                    <ci type="logical">The treatment remains clinically appropriate and patient is
                    benefitting from treatment</ci>
                    <ci type="logical">Atezolizumab to be used at a maximum dose of 1200 mg every three
                    weeks (or equivalent)</ci>
                    <ci type="logical">Treatment with atezolizumab to cease after a total duration of 24
                    months from commencement (or equivalent of 35 cycles dosed every 3 weeks)</ci>
                  </apply>
                </math>
                <Applicant>medical oncologist</Applicant>
                <Applicant Referring="medical oncologist">any relevant practitioner</Applicant>
                <Term Measure="month">4</Term>
              </Case>
            </Request>
            <Formulation ID="F250705417425" Rank="4" Units="Inj" Weight="60">
              <Name>Inj 60 mg per ml, 20 ml vial</Name>
              <Brand ID="B25070541742525">
                <Name>Tecentriq</Name>
                <Pack ID="P2524953" Specified="true" nzmt:ctpp_id="50237251000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>9503.00</Subsidy>
                  <Price>9503.00</Price>
                  <Alternate>9503.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250705417426" Rank="10" Units="mg">
              <Name>Inj 1 mg for ECP</Name>
              <Brand ID="B25070541742625">
                <Name>Baxter</Name>
                <Pack ID="P2655233" Specified="true">
                  <Quantity>1</Quantity>
                  <Subsidy>8.08</Subsidy>
                  <Price>8.08</Price>
                  <Alternate>8.08</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250706">
          <Name>Other Immunosuppressants</Name>
          <Chemical ID="C2507061088">
            <Name>Tacrolimus</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2271"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2271">
              <Title>
                <range>Tacrolimus</range>
              </Title>
              <Case When="Initial application" Category="organ transplant">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The patient is an organ transplant recipient</ci>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Subsidy applies for either primary or rescue therapy.</p>
                </div>
              </Case>
              <Case When="Initial application" Category="non-transplant indications*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient requires long-term systemic immunosuppression</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response</ci>
                      <ci type="logical" class="Indication">Patient is a child with nephrotic syndrome*</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250706108801" Rank="2" Units="cap" Weight="1">
              <Name>Cap 1 mg</Name>
              <Brand ID="B25070610880125">
                <Name>Tacrolimus Sandoz</Name>
                <Pack ID="P2431246" Specified="true" nzmt:ctpp_id="50179421000117102">
                  <Quantity>100</Quantity>
                  <Subsidy>84.30</Subsidy>
                  <Price>84.30</Price>
                  <Alternate>84.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706108802" Rank="2" Units="cap" Weight="5">
              <Name>Cap 5 mg</Name>
              <Brand ID="B25070610880225">
                <Name>Tacrolimus Sandoz</Name>
                <Pack ID="P2431254" Specified="true" nzmt:ctpp_id="50179431000117104">
                  <Quantity>50</Quantity>
                  <Subsidy>248.20</Subsidy>
                  <Price>248.20</Price>
                  <Alternate>248.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706108825" Rank="2" Units="cap" Weight="0.5">
              <Name>Cap 0.5 mg</Name>
              <Brand ID="B25070610882526">
                <Name>Tacrolimus Sandoz</Name>
                <Pack ID="P2431238" Specified="true" nzmt:ctpp_id="50179411000117108">
                  <Quantity>100</Quantity>
                  <Subsidy>49.60</Subsidy>
                  <Price>49.60</Price>
                  <Alternate>49.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706108826" Rank="2" Units="cap" Weight="0.75">
              <Name>Cap 0.75 mg</Name>
              <Brand ID="B25070610882625">
                <Name>Tacrolimus Sandoz</Name>
                <Pack ID="P2573938" Specified="true" nzmt:ctpp_id="50257171000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>99.30</Subsidy>
                  <Price>99.30</Price>
                  <Alternate>99.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507062421">
            <Name>Ciclosporin</Name>
            <Formulation ID="F250706242101" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B25070624210102">
                <Name>Neoral</Name>
                <Pack ID="P455598" Specified="true" nzmt:ctpp_id="50086851000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>177.81</Subsidy>
                  <Price>177.81</Price>
                  <Alternate>177.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706242102" Rank="2" Units="cap" Weight="25">
              <Name>Cap 25 mg</Name>
              <Brand ID="B25070624210202">
                <Name>Neoral</Name>
                <Pack ID="P455571" Specified="true" nzmt:ctpp_id="50086841000117103">
                  <Quantity>50</Quantity>
                  <Subsidy>44.63</Subsidy>
                  <Price>44.63</Price>
                  <Alternate>44.63</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706242103" Rank="3" Units="ml" Weight="100">
              <Name>Oral liq 100 mg per ml</Name>
              <Brand ID="B25070624210302">
                <Name>Neoral</Name>
                <Pack ID="P455563" Specified="true" OP="true" nzmt:ctpp_id="50086831000117106">
                  <Quantity>50</Quantity>
                  <Subsidy>198.13</Subsidy>
                  <Price>198.13</Price>
                  <Alternate>198.13</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706242125" Rank="2" Units="cap" Weight="50">
              <Name>Cap 50 mg</Name>
              <Brand ID="B25070624212525">
                <Name>Neoral</Name>
                <Pack ID="P2011344" Specified="true" nzmt:ctpp_id="50001411000117105">
                  <Quantity>50</Quantity>
                  <Subsidy>88.91</Subsidy>
                  <Price>88.91</Price>
                  <Alternate>88.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507063869">
            <Name>Sirolimus</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2270"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2270">
              <Title>
                <range>Sirolimus (Rapamune)</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="use">The drug is to be used for rescue therapy for an organ
        transplant recipient</ci>
                </math>
                <Applicant>medical practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by
        refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the
        following: </p>
                  <ul>
                    <li>
                      <p>GFR&lt;30 ml/min; or</p>
                    </li>
                    <li>
                      <p>Rapidly progressive transplant vasculopathy; or </p>
                    </li>
                    <li>
                      <p>Rapidly progressive obstructive bronchiolitis; or </p>
                    </li>
                    <li>
                      <p>HUS or TTP; or</p>
                    </li>
                    <li>
                      <p>Leukoencepthalopathy; or</p>
                    </li>
                    <li>
                      <p>Significant malignant disease</p>
                    </li>
                  </ul>
                </div>
              </Case>
              <Case When="Initial application" Category="severe non-malignant lymphovascular malformations*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has severe non-malignant lymphovascular
          malformation*</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Malformations are not adequately controlled by
            sclerotherapy and surgery</ci>
                      <ci type="logical" class="Indication">Malformations are widespread/extensive and
            sclerotherapy and surgery are not considered clinically appropriate</ci>
                      <ci type="logical" class="Indication">Sirolimus is to be used to reduce malformation prior
            to consideration of surgery</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is being treated by a specialist
          lymphovascular malformation multi-disciplinary team</ci>
                    <ci type="logical" class="Indication">Patient has measurable disease as defined by RECIST
          version 1.1 (see Note)</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="severe non-malignant lymphovascular malformations*" Form="SA0866 SA2005 SA2218 SA2270">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patientâ€™s disease has had either a complete response
            or a partial response to treatment, or patient has stable disease according to RECIST
            version 1.1 (see Note)</ci>
                      <ci type="logical" class="Indication">Patientâ€™s disease has stabilised or responded
            clinically and disease response to treatment has been clearly documents in patient
            notes</ci>
                    </apply>
                    <ci type="logical" class="Indication">No evidence of progressive disease</ci>
                    <ci type="logical" class="Indication">The treatment remains clinically appropriate and the
          patient is benefitting from the treatment</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Baseline assessment and disease responses to be assessed according to the Response
        Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer
        2009;45:228-47)</p>
                  <p>Indications marked with * are unapproved indications</p>
                </div>
              </Case>
              <Case When="Initial application" Category="renal angiomyolipoma(s) associated with tuberous sclerosis complex*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has tuberous sclerosis complex*</ci>
                    <ci type="logical" class="Indication">Evidence of renal angiomyolipoma(s) measuring 3 cm or
          greater and that have shown interval growth</ci>
                  </apply>
                </math>
                <Applicant>nephrologist</Applicant>
                <Applicant>urologist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="renal angiomyolipoma(s) associated with tuberous sclerosis complex*" Form="SA0866 SA2005 SA2218 SA2270">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Documented evidence of renal angiomyolipoma reduction
          or stability by magnetic resonance imaging (MRI) or ultrasound</ci>
                    <ci type="logical" class="Indication">Demonstrated stabilisation or improvement in renal
          function</ci>
                    <ci type="logical" class="Indication">The patient has not experienced angiomyolipoma
          haemorrhage or significant adverse effects to sirolimus treatment</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is
          benefitting from treatment</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications</p>
                </div>
              </Case>
              <Case When="Initial application" Category="refractory seizures associated with tuberous sclerosis complex*">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has epilepsy with a background of documented
          tuberous sclerosis complex</ci>
                    <apply>
                      <or/>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Vigabatrin has been trialled and has not
              adequately controlled seizures</ci>
                        <ci type="logical" class="Indication">Seizures are not adequately controlled by, or the
              patient has experienced unacceptable side effects from, optimal treatment with at
              least two of the following: sodium valproate, topiramate, levetiracetam,
              carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note)</ci>
                      </apply>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Vigabatrin is contraindicated</ci>
                        <ci type="logical" class="Indication">Seizures are not adequately controlled by, or the
              patient has experienced unacceptable side effects from, optimal treatment with at
              least three of the following: sodium valproate, topiramate, levetiracetam,
              carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note)</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Seizures have a significant impact on quality of
          life</ci>
                    <ci type="logical" class="Indication">Patient has been assessed and surgery is considered
          inappropriate for this patient, or the patient has been assessed and would benefit from
          mTOR inhibitor treatment prior to surgery</ci>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Those of childbearing age potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.</p>
                </div>
              </Case>
              <Case When="Renewal" Category="refractory seizures associated with tuberous sclerosis complex*" Form="SA0866 SA2005 SA2218 SA2270">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment</ci>
                </math>
                <Applicant>neurologist</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>Indications marked with * are unapproved indications</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F250706386925" Rank="1" Units="tab">
              <Name>Tab 1 mg</Name>
              <Brand ID="B25070638692525">
                <Name>Rapamune</Name>
                <Pack ID="P2109638" Specified="true" nzmt:ctpp_id="50019561000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>749.99</Subsidy>
                  <Price>749.99</Price>
                  <Alternate>749.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706386926" Rank="3" Units="ml">
              <Name>Oral liq 1 mg per ml</Name>
              <Brand ID="B25070638692625">
                <Name>Rapamune</Name>
                <Pack ID="P2059339" Specified="true" OP="true" nzmt:ctpp_id="50010601000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>449.99</Subsidy>
                  <Price>449.99</Price>
                  <Alternate>449.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706386927" Rank="1" Units="tab">
              <Name>Tab 2 mg</Name>
              <Brand ID="B25070638692725">
                <Name>Rapamune</Name>
                <Pack ID="P2258218" Specified="true" nzmt:ctpp_id="50040831000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>1499.99</Subsidy>
                  <Price>1499.99</Price>
                  <Alternate>1499.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2507064040">
            <Name>Everolimus</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2008"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2008">
              <Title>
                <range>Everolimus</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has tuberous sclerosis</ci>
                    <ci type="logical" class="Indication">Patient has progressively enlarging
                    sub-ependymal giant cell astrocytomas (SEGAs) that require treatment</ci>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>oncologist</Applicant>
                <Term Measure="month">3</Term>
              </Case>
              <Case When="Renewal" Form="SA1491 SA1913 SA2008">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Documented evidence of SEGA reduction or
                    stabilisation by MRI within the last 3 months</ci>
                    <ci type="logical" class="Indication">The treatment remains appropriate and the
                    patient is benefiting from treatment</ci>
                    <ci type="logical" class="Indication">Everolimus to be discontinued at progression
                    of SEGAs</ci>
                  </apply>
                </math>
                <Applicant>neurologist</Applicant>
                <Applicant>oncologist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F250706404025" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B25070640402525">
                <Name>Afinitor</Name>
                <Pack ID="P2334860" Specified="true" nzmt:ctpp_id="50120081000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>4555.76</Subsidy>
                  <Price>4555.76</Price>
                  <Alternate>4555.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F250706404026" Rank="1" Units="tab">
              <Name>Tab 10 mg</Name>
              <Brand ID="B25070640402625">
                <Name>Afinitor</Name>
                <Pack ID="P2334879" Specified="true" nzmt:ctpp_id="50120091000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>6512.29</Subsidy>
                  <Price>6512.29</Price>
                  <Alternate>6512.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A250708">
          <Name>JAK inhibitors</Name>
          <Chemical ID="C2507084150">
            <Name>Upadacitinib</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2079"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2079">
              <Title>
                <range>Upadacitinib</range>
              </Title>
              <Case When="Initial application" Category="Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Use">The patient has had an initial Special Authority approval
            for adalimumab and/or etanercept for rheumatoid arthritis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has experienced intolerable side
              effects from adalimumab and/or etanercept</ci>
                      <ci type="logical" class="Use">The patient has received insufficient benefit from at
              least a three-month trial of adalimumab and/or etanercept such that they do not meet
              the renewal criteria for rheumatoid arthritis</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient is seronegative for both anti-cyclic
              citrullinated peptide (CCP) antibodies and rheumatoid factor</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient has been started on rituximab for
                rheumatoid arthritis in a Te Whatu Ora Hospital</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">The patient has experienced intolerable side
                  effects from rituximab</ci>
                          <ci type="logical" class="Use">At four months following the initial course of
                  rituximab the patient has received insufficient benefit such that they do not meet
                  the renewal criteria for rheumatoid arthritis</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Rheumatoid Arthritis" Form="SA2079">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Following 6 months' initial treatment, the patient has
          at least a 50% decrease in active joint count from baseline and a clinically significant
          response to treatment in the opinion of the physician</ci>
                    <ci type="logical" class="Indication">On subsequent reapplications, the patient demonstrates
          at least a continuing 30% improvement in active joint count from baseline and a clinically
          significant response to treatment in the opinion of the physician</ci>
                  </apply>
                </math>
                <Applicant>rheumatologist</Applicant>
                <Applicant Referring="rheumatologist">Practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F250708415025" Rank="1" Units="tab" Weight="15">
              <Name>Tab 15 mg</Name>
              <Brand ID="B25070841502525">
                <Name>RINVOQ</Name>
                <Pack ID="P2619415" Specified="true" nzmt:ctpp_id="50260941000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>1271.00</Subsidy>
                  <Price>1271.00</Price>
                  <Alternate>1271.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A28">
      <Name>Respiratory System and Allergies</Name>
      <ATC2 ID="A2801">
        <Name>Antiallergy Preparations</Name>
        <ATC3 ID="A280104">
          <Name>Allergic Emergencies</Name>
          <Chemical ID="C2801041015">
            <Name>Adrenaline</Name>
            <Rule Type="FormMax" Value="2" Attribute="Rx"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Additional prescriptions limited to replacement of up to two devices prior to expiry, or replacement of used device for treatment of anaphylaxis.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2185"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2185">
              <Title>
                <range>Adrenaline</range>
              </Title>
              <Case When="Initial application" Category="anaphylaxis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has experienced an anaphylactic
                        reaction which has resulted in presentation to a hospital or emergency
                        department</ci>
                      <ci type="logical" class="Indication">Patient has been assessed to be at
                        significant risk of anaphylaxis by a relevant practitioner</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patient is not to be prescribed more than two
                    devices in initial prescription</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F280104101525" Rank="4" Units="inj">
              <Name>Inj 0.15 mg per 0.3 ml auto-injector</Name>
              <Brand ID="B28010410152525" PSS="2025-06-30">
                <Name>Epipen Jr</Name>
                <Pack ID="P208191" Specified="true" OP="true" nzmt:ctpp_id="50013511000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>90.00</Subsidy>
                  <Price>90.00</Price>
                  <Alternate>90.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280104101526" Rank="4" Units="inj">
              <Name>Inj 0.3 mg per 0.3 ml auto-injector</Name>
              <Brand ID="B28010410152625" PSS="2025-06-30">
                <Name>Epipen</Name>
                <Pack ID="P223972" Specified="true" OP="true" nzmt:ctpp_id="50038111000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>90.00</Subsidy>
                  <Price>90.00</Price>
                  <Alternate>90.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2801044052">
            <Name>Icatibant</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1558"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1558">
              <Title>
                <range>Icatibant</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for
                    patients with confirmed diagnosis of C1-esterase inhibitor deficiency</ci>
                    <ci type="logical" class="Indication">The patient has undergone product training and has agreed upon an action plan for self-administration</ci>
                  </apply>
                </math>
                <Applicant>clinical immunologist</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Form="SA1558">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">12</Term>
              </Case>
            </Request>
            <Formulation ID="F280104405225" Rank="4" Units="inj" Weight="30">
              <Name>Inj 10 mg per ml, 3 ml prefilled syringe</Name>
              <Brand ID="B28010440522525">
                <Name>Firazyr</Name>
                <Pack ID="P2617560" Specified="true" nzmt:ctpp_id="50221871000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>2668.00</Subsidy>
                  <Price>2668.00</Price>
                  <Alternate>2668.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A280108">
          <Name>Allergy Desensitisation</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA1367">
            <Title>
              <range>Bee or wasp venom allergy treatment</range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">RAST or skin test positive</ci>
                  <ci type="logical" class="Indication">Patient has had severe generalised reaction to the sensitising agent</ci>
                </apply>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Renewal" Form="SA0053 SA1367">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
              </math>
              <Applicant>relevant specialist</Applicant>
              <Term Measure="year">2</Term>
            </Case>
          </Request>
          <Chemical ID="C2801081174">
            <Name>Wasp venom allergy treatment</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1367"/>
            <Formulation ID="F280108117401" Rank="10" Units="txpk">
              <Name>Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml</Name>
              <Brand ID="B28010811740101">
                <Name>Albey</Name>
                <Pack ID="P660825" Specified="true" OP="true" nzmt:ctpp_id="50100801000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108117402" Rank="10" Units="txpk">
              <Name>Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml</Name>
              <Brand ID="B28010811740201">
                <Name>Albey</Name>
                <Pack ID="P478474" Specified="true" OP="true" nzmt:ctpp_id="50177611000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108117425" Rank="10" Units="txpk">
              <Name>Treatment kit (Paper wasp venom) - 6 vials 120 mcg freeze dried venom, with diluent</Name>
              <Brand ID="B28010811742525" S29="true">
                <Name>Venomil</Name>
                <Pack ID="P2493942" Specified="true" OP="true" nzmt:ctpp_id="50229921000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108117426" Rank="10" Units="txpk">
              <Name>Treatment kit (Yellow jacket venom) - 6 vials 120 mcg freeze dried venom, with diluent</Name>
              <Brand ID="B28010811742625" S29="true">
                <Name>Venomil</Name>
                <Pack ID="P2493950" Specified="true" OP="true" nzmt:ctpp_id="50229911000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108117427" Rank="10" Units="txpk">
              <Name>Treatment kit (Yellow Jacket venom) - 1 vial 550 mcg freeze dried venom, with diluent</Name>
              <Brand ID="B28010811742725" S29="true">
                <Name>Hymenoptera</Name>
                <Pack ID="P2549786" Specified="true" OP="true" nzmt:ctpp_id="50257001000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108117428" Rank="10" Units="txpk">
              <Name>Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried venom, with diluent</Name>
              <Brand ID="B28010811742825" S29="true">
                <Name>Hymenoptera</Name>
                <Pack ID="P2549794" Specified="true" OP="true" nzmt:ctpp_id="50257021000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2801086004">
            <Name>Bee venom allergy treatment</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1367"/>
            <Formulation ID="F280108600404" Rank="10" Units="txpk">
              <Name>Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml</Name>
              <Brand ID="B28010860040401">
                <Name>Albey</Name>
                <Pack ID="P660817" Specified="true" OP="true" nzmt:ctpp_id="50177591000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108600405" Rank="10" Units="txpk">
              <Name>Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent </Name>
              <Brand ID="B28010860040525" S29="true">
                <Name>Venomil</Name>
                <Pack ID="P2493934" Specified="true" OP="true" nzmt:ctpp_id="50229901000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>285.00</Subsidy>
                  <Price>285.00</Price>
                  <Alternate>285.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108600425" Rank="10" Units="vial">
              <Name>Treatment kit - 1 vial 550 mcg freeze dried venom, with diluent</Name>
              <Brand ID="B28010860042525" S29="true">
                <Name>Hymenoptera</Name>
                <Pack ID="P2549778" Specified="true" OP="true" nzmt:ctpp_id="50256991000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108600426" Rank="10" Units="pack">
              <Name>Initiation kit - 5 vials freeze dried venom with diluent</Name>
              <Brand ID="B28010860042625" S29="true">
                <Name>VENOX</Name>
                <Pack ID="P2596822" Specified="true" OP="true" nzmt:ctpp_id="50282931000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280108600427" Rank="10" Units="pack">
              <Name>Maintenance kit - 1 vial freeze dried venom with diluent</Name>
              <Brand ID="B28010860042725" S29="true">
                <Name>VENOX</Name>
                <Pack ID="P2596814" Specified="true" OP="true" nzmt:ctpp_id="50282941000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>305.00</Subsidy>
                  <Price>305.00</Price>
                  <Alternate>305.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2804">
        <Name>Antihistamines</Name>
        <ATC3 ID="A280401">
          <Name>Antihistamines</Name>
          <Chemical ID="C2804011194" Statim="Must">
            <Name>Fexofenadine hydrochloride</Name>
            <Formulation ID="F280401119402" Rank="1" Units="tab" Weight="120">
              <Name>Tab 120 mg</Name>
              <Brand ID="B28040111940201">
                <Name>Telfast</Name>
                <Pack ID="P436534" Specified="true" nzmt:ctpp_id="50085581000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>14.22</Subsidy>
                  <Price>26.44</Price>
                  <Alternate>14.22</Alternate>
                  <Surcharge>0.40733</Surcharge>
                </Pack>
                <Pack ID="P490504" Specified="true" nzmt:ctpp_id="50091731000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>4.74</Subsidy>
                  <Price>8.23</Price>
                  <Alternate>4.74</Alternate>
                  <Surcharge>0.34900</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280401119403" Rank="1" Units="tab" Weight="60">
              <Name>Tab 60 mg</Name>
              <Brand ID="B28040111940301">
                <Name>Telfast</Name>
                <Pack ID="P949841" Specified="true" nzmt:ctpp_id="50118441000117106">
                  <Quantity>20</Quantity>
                  <Subsidy>4.34</Subsidy>
                  <Price>8.23</Price>
                  <Alternate>4.34</Alternate>
                  <Surcharge>0.19450</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2804012469" Statim="Must">
            <Name>Chlorpheniramine maleate</Name>
            <Formulation ID="F280401246903" Rank="3" Units="ml" Weight="0.4">
              <Name>Oral liq 2 mg per 5 ml</Name>
              <Brand ID="B28040124690301" ToBeDelisted="2024-08-01">
                <Name>Histafen</Name>
                <Pack ID="P240311" Specified="true" nzmt:ctpp_id="50051481000117105">
                  <Quantity>500</Quantity>
                  <Subsidy>9.37</Subsidy>
                  <Price>9.37</Price>
                  <Alternate>9.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2804012471" Statim="Must">
            <Name>Dextrochlorpheniramine maleate</Name>
            <Formulation ID="F280401247101" Rank="1" Units="tab" Weight="2">
              <Name>Tab 2 mg</Name>
              <Brand ID="B28040124710101">
                <Name>Polaramine</Name>
                <Pack ID="P2327570" Specified="true" nzmt:ctpp_id="50049161000117107">
                  <Quantity>20</Quantity>
                  <Subsidy>1.01</Subsidy>
                  <Price>5.99</Price>
                  <Alternate>1.01</Alternate>
                  <Surcharge>0.24900</Surcharge>
                </Pack>
                <Pack ID="P2327589" Specified="true" nzmt:ctpp_id="50049171000117102">
                  <Quantity>40</Quantity>
                  <Subsidy>2.02</Subsidy>
                  <Price>8.40</Price>
                  <Alternate>2.02</Alternate>
                  <Surcharge>0.15950</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280401247103" Rank="3" Units="ml" Weight="0.4">
              <Name>Oral liq 2 mg per 5 ml</Name>
              <Brand ID="B28040124710301">
                <Name>Polaramine</Name>
                <Pack ID="P316687" Specified="true" nzmt:ctpp_id="50070881000117101">
                  <Quantity>100</Quantity>
                  <Subsidy>1.77</Subsidy>
                  <Price>10.29</Price>
                  <Alternate>1.77</Alternate>
                  <Surcharge>0.08520</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2804012478" Statim="Must">
            <Name>Promethazine hydrochloride</Name>
            <Formulation ID="F280401247801" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B28040124780125" PSS="2025-06-30">
                <Name>Allersoothe</Name>
                <Pack ID="P2238098" Specified="true" nzmt:ctpp_id="50037941000117100">
                  <Quantity>50</Quantity>
                  <Subsidy>1.39</Subsidy>
                  <Price>1.39</Price>
                  <Alternate>1.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280401247802" Rank="1" Units="tab" Weight="25">
              <Name>Tab 25 mg</Name>
              <Brand ID="B28040124780225" PSS="2025-06-30">
                <Name>Allersoothe</Name>
                <Pack ID="P2238128" Specified="true" nzmt:ctpp_id="50037961000117101">
                  <Quantity>50</Quantity>
                  <Subsidy>1.58</Subsidy>
                  <Price>1.58</Price>
                  <Alternate>1.58</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280401247803" Rank="3" Units="ml" Weight="1">
              <Name>Oral liq 1 mg per 1 ml</Name>
              <Brand ID="B28040124780326">
                <Name>Allersoothe</Name>
                <Pack ID="P2404281" Specified="true" nzmt:ctpp_id="50147151000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>3.39</Subsidy>
                  <Price>3.39</Price>
                  <Alternate>3.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280401247805" Rank="4" Units="inj" Weight="50">
              <Name>Inj 25 mg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B28040124780502">
                <Name>Hospira</Name>
                <Pack ID="P722952" Specified="true" nzmt:ctpp_id="50105791000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>21.09</Subsidy>
                  <Price>21.09</Price>
                  <Alternate>21.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2804012831" Statim="Must">
            <Name>Loratadine</Name>
            <Formulation ID="F280401283101" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B28040128310128" PSS="2025-06-30">
                <Name>Lorafix</Name>
                <Pack ID="P2443996" Specified="true" nzmt:ctpp_id="50147201000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>1.78</Subsidy>
                  <Price>1.78</Price>
                  <Alternate>1.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280401283102" Rank="3" Units="ml" Weight="1">
              <Name>Oral liq 1 mg per ml</Name>
              <Brand ID="B28040128310227">
                <Name>Haylor syrup</Name>
                <Pack ID="P2605678" Specified="true" nzmt:ctpp_id="50282461000117107">
                  <Quantity>100</Quantity>
                  <Subsidy>1.43</Subsidy>
                  <Price>1.43</Price>
                  <Alternate>1.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2804012833" Statim="Must">
            <Name>Cetirizine hydrochloride</Name>
            <Formulation ID="F280401283301" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B28040128330127" PSS="2026-06-30">
                <Name>Zista</Name>
                <Pack ID="P2500728" Specified="true" nzmt:ctpp_id="50205841000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>1.71</Subsidy>
                  <Price>1.71</Price>
                  <Alternate>1.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F280401283325" Rank="3" Units="ml">
              <Name>Oral liq 1 mg per ml</Name>
              <Brand ID="B28040128332527" PSS="2024-06-30">
                <Name>Histaclear</Name>
                <Pack ID="P2461625" Specified="true" nzmt:ctpp_id="50202791000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>2.84</Subsidy>
                  <Price>2.84</Price>
                  <Alternate>2.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2810">
        <Name>Inhaled Corticosteroids</Name>
        <ATC3 ID="A281001">
          <Name>Inhaled Corticosteroids</Name>
          <Chemical ID="C2810011065">
            <Name>Fluticasone</Name>
            <Formulation ID="F281001106502" Rank="6" Units="dose" Weight="50">
              <Name>Aerosol inhaler, 50 mcg per dose</Name>
              <Brand ID="B28100110650201">
                <Name>Flixotide</Name>
                <Pack ID="P2004887" Specified="true" OP="true" nzmt:ctpp_id="50000431000117108">
                  <Quantity>120</Quantity>
                  <Subsidy>7.19</Subsidy>
                  <Price>7.19</Price>
                  <Alternate>7.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001106503" Rank="6" Units="dose" Weight="125">
              <Name>Aerosol inhaler, 125 mcg per dose</Name>
              <Brand ID="B28100110650301">
                <Name>Flixotide</Name>
                <Pack ID="P472859" Specified="true" OP="true" nzmt:ctpp_id="50089161000117100">
                  <Quantity>120</Quantity>
                  <Subsidy>13.60</Subsidy>
                  <Price>13.60</Price>
                  <Alternate>13.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001106504" Rank="6" Units="dose" Weight="250">
              <Name>Aerosol inhaler, 250 mcg per dose</Name>
              <Brand ID="B28100110650401">
                <Name>Flixotide</Name>
                <Pack ID="P472867" Specified="true" OP="true" nzmt:ctpp_id="50089171000117105">
                  <Quantity>120</Quantity>
                  <Subsidy>24.62</Subsidy>
                  <Price>24.62</Price>
                  <Alternate>24.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001106511" Rank="6" Units="dose" Weight="50">
              <Name>Powder for inhalation, 50 mcg per dose</Name>
              <Brand ID="B28100110651101">
                <Name>Flixotide Accuhaler</Name>
                <Pack ID="P402958" Specified="true" OP="true" nzmt:ctpp_id="50082201000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>8.61</Subsidy>
                  <Price>8.61</Price>
                  <Alternate>8.61</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001106512" Rank="6" Units="dose" Weight="100">
              <Name>Powder for inhalation, 100 mcg per dose</Name>
              <Brand ID="B28100110651201">
                <Name>Flixotide Accuhaler</Name>
                <Pack ID="P402974" Specified="true" OP="true" nzmt:ctpp_id="50082211000117100">
                  <Quantity>60</Quantity>
                  <Subsidy>7.81</Subsidy>
                  <Price>7.81</Price>
                  <Alternate>7.81</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001106513" Rank="6" Units="dose" Weight="250">
              <Name>Powder for inhalation, 250 mcg per dose</Name>
              <Brand ID="B28100110651301">
                <Name>Flixotide Accuhaler</Name>
                <Pack ID="P402990" Specified="true" OP="true" nzmt:ctpp_id="50082221000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>11.93</Subsidy>
                  <Price>11.93</Price>
                  <Alternate>11.93</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2810011108">
            <Name>Beclomethasone dipropionate</Name>
            <Formulation ID="F281001110801" Rank="6" Units="dose" Weight="50">
              <Name>Aerosol inhaler, 50 mcg per dose</Name>
              <Brand ID="B28100111080126">
                <Name>Qvar</Name>
                <Pack ID="P2023873" Specified="true" OP="true" nzmt:ctpp_id="50004821000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>14.01</Subsidy>
                  <Price>14.01</Price>
                  <Alternate>14.01</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001110802" Rank="6" Units="dose" Weight="100">
              <Name>Aerosol inhaler, 100 mcg per dose</Name>
              <Brand ID="B28100111080226">
                <Name>Qvar</Name>
                <Pack ID="P2023857" Specified="true" OP="true" nzmt:ctpp_id="50004801000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>17.52</Subsidy>
                  <Price>17.52</Price>
                  <Alternate>17.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001110825" Rank="6" Units="dose" Weight="50">
              <Name>Aerosol inhaler, 50 mcg per dose CFC-free</Name>
              <Brand ID="B28100111082525">
                <Name>Beclazone 50</Name>
                <Pack ID="P2326159" Specified="true" OP="true" nzmt:ctpp_id="50049091000117102">
                  <Quantity>200</Quantity>
                  <Subsidy>8.54</Subsidy>
                  <Price>8.54</Price>
                  <Alternate>8.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001110826" Rank="6" Units="dose" Weight="100">
              <Name>Aerosol inhaler, 100 mcg per dose CFC-free</Name>
              <Brand ID="B28100111082625">
                <Name>Beclazone 100</Name>
                <Pack ID="P2326167" Specified="true" OP="true" nzmt:ctpp_id="50049101000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>12.50</Subsidy>
                  <Price>12.50</Price>
                  <Alternate>12.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001110827" Rank="6" Units="dose" Weight="250">
              <Name>Aerosol inhaler, 250 mcg per dose CFC-free</Name>
              <Brand ID="B28100111082725">
                <Name>Beclazone 250</Name>
                <Pack ID="P2326175" Specified="true" OP="true" nzmt:ctpp_id="50049111000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>22.67</Subsidy>
                  <Price>22.67</Price>
                  <Alternate>22.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2810011168">
            <Name>Budesonide</Name>
            <Formulation ID="F281001116802" Rank="6" Units="dose" Weight="100">
              <Name>Powder for inhalation, 100 mcg per dose</Name>
              <Brand ID="B28100111680201">
                <Name>Pulmicort Turbuhaler</Name>
                <Pack ID="P682128" Specified="true" OP="true" nzmt:ctpp_id="50101881000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>17.00</Subsidy>
                  <Price>17.00</Price>
                  <Alternate>17.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001116803" Rank="6" Units="dose" Weight="200">
              <Name>Powder for inhalation, 200 mcg per dose</Name>
              <Brand ID="B28100111680301">
                <Name>Pulmicort Turbuhaler</Name>
                <Pack ID="P674273" Specified="true" OP="true" nzmt:ctpp_id="50101471000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>19.00</Subsidy>
                  <Price>19.00</Price>
                  <Alternate>19.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F281001116804" Rank="6" Units="dose" Weight="400">
              <Name>Powder for inhalation, 400 mcg per dose</Name>
              <Brand ID="B28100111680401">
                <Name>Pulmicort Turbuhaler</Name>
                <Pack ID="P674281" Specified="true" OP="true" nzmt:ctpp_id="50101481000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>32.00</Subsidy>
                  <Price>32.00</Price>
                  <Alternate>32.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2824">
        <Name>Inhaled Long-acting Beta-adrenoceptor Agonists</Name>
        <ATC3 ID="A282402">
          <Name>Inhaled Long-acting Beta-adrenoceptor Agonists</Name>
          <Chemical ID="C2824021066">
            <Name>Salmeterol</Name>
            <Formulation ID="F282402106603" Rank="6" Units="dose" Weight="50">
              <Name>Powder for inhalation, 50 mcg per dose, breath activated</Name>
              <Brand ID="B28240210660301">
                <Name>Serevent Accuhaler</Name>
                <Pack ID="P479489" Specified="true" OP="true" nzmt:ctpp_id="50090411000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>26.25</Subsidy>
                  <Price>26.25</Price>
                  <Alternate>26.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282402106625" Rank="6" Units="dose">
              <Name>Aerosol inhaler CFC-free, 25 mcg per dose</Name>
              <Brand ID="B28240210662525">
                <Name>Serevent</Name>
                <Pack ID="P2243903" Specified="true" OP="true" nzmt:ctpp_id="50038641000117108">
                  <Quantity>120</Quantity>
                  <Subsidy>26.25</Subsidy>
                  <Price>26.25</Price>
                  <Alternate>26.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2824024042">
            <Name>Indacaterol</Name>
            <Formulation ID="F282402404225" Rank="6" Units="dose" Weight="0.01">
              <Name>Powder for inhalation 150 mcg</Name>
              <Brand ID="B28240240422525">
                <Name>Onbrez Breezhaler</Name>
                <Pack ID="P2465922" Specified="true" OP="true" nzmt:ctpp_id="50186981000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>61.00</Subsidy>
                  <Price>61.00</Price>
                  <Alternate>61.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282402404226" Rank="6" Units="dose" Weight="0.03">
              <Name>Powder for inhalation 300 mcg</Name>
              <Brand ID="B28240240422625">
                <Name>Onbrez Breezhaler</Name>
                <Pack ID="P2465930" Specified="true" OP="true" nzmt:ctpp_id="50187001000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>61.00</Subsidy>
                  <Price>61.00</Price>
                  <Alternate>61.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2824024112">
            <Name>Eformoterol fumarate dihydrate</Name>
            <Formulation ID="F282402411225" Rank="6" Units="dose" Weight="6">
              <Name>Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose)</Name>
              <Brand ID="B28240241122525">
                <Name>Oxis Turbuhaler</Name>
                <Pack ID="P2554232" Specified="true" OP="true" nzmt:ctpp_id="50259251000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>10.32</Subsidy>
                  <Price>16.90</Price>
                  <Alternate>10.32</Alternate>
                  <Surcharge>0.10967</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A282404">
          <Name>Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists</Name>
          <Chemical ID="C2824043758">
            <Name>Budesonide with eformoterol</Name>
            <Formulation ID="F282404375825" Rank="6" Units="dose" Weight="106">
              <Name>Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg</Name>
              <Brand ID="B28240437582525">
                <Name>Symbicort Turbuhaler 100/6</Name>
                <Pack ID="P2035952" Specified="true" OP="true" nzmt:ctpp_id="50007051000117105">
                  <Quantity>120</Quantity>
                  <Subsidy>33.74</Subsidy>
                  <Price>33.74</Price>
                  <Alternate>33.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404375826" Rank="6" Units="dose" Weight="206">
              <Name>Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg</Name>
              <Brand ID="B28240437582625">
                <Name>Symbicort Turbuhaler 200/6</Name>
                <Pack ID="P2035960" Specified="true" OP="true" nzmt:ctpp_id="50007061000117107">
                  <Quantity>120</Quantity>
                  <Subsidy>33.74</Subsidy>
                  <Price>33.74</Price>
                  <Alternate>33.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404375827" Rank="6" Units="dose" Weight="412">
              <Name>Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg</Name>
              <Rule Type="DoseDMax" Value="2"/>
              <Brand ID="B28240437582725">
                <Name>Symbicort Turbuhaler 400/12</Name>
                <Pack ID="P2228009" Specified="true" OP="true" nzmt:ctpp_id="50036661000117108">
                  <Quantity>60</Quantity>
                  <Subsidy>33.74</Subsidy>
                  <Price>33.74</Price>
                  <Alternate>33.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404375828" Rank="6" Units="dose" Weight="106">
              <Name>Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg</Name>
              <Brand ID="B28240437582826">
                <Name>Vannair</Name>
                <Pack ID="P2288966" Specified="true" OP="true" nzmt:ctpp_id="50044321000117102">
                  <Quantity>120</Quantity>
                  <Subsidy>18.23</Subsidy>
                  <Price>18.23</Price>
                  <Alternate>18.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404375829" Rank="6" Units="dose" Weight="206">
              <Name>Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg</Name>
              <Brand ID="B28240437582926">
                <Name>Vannair</Name>
                <Pack ID="P2288974" Specified="true" OP="true" nzmt:ctpp_id="50044331000117104">
                  <Quantity>120</Quantity>
                  <Subsidy>21.40</Subsidy>
                  <Price>21.40</Price>
                  <Alternate>21.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404375830" Rank="6" Units="dose">
              <Name>Powder for inhalation 160 mcg with 4.5 mcg eformoterol fumarate per dose (equivalent to 200 mcg budesonide with 6 mcg eformoterol fumarate metered dose)</Name>
              <Brand ID="B28240437583025">
                <Name>DuoResp Spiromax</Name>
                <Pack ID="P2576031" Specified="true" OP="true" nzmt:ctpp_id="50251641000117109">
                  <Quantity>120</Quantity>
                  <Subsidy>41.50</Subsidy>
                  <Price>41.50</Price>
                  <Alternate>41.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404375831" Rank="6" Units="dose">
              <Name>Powder for inhalation 320 mcg with 9 mcg eformoterol fumarate per dose (equivalent to 400 mcg budesonide with 12 mcg eformoterol fumarate metered dose)</Name>
              <Rule Type="DoseDMax" Value="2"/>
              <Brand ID="B28240437583125">
                <Name>DuoResp Spiromax</Name>
                <Pack ID="P2576058" Specified="true" OP="true" nzmt:ctpp_id="50251761000117101">
                  <Quantity>120</Quantity>
                  <Subsidy>82.50</Subsidy>
                  <Price>82.50</Price>
                  <Alternate>82.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2824043858">
            <Name>Fluticasone with salmeterol</Name>
            <Formulation ID="F282404385825" Rank="6" Units="dose" Weight="75">
              <Name>Aerosol inhaler 50 mcg with salmeterol 25 mcg</Name>
              <Brand ID="B28240438582525">
                <Name>Seretide</Name>
                <Pack ID="P2120194" Specified="true" OP="true" nzmt:ctpp_id="50021661000117101">
                  <Quantity>120</Quantity>
                  <Subsidy>25.79</Subsidy>
                  <Price>25.79</Price>
                  <Alternate>25.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404385826" Rank="6" Units="dose" Weight="149">
              <Name>Aerosol inhaler 125 mcg with salmeterol 25 mcg</Name>
              <Brand ID="B28240438582625">
                <Name>Seretide</Name>
                <Pack ID="P2120208" Specified="true" OP="true" nzmt:ctpp_id="50021671000117106">
                  <Quantity>120</Quantity>
                  <Subsidy>32.60</Subsidy>
                  <Price>32.60</Price>
                  <Alternate>32.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404385827" Rank="6" Units="dose" Weight="150">
              <Name>Powder for inhalation 100 mcg with salmeterol 50 mcg</Name>
              <Rule Type="DoseDMax" Value="2"/>
              <Brand ID="B28240438582725">
                <Name>Seretide Accuhaler</Name>
                <Pack ID="P2120216" Specified="true" OP="true" nzmt:ctpp_id="50021681000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>33.74</Subsidy>
                  <Price>33.74</Price>
                  <Alternate>33.74</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F282404385828" Rank="6" Units="dose" Weight="300">
              <Name>Powder for inhalation 250 mcg with salmeterol 50 mcg</Name>
              <Rule Type="DoseDMax" Value="2"/>
              <Brand ID="B28240438582825">
                <Name>Seretide Accuhaler</Name>
                <Pack ID="P2120224" Specified="true" OP="true" nzmt:ctpp_id="50021691000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>44.08</Subsidy>
                  <Price>44.08</Price>
                  <Alternate>44.08</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2824044056">
            <Name>Fluticasone furoate with vilanterol</Name>
            <Formulation ID="F282404405625" Rank="6" Units="dose" Weight="125">
              <Name>Powder for inhalation 100 mcg with vilanterol 25 mcg</Name>
              <Brand ID="B28240440562525">
                <Name>Breo Ellipta</Name>
                <Pack ID="P2494299" Specified="true" OP="true" nzmt:ctpp_id="50226721000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>44.08</Subsidy>
                  <Price>44.08</Price>
                  <Alternate>44.08</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2830">
        <Name>Beta-Adrenoceptor Agonists</Name>
        <ATC3 ID="A283001">
          <Name>Beta-Adrenoceptor Agonists</Name>
          <Chemical ID="C2830012096">
            <Name>Salbutamol</Name>
            <Formulation ID="F283001209603" Rank="3" Units="ml" Weight="0.4">
              <Name>Oral liq 400 mcg per ml</Name>
              <Brand ID="B28300120960301" PSS="2024-06-30">
                <Name>Ventolin</Name>
                <Pack ID="P2140543" Specified="true" nzmt:ctpp_id="50024241000117100">
                  <Quantity>150</Quantity>
                  <Subsidy>40.00</Subsidy>
                  <Price>40.00</Price>
                  <Alternate>40.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283001209604" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mcg per ml, 1 ml</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B28300120960401">
                <Name>Ventolin</Name>
                <Pack ID="P257915" Specified="true" nzmt:ctpp_id="50056061000117100">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>53.00</Subsidy>
                  <Price>53.00</Price>
                  <Alternate>53.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283001209605" Rank="4" Units="inf" Weight="5">
              <Name>Infusion 1 mg per ml, 5 ml</Name>
              <Brand ID="B28300120960501">
                <Name>Ventolin</Name>
                <Pack ID="P257923" Specified="true" nzmt:ctpp_id="50056071000117105">
                  <Quantity>10</Quantity>
                  <Subsidy>118.38</Subsidy>
                  <Price>118.38</Price>
                  <Alternate>118.38</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A283010">
          <Name>Inhaled Beta-Adrenoceptor Agonists</Name>
          <Chemical ID="C2830102096">
            <Name>Salbutamol</Name>
            <Formulation ID="F283010209614" Rank="8" Units="neb" Weight="2.5">
              <Name>Nebuliser soln, 1 mg per ml, 2.5 ml ampoule</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B28301020961402" S29="true">
                <Name>Ventolin Nebules</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2663775" Specified="true" nzmt:ctpp_id="50321651000117102">
                  <Quantity>20</Quantity>
                  <Subsidy>8.96</Subsidy>
                  <Price>8.96</Price>
                  <Alternate>8.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28301020961426" PSS="2024-06-30">
                <Name>Asthalin</Name>
                <Pack ID="P2154315" Specified="true" nzmt:ctpp_id="50026451000117106">
                  <Quantity>20</Quantity>
                  <Subsidy>8.96</Subsidy>
                  <Price>8.96</Price>
                  <Alternate>8.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28301020961427" S29="true">
                <Name>Accord</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2663686" Specified="true" nzmt:ctpp_id="50321641000117104">
                  <Quantity>20</Quantity>
                  <Subsidy>51.11</Subsidy>
                  <Price>51.11</Price>
                  <Alternate>51.11</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28301020961428" S29="true" Update="New Listing">
                <Name>Teva-Salbutamol Sterinebs P.F.</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2674319" Specified="true" nzmt:ctpp_id="50329841000117104">
                  <Quantity>20</Quantity>
                  <Subsidy>8.96</Subsidy>
                  <Price>8.96</Price>
                  <Alternate>8.96</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283010209615" Rank="8" Units="neb" Weight="5">
              <Name>Nebuliser soln, 2 mg per ml, 2.5 ml ampoule</Name>
              <Rule Type="FormMax" Value="30" Attribute="PSO"/>
              <Brand ID="B28301020961526" PSS="2024-06-30">
                <Name>Asthalin</Name>
                <Pack ID="P2154323" Specified="true" nzmt:ctpp_id="50026461000117108">
                  <Quantity>20</Quantity>
                  <Subsidy>9.43</Subsidy>
                  <Price>9.43</Price>
                  <Alternate>9.43</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28301020961527" S29="true">
                <Name>Salbutamol Cipla</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2672529" Specified="true" nzmt:ctpp_id="50328741000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>14.15</Subsidy>
                  <Price>14.15</Price>
                  <Alternate>14.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283010209616" Rank="6" Units="dose" Weight="100">
              <Name>Aerosol inhaler, 100 mcg per dose CFC free</Name>
              <Rule Type="FormMax" Value="1000" Attribute="PSO"/>
              <Brand ID="B28301020961625">
                <Name>Ventolin</Name>
                <Pack ID="P2026414" Specified="true" OP="true" nzmt:ctpp_id="50005221000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>3.80</Subsidy>
                  <Price>6.20</Price>
                  <Alternate>3.80</Alternate>
                  <Surcharge>0.01200</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28301020961627" ToBeDelisted="2024-09-01">
                <Name>Respigen</Name>
                <Pack ID="P2272911" Specified="true" OP="true" nzmt:ctpp_id="50042871000117104">
                  <Quantity>200</Quantity>
                  <Subsidy>3.80</Subsidy>
                  <Price>3.80</Price>
                  <Alternate>3.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28301020961628">
                <Name>SalAir</Name>
                <Pack ID="P2404516" Specified="true" OP="true" nzmt:ctpp_id="50226901000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>3.80</Subsidy>
                  <Price>3.80</Price>
                  <Alternate>3.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2830102404">
            <Name>Terbutaline sulphate</Name>
            <Formulation ID="F283010240425" Rank="6" Units="dose" Weight="250">
              <Name>Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated</Name>
              <Brand ID="B28301024042525">
                <Name>Bricanyl Turbuhaler</Name>
                <Pack ID="P2578417" Specified="true" OP="true" nzmt:ctpp_id="50264521000117109">
                  <Quantity>120</Quantity>
                  <Subsidy>22.20</Subsidy>
                  <Price>22.20</Price>
                  <Alternate>22.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2834">
        <Name>Anticholinergic Agents</Name>
        <ATC3 ID="A283401">
          <Name>Anticholinergic Agents</Name>
          <Chemical ID="C2834011492">
            <Name>Ipratropium bromide</Name>
            <Formulation ID="F283401149203" Rank="8" Units="neb" Weight="500">
              <Name>Nebuliser soln, 250 mcg per ml, 2 ml ampoule</Name>
              <Rule Type="FormMax" Value="40" Attribute="PSO"/>
              <Brand ID="B28340114920326">
                <Name>Univent</Name>
                <Pack ID="P2154307" Specified="true" nzmt:ctpp_id="50026441000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>11.73</Subsidy>
                  <Price>11.73</Price>
                  <Alternate>11.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28340114920327" S29="true">
                <Name>Accord</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2643154" Specified="true" nzmt:ctpp_id="50304571000117101">
                  <Quantity>20</Quantity>
                  <Subsidy>28.20</Subsidy>
                  <Price>28.20</Price>
                  <Alternate>28.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283401149225" Rank="6" Units="dose" Weight="20">
              <Name>Aerosol inhaler, 20 mcg per dose CFC-free</Name>
              <Rule Type="FormMax" Value="400" Attribute="PSO"/>
              <Brand ID="B28340114922525">
                <Name>Atrovent</Name>
                <Pack ID="P2145782" Specified="true" OP="true" nzmt:ctpp_id="50025151000117105">
                  <Quantity>200</Quantity>
                  <Subsidy>16.20</Subsidy>
                  <Price>16.20</Price>
                  <Alternate>16.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A283410">
          <Name>Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents</Name>
          <Chemical ID="C2834106311">
            <Name>Salbutamol with ipratropium bromide</Name>
            <Formulation ID="F283410631102" Rank="8" Units="neb" Weight="1">
              <Name>Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule</Name>
              <Rule Type="FormMax" Value="20" Attribute="PSO"/>
              <Brand ID="B28341063110225" PSS="2024-06-30">
                <Name>Duolin</Name>
                <Pack ID="P2039281" Specified="true" nzmt:ctpp_id="50007571000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>11.04</Subsidy>
                  <Price>11.04</Price>
                  <Alternate>11.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B28341063110226" S29="true">
                <Name>Duolin Respules</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2662159" Specified="true" nzmt:ctpp_id="50324531000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>33.12</Subsidy>
                  <Price>33.12</Price>
                  <Alternate>33.12</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283410631125" Rank="6" Units="dose">
              <Name>Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free</Name>
              <Brand ID="B28341063112525">
                <Name>Duolin HFA</Name>
                <Pack ID="P2349337" Specified="true" OP="true" nzmt:ctpp_id="50121521000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>12.19</Subsidy>
                  <Price>12.19</Price>
                  <Alternate>12.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A283414">
          <Name>Long-Acting Muscarinic Antagonists</Name>
          <Chemical ID="C2834143805">
            <Name>Tiotropium bromide</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Tiotropium treatment will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.</p>
            </div>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Tiotropium bromide is subsidised only for patients who have been diagnosed as having COPD
      using spirometry if spirometry is possible, and the prescription is endorsed accordingly.
      Patients who had tiotropium dispensed before 1 October 2018 with a valid Special Authority are
      deemed endorsed.</p>
            </div>
            <Formulation ID="F283414380525" Rank="6" Units="dose">
              <Name>Powder for inhalation, 18 mcg per dose</Name>
              <Brand ID="B28341438052525">
                <Name>Spiriva</Name>
                <Pack ID="P2115468" Specified="true" nzmt:ctpp_id="50020441000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>50.37</Subsidy>
                  <Price>50.37</Price>
                  <Alternate>50.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283414380526" Rank="6" Units="dose" Weight="2">
              <Name>Soln for inhalation 2.5 mcg per dose</Name>
              <Brand ID="B28341438052625">
                <Name>Spiriva Respimat</Name>
                <Pack ID="P2494019" Specified="true" OP="true" nzmt:ctpp_id="50227671000117105">
                  <Quantity>60</Quantity>
                  <Subsidy>50.37</Subsidy>
                  <Price>50.37</Price>
                  <Alternate>50.37</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2834144043">
            <Name>Glycopyrronium</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Inhaled glycopyrronium treatment will not be subsidised if patient is also receiving treatment with subsidised tiotropium or umeclidinium.</p>
            </div>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Glycopyrronium powder for inhalation 50 mcg per dose is subsidised only for patients who have
        been diagnosed as having COPD using spirometry if spirometry is possible, and the
        prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F283414404325" Rank="6" Units="dose">
              <Name>Powder for inhalation 50 mcg per dose</Name>
              <Brand ID="B28341440432525">
                <Name>Seebri Breezhaler</Name>
                <Pack ID="P2465949" Specified="true" OP="true" nzmt:ctpp_id="50209791000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>61.00</Subsidy>
                  <Price>61.00</Price>
                  <Alternate>61.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2834144057">
            <Name>Umeclidinium</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Umeclidinium will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.</p>
            </div>
            <Rule Type="SubRxF"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Umeclidinium powder for inhalation 62.5 mcg per dose is subsidised only for patients who have
        been diagnosed as having COPD using spirometry if spirometry is possible, and the
        prescription is endorsed accordingly.</p>
            </div>
            <Formulation ID="F283414405725" Rank="6" Units="dose" Weight="62">
              <Name>Powder for inhalation 62.5 mcg per dose</Name>
              <Brand ID="B28341440572525">
                <Name>Incruse Ellipta</Name>
                <Pack ID="P2494280" Specified="true" OP="true" nzmt:ctpp_id="50208191000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>61.50</Subsidy>
                  <Price>61.50</Price>
                  <Alternate>61.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A283416">
          <Name>Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists</Name>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
            <p>Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.</p>
          </div>
          <Request To="HealthPAC" For="Subsidy" Form="SA1584">
            <Title>
              <range>Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists</range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient has been stabilised on a long acting muscarinic antagonist</ci>
                  <ci type="logical" class="Indication">The prescriber considers that the patient would receive additional benefit from switching to a combination product</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
            <Case When="Renewal" Form="SA1584">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Patient is compliant with the medication</ci>
                  <ci type="logical" class="Indication">Patient has experienced improved COPD symptom control (prescriber determined)</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">2</Term>
            </Case>
          </Request>
          <Chemical ID="C2834164058">
            <Name>Glycopyrronium with indacaterol</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1584"/>
            <Formulation ID="F283416405825" Rank="6" Units="dose" Weight="160">
              <Name>Powder for Inhalation 50 mcg with indacaterol 110 mcg</Name>
              <Brand ID="B28341640582525">
                <Name>Ultibro Breezhaler</Name>
                <Pack ID="P2495562" Specified="true" OP="true" nzmt:ctpp_id="50215691000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>81.00</Subsidy>
                  <Price>81.00</Price>
                  <Alternate>81.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2834164059">
            <Name>Tiotropium bromide with olodaterol</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1584"/>
            <Formulation ID="F283416405925" Rank="6" Units="dose" Weight="5">
              <Name>Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg</Name>
              <Brand ID="B28341640592525">
                <Name>Spiolto Respimat</Name>
                <Pack ID="P2494027" Specified="true" OP="true" nzmt:ctpp_id="50207051000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>81.00</Subsidy>
                  <Price>81.00</Price>
                  <Alternate>81.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2834164060">
            <Name>Umeclidinium with vilanterol</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1584"/>
            <Formulation ID="F283416406025" Rank="6" Units="dose" Weight="87">
              <Name>Powder for inhalation 62.5 mcg with vilanterol 25 mcg</Name>
              <Brand ID="B28341640602525">
                <Name>Anoro Ellipta</Name>
                <Pack ID="P2494272" Specified="true" OP="true" nzmt:ctpp_id="50169371000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>77.00</Subsidy>
                  <Price>77.00</Price>
                  <Alternate>77.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2835">
        <Name>Antifibrotics</Name>
        <ATC3 ID="A283501">
          <Name>Antifibrotics</Name>
          <Chemical ID="C2835014079">
            <Name>Pirfenidone</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
              <p>Note: Pirfenidone is not subsidised in combination with subsidised nintedanib.</p>
            </div>
            <Rule Type="SpecEnd" Attribute="Retail"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2013"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2013">
              <Title>
                <range>Pirfenidone</range>
              </Title>
              <Case When="Initial application" Category="idiopathic pulmonary fibrosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist</ci>
                    <ci type="logical" class="Indication">Forced vital capacity is between 50% and 90% predicted</ci>
                    <ci type="logical" class="Indication">Pirfenidone is to be discontinued at disease progression (See Note)</ci>
                    <ci type="logical" class="Indication">Pirfenidone is not to be used in combination with subsidised nintedanib</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has not previously received treatment with nintedanib</ci>
                      <ci type="logical" class="Indication">Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance</ci>
                      <ci type="logical" class="Indication">Patient has previously received nintedanib, but the patientâ€™s disease has not progressed (disease progression defined as 10% or more decline
                        in predicted FVC within any 12 month period since starting treatment with nintedanib)</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="idiopathic pulmonary fibrosis" Form="SA1628 SA1748 SA1864 SA1929 SA2013">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment</ci>
                    <ci type="logical" class="Indication">Pirfenidone is not to be used in combination with subsidised nintedanib</ci>
                    <ci type="logical" class="Indication">Pirfenidone is to be discontinued at disease progression (See Note)</ci>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.</p>
              </div>
            </Request>
            <Formulation ID="F283501407926" Rank="1" Units="tab">
              <Name>Tab 801 mg</Name>
              <Brand ID="B28350140792625">
                <Name>Esbriet</Name>
                <Pack ID="P2575833" Specified="true" OP="true" nzmt:ctpp_id="50240021000117104">
                  <Quantity>90</Quantity>
                  <Subsidy>3645.00</Subsidy>
                  <Price>3645.00</Price>
                  <Alternate>3645.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283501407927" Rank="1" Units="tab" Weight="267">
              <Name>Tab 267 mg</Name>
              <Brand ID="B28350140792725">
                <Name>Esbriet</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2602156" Specified="true" nzmt:ctpp_id="50240031000117101">
                  <Quantity>90</Quantity>
                  <Subsidy>1215.00</Subsidy>
                  <Price>1215.00</Price>
                  <Alternate>1215.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2835014108">
            <Name>Nintedanib</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: Nintedanib not subsidised in combination with subsidised pirfenidone.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2012"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2012">
              <Title>
                <range>Nintedanib</range>
              </Title>
              <Case When="Initial application" Category="idiopathic pulmonary fibrosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist</ci>
                    <ci type="logical" class="Indication">Forced vital capacity is between 50% and 90% predicted</ci>
                    <ci type="logical" class="Indication">Nintedanib is to be discontinued at disease progression (See Note)</ci>
                    <ci type="logical" class="Indication">Nintedanib is not to be used in combination with subsidised pirfenidone</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">The patient has not previously received treatment with pirfenidone</ci>
                      <ci type="logical" class="Indication">Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance</ci>
                      <ci type="logical" class="Indication">Patient has previously received pirfenidone, but the patientâ€™s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone)</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="idiopathic pulmonary fibrosis" Form="SA1755 SA1928 SA2012">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment</ci>
                    <ci type="logical" class="Indication">Nintedanib is not to be used in combination with subsidised pirfenidone</ci>
                    <ci type="logical" class="Indication">Nintedanib is to be discontinued at disease progression (See Note)</ci>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.</p>
              </div>
            </Request>
            <Formulation ID="F283501410825" Rank="2" Units="cap" Weight="100">
              <Name>Cap 100 mg</Name>
              <Brand ID="B28350141082525">
                <Name>Ofev</Name>
                <Pack ID="P2553694" Specified="true" OP="true" nzmt:ctpp_id="50212751000117101">
                  <Quantity>60</Quantity>
                  <Subsidy>2554.00</Subsidy>
                  <Price>2554.00</Price>
                  <Alternate>2554.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283501410826" Rank="2" Units="cap" Weight="150">
              <Name>Cap 150 mg</Name>
              <Brand ID="B28350141082625">
                <Name>Ofev</Name>
                <Pack ID="P2553708" Specified="true" OP="true" nzmt:ctpp_id="50213141000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>3870.00</Subsidy>
                  <Price>3870.00</Price>
                  <Alternate>3870.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2837">
        <Name>Leukotriene Receptor Antagonists</Name>
        <ATC3 ID="A283704">
          <Name>Leukotriene Receptor Antagonists</Name>
          <Chemical ID="C2837043967" Statim="Must">
            <Name>Montelukast</Name>
            <Formulation ID="F283704396725" Rank="1" Units="tab" Weight="4">
              <Name>Tab 4 mg</Name>
              <Brand ID="B28370439672528" PSS="2025-06-30">
                <Name>Montelukast Viatris</Name>
                <Pack ID="P2643618" Specified="true" nzmt:ctpp_id="50295171000117101">
                  <Quantity>28</Quantity>
                  <Subsidy>3.10</Subsidy>
                  <Price>3.10</Price>
                  <Alternate>3.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283704396726" Rank="1" Units="tab" Weight="5">
              <Name>Tab 5 mg</Name>
              <Brand ID="B28370439672628" PSS="2025-06-30">
                <Name>Montelukast Viatris</Name>
                <Pack ID="P2643626" Specified="true" nzmt:ctpp_id="50295191000117100">
                  <Quantity>28</Quantity>
                  <Subsidy>3.10</Subsidy>
                  <Price>3.10</Price>
                  <Alternate>3.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F283704396727" Rank="1" Units="tab" Weight="10">
              <Name>Tab 10 mg</Name>
              <Brand ID="B28370439672729" PSS="2025-06-30">
                <Name>Montelukast Viatris</Name>
                <Pack ID="P2643634" Specified="true" nzmt:ctpp_id="50295211000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>2.90</Subsidy>
                  <Price>2.90</Price>
                  <Alternate>2.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2843">
        <Name>Methylxanthines</Name>
        <ATC3 ID="A284302">
          <Name>Methylxanthines</Name>
          <Chemical ID="C2843021056" Statim="Must">
            <Name>Aminophylline</Name>
            <Formulation ID="F284302105601" Rank="4" Units="inj" Weight="250">
              <Name>Inj 25 mg per ml, 10 ml ampoule</Name>
              <Rule Type="FormMax" Value="5" Attribute="PSO"/>
              <Brand ID="B28430210560101">
                <Name>DBL Aminophylline</Name>
                <Pack ID="P333956" Specified="true" nzmt:ctpp_id="50074201000117103">
                  <Quantity>5</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>180.00</Subsidy>
                  <Price>180.00</Price>
                  <Alternate>180.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2843021580" Statim="Must">
            <Name>Theophylline</Name>
            <Formulation ID="F284302158006" Rank="1" Units="tab" Weight="250">
              <Name>Tab long-acting 250 mg</Name>
              <Brand ID="B28430215800601">
                <Name>Nuelin-SR</Name>
                <Pack ID="P255149" Specified="true" nzmt:ctpp_id="50054871000117106">
                  <Quantity>100</Quantity>
                  <Subsidy>23.94</Subsidy>
                  <Price>23.94</Price>
                  <Alternate>23.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F284302158015" Rank="3" Units="ml">
              <Name>Oral liq 80 mg per 15 ml</Name>
              <Brand ID="B28430215801501">
                <Name>Nuelin</Name>
                <Pack ID="P255092" Specified="true" nzmt:ctpp_id="50054831000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>17.62</Subsidy>
                  <Price>17.62</Price>
                  <Alternate>17.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2849">
        <Name>Mucolytics</Name>
        <ATC3 ID="A284902">
          <Name>Mucolytics</Name>
          <Chemical ID="C2849021010">
            <Name>Dornase alfa</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1978"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1978">
              <Title>
                <range>Dornase Alfa</range>
              </Title>
              <Case When="Initial application" Category="cystic fibrosis">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a confirmed diagnosis of cystic fibrosis</ci>
                    <ci type="logical" class="Indication">Patient has previously undergone a trial with, or is currently being treated with, hypertonic saline</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has required one or more hospital inpatient respiratory admissions in the previous 12 month period</ci>
                      <ci type="logical" class="Indication">Patient has had 3 exacerbations due to CF, requiring oral or intravenous (IV) antibiotics in the previous 12 month period</ci>
                      <ci type="logical" class="Indication">Patient has had 1 exacerbation due to CF, requiring oral or IV antibiotics in the previous 12 month period and a Brasfield score of &lt;22/25</ci>
                      <ci type="logical" class="Indication">Patient has a diagnosis of allergic bronchopulmonary aspergillosis (ABPA)</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>respiratory physician</Applicant>
                <Applicant>paediatrician</Applicant>
                <Term Measure="month">12</Term>
              </Case>
              <Case When="Renewal" Category="cystic fibrosis" Form="SA1978">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">the treatment remains appropriate and the patient continues to benefit from treatment</ci>
                </math>
                <Applicant>respiratory physician</Applicant>
                <Applicant>paediatrician</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F284902101001" Rank="4" Units="amp" Weight="2.5">
              <Name>Nebuliser soln, 2.5 mg per 2.5 ml ampoule</Name>
              <Brand ID="B28490210100101">
                <Name>Pulmozyme</Name>
                <Pack ID="P239070" Specified="true" nzmt:ctpp_id="50051371000117101">
                  <Quantity>6</Quantity>
                  <Subsidy>250.00</Subsidy>
                  <Price>250.00</Price>
                  <Alternate>250.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2849022135">
            <Name>Sodium chloride</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Not funded for use as a nasal drop.</p>
            </div>
            <Formulation ID="F284902213526" Rank="3" Units="ml" Weight="7">
              <Name>Soln 7%</Name>
              <Brand ID="B28490221352625" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P2378701" Specified="true" OP="true" nzmt:ctpp_id="50121531000117102">
                  <Quantity>90</Quantity>
                  <Subsidy>24.50</Subsidy>
                  <Price>24.50</Price>
                  <Alternate>24.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2849024139">
            <Name>Ivacaftor</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Type="SpecEnd" Attribute="Hospital"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2017"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2017">
              <Title>
                <range>Ivacaftor</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with cystic fibrosis</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient must have G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on at least 1 allele</ci>
                      <ci type="logical" class="Indication">Patient must have other gating (class III) mutation (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R) in the CFTR gene on at least 1 allele</ci>
                    </apply>
                    <ci type="logical" class="Indication">Patients must have a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system</ci>
                    <ci type="logical" class="Indication">Treatment with ivacaftor must be given concomitantly with standard therapy for this condition</ci>
                    <ci type="logical" class="Indication">Patient must not have an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing treatment with ivacaftor</ci>
                    <ci type="logical" class="Indication">The dose of ivacaftor will not exceed one tablet or one sachet twice daily</ci>
                    <ci type="logical" class="Indication">Applicant has experience and expertise in the management of cystic fibrosis</ci>
                  </apply>
                </math>
                <Applicant>respiratory specialist</Applicant>
                <Applicant>paediatrician</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F284902413925" Rank="1" Units="tab" Weight="150">
              <Name>Tab 150 mg</Name>
              <Brand ID="B28490241392525">
                <Name>Kalydeco</Name>
                <Pack ID="P2586118" Specified="true" nzmt:ctpp_id="50177711000117106">
                  <Quantity>56</Quantity>
                  <Subsidy>29386.00</Subsidy>
                  <Price>29386.00</Price>
                  <Alternate>29386.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F284902413926" Rank="10" Units="ea" Weight="50">
              <Name>Oral granules 50 mg, sachet</Name>
              <Brand ID="B28490241392625">
                <Name>Kalydeco</Name>
                <Pack ID="P2586134" Specified="true" nzmt:ctpp_id="50274751000117104">
                  <Quantity>56</Quantity>
                  <Subsidy>29386.00</Subsidy>
                  <Price>29386.00</Price>
                  <Alternate>29386.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F284902413927" Rank="10" Units="ea" Weight="75">
              <Name>Oral granules 75 mg, sachet</Name>
              <Brand ID="B28490241392725">
                <Name>Kalydeco</Name>
                <Pack ID="P2586126" Specified="true" nzmt:ctpp_id="50274761000117102">
                  <Quantity>56</Quantity>
                  <Subsidy>29386.00</Subsidy>
                  <Price>29386.00</Price>
                  <Alternate>29386.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2849024175">
            <Name>Elexacaftor with tezacaftor, ivacaftor and ivacaftor</Name>
            <Rule Type="PCT" Attribute="only"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2196"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2196">
              <Title>
                <range>Elexacaftor with tezacaftor, ivacaftor and ivacaftor</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has been diagnosed with cystic fibrosis</ci>
                    <ci type="logical" class="Indication">Patient is 6 years of age or older</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental
                        allele)</ci>
                      <ci type="logical" class="Indication">Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection
                        system</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has a heterozygous or homozygous F508del mutation</ci>
                      <ci type="logical" class="Indication">Patient has a G551D mutation or other mutation responsive in vitro to elexacaftor/tezacaftor/ivacaftor (see note a)</ci>
                    </apply>
                    <ci type="logical" class="Indication">The treatment must be the sole funded CFTR modulator therapy for this condition</ci>
                    <ci type="logical" class="Indication">Treatment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition</ci>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="patient's lifetime"/>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information</p>
                      <p>
                        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf"> https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf</a>
                      </p>
                    </li>
                  </ol>
                </div>
              </Case>
            </Request>
            <Formulation ID="F284902417525" Rank="1" Units="tab" Weight="50">
              <Name>Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg (56) and ivacaftor 75 mg (28)</Name>
              <Brand ID="B28490241752525">
                <Name>Trikafta</Name>
                <Pack ID="P2649748" Specified="true" OP="true" nzmt:ctpp_id="50287441000117105">
                  <Quantity>84</Quantity>
                  <Subsidy>27647.39</Subsidy>
                  <Price>27647.39</Price>
                  <Alternate>27647.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F284902417526" Rank="1" Units="tab" Weight="100">
              <Name>Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (56) and ivacaftor 150 mg (28)</Name>
              <Brand ID="B28490241752625">
                <Name>Trikafta</Name>
                <Pack ID="P2611694" Specified="true" OP="true" nzmt:ctpp_id="50287431000117102">
                  <Quantity>84</Quantity>
                  <Subsidy>27647.39</Subsidy>
                  <Price>27647.39</Price>
                  <Alternate>27647.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2851">
        <Name>Nasal Preparations</Name>
        <ATC3 ID="A285102">
          <Name>Allergy Prophylactics</Name>
          <Chemical ID="C2851021168">
            <Name>Budesonide</Name>
            <Formulation ID="F285102116807" Rank="6" Units="dose" Weight="50">
              <Name>Metered aqueous nasal spray, 50 mcg per dose</Name>
              <Brand ID="B28510211680704">
                <Name>SteroClear</Name>
                <Pack ID="P2541149" Specified="true" OP="true" nzmt:ctpp_id="50250101000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>2.89</Subsidy>
                  <Price>2.89</Price>
                  <Alternate>2.89</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F285102116808" Rank="6" Units="dose" Weight="100">
              <Name>Metered aqueous nasal spray, 100 mcg per dose</Name>
              <Brand ID="B28510211680804">
                <Name>SteroClear</Name>
                <Pack ID="P2541068" Specified="true" OP="true" nzmt:ctpp_id="50250111000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>3.29</Subsidy>
                  <Price>3.29</Price>
                  <Alternate>3.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2851021492">
            <Name>Ipratropium bromide</Name>
            <Formulation ID="F285102149206" Rank="3" Units="ml">
              <Name>Aqueous nasal spray, 0.03%</Name>
              <Brand ID="B28510214920626">
                <Name>Univent</Name>
                <Pack ID="P2372908" Specified="true" OP="true" nzmt:ctpp_id="50122511000117104">
                  <Quantity>15</Quantity>
                  <Subsidy>5.23</Subsidy>
                  <Price>5.23</Price>
                  <Alternate>5.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2851023903">
            <Name>Fluticasone propionate</Name>
            <Formulation ID="F285102390325" Rank="6" Units="dose">
              <Name>Metered aqueous nasal spray, 50 mcg per dose</Name>
              <Brand ID="B28510239032525" PSS="2024-06-30">
                <Name>Flixonase Hayfever &amp; Allergy</Name>
                <Pack ID="P2407000" Specified="true" OP="true" nzmt:ctpp_id="50157831000117105">
                  <Quantity>120</Quantity>
                  <Subsidy>1.98</Subsidy>
                  <Price>1.98</Price>
                  <Alternate>1.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2853">
        <Name>Respiratory Devices</Name>
        <ATC3 ID="A285302">
          <Name>Respiratory Devices</Name>
          <Chemical ID="C2853021827">
            <Name>Peak flow meter</Name>
            <Rule Type="FormMax" Value="25" Attribute="PSO"/>
            <Rule Type="FormReqd" Attribute="PSO"/>
            <Formulation ID="F285302182701" Rank="10" Units="dev">
              <Name>Low range</Name>
              <Brand ID="B28530218270127">
                <Name>Mini-Wright AFS Low Range</Name>
                <Pack ID="P2489945" Specified="true" nzmt:ctpp_id="50227471000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>9.54</Subsidy>
                  <Price>9.54</Price>
                  <Alternate>9.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F285302182702" Rank="10" Units="dev">
              <Name>Normal range</Name>
              <Brand ID="B28530218270227">
                <Name>Mini-Wright Standard</Name>
                <Pack ID="P2489953" Specified="true" nzmt:ctpp_id="50030591000117103">
                  <Quantity>1</Quantity>
                  <Subsidy>9.54</Subsidy>
                  <Price>9.54</Price>
                  <Alternate>9.54</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2853021829">
            <Name>Spacer device</Name>
            <Rule Type="FormMax" Value="50" Attribute="PSO"/>
            <Rule Type="FormReqd" Attribute="PSO"/>
            <Formulation ID="F285302182926" Rank="10" Units="dev">
              <Name>800 ml</Name>
              <Brand ID="B28530218292625">
                <Name>Volumatic</Name>
                <Pack ID="P529613" Specified="true" nzmt:ctpp_id="50094511000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F285302182927" Rank="10" Units="dev">
              <Name>220 ml (single patient)</Name>
              <Brand ID="B28530218292725">
                <Name>e-chamber Turbo</Name>
                <Pack ID="P2490072" Specified="true" nzmt:ctpp_id="50227481000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>3.65</Subsidy>
                  <Price>3.65</Price>
                  <Alternate>3.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F285302182928" Rank="10" Units="dev">
              <Name>510 ml (single patient)</Name>
              <Brand ID="B28530218292825">
                <Name>e-chamber La Grande</Name>
                <Pack ID="P2490080" Specified="true" nzmt:ctpp_id="50227491000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>5.95</Subsidy>
                  <Price>5.95</Price>
                  <Alternate>5.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C2853021832">
            <Name>Mask for spacer device</Name>
            <Rule Type="FormMax" Value="50" Attribute="PSO"/>
            <Rule Type="FormReqd" Attribute="PSO"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only for children aged six years and under</p>
            </div>
            <Formulation ID="F285302183225" Rank="10" Units="dev">
              <Name>Small</Name>
              <Brand ID="B28530218322525">
                <Name>e-chamber Mask</Name>
                <Pack ID="P2490099" Specified="true" nzmt:ctpp_id="50227461000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>2.70</Subsidy>
                  <Price>2.70</Price>
                  <Alternate>2.70</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A2856">
        <Name>Respiratory Stimulants</Name>
        <ATC3 ID="A285601">
          <Name>Respiratory Stimulants</Name>
          <Chemical ID="C2856013933">
            <Name>Caffeine citrate</Name>
            <Formulation ID="F285601393325" Rank="3" Units="ml" Weight="20">
              <Name>Oral liq 20 mg per ml (10 mg base per ml)</Name>
              <Brand ID="B28560139332525" S26="true">
                <Name>Biomed</Name>
                <Pack ID="P461253" Specified="true" OP="true" nzmt:ctpp_id="50087561000117103">
                  <Quantity>25</Quantity>
                  <Subsidy>16.10</Subsidy>
                  <Price>16.10</Price>
                  <Alternate>16.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A31">
      <Name>Sensory Organs</Name>
      <ATC2 ID="A3101">
        <Name>Ear Preparations</Name>
        <ATC3 ID="A310101">
          <Name>Ear Preparations</Name>
          <Chemical ID="C3101011516">
            <Name>Flumetasone pivalate</Name>
            <Formulation ID="F310101151601" Rank="3" Units="ml">
              <Name>Ear drops 0.02% with clioquinol 1%</Name>
              <Brand ID="B31010115160101">
                <Name>Locorten-Vioform</Name>
                <Pack ID="P259799" Specified="true" OP="true" nzmt:ctpp_id="50056791000117108">
                  <Quantity>7.5</Quantity>
                  <Subsidy>4.46</Subsidy>
                  <Price>4.46</Price>
                  <Alternate>4.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B31010115160125">
                <Name>Locacorten-Viaform ED's</Name>
                <Pack ID="P2360403" Specified="true" OP="true" nzmt:ctpp_id="50050941000117100">
                  <Quantity>7.5</Quantity>
                  <Subsidy>4.46</Subsidy>
                  <Price>4.46</Price>
                  <Alternate>4.46</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3101012387">
            <Name>Triamcinolone acetonide with gramicidin, neomycin and nystatin</Name>
            <Formulation ID="F310101238701" Rank="3" Units="ml">
              <Name>Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g</Name>
              <Brand ID="B31010123870101">
                <Name>Kenacomb</Name>
                <Pack ID="P253634" Specified="true" OP="true" nzmt:ctpp_id="50053971000117104">
                  <Quantity>7.5</Quantity>
                  <Subsidy>5.16</Subsidy>
                  <Price>5.16</Price>
                  <Alternate>5.16</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A3102">
        <Name>Ear/Eye Preparations</Name>
        <ATC3 ID="A310201">
          <Name>Ear/Eye Preparations</Name>
          <Chemical ID="C3102011381">
            <Name>Dexamethasone with framycetin and gramicidin</Name>
            <Formulation ID="F310201138101" Rank="3" Units="ml">
              <Name>Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml</Name>
              <Brand ID="B31020113810101">
                <Name>Sofradex</Name>
                <Pack ID="P208728" Specified="true" OP="true" nzmt:ctpp_id="50015521000117104">
                  <Quantity>8</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>9.27</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.59625</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B31020113810102" S29="true">
                <Name>Otodex</Name>
                <Pack ID="P2660849" Specified="true" OP="true" nzmt:ctpp_id="50320061000117102">
                  <Quantity>8</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>9.27</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.59625</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3102012440">
            <Name>Framycetin sulphate</Name>
            <Formulation ID="F310201244003" Rank="3" Units="ml">
              <Name>Ear/Eye drops 0.5%</Name>
              <Brand ID="B31020124400301">
                <Name>Soframycin</Name>
                <Pack ID="P254894" Specified="true" OP="true" nzmt:ctpp_id="50054701000117108">
                  <Quantity>8</Quantity>
                  <Subsidy>4.13</Subsidy>
                  <Price>8.65</Price>
                  <Alternate>4.13</Alternate>
                  <Surcharge>0.56500</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A3103">
        <Name>Eye Preparations</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
          <p>Eye preparations are only funded for use in the eye, unless explicitly stated otherwise.</p>
        </div>
        <ATC3 ID="A310301">
          <Name>Anti-Infective Preparations</Name>
          <Chemical ID="C3103011259">
            <Name>Chloramphenicol</Name>
            <Formulation ID="F310301125901" Rank="3" Units="ml">
              <Name>Eye drops 0.5%</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Funded for use in the ear*.</p>
                <p>Indications marked with * are unapproved indications.</p>
              </div>
              <Brand ID="B31030112590102" PSS="2025-06-30">
                <Name>Chlorsig</Name>
                <Pack ID="P335142" Specified="true" OP="true" nzmt:ctpp_id="50074271000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>1.45</Subsidy>
                  <Price>1.45</Price>
                  <Alternate>1.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310301125904" Rank="3" Units="g">
              <Name>Eye oint 1%</Name>
              <Brand ID="B31030112590405" PSS="2025-06-30">
                <Name>Devatis</Name>
                <Pack ID="P2576902" Specified="true" OP="true" nzmt:ctpp_id="50267541000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>1.09</Subsidy>
                  <Price>1.09</Price>
                  <Alternate>1.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103011546">
            <Name>Sodium Fusidate [fusidic acid]</Name>
            <Formulation ID="F310301154604" Rank="3" Units="g">
              <Name>Eye drops 1%</Name>
              <Brand ID="B31030115460401">
                <Name>Fucithalmic</Name>
                <Pack ID="P716634" Specified="true" OP="true" nzmt:ctpp_id="50105131000117100">
                  <Quantity>5</Quantity>
                  <Subsidy>5.29</Subsidy>
                  <Price>5.29</Price>
                  <Alternate>5.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103012274">
            <Name>Tobramycin</Name>
            <Formulation ID="F310301227404" Rank="3" Units="ml">
              <Name>Eye drops 0.3%</Name>
              <Brand ID="B31030122740401">
                <Name>Tobrex</Name>
                <Pack ID="P308390" Specified="true" OP="true" nzmt:ctpp_id="50069141000117101">
                  <Quantity>5</Quantity>
                  <Subsidy>11.48</Subsidy>
                  <Price>11.48</Price>
                  <Alternate>11.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310301227405" Rank="3" Units="g">
              <Name>Eye oint 0.3%</Name>
              <Brand ID="B31030122740501">
                <Name>Tobrex</Name>
                <Pack ID="P331767" Specified="true" OP="true" nzmt:ctpp_id="50073531000117109">
                  <Quantity>3.5</Quantity>
                  <Subsidy>10.45</Subsidy>
                  <Price>10.45</Price>
                  <Alternate>10.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103012483" Statim="Must">
            <Name>Aciclovir</Name>
            <Formulation ID="F310301248304" Rank="3" Units="g">
              <Name>Eye oint 3%</Name>
              <Brand ID="B31030124830425" PSS="2024-06-30">
                <Name>ViruPOS</Name>
                <Pack ID="P2490803" Specified="true" OP="true" nzmt:ctpp_id="50232991000117103">
                  <Quantity>4.5</Quantity>
                  <Subsidy>14.88</Subsidy>
                  <Price>14.88</Price>
                  <Alternate>14.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103012819">
            <Name>Ciprofloxacin</Name>
            <Formulation ID="F310301281904" Rank="3" Units="ml">
              <Name>Eye drops 0.3%</Name>
              <Rule Type="SubRxF"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>When prescribed for the treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol; or for the second line treatment of chronic suppurative otitis media
        (CSOM)*; and the prescription is endorsed accordingly.</p>
                <p>Note: Indication marked with a * is an unapproved indication.</p>
              </div>
              <Brand ID="B31030128190402" PSS="2024-06-30">
                <Name>Ciprofloxacin Teva</Name>
                <Pack ID="P2539144" Specified="true" OP="true" nzmt:ctpp_id="50252581000117107">
                  <Quantity>5</Quantity>
                  <Subsidy>9.73</Subsidy>
                  <Price>9.73</Price>
                  <Alternate>9.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310304">
          <Name>Corticosteroids and Other Anti-Inflammatory Preparations</Name>
          <Chemical ID="C3103041064" Statim="Must">
            <Name>Dexamethasone with neomycin sulphate and polymyxin B sulphate</Name>
            <Formulation ID="F310304106401" Rank="3" Units="ml">
              <Name>Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml</Name>
              <Brand ID="B31030410640101">
                <Name>Maxitrol</Name>
                <Pack ID="P207454" Specified="true" OP="true" nzmt:ctpp_id="50012341000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>4.50</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310304106402" Rank="3" Units="g">
              <Name>Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g</Name>
              <Brand ID="B31030410640201">
                <Name>Maxitrol</Name>
                <Pack ID="P207381" Specified="true" OP="true" nzmt:ctpp_id="50012301000117107">
                  <Quantity>3.5</Quantity>
                  <Subsidy>5.39</Subsidy>
                  <Price>5.39</Price>
                  <Alternate>5.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103041103">
            <Name>Lodoxamide</Name>
            <Formulation ID="F310304110301" Rank="3" Units="ml">
              <Name>Eye drops 0.1%</Name>
              <Brand ID="B31030411030101">
                <Name>Lomide</Name>
                <Pack ID="P424544" Specified="true" OP="true" nzmt:ctpp_id="50084301000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>8.71</Subsidy>
                  <Price>8.71</Price>
                  <Alternate>8.71</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103041383">
            <Name>Dexamethasone</Name>
            <Formulation ID="F310304138303" Rank="3" Units="ml" Statim="Must">
              <Name>Eye drops 0.1%</Name>
              <Brand ID="B31030413830301">
                <Name>Maxidex</Name>
                <Pack ID="P207446" Specified="true" OP="true" nzmt:ctpp_id="50012331000117101">
                  <Quantity>5</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>4.50</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310304138306" Rank="3" Units="g" Statim="Must">
              <Name>Eye oint 0.1%</Name>
              <Brand ID="B31030413830601">
                <Name>Maxidex</Name>
                <Pack ID="P207373" Specified="true" OP="true" nzmt:ctpp_id="50012291000117106">
                  <Quantity>3.5</Quantity>
                  <Subsidy>5.86</Subsidy>
                  <Price>5.86</Price>
                  <Alternate>5.86</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310304138326" Rank="10" Units="each" Weight="700">
              <Name>Ocular implant 700 mcg</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1680"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA1680">
                <Title>
                  <range>Dexamethasone 700 mcg ocular implants</range>
                </Title>
                <Case When="Initial application" Category="Diabetic macular oedema">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has diabetic macular oedema with pseudophakic lens</ci>
                      <ci type="logical" class="Indication">Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Patient's disease has progressed despite 3 injections with bevacizumab</ci>
                        <ci type="logical" class="Indication">Patient is unsuitable or contraindicated to treatment with anti-VEGF agents</ci>
                      </apply>
                      <ci type="logical" class="Indication">Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year</ci>
                    </apply>
                  </math>
                  <Applicant>ophthalmologist</Applicant>
                  <Term Measure="month">12</Term>
                </Case>
                <Case When="Renewal" Form="SA1680" Category="Diabetic macular oedema">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient's vision is stable or has improved (prescriber determined)</ci>
                      <ci type="logical" class="Indication">Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year</ci>
                    </apply>
                  </math>
                  <Applicant>ophthalmologist</Applicant>
                  <Term Measure="month">12</Term>
                </Case>
                <Case When="Initial application" Category="Women of child bearing age with diabetic macular oedema">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has diabetic macular oedema</ci>
                      <ci type="logical" class="Indication">Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision</ci>
                      <ci type="logical" class="Indication">Patient is of child bearing potential and has not yet completed a family</ci>
                      <ci type="logical" class="Indication">Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year</ci>
                    </apply>
                  </math>
                  <Applicant>ophthalmologist</Applicant>
                  <Term Measure="month">12</Term>
                </Case>
                <Case When="Renewal" Form="SA1680" Category="Women of child bearing age with diabetic macular oedema">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient's vision is stable or has improved (prescriber determined)</ci>
                      <ci type="logical" class="Indication">Patient is of child bearing potential and has not yet completed a family</ci>
                      <ci type="logical" class="Indication">Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year</ci>
                    </apply>
                  </math>
                  <Applicant>ophthalmologist</Applicant>
                  <Term Measure="month">12</Term>
                </Case>
              </Request>
              <Brand ID="B31030413832625">
                <Name>Ozurdex</Name>
                <Pack ID="P2529610" Specified="true" nzmt:ctpp_id="50246951000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>1444.50</Subsidy>
                  <Price>1444.50</Price>
                  <Alternate>1444.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103041401">
            <Name>Diclofenac sodium</Name>
            <Formulation ID="F310304140110" Rank="3" Units="ml">
              <Name>Eye drops 0.1%</Name>
              <Brand ID="B31030414011001" PSS="2024-06-30" ToBeDelisted="2024-12-01">
                <Name>Voltaren Ophtha</Name>
                <Pack ID="P781851" Specified="true" OP="true" nzmt:ctpp_id="50113641000117102">
                  <Quantity>5</Quantity>
                  <Subsidy>8.80</Subsidy>
                  <Price>8.80</Price>
                  <Alternate>8.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103041527" Statim="Must">
            <Name>Fluorometholone</Name>
            <Formulation ID="F310304152701" Rank="3" Units="ml">
              <Name>Eye drops 0.1%</Name>
              <Brand ID="B31030415270101">
                <Name>FML</Name>
                <Pack ID="P264415" Specified="true" OP="true" nzmt:ctpp_id="50058651000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>3.09</Subsidy>
                  <Price>3.09</Price>
                  <Alternate>3.09</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B31030415270102">
                <Name>Flucon</Name>
                <Pack ID="P284866" Specified="true" OP="true" nzmt:ctpp_id="50063951000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>5.20</Subsidy>
                  <Price>5.20</Price>
                  <Alternate>5.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103042032">
            <Name>Prednisolone acetate</Name>
            <Formulation ID="F310304203202" Rank="3" Units="ml">
              <Name>Eye drops 1%</Name>
              <Brand ID="B31030420320201">
                <Name>Pred Forte</Name>
                <Pack ID="P260533" Specified="true" OP="true" nzmt:ctpp_id="50057171000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B31030420320225">
                <Name>Prednisolone-AFT</Name>
                <Pack ID="P2501511" Specified="true" OP="true" nzmt:ctpp_id="50227681000117108">
                  <Quantity>10</Quantity>
                  <Subsidy>6.92</Subsidy>
                  <Price>6.92</Price>
                  <Alternate>6.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103042144">
            <Name>Sodium cromoglicate</Name>
            <Formulation ID="F310304214407" Rank="3" Units="ml">
              <Name>Eye drops 2%</Name>
              <Brand ID="B31030421440728" PSS="2025-06-30">
                <Name>Allerfix</Name>
                <Pack ID="P2645416" Specified="true" OP="true" nzmt:ctpp_id="50306321000117102">
                  <Quantity>10</Quantity>
                  <Subsidy>2.62</Subsidy>
                  <Price>2.62</Price>
                  <Alternate>2.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103042853">
            <Name>Levocabastine</Name>
            <Formulation ID="F310304285301" Rank="3" Units="ml">
              <Name>Eye drops 0.5 mg per ml</Name>
              <Brand ID="B31030428530101">
                <Name>Livostin</Name>
                <Pack ID="P799882" Specified="true" OP="true" nzmt:ctpp_id="50117411000117106">
                  <Quantity>4</Quantity>
                  <Subsidy>8.71</Subsidy>
                  <Price>10.34</Price>
                  <Alternate>8.71</Alternate>
                  <Surcharge>0.40750</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103044050">
            <Name>Prednisolone sodium phosphate</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1715"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1715">
              <Title>
                <range>Prednisolone sodium phosphate</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has severe inflammation</ci>
                    <ci type="logical" class="Indication">Patient has a confirmed allergic reaction to preservative in eye drops</ci>
                  </apply>
                </math>
                <Applicant>ophthalmologist</Applicant>
                <Applicant>optometrist</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Form="SA1547 SA1715">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F310304405025" Rank="6" Units="dose">
              <Name>Eye drops 0.5%, single dose (preservative free)</Name>
              <Brand ID="B31030440502525">
                <Name>Minims Prednisolone</Name>
                <Pack ID="P307475" Specified="true" nzmt:ctpp_id="50068881000117105">
                  <Quantity>20</Quantity>
                  <Subsidy>41.20</Subsidy>
                  <Price>41.20</Price>
                  <Alternate>41.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103044136">
            <Name>Nepafenac</Name>
            <Formulation ID="F310304413625" Rank="3" Units="ml">
              <Name>Eye drops 0.3%</Name>
              <Brand ID="B31030441362525">
                <Name>Ilevro</Name>
                <Pack ID="P2655969" Specified="true" OP="true" nzmt:ctpp_id="50315221000117101">
                  <Quantity>3</Quantity>
                  <Subsidy>8.80</Subsidy>
                  <Price>8.80</Price>
                  <Alternate>8.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310305">
          <Name>Glaucoma Preparations - Beta Blockers</Name>
          <Chemical ID="C3103051149" Statim="Must">
            <Name>Betaxolol</Name>
            <Formulation ID="F310305114901" Rank="3" Units="ml">
              <Name>Eye drops 0.25%</Name>
              <Brand ID="B31030511490101" ToBeDelisted="2025-07-01">
                <Name>Betoptic S</Name>
                <Pack ID="P214558" Specified="true" OP="true" nzmt:ctpp_id="50025131000117100">
                  <Quantity>5</Quantity>
                  <Subsidy>11.80</Subsidy>
                  <Price>11.80</Price>
                  <Alternate>11.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310305114902" Rank="3" Units="ml">
              <Name>Eye drops 0.5%</Name>
              <Brand ID="B31030511490201" ToBeDelisted="2025-07-01">
                <Name>Betoptic</Name>
                <Pack ID="P535982" Specified="true" OP="true" nzmt:ctpp_id="50094921000117105">
                  <Quantity>5</Quantity>
                  <Subsidy>7.50</Subsidy>
                  <Price>7.50</Price>
                  <Alternate>7.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103052266" Statim="Must">
            <Name>Timolol</Name>
            <Formulation ID="F310305226602" Rank="3" Units="ml">
              <Name>Eye drops 0.25%</Name>
              <Brand ID="B31030522660226" PSS="2026-06-30">
                <Name>Arrow-Timolol</Name>
                <Pack ID="P2390663" Specified="true" OP="true" nzmt:ctpp_id="50125551000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>2.42</Subsidy>
                  <Price>2.42</Price>
                  <Alternate>2.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310305226604" Rank="3" Units="ml">
              <Name>Eye drops 0.5%</Name>
              <Brand ID="B31030522660426" PSS="2026-06-30">
                <Name>Arrow-Timolol</Name>
                <Pack ID="P2390655" Specified="true" OP="true" nzmt:ctpp_id="50125561000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>2.50</Subsidy>
                  <Price>2.50</Price>
                  <Alternate>2.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310306">
          <Name>Glaucoma Preparations - Carbonic Anhydrase Inhibitors</Name>
          <Chemical ID="C3103061003" Statim="Must">
            <Name>Acetazolamide</Name>
            <Formulation ID="F310306100301" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg</Name>
              <Brand ID="B31030610030101">
                <Name>Diamox</Name>
                <Pack ID="P2164795" Specified="true" nzmt:ctpp_id="50027581000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>17.03</Subsidy>
                  <Price>17.03</Price>
                  <Alternate>17.03</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103063781" Statim="Must">
            <Name>Dorzolamide with timolol</Name>
            <Formulation ID="F310306378125" Rank="3" Units="ml">
              <Name>Eye drops 2% with timolol 0.5%</Name>
              <Brand ID="B31030637812527" PSS="2024-06-30">
                <Name>Dortimopt</Name>
                <Pack ID="P2398354" Specified="true" OP="true" nzmt:ctpp_id="50255151000117104">
                  <Quantity>5</Quantity>
                  <Subsidy>2.73</Subsidy>
                  <Price>2.73</Price>
                  <Alternate>2.73</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103063792" Statim="Must">
            <Name>Brinzolamide</Name>
            <Formulation ID="F310306379225" Rank="3" Units="ml" Weight="1">
              <Name>Eye drops 1%</Name>
              <Brand ID="B31030637922525" PSS="2024-06-30">
                <Name>Azopt</Name>
                <Pack ID="P2117061" Specified="true" OP="true" nzmt:ctpp_id="50020791000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>7.30</Subsidy>
                  <Price>7.30</Price>
                  <Alternate>7.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310308">
          <Name>Glaucoma Preparations - Prostaglandin Analogues</Name>
          <Chemical ID="C3103081250" Statim="Must">
            <Name>Latanoprost</Name>
            <Formulation ID="F310308125001" Rank="3" Units="ml">
              <Name>Eye drops 0.005%</Name>
              <Brand ID="B31030812500126" PSS="2024-06-30">
                <Name>Teva</Name>
                <Pack ID="P2553139" Specified="true" OP="true" nzmt:ctpp_id="50246471000117108">
                  <Quantity>2.5</Quantity>
                  <Subsidy>1.82</Subsidy>
                  <Price>1.82</Price>
                  <Alternate>1.82</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103083794" Statim="Must">
            <Name>Travoprost</Name>
            <Formulation ID="F310308379425" Rank="3" Units="ml">
              <Name>Eye drops 0.004%</Name>
              <Brand ID="B31030837942525" PSS="2024-06-30">
                <Name>Travatan</Name>
                <Pack ID="P2550091" Specified="true" OP="true" nzmt:ctpp_id="50024921000117104">
                  <Quantity>2.5</Quantity>
                  <Subsidy>9.75</Subsidy>
                  <Price>9.75</Price>
                  <Alternate>9.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103083824" Statim="Must">
            <Name>Bimatoprost</Name>
            <Formulation ID="F310308382425" Rank="3" Units="ml">
              <Name>Eye drops 0.03%</Name>
              <Brand ID="B31030838242527" PSS="2024-06-30">
                <Name>Bimatoprost Multichem</Name>
                <Pack ID="P2545128" Specified="true" OP="true" nzmt:ctpp_id="50229761000117104">
                  <Quantity>3</Quantity>
                  <Subsidy>5.95</Subsidy>
                  <Price>5.95</Price>
                  <Alternate>5.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310309">
          <Name>Glaucoma Preparations - Other</Name>
          <Chemical ID="C3103091987" Statim="Must">
            <Name>Pilocarpine hydrochloride</Name>
            <Formulation ID="F310309198702" Rank="3" Units="ml">
              <Name>Eye drops 1%</Name>
              <Brand ID="B31030919870201">
                <Name>Isopto Carpine</Name>
                <Pack ID="P252514" Specified="true" OP="true" nzmt:ctpp_id="50053381000117102">
                  <Quantity>15</Quantity>
                  <Subsidy>4.26</Subsidy>
                  <Price>4.26</Price>
                  <Alternate>4.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310309198703" Rank="3" Units="ml">
              <Name>Eye drops 2%</Name>
              <Brand ID="B31030919870301">
                <Name>Isopto Carpine</Name>
                <Pack ID="P252522" Specified="true" OP="true" nzmt:ctpp_id="50053391000117104">
                  <Quantity>15</Quantity>
                  <Subsidy>5.35</Subsidy>
                  <Price>5.35</Price>
                  <Alternate>5.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310309198705" Rank="3" Units="ml">
              <Name>Eye drops 4%</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Subsidised for oral use pursuant to the Standard Formulae.</p>
              </div>
              <Brand ID="B31030919870501">
                <Name>Isopto Carpine</Name>
                <Pack ID="P252549" Specified="true" OP="true" nzmt:ctpp_id="50053411000117104">
                  <Quantity>15</Quantity>
                  <Subsidy>7.99</Subsidy>
                  <Price>7.99</Price>
                  <Alternate>7.99</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103091988" Statim="Must">
            <Name>Pilocarpine nitrate</Name>
            <Formulation ID="F310309198807" Rank="6" Units="dose">
              <Name>Eye drops 2% single dose</Name>
              <Rule Attribute="Subsidy" Type="Special" xlink:href="SA0895"/>
              <Request To="HealthPAC" For="Subsidy" Form="SA0895">
                <Title>
                  <range>Pilocarpine â€“ Eye drops 2% single dose</range>
                </Title>
                <Case When="Initial application">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci>
                      <ci type="logical" class="Indication">Patient wears soft contact lenses</ci>
                    </apply>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="year">2</Term>
                  <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                    <p>Minims for a general practice are considered to be â€œtools of tradeâ€ and are not approved as special authority items.</p>
                  </div>
                </Case>
                <Case When="Renewal" Form="SA0121 SA0895">
                  <math xmlns="http://www.w3.org/1998/Math/MathML">
                    <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  </math>
                  <Applicant>any relevant practitioner</Applicant>
                  <Term Measure="year">2</Term>
                </Case>
              </Request>
              <Brand ID="B31030919880701">
                <Name>Minims Pilocarpine</Name>
                <Pack ID="P307335" Specified="true" nzmt:ctpp_id="50068751000117108">
                  <Quantity>20</Quantity>
                  <Subsidy>34.19</Subsidy>
                  <Price>34.19</Price>
                  <Alternate>34.19</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103093713" Statim="Must">
            <Name>Brimonidine tartrate</Name>
            <Formulation ID="F310309371325" Rank="3" Units="ml">
              <Name>Eye drops 0.2%</Name>
              <Brand ID="B31030937132527" PSS="2024-06-30">
                <Name>Arrow-Brimonidine</Name>
                <Pack ID="P2396513" Specified="true" OP="true" nzmt:ctpp_id="50127571000117109">
                  <Quantity>5</Quantity>
                  <Subsidy>4.29</Subsidy>
                  <Price>4.29</Price>
                  <Alternate>4.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103093839" Statim="Must">
            <Name>Brimonidine tartrate with timolol maleate</Name>
            <Formulation ID="F310309383925" Rank="3" Units="ml">
              <Name>Eye drops 0.2% with timolol maleate 0.5%</Name>
              <Brand ID="B31030938392525">
                <Name>Combigan</Name>
                <Pack ID="P2203502" Specified="true" OP="true" nzmt:ctpp_id="50032171000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>18.50</Subsidy>
                  <Price>18.50</Price>
                  <Alternate>18.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103094140">
            <Name>Latanoprost with timolol</Name>
            <Formulation ID="F310309414025" Rank="3" Units="ml">
              <Name>Eye drops 0.005% with timolol 0.5%</Name>
              <Brand ID="B31030941402525" PSS="2026-06-30">
                <Name>Arrow - Lattim</Name>
                <Pack ID="P2597861" Specified="true" OP="true" nzmt:ctpp_id="50159261000117107">
                  <Quantity>2.5</Quantity>
                  <Subsidy>4.95</Subsidy>
                  <Price>4.95</Price>
                  <Alternate>4.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310310">
          <Name>Mydriatics and Cycloplegics</Name>
          <Chemical ID="C3103101097" Statim="Must">
            <Name>Atropine sulphate</Name>
            <Formulation ID="F310310109706" Rank="3" Units="ml">
              <Name>Eye drops 1%</Name>
              <Brand ID="B31031010970601" PSS="2026-06-30">
                <Name>Atropt</Name>
                <Pack ID="P200905" Specified="true" OP="true" nzmt:ctpp_id="50000941000117105">
                  <Quantity>15</Quantity>
                  <Subsidy>18.27</Subsidy>
                  <Price>18.27</Price>
                  <Alternate>18.27</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103101370" Statim="Must">
            <Name>Cyclopentolate hydrochloride</Name>
            <Formulation ID="F310310137001" Rank="3" Units="ml">
              <Name>Eye drops 1%</Name>
              <Brand ID="B31031013700101">
                <Name>Cyclogyl</Name>
                <Pack ID="P203351" Specified="true" OP="true" nzmt:ctpp_id="50006351000117105">
                  <Quantity>15</Quantity>
                  <Subsidy>8.76</Subsidy>
                  <Price>8.76</Price>
                  <Alternate>8.76</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310310137025" Rank="6" Units="dose">
              <Name>Eye drops 1%, single dose (preservative free)</Name>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Brand ID="B31031013702525">
                <Name>Minims Cyclopentolate</Name>
                <Pack ID="P2603160" Specified="true" nzmt:ctpp_id="50068701000117109">
                  <Quantity>20</Quantity>
                  <Subsidy>84.85</Subsidy>
                  <Price>84.85</Price>
                  <Alternate>84.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103102305" Statim="Must">
            <Name>Tropicamide</Name>
            <Formulation ID="F310310230501" Rank="3" Units="ml">
              <Name>Eye drops 0.5%</Name>
              <Brand ID="B31031023050101">
                <Name>Mydriacyl</Name>
                <Pack ID="P253995" Specified="true" OP="true" nzmt:ctpp_id="50054201000117101">
                  <Quantity>15</Quantity>
                  <Subsidy>7.15</Subsidy>
                  <Price>7.15</Price>
                  <Alternate>7.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F310310230502" Rank="3" Units="ml">
              <Name>Eye drops 1%</Name>
              <Brand ID="B31031023050201">
                <Name>Mydriacyl</Name>
                <Pack ID="P254002" Specified="true" OP="true" nzmt:ctpp_id="50054211000117103">
                  <Quantity>15</Quantity>
                  <Subsidy>8.66</Subsidy>
                  <Price>8.66</Price>
                  <Alternate>8.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310313">
          <Name>Preparations for Tear Deficiency</Name>
          <div xmlns="http://www.w3.org/1999/xhtml" class="Xref">
            <p xlink:type="simple" xlink:href="standard-formulae">For acetylcysteine eye drops refer Standard Formulae</p>
          </div>
          <Chemical ID="C3103131630" Statim="Must">
            <Name>Hypromellose with dextran</Name>
            <Formulation ID="F310313163001" Rank="3" Units="ml">
              <Name>Eye drops 0.3% with dextran 0.1%</Name>
              <Brand ID="B31031316300101">
                <Name>Poly-Tears</Name>
                <Pack ID="P229075" Specified="true" OP="true" nzmt:ctpp_id="50044621000117109">
                  <Quantity>15</Quantity>
                  <Subsidy>2.30</Subsidy>
                  <Price>2.30</Price>
                  <Alternate>2.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103131633" Statim="Must">
            <Name>Hypromellose</Name>
            <Formulation ID="F310313163302" Rank="3" Units="ml">
              <Name>Eye drops 0.5%</Name>
              <Brand ID="B31031316330203">
                <Name>Methopt</Name>
                <Pack ID="P2603608" Specified="true" OP="true" nzmt:ctpp_id="50012351000117106">
                  <Quantity>15</Quantity>
                  <Subsidy>19.50</Subsidy>
                  <Price>19.50</Price>
                  <Alternate>19.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310315">
          <Name>Preservative Free Ocular Lubricants</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA2134">
            <Title>
              <range>Preservative Free Ocular Lubricants</range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp or Schirmer test of severe secretory dry eye</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci>
                    <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="month">12</Term>
            </Case>
            <Case When="Renewal" Form="SA1388 SA2134">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="month">24</Term>
            </Case>
          </Request>
          <Chemical ID="C3103154010">
            <Name>Sodium hyaluronate [Hyaluronic acid]</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2134"/>
            <Formulation ID="F310315401025" Rank="3" Units="ml">
              <Name>Eye drops 1 mg per ml</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Procedures Manual restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed.</p>
              </div>
              <Brand ID="B31031540102525" PSS="2024-06-30">
                <Name>Hylo-Fresh</Name>
                <Pack ID="P2608162" Specified="true" OP="true" nzmt:ctpp_id="50137101000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>13.85</Subsidy>
                  <Price>13.85</Price>
                  <Alternate>13.85</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103154013">
            <Name>Polyethylene glycol 400 and propylene glycol</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2134"/>
            <Formulation ID="F310315401326" Rank="10" Units="vial">
              <Name>Eye drops 0.4% and propylene glycol 0.3%, 0.8 ml</Name>
              <Brand ID="B31031540132625">
                <Name>Systane Unit Dose</Name>
                <Pack ID="P2640120" Specified="true" nzmt:ctpp_id="50290361000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>10.78</Subsidy>
                  <Price>10.78</Price>
                  <Alternate>10.78</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103154014">
            <Name>Carbomer</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2134"/>
            <Formulation ID="F310315401425" Rank="10" Units="vial">
              <Name>Ophthalmic gel 0.3%, 0.5 g</Name>
              <Brand ID="B31031540142525">
                <Name>Poly-Gel</Name>
                <Pack ID="P2181827" Specified="true" nzmt:ctpp_id="50029801000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>8.25</Subsidy>
                  <Price>8.25</Price>
                  <Alternate>8.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A310317">
          <Name>Other Eye Preparations</Name>
          <Chemical ID="C3103171843" Statim="Must">
            <Name>Naphazoline hydrochloride</Name>
            <Formulation ID="F310317184301" Rank="3" Units="ml">
              <Name>Eye drops 0.1%</Name>
              <Brand ID="B31031718430102">
                <Name>Naphcon Forte</Name>
                <Pack ID="P211265" Specified="true" OP="true" nzmt:ctpp_id="50019891000117101">
                  <Quantity>15</Quantity>
                  <Subsidy>4.15</Subsidy>
                  <Price>4.15</Price>
                  <Alternate>4.15</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103172486" Statim="Must">
            <Name>Paraffin liquid with wool fat</Name>
            <Formulation ID="F310317248601" Rank="3" Units="g">
              <Name>Eye oint 3% with wool fat 3%</Name>
              <Brand ID="B31031724860125">
                <Name>Poly-Visc</Name>
                <Pack ID="P2035812" Specified="true" OP="true" nzmt:ctpp_id="50007031000117100">
                  <Quantity>3.5</Quantity>
                  <Subsidy>3.63</Subsidy>
                  <Price>3.63</Price>
                  <Alternate>3.63</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103173995">
            <Name>Olopatadine</Name>
            <Formulation ID="F310317399525" Rank="3" Units="ml">
              <Name>Eye drops 0.1%</Name>
              <Brand ID="B31031739952526" PSS="2025-06-30">
                <Name>Olopatadine Teva</Name>
                <Pack ID="P2588048" Specified="true" OP="true" nzmt:ctpp_id="50247531000117106">
                  <Quantity>5</Quantity>
                  <Subsidy>2.17</Subsidy>
                  <Price>2.17</Price>
                  <Alternate>2.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3103174011">
            <Name>Retinol palmitate</Name>
            <Formulation ID="F310317401125" Rank="3" Units="g">
              <Name>Eye oint 138 mcg per g</Name>
              <Brand ID="B31031740112525">
                <Name>VitA-POS</Name>
                <Pack ID="P2396246" Specified="true" OP="true" nzmt:ctpp_id="50176251000117100">
                  <Quantity>5</Quantity>
                  <Subsidy>3.80</Subsidy>
                  <Price>3.80</Price>
                  <Alternate>3.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
    <ATC1 ID="A35">
      <Name>Various</Name>
      <ATC2 ID="A3501">
        <Name>Various</Name>
        <ATC3 ID="A350101">
          <Name>Various</Name>
          <Rule Type="MaxCoPayment" Value="0"/>
          <Chemical ID="C3501013917" Statim="Must">
            <Name>Pharmacy Services</Name>
            <Formulation ID="F350101391725" Rank="10" Units="fee">
              <Name>Brand switch fee</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>May only be claimed once per patient.</p>
              </div>
              <Brand ID="B35010139172561" ToBeDelisted="2024-06-01">
                <Name>BSF Wockhardt</Name>
                <Pack ID="P2669986" Specified="true" nzmt:ctpp_id="50325461000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>4.50</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139172562" ToBeDelisted="2024-06-01" Update="New Listing">
                <Name>BSF Noumed Dexamfetamine</Name>
                <Pack ID="P2673886" Specified="true" nzmt:ctpp_id="50329361000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>4.50</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F350101391727" Rank="10" Units="fee" Weight="1">
              <Name>Immunisation administration fee</Name>
              <Brand ID="B35010139172725">
                <Name>Immunisation Administration</Name>
                <Pack ID="P2660733" Specified="true" nzmt:ctpp_id="50320481000117101">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F350101391728" Rank="10" Units="fee" Weight="1">
              <Name>Immunisation co-administration fee</Name>
              <Brand ID="B35010139172825">
                <Name>Immunisation Co-administration</Name>
                <Pack ID="P2664453" Specified="true" nzmt:ctpp_id="50322151000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F350101391730" Rank="10" Units="fee" Weight="1">
              <Name>COVID-19 Services</Name>
              <Brand ID="B35010139173025">
                <Name>Med Mgmt 15 min</Name>
                <Pack ID="P2664801" Specified="true" nzmt:ctpp_id="50321991000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173026">
                <Name>Med Mgmt 30 min</Name>
                <Pack ID="P2664879" Specified="true" nzmt:ctpp_id="50322181000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173027">
                <Name>Med Mgmt 45 min</Name>
                <Pack ID="P2664887" Specified="true" nzmt:ctpp_id="50322191000117108">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173028">
                <Name>After Hours Med Mgmt 15 min</Name>
                <Pack ID="P2664828" Specified="true" nzmt:ctpp_id="50322001000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173029">
                <Name>After Hours Med Mgmt 30 min</Name>
                <Pack ID="P2664852" Specified="true" nzmt:ctpp_id="50322201000117106">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173030">
                <Name>Compliance Packaging</Name>
                <Pack ID="P2664836" Specified="true" nzmt:ctpp_id="50322011000117104">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173031">
                <Name>After Hours Med Mgmt 45 min</Name>
                <Pack ID="P2664860" Specified="true" nzmt:ctpp_id="50322211000117109">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173035">
                <Name>Medicine Delivery</Name>
                <Pack ID="P2664844" Specified="true" nzmt:ctpp_id="50322021000117105">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35010139173038">
                <Name>Antivirals Eligibility Review</Name>
                <Pack ID="P2664798" Specified="true" nzmt:ctpp_id="50321981000117102">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A3504">
        <Name>Agents Used in the Treatment of Poisonings</Name>
        <ATC3 ID="A350404">
          <Name>Antidotes</Name>
          <Chemical ID="C3504041841" Statim="Must">
            <Name>Naloxone hydrochloride</Name>
            <Rule Type="FormMax" Value="10" Attribute="PSO"/>
            <Rule Type="FormReqd" Attribute="PSO"/>
            <Formulation ID="F350404184102" Rank="4" Units="inj" Weight="400">
              <Name>Inj 400 mcg per ml, 1 ml ampoule</Name>
              <Brand ID="B35040418410203" PSS="2024-06-30">
                <Name>Hameln</Name>
                <Pack ID="P2634090" Specified="true" nzmt:ctpp_id="50220971000117101">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>35.26</Subsidy>
                  <Price>35.26</Price>
                  <Alternate>35.26</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3504046047">
            <Name>Acetylcysteine</Name>
            <Formulation ID="F350404604702" Rank="4" Units="inj" Weight="2000">
              <Name>Inj 200 mg per ml, 10 ml ampoule</Name>
              <Brand ID="B35040460470227" PSS="2024-06-30">
                <Name>Martindale Pharma</Name>
                <Pack ID="P2634864" Specified="true" nzmt:ctpp_id="50048471000117104">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>52.88</Subsidy>
                  <Price>52.88</Price>
                  <Alternate>52.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A350408">
          <Name>Removal and Elimination</Name>
          <Chemical ID="C3504081378" Statim="Must">
            <Name>Desferrioxamine mesilate</Name>
            <Formulation ID="F350408137801" Rank="4" Units="inj" Weight="500">
              <Name>Inj 500 mg vial</Name>
              <Brand ID="B35040813780102">
                <Name>DBL Desferrioxamine Mesylate for Inj BP</Name>
                <Pack ID="P461598" Specified="true" nzmt:ctpp_id="50087711000117106">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>151.31</Subsidy>
                  <Price>151.31</Price>
                  <Alternate>151.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B35040813780103" S29="true">
                <Name>Deferoxamine Pfizer S29</Name>
                <Rule Type="Wastage"/>
                <Pack ID="P2163519" Specified="true" nzmt:ctpp_id="50303641000117106">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>151.31</Subsidy>
                  <Price>151.31</Price>
                  <Alternate>151.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3504082132" Statim="Must">
            <Name>Sodium calcium edetate</Name>
            <Formulation ID="F350408213201" Rank="4" Units="inj" Weight="1000">
              <Name>Inj 200 mg per ml, 5 ml</Name>
              <Brand ID="B35040821320101">
                <Name>Calcium Disodium Versenate</Name>
                <Pack ID="P252395" Specified="true" nzmt:ctpp_id="50053301000117109">
                  <Quantity>6</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>53.31</Subsidy>
                  <Price>156.71</Price>
                  <Alternate>53.31</Alternate>
                  <Surcharge>17.23333</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3504082414" Statim="Must">
            <Name>Charcoal</Name>
            <Formulation ID="F350408241425" Rank="3" Units="ml" Weight="50">
              <Name>Oral liq 50 g per 250 ml</Name>
              <Rule Type="FormMax" Value="250" Attribute="PSO"/>
              <Rule Type="FormReqd" Attribute="PSO"/>
              <Brand ID="B35040824142526">
                <Name>Carbosorb-X</Name>
                <Pack ID="P2189186" Specified="true" OP="true" nzmt:ctpp_id="50030711000117101">
                  <Quantity>250</Quantity>
                  <Subsidy>43.50</Subsidy>
                  <Price>43.50</Price>
                  <Alternate>43.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3504083914">
            <Name>Deferiprone</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1480"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1480">
              <Title>
                <range>Deferiprone</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia</ci>
                    <ci type="logical" class="Indication">The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="patient's lifetime"/>
              </Case>
            </Request>
            <Formulation ID="F350408391425" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg</Name>
              <Brand ID="B35040839142525">
                <Name>Ferriprox</Name>
                <Pack ID="P2369532" Specified="true" nzmt:ctpp_id="50119731000117100">
                  <Quantity>100</Quantity>
                  <Subsidy>533.17</Subsidy>
                  <Price>533.17</Price>
                  <Alternate>533.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F350408391426" Rank="3" Units="ml" Weight="100">
              <Name>Oral liq 100 mg per 1 ml</Name>
              <Brand ID="B35040839142625">
                <Name>Ferriprox</Name>
                <Pack ID="P2369524" Specified="true" OP="true" nzmt:ctpp_id="50119741000117108">
                  <Quantity>250</Quantity>
                  <Subsidy>266.59</Subsidy>
                  <Price>266.59</Price>
                  <Alternate>266.59</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3504084041">
            <Name>Deferasirox</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1492"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1492">
              <Title>
                <range>Deferasirox</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Therapy">The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia</ci>
                    <ci type="logical" class="Therapy">Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Trial">Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*</ci>
                      <ci type="logical" class="Trial">Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea</ci>
                      <ci type="logical" class="Trial">Treatment with deferiprone has resulted in arthritis</ci>
                      <ci type="logical" class="Trial">Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of &lt; 0.5 cells per ÂµL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per ÂµL)</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="year">2</Term>
              </Case>
              <Case When="Renewal" Form="SA1492">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Therapy">For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels</ci>
                    <ci type="logical" class="Use">For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels</ci>
                  </apply>
                </math>
                <Applicant>haematologist</Applicant>
                <Term Measure="year">2</Term>
              </Case>
            </Request>
            <Rule Type="Wastage"/>
            <Formulation ID="F350408404125" Rank="1" Units="tab" Weight="125">
              <Name>Tab 125 mg dispersible</Name>
              <Brand ID="B35040840412525">
                <Name>Exjade</Name>
                <Pack ID="P2234769" Specified="true" nzmt:ctpp_id="50037341000117104">
                  <Quantity>28</Quantity>
                  <Subsidy>276.00</Subsidy>
                  <Price>276.00</Price>
                  <Alternate>276.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F350408404126" Rank="1" Units="tab" Weight="250">
              <Name>Tab 250 mg dispersible</Name>
              <Brand ID="B35040840412625">
                <Name>Exjade</Name>
                <Pack ID="P2234777" Specified="true" nzmt:ctpp_id="50037351000117102">
                  <Quantity>28</Quantity>
                  <Subsidy>552.00</Subsidy>
                  <Price>552.00</Price>
                  <Alternate>552.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F350408404127" Rank="1" Units="tab" Weight="500">
              <Name>Tab 500 mg dispersible</Name>
              <Brand ID="B35040840412725">
                <Name>Exjade</Name>
                <Pack ID="P2234750" Specified="true" nzmt:ctpp_id="50037331000117107">
                  <Quantity>28</Quantity>
                  <Subsidy>1105.00</Subsidy>
                  <Price>1105.00</Price>
                  <Alternate>1105.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
  </Section>
  <Section ID="C">
    <Name>Extemporaneously Compounded Preparations and Galenicals</Name>
    <ATC1 ID="A38">
      <Name>Extemporaneously Compounded Preparations and Galenicals</Name>
      <ATC2 ID="A3801">
        <Name>Extemporaneously Compounded Preparations and Galenicals</Name>
        <ATC3 ID="A380101">
          <Name>Extemporaneously Compounded Preparations and Galenicals</Name>
          <Chemical ID="C3801011239">
            <Name>Compound hydroxybenzoate</Name>
            <Rule Type="Combined"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only in extemporaneously compounded oral mixtures.</p>
            </div>
            <Formulation ID="F380101123901" Rank="3" Units="ml">
              <Name>Soln</Name>
              <Brand ID="B38010112390125">
                <Name>Midwest</Name>
                <Pack ID="P2460149" Specified="true" nzmt:ctpp_id="50205381000117104">
                  <Quantity>100</Quantity>
                  <Subsidy>30.00</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>30.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801011240">
            <Name>Propylene glycol</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.</p>
            </div>
            <Formulation ID="F380101124001" Rank="3" Units="ml">
              <Name>Liq</Name>
              <Brand ID="B38010112400126">
                <Name>Midwest</Name>
                <Pack ID="P2177447" Specified="true" nzmt:ctpp_id="50029141000117106">
                  <Quantity>500</Quantity>
                  <Subsidy>11.25</Subsidy>
                  <Price>11.25</Price>
                  <Alternate>11.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801011332">
            <Name>Codeine phosphate</Name>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F380101133205" Rank="3" Units="g">
              <Name>Powder</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only in extemporaneously compounded codeine linctus.</p>
              </div>
              <Brand ID="B38010113320501">
                <Name>Douglas</Name>
                <Pack ID="P316881" Specified="true" nzmt:ctpp_id="50070941000117102">
                  <Quantity>25</Quantity>
                  <Subsidy>63.09</Subsidy>
                  <Price>90.09</Price>
                  <Alternate>63.09</Alternate>
                  <Surcharge>1.08000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801011574" Statim="Must">
            <Name>Glycerol</Name>
            <Formulation ID="F380101157406" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only in extemporaneously compounded oral liquid preparations.</p>
              </div>
              <Brand ID="B38010115740628">
                <Name>healthE Glycerol BP</Name>
                <Pack ID="P2341026" Specified="true" nzmt:ctpp_id="50212951000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>3.23</Subsidy>
                  <Price>3.23</Price>
                  <Alternate>3.23</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801011795">
            <Name>Methadone hydrochloride</Name>
            <Rule Type="Controlled"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).</p>
            </div>
            <Rule Type="SafetyListMedicine"/>
            <Formulation ID="F380101179504" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B38010117950425">
                <Name>AFT</Name>
                <Pack ID="P2139049" Specified="true" nzmt:ctpp_id="50023971000117100">
                  <Quantity>1</Quantity>
                  <Subsidy>7.84</Subsidy>
                  <Price>7.84</Price>
                  <Alternate>7.84</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801011956">
            <Name>Phenobarbitone sodium</Name>
            <Formulation ID="F380101195605" Rank="3" Units="g">
              <Name>Powder</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only in children up to 12 years</p>
              </div>
              <Brand ID="B38010119560525">
                <Name>MidWest</Name>
                <Pack ID="P2152002" Specified="true" nzmt:ctpp_id="50026341000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>325.00</Subsidy>
                  <Price>325.00</Price>
                  <Alternate>325.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2338963" Specified="true" nzmt:ctpp_id="50049771000117101">
                  <Quantity>10</Quantity>
                  <Subsidy>52.50</Subsidy>
                  <Price>52.50</Price>
                  <Alternate>52.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801012128">
            <Name>Sodium bicarbonate</Name>
            <Formulation ID="F380101212825" Rank="3" Units="g">
              <Name>Powder BP</Name>
              <Rule Type="Combined"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Only in extemporaneously compounded omeprazole and lansoprazole suspension.</p>
              </div>
              <Brand ID="B38010121282528">
                <Name>Midwest</Name>
                <Pack ID="P2032880" Specified="true" nzmt:ctpp_id="50121131000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>10.05</Subsidy>
                  <Price>10.05</Price>
                  <Alternate>10.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801012332">
            <Name>Water</Name>
            <Formulation ID="F380101233205" Rank="3" Units="ml">
              <Name>Tap</Name>
              <Rule Type="Combined"/>
              <Brand ID="B38010123320501">
                <Name>Tap water</Name>
                <Pack ID="P478008" Specified="true" nzmt:ctpp_id="50090111000117107">
                  <Quantity>1</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013270">
            <Name>Collodion flexible</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Note: This product is no longer being manufactured by the supplier and will be delisted from the Schedule at a date to be determined.</p>
            </div>
            <Formulation ID="F380101327001" Rank="3" Units="ml">
              <Name>Collodion flexible</Name>
              <Brand ID="B38010132700101">
                <Name>PSM</Name>
                <Pack ID="P282103" Specified="true" nzmt:ctpp_id="50062711000117105">
                  <Quantity>100</Quantity>
                  <Subsidy>19.30</Subsidy>
                  <Price>19.30</Price>
                  <Alternate>19.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013337">
            <Name>Methylcellulose</Name>
            <Formulation ID="F380101333701" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B38010133370125">
                <Name>MidWest</Name>
                <Pack ID="P2121131" Specified="true" nzmt:ctpp_id="50021981000117103">
                  <Quantity>100</Quantity>
                  <Subsidy>36.95</Subsidy>
                  <Price>36.95</Price>
                  <Alternate>36.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F380101333725" Rank="3" Units="ml">
              <Name>Suspension</Name>
              <Rule Type="Combined"/>
              <Brand ID="B38010133372525">
                <Name>Ora-Plus</Name>
                <Pack ID="P2377233" Specified="true" nzmt:ctpp_id="50014601000117109">
                  <Quantity>473</Quantity>
                  <Subsidy>30.95</Subsidy>
                  <Price>30.95</Price>
                  <Alternate>30.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013439">
            <Name>Methyl hydroxybenzoate</Name>
            <Formulation ID="F380101343901" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B38010134390126">
                <Name>Midwest</Name>
                <Pack ID="P2018853" Specified="true" nzmt:ctpp_id="50121141000117101">
                  <Quantity>25</Quantity>
                  <Subsidy>8.98</Subsidy>
                  <Price>8.98</Price>
                  <Alternate>8.98</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013870">
            <Name>Syrup (pharmaceutical grade)</Name>
            <Rule Type="Combined"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only in extemporaneously compounded oral liquid preparations.</p>
            </div>
            <Formulation ID="F380101387025" Rank="3" Units="ml">
              <Name>Liq</Name>
              <Brand ID="B38010138702525">
                <Name>Midwest</Name>
                <Pack ID="P2572346" Specified="true" nzmt:ctpp_id="50267161000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>14.95</Subsidy>
                  <Price>14.95</Price>
                  <Alternate>14.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013928">
            <Name>Methylcellulose with glycerin and sucrose</Name>
            <Rule Type="Combined"/>
            <Formulation ID="F380101392825" Rank="3" Units="ml">
              <Name>Suspension</Name>
              <Brand ID="B38010139282525">
                <Name>Ora-Blend</Name>
                <Pack ID="P2377217" Specified="true" nzmt:ctpp_id="50121151000117104">
                  <Quantity>473</Quantity>
                  <Subsidy>30.95</Subsidy>
                  <Price>30.95</Price>
                  <Alternate>30.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013929">
            <Name>Methylcellulose with glycerin and sodium saccharin</Name>
            <Rule Type="Combined"/>
            <Formulation ID="F380101392925" Rank="3" Units="ml">
              <Name>Suspension</Name>
              <Brand ID="B38010139292525">
                <Name>Ora-Blend SF</Name>
                <Pack ID="P2377225" Specified="true" nzmt:ctpp_id="50121161000117102">
                  <Quantity>473</Quantity>
                  <Subsidy>30.95</Subsidy>
                  <Price>30.95</Price>
                  <Alternate>30.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013930">
            <Name>Glycerin with sucrose</Name>
            <Rule Type="Combined"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only in combination with Ora-Plus or when used in the vancomycin oral lquuid Standard Formulae.</p>
            </div>
            <Formulation ID="F380101393025" Rank="3" Units="ml">
              <Name>Suspension</Name>
              <Brand ID="B38010139302525">
                <Name>Ora-Sweet</Name>
                <Pack ID="P2377241" Specified="true" nzmt:ctpp_id="50121171000117107">
                  <Quantity>473</Quantity>
                  <Subsidy>30.95</Subsidy>
                  <Price>30.95</Price>
                  <Alternate>30.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C3801013931">
            <Name>Glycerin with sodium saccharin</Name>
            <Rule Type="Combined"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Only in combination with Ora-Plus or when used in the vancomycin oral lquuid Standard Formulae.</p>
            </div>
            <Formulation ID="F380101393125" Rank="3" Units="ml">
              <Name>Suspension</Name>
              <Brand ID="B38010139312525">
                <Name>Ora-Sweet SF</Name>
                <Pack ID="P2377268" Specified="true" nzmt:ctpp_id="50014611000117107">
                  <Quantity>473</Quantity>
                  <Subsidy>30.95</Subsidy>
                  <Price>30.95</Price>
                  <Alternate>30.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
  </Section>
  <Section ID="D">
    <Name>Special Foods</Name>
    <ATC1 ID="A42">
      <Name>Special Foods</Name>
      <ATC2 ID="A4202">
        <Name>Nutrient Modules</Name>
        <ATC3 ID="A420201">
          <Name>Carbohydrate</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1930">
            <Title>
              <range>Carbohydrate<instance>Moducal</instance><instance>Polycal</instance></range>
            </Title>
            <Case When="Initial application" Category="Cystic fibrosis or kidney disease">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">cystic fibrosis</ci>
                  <ci type="logical" class="Indication">chronic kidney disease</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Initial application" Category="Indications other than cystic fibrosis or renal failure">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">cancer in children</ci>
                  <ci type="logical" class="Indication">cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years</ci>
                  <ci type="logical" class="Indication">faltering growth in an infant/child</ci>
                  <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci>
                  <ci type="logical" class="Indication">premature and post premature infant</ci>
                  <ci type="logical" class="Indication">for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.</p>
              </div>
            </Case>
            <Case When="Initial application" Category="Inborn errors of metabolism">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="patient's lifetime"/>
            </Case>
            <Case When="Renewal" Category="Cystic fibrosis or renal failure" Form="SA0579 SA0912 SA1090 SA1373 SA1522 SA1930">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian,relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Renewal" Category="Indications other than cystic fibrosis or renal failure" Form="SA0579 SA0912 SA1090 SA1373 SA1522 SA1930">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4202012908">
            <Name>Carbohydrate supplement</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1930"/>
            <Formulation ID="F420201290801" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42020129080106">
                <Name>Polycal</Name>
                <Pack ID="P408050" Specified="true" OP="true" nzmt:ctpp_id="50082711000117108">
                  <Quantity>400</Quantity>
                  <Subsidy>5.29</Subsidy>
                  <Price>5.29</Price>
                  <Alternate>5.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420202">
          <Name>Carbohydrate And Fat</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1376">
            <Title>
              <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range>
            </Title>
            <Case When="Initial application" Category="Cystic fibrosis">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Infant or child aged four years or under</ci>
                  <ci type="logical" class="Indication">cystic fibrosis</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Initial application" Category="Indications other than cystic fibrosis">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">infant or child aged four years or under</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">cancer in children</ci>
                    <ci type="logical" class="Indication">faltering growth</ci>
                    <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci>
                    <ci type="logical" class="Indication">premature and post premature infants</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Form="SA0581 SA1091 SA1376" Category="Cystic fibrosis">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Renewal" Form="SA0581 SA1091 SA1376" Category="Indications other than cystic fibrosis">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4202022907">
            <Name>Carbohydrate and fat supplement</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1376"/>
            <Formulation ID="F420202290701" Rank="3" Units="g">
              <Name>Powder (neutral)</Name>
              <Brand ID="B42020229070101">
                <Name>Duocal Super Soluble Powder</Name>
                <Pack ID="P727113" Specified="true" OP="true" nzmt:ctpp_id="50106371000117109">
                  <Quantity>400</Quantity>
                  <Subsidy>60.31</Subsidy>
                  <Price>60.31</Price>
                  <Alternate>60.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420203">
          <Name>Fat</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA2204">
            <Title>
              <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range>
            </Title>
            <Case When="Initial application" Category="Inborn errors of metabolism">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">the patient has an inborn error of metabolism</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="patient's lifetime"/>
            </Case>
            <Case When="Initial application" Category="Indications other than inborn errors of metabolism">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">faltering growth in an infant/child</ci>
                  <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci>
                  <ci type="logical" class="Indication">fat malabsorption</ci>
                  <ci type="logical" class="Indication">lymphangiectasia</ci>
                  <ci type="logical" class="Indication">short bowel syndrome</ci>
                  <ci type="logical" class="Indication">infants with necrotising enterocolitis</ci>
                  <ci type="logical" class="Indication">biliary atresia</ci>
                  <ci type="logical" class="Indication">for use in a ketogenic diet</ci>
                  <ci type="logical" class="Indication">chyle leak</ci>
                  <ci type="logical" class="Indication">ascites</ci>
                  <ci type="logical" class="Indication">for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.</p>
              </div>
            </Case>
            <Case When="Renewal" Category="Indications other than inborn errors of metabolism" Form="SA0580 SA0899 SA1092 SA1374 SA1523 SA2204">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4202032917">
            <Name>Fat supplement</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2204"/>
            <Formulation ID="F420203291701" Rank="3" Units="ml">
              <Name>Emulsion (neutral)</Name>
              <Brand ID="B42020329170101">
                <Name>Calogen</Name>
                <Pack ID="P2222051" Specified="true" OP="true" nzmt:ctpp_id="50035211000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>30.75</Subsidy>
                  <Price>30.75</Price>
                  <Alternate>30.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2253933" Specified="true" OP="true" nzmt:ctpp_id="50040291000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>12.30</Subsidy>
                  <Price>12.30</Price>
                  <Alternate>12.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420203291702" Rank="3" Units="ml">
              <Name>Emulsion (strawberry)</Name>
              <Brand ID="B42020329170201">
                <Name>Calogen</Name>
                <Pack ID="P2253941" Specified="true" OP="true" nzmt:ctpp_id="50040301000117104">
                  <Quantity>200</Quantity>
                  <Subsidy>12.30</Subsidy>
                  <Price>12.30</Price>
                  <Alternate>12.30</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420203291703" Rank="3" Units="ml">
              <Name>Oil</Name>
              <Brand ID="B42020329170303">
                <Name>MCT oil (Nutricia)</Name>
                <Pack ID="P413933" Specified="true" OP="true" nzmt:ctpp_id="50083321000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>30.00</Subsidy>
                  <Price>30.00</Price>
                  <Alternate>30.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420203291704" Rank="10" Units="pack">
              <Name>MCT Emulsion, 250 ml</Name>
              <Brand ID="B42020329170401">
                <Name>Liquigen</Name>
                <Pack ID="P2441241" Specified="true" OP="true" nzmt:ctpp_id="50176621000117109">
                  <Quantity>4</Quantity>
                  <Subsidy>114.92</Subsidy>
                  <Price>114.92</Price>
                  <Alternate>114.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420204">
          <Name>Protein</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1524">
            <Title>
              <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">protein losing enteropathy</ci>
                  <ci type="logical" class="Indication">high protein needs</ci>
                  <ci type="logical" class="Indication">for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.</p>
              </div>
            </Case>
            <Case When="Renewal" Form="SA0582 SA1093 SA1375 SA1524">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4202042937">
            <Name>Protein supplement</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1524"/>
            <Formulation ID="F420204293701" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42020429370102">
                <Name>Protifar</Name>
                <Pack ID="P279269" Specified="true" OP="true" nzmt:ctpp_id="50062081000117102">
                  <Quantity>225</Quantity>
                  <Subsidy>7.90</Subsidy>
                  <Price>7.90</Price>
                  <Alternate>7.90</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42020429370125">
                <Name>Resource Beneprotein</Name>
                <Pack ID="P2264471" Specified="true" OP="true" nzmt:ctpp_id="50041681000117106">
                  <Quantity>227</Quantity>
                  <Subsidy>8.95</Subsidy>
                  <Price>8.95</Price>
                  <Alternate>8.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A4206">
        <Name>Oral and Enteral Feeds</Name>
        <ATC3 ID="A420603">
          <Name>Diabetic Products</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1095">
            <Title>
              <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Form="SA0594 SA1095">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4206032909">
            <Name>Diabetic enteral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1095"/>
            <Formulation ID="F420603290901" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42060329090128">
                <Name>Glucerna Select</Name>
                <Pack ID="P2605651" Specified="true" OP="true" nzmt:ctpp_id="50285691000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>4.65</Subsidy>
                  <Price>4.65</Price>
                  <Alternate>4.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060329090129" ToBeDelisted="2024-07-01">
                <Name>Nutrison Advanced Diason</Name>
                <Pack ID="P2633000" Specified="true" OP="true" nzmt:ctpp_id="50298891000117103">
                  <Quantity>1000</Quantity>
                  <Subsidy>7.50</Subsidy>
                  <Price>7.50</Price>
                  <Alternate>7.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206032930">
            <Name>Diabetic oral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1095"/>
            <Formulation ID="F420603293003" Rank="3" Units="ml">
              <Name>Liquid (strawberry)</Name>
              <Brand ID="B42060329300325">
                <Name>Diasip</Name>
                <Pack ID="P2224437" Specified="true" OP="true" nzmt:ctpp_id="50035741000117105">
                  <Quantity>200</Quantity>
                  <Subsidy>1.50</Subsidy>
                  <Price>1.50</Price>
                  <Alternate>1.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420603293004" Rank="3" Units="ml">
              <Name>Liquid (vanilla)</Name>
              <Brand ID="B42060329300425">
                <Name>Diasip</Name>
                <Pack ID="P2224429" Specified="true" OP="true" nzmt:ctpp_id="50035731000117102">
                  <Quantity>200</Quantity>
                  <Subsidy>1.50</Subsidy>
                  <Price>1.50</Price>
                  <Alternate>1.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060329300428">
                <Name>Nutren Diabetes</Name>
                <Pack ID="P2605570" Specified="true" OP="true" nzmt:ctpp_id="50286361000117102">
                  <Quantity>200</Quantity>
                  <Subsidy>2.10</Subsidy>
                  <Price>2.10</Price>
                  <Alternate>2.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420604">
          <Name>Fat Modified Products</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA2205">
            <Title>
              <range>Fat Modified Products<instance>Monogen</instance></range>
            </Title>
            <Case When="Initial application" Category="Inborn errors of metabolism">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">the patient has an inborn error of metabolism</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="patient's lifetime"/>
            </Case>
            <Case When="Initial application" Category="Indications other than errors of inborn metabolism">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Patient has a chyle leak</ci>
                  <ci type="logical" class="Indication">Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.</p>
              </div>
            </Case>
            <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381 SA1525 SA2205">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4206042916">
            <Name>Fat modified feed</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2205"/>
            <Formulation ID="F420604291601" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42060429160101">
                <Name>Monogen</Name>
                <Pack ID="P2601443" Specified="true" OP="true" nzmt:ctpp_id="50285751000117107">
                  <Quantity>400</Quantity>
                  <Subsidy>60.48</Subsidy>
                  <Price>60.48</Price>
                  <Alternate>60.48</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420606">
          <Name>Paediatric Products For Children Awaiting Liver Transplant</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1098">
            <Title>
              <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Renewal" Form="SA0607 SA1098">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
          </Request>
          <Chemical ID="C4206062915">
            <Name>Enteral/oral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1098"/>
            <Formulation ID="F420606291525" Rank="3" Units="g" Weight="400">
              <Name>Powder (unflavoured)</Name>
              <Brand ID="B42060629152525">
                <Name>Heparon Junior</Name>
                <Pack ID="P2615568" Specified="true" OP="true" nzmt:ctpp_id="50289761000117107">
                  <Quantity>400</Quantity>
                  <Subsidy>78.97</Subsidy>
                  <Price>78.97</Price>
                  <Alternate>78.97</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420607">
          <Name>Paediatric Products For Children With Chronic Renal Failure</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1099">
            <Title>
              <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Renewal" Form="SA0606 SA1099">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
          </Request>
          <Chemical ID="C4206072915">
            <Name>Enteral/oral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1099"/>
            <Formulation ID="F420607291526" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42060729152625">
                <Name>Kindergen</Name>
                <Pack ID="P2601427" Specified="true" OP="true" nzmt:ctpp_id="50284971000117101">
                  <Quantity>400</Quantity>
                  <Subsidy>54.00</Subsidy>
                  <Price>54.00</Price>
                  <Alternate>54.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420608">
          <Name>Paediatric Products</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1379">
            <Title>
              <range>Paediatric Products</range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Child is aged one to ten years</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci>
                    <ci type="logical" class="Indication">any condition causing malabsorption</ci>
                    <ci type="logical" class="Indication">faltering growth in an infant/child</ci>
                    <ci type="logical" class="Indication">increased nutritional requirements</ci>
                    <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Form="SA0590 SA0896 SA1100 SA1224 SA1379">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4206082933">
            <Name>Paediatric enteral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608293301" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42060829330101">
                <Name>Nutrini RTH</Name>
                <Pack ID="P2632918" Specified="true" OP="true" nzmt:ctpp_id="50307181000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>2.68</Subsidy>
                  <Price>2.68</Price>
                  <Alternate>2.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060829330103">
                <Name>Pediasure RTH</Name>
                <Pack ID="P367958" Specified="true" OP="true" nzmt:ctpp_id="50288011000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>3.32</Subsidy>
                  <Price>3.32</Price>
                  <Alternate>3.32</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060829330104">
                <Name>Frebini Original</Name>
                <Pack ID="P2651777" Specified="true" OP="true" nzmt:ctpp_id="50308841000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206082941">
            <Name>Paediatric oral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608294101" Rank="3" Units="ml">
              <Name>Liquid (chocolate)</Name>
              <Brand ID="B42060829410101">
                <Name>Pediasure</Name>
                <Pack ID="P2444852" Specified="true" OP="true" nzmt:ctpp_id="50287201000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>1.33</Subsidy>
                  <Price>1.33</Price>
                  <Alternate>1.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420608294102" Rank="3" Units="ml">
              <Name>Liquid (strawberry)</Name>
              <Brand ID="B42060829410201">
                <Name>Pediasure</Name>
                <Pack ID="P2444860" Specified="true" OP="true" nzmt:ctpp_id="50287211000117105">
                  <Quantity>200</Quantity>
                  <Subsidy>1.33</Subsidy>
                  <Price>1.33</Price>
                  <Alternate>1.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420608294103" Rank="3" Units="ml">
              <Name>Liquid (vanilla)</Name>
              <Brand ID="B42060829410301">
                <Name>Pediasure</Name>
                <Pack ID="P2444844" Specified="true" OP="true" nzmt:ctpp_id="50287221000117104">
                  <Quantity>200</Quantity>
                  <Subsidy>1.33</Subsidy>
                  <Price>1.33</Price>
                  <Alternate>1.33</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2444879" Specified="true" OP="true" nzmt:ctpp_id="50287251000117106">
                  <Quantity>250</Quantity>
                  <Subsidy>1.66</Subsidy>
                  <Price>1.66</Price>
                  <Alternate>1.66</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206083782">
            <Name>Paediatric enteral feed 1.5kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608378225" Rank="3" Units="ml" Weight="1">
              <Name>Liquid</Name>
              <Brand ID="B42060837822525">
                <Name>Nutrini Energy RTH</Name>
                <Pack ID="P2632926" Specified="true" OP="true" nzmt:ctpp_id="50298951000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060837822526">
                <Name>Frebini Energy</Name>
                <Pack ID="P2651793" Specified="true" OP="true" nzmt:ctpp_id="50308801000117101">
                  <Quantity>500</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206083795">
            <Name>Paediatric enteral feed with fibre 1.5kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608379525" Rank="3" Units="ml" Weight="1">
              <Name>Liquid</Name>
              <Brand ID="B42060837952526">
                <Name>Nutrini Energy Multi Fibre</Name>
                <Pack ID="P2632934" Specified="true" OP="true" nzmt:ctpp_id="50298961000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>6.00</Subsidy>
                  <Price>6.00</Price>
                  <Alternate>6.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060837952527">
                <Name>Frebini Energy Fibre</Name>
                <Pack ID="P2651807" Specified="true" OP="true" nzmt:ctpp_id="50308791000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206083796">
            <Name>Paediatric oral feed 1.5kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608379625" Rank="3" Units="ml" Weight="1">
              <Name>Liquid (strawberry)</Name>
              <Brand ID="B42060837962525">
                <Name>Fortini</Name>
                <Pack ID="P2224496" Specified="true" OP="true" nzmt:ctpp_id="50035801000117102">
                  <Quantity>200</Quantity>
                  <Subsidy>1.60</Subsidy>
                  <Price>1.60</Price>
                  <Alternate>1.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420608379626" Rank="3" Units="ml" Weight="1">
              <Name>Liquid (vanilla)</Name>
              <Brand ID="B42060837962625">
                <Name>Fortini</Name>
                <Pack ID="P2224488" Specified="true" OP="true" nzmt:ctpp_id="50035791000117103">
                  <Quantity>200</Quantity>
                  <Subsidy>1.60</Subsidy>
                  <Price>1.60</Price>
                  <Alternate>1.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060837962627">
                <Name>Pediasure Plus</Name>
                <Pack ID="P2372649" Specified="true" OP="true" nzmt:ctpp_id="50297101000117100">
                  <Quantity>500</Quantity>
                  <Subsidy>8.67</Subsidy>
                  <Price>8.67</Price>
                  <Alternate>8.67</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206083797">
            <Name>Paediatric oral feed with fibre 1.5kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608379725" Rank="3" Units="ml" Weight="1">
              <Name>Liquid (chocolate)</Name>
              <Brand ID="B42060837972525">
                <Name>Fortini Multi Fibre</Name>
                <Pack ID="P2224461" Specified="true" OP="true" nzmt:ctpp_id="50287261000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>1.60</Subsidy>
                  <Price>1.60</Price>
                  <Alternate>1.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420608379726" Rank="3" Units="ml" Weight="1">
              <Name>Liquid (strawberry)</Name>
              <Brand ID="B42060837972625">
                <Name>Fortini Multi Fibre</Name>
                <Pack ID="P2224453" Specified="true" OP="true" nzmt:ctpp_id="50287281000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>1.60</Subsidy>
                  <Price>1.60</Price>
                  <Alternate>1.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420608379727" Rank="3" Units="ml" Weight="1">
              <Name>Liquid (vanilla)</Name>
              <Brand ID="B42060837972725">
                <Name>Fortini Multi Fibre</Name>
                <Pack ID="P2224445" Specified="true" OP="true" nzmt:ctpp_id="50287271000117103">
                  <Quantity>200</Quantity>
                  <Subsidy>1.60</Subsidy>
                  <Price>1.60</Price>
                  <Alternate>1.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420608379728" Rank="3" Units="ml">
              <Name>Liquid (unflavoured)</Name>
              <Brand ID="B42060837972825">
                <Name>Fortini Multi Fibre</Name>
                <Pack ID="P2558394" Specified="true" OP="true" nzmt:ctpp_id="50287291000117102">
                  <Quantity>200</Quantity>
                  <Subsidy>1.60</Subsidy>
                  <Price>1.60</Price>
                  <Alternate>1.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206084082">
            <Name>Peptide-based oral feed</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608408225" Rank="3" Units="g" Weight="400">
              <Name>Powder</Name>
              <Brand ID="B42060840822525">
                <Name>Peptamen Junior</Name>
                <Pack ID="P2522349" Specified="true" OP="true" nzmt:ctpp_id="50200931000117106">
                  <Quantity>400</Quantity>
                  <Subsidy>43.60</Subsidy>
                  <Price>43.60</Price>
                  <Alternate>43.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206084169">
            <Name>Paediatric enteral feed with fibre 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1379"/>
            <Formulation ID="F420608416925" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42060841692525">
                <Name>Frebini Original Fibre</Name>
                <Pack ID="P2651785" Specified="true" OP="true" nzmt:ctpp_id="50308831000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420609">
          <Name>Renal Products</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1101">
            <Title>
              <range>Renal Products<instance>Nepro</instance><instance>NovaSource Renal</instance><instance>Renilon 7.5</instance><instance>Suplena</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The patient has acute or chronic kidney disease</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Renewal" Form="SA0586 SA0587 SA1103 SA1101">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
          </Request>
          <Chemical ID="C4206092944">
            <Name>Renal oral feed 2 kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1101"/>
            <Formulation ID="F420609294402" Rank="10" Units="pack">
              <Name>Liquid (apricot) 125 ml</Name>
              <Brand ID="B42060929440201">
                <Name>Renilon 7.5</Name>
                <Pack ID="P2439379" Specified="true" OP="true" nzmt:ctpp_id="50176611000117103">
                  <Quantity>4</Quantity>
                  <Subsidy>11.52</Subsidy>
                  <Price>11.52</Price>
                  <Alternate>11.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420609294403" Rank="10" Units="pack">
              <Name>Liquid (caramel) 125 ml</Name>
              <Brand ID="B42060929440325">
                <Name>Renilon 7.5</Name>
                <Pack ID="P2439387" Specified="true" OP="true" nzmt:ctpp_id="50176601000117101">
                  <Quantity>4</Quantity>
                  <Subsidy>11.52</Subsidy>
                  <Price>11.52</Price>
                  <Alternate>11.52</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420609294427" Rank="10" Units="">
              <Name>Liquid, 200 ml bottle</Name>
              <Brand ID="B42060929442725">
                <Name>NovaSource Renal</Name>
                <Pack ID="P2632195" Specified="true" OP="true" nzmt:ctpp_id="50297701000117101">
                  <Quantity>4</Quantity>
                  <Subsidy>11.52</Subsidy>
                  <Price>13.24</Price>
                  <Alternate>11.52</Alternate>
                  <Surcharge>0.43000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206094027">
            <Name>Renal enteral  feed 1.8 kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1101"/>
            <Formulation ID="F420609402725" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42060940272525" ToBeDelisted="2024-08-01">
                <Name>Nepro HP RTH</Name>
                <Pack ID="P2457776" Specified="true" OP="true" nzmt:ctpp_id="50205401000117104">
                  <Quantity>500</Quantity>
                  <Subsidy>6.08</Subsidy>
                  <Price>6.08</Price>
                  <Alternate>6.08</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206094028">
            <Name>Renal oral feed 1.8 kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1101"/>
            <Formulation ID="F420609402825" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42060940282525">
                <Name>Nepro HP (vanilla)</Name>
                <Pack ID="P2457741" Specified="true" OP="true" nzmt:ctpp_id="50205421000117107">
                  <Quantity>220</Quantity>
                  <Subsidy>3.31</Subsidy>
                  <Price>3.31</Price>
                  <Alternate>3.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42060940282526">
                <Name>Nepro HP (strawberry)</Name>
                <Pack ID="P2457768" Specified="true" OP="true" nzmt:ctpp_id="50205411000117101">
                  <Quantity>220</Quantity>
                  <Subsidy>3.31</Subsidy>
                  <Price>3.31</Price>
                  <Alternate>3.31</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420610">
          <Name>Specialised And Elemental Products</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1377">
            <Title>
              <range>Specialised And Elemental Products</range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">malabsorption</ci>
                  <ci type="logical" class="Indication">short bowel syndrome</ci>
                  <ci type="logical" class="Indication">enterocutaneous fistulas</ci>
                  <ci type="logical" class="Indication">eosinophilic oesophagitis</ci>
                  <ci type="logical" class="Indication">inflammatory bowel disease</ci>
                  <ci type="logical" class="Indication">patients with multiple food allergies requiring enteral feeding</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.</p>
                <p>Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.</p>
              </div>
            </Case>
            <Case When="Renewal" Form="SA0592 SA1102 SA1377">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4206102927">
            <Name>Oral elemental feed 0.8kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1377"/>
            <Formulation ID="F420610292725" Rank="10" Units="pack">
              <Name>Liquid (grapefruit), 250 ml carton</Name>
              <Brand ID="B42061029272525">
                <Name>Elemental 028 Extra</Name>
                <Pack ID="P2450771" Specified="true" OP="true" nzmt:ctpp_id="50196941000117101">
                  <Quantity>18</Quantity>
                  <Subsidy>171.00</Subsidy>
                  <Price>171.00</Price>
                  <Alternate>171.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420610292726" Rank="10" Units="pack">
              <Name>Liquid (summer fruits), 250 ml carton</Name>
              <Brand ID="B42061029272625">
                <Name>Elemental 028 Extra</Name>
                <Pack ID="P2450798" Specified="true" OP="true" nzmt:ctpp_id="50196931000117109">
                  <Quantity>18</Quantity>
                  <Subsidy>171.00</Subsidy>
                  <Price>171.00</Price>
                  <Alternate>171.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420610292727" Rank="10" Units="pack">
              <Name>Liquid (pineapple &amp; orange), 250 ml carton</Name>
              <Brand ID="B42061029272725">
                <Name>Elemental 028 Extra</Name>
                <Pack ID="P2450801" Specified="true" OP="true" nzmt:ctpp_id="50196951000117104">
                  <Quantity>18</Quantity>
                  <Subsidy>171.00</Subsidy>
                  <Price>171.00</Price>
                  <Alternate>171.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206102928">
            <Name>Oral elemental feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1377"/>
            <Formulation ID="F420610292804" Rank="3" Units="g">
              <Name>Powder (unflavoured)</Name>
              <Brand ID="B42061029280401">
                <Name>Vivonex TEN</Name>
                <Pack ID="P2494450" Specified="true" OP="true" nzmt:ctpp_id="50232281000117105">
                  <Quantity>80</Quantity>
                  <Subsidy>4.50</Subsidy>
                  <Price>4.50</Price>
                  <Alternate>4.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206102938">
            <Name>Semi-elemental enteral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1377"/>
            <Formulation ID="F420610293801" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42061029380102" ToBeDelisted="2024-07-01">
                <Name>Nutrison Advanced Peptisorb</Name>
                <Pack ID="P2632977" Specified="true" OP="true" nzmt:ctpp_id="50298851000117107">
                  <Quantity>1000</Quantity>
                  <Subsidy>12.04</Subsidy>
                  <Price>12.04</Price>
                  <Alternate>12.04</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2665433" Specified="true" OP="true" nzmt:ctpp_id="50323711000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>6.02</Subsidy>
                  <Price>6.02</Price>
                  <Alternate>6.02</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42061029380103">
                <Name>Survimed OPD</Name>
                <Pack ID="P2651769" Specified="true" OP="true" nzmt:ctpp_id="50308911000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>9.60</Subsidy>
                  <Price>9.60</Price>
                  <Alternate>9.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206104051">
            <Name>Enteral/oral semi-elemental feed 1.5kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1377"/>
            <Formulation ID="F420610405125" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42061040512525">
                <Name>Vital</Name>
                <Pack ID="P2492989" Specified="true" OP="true" nzmt:ctpp_id="50228681000117107">
                  <Quantity>1000</Quantity>
                  <Subsidy>22.39</Subsidy>
                  <Price>22.39</Price>
                  <Alternate>22.39</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420615">
          <Name>Paediatric Products For Children With Low Energy Requirements</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1196">
            <Title>
              <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML" overflow="scroll">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Child aged one to eight years</ci>
                  <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Form="SA1196">
              <math xmlns="http://www.w3.org/1998/Math/MathML" overflow="scroll">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4206153946">
            <Name>Paediatric Enteral Feed with Fibre 0.76 kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1196"/>
            <Formulation ID="F420615394625" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42061539462525">
                <Name>Nutrini Low Energy Multi Fibre </Name>
                <Pack ID="P2565234" Specified="true" OP="true" nzmt:ctpp_id="50267281000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>4.00</Subsidy>
                  <Price>4.00</Price>
                  <Alternate>4.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420631">
          <Name>Standard Supplements</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1859">
            <Title>
              <range>Standard Supplements</range>
            </Title>
            <Case When="Initial application" Category="Children - indications other than exclusive enteral nutrition for Crohn's disease">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The patient is under 18 years of age</ci>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci>
                    <ci type="logical" class="Indication">The patient has failure to thrive</ci>
                    <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci>
                  </apply>
                  <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Category="Children - indications other than exclusive enteral nutrition for Crohn's disease" Form="SA0583 SA0702 SA1104 SA1228 SA1554 SA1859">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The patient is under 18 years of age</ci>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="logical" class="Indication">A nutrition goal has been set (eg reach a specific weight or BMI)</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Initial application" Category="Children - exclusive enteral nutrition for Crohn's disease">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The patient is under 18 years of age</ci>
                  <ci type="logical" class="Indication">It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease</ci>
                  <ci type="logical" class="Indication">Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted</ci>
                </apply>
              </math>
              <Applicant>gastroenterologist</Applicant>
              <Applicant Referring="gastroenterologist">dietitian</Applicant>
              <Term Measure="month">3</Term>
            </Case>
            <Case When="Renewal" Category="Children - exclusive enteral nutrition for Crohn's disease" Form="SA0583 SA0702 SA1104 SA1228 SA1554 SA1859">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The patient is under 18 years of age</ci>
                  <ci type="logical" class="Indication">It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease</ci>
                  <ci type="text" class="Details">General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted</ci>
                </apply>
              </math>
              <Applicant Referring="gastroenterologist">any relevant practitioner</Applicant>
              <Term Measure="month">3</Term>
            </Case>
            <Case When="Initial application" Category="Adults">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <apply>
                    <or/>
                    <mi class="heading">Patient is Malnourished</mi>
                    <ci type="logical" class="Indication">Patient has a body mass index (BMI) of less than 18.5 kg/mÂ²</ci>
                    <ci type="logical" class="Indication">Patient has unintentional weight loss greater than 10% within the last 3-6 months</ci>
                    <ci type="logical" class="Indication">Patient has a BMI of less than 20 kg/mÂ² and unintentional weight loss greater than 5% within the last 3-6 months</ci>
                  </apply>
                  <apply>
                    <or/>
                    <mi class="heading">Patient has not responded to first-line dietary measures over a 4 week period by:</mi>
                    <ci type="logical" class="Indication">Increasing their food intake frequency (eg snacks between meals)</ci>
                    <ci type="logical" class="Indication">Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc)</ci>
                    <ci type="logical" class="Indication">Using over the counter supplements (e.g. Complan)</ci>
                  </apply>
                  <ci type="logical" class="Indication">A nutrition goal has been set (e.g. to reach a specific weight or BMI)</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="month">3</Term>
            </Case>
            <Case When="Renewal" Category="Adults" Form="SA0583 SA0702 SA1104 SA1228 SA1554 SA1859">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">A nutrition goal has been set (eg reach a specific weight or BMI)</ci>
                  <apply>
                    <or/>
                    <mi class="heading">Patient is Malnourished</mi>
                    <ci type="logical" class="Indication">Patient has a body mass index (BMI) of less than 18.5 kg/mÂ²</ci>
                    <ci type="logical" class="Indication">Patient has unintentional weight loss greater than 10% within the last 3-6 months</ci>
                    <ci type="logical" class="Indication">Patient has a BMI of less than 20 kg/mÂ² and unintentional weight loss greater than 5% within the last 3-6 months</ci>
                  </apply>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="month">6</Term>
            </Case>
            <Case When="Initial application" Category="Short-term medical condition">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding</ci>
                  <ci type="logical" class="Indication">Malignancy and is considered likely to develop malnutrition as a result</ci>
                  <ci type="logical" class="Indication">Is undergoing a bone marrow transplant</ci>
                  <ci type="logical" class="Indication">Tempomandibular surgery or glossectomy</ci>
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Pregnant</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is in early pregnancy (&lt;13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum</ci>
                      <ci type="logical" class="Indication">Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicineâ€™s (1990) recommended weight gain guidelines for pregnancy or the patientâ€™s weight has not increased past her booking/pre-pregnancy weight</ci>
                      <ci type="logical" class="Indication">Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met</ci>
                    </apply>
                  </apply>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Category="Short-term medical condition" Form="SA0583 SA0702 SA1104 SA1228 SA1554 SA1859">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Is being fed via a nasogastric tube</ci>
                  <ci type="logical" class="Indication">Malignancy and is considered likely to develop malnutrition as a result</ci>
                  <ci type="logical" class="Indication">Has undergone a bone marrow transplant</ci>
                  <ci type="logical" class="Indication">Tempomandibular surgery or glossectomy</ci>
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Pregnant</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Patient is in early pregnancy (&lt;13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum</ci>
                      <ci type="logical" class="Indication">Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicineâ€™s (1990) recommended weight gain guidelines for pregnancy or the patientâ€™s weight has not increased past her booking/pre-pregnancy weight</ci>
                      <ci type="logical" class="Indication">Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met</ci>
                    </apply>
                  </apply>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Initial application" Category="Long-term medical condition">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria)</ci>
                  <ci type="logical" class="Indication">Cystic Fibrosis</ci>
                  <ci type="logical" class="Indication">Liver disease</ci>
                  <ci type="logical" class="Indication">Chronic Renal failure</ci>
                  <ci type="logical" class="Indication">Inflammatory bowel disease</ci>
                  <ci type="logical" class="Indication">Chronic obstructive pulmonary disease with hypercapnia</ci>
                  <ci type="logical" class="Indication">Short bowel syndrome</ci>
                  <ci type="logical" class="Indication">Bowel fistula</ci>
                  <ci type="logical" class="Indication">Severe chronic neurological conditions</ci>
                  <ci type="logical" class="Indication">Epidermolysis bullosa</ci>
                  <ci type="logical" class="Indication">AIDS (CD4 count &lt; 200 cells/mmÂ³)</ci>
                  <ci type="logical" class="Indication">Chronic pancreatitis</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="patient's lifetime"/>
            </Case>
            <Case When="Renewal" Form="SA0583 SA0702 SA1104 SA1228 SA1554 SA1859" Category="Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <or/>
                  <ci type="logical" class="Indication">Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria)</ci>
                  <ci type="logical" class="Indication">Cystic Fibrosis</ci>
                  <ci type="logical" class="Indication">Liver disease</ci>
                  <ci type="logical" class="Indication">Chronic Renal failure</ci>
                  <ci type="logical" class="Indication">Inflammatory bowel disease</ci>
                  <ci type="logical" class="Indication">Chronic obstructive pulmonary disease with hypercapnia</ci>
                  <ci type="logical" class="Indication">Short bowel syndrome</ci>
                  <ci type="logical" class="Indication">Bowel fistula</ci>
                  <ci type="logical" class="Indication">Severe chronic neurological conditions</ci>
                </apply>
              </math>
              <Applicant>any relevant practitioner</Applicant>
              <Term Measure="patient's lifetime"/>
            </Case>
          </Request>
          <Chemical ID="C4206312901">
            <Name>Enteral feed 1.5kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631290125" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063129012501">
                <Name>Ensure Plus HN RTH</Name>
                <Pack ID="P2217171" Specified="true" OP="true" nzmt:ctpp_id="50287961000117101">
                  <Quantity>1000</Quantity>
                  <Subsidy>8.68</Subsidy>
                  <Price>8.68</Price>
                  <Alternate>8.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129012525">
                <Name>Nutrison Energy</Name>
                <Pack ID="P2632950" Specified="true" OP="true" nzmt:ctpp_id="50298821000117100">
                  <Quantity>1000</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129012526">
                <Name>Ensure Plus HN</Name>
                <Pack ID="P2372665" Specified="true" OP="true" nzmt:ctpp_id="50201411000117103">
                  <Quantity>250</Quantity>
                  <Subsidy>2.17</Subsidy>
                  <Price>2.17</Price>
                  <Alternate>2.17</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129012527">
                <Name>Fresubin HP Energy</Name>
                <Pack ID="P2651718" Specified="true" OP="true" nzmt:ctpp_id="50308871000117105">
                  <Quantity>1000</Quantity>
                  <Subsidy>9.60</Subsidy>
                  <Price>9.60</Price>
                  <Alternate>9.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206312902">
            <Name>Enteral feed 1kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631290201" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063129020107">
                <Name>Isosource Standard</Name>
                <Pack ID="P283207" Specified="true" OP="true" nzmt:ctpp_id="50063151000117101">
                  <Quantity>250</Quantity>
                  <Subsidy>1.24</Subsidy>
                  <Price>1.24</Price>
                  <Alternate>1.24</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129020111">
                <Name>Nutrison Standard RTH</Name>
                <Pack ID="P2632969" Specified="true" OP="true" nzmt:ctpp_id="50298831000117102">
                  <Quantity>1000</Quantity>
                  <Subsidy>5.29</Subsidy>
                  <Price>5.29</Price>
                  <Alternate>5.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129020113">
                <Name>Osmolite RTH</Name>
                <Pack ID="P2217155" Specified="true" OP="true" nzmt:ctpp_id="50034541000117101">
                  <Quantity>1000</Quantity>
                  <Subsidy>6.56</Subsidy>
                  <Price>6.56</Price>
                  <Alternate>6.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129020128">
                <Name>Fresubin Original</Name>
                <Pack ID="P2651734" Specified="true" OP="true" nzmt:ctpp_id="50308901000117105">
                  <Quantity>1000</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206312912">
            <Name>Enteral feed with fibre 1 kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631291201" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063129120106">
                <Name>Jevity RTH</Name>
                <Pack ID="P2217147" Specified="true" OP="true" nzmt:ctpp_id="50034531000117109">
                  <Quantity>1000</Quantity>
                  <Subsidy>6.56</Subsidy>
                  <Price>6.56</Price>
                  <Alternate>6.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129120108">
                <Name>Nutrison Multi Fibre</Name>
                <Pack ID="P2632993" Specified="true" OP="true" nzmt:ctpp_id="50298881000117101">
                  <Quantity>1000</Quantity>
                  <Subsidy>5.29</Subsidy>
                  <Price>5.29</Price>
                  <Alternate>5.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129120127">
                <Name>Fresubin Original Fibre</Name>
                <Pack ID="P2651726" Specified="true" OP="true" nzmt:ctpp_id="50308891000117106">
                  <Quantity>1000</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206312913">
            <Name>Enteral feed with fibre 1.5kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631291301" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063129130125">
                <Name>Nutrison Energy Multi Fibre</Name>
                <Pack ID="P2632985" Specified="true" OP="true" nzmt:ctpp_id="50298861000117109">
                  <Quantity>1000</Quantity>
                  <Subsidy>7.00</Subsidy>
                  <Price>7.00</Price>
                  <Alternate>7.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129130127">
                <Name>Jevity HiCal RTH</Name>
                <Pack ID="P2217139" Specified="true" OP="true" nzmt:ctpp_id="50287951000117103">
                  <Quantity>1000</Quantity>
                  <Subsidy>8.68</Subsidy>
                  <Price>8.68</Price>
                  <Alternate>8.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129130128">
                <Name>Fresubin HP Energy Fibre</Name>
                <Pack ID="P2651742" Specified="true" OP="true" nzmt:ctpp_id="50308861000117100">
                  <Quantity>1000</Quantity>
                  <Subsidy>9.80</Subsidy>
                  <Price>9.80</Price>
                  <Alternate>9.80</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206312929">
            <Name>Oral feed 1.5kcal/ml</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, who have severe epidermolysis bullosa, or as exclusive enteral nutrition in children under the
    age of 18 years for the treatment of Crohn's disease, or for patients with COPD and hypercapnia, defined as CO2 value exceeding 55mmHg. The prescription must be endorsed accordingly.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631292901" Rank="3" Units="ml">
              <Name>Liquid (banana)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063129290101">
                <Name>Ensure Plus</Name>
                <Pack ID="P234885" Specified="true" OP="true" nzmt:ctpp_id="50050371000117105">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129290102">
                <Name>Fortisip</Name>
                <Pack ID="P2220857" Specified="true" OP="true" nzmt:ctpp_id="50035141000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420631292902" Rank="3" Units="ml">
              <Name>Liquid (chocolate)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063129290201">
                <Name>Ensure Plus</Name>
                <Pack ID="P234680" Specified="true" OP="true" nzmt:ctpp_id="50050251000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129290202">
                <Name>Fortisip</Name>
                <Pack ID="P2220830" Specified="true" OP="true" nzmt:ctpp_id="50035121000117101">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420631292904" Rank="3" Units="ml">
              <Name>Liquid (fruit of the forest)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063129290401">
                <Name>Ensure Plus</Name>
                <Pack ID="P234893" Specified="true" OP="true" nzmt:ctpp_id="50050381000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420631292905" Rank="3" Units="ml">
              <Name>Liquid (strawberry)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063129290502">
                <Name>Fortisip</Name>
                <Pack ID="P2220849" Specified="true" OP="true" nzmt:ctpp_id="50035131000117103">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420631292908" Rank="3" Units="ml">
              <Name>Liquid (vanilla)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063129290801">
                <Name>Ensure Plus</Name>
                <Pack ID="P234672" Specified="true" OP="true" nzmt:ctpp_id="50050241000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
                <Pack ID="P308455" Specified="true" OP="true" nzmt:ctpp_id="50069151000117104">
                  <Quantity>237</Quantity>
                  <Subsidy>0.85</Subsidy>
                  <Price>1.33</Price>
                  <Alternate>1.33</Alternate>
                  <Surcharge>0.00203</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129290802">
                <Name>Fortisip</Name>
                <Pack ID="P2220822" Specified="true" OP="true" nzmt:ctpp_id="50035111000117107">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206312932">
            <Name>Oral feed (powder)</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631293205" Rank="3" Units="g">
              <Name>Powder (chocolate)</Name>
              <Brand ID="B42063129320501">
                <Name>Ensure</Name>
                <Pack ID="P2504324" Specified="true" OP="true" nzmt:ctpp_id="50287981000117109">
                  <Quantity>850</Quantity>
                  <Subsidy>26.00</Subsidy>
                  <Price>26.00</Price>
                  <Alternate>26.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129320503">
                <Name>Sustagen Hospital Formula</Name>
                <Pack ID="P2538997" Specified="true" OP="true" nzmt:ctpp_id="50227111000117105">
                  <Quantity>840</Quantity>
                  <Subsidy>14.00</Subsidy>
                  <Price>14.00</Price>
                  <Alternate>14.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420631293207" Rank="3" Units="g">
              <Name>Powder (vanilla)</Name>
              <Brand ID="B42063129320701">
                <Name>Ensure</Name>
                <Pack ID="P2504316" Specified="true" OP="true" nzmt:ctpp_id="50287991000117107">
                  <Quantity>850</Quantity>
                  <Subsidy>26.00</Subsidy>
                  <Price>26.00</Price>
                  <Alternate>26.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063129320726">
                <Name>Sustagen Hospital Formula Active</Name>
                <Pack ID="P2539004" Specified="true" OP="true" nzmt:ctpp_id="50227121000117104">
                  <Quantity>840</Quantity>
                  <Subsidy>14.00</Subsidy>
                  <Price>14.00</Price>
                  <Alternate>14.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206313852">
            <Name>Oral feed with fibre 1.5 kcal/ml</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa.  The prescription must be endorsed accordingly.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631385225" Rank="3" Units="ml">
              <Name>Liquid (vanilla)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063138522525">
                <Name>Fortisip Multi Fibre</Name>
                <Pack ID="P2224410" Specified="true" OP="true" nzmt:ctpp_id="50035721000117100">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420631385226" Rank="3" Units="ml">
              <Name>Liquid (chocolate)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063138522625">
                <Name>Fortisip Multi Fibre</Name>
                <Pack ID="P2224399" Specified="true" OP="true" nzmt:ctpp_id="50035701000117108">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F420631385227" Rank="3" Units="ml">
              <Name>Liquid (strawberry)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063138522725">
                <Name>Fortisip Multi Fibre</Name>
                <Pack ID="P2224402" Specified="true" OP="true" nzmt:ctpp_id="50035711000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>0.72</Subsidy>
                  <Price>1.26</Price>
                  <Alternate>1.26</Alternate>
                  <Surcharge>0.00270</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206314074">
            <Name>Enteral feed with fibre 0.83 kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631407425" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063140742525">
                <Name>Nutrison 800 Complete Multi Fibre</Name>
                <Pack ID="P2572982" Specified="true" OP="true" nzmt:ctpp_id="50271881000117104">
                  <Quantity>1000</Quantity>
                  <Subsidy>5.29</Subsidy>
                  <Price>5.29</Price>
                  <Alternate>5.29</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206314153">
            <Name>Enteral feed with fibre 1.2kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631415325" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063141532525">
                <Name>Jevity Plus RTH</Name>
                <Pack ID="P2217120" Specified="true" OP="true" nzmt:ctpp_id="50287931000117108">
                  <Quantity>1000</Quantity>
                  <Subsidy>7.87</Subsidy>
                  <Price>7.87</Price>
                  <Alternate>7.87</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206314170">
            <Name>Enteral feed with protein 1.2kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1859"/>
            <Formulation ID="F420631417025" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063141702525">
                <Name>Fresubin Intensive</Name>
                <Pack ID="P2651750" Specified="true" OP="true" nzmt:ctpp_id="50308881000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>9.60</Subsidy>
                  <Price>9.60</Price>
                  <Alternate>9.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A420632">
          <Name>High Calorie Products </Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1195">
            <Title>
              <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range>
            </Title>
            <Case When="Initial application" Category="Cystic fibrosis">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">Cystic fibrosis</ci>
                  <ci type="logical" class="Trial">other lower calorie products have been tried</ci>
                  <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Initial application" Category="Indications other than cystic fibrosis">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">any condition causing malabsorption</ci>
                    <ci type="logical" class="Indication">faltering growth in an infant/child</ci>
                    <ci type="logical" class="Indication">increased nutritional requirements</ci>
                    <ci type="logical" class="Indication">fluid restricted</ci>
                  </apply>
                  <ci type="logical" class="Trial">other lower calorie products have been tried</ci>
                  <ci type="logical" class="Indication">patient has substantially increased metabolic requirements or is fluid restricted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Category="Cystic fibrosis" Form="SA0585 SA1105 SA1195">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">3</Term>
            </Case>
            <Case When="Renewal" Category="Indications other than cystic fibrosis" Form="SA0585 SA1105 SA1195">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4206322911">
            <Name>Enteral feed 2 kcal/ml</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1195"/>
            <Formulation ID="F420632291101" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42063229110101">
                <Name>Nutrison Concentrated</Name>
                <Pack ID="P2572966" Specified="true" OP="true" nzmt:ctpp_id="50270261000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>5.50</Subsidy>
                  <Price>5.50</Price>
                  <Alternate>5.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063229110126">
                <Name>Ensure Two Cal HN RTH</Name>
                <Pack ID="P2614162" Specified="true" OP="true" nzmt:ctpp_id="50289061000117109">
                  <Quantity>1000</Quantity>
                  <Subsidy>13.64</Subsidy>
                  <Price>13.64</Price>
                  <Alternate>13.64</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42063229110127">
                <Name>Fresubin 2kcal HP</Name>
                <Pack ID="P2651696" Specified="true" OP="true" nzmt:ctpp_id="50308851000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>6.50</Subsidy>
                  <Price>6.50</Price>
                  <Alternate>6.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4206322931">
            <Name>Oral feed 2 kcal/ml</Name>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.</p>
            </div>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1195"/>
            <Formulation ID="F420632293102" Rank="3" Units="ml">
              <Name>Liquid (vanilla)</Name>
              <Rule Attribute="Endorsement" Type="Alternate"/>
              <Brand ID="B42063229310201">
                <Name>Two Cal HN</Name>
                <Pack ID="P2443228" Specified="true" OP="true" nzmt:ctpp_id="50287971000117106">
                  <Quantity>200</Quantity>
                  <Subsidy>0.96</Subsidy>
                  <Price>1.90</Price>
                  <Alternate>1.90</Alternate>
                  <Surcharge>0.00470</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A4208">
        <Name>Food Thickeners</Name>
        <Request To="HealthPAC" For="Subsidy" Form="SA1106">
          <Title>
            <range>Food Thickeners<instance>Karicare Food Thickener</instance><instance>Nutilis</instance></range>
          </Title>
          <Case When="Initial application">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <ci type="logical" class="Indication">The patient has motor neurone disease with swallowing disorder</ci>
            </math>
            <Applicant>dietitian</Applicant>
            <Applicant>relevant specialist</Applicant>
            <Applicant>vocationally registered general practitioner</Applicant>
            <Term Measure="year">1</Term>
          </Case>
          <Case When="Renewal" Form="SA0595 SA1106">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <apply>
                <and/>
                <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
              </apply>
            </math>
            <Applicant>dietitian</Applicant>
            <Applicant>relevant specialist</Applicant>
            <Applicant>vocationally registered general practitioner</Applicant>
            <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
            <Term Measure="year">1</Term>
          </Case>
        </Request>
        <ATC3 ID="A420801">
          <Name>Food Thickeners</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4208012925">
            <Name>Food thickener</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1106"/>
            <Formulation ID="F420801292501" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42080129250102">
                <Name>Feed Thickener Karicare Aptamil</Name>
                <Pack ID="P2241889" OP="true">
                  <Quantity>380</Quantity>
                  <Subsidy>7.25</Subsidy>
                  <Price>7.25</Price>
                  <Alternate>7.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2432129" Specified="true" OP="true" nzmt:ctpp_id="50262481000117102">
                  <Quantity>380</Quantity>
                  <Subsidy>7.25</Subsidy>
                  <Price>7.25</Price>
                  <Alternate>7.25</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42080129250125">
                <Name>Nutilis</Name>
                <Pack ID="P2400456" Specified="true" OP="true" nzmt:ctpp_id="50199671000117109">
                  <Quantity>300</Quantity>
                  <Subsidy>6.53</Subsidy>
                  <Price>6.53</Price>
                  <Alternate>6.53</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A4210">
        <Name>Gluten Free Foods</Name>
        <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
          <p>The funding of gluten free foods is no longer being actively managed by Pharmac from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.</p>
        </div>
        <Request To="HealthPAC" For="Subsidy" Form="SA1729">
          <Title>
            <range>Gluten Free Foods<instance>Bakels Gluten Free Health Bread Mix</instance><instance>Horleys Bread Mix</instance><instance>Horleys Flour</instance><instance>NZB Low Gluten Bread Mix</instance><instance>Orgran</instance><instance>Healtheries Simple Baking Mix</instance></range>
          </Title>
          <Case When="Initial application" Category="all patients">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <apply>
                <or/>
                <ci type="logical" class="Indication">Gluten enteropathy has been diagnosed by biopsy</ci>
                <ci type="logical" class="Indication">Patient suffers from dermatitis herpetiformis</ci>
              </apply>
            </math>
            <Applicant>dietitian</Applicant>
            <Applicant>relevant specialist</Applicant>
            <Applicant>vocationally registered general practitioner</Applicant>
            <Term Measure="patient's lifetime"/>
          </Case>
          <Case When="Initial application" Category="paediatric patients diagnosed by ESPGHAN criteria">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <ci type="logical" class="Indication">the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease</ci>
            </math>
            <Applicant>paediatric gastroenterologist</Applicant>
            <Term Measure="patient's lifetime"/>
          </Case>
        </Request>
        <ATC3 ID="A421001">
          <Name>Gluten Free Foods</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4210012918">
            <Name>Gluten free baking mix</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1729"/>
            <Formulation ID="F421001291801" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42100129180125">
                <Name>Healtheries Simple Baking Mix</Name>
                <Pack ID="P2190702" Specified="true" OP="true" nzmt:ctpp_id="50030921000117109">
                  <Quantity>1000</Quantity>
                  <Subsidy>2.81</Subsidy>
                  <Price>5.15</Price>
                  <Alternate>2.81</Alternate>
                  <Surcharge>0.00234</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4210012919">
            <Name>Gluten free bread mix</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1729"/>
            <Formulation ID="F421001291901" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42100129190103">
                <Name>Horleys Bread Mix</Name>
                <Pack ID="P672726" Specified="true" OP="true" nzmt:ctpp_id="50101371000117102">
                  <Quantity>1000</Quantity>
                  <Subsidy>3.51</Subsidy>
                  <Price>10.87</Price>
                  <Alternate>3.51</Alternate>
                  <Surcharge>0.00736</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42100129190104">
                <Name>NZB Low Gluten Bread Mix</Name>
                <Pack ID="P457809" Specified="true" OP="true" nzmt:ctpp_id="50087141000117106">
                  <Quantity>1000</Quantity>
                  <Subsidy>3.93</Subsidy>
                  <Price>7.32</Price>
                  <Alternate>3.93</Alternate>
                  <Surcharge>0.00339</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4210012920">
            <Name>Gluten free flour</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1729"/>
            <Formulation ID="F421001292001" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42100129200101">
                <Name>Horleys Flour</Name>
                <Pack ID="P672734" Specified="true" OP="true" nzmt:ctpp_id="50101381000117104">
                  <Quantity>2000</Quantity>
                  <Subsidy>5.62</Subsidy>
                  <Price>18.10</Price>
                  <Alternate>5.62</Alternate>
                  <Surcharge>0.00624</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4210012921">
            <Name>Gluten free pasta</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1729"/>
            <Formulation ID="F421001292102" Rank="3" Units="g">
              <Name>Buckwheat Spirals</Name>
              <Brand ID="B42100129210201">
                <Name>Orgran</Name>
                <Pack ID="P290319" Specified="true" OP="true" nzmt:ctpp_id="50065461000117106">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>3.11</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00444</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292106" Rank="3" Units="g">
              <Name>Corn and Vegetable Shells</Name>
              <Brand ID="B42100129210601">
                <Name>Orgran</Name>
                <Pack ID="P289175" Specified="true" OP="true" nzmt:ctpp_id="50065181000117108">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.92</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00368</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292112" Rank="3" Units="g">
              <Name>Rice and Maize Pasta Spirals</Name>
              <Brand ID="B42100129211201">
                <Name>Orgran</Name>
                <Pack ID="P376744" Specified="true" OP="true" nzmt:ctpp_id="50079281000117109">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.92</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00368</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292114" Rank="3" Units="g">
              <Name>Rice and Millet Spirals</Name>
              <Brand ID="B42100129211401">
                <Name>Orgran</Name>
                <Pack ID="P289213" Specified="true" OP="true" nzmt:ctpp_id="50065201000117109">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>3.11</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00444</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292118" Rank="3" Units="g">
              <Name>Vegetable and Rice Spirals</Name>
              <Brand ID="B42100129211801">
                <Name>Orgran</Name>
                <Pack ID="P289353" Specified="true" OP="true" nzmt:ctpp_id="50065241000117106">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.92</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00368</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292125" Rank="3" Units="g">
              <Name>Rice and Corn Macaroni</Name>
              <Brand ID="B42100129212525">
                <Name>Orgran</Name>
                <Pack ID="P2162326" Specified="true" OP="true" nzmt:ctpp_id="50027481000117103">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.92</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00368</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292126" Rank="3" Units="g">
              <Name>Rice and Corn Penne</Name>
              <Brand ID="B42100129212625">
                <Name>Orgran</Name>
                <Pack ID="P2162318" Specified="true" OP="true" nzmt:ctpp_id="50027471000117101">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.92</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00368</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292128" Rank="3" Units="g">
              <Name>Rice and Corn Lasagne Sheets</Name>
              <Brand ID="B42100129212825">
                <Name>Orgran</Name>
                <Pack ID="P2162288" Specified="true" OP="true" nzmt:ctpp_id="50027451000117109">
                  <Quantity>200</Quantity>
                  <Subsidy>1.60</Subsidy>
                  <Price>3.82</Price>
                  <Alternate>1.60</Alternate>
                  <Surcharge>0.01110</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292129" Rank="3" Units="g">
              <Name>Rice and corn spaghetti noodles</Name>
              <Brand ID="B42100129212925">
                <Name>Orgran</Name>
                <Pack ID="P2130351" Specified="true" OP="true" nzmt:ctpp_id="50023461000117102">
                  <Quantity>375</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.92</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00245</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292130" Rank="3" Units="g">
              <Name>Corn and Vegetable Spirals</Name>
              <Brand ID="B42100129213025">
                <Name>Orgran</Name>
                <Pack ID="P2280698" Specified="true" OP="true" nzmt:ctpp_id="50043561000117103">
                  <Quantity>250</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>2.92</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00368</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421001292132" Rank="3" Units="g" Weight="220">
              <Name>Italian long style spaghetti</Name>
              <Brand ID="B42100129213225">
                <Name>Orgran</Name>
                <Pack ID="P2310457" Specified="true" OP="true" nzmt:ctpp_id="50046991000117108">
                  <Quantity>220</Quantity>
                  <Subsidy>2.00</Subsidy>
                  <Price>3.11</Price>
                  <Alternate>2.00</Alternate>
                  <Surcharge>0.00505</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A4212">
        <Name>Foods And Supplements For Inherited Metabolic Disease</Name>
        <Request To="HealthPAC" For="Subsidy" Form="SA2300">
          <Title>
            <range>Foods and Supplements For Inborn Errors Of Metabolism<instance>Easiphen Liquid</instance><instance>Loprofin Mix</instance><instance>Loprofin</instance><instance>Minaphlex</instance><instance>MSUD Maxamaid</instance><instance>MSUD Maxamum</instance><instance>Phlexy 10</instance><instance>PKU Anamix Junior LQ</instance> <instance>PKU Lophlex LQ</instance><instance>PKU Anamix Infant</instance><instance>XP Maxamaid</instance><instance>XP Maxamum</instance><instance>XMET Maxamum</instance></range>
          </Title>
          <Case When="Initial application">
            <math xmlns="http://www.w3.org/1998/Math/MathML">
              <apply>
                <or/>
                <ci type="logical" class="Indication">Dietary management of inherited metabolic disease</ci>
                <ci type="logical" class="Indication">For use as a supplement to a Ketogenic diet in patients diagnosed with epilepsy</ci>
              </apply>
            </math>
            <Applicant>any relevant practitioner</Applicant>
            <Term Measure="patient's lifetime"/>
          </Case>
        </Request>
        <ATC3 ID="A421201">
          <Name>Supplements For Homocystinuria</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212012904">
            <Name>Aminoacid formula without methionine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421201290401" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42120129040102">
                <Name>XMET Maxamum</Name>
                <Pack ID="P949027" Specified="true" OP="true" nzmt:ctpp_id="50118251000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>461.94</Subsidy>
                  <Price>461.94</Price>
                  <Alternate>461.94</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421201290425" Rank="2" Units="sach">
              <Name>Powder, 12.5 g sachets</Name>
              <Brand ID="B42120129042525">
                <Name>HCU Explore 5</Name>
                <Pack ID="P2668548" Specified="true" nzmt:ctpp_id="50328231000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>349.65</Subsidy>
                  <Price>349.65</Price>
                  <Alternate>349.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421201290426" Rank="2" Units="sach">
              <Name>Powder, 25 g sachets</Name>
              <Brand ID="B42120129042625">
                <Name>HCU Express 15</Name>
                <Pack ID="P2668556" Specified="true" nzmt:ctpp_id="50328271000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>1048.95</Subsidy>
                  <Price>1048.95</Price>
                  <Alternate>1048.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421202">
          <Name>Supplements For MSUD and short chain enoyl coA hydratase deficiency</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212022906">
            <Name>Aminoacid formula without valine, leucine and isoleucine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421202290601" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42120229060102">
                <Name>MSUD Maxamum</Name>
                <Pack ID="P469564" Specified="true" OP="true" nzmt:ctpp_id="50088441000117102">
                  <Quantity>500</Quantity>
                  <Subsidy>437.22</Subsidy>
                  <Price>437.22</Price>
                  <Alternate>437.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421202290625" Rank="2" Units="sach">
              <Name>Powder, 12.5 g sachets</Name>
              <Brand ID="B42120229062525">
                <Name>MSUD Explore 5</Name>
                <Pack ID="P2668580" Specified="true" nzmt:ctpp_id="50328261000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>349.65</Subsidy>
                  <Price>349.65</Price>
                  <Alternate>349.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421202290626" Rank="2" Units="sach">
              <Name>Powder, 25 g sachets</Name>
              <Brand ID="B42120229062625">
                <Name>MSUD Express 15</Name>
                <Pack ID="P2668599" Specified="true" nzmt:ctpp_id="50328221000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>1048.95</Subsidy>
                  <Price>1048.95</Price>
                  <Alternate>1048.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421205">
          <Name>Supplements For PKU</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212052905">
            <Name>Aminoacid formula without phenylalanine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421205290505" Rank="3" Units="g">
              <Name>Infant formula</Name>
              <Brand ID="B42120529050525">
                <Name>PKU Anamix Infant</Name>
                <Pack ID="P2595923" Specified="true" OP="true" nzmt:ctpp_id="50283931000117101">
                  <Quantity>400</Quantity>
                  <Subsidy>174.72</Subsidy>
                  <Price>174.72</Price>
                  <Alternate>174.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290506" Rank="3" Units="g">
              <Name>Powder (orange)</Name>
              <Brand ID="B42120529050602">
                <Name>XP Maxamum</Name>
                <Pack ID="P212059" Specified="true" OP="true" nzmt:ctpp_id="50021821000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>320.00</Subsidy>
                  <Price>320.00</Price>
                  <Alternate>320.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290507" Rank="3" Units="g">
              <Name>Powder (unflavoured)</Name>
              <Brand ID="B42120529050704">
                <Name>XP Maxamum</Name>
                <Pack ID="P459828" Specified="true" OP="true" nzmt:ctpp_id="50087441000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>320.00</Subsidy>
                  <Price>320.00</Price>
                  <Alternate>320.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290526" Rank="1" Units="tab">
              <Name>Tabs</Name>
              <Brand ID="B42120529052625">
                <Name>Phlexy 10</Name>
                <Pack ID="P2198460" Specified="true" OP="true" nzmt:ctpp_id="50031731000117104">
                  <Quantity>75</Quantity>
                  <Subsidy>99.00</Subsidy>
                  <Price>99.00</Price>
                  <Alternate>99.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290530" Rank="3" Units="ml">
              <Name>Liquid (orange)</Name>
              <Brand ID="B42120529053027">
                <Name>PKU Anamix Junior LQ</Name>
                <Pack ID="P2400502" Specified="true" OP="true" nzmt:ctpp_id="50129541000117109">
                  <Quantity>125</Quantity>
                  <Subsidy>13.10</Subsidy>
                  <Price>13.10</Price>
                  <Alternate>13.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290531" Rank="3" Units="ml">
              <Name>Liquid (berry)</Name>
              <Brand ID="B42120529053127">
                <Name>PKU Anamix Junior LQ</Name>
                <Pack ID="P2400499" Specified="true" OP="true" nzmt:ctpp_id="50129531000117101">
                  <Quantity>125</Quantity>
                  <Subsidy>13.10</Subsidy>
                  <Price>13.10</Price>
                  <Alternate>13.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290533" Rank="3" Units="ml">
              <Name>Liquid (unflavoured)</Name>
              <Brand ID="B42120529053325">
                <Name>PKU Anamix Junior LQ</Name>
                <Pack ID="P2400510" Specified="true" OP="true" nzmt:ctpp_id="50129551000117106">
                  <Quantity>125</Quantity>
                  <Subsidy>13.10</Subsidy>
                  <Price>13.10</Price>
                  <Alternate>13.10</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290534" Rank="10" Units="pack">
              <Name>Liquid (forest berries), 250 ml carton</Name>
              <Brand ID="B42120529053425">
                <Name>Easiphen Liquid</Name>
                <Pack ID="P2450828" Specified="true" OP="true" nzmt:ctpp_id="50200241000117107">
                  <Quantity>18</Quantity>
                  <Subsidy>540.00</Subsidy>
                  <Price>540.00</Price>
                  <Alternate>540.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290535" Rank="10" Units="pack" Weight="10">
              <Name>Liquid (juicy citrus) 62.5 ml</Name>
              <Brand ID="B42120529053525">
                <Name>PKU Lophlex LQ 10</Name>
                <Pack ID="P2470578" Specified="true" OP="true" nzmt:ctpp_id="50220321000117103">
                  <Quantity>60</Quantity>
                  <Subsidy>939.00</Subsidy>
                  <Price>939.00</Price>
                  <Alternate>939.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290537" Rank="10" Units="pack" Weight="10">
              <Name>Liquid (juicy berries) 62.5 ml</Name>
              <Brand ID="B42120529053725">
                <Name>PKU Lophlex LQ 10</Name>
                <Pack ID="P2470586" Specified="true" OP="true" nzmt:ctpp_id="50220311000117109">
                  <Quantity>60</Quantity>
                  <Subsidy>939.00</Subsidy>
                  <Price>939.00</Price>
                  <Alternate>939.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290538" Rank="10" Units="pack" Weight="20">
              <Name>Liquid (juicy berries) 125 ml</Name>
              <Brand ID="B42120529053825">
                <Name>PKU Lophlex LQ 20</Name>
                <Pack ID="P2470535" Specified="true" OP="true" nzmt:ctpp_id="50220271000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>936.00</Subsidy>
                  <Price>936.00</Price>
                  <Alternate>936.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290539" Rank="10" Units="pack" Weight="10">
              <Name>Liquid (juicy orange) 62.5 ml</Name>
              <Brand ID="B42120529053925">
                <Name>PKU Lophlex LQ 10</Name>
                <Pack ID="P2470551" Specified="true" OP="true" nzmt:ctpp_id="50220301000117106">
                  <Quantity>60</Quantity>
                  <Subsidy>939.00</Subsidy>
                  <Price>939.00</Price>
                  <Alternate>939.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290540" Rank="10" Units="pack" Weight="20">
              <Name>Liquid (juicy orange) 125 ml</Name>
              <Brand ID="B42120529054025">
                <Name>PKU Lophlex LQ 20</Name>
                <Pack ID="P2470543" Specified="true" OP="true" nzmt:ctpp_id="50220291000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>936.00</Subsidy>
                  <Price>936.00</Price>
                  <Alternate>936.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290542" Rank="10" Units="pack">
              <Name>Liquid (juicy tropical) 125 ml</Name>
              <Brand ID="B42120529054225">
                <Name>PKU Lophlex LQ 20</Name>
                <Pack ID="P2528592" Specified="true" OP="true" nzmt:ctpp_id="50252651000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>936.00</Subsidy>
                  <Price>936.00</Price>
                  <Alternate>936.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290543" Rank="10" Units="pack">
              <Name>Oral semi-solid (berries) 109 g</Name>
              <Brand ID="B42120529054325">
                <Name>PKU Lophlex Sensation 20</Name>
                <Pack ID="P2528606" Specified="true" OP="true" nzmt:ctpp_id="50253021000117109">
                  <Quantity>36</Quantity>
                  <Subsidy>1123.20</Subsidy>
                  <Price>1123.20</Price>
                  <Alternate>1123.20</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290545" Rank="2" Units="sach">
              <Name>Powder (vanilla) 36 g sachet</Name>
              <Brand ID="B42120529054525">
                <Name>PKU Anamix Junior Vanilla</Name>
                <Pack ID="P2556162" Specified="true" nzmt:ctpp_id="50304811000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>393.00</Subsidy>
                  <Price>393.00</Price>
                  <Alternate>393.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290546" Rank="2" Units="sach">
              <Name>Powder (chocolate) 36 g sachet</Name>
              <Brand ID="B42120529054625">
                <Name>PKU Anamix Junior Chocolate</Name>
                <Pack ID="P2556154" Specified="true" nzmt:ctpp_id="50304791000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>393.00</Subsidy>
                  <Price>393.00</Price>
                  <Alternate>393.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290548" Rank="2" Units="sach">
              <Name>Powder (orange) 36 g sachet</Name>
              <Brand ID="B42120529054825">
                <Name>PKU Anamix Junior Orange</Name>
                <Pack ID="P2609657" Specified="true" nzmt:ctpp_id="50304801000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>393.00</Subsidy>
                  <Price>393.00</Price>
                  <Alternate>393.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290549" Rank="2" Units="sach">
              <Name>Powder (berry) 28 g sachets</Name>
              <Brand ID="B42120529054925">
                <Name>PKU Lophlex Powder</Name>
                <Pack ID="P2593882" Specified="true" nzmt:ctpp_id="50293611000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>936.00</Subsidy>
                  <Price>936.00</Price>
                  <Alternate>936.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290550" Rank="2" Units="sach">
              <Name>Powder (orange) 28 g sachets</Name>
              <Brand ID="B42120529055025">
                <Name>PKU Lophlex Powder</Name>
                <Pack ID="P2593890" Specified="true" nzmt:ctpp_id="50293601000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>936.00</Subsidy>
                  <Price>936.00</Price>
                  <Alternate>936.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290551" Rank="2" Units="sach">
              <Name>Powder (neutral) 28 g sachets</Name>
              <Brand ID="B42120529055125">
                <Name>PKU Lophlex Powder</Name>
                <Pack ID="P2642999" Specified="true" nzmt:ctpp_id="50304431000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>936.00</Subsidy>
                  <Price>936.00</Price>
                  <Alternate>936.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290552" Rank="2" Units="sach">
              <Name>Powder (neutral) 36 g sachets</Name>
              <Brand ID="B42120529055225">
                <Name>PKU Anamix Junior</Name>
                <Pack ID="P2642980" Specified="true" nzmt:ctpp_id="50304441000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>393.00</Subsidy>
                  <Price>393.00</Price>
                  <Alternate>393.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290553" Rank="3" Units="g">
              <Name>Powder (neutral)</Name>
              <Brand ID="B42120529055325">
                <Name>PKU Start</Name>
                <Pack ID="P2668688" Specified="true" OP="true" nzmt:ctpp_id="50328381000117105">
                  <Quantity>400</Quantity>
                  <Subsidy>178.79</Subsidy>
                  <Price>178.79</Price>
                  <Alternate>178.79</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290554" Rank="2" Units="sach">
              <Name>Powder (Neutral), 12.5 g sachets</Name>
              <Brand ID="B42120529055425">
                <Name>PKU Explore 5</Name>
                <Pack ID="P2668602" Specified="true" nzmt:ctpp_id="50328451000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>220.88</Subsidy>
                  <Price>220.88</Price>
                  <Alternate>220.88</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290555" Rank="2" Units="sach">
              <Name>Powder (Raspberry), 25 g sachets</Name>
              <Brand ID="B42120529055525">
                <Name>PKU Explore 10</Name>
                <Pack ID="P2668629" Specified="true" nzmt:ctpp_id="50328431000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>441.75</Subsidy>
                  <Price>441.75</Price>
                  <Alternate>441.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290556" Rank="2" Units="sach">
              <Name>Powder (Orange), 34 g sachets</Name>
              <Brand ID="B42120529055625">
                <Name>PKU Express 20</Name>
                <Pack ID="P2668645" Specified="true" nzmt:ctpp_id="50328411000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>883.50</Subsidy>
                  <Price>883.50</Price>
                  <Alternate>883.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290557" Rank="2" Units="sach">
              <Name>Powder (Neutral), 34 g sachets</Name>
              <Brand ID="B42120529055725">
                <Name>PKU Express 20</Name>
                <Pack ID="P2668661" Specified="true" nzmt:ctpp_id="50328391000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>883.50</Subsidy>
                  <Price>883.50</Price>
                  <Alternate>883.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290558" Rank="2" Units="sach">
              <Name>Powder (Lemon), 34 g sachets</Name>
              <Brand ID="B42120529055825">
                <Name>PKU Express 20</Name>
                <Pack ID="P2668637" Specified="true" nzmt:ctpp_id="50328421000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>883.50</Subsidy>
                  <Price>883.50</Price>
                  <Alternate>883.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290559" Rank="2" Units="sach">
              <Name>Powder (Tropical), 34 g sachets</Name>
              <Brand ID="B42120529055925">
                <Name>PKU Express 20</Name>
                <Pack ID="P2668653" Specified="true" nzmt:ctpp_id="50328401000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>883.50</Subsidy>
                  <Price>883.50</Price>
                  <Alternate>883.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205290560" Rank="2" Units="sach">
              <Name>Powder (Orange), 25 g sachets</Name>
              <Brand ID="B42120529056025">
                <Name>PKU Explore 10</Name>
                <Pack ID="P2668610" Specified="true" nzmt:ctpp_id="50328441000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>441.75</Subsidy>
                  <Price>441.75</Price>
                  <Alternate>441.75</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212054177">
            <Name>Glycomacropeptide and amino acid contains some phenylalanine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421205417725" Rank="2" Units="sach">
              <Name>Powder (Lemonade) 33.4 g sachets</Name>
              <Brand ID="B42120541772525">
                <Name>PKU GMPro Ultra Lemonade</Name>
                <Pack ID="P2657201" Specified="true" nzmt:ctpp_id="50315281000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>936.00</Subsidy>
                  <Price>936.00</Price>
                  <Alternate>936.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417726" Rank="2" Units="sach" Weight="30">
              <Name>Powder (Vanilla) 35 g sachets</Name>
              <Brand ID="B42120541772625">
                <Name>PKU sphere20 Vanilla</Name>
                <Pack ID="P2659808" Specified="true" nzmt:ctpp_id="50318851000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>930.00</Subsidy>
                  <Price>930.00</Price>
                  <Alternate>930.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417727" Rank="2" Units="sach" Weight="30">
              <Name>Powder (Red Berry) 35 g sachets</Name>
              <Brand ID="B42120541772725">
                <Name>PKU sphere20 Red Berry</Name>
                <Pack ID="P2659794" Specified="true" nzmt:ctpp_id="50318841000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>930.00</Subsidy>
                  <Price>930.00</Price>
                  <Alternate>930.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417728" Rank="2" Units="sach">
              <Name>Powder (Lemon) 35 g sachets</Name>
              <Brand ID="B42120541772825">
                <Name>PKU sphere20 Lemon</Name>
                <Pack ID="P2659786" Specified="true" nzmt:ctpp_id="50318881000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>930.00</Subsidy>
                  <Price>930.00</Price>
                  <Alternate>930.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417729" Rank="2" Units="sach">
              <Name>Powder (Chocolate) 35 g sachets</Name>
              <Brand ID="B42120541772925">
                <Name>PKU sphere20 Chocolate</Name>
                <Pack ID="P2659778" Specified="true" nzmt:ctpp_id="50318861000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>930.00</Subsidy>
                  <Price>930.00</Price>
                  <Alternate>930.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417730" Rank="2" Units="sach">
              <Name>Powder (Banana) 35 g sachets</Name>
              <Brand ID="B42120541773025">
                <Name>PKU sphere20 Banana</Name>
                <Pack ID="P2659751" Specified="true" nzmt:ctpp_id="50318871000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>930.00</Subsidy>
                  <Price>930.00</Price>
                  <Alternate>930.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417731" Rank="2" Units="sach">
              <Name>Powder (Smooth) 32 g Sachets</Name>
              <Brand ID="B42120541773125">
                <Name>PKU Build 20 Smooth </Name>
                <Pack ID="P2663384" Specified="true" nzmt:ctpp_id="50321331000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>898.56</Subsidy>
                  <Price>898.56</Price>
                  <Alternate>898.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417732" Rank="2" Units="sach">
              <Name>Powder (Raspberry Lemonade) 32 g Sachets</Name>
              <Brand ID="B42120541773225">
                <Name>PKU Build 20 Raspberry Lemonade</Name>
                <Pack ID="P2663392" Specified="true" nzmt:ctpp_id="50321321000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>898.56</Subsidy>
                  <Price>898.56</Price>
                  <Alternate>898.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417733" Rank="2" Units="sach">
              <Name>Powder (Vanilla) 32 g Sachets</Name>
              <Brand ID="B42120541773325">
                <Name>PKU Build 20 Vanilla</Name>
                <Pack ID="P2663376" Specified="true" nzmt:ctpp_id="50321341000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>898.56</Subsidy>
                  <Price>898.56</Price>
                  <Alternate>898.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417734" Rank="2" Units="sach">
              <Name>Powder (Chocolate) 32 g Sachets</Name>
              <Brand ID="B42120541773425">
                <Name>PKU Build 20 Chocolate</Name>
                <Pack ID="P2663368" Specified="true" nzmt:ctpp_id="50321311000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>898.56</Subsidy>
                  <Price>898.56</Price>
                  <Alternate>898.56</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417735" Rank="2" Units="sach">
              <Name>Powder (Berry), 20 g sachets</Name>
              <Brand ID="B42120541773525">
                <Name>PKU Restore Powder</Name>
                <Pack ID="P2672103" Specified="true" nzmt:ctpp_id="50328561000117107">
                  <Quantity>60</Quantity>
                  <Subsidy>449.28</Subsidy>
                  <Price>449.28</Price>
                  <Alternate>449.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417736" Rank="2" Units="sach">
              <Name>Powder (neutral), 40 g sachets</Name>
              <Brand ID="B42120541773625">
                <Name>Camino Pro Bettermilk</Name>
                <Pack ID="P2672081" Specified="true" nzmt:ctpp_id="50328481000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>673.92</Subsidy>
                  <Price>673.92</Price>
                  <Alternate>673.92</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417737" Rank="10" Units="pack" Weight="250">
              <Name>Liquid (neutral), 250 ml carton</Name>
              <Brand ID="B42120541773725">
                <Name>PKU Glytactin RTD 15</Name>
                <Pack ID="P2672049" Specified="true" OP="true" nzmt:ctpp_id="50328511000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>684.45</Subsidy>
                  <Price>684.45</Price>
                  <Alternate>684.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417738" Rank="10" Units="pack" Weight="250">
              <Name>Liquid (vanilla), 250 ml carton</Name>
              <Brand ID="B42120541773825">
                <Name>PKU Glytactin RTD 15 Lite</Name>
                <Pack ID="P2672065" Specified="true" OP="true" nzmt:ctpp_id="50328531000117100">
                  <Quantity>30</Quantity>
                  <Subsidy>684.45</Subsidy>
                  <Price>684.45</Price>
                  <Alternate>684.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417739" Rank="10" Units="pack" Weight="250">
              <Name>Liquid (chocolate), 250 ml carton</Name>
              <Brand ID="B42120541773925">
                <Name>PKU Glytactin RTD 15</Name>
                <Pack ID="P2672057" Specified="true" OP="true" nzmt:ctpp_id="50328501000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>684.45</Subsidy>
                  <Price>684.45</Price>
                  <Alternate>684.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417740" Rank="2" Units="sach">
              <Name>Powder (Orange), 20 g sachets</Name>
              <Brand ID="B42120541774025">
                <Name>PKU Restore Powder</Name>
                <Pack ID="P2672480" Specified="true" nzmt:ctpp_id="50328571000117102">
                  <Quantity>60</Quantity>
                  <Subsidy>449.28</Subsidy>
                  <Price>449.28</Price>
                  <Alternate>449.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417741" Rank="2" Units="sach">
              <Name>Powder (Neutral), 16 g sachets</Name>
              <Brand ID="B42120541774125">
                <Name>PKU Build 10</Name>
                <Pack ID="P2672030" Specified="true" nzmt:ctpp_id="50328551000117105">
                  <Quantity>30</Quantity>
                  <Subsidy>449.28</Subsidy>
                  <Price>449.28</Price>
                  <Alternate>449.28</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421205417742" Rank="10" Units="pack" Weight="250">
              <Name>Liquid (Coffee Mocha), 250 ml carton</Name>
              <Brand ID="B42120541774225">
                <Name>PKU Glytactin RTD 15 Lite</Name>
                <Pack ID="P2672073" Specified="true" OP="true" nzmt:ctpp_id="50328521000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>684.45</Subsidy>
                  <Price>684.45</Price>
                  <Alternate>684.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421207">
          <Name>Foods</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212072934">
            <Name>Low protein baking mix</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421207293401" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42120729340102">
                <Name>Loprofin Mix</Name>
                <Pack ID="P818402" Specified="true" OP="true" nzmt:ctpp_id="50117501000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>8.22</Subsidy>
                  <Price>8.22</Price>
                  <Alternate>8.22</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212072935">
            <Name>Low protein pasta</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421207293501" Rank="3" Units="g">
              <Name>Low protein rice pasta</Name>
              <Brand ID="B42120729350125">
                <Name>Loprofin</Name>
                <Pack ID="P2218259" Specified="true" OP="true" nzmt:ctpp_id="50034651000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>11.91</Subsidy>
                  <Price>11.91</Price>
                  <Alternate>11.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421207293502" Rank="3" Units="g">
              <Name>Macaroni</Name>
              <Brand ID="B42120729350201">
                <Name>Loprofin</Name>
                <Pack ID="P2304333" Specified="true" OP="true" nzmt:ctpp_id="50045891000117106">
                  <Quantity>250</Quantity>
                  <Subsidy>5.95</Subsidy>
                  <Price>5.95</Price>
                  <Alternate>5.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421207293503" Rank="3" Units="g">
              <Name>Spaghetti</Name>
              <Brand ID="B42120729350301">
                <Name>Loprofin</Name>
                <Pack ID="P475963" Specified="true" OP="true" nzmt:ctpp_id="50089661000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>11.91</Subsidy>
                  <Price>11.91</Price>
                  <Alternate>11.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421207293504" Rank="3" Units="g">
              <Name>Spirals</Name>
              <Brand ID="B42120729350401">
                <Name>Loprofin</Name>
                <Pack ID="P487171" Specified="true" OP="true" nzmt:ctpp_id="50091481000117103">
                  <Quantity>500</Quantity>
                  <Subsidy>11.91</Subsidy>
                  <Price>11.91</Price>
                  <Alternate>11.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421207293525" Rank="3" Units="g">
              <Name>Lasagne</Name>
              <Brand ID="B42120729352525">
                <Name>Loprofin</Name>
                <Pack ID="P2304309" Specified="true" OP="true" nzmt:ctpp_id="50045861000117100">
                  <Quantity>250</Quantity>
                  <Subsidy>5.95</Subsidy>
                  <Price>5.95</Price>
                  <Alternate>5.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421207293526" Rank="3" Units="g">
              <Name>Penne</Name>
              <Brand ID="B42120729352625">
                <Name>Loprofin</Name>
                <Pack ID="P2304325" Specified="true" OP="true" nzmt:ctpp_id="50045881000117108">
                  <Quantity>500</Quantity>
                  <Subsidy>11.91</Subsidy>
                  <Price>11.91</Price>
                  <Alternate>11.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421207293527" Rank="3" Units="g">
              <Name>Animal shapes</Name>
              <Brand ID="B42120729352725">
                <Name>Loprofin</Name>
                <Pack ID="P2304317" Specified="true" OP="true" nzmt:ctpp_id="50045871000117105">
                  <Quantity>500</Quantity>
                  <Subsidy>11.91</Subsidy>
                  <Price>11.91</Price>
                  <Alternate>11.91</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421212">
          <Name>Supplements for Tyrosinaemia</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212124184">
            <Name>Aminoacid formula without phenylalanine and tyrosine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421212418425" Rank="2" Units="sach">
              <Name>Powder (Neutral), 12.5 g sachets</Name>
              <Brand ID="B42121241842525">
                <Name>TYR Explore 5</Name>
                <Pack ID="P2668696" Specified="true" nzmt:ctpp_id="50328291000117104">
                  <Quantity>30</Quantity>
                  <Subsidy>349.65</Subsidy>
                  <Price>349.65</Price>
                  <Alternate>349.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212124185">
            <Name>Glycomacropeptide and amino acid contains some tyrosine and phenylalanine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421212418525" Rank="2" Units="sach">
              <Name>Powder (Red Berry), 35 g sachets</Name>
              <Brand ID="B42121241852525">
                <Name>TYR Sphere 20</Name>
                <Pack ID="P2668726" Specified="true" nzmt:ctpp_id="50317301000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>1398.60</Subsidy>
                  <Price>1398.60</Price>
                  <Alternate>1398.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421212418526" Rank="2" Units="sach">
              <Name>Powder (Vanilla), 35 g sachets</Name>
              <Brand ID="B42121241852625">
                <Name>TYR Sphere 20</Name>
                <Pack ID="P2668734" Specified="true" nzmt:ctpp_id="50328591000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>1398.60</Subsidy>
                  <Price>1398.60</Price>
                  <Alternate>1398.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421214">
          <Name>Supplements for Organic Acidaemias</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212144186">
            <Name>Aminoacid formula without methionine, threonine and valine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421214418625" Rank="2" Units="sach">
              <Name>Powder, 12.5 g sachets</Name>
              <Brand ID="B42121441862525">
                <Name>MMA/PA Explore 5</Name>
                <Pack ID="P2668564" Specified="true" nzmt:ctpp_id="50328241000117106">
                  <Quantity>30</Quantity>
                  <Subsidy>349.65</Subsidy>
                  <Price>349.65</Price>
                  <Alternate>349.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421214418626" Rank="2" Units="sach">
              <Name>Powder, 25 g sachets</Name>
              <Brand ID="B42121441862625">
                <Name>MMA/PA Express 15</Name>
                <Pack ID="P2668572" Specified="true" nzmt:ctpp_id="50328251000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>1048.95</Subsidy>
                  <Price>1048.95</Price>
                  <Alternate>1048.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421215">
          <Name>Supplements for Glutaric Aciduria type 1</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212154187">
            <Name>Aminoacid formula without lysine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421215418725" Rank="2" Units="sach">
              <Name>Powder, 12.5 g sachets</Name>
              <Brand ID="B42121541872525">
                <Name>GA Explore 5</Name>
                <Pack ID="P2668521" Specified="true" nzmt:ctpp_id="50328281000117102">
                  <Quantity>30</Quantity>
                  <Subsidy>349.65</Subsidy>
                  <Price>349.65</Price>
                  <Alternate>349.65</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421215418726" Rank="2" Units="sach">
              <Name>Powder, 25 g sachets</Name>
              <Brand ID="B42121541872625">
                <Name>GA Express 15</Name>
                <Pack ID="P2671247" Specified="true" nzmt:ctpp_id="50327611000117109">
                  <Quantity>30</Quantity>
                  <Subsidy>1048.95</Subsidy>
                  <Price>1048.95</Price>
                  <Alternate>1048.95</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421218">
          <Name>Supplements for Glycogen Storage Disease</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212184188">
            <Name>High amylopectin corn-starch</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421218418825" Rank="2" Units="sach">
              <Name>Powder, 60 g sachets</Name>
              <Brand ID="B42121841882525">
                <Name>Glycosade</Name>
                <Pack ID="P2456834" Specified="true" nzmt:ctpp_id="50326571000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>241.62</Subsidy>
                  <Price>241.62</Price>
                  <Alternate>241.62</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421220">
          <Name>Single dose amino acids</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4212204144">
            <Name>Arginine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421220414430" Rank="2" Units="sach">
              <Name>Powder, 4 g sachets</Name>
              <Brand ID="B42122041443025">
                <Name>Arginine2000</Name>
                <Pack ID="P2668750" Specified="true" nzmt:ctpp_id="50302871000117108">
                  <Quantity>30</Quantity>
                  <Subsidy>211.45</Subsidy>
                  <Price>211.45</Price>
                  <Alternate>211.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212204189">
            <Name>Phenylalanine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421220418925" Rank="2" Units="sach">
              <Name>Powder, 4 g sachets</Name>
              <Brand ID="B42122041892525">
                <Name>Phenylalanine50</Name>
                <Pack ID="P2474557" Specified="true" nzmt:ctpp_id="50326501000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>141.05</Subsidy>
                  <Price>141.05</Price>
                  <Alternate>141.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212204190">
            <Name>Valine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421220419025" Rank="2" Units="sach">
              <Name>Powder, 4 g sachets</Name>
              <Brand ID="B42122041902525">
                <Name>Valine50</Name>
                <Pack ID="P2514079" Specified="true" nzmt:ctpp_id="50327661000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>141.05</Subsidy>
                  <Price>141.05</Price>
                  <Alternate>141.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212204191">
            <Name>Isoleucine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421220419125" Rank="2" Units="sach">
              <Name>Powder, 4 g sachets</Name>
              <Brand ID="B42122041912525">
                <Name>Isoleucine50</Name>
                <Pack ID="P2514060" Specified="true" nzmt:ctpp_id="50326031000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>141.05</Subsidy>
                  <Price>141.05</Price>
                  <Alternate>141.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212204192">
            <Name>Leucine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421220419225" Rank="2" Units="sach">
              <Name>Powder, 4 g sachets</Name>
              <Brand ID="B42122041922525">
                <Name>Leucine100</Name>
                <Pack ID="P2622572" Specified="true" nzmt:ctpp_id="50292431000117101">
                  <Quantity>30</Quantity>
                  <Subsidy>141.05</Subsidy>
                  <Price>141.05</Price>
                  <Alternate>141.05</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212204193">
            <Name>Tyrosine</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421220419325" Rank="2" Units="sach">
              <Name>Powder, 4 g sachets</Name>
              <Brand ID="B42122041932525">
                <Name>Tyrosine1000</Name>
                <Pack ID="P2668742" Specified="true" nzmt:ctpp_id="50328371000117107">
                  <Quantity>30</Quantity>
                  <Subsidy>211.45</Subsidy>
                  <Price>211.45</Price>
                  <Alternate>211.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4212204194">
            <Name>Citrulline</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2300"/>
            <Formulation ID="F421220419425" Rank="2" Units="sach">
              <Name>Powder, 4 g sachets</Name>
              <Brand ID="B42122041942525">
                <Name>Citrulline1000</Name>
                <Pack ID="P2632330" Specified="true" nzmt:ctpp_id="50297711000117103">
                  <Quantity>30</Quantity>
                  <Subsidy>211.45</Subsidy>
                  <Price>211.45</Price>
                  <Alternate>211.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A4218">
        <Name>Infant Formulae</Name>
        <ATC3 ID="A421804">
          <Name>For Williams Syndrome</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Request To="HealthPAC" For="Subsidy" Form="SA1110">
            <Title>
              <range>Infant Formulae - For Williams Syndrome<instance>Locasol</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Indication">The patient is an infant suffering from Williams Syndrome and associated hypercalcaemia</ci>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
            <Case When="Renewal" Form="SA0601 SA1110">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <apply>
                  <and/>
                  <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci>
                  <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci>
                </apply>
              </math>
              <Applicant>dietitian</Applicant>
              <Applicant>relevant specialist</Applicant>
              <Applicant>vocationally registered general practitioner</Applicant>
              <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
              <Term Measure="year">1</Term>
            </Case>
          </Request>
          <Chemical ID="C4218042924">
            <Name>Low calcium infant formula</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1110"/>
            <Formulation ID="F421804292401" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42180429240101">
                <Name>Locasol</Name>
                <Pack ID="P2601451" Specified="true" OP="true" nzmt:ctpp_id="50285741000117105">
                  <Quantity>400</Quantity>
                  <Subsidy>44.40</Subsidy>
                  <Price>44.40</Price>
                  <Alternate>44.40</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421806">
          <Name>Gastrointestinal and Other Malabsorptive Problems</Name>
          <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
          <Chemical ID="C4218062945">
            <Name>Amino acid formula</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA2092"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA2092">
              <Title>
                <range>Amino acid formula<instance>Alfamino Junior</instance><instance>Elecare</instance><instance>Neocate</instance></range>
              </Title>
              <Case When="Initial application" Category="Infants under 12 months of age">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <ci type="logical" class="Indication">History of anaphylaxis to cowâ€™s milk protein
                    formula or dairy products</ci>
                    <ci type="logical" class="Indication">Eosinophilic oesophagitis</ci>
                    <ci type="logical" class="Indication">Ultra-short gut</ci>
                    <ci type="logical" class="Indication">Severe Immune deficiency</ci>
                    <ci type="logical" class="Indication">Extensively hydrolysed formula has been
                    trialled in an inpatient setting and is clinically inappropriate</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Extensively hydrolysed formula has been
                        reasonably trialled for 2-4 weeks and is inappropriate due to documented
                        severe intolerance or allergy or malabsorption</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">The patient has a valid Special
                            Authority approval for extensively hydrolysed formula: approval
                            number</ci>
                        <ci type="logical" class="Indication">Patient has IgE mediated allergy</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="Children 12 months of age and over">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a paediatrician, paediatric
                        gastroenterologist or paediatric immunologist</ci>
                      <ci type="logical" class="Indication">Applicant is a dietitian and confirms that
                        a paediatrician, paediatric gastroenterologist or paediatric immunologist
                        has been consulted within the last 12 months and has recommended treatment
                        for the patient</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">History of anaphylaxis to cowâ€™s milk
                        protein formula or dairy products</ci>
                      <ci type="logical" class="Indication">Eosinophilic oesophagitis</ci>
                      <ci type="logical" class="Indication">Ultra-short gut</ci>
                      <ci type="logical" class="Indication">Severe Immune deficiency</ci>
                      <ci type="logical" class="Indication">Extensively hydrolysed formula has been
                        trialled in an inpatient setting and is clinically inappropriate</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Extensively hydrolysed formula has
                            been reasonably trialled for 2-4 weeks and is inappropriate due to
                            documented severe intolerance or allergy or malabsorption</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">The patient has a valid Special
                                Authority approval for extensively hydrolysed formula: approval
                                number</ci>
                          <ci type="logical" class="Indication">Patient has IgE mediated
                                allergy</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>paediatric gastroenterologist</Applicant>
                <Applicant>paediatric immunologist</Applicant>
                <Applicant Referring="paediatrician, paediatric gastroenterologist or paediatric immunologist">dietitian</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Infants up to 12 months of age" Form="SA1111 SA1219 SA1940 SA2092">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has IgE mediated allergy</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Patient remains allergic to cowâ€™s
                            milk</ci>
                        <ci type="logical" class="Indication">An assessment as to whether the infant
                            can be transitioned to a cowâ€™s milk protein, soy or extensively
                            hydrolysed infant formula has been undertaken</ci>
                        <ci type="logical" class="Indication">The outcome of the assessment is that
                            the infant continues to require an amino acid infant formula</ci>
                        <ci type="logical" class="Indication">Amino acid formula is required for a
                            nutritional deficit</ci>
                        <ci type="logical" class="Indication">It has been more than three months
                            from the previous approval</ci>
                      </apply>
                    </apply>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Patient has non IgE mediated severe
                        gastrointestinal intolerance (including eosinophilic oesophagitis,
                        ultra-short gut and severe immune deficiency)</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">An assessment as to whether the infant
                            can be transitioned to a cowâ€™s milk protein, soy, or extensively
                            hydrolysed infant formula has been undertaken</ci>
                        <ci type="logical" class="Indication">The outcome of the assessment is that
                            the infant continues to require an amino acid infant formula</ci>
                        <ci type="logical" class="Indication">Amino acid formula is required for a
                            nutritional deficit</ci>
                        <ci type="logical" class="Indication">It has been more than three months
                            from the previous approval</ci>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>any relevant practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Renewal" Category="Children 12 months of age and over" Form="SA1111 SA1219 SA1940 SA2092">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Applicant is a paediatrician, paediatric
                        gastroenterologist or paediatric immunologist</ci>
                      <ci type="logical" class="Indication">Applicant is a dietitian and confirms that
                        a paediatrician, paediatric gastroenterologist or paediatric immunologist
                        has been consulted within the last 12 months and has recommended treatment
                        for the patient</ci>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">History of anaphylaxis to cowâ€™s milk
                        protein formula or dairy products</ci>
                      <ci type="logical" class="Indication">Eosinophilic oesophagitis</ci>
                      <ci type="logical" class="Indication">Ultra-short gut</ci>
                      <ci type="logical" class="Indication">Severe Immune deficiency</ci>
                      <ci type="logical" class="Indication">Extensively hydrolysed formula has been
                        trialled in an inpatient setting and is clinically inappropriate</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">Extensively hydrolysed formula has
                            been reasonably trialled for 2-4 weeks and is inappropriate due to
                            documented severe intolerance or allergy or malabsorption</ci>
                        <apply>
                          <or/>
                          <ci type="logical" class="Indication">The patient has a valid Special
                                Authority approval for extensively hydrolysed formula: approval
                                number</ci>
                          <ci type="logical" class="Indication">Patient has IgE mediated
                                allergy</ci>
                        </apply>
                      </apply>
                    </apply>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>paediatric gastroenterologist</Applicant>
                <Applicant>paediatric immunologist</Applicant>
                <Applicant Referring="paediatrician, paediatric gastroenterologist or paediatric immunologist">dietitian</Applicant>
                <Term Measure="month">6</Term>
              </Case>
              <Case When="Initial application" Category="for patients who have a current funding under Special Authority form SA1557">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has a valid Special Authority approval
                    for extensively hydrolysed formula (SA1557)</ci>
                    <ci type="logical" class="Indication">Extensively hydrolysed formula (Aptamil Gold+
                    Pepti Junior, AllerPro SYNEO 1 and 2) is unable to be supplied at this time</ci>
                    <ci type="logical">The approval only applies to funded dispensings of Neocate Gold
                    and Neocate Syneo</ci>
                  </apply>
                </math>
                <Applicant>dietitian</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Applicant>vocationally registered general practitioner</Applicant>
                <Term Measure="month">3</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>This criteria is short term funding to cover an out-of-stock situation on some
                extensively hydrolysed formula powder funded under Special Authority form SA1557.
                There is no renewal criteria under this restriction.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F421806294501" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42180629450126">
                <Name>Alfamino Junior</Name>
                <Pack ID="P2634848" Specified="true" OP="true" nzmt:ctpp_id="50237861000117101">
                  <Quantity>400</Quantity>
                  <Subsidy>43.60</Subsidy>
                  <Price>43.60</Price>
                  <Alternate>43.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629450127">
                <Name>Alfamino</Name>
                <Pack ID="P2632187" Specified="true" OP="true" nzmt:ctpp_id="50290391000117106">
                  <Quantity>400</Quantity>
                  <Subsidy>43.60</Subsidy>
                  <Price>43.60</Price>
                  <Alternate>43.60</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421806294525" Rank="3" Units="g">
              <Name>Powder (unflavoured)</Name>
              <Brand ID="B42180629452526">
                <Name>Elecare</Name>
                <Pack ID="P2372568" Specified="true" OP="true" nzmt:ctpp_id="50288021000117107">
                  <Quantity>400</Quantity>
                  <Subsidy>65.72</Subsidy>
                  <Price>65.72</Price>
                  <Alternate>65.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629452527">
                <Name>Elecare LCP</Name>
                <Pack ID="P2372541" Specified="true" OP="true" nzmt:ctpp_id="50288031000117105">
                  <Quantity>400</Quantity>
                  <Subsidy>65.72</Subsidy>
                  <Price>65.72</Price>
                  <Alternate>65.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629452528">
                <Name>Neocate Gold</Name>
                <Pack ID="P2400464" Specified="true" OP="true" nzmt:ctpp_id="50129631000117102">
                  <Quantity>400</Quantity>
                  <Subsidy>53.00</Subsidy>
                  <Price>53.00</Price>
                  <Alternate>53.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629452529">
                <Name>Neocate Junior Unflavoured</Name>
                <Pack ID="P2530252" Specified="true" OP="true" nzmt:ctpp_id="50248181000117102">
                  <Quantity>400</Quantity>
                  <Subsidy>53.00</Subsidy>
                  <Price>53.00</Price>
                  <Alternate>53.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629452530">
                <Name>Neocate SYNEO</Name>
                <Pack ID="P2555271" OP="true" nzmt:ctpp_id="50259261000117109">
                  <Quantity>400</Quantity>
                  <Subsidy>53.00</Subsidy>
                  <Price>53.00</Price>
                  <Alternate>53.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2587955" Specified="true" OP="true" nzmt:ctpp_id="50276781000117101">
                  <Quantity>400</Quantity>
                  <Subsidy>53.00</Subsidy>
                  <Price>53.00</Price>
                  <Alternate>53.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421806294527" Rank="3" Units="g">
              <Name>Powder (vanilla)</Name>
              <Brand ID="B42180629452725">
                <Name>Elecare</Name>
                <Pack ID="P2372533" Specified="true" OP="true" nzmt:ctpp_id="50288041000117102">
                  <Quantity>400</Quantity>
                  <Subsidy>65.72</Subsidy>
                  <Price>65.72</Price>
                  <Alternate>65.72</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629452727">
                <Name>Neocate Junior Vanilla</Name>
                <Pack ID="P2573008" Specified="true" OP="true" nzmt:ctpp_id="50268981000117108">
                  <Quantity>400</Quantity>
                  <Subsidy>53.00</Subsidy>
                  <Price>53.00</Price>
                  <Alternate>53.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4218062946">
            <Name>Extensively hydrolysed formula</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1557"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1557">
              <Title>
                <range>Extensively hydrolysed formula</range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <or/>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content</ci>
                      <apply>
                        <or/>
                        <ci type="logical" class="Indication">Soy milk formula has been reasonably trialled without resolution of symptoms</ci>
                        <ci type="logical" class="Indication">Soy milk formula is considered clinically inappropriate or contraindicated</ci>
                      </apply>
                    </apply>
                    <ci type="logical" class="Indication">Severe malabsorption</ci>
                    <ci type="logical" class="Indication">Short bowel syndrome</ci>
                    <ci type="logical" class="Indication">Intractable diarrhoea</ci>
                    <ci type="logical" class="Indication">Biliary atresia</ci>
                    <ci type="logical" class="Indication">Cholestatic liver diseases causing malsorption</ci>
                    <ci type="logical" class="Indication">Cystic fibrosis</ci>
                    <ci type="logical" class="Indication">Proven fat malabsorption</ci>
                    <ci type="logical" class="Indication">Severe intestinal motility disorders causing significant malabsorption</ci>
                    <ci type="logical" class="Indication">Intestinal failure</ci>
                    <apply>
                      <and/>
                      <ci type="logical" class="Indication">For step down from Amino Acid Formula</ci>
                      <ci type="logical" class="Indication">The infant is currently receiving funded amino acid formula</ci>
                      <ci type="logical" class="Indication">The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula</ci>
                      <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>dietitian</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Applicant>vocationally registered general practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1112 SA1220 SA1380 SA1557">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken</ci>
                    <ci type="logical" class="Indication">The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula</ci>
                    <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted</ci>
                  </apply>
                </math>
                <Applicant>dietitian</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Applicant>vocationally registered general practitioner</Applicant>
                <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F421806294601" Rank="3" Units="g">
              <Name>Powder</Name>
              <Brand ID="B42180629460130">
                <Name>Allerpro Syneo 1</Name>
                <Pack ID="P2641283" Specified="true" OP="true" nzmt:ctpp_id="50303891000117100">
                  <Quantity>900</Quantity>
                  <Subsidy>30.42</Subsidy>
                  <Price>30.42</Price>
                  <Alternate>30.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629460131">
                <Name>Allerpro Syneo 2</Name>
                <Pack ID="P2641291" Specified="true" OP="true" nzmt:ctpp_id="50303901000117101">
                  <Quantity>900</Quantity>
                  <Subsidy>30.42</Subsidy>
                  <Price>30.42</Price>
                  <Alternate>30.42</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42180629460132">
                <Name>Pepti-Junior</Name>
                <Pack ID="P2641305" Specified="true" OP="true" nzmt:ctpp_id="50004861000117109">
                  <Quantity>450</Quantity>
                  <Subsidy>15.21</Subsidy>
                  <Price>15.21</Price>
                  <Alternate>15.21</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4218064130">
            <Name>Enteral liquid peptide formula</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1953"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1953">
              <Title>
                <range>Enteral liquid peptide formula<instance>Nutrini Peptisorb</instance><instance>Nutrini Peptisorb Energy</instance></range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable</ci>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">Severe malabsorption</ci>
                      <ci type="logical" class="Indication">Short bowel syndrome</ci>
                      <ci type="logical" class="Indication">Intractable diarrhoea</ci>
                      <ci type="logical" class="Indication">Biliary atresia</ci>
                      <ci type="logical" class="Indication">Cholestatic liver diseases causing malabsorption</ci>
                      <ci type="logical" class="Indication">Cystic fibrosis</ci>
                      <ci type="logical" class="Indication">Proven fat malabsorption</ci>
                      <ci type="logical" class="Indication">Severe intestinal motility disorders causing significant malabsorption</ci>
                      <ci type="logical" class="Indication">Intestinal failure</ci>
                      <apply>
                        <and/>
                        <ci type="logical" class="Indication">The patient is currently receiving funded amino acid formula</ci>
                        <ci type="logical" class="Indication">The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula</ci>
                      </apply>
                    </apply>
                    <apply>
                      <or/>
                      <ci type="logical" class="Indication">A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable</ci>
                      <ci type="logical" class="Indication">For step down from intravenous nutrition</ci>
                    </apply>
                  </apply>
                </math>
                <Applicant>dietitian</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Applicant>vocationally registered general practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>A reasonable trial is defined as a 2-4 week trial.</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1953">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken</ci>
                    <ci type="logical" class="Indication">The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula</ci>
                    <ci type="logical" class="Indication">General practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted</ci>
                  </apply>
                </math>
                <Applicant>dietitian</Applicant>
                <Applicant>relevant specialist</Applicant>
                <Applicant>vocationally registered general practitioner</Applicant>
                <Applicant Referring="dietitian, relevant specialist or vocationally registered general practitioner">general practitioner</Applicant>
                <Term Measure="month">6</Term>
              </Case>
            </Request>
            <Formulation ID="F421806413025" Rank="3" Units="ml">
              <Name>Liquid 1 kcal/ml</Name>
              <Brand ID="B42180641302525">
                <Name>Nutrini Peptisorb</Name>
                <Pack ID="P2632942" Specified="true" OP="true" nzmt:ctpp_id="50280601000117109">
                  <Quantity>500</Quantity>
                  <Subsidy>10.45</Subsidy>
                  <Price>10.45</Price>
                  <Alternate>10.45</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F421806413026" Rank="3" Units="ml">
              <Name>Liquid 1.5 kcal/ml</Name>
              <Brand ID="B42180641302625">
                <Name>Nutrini Peptisorb Energy</Name>
                <Pack ID="P2594897" Specified="true" OP="true" nzmt:ctpp_id="50280611000117107">
                  <Quantity>500</Quantity>
                  <Subsidy>15.68</Subsidy>
                  <Price>15.68</Price>
                  <Alternate>15.68</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
        <ATC3 ID="A421812">
          <Name>Fluid Restricted</Name>
          <Chemical ID="C4218124095">
            <Name>Paediatric oral/enteral feed 1 kcal/ml</Name>
            <Rule Type="Dispensary" Attribute="HP3" NonPrinting="true"/>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1698"/>
            <Request To="HealthPAC" For="Subsidy" Form="SA1698">
              <Title>
                <range>Paediatric oral/enteral feed 1 kcal/ml<instance>Infatrini</instance></range>
              </Title>
              <Case When="Initial application">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth</ci>
                    <ci type="logical" class="Indication">Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula</ci>
                    <ci type="logical" class="Indication">Patient is under 18 months of age or weighs less than 8 kg</ci>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>dietitian</Applicant>
                <Applicant Referring="paediatrician or dietitian">general practitioner</Applicant>
                <Term Measure="month">12</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled
                appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.</p>
                </div>
              </Case>
              <Case When="Renewal" Form="SA1698">
                <math xmlns="http://www.w3.org/1998/Math/MathML">
                  <apply>
                    <and/>
                    <ci type="logical" class="Indication">Patient continues to be fluid restricted or volume intolerant and has faltering growth</ci>
                    <ci type="logical" class="Indication">Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula</ci>
                    <ci type="logical" class="Indication">Patient is under 18 months of age or weighs less than 8 kg</ci>
                  </apply>
                </math>
                <Applicant>paediatrician</Applicant>
                <Applicant>dietitian</Applicant>
                <Applicant Referring="paediatrician or dietitian">general practitioner</Applicant>
                <Term Measure="month">6</Term>
                <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                  <p>'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled
                appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.</p>
                </div>
              </Case>
            </Request>
            <Formulation ID="F421812409525" Rank="3" Units="ml">
              <Name>Liquid</Name>
              <Brand ID="B42181240952525">
                <Name>Infatrini</Name>
                <Pack ID="P2537923" Specified="true" OP="true" nzmt:ctpp_id="50251101000117101">
                  <Quantity>125</Quantity>
                  <Subsidy>2.35</Subsidy>
                  <Price>2.35</Price>
                  <Alternate>2.35</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A4225">
        <Name>Ketogenic Diet</Name>
        <ATC3 ID="A422501">
          <Name>Ketogenic Diet</Name>
          <Request To="HealthPAC" For="Subsidy" Form="SA1197">
            <Title>
              <range>High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate <instance>KetoCal</instance></range>
            </Title>
            <Case When="Initial application">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Trial">The patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet</ci>
              </math>
              <Applicant>metabolic physician</Applicant>
              <Applicant>paediatric neurologist</Applicant>
              <Term Measure="month">3</Term>
            </Case>
            <Case When="Renewal" Form="SA1197">
              <math xmlns="http://www.w3.org/1998/Math/MathML">
                <ci type="logical" class="Trial">The patient is on a ketogenic diet and the patient is benefiting from the diet</ci>
              </math>
              <Applicant>metabolic physician</Applicant>
              <Applicant>paediatric neurologist</Applicant>
              <Term Measure="year">2</Term>
            </Case>
          </Request>
          <Chemical ID="C4225013947">
            <Name>High fat low carbohydrate formula</Name>
            <Rule Attribute="Subsidy" Type="Special" xlink:href="SA1197"/>
            <Formulation ID="F422501394725" Rank="3" Units="g" Weight="300">
              <Name>Powder (vanilla)</Name>
              <Brand ID="B42250139472525">
                <Name>KetoCal 4:1</Name>
                <Pack ID="P2639386" Specified="true" OP="true" nzmt:ctpp_id="50303921000117109">
                  <Quantity>300</Quantity>
                  <Subsidy>35.50</Subsidy>
                  <Price>35.50</Price>
                  <Alternate>35.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F422501394726" Rank="3" Units="g">
              <Name>Powder (unflavoured)</Name>
              <Brand ID="B42250139472625">
                <Name>Ketocal 3:1</Name>
                <Pack ID="P2610590" Specified="true" OP="true" nzmt:ctpp_id="50291281000117106">
                  <Quantity>300</Quantity>
                  <Subsidy>35.50</Subsidy>
                  <Price>35.50</Price>
                  <Alternate>35.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
              <Brand ID="B42250139472626">
                <Name>KetoCal 4:1</Name>
                <Pack ID="P2639378" Specified="true" OP="true" nzmt:ctpp_id="50303911000117103">
                  <Quantity>300</Quantity>
                  <Subsidy>35.50</Subsidy>
                  <Price>35.50</Price>
                  <Alternate>35.50</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
  </Section>
  <Section ID="I">
    <Name>National Immunisation Schedule</Name>
    <ATC1 ID="A45">
      <Name>National Immunisation Schedule</Name>
      <ATC2 ID="A4525">
        <Name>Vaccinations</Name>
        <ATC3 ID="A452501">
          <Name>Vaccinations</Name>
          <Chemical ID="C4525013804">
            <Name>Influenza vaccine</Name>
            <Formulation ID="F452501380426" Rank="4" Units="inj" Weight="60">
              <Name>Inj 60 mcg in 0.5 ml syringe  (quadrivalent vaccine)</Name>
              <Rule Type="FormMax" Value="1" Attribute="Rx"/>
              <Rule Type="FormReqd" Attribute="Rx"/>
              <Rule Type="MaxCoPayment" Value="0"/>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <ol style="list-style-type: upper-alpha">
                  <li>
                    <h4>INFLUENZA VACCINE</h4>
                    <p>is available each year for patients who meet the following
                criteria, as set by Pharmac:</p>
                    <ol style="list-style-type: lower-alpha">
                      <li>
                        <p>all people 65 years of age and over; or</p>
                      </li>
                      <li>
                        <p>people under 65 years of age who:</p>
                        <ol style="list-style-type: lower-roman">
                          <li>
                            <p>have any of the following cardiovascular diseases:</p>
                            <ol style="list-style-type: lower-alpha">
                              <li>
                                <p>ischaemic heart disease, or</p>
                              </li>
                              <li>
                                <p>congestive heart failure, or</p>
                              </li>
                              <li>
                                <p>rheumatic heart disease, or</p>
                              </li>
                              <li>
                                <p>congenital heart disease, or</p>
                              </li>
                              <li>
                                <p>cerebo-vascular disease; or</p>
                              </li>
                            </ol>
                          </li>
                          <li>
                            <p>have either of the following chronic respiratory diseases:</p>
                            <ol style="list-style-type: lower-alpha">
                              <li>
                                <p>asthma, if on a regular preventative therapy, or</p>
                              </li>
                              <li>
                                <p>other chronic respiratory disease with impaired lung
                                        function; or</p>
                              </li>
                            </ol>
                          </li>
                          <li>
                            <p>have diabetes; or</p>
                          </li>
                          <li>
                            <p>have chronic renal disease; or</p>
                          </li>
                          <li>
                            <p>have any cancer, excluding basal and squamous skin cancers if not
                                invasive; or</p>
                          </li>
                          <li>
                            <p>have any of the following other conditions:</p>
                            <ol style="list-style-type: lower-alpha">
                              <li>
                                <p>autoimmune disease, or</p>
                              </li>
                              <li>
                                <p>immune suppression or immune deficiency, or</p>
                              </li>
                              <li>
                                <p>HIV, or</p>
                              </li>
                              <li>
                                <p>transplant recipients, or</p>
                              </li>
                              <li>
                                <p>neuromuscular and CNS diseases/disorders, or</p>
                              </li>
                              <li>
                                <p>haemoglobinopathies, or</p>
                              </li>
                              <li>
                                <p>are children on long term aspirin, or</p>
                              </li>
                              <li>
                                <p>have a cochlear implant, or</p>
                              </li>
                              <li>
                                <p>errors of metabolism at risk of major metabolic
                                        decompensation, or</p>
                              </li>
                              <li>
                                <p>pre and post splenectomy, or</p>
                              </li>
                              <li>
                                <p>Down syndrome, or</p>
                              </li>
                            </ol>
                          </li>
                          <li>
                            <p>are pregnant; or</p>
                          </li>
                        </ol>
                      </li>
                      <li>
                        <p>children 4 years of age and under who have been hospitalised for
                        respiratory illness or have a history of significant respiratory
                        illness; or</p>
                      </li>
                      <li>
                        <p>people under 65 years of age who:</p>
                        <ol style="list-style-type: lower-roman">
                          <li>
                            <p>have any of the following serious mental health conditions:</p>
                            <ol style="list-style-type: lower-alpha">
                              <li>
                                <p>schizophrenia, or</p>
                              </li>
                              <li>
                                <p>major depressive disorder, or</p>
                              </li>
                              <li>
                                <p>bipolar disorder, or</p>
                              </li>
                              <li>
                                <p>schizoaffective disorder, or</p>
                              </li>
                            </ol>
                          </li>
                          <li>
                            <p>are currently accessing secondary or tertiary mental health and addiction services; or</p>
                          </li>
                        </ol>
                      </li>
                    </ol>
                    <p>Unless meeting the criteria set out above, the following conditions are excluded from
                funding:</p>
                    <ol style="list-style-type: lower-alpha">
                      <li>
                        <p>asthma not requiring regular preventative therapy, </p>
                      </li>
                      <li>
                        <p>hypertension and/or dyslipidaemia without evidence of end-organ disease.</p>
                      </li>
                    </ol>
                  </li>
                  <li>
                    <p>Contractors will be entitled to claim payment for the supply of
                influenza vaccine to patients eligible under the above criteria pursuant to their
                contract with Te Whatu Ora for subsidised immunisation, and they may only do so in
                respect of the influenza vaccine listed in the Pharmaceutical Schedule. </p>
                  </li>
                  <li>
                    <p>Contractors may only claim for patient populations within the criteria that are
                covered by their contract, which may be a sub-set of the population described in
                paragraph A above.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B45250138042633">
                <Name>Influvac Tetra (2024 formulation)</Name>
                <Pack ID="P2670143" Specified="true" nzmt:ctpp_id="50328191000117106">
                  <Quantity>10</Quantity>
                  <Subsidy>120.00</Subsidy>
                  <Price>120.00</Price>
                  <Alternate>120.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013953">
            <Name>Hepatitis B recombinant vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Formulation ID="F452501395328" Rank="4" Units="inj" Weight="20">
              <Name>Inj 20 mcg per 1 ml prefilled syringe</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Funded for patients meeting any of the following criteria:</p>
                <ol style="list-style-type: decimal">
                  <li>
                    <p>for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or</p>
                  </li>
                  <li>
                    <p>for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or </p>
                  </li>
                  <li>
                    <p>for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or </p>
                  </li>
                  <li>
                    <p>for HIV positive patients; or </p>
                  </li>
                  <li>
                    <p>for hepatitis C positive patients; or </p>
                  </li>
                  <li>
                    <p>for patients following non-consensual sexual intercourse; or </p>
                  </li>
                  <li>
                    <p>for patients following immunosuppression; or </p>
                  </li>
                  <li>
                    <p>for solid organ transplant patients; or</p>
                  </li>
                  <li>
                    <p>for post-haematopoietic stem cell transplant (HSCT) patients; or</p>
                  </li>
                  <li>
                    <p>following needle stick injury; or</p>
                  </li>
                  <li>
                    <p>for dialysis patients; or</p>
                  </li>
                  <li>
                    <p>for liver or kidney transplant patients.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B45250139532825" SoleSupply="2024-06-30">
                <Name>Engerix-B</Name>
                <Pack ID="P2534533" Specified="true" nzmt:ctpp_id="50152361000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F452501395329" Rank="4" Units="inj" Weight="10">
              <Name>Inj 10 mcg per 0.5 ml prefilled syringe</Name>
              <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
                <p>Funded for patients meeting any of the following criteria:</p>
                <ol style="list-style-type: decimal">
                  <li>
                    <p>for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or</p>
                  </li>
                  <li>
                    <p>for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or </p>
                  </li>
                  <li>
                    <p>for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or </p>
                  </li>
                  <li>
                    <p>for HIV positive patients; or </p>
                  </li>
                  <li>
                    <p>for hepatitis C positive patients; or </p>
                  </li>
                  <li>
                    <p>for patients following non-consensual sexual intercourse; or </p>
                  </li>
                  <li>
                    <p>for patients following immunosuppression; or </p>
                  </li>
                  <li>
                    <p>for solid organ transplant patients; or</p>
                  </li>
                  <li>
                    <p>for post-haematopoietic stem cell transplant (HSCT) patients; or</p>
                  </li>
                  <li>
                    <p>following needle stick injury.</p>
                  </li>
                </ol>
              </div>
              <Brand ID="B45250139532925">
                <Name>Engerix-B</Name>
                <Pack ID="P2601044" Specified="true" nzmt:ctpp_id="50201081000117104">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013954">
            <Name>Diphtheria, tetanus, pertussis and polio vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Funded for any of the following:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>A single dose for children up to the age of 7 who have completed primary immunisation; or</p>
                </li>
                <li>
                  <p>A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or</p>
                </li>
                <li>
                  <p>An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or</p>
                </li>
                <li>
                  <p>Five doses will be funded for children requiring solid organ transplantation.</p>
                </li>
              </ol>
              <p>Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.</p>
            </div>
            <Formulation ID="F452501395425" Rank="4" Units="inj">
              <Name>Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe</Name>
              <Brand ID="B45250139542525" SoleSupply="2024-06-30">
                <Name>Infanrix IPV</Name>
                <Pack ID="P2086417" Specified="true" nzmt:ctpp_id="50014751000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013955">
            <Name>Haemophilus influenzae type B vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>One dose for patients meeting any of the following:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>For primary vaccination in children; or</p>
                </li>
                <li>
                  <p>An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post
                splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or</p>
                </li>
                <li>
                  <p>For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501395526" Rank="4" Units="inj">
              <Name>Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml</Name>
              <Brand ID="B45250139552625">
                <Name>Hiberix</Name>
                <Pack ID="P2087758" Specified="true" nzmt:ctpp_id="50015851000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013956">
            <Name>Measles, mumps and rubella vaccine</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: upper-alpha">
                <li>
                  <h4>Measles, mumps and rubella vaccine</h4>
                  <p>A maximum of two doses for any patient meeting the following criteria:</p>
                  <ol style="list-style-type: decimal">
                    <li>
                      <p>For primary vaccination in children; or</p>
                    </li>
                    <li>
                      <p>For revaccination following immunosuppression; or</p>
                    </li>
                    <li>
                      <p>For any individual susceptible to measles, mumps or rubella; or</p>
                    </li>
                    <li>
                      <p>A maximum of three doses for children who have had their first dose prior to 12 months.</p>
                    </li>
                  </ol>
                  <p>Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes. Although a price is listed for the vaccine, doctors can still order measles mumps and rubella vaccine free of charge, as with other Schedule vaccines.</p>
                </li>
                <li>
                  <p>Contractors will be entitled to claim payment for the supply of measles, mumps and rubella vaccine to patients eligible under the above criteria pursuant to their contract with Te Whatu Ora for subsidised immunisation, and they may only do so in respect of the measles, mumps and rubella vaccine listed in the Pharmaceutical Schedule.</p>
                </li>
                <li>
                  <p>Contractors can only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501395626" Rank="4" Units="inj">
              <Name>Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml</Name>
              <Brand ID="B45250139562625" SoleSupply="2024-06-30">
                <Name>Priorix</Name>
                <Pack ID="P2509369" Specified="true" nzmt:ctpp_id="50199491000117107">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013958">
            <Name>Pneumococcal (PCV13) conjugate vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Any of the following:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>A course of three doses for previously unvaccinated children up to the age of 59
                months inclusive; or</p>
                </li>
                <li>
                  <p>Two doses are funded for high risk individuals (over the age of 12 months and under 18
                years) who have previously received two doses of the primary course of PCV10; or</p>
                </li>
                <li>
                  <p>Up to an additional four doses (as appropriate) are funded for the (re)immunisation
                of high risk children aged under 5 years with any of the following:</p>
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>on immunosuppressive therapy or radiation therapy, vaccinate when there is
                        expected to be a sufficient immune response; or </p>
                    </li>
                    <li>
                      <p>primary immune deficiencies; or</p>
                    </li>
                    <li>
                      <p>HIV infection; or</p>
                    </li>
                    <li>
                      <p>renal failure, or nephrotic syndrome; or</p>
                    </li>
                    <li>
                      <p>who are immune-suppressed following organ transplantation (including
                        haematopoietic stem cell transplant); or</p>
                    </li>
                    <li>
                      <p>cochlear implants or intracranial shunts; or</p>
                    </li>
                    <li>
                      <p>cerebrospinal fluid leaks; or</p>
                    </li>
                    <li>
                      <p>receiving corticosteroid therapy for more than two weeks, and who are on an
                        equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or
                        children who weigh more than 10 kg on a total daily dosage of 20 mg or
                        greater; or</p>
                    </li>
                    <li>
                      <p>chronic pulmonary disease (including asthma treated with high-dose
                        corticosteroid therapy); or</p>
                    </li>
                    <li>
                      <p>pre term infants, born before 28 weeks gestation; or</p>
                    </li>
                    <li>
                      <p>cardiac disease, with cyanosis or failure; or</p>
                    </li>
                    <li>
                      <p>diabetes; or</p>
                    </li>
                    <li>
                      <p>Down syndrome; or</p>
                    </li>
                    <li>
                      <p>who are pre-or post-splenectomy, or with functional asplenia; or</p>
                    </li>
                  </ol>
                </li>
                <li>
                  <p>Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of
                individuals 5 years and over with HIV, pre or post haematopoietic stem cell
                transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia,
                pre- or post- solid organ transplant, renal dialysis, complement deficiency
                (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid
                leaks or primary immunodeficiency; or</p>
                </li>
                <li>
                  <p>For use in testing for primary immunodeficiency diseases, on the recommendation of an
                internal medicine physician or paediatrician.</p>
                </li>
              </ol>
              <p>Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up
        programmes</p>
            </div>
            <Formulation ID="F452501395825" Rank="4" Units="inj">
              <Name>Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml syringe</Name>
              <Brand ID="B45250139582525">
                <Name>Prevenar 13</Name>
                <Pack ID="P2383047" Specified="true" nzmt:ctpp_id="50123821000117103">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>145.00000</Surcharge>
                </Pack>
                <Pack ID="P2451085" Specified="true" nzmt:ctpp_id="50195241000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013959">
            <Name>Pneumococcal (PCV10) conjugate vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: decimal">
                <li>
                  <p>A primary course of three doses for previously unvaccinated individuals up to the age of 59 months inclusive</p>
                </li>
              </ol>
              <p>Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up
        programmes</p>
            </div>
            <Formulation ID="F452501395925" Rank="4" Units="inj">
              <Name>Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe</Name>
              <Brand ID="B45250139592525" SoleSupply="2024-06-30">
                <Name>Synflorix</Name>
                <Pack ID="P2404729" Specified="true" nzmt:ctpp_id="50138651000117101">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013960">
            <Name>Pneumococcal (PPV23) polysaccharide vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Either:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>Up to three doses (as appropriate) for patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy or with functional asplenia, pre-
                or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or</p>
                </li>
                <li>
                  <p>All of the following:</p>
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>Patient is a child under 18 years for (re-)immunisation; and </p>
                    </li>
                    <li>
                      <p>Treatment is for a maximum of two doses; and</p>
                    </li>
                    <li>
                      <p>Any of the following:</p>
                      <ol style="list-style-type: lower-roman">
                        <li>
                          <p>on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or </p>
                        </li>
                        <li>
                          <p>with primary immune deficiencies; or</p>
                        </li>
                        <li>
                          <p>with HIV infection; or</p>
                        </li>
                        <li>
                          <p>with renal failure, or nephrotic syndrome; or</p>
                        </li>
                        <li>
                          <p>who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or</p>
                        </li>
                        <li>
                          <p>with cochlear implants or intracranial shunts; or</p>
                        </li>
                        <li>
                          <p>with cerebrospinal fluid leaks; or</p>
                        </li>
                        <li>
                          <p>receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or</p>
                        </li>
                        <li>
                          <p>with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or</p>
                        </li>
                        <li>
                          <p>pre term infants, born before 28 weeks gestation; or</p>
                        </li>
                        <li>
                          <p>with cardiac disease, with cyanosis or failure; or</p>
                        </li>
                        <li>
                          <p>with diabetes; or</p>
                        </li>
                        <li>
                          <p>with Down syndrome; or</p>
                        </li>
                        <li>
                          <p>who are pre-or post-splenectomy, or with functional asplenia.</p>
                        </li>
                      </ol>
                    </li>
                  </ol>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501396026" Rank="4" Units="inj">
              <Name>Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)</Name>
              <Brand ID="B45250139602625" SoleSupply="2024-06-30">
                <Name>Pneumovax 23</Name>
                <Pack ID="P2478838" Specified="true" nzmt:ctpp_id="50222761000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013961">
            <Name>Diphtheria, tetanus and pertussis vaccine</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: upper-alpha">
                <li>
                  <p>Funded for any of the following criteria:</p>
                  <ol style="list-style-type: decimal">
                    <li>
                      <p>A single dose for pregnant women in the second or third trimester of each pregnancy; or</p>
                    </li>
                    <li>
                      <p>A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or</p>
                    </li>
                    <li>
                      <p>A course of up to four doses is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or</p>
                    </li>
                    <li>
                      <p>An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or</p>
                    </li>
                    <li>
                      <p>A single dose for vaccination of patients aged from 65 years old; or</p>
                    </li>
                    <li>
                      <p>A single dose for vaccination of patients aged from 45 years old who have not had 4 previous tetanus doses; or</p>
                    </li>
                    <li>
                      <p>For vaccination of previously unimmunised or partially immunised patients; or</p>
                    </li>
                    <li>
                      <p>For revaccination following immunosuppression; or</p>
                    </li>
                    <li>
                      <p>For boosting of patients with tetanus-prone wounds.</p>
                    </li>
                  </ol>
                  <p>Notes: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.</p>
                </li>
                <li>
                  <p>Contractors will be entitled to claim payment from the Funder for the supply of diphtheria, tetanus and pertussis vaccine to patients eligible under the above criteria pursuant to their contract with Te Whatu Ora Health New Zealand for subsidised immunisation, and they may only do so in respect of the diphtheria, tetanus and pertussis vaccine listed in the Pharmaceutical Schedule.</p>
                </li>
                <li>
                  <p>Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs 1 â€“ 9 above.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501396125" Rank="4" Units="inj">
              <Name>Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe</Name>
              <Brand ID="B45250139612525" SoleSupply="2024-06-30">
                <Name>Boostrix</Name>
                <Pack ID="P2459418" Specified="true" nzmt:ctpp_id="50158241000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013962">
            <Name>Bacillus Calmette-Guerin vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>For infants at increased risk of tuberculosis. Increased risk is defined as:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>living in a house or family with a person with current or past history of TB; or </p>
                </li>
                <li>
                  <p>having one or more household members or carers who within the last 5 years lived in a country with a rate of TB &gt; or equal to 40 per 100,000 for 6 months or longer; or</p>
                </li>
                <li>
                  <p>during their first 5 years will be living 3 months or longer in a country with a rate of TB &gt; or equal to 40 per 100,000 </p>
                </li>
              </ol>
              <p>Note a list of countries with high rates of TB are available at www.health.govt.nz/tuberculosis (search for downloads) or www.bcgatlas.org/index.php.</p>
            </div>
            <Formulation ID="F452501396225" Rank="4" Units="inj">
              <Name>Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent</Name>
              <Brand ID="B45250139622525" SoleSupply="2024-06-30">
                <Name>BCG Vaccine</Name>
                <Pack ID="P2461854" Specified="true" nzmt:ctpp_id="50298481000117103">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013963">
            <Name>Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Funded for patients meeting any of the following criteria:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>Up to four doses for children up to and under the age of 10 for primary immunisation;
                or</p>
                </li>
                <li>
                  <p>An additional four doses (as appropriate) are funded for (re-)immunisation for
                children up to and under the age of 10 who are patients post haematopoietic stem
                cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid
                organ transplant, renal dialysis and other severely immunosuppressive regimens;
                or</p>
                </li>
                <li>
                  <p>Up to five doses for children up to and under the age of 10 receiving solid organ
                transplantation.</p>
                </li>
              </ol>
              <p>Note: A course of up-to four vaccines is funded for catch up programmes for children (up to
        and under the age of 10 years) to complete full primary immunisation. Please refer to the
        Immunisation Handbook for the appropriate schedule for catch up programmes.</p>
            </div>
            <Formulation ID="F452501396325" Rank="4" Units="inj">
              <Name>Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-Ag U polio virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe</Name>
              <Brand ID="B45250139632525" SoleSupply="2024-06-30">
                <Name>Infanrix-hexa</Name>
                <Pack ID="P2459396" Specified="true" nzmt:ctpp_id="50129661000117109">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525013965">
            <Name>Poliomyelitis vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Up to three doses for patients meeting either of the following:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>For partially vaccinated or previously unvaccinated individuals; or</p>
                </li>
                <li>
                  <p>For revaccination following immunosuppression.</p>
                </li>
              </ol>
              <p>Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.</p>
            </div>
            <Formulation ID="F452501396525" Rank="4" Units="inj">
              <Name>Inj 80D antigen units in 0.5 ml syringe</Name>
              <Brand ID="B45250139652525" SoleSupply="2024-06-30">
                <Name>IPOL</Name>
                <Pack ID="P216909" Specified="true" nzmt:ctpp_id="50329341000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>40.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014023">
            <Name>Hepatitis A vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Funded for patients meeting any of the following criteria:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>Two vaccinations for use in transplant patients; or</p>
                </li>
                <li>
                  <p>Two vaccinations for use in children with chronic liver disease; or</p>
                </li>
                <li>
                  <p>One dose of vaccine for close contacts of known hepatitis A cases.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501402325" Rank="4" Units="inj">
              <Name>Inj 720 ELISA units in 0.5 ml syringe</Name>
              <Brand ID="B45250140232525" SoleSupply="2024-06-30">
                <Name>Havrix Junior</Name>
                <Pack ID="P793582" Specified="true" nzmt:ctpp_id="50116211000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>32.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F452501402326" Rank="4" Units="inj">
              <Name>Inj 1440 ELISA units in 1 ml syringe</Name>
              <Brand ID="B45250140232625" SoleSupply="2024-06-30">
                <Name>Havrix</Name>
                <Pack ID="P2061937" Specified="true" nzmt:ctpp_id="50062911000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014029">
            <Name>Meningococcal (groups A, C, Y and W-135) conjugate vaccine</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: lower-alpha">
                <li>
                  <ol style="list-style-type: upper-alpha">
                    <li>
                      <p>Any of the following:</p>
                      <ol style="list-style-type: decimal">
                        <li>
                          <p>Up to three doses and a booster every five years for patients pre-
                                and post splenectomy and for patients with functional or anatomic
                                asplenia, HIV, complement deficiency (acquired or inherited), or pre
                                or post solid organ transplant; or</p>
                        </li>
                        <li>
                          <p>One dose for close contacts of meningococcal cases of any group;
                                or</p>
                        </li>
                        <li>
                          <p>One dose for person who has previously had meningococcal disease of
                                any group; or</p>
                        </li>
                        <li>
                          <p>A maximum of two doses for bone marrow transplant patients; or</p>
                        </li>
                        <li>
                          <p>A maximum of two doses for person pre- and post-immunosuppression*;
                                or</p>
                        </li>
                      </ol>
                    </li>
                    <li>
                      <p>Both:</p>
                      <ol style="list-style-type: decimal">
                        <li>
                          <p>Person is aged between 13 and 25 years, inclusive; and</p>
                        </li>
                        <li>
                          <p>One dose for individuals who are entering within the next three
                                months, or in their first year of living in boarding school hostels,
                                tertiary education halls of residence, military barracks, Youth
                                Justice residences, or prisons.</p>
                        </li>
                      </ol>
                    </li>
                    <li>
                      <p>Contractors will be entitled to claim payment from the Funder for the supply
                        of Meningococcal A, C, Y and W-135 vaccine to patients eligible under the
                        above criteria pursuant to their contract with Te Whatu Ora Health New
                        Zealand for subsidised immunisation, and they may only do so in respect of
                        the Meningococcal A, C, Y and W-135 vaccine listed in the Pharmaceutical
                        Schedule.</p>
                    </li>
                    <li>
                      <p>Contractors may only claim for patient populations within the criteria that
                        are covered by their contract, which may be a sub-set of the population
                        described in paragraphs A-B above.</p>
                    </li>
                  </ol>
                </li>
              </ol>
              <p>Note: children under seven years of age require two doses 8 weeks apart, a booster dose three
        years after the primary series and then five yearly.</p>
              <p/>
              <p>*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of
        greater than 28 days.</p>
            </div>
            <Formulation ID="F452501402926" Rank="4" Units="inj">
              <Name>Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial</Name>
              <Brand ID="B45250140292625">
                <Name>MenQuadfi</Name>
                <Pack ID="P2649012" Specified="true" nzmt:ctpp_id="50296211000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014030">
            <Name>Varicella vaccine [Chickenpox vaccine]</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Either:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>Maximum of one dose for primary vaccination for either:</p>
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>Any infant born on or after 1 April 2016; or</p>
                    </li>
                    <li>
                      <p>For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox), or</p>
                    </li>
                  </ol>
                </li>
                <li>
                  <p>Maximum of two doses for any of the following:</p>
                  <ol style="list-style-type: lower-alpha">
                    <li>
                      <p>Any of the following for non-immune patients:</p>
                      <ol style="list-style-type: lower-roman">
                        <li>
                          <p>with chronic liver disease who may in future be candidates for transplantation; or</p>
                        </li>
                        <li>
                          <p>with deteriorating renal function before transplantation; or</p>
                        </li>
                        <li>
                          <p>prior to solid organ transplant; or</p>
                        </li>
                        <li>
                          <p>prior to any elective immunosuppression*, or</p>
                        </li>
                        <li>
                          <p>for post exposure prophylaxis who are immune competent inpatients.; or</p>
                        </li>
                      </ol>
                    </li>
                    <li>
                      <p>For patients at least 2 years after bone marrow transplantation, on advice of their specialist, or</p>
                    </li>
                    <li>
                      <p>For patients at least 6 months after completion of chemotherapy, on advice of their specialist, or</p>
                    </li>
                    <li>
                      <p>For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist, or</p>
                    </li>
                    <li>
                      <p>For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella, or</p>
                    </li>
                    <li>
                      <p>For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella, or</p>
                    </li>
                    <li>
                      <p>For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.</p>
                    </li>
                  </ol>
                </li>
              </ol>
              <p>* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days</p>
            </div>
            <Formulation ID="F452501403026" Rank="4" Units="inj">
              <Name>Inj 1350 PFU prefilled syringe</Name>
              <Brand ID="B45250140302625" SoleSupply="2024-06-30">
                <Name>Varivax</Name>
                <Pack ID="P2173085" Specified="true" nzmt:ctpp_id="50029001000117105">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2593793" Specified="true" nzmt:ctpp_id="50157131000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014032">
            <Name>Meningococcal C conjugate vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Both:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>The child is under 12 months of age; and</p>
                </li>
                <li>
                  <p>Any of the following:</p>
                  <ol style="list-style-type: decimal">
                    <li>
                      <p>Up to three doses for patients pre- and post
               splenectomy and for patients with functional or anatomic asplenia, HIV, complement
               deficiency (acquired or inherited), or pre or post
               solid organ transplant; or
            </p>
                    </li>
                    <li>
                      <p>Two doses for close contacts of meningococcal cases of any group; or</p>
                    </li>
                    <li>
                      <p>Two doses for child who has previously had meningococcal disease of any group; or</p>
                    </li>
                    <li>
                      <p>A maximum of two doses for bone marrow transplant patients; or</p>
                    </li>
                    <li>
                      <p>A maximum of two doses for child pre- and post-immunosuppression*.</p>
                    </li>
                  </ol>
                  <p>Note: children under 12 months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine.</p>
                  <p>*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of
         greater than 28 days.
      </p>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501403225" Rank="4" Units="inj">
              <Name>Inj 10 mcg in 0.5 ml syringe</Name>
              <Brand ID="B45250140322525">
                <Name>Neisvac-C</Name>
                <Pack ID="P2461919" Specified="true" nzmt:ctpp_id="50163811000117101">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014080">
            <Name>Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]</Name>
            <Rule Type="FormMax" Value="1" Attribute="Rx"/>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: lower-alpha">
                <li>
                  <ol style="list-style-type: upper-alpha">
                    <li>
                      <p>Any of the following:</p>
                      <ol style="list-style-type: decimal">
                        <li>
                          <p>Maximum of two doses for children aged 14 years and under; or</p>
                        </li>
                        <li>
                          <p>Maximum of three doses for patients meeting any of the following criteria:</p>
                          <ol style="list-style-type: decimal">
                            <li>
                              <p>People aged 15 to 26 years inclusive; or</p>
                            </li>
                            <li>
                              <p>Either:</p>
                              <p> People aged 9 to 26 years inclusive</p>
                              <ol style="list-style-type: decimal">
                                <li>
                                  <p>Confirmed HIV infection; or</p>
                                </li>
                                <li>
                                  <p>Transplant (including stem cell) patients: or</p>
                                </li>
                              </ol>
                            </li>
                          </ol>
                        </li>
                        <li>
                          <p>Maximum of four doses for people aged 9 to 26 years inclusive post chemotherapy</p>
                        </li>
                      </ol>
                    </li>
                    <li>
                      <p>Contractors will be entitled to claim payment from the Funder for the supply of Human
            papillomavirus vaccine to patients eligible under the above criteria pursuant to their
            contract with Te Whatu Ora Health New Zealand for subsidised immunisation, and they may
            only do so in respect of the Human papillomavirus vaccine listed in the Pharmaceutical
            Schedule.</p>
                    </li>
                    <li>
                      <p>Contractors may only claim for patient populations within the criteria that are
            covered by their contract, which may be a sub-set of the population described in
            paragraphs A above.</p>
                    </li>
                  </ol>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501408025" Rank="4" Units="inj" Weight="270">
              <Name>Inj 270 mcg in 0.5 ml syringe</Name>
              <Brand ID="B45250140802525" SoleSupply="2024-06-30">
                <Name>Gardasil 9</Name>
                <Pack ID="P2506254" Specified="true" nzmt:ctpp_id="50225581000117100">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014085">
            <Name>Rotavirus oral vaccine</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <p>Maximum of two doses for patients meeting the following:</p>
              <ol style="list-style-type: decimal">
                <li>
                  <p>first dose to be administered in infants aged under 14 weeks of age; and</p>
                </li>
                <li>
                  <p>no vaccination being administered to children aged 24 weeks or over.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501408525" Rank="10" Units="each">
              <Name>Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator</Name>
              <Brand ID="B45250140852525" SoleSupply="2024-06-30">
                <Name>Rotarix</Name>
                <Pack ID="P2509415" Specified="true" nzmt:ctpp_id="50187811000117107">
                  <Quantity>10</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
            <Formulation ID="F452501408526" Rank="9" Units="tube">
              <Name>Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube</Name>
              <Brand ID="B45250140852625">
                <Name>Rotarix</Name>
                <Pack ID="P2650290" Specified="true" nzmt:ctpp_id="50308961000117106">
                  <Quantity>10</Quantity>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014147">
            <Name>Meningococcal B multicomponent vaccine</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: lower-alpha">
                <li>
                  <p>Any of the following:</p>
                  <ol style="list-style-type: upper-alpha">
                    <li>
                      <p>Three doses for children up to 12 months of age (inclusive) for primary
                        immunisation; or</p>
                    </li>
                    <li>
                      <p>Up to three doses (dependent on age at first dose) for a catch-up programme
                        for children from 13 months to 59 months of age (inclusive) for primary
                        immunisation, from 1 March 2023 to 31 August 2025; or</p>
                    </li>
                    <li>
                      <p>Both:</p>
                      <ol style="list-style-type: decimal">
                        <li>
                          <p>Person is one year of age or over; and</p>
                        </li>
                        <li>
                          <p>Any of the following:</p>
                          <ol style="list-style-type: lower-roman">
                            <li>
                              <p>up to two doses and a booster every five years for patients
                                        pre- and post-splenectomy and for patients with functional
                                        or anatomic asplenia, HIV, complement deficiency (acquired
                                        or inherited), or pre- or post-solid organ transplant;
                                        or</p>
                            </li>
                            <li>
                              <p>up to two doses for close contacts of meningococcal cases of
                                        any group; or</p>
                            </li>
                            <li>
                              <p>up to two doses for person who has previously had
                                        meningococcal disease of any group; or</p>
                            </li>
                            <li>
                              <p>up to two doses for bone marrow transplant patients; or</p>
                            </li>
                            <li>
                              <p>up to two doses for person pre- and post-immunosuppression*;
                                        or</p>
                            </li>
                          </ol>
                        </li>
                      </ol>
                    </li>
                    <li>
                      <p>Both:</p>
                      <ol style="list-style-type: decimal">
                        <li>
                          <p>Person is aged between 13 and 25 years (inclusive); and</p>
                        </li>
                        <li>
                          <p>Either:</p>
                          <ol style="list-style-type: lower-roman">
                            <li>
                              <p>Two doses for individuals who are entering within the next
                                        three months, or in their first year of living in boarding
                                        school hostels, tertiary education halls of residence,
                                        military barracks, Youth Justice residences or prisons; or</p>
                            </li>
                            <li>
                              <p>Two doses for individuals who are currently living in
                                        boarding school hostels, tertiary education halls of
                                        residence, military barracks, or prisons, from 1 March 2023
                                        to 28 February 2024.</p>
                            </li>
                          </ol>
                        </li>
                      </ol>
                    </li>
                    <li>
                      <p>Contractors will be entitled to claim payment from the Funder for the supply
                        of Meningococcal B multicomponent vaccine to patients eligible under the
                        above criteria pursuant to their contract with Te Whatu Ora Health New
                        Zealand for subsidised immunisation, and they may only do so in respect of
                        the Meningococcal B multicomponent vaccine listed in the Pharmaceutical
                        Schedule.</p>
                    </li>
                    <li>
                      <p>Contractors may only claim for patient populations within the criteria that
                        are covered by their contract, which may be a sub-set of the population
                        described in paragraphs A-D above.</p>
                    </li>
                  </ol>
                </li>
              </ol>
              <p>*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a
        period of greater than 28 days.</p>
            </div>
            <Formulation ID="F452501414725" Rank="4" Units="inj">
              <Name>Inj 175 mcg per 0.5 ml prefilled syringe</Name>
              <Brand ID="B45250141472525">
                <Name>Bexsero</Name>
                <Pack ID="P2556251" nzmt:ctpp_id="50247291000117107">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2669668" Specified="true" nzmt:ctpp_id="50247281000117109">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2671948" Specified="true" nzmt:ctpp_id="50308971000117101">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
          <Chemical ID="C4525014162">
            <Name>Varicella zoster vaccine [Shingles vaccine]</Name>
            <Rule Type="FormReqd" Attribute="Rx"/>
            <Rule Type="MaxCoPayment" Value="0"/>
            <div xmlns="http://www.w3.org/1999/xhtml" class="Note">
              <ol style="list-style-type: upper-alpha">
                <li>
                  <p>Funded for patients meeting the following criteria:</p>
                  <ol style="list-style-type: decimal">
                    <li>
                      <p>Two doses for all people aged 65 years</p>
                    </li>
                  </ol>
                </li>
                <li>
                  <p>Contractors will be entitled to claim payment from the Funder for the supply of
                Varicella zoster vaccine (Shingles vaccine) to patients eligible under the above
                criteria pursuant to their contract with Te Whatu Ora Health New Zealand for
                subsidised immunisation, and they may only do so in respect of the Varicella zoster
                vaccine [Shingles vaccine] listed in the Pharmaceutical Schedule.</p>
                </li>
                <li>
                  <p>Contractors may only claim for patient populations within the criteria that are
                covered by their contract, which may be a sub-set of the population described in
                paragraph A above.</p>
                </li>
              </ol>
            </div>
            <Formulation ID="F452501416225" Rank="4" Units="inj">
              <Name>Inj 50 mcg per 0.5 ml vial plus vial</Name>
              <Brand ID="B45250141622525">
                <Name>Shingrix</Name>
                <Pack ID="P2631687" Specified="true" nzmt:ctpp_id="50256931000117102">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
                <Pack ID="P2671921" Specified="true" nzmt:ctpp_id="50256941000117105">
                  <Quantity>10</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
      <ATC2 ID="A4530">
        <Name>Diagnostic Agents</Name>
        <ATC3 ID="A453004">
          <Name>Diagnostic Agents</Name>
          <Chemical ID="C4530044086">
            <Name>Tuberculin PPD [Mantoux] test</Name>
            <Rule Type="Dispensary" Attribute="Xpharm"/>
            <Formulation ID="F453004408625" Rank="4" Units="inj">
              <Name>Inj 5 TU per 0.1 ml, 1 ml vial</Name>
              <Brand ID="B45300440862525" SoleSupply="2024-06-30">
                <Name>Tubersol</Name>
                <Pack ID="P703338" Specified="true" nzmt:ctpp_id="50103681000117108">
                  <Quantity>1</Quantity>
                  <Multiple>1</Multiple>
                  <Subsidy>0.00</Subsidy>
                  <Price>0.00</Price>
                  <Alternate>0.00</Alternate>
                  <Surcharge>0.00000</Surcharge>
                </Pack>
              </Brand>
            </Formulation>
          </Chemical>
        </ATC3>
      </ATC2>
    </ATC1>
  </Section>
</Schedule>
